<SEC-DOCUMENT>0001564590-22-037656.txt : 20221114
<SEC-HEADER>0001564590-22-037656.hdr.sgml : 20221114
<ACCEPTANCE-DATETIME>20221114164611
ACCESSION NUMBER:		0001564590-22-037656
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221114
DATE AS OF CHANGE:		20221114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			T2 Biosystems, Inc.
		CENTRAL INDEX KEY:			0001492674
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				204827488
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36571
		FILM NUMBER:		221386877

	BUSINESS ADDRESS:	
		STREET 1:		101 HARTWELL AVENUE
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
		BUSINESS PHONE:		781-457-1200

	MAIL ADDRESS:	
		STREET 1:		101 HARTWELL AVENUE
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ttoo-10q_20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-11-14T20:33:37.7070773+00:00 -->
<!-- Version            : 5.0.1.753 -->
<!-- Package ID         : e9bee4ab4d8b4c8a9f469bea6de545b7 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ttoo="http://www.t2biosystems.com/20220930" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
ttoo-10q_20220930.htm
</title>
</head>
<!-- NG Converter v5.0.2.73 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001492674_20220101_20220930">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001492674_20220101_20220930">2022</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001492674_20220101_20220930">Q3</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityCentralIndexKey" contextRef="C_0001492674_20220101_20220930">0001492674</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001492674_20220101_20220930">--12-31</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000445_2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011_20221011" decimals="2">0.02</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000449" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221012_20221012" decimals="2">0.02</ix:nonFraction>
			<ix:nonNumeric id="F_000524" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202006Member_20220930">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000526" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202006Member_20220930">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000527" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202104Member_20220930">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000529" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202104Member_20220930">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000530" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202110Member_20220930">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000532" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202110Member_20220930">true</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000785" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001492674_20220101_20220930" decimals="2">0.02</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000835" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011_20221011" decimals="2">0.02</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000445" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011_20221011" decimals="2">0.02</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000449_2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221012_20221012" decimals="2">0.02</ix:nonFraction>
			<ix:nonNumeric id="F_000485" name="ttoo:MaintenanceServiceTermOfAdditionalPeriod" contextRef="C_0001492674_srtProductOrServiceAxis_ttooT2DxMember_20220101_20220930">P1Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000624" name="us-gaap:DebtInstrumentTerm" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161201_20161231">P6Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000785_2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001492674_20220101_20220930" decimals="2">0.02</ix:nonFraction>
			<ix:nonNumeric id="F_000807" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoMay2013Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeLaboratoryAndManufacturingSpaceMember_20180801_20180831">2020-12-31</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000835_2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011_20221011" decimals="2">0.02</ix:nonFraction>
			<ix:nonNumeric id="F_000698" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20210101_20211231">P7Y1M2D</ix:nonNumeric>
			<ix:nonNumeric id="F_000699" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930">P6Y9M10D</ix:nonNumeric>
			<ix:nonNumeric id="F_000700" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930">P5Y10M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000701" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930">P6Y7M28D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001492674_20220930" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001492674_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:PreferredStockValue" contextRef="C_0001492674_20220930" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:PreferredStockValue" contextRef="C_0001492674_20211231" xsi:nil="true"></ix:nonFraction>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="ttoo-20220930.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001492674_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001492674_20221108">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-11-08</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001492674_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooContributionMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooContributionMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooContributionMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooContributionMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220401_20220630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-04-01</xbrli:startDate>
					<xbrli:endDate>2022-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_20220401_20220630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-04-01</xbrli:startDate>
					<xbrli:endDate>2022-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220401_20220630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-04-01</xbrli:startDate>
					<xbrli:endDate>2022-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20220401_20220630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-04-01</xbrli:startDate>
					<xbrli:endDate>2022-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220401_20220630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-04-01</xbrli:startDate>
					<xbrli:endDate>2022-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_20220630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttoo:TermLoanAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ttoo:CRGMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220201_20220228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttoo:TermLoanAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ttoo:CRGMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-02-01</xbrli:startDate>
					<xbrli:endDate>2022-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221113_20221114">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttoo:TermLoanAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ttoo:CRGMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-11-13</xbrli:startDate>
					<xbrli:endDate>2022-11-14</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtRangeAxis_srtMaximumMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_20211105">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-11-05</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtRangeAxis_srtMinimumMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011_20221011">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-10-11</xbrli:startDate>
					<xbrli:endDate>2022-10-11</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_20220722">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-07-22</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_20220824">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-08-24</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221012_20221012">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-10-12</xbrli:startDate>
					<xbrli:endDate>2022-10-12</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_ttooSegment">
				<xbrli:measure>ttoo:Segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtMajorCustomersAxis_ttooCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ttoo:CustomerAMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtMajorCustomersAxis_ttooCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ttoo:CustomerAMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtMajorCustomersAxis_ttooCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ttoo:CustomerAMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtMajorCustomersAxis_ttooCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ttoo:CustomerAMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtMajorCustomersAxis_ttooCustomerBMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ttoo:CustomerBMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtMajorCustomersAxis_ttooCustomerBMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ttoo:CustomerBMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtMajorCustomersAxis_ttooCustomerCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ttoo:CustomerCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooT2DxMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:T2DxMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooProductInstrumentsMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ProductInstrumentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooProductInstrumentsMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ProductInstrumentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooProductInstrumentsMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ProductInstrumentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooProductInstrumentsMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ProductInstrumentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooProductConsumablesMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ProductConsumablesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooProductConsumablesMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ProductConsumablesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooProductConsumablesMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ProductConsumablesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooProductConsumablesMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ProductConsumablesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooInstrumentRentalsMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:InstrumentRentalsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooInstrumentRentalsMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:InstrumentRentalsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooInstrumentRentalsMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:InstrumentRentalsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooInstrumentRentalsMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:InstrumentRentalsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooContributionRevenueMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooContributionRevenueMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooContributionRevenueMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_ttooContributionRevenueMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtRangeAxis_srtMaximumMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-10-01_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
							<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
						</xbrldi:typedMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentAssetsMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentAssetsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202006Member_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202104Member_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202104Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202110Member_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202110Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ttoo:CRGMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttoo:TermLoanAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapContingentConsiderationByTypeAxis_ttooScenarioOneMember_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttoo:TermLoanAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ttoo:CRGMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ttoo:ScenarioOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ttoo:CRGMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttoo:TermLoanAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapValuationTechniqueAxis_ttooProbabilityWeightedDiscountedCashFlowModelMember_20220101_20220630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ttoo:ProbabilityWeightedDiscountedCashFlowModelMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapValuationTechniqueAxis_ttooProbabilityWeightedDiscountedCashFlowModelMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ttoo:ProbabilityWeightedDiscountedCashFlowModelMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_ttooFacility">
				<xbrli:measure>ttoo:Facility</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapToolsDiesAndMoldsMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapToolsDiesAndMoldsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooT2DxInstrumentsAndComponentsMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:T2DxInstrumentsAndComponentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooT2DxInstrumentsAndComponentsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:T2DxInstrumentsAndComponentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooT2OwnedInstrumentsInServiceMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:T2OwnedInstrumentsInServiceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooT2OwnedInstrumentsInServiceMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:T2OwnedInstrumentsInServiceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooT2OwnedInstrumentsInServiceMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:T2OwnedInstrumentsInServiceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161201_20161231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ttoo:CRGMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttoo:TermLoanAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-12-01</xbrli:startDate>
					<xbrli:endDate>2016-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ttoo:CRGMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttoo:TermLoanAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ttoo:CRGMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttoo:TermLoanAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ttoo:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:PurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-08-15</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:PurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-08-15</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ttoo:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:PurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-08-15</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ttoo:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:PurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815_20220815">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:PurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-08-15</xbrli:startDate>
					<xbrli:endDate>2022-08-15</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:PurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-08-15</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_20210701">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20210330_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:NewSalesAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ttoo:CanaccordGenuityLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-30</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooOriginalSalesAgreementMember_20190730_20190730">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:OriginalSalesAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ttoo:CanaccordGenuityLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-30</xbrli:startDate>
					<xbrli:endDate>2019-07-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20190730_20190730">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:NewSalesAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ttoo:CanaccordGenuityLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-30</xbrli:startDate>
					<xbrli:endDate>2019-07-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:NewSalesAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ttoo:CanaccordGenuityLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:NewSalesAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ttoo:CanaccordGenuityLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:NewSalesAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ttoo:CanaccordGenuityLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:NewSalesAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ttoo:CanaccordGenuityLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2006Member_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlan2006Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlan2014Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlan2014Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPlanNameAxis_ttooInducementAwardPlanMember_20180331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:InducementAwardPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPlanNameAxis_ttooInducementAwardPlanMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:InducementAwardPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlan2014Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlan2014Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlan2014Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200806">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-08-06</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIModificationMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:TypeIModificationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIModificationMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:TypeIModificationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIIIModificationMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:TypeIIIModificationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIIIModificationMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:TypeIIIModificationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesAConvertiblePreferredStockMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ttoo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ttoo:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ttoo:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20200901_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-09-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20210901_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-09-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20220101_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20220901_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-09-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srtProductOrServiceAxis_ttooContributionMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20220701_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-07-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srtProductOrServiceAxis_ttooContributionMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srtProductOrServiceAxis_ttooContributionMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srtProductOrServiceAxis_ttooContributionMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20210101_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeSpaceLaboratorySpaceAndEquipmentMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:OfficeSpaceLaboratorySpaceAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeSpaceLaboratorySpaceAndEquipmentMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:OfficeSpaceLaboratorySpaceAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtMortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_srtOfficeBuildingMember_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20150401_20150430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoNovember2014Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-04-01</xbrli:startDate>
					<xbrli:endDate>2015-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtMortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_srtOfficeBuildingMember_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20170901_20170930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoNovember2014Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-09-01</xbrli:startDate>
					<xbrli:endDate>2017-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoMay2013Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeLaboratoryAndManufacturingSpaceMember_20180801_20180831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoMay2013Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:OfficeLaboratoryAndManufacturingSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-08-01</xbrli:startDate>
					<xbrli:endDate>2018-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoMay2013Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeLaboratoryAndManufacturingSpaceMember_20201001_20201031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoMay2013Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:OfficeLaboratoryAndManufacturingSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2020-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoMay2013Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeLaboratoryAndManufacturingSpaceMember_20220901_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoMay2013Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:OfficeLaboratoryAndManufacturingSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-09-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtMortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_srtOfficeBuildingMember_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20141130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoNovember2014Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2014-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtMortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_srtOfficeBuildingMember_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20141130_20141130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoNovember2014Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2014-11-30</xbrli:startDate>
					<xbrli:endDate>2014-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoMay2013Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeLaboratoryAndManufacturingSpaceMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoMay2013Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:OfficeLaboratoryAndManufacturingSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20141130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoNovember2014Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:LaboratorySpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2014-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoNovember2014Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:LaboratorySpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20141101_20141130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoNovember2014Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:LaboratorySpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2014-11-01</xbrli:startDate>
					<xbrli:endDate>2014-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20201001_20201031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoNovember2014Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:LaboratorySpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2020-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoNovember2014Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:LaboratorySpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoNovember2014Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:LaboratorySpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoSeptember2021Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeResearchLaboratoryAndManufacturingSpaceMember_20210901_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoSeptember2021Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:OfficeResearchLaboratoryAndManufacturingSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-09-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoSeptember2021Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeResearchLaboratoryAndManufacturingSpaceMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoSeptember2021Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:OfficeResearchLaboratoryAndManufacturingSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20061231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2006-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20061231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2006-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20060101_20071231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2006-01-01</xbrli:startDate>
					<xbrli:endDate>2007-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20220101_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-01-01</xbrli:startDate>
					<xbrli:endDate>2022-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20220930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20221001_20221109">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:NewSalesAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-10-01</xbrli:startDate>
					<xbrli:endDate>2022-11-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011_20221011">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-10-11</xbrli:startDate>
					<xbrli:endDate>2022-10-11</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-10-11</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20221026">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001492674</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:PurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ttoo:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-10-26</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="border-top:Solid 0.75pt #000000;padding-top:0pt;text-align:center;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="border-top:Solid 0.75pt;padding-top:1pt;text-align:center;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;line-height:4pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM&#160;<ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001492674_20220101_20220930">10-Q</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;line-height:4pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark One) </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:13pt;font-family:MS Mincho;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:MS Mincho;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000026" name="dei:DocumentQuarterlyReport" contextRef="C_0001492674_20220101_20220930" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:13pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the quarterly period ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001492674_20220101_20220930" format="ixt:datemonthdayyearen">September&#160;30, 2022</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:4pt;line-height:13pt;font-family:MS Mincho;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:MS Mincho;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000027" name="dei:DocumentTransitionReport" contextRef="C_0001492674_20220101_20220930" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:4pt;line-height:13pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from <span style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> to <span style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission file number:&#160;<ix:nonNumeric id="F_000014" name="dei:EntityFileNumber" contextRef="C_0001492674_20220101_20220930">001-36571</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;line-height:4pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;line-height:26pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityRegistrantName" contextRef="C_0001492674_20220101_20220930">T2 Biosystems, Inc.</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter) </p>
<p style="margin-top:2pt;text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;line-height:4pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000025" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001492674_20220101_20220930" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001492674_20220101_20220930">20-4827488</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of incorporation or organization)</p></td>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr style="height:4.5pt;">
<td valign="middle" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&#160;</p></td>
<td valign="middle" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:EntityAddressAddressLine1" contextRef="C_0001492674_20220101_20220930">101 Hartwell Avenue</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:EntityAddressCityOrTown" contextRef="C_0001492674_20220101_20220930">Lexington</ix:nonNumeric>, <ix:nonNumeric id="F_000018" name="dei:EntityAddressStateOrProvince" contextRef="C_0001492674_20220101_20220930" format="ixt-sec:stateprovnameen">Massachusetts</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:EntityAddressPostalZipCode" contextRef="C_0001492674_20220101_20220930">02421</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric id="F_000020" name="dei:CityAreaCode" contextRef="C_0001492674_20220101_20220930">781</ix:nonNumeric>) <ix:nonNumeric id="F_000021" name="dei:LocalPhoneNumber" contextRef="C_0001492674_20220101_20220930">761-4646</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;line-height:4pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:15%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:Security12bTitle" contextRef="C_0001492674_20220101_20220930">Common Stock, par value $0.001</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="width:15%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0001492674_20220101_20220930">TTOO</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <ix:nonNumeric id="F_000024" name="dei:SecurityExchangeName" contextRef="C_0001492674_20220101_20220930" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000012" name="dei:EntityCurrentReportingStatus" contextRef="C_0001492674_20220101_20220930">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:MS Mincho;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:MS Mincho;">&#9744;</span> </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000022" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001492674_20220101_20220930">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:MS Mincho;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:MS Mincho;">&#9744;</span> </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:44.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top" style="width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated filer</p></td>
<td valign="top" style="width:5.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="top" style="width:44.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="top" style="width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="top" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="top" style="width:5.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:44.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityFilerCategory" contextRef="C_0001492674_20220101_20220930" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td>
<td valign="top" style="width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top" style="width:5.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntitySmallBusiness" contextRef="C_0001492674_20220101_20220930" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:44.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="top" style="width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="top" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
<td valign="top" style="width:5.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:44.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging&#160;growth&#160;company</p></td>
<td valign="top" style="width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000011" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001492674_20220101_20220930" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant of Section&#160;13(a) of the Exchange Act&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:MS Mincho;"><ix:nonNumeric id="F_000013" name="dei:EntityShellCompany" contextRef="C_0001492674_20220101_20220930" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:MS Mincho;">&#9746;</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of November 8, 2022, the registrant had <ix:nonFraction unitRef="U_xbrlishares" id="F_000028" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001492674_20221108" decimals="INF" format="ixt:numdotdecimal">7,319,105</ix:nonFraction> shares of common stock outstanding. </p>
<p style="margin-top:0pt;border-top:Solid 0.75pt #000000;padding-top:0pt;text-align:center;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="border-top:Solid 0.75pt;padding-top:1pt;text-align:center;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">T2 BIOSYSTEMS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page<span style="font-weight:normal;"> &#160;</span></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:6.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:86.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><span style="text-decoration:underline;">PART&#160;I FINANCIAL INFORMATION </span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FINANCIAL_STATEMENTS"><span style="text-decoration:underline;">Financial Statements (unaudited)</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:underline;">Condensed Consolidated Balance Sheets as of September&#160;30, 2022 and December&#160;31, 2021</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_OPERAT"><span style="text-decoration:underline;">Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September&#160;30, 2022 and 2021</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENTS_STOCKH"><span style="text-decoration:underline;">Condensed Consolidated Statements of Series A Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) for the three and nine months ended September 30, 2022 and 2021</span></a></p></td>
<td valign="middle" style="width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEMENT_CASH_FL"><span style="text-decoration:underline;">Condensed Consolidated Statements of Cash Flows for the nine months ended September&#160;30, 2022 and 2021 </span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA"><span style="text-decoration:underline;">Notes to Condensed Consolidated Financial Statements</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="bottom" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="bottom" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures about Market Risk</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="bottom" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:86.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><span style="text-decoration:underline;">PART&#160;II OTHER INFORMATION</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="bottom" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">Legal Proceedings</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="bottom" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">Risk Factors</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="bottom" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"><span style="text-decoration:underline;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="bottom" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES"><span style="text-decoration:underline;">Defaults Upon Senior Securities</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="bottom" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 5.</p></td>
<td valign="bottom" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_OR_INFORMATION"><span style="text-decoration:underline;">Other Information</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 6.</p></td>
<td valign="bottom" style="width:86.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_EXHIBITS_FINANCIAL_STATEMENT_SCHE"><span style="text-decoration:underline;">Exhibits, Financial Statement Schedules</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
</tr>
<tr style="height:6pt;">
<td colspan="2" valign="middle" style="width:93.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="width:93.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:underline;">SIGNATURES</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I">PART I. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FINANCIAL INFORMATION </p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_FINANCIAL_STATEMENTS">Item&#160;1. Financial Statements </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T2 BIOSYSTEMS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_BALANCE_SHEETS">CONDENSED CONSOLIDATED BALANCE SHEETS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share data) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000029" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">20,366</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000030" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,245</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000031" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,996</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000032" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,578</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000033" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,134</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000034" name="us-gaap:InventoryNet" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,242</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:InventoryNet" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,909</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,690</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:AssetsCurrent" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">28,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:AssetsCurrent" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,394</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,734</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,675</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">9,058</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,766</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,131</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,551</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001492674_20220930" decimals="-3" scale="3">153</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001492674_20211231" decimals="-3" scale="3">153</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:Assets" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">43,952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:Assets" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">60,539</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, Series A redeemable convertible preferred stock and stockholders&#8217; deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,063</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,832</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">8,531</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,338</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative warrant liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="C_0001492674_20220930" decimals="-3" scale="3">186</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001492674_20220930" decimals="-3" scale="3">163</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001492674_20211231" decimals="-3" scale="3">518</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">10,943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,688</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:LongTermNotesPayable" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">49,188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:LongTermNotesPayable" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">47,790</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, net of current portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">8,569</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,359</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, net of current portion</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001492674_20220930" decimals="-3" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001492674_20211231" decimals="-3" scale="3">28</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,791</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,577</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (see Note 14)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000068">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000069">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A redeemable convertible preferred stock&#59; $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000084" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_0001492674_20220930" decimals="INF">0.001</ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000085" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001492674_20220930" decimals="INF" format="ixt:numdotdecimal">3,000</ix:nonFraction> shares authorized at September 30, 2022&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000086" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001492674_20220930" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000088" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001492674_20220930" decimals="INF" format="ixt:numdotdecimal">3,000</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September 30, 2022&#59; liquidation value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">330,000</ix:nonFraction>&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000087" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001492674_20211231" decimals="INF"><ix:nonFraction unitRef="U_xbrlishares" id="F_000089" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001492674_20211231" decimals="INF">0</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2021 (see Note 7)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" contextRef="C_0001492674_20220930" decimals="-3" scale="3">330</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000091" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001492674_20220930" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000092" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001492674_20211231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000093" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001492674_20220930" decimals="INF" format="ixt:numdotdecimal">9,997,000</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000094" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001492674_20211231" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction> shares authorized at September 30, 2022 and December 31, 2021, respectively&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000095" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001492674_20220930" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000096" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001492674_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000097" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001492674_20220930" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000098" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001492674_20211231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; outstanding at September&#160;30, 2022 and December&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000071">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000072">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000099" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001492674_20220930" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000100" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001492674_20211231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000101" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001492674_20220930" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000102" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001492674_20211231" decimals="INF" format="ixt:numdotdecimal">400,000,000</ix:nonFraction></ix:nonFraction> shares authorized&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000103" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001492674_20220930" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000105" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001492674_20220930" decimals="INF" format="ixt:numdotdecimal">7,050,849</ix:nonFraction></ix:nonFraction> and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000104" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001492674_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000106" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001492674_20211231" decimals="INF" format="ixt:numdotdecimal">3,328,017</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021, respectively</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:CommonStockValue" contextRef="C_0001492674_20220930" decimals="-3" scale="3">7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:CommonStockValue" contextRef="C_0001492674_20211231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">492,444</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">459,314</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001492674_20211231" decimals="-3" sign="-" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001492674_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">524,120</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001492674_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">472,216</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">31,669</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">12,903</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities, Series A convertible redeemable preferred stock and stockholders&#8217; deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">43,952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">60,539</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to condensed consolidated financial statements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T2 BIOSYSTEMS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_STATEMENTS_OPERAT">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share data) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="8" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20220701_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,641</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,306</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">9,044</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">12,634</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contribution revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_ttooContributionMember_20220701_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,036</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_ttooContributionMember_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">3,122</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_ttooContributionMember_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">7,778</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_ttooContributionMember_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">8,444</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_20220701_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">3,677</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">7,428</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">16,822</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">21,078</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20220701_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">6,085</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,720</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">17,371</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">15,341</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001492674_20220701_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">6,375</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001492674_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">6,384</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001492674_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">21,056</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001492674_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">16,448</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001492674_20220701_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">7,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001492674_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">8,536</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001492674_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">24,071</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001492674_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">21,983</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total costs and expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:CostsAndExpenses" contextRef="C_0001492674_20220701_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">19,477</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:CostsAndExpenses" contextRef="C_0001492674_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">19,640</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:CostsAndExpenses" contextRef="C_0001492674_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">62,498</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:CostsAndExpenses" contextRef="C_0001492674_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">53,772</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001492674_20220701_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">15,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001492674_20210701_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">12,212</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">45,676</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000138" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001492674_20210101_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">32,694</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001492674_20220701_20220930" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001492674_20210701_20210930" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001492674_20220101_20220930" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001492674_20210101_20210930" decimals="-3" scale="3">18</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="us-gaap:InterestExpense" contextRef="C_0001492674_20220701_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,560</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:InterestExpense" contextRef="C_0001492674_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,919</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:InterestExpense" contextRef="C_0001492674_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:InterestExpense" contextRef="C_0001492674_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">5,642</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative instrument</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="C_0001492674_20220701_20220930" decimals="-3" sign="-" scale="3">117</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="C_0001492674_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,010</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative warrant liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="ttoo:ChangeInFairValueOfDerivativeWarrantLiability" contextRef="C_0001492674_20220701_20220930" decimals="-3" scale="3">179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="ttoo:ChangeInFairValueOfDerivativeWarrantLiability" contextRef="C_0001492674_20220101_20220930" decimals="-3" scale="3">179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001492674_20220701_20220930" decimals="-3" sign="-" scale="3">78</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001492674_20210701_20210930" decimals="-3" scale="3">163</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" scale="3">65</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001492674_20210101_20210930" decimals="-3" scale="3">211</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001492674_20220701_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,575</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001492674_20210701_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,750</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">6,228</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001492674_20210101_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,403</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:NetIncomeLoss" contextRef="C_0001492674_20220701_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,375</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:NetIncomeLoss" contextRef="C_0001492674_20210701_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">13,962</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:NetIncomeLoss" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">51,904</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:NetIncomeLoss" contextRef="C_0001492674_20210101_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,097</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed dividend on Series A redeemable convertible preferred stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="us-gaap:TemporaryEquityDividendsAdjustment" contextRef="C_0001492674_20220701_20220930" decimals="-3" scale="3">330</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="us-gaap:TemporaryEquityDividendsAdjustment" contextRef="C_0001492674_20220101_20220930" decimals="-3" scale="3">330</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_0001492674_20220701_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,705</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_0001492674_20210701_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">13,962</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,234</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_0001492674_20210101_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,097</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share &#8212; basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000192" name="us-gaap:EarningsPerShareDiluted" contextRef="C_0001492674_20220701_20220930" decimals="2" sign="-"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000170" name="us-gaap:EarningsPerShareBasic" contextRef="C_0001492674_20220701_20220930" decimals="2" sign="-">2.95</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000193" name="us-gaap:EarningsPerShareDiluted" contextRef="C_0001492674_20210701_20210930" decimals="2" sign="-"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000171" name="us-gaap:EarningsPerShareBasic" contextRef="C_0001492674_20210701_20210930" decimals="2" sign="-">4.21</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000194" name="us-gaap:EarningsPerShareDiluted" contextRef="C_0001492674_20220101_20220930" decimals="2" sign="-"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000172" name="us-gaap:EarningsPerShareBasic" contextRef="C_0001492674_20220101_20220930" decimals="2" sign="-">12.08</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000195" name="us-gaap:EarningsPerShareDiluted" contextRef="C_0001492674_20210101_20210930" decimals="2" sign="-"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000173" name="us-gaap:EarningsPerShareBasic" contextRef="C_0001492674_20210101_20210930" decimals="2" sign="-">11.86</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average number of common shares used in computing</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net loss per share &#8212; basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000196" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_0001492674_20220701_20220930" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000174" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_0001492674_20220701_20220930" decimals="0" format="ixt:numdotdecimal">6,008,819</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000197" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_0001492674_20210701_20210930" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000175" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_0001492674_20210701_20210930" decimals="0" format="ixt:numdotdecimal">3,317,646</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000198" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_0001492674_20220101_20220930" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000176" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_0001492674_20220101_20220930" decimals="0" format="ixt:numdotdecimal">4,323,452</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000199" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_0001492674_20210101_20210930" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000177" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_0001492674_20210101_20210930" decimals="0" format="ixt:numdotdecimal">3,127,951</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:NetIncomeLoss" contextRef="C_0001492674_20220701_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,375</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:NetIncomeLoss" contextRef="C_0001492674_20210701_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">13,962</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:NetIncomeLoss" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">51,904</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:NetIncomeLoss" contextRef="C_0001492674_20210101_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,097</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net unrealized gain on marketable securities arising during the period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" contextRef="C_0001492674_20220101_20220930" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" contextRef="C_0001492674_20210101_20210930" decimals="-3" scale="3">9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net realized (gain) loss on marketable securities included in net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_0001492674_20210101_20210930" decimals="-3" scale="3">14</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other comprehensive (loss) income, net of taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="C_0001492674_20220101_20220930" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="C_0001492674_20210101_20210930" decimals="-3" sign="-" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001492674_20220701_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,375</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001492674_20210701_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">13,962</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">51,900</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001492674_20210101_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,102</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to condensed consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T2 BIOSYSTEMS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_STATEMENTS_STOCKH">CONDENSED CONSOLIDATED STATEMENTS OF SERIES A CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share data) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Temporary Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="22" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Permanent Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A Redeemable Convertible Preferred Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity (Deficit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000200" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">2,961,579</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">431,689</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">422,975</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" scale="3">9</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,726</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,308</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000207" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001492674_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,308</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from vesting of restricted stock and exercise of stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000208" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">8,253</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" scale="3">53</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001492674_20210101_20210331" decimals="-3" scale="3">53</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331" decimals="-3" scale="3">7</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001492674_20210101_20210331" decimals="-3" scale="3">7</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="us-gaap:NetIncomeLoss" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">10,660</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="us-gaap:NetIncomeLoss" contextRef="C_0001492674_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">10,660</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000215" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="INF" format="ixt:numdotdecimal">2,969,832</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">433,050</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">433,635</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331" decimals="-3" scale="3">16</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_20210331" decimals="-3" sign="-" scale="3">566</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,843</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001492674_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,843</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000223" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="INF" format="ixt:numdotdecimal">9,253</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630" decimals="-3" scale="3">251</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001492674_20210401_20210630" decimals="-3" scale="3">251</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from secondary public offering, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000226" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630" decimals="INF" format="ixt:numdotdecimal">336,188</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">19,968</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001492674_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">19,968</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630" decimals="-3" sign="-" scale="3">12</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001492674_20210401_20210630" decimals="-3" sign="-" scale="3">12</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="us-gaap:NetIncomeLoss" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">12,475</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="us-gaap:NetIncomeLoss" contextRef="C_0001492674_20210401_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">12,475</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at June 30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000233" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630" decimals="INF" format="ixt:numdotdecimal">3,315,273</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">455,112</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000236" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">446,110</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210630" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">9,009</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000239" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,466</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001492674_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,466</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from vesting of restricted stock and exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000241" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210701_20210930" decimals="INF" format="ixt:numdotdecimal">4,082</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210701_20210930" decimals="-3" scale="3">24</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001492674_20210701_20210930" decimals="-3" scale="3">24</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="us-gaap:NetIncomeLoss" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210701_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">13,962</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="us-gaap:NetIncomeLoss" contextRef="C_0001492674_20210701_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">13,962</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000246" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210930" decimals="INF" format="ixt:numdotdecimal">3,319,355</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210930" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">457,602</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">460,072</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210930" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,463</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Temporary Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="22" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Permanent Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A Redeemable Convertible Preferred Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity (Deficit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000252" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">3,328,017</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">459,314</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">472,216</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231" decimals="-3" sign="-" scale="3">4</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">12,903</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,552</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001492674_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,552</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from vesting of restricted stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000260" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">40,028</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Surrender of shares due to tax withholding</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000261" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">10,781</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331" decimals="-3" scale="3">231</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001492674_20220101_20220331" decimals="-3" scale="3">231</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from secondary offering, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000264" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331" decimals="INF" format="ixt:numdotdecimal">70,981</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,433</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001492674_20220101_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,433</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20220101_20220331" decimals="-3" sign="-" scale="3">7</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001492674_20220101_20220331" decimals="-3" sign="-" scale="3">7</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="us-gaap:NetIncomeLoss" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">16,495</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="us-gaap:NetIncomeLoss" contextRef="C_0001492674_20220101_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">16,495</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000271" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331" decimals="INF" format="ixt:numdotdecimal">3,428,245</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220331" decimals="-3" format="ixt:numdotdecimal" scale="3">463,068</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">488,711</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20220331" decimals="-3" sign="-" scale="3">11</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_20220331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">25,651</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220401_20220630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,534</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001492674_20220401_20220630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,534</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000279" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220401_20220630" decimals="INF" format="ixt:numdotdecimal">23,386</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220401_20220630" decimals="-3" scale="3">139</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000281" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001492674_20220401_20220630" decimals="-3" scale="3">139</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Surrender of shares due to tax withholding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220401_20220630" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001492674_20220401_20220630" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from secondary offering, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000284" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220401_20220630" decimals="INF" format="ixt:numdotdecimal">517,352</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220401_20220630" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220401_20220630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,493</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001492674_20220401_20220630" decimals="-3" format="ixt:numdotdecimal" scale="3">4,494</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20220401_20220630" decimals="-3" scale="3">11</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001492674_20220401_20220630" decimals="-3" scale="3">11</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="us-gaap:NetIncomeLoss" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220401_20220630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">18,034</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:NetIncomeLoss" contextRef="C_0001492674_20220401_20220630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">18,034</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at June 30, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000292" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220630" decimals="INF" format="ixt:numdotdecimal">3,968,983</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220630" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220630" decimals="-3" format="ixt:numdotdecimal" scale="3">469,222</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">506,745</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_20220630" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,519</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000297" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220701_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,372</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001492674_20220701_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,372</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from vesting of restricted stock and exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000299" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220701_20220930" decimals="INF" format="ixt:numdotdecimal">1,365</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from secondary offering, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000300" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220701_20220930" decimals="INF" format="ixt:numdotdecimal">3,080,451</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220701_20220930" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000302" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220701_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">22,180</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001492674_20220701_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">22,183</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series A redeemable convertible preferred stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000304" name="ttoo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20220701_20220930" decimals="INF" format="ixt:numdotdecimal">3,000</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed dividend on Series A redeemable convertible preferred stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000305" name="us-gaap:TemporaryEquityAccretionOfDividends" contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20220701_20220930" decimals="-3" scale="3">330</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000306" name="us-gaap:DividendsPreferredStock" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220701_20220930" decimals="-3" scale="3">330</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000307" name="us-gaap:DividendsPreferredStock" contextRef="C_0001492674_20220701_20220930" decimals="-3" scale="3">330</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Misc adjustment to reflect rounding on reverse stock split</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000308" name="ttoo:MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220701_20220930" decimals="INF">50</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000309" name="us-gaap:NetIncomeLoss" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220701_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,375</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="us-gaap:NetIncomeLoss" contextRef="C_0001492674_20220701_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,375</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000311" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20220930" decimals="INF" format="ixt:numdotdecimal">3,000</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000312" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20220930" decimals="-3" scale="3">330</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000313" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220930" decimals="INF" format="ixt:numdotdecimal">7,050,849</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220930" decimals="-3" scale="3">7</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">492,444</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000316" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">524,120</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000317" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">31,669</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to condensed consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T2 BIOSYSTEMS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_STATEMENT_CASH_FL">CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000318" name="us-gaap:ProfitLoss" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">51,904</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000319" name="us-gaap:ProfitLoss" contextRef="C_0001492674_20210101_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,097</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000320" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001492674_20220101_20220930" decimals="-3" scale="3">792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000321" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001492674_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of bond premium</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="us-gaap:InvestmentIncomeAmortizationOfPremium" contextRef="C_0001492674_20210101_20210930" decimals="-3" scale="3">114</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of operating lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="C_0001492674_20220101_20220930" decimals="-3" scale="3">907</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="C_0001492674_20210101_20210930" decimals="-3" scale="3">982</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:ShareBasedCompensation" contextRef="C_0001492674_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">5,458</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="us-gaap:ShareBasedCompensation" contextRef="C_0001492674_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">5,617</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative instrument</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="C_0001492674_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,010</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative warrant liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000329" name="ttoo:ChangeInFairValueOfDerivativeWarrantLiability" contextRef="C_0001492674_20220101_20220930" decimals="-3" scale="3">179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Gain) loss on sales of marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000330" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000331" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" contextRef="C_0001492674_20210101_20210930" decimals="-3" scale="3">14</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Gain) loss on issuance of Series A redeemable convertible preferred stock and derivative warrant liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000332" name="ttoo:GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">65</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment of property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000333" name="us-gaap:ProductionRelatedImpairmentsOrCharges" contextRef="C_0001492674_20220101_20220930" decimals="-3" scale="3">30</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash interest expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000334" name="us-gaap:PaidInKindInterest" contextRef="C_0001492674_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,613</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000335" name="us-gaap:PaidInKindInterest" contextRef="C_0001492674_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000336" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000337" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001492674_20210101_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">877</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000338" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">356</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000339" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001492674_20210101_20210930" decimals="-3" scale="3">692</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000340" name="us-gaap:IncreaseDecreaseInInventories" contextRef="C_0001492674_20220101_20220930" decimals="-3" scale="3">815</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000341" name="us-gaap:IncreaseDecreaseInInventories" contextRef="C_0001492674_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,915</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000342" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" scale="3">791</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000343" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001492674_20210101_20210930" decimals="-3" scale="3">523</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000344" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_0001492674_20220101_20220930" decimals="-3" scale="3">61</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000345" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_0001492674_20210101_20210930" decimals="-3" scale="3">619</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000346" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" scale="3">375</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000347" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001492674_20210101_20210930" decimals="-3" scale="3">9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000348" name="ttoo:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" scale="3">868</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="ttoo:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="C_0001492674_20210101_20210930" decimals="-3" sign="-" scale="3">848</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000350" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">40,300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000351" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001492674_20210101_20210930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">29,032</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from maturities of marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000352" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" contextRef="C_0001492674_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">15,251</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sales of marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000353" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="C_0001492674_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">9,998</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases and manufacture of property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000354" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001492674_20220101_20220930" decimals="-3" scale="3">303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000355" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001492674_20210101_20210930" decimals="-3" scale="3">261</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000356" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001492674_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">9,695</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000357" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001492674_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">14,990</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of employee restricted stock tax withholdings</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000358" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001492674_20220101_20220930" decimals="-3" scale="3">243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of shares from employee stock purchase plan and stock option exercises</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000359" name="ttoo:ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises" contextRef="C_0001492674_20220101_20220930" decimals="-3" scale="3">139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000360" name="ttoo:ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises" contextRef="C_0001492674_20210101_20210930" decimals="-3" scale="3">328</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock in public offerings, net of offering costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000361" name="ttoo:ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts" contextRef="C_0001492674_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">28,110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000362" name="ttoo:ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts" contextRef="C_0001492674_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">19,968</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of Series A redeemable convertible preferred stock and derivative warrant liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000363" name="ttoo:ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability" contextRef="C_0001492674_20220101_20220930" decimals="-3" scale="3">300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000364" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001492674_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">28,306</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000365" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001492674_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">20,296</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net change in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000366" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,299</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000367" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001492674_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">6,254</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at beginning of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000368" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,796</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000369" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001492674_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,344</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at end of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000370" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">21,497</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000371" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001492674_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">23,598</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosures of cash flow information</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000372" name="us-gaap:InterestPaidNet" contextRef="C_0001492674_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,916</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000373" name="us-gaap:InterestPaidNet" contextRef="C_0001492674_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,815</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosures of noncash activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transfer of T2 owned instruments and components (from) to inventory</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000374" name="ttoo:TransferOfT2OwnedInstrumentsAndComponentsToFromInventory" contextRef="C_0001492674_20220101_20220930" decimals="-3" sign="-" scale="3">482</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000375" name="ttoo:TransferOfT2OwnedInstrumentsAndComponentsToFromInventory" contextRef="C_0001492674_20210101_20210930" decimals="-3" sign="-" scale="3">729</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed dividend on Series A redeemable convertible preferred stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000376" name="ttoo:DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock" contextRef="C_0001492674_20220101_20220930" decimals="-3" scale="3">330</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for new operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000377" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001492674_20220101_20220930" decimals="-3" scale="3">199</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment included in accounts payable and accrued expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000378" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001492674_20220101_20220930" decimals="-3" scale="3">72</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000379" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001492674_20210101_20210930" decimals="-3" scale="3">80</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of cash, cash equivalents and restricted cash at end of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000380" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">20,366</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000381" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001492674_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">22,047</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000382" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,131</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000383" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="C_0001492674_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,551</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000384" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">21,497</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000385" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001492674_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">23,598</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to condensed consolidated financial statements.<span style="font-size:1pt;">&#160;</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T2 BIOSYSTEMS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited) </p><ix:nonNumeric id="F_000386" name="us-gaap:NatureOfOperations" contextRef="C_0001492674_20220101_20220930" escape="true" continuedAt="F_000386_dcnt_fcd219a2-d577-462e-9301-e7a59240fa11">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T2 Biosystems, Inc. and its subsidiary (the &#8220;Company,&#8221; &#8220;we,&#8221; or &#8220;T2&#8221;) have operations based in Lexington, Massachusetts. T2 Biosystems, Inc. was incorporated on April 27, 2006 as a Delaware corporation. The Company is an&#160;<span style="font-style:italic;">in vitro</span>&#160;diagnostics company that has developed an innovative and proprietary technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company has developed a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. Our technology enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (&#8220;CFU/mL&#8221;). The Company&#8217;s initial development efforts target the detection of pathogens that cause sepsis, which is an area of significant unmet medical need in which existing therapies could be more effective with improved diagnostics. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Going Concern </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September&#160;30, 2022, the Company had cash, cash equivalents, and restricted cash of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000435" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001492674_20220930" decimals="-5" scale="6">21.5</ix:nonFraction> million, an accumulated deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000436" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001492674_20220930" decimals="-5" sign="-" format="ixt:numdotdecimal" scale="6">524.1</ix:nonFraction> million and stockholders&#8217; deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000437" name="us-gaap:StockholdersEquity" contextRef="C_0001492674_20220930" decimals="-5" sign="-" format="ixt:numdotdecimal" scale="6">31.7</ix:nonFraction> million. The Company has historically experienced cash outflows from operating activities. The future success of the Company is dependent on its ability to successfully commercialize its products, obtain regulatory clearance for and successfully launch its future product candidates, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through proceeds from its August 2014 initial public offering, its December 2015 public offering, its September 2016 private investment in public equity (&#8220;PIPE&#8221;) financing, its September 2017 public offering, its June 2018 public offering, its July 2019 establishment of an Equity Distribution Agreement and Equity Purchase Agreement (Note 8), its March 2021 establishment of an Equity Distribution Agreement (Note 8), private placements of redeemable convertible preferred stock as well as borrowings from debt financing arrangements.&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks similar to other early commercial stage life science companies, including, but not limited to commercially launching the Company&#8217;s products, development and market acceptance of the Company&#8217;s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has impacted and may continue to impact the Company&#8217;s operations. Although the Company did not see any material impact to accounts receivable during the three and nine month period ended September 30, 2022, the Company&#8217;s exposure may increase if its customers continue to be adversely affected by the COVID-19 pandemic, including as a result of the spread of variants of the virus. Customers may reduce their purchases of products, depending on their needs and cash flow, which could negatively impact revenue. The Company has a significant development contract with the Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;) and should BARDA reduce, cancel or not grant additional milestone projects, the Company&#8217;s ability to continue its future product development may be impacted. The ability of the Company&#8217;s shipping carriers to deliver products to customers may be disrupted. The Company has reviewed its suppliers and quantities of key materials and believes that it has sufficient stocks and alternate sources of critical materials including personal protective equipment should the supply chains continue to be disrupted, although raw materials and plastics for the manufacturing of reagents and consumables are in high demand, and interruptions in supply are difficult to predict. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since authorization from the United States Food and Drug Administration, or FDA, was obtained to market the T2Dx Instrument, T2Candida Panel, and T2Bacteria Panel, and Emergency Use Authorization, or EUA, was issued for the T2SARS-CoV-2 Panel, the Company has incurred significant commercialization expenses related to product sales, marketing, manufacturing and distribution. If the FDA rescinds EUA, the Company would be unable to sell its T2SARS-CoV-2 tests. The Company may seek to fund its operations through public equity, private equity or debt financings, as well as other sources. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed, on favorable terms, or at all. The Company&#8217;s failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on the Company&#8217;s business, results of operations, financial condition and the Company&#8217;s ability to develop and commercialize T2Dx, T2Candida, T2Bacteria, T2SARS-CoV-2, and other product candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Accounting Standards Codification (&#8220;ASC&#8221;) 205-40,&#160;<span style="font-style:italic;">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</span>, management must evaluate whether there are conditions or events, considered in the </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000386_dcnt_fcd219a2-d577-462e-9301-e7a59240fa11" continuedAt="F_000386_dcnt_205254b0-8b50-49a0-a993-fd131f5bae31">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its cash, cash equivalents, and restricted cash of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000438" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001492674_20220930" decimals="-5" scale="6">21.5</ix:nonFraction> million at September 30, 2022 will not be sufficient to fund its current operating plan for at least one year from issuance of these financial statements, as certain elements of our operating plan cannot be considered probable. Absent any reductions in current operating expenses, the Company believes it will require additional financing during the first quarter of 2023. Under ASC 205-40, the future receipt of potential funding from co-development partners and other resources cannot be considered probable at this time because none of the plans are entirely within the Company&#8217;s control.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Term Loan Agreement with CRG Servicing LLC (&#8220;CRG&#8221;) (Note 6) has a minimum liquidity covenant which requires the Company to maintain a minimum cash balance of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000439" name="us-gaap:RestrictedCash" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220930" decimals="-5" scale="6">5.0</ix:nonFraction> million. There can be no assurances that the Company will continue to be in compliance with the cash covenant in future periods without additional funding. In February 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to <ix:nonNumeric id="F_000440" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220201_20220228" format="ixt:datemonthdayyearen">December 30, 2023</ix:nonNumeric>. In November 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to <ix:nonNumeric id="F_000441" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221113_20221114" format="ixt:datemonthdayyearen">December 30, 2024</ix:nonNumeric>.  </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s stock had been trading under $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000442" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_20220930" decimals="INF">1.00</ix:nonFraction> since September 27, 2021. <span style="color:#000000;">On November 5, 2021, the Company received a letter from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) indicating that the Company was not in compliance with the requirement of Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market as a result of the closing bid price of the Company&#8217;s common stock being below </span>$<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000443" name="ttoo:MinimumBidPriceOfCommonStock" contextRef="C_0001492674_20211105" decimals="INF">1.00</ix:nonFraction> <span style="color:#000000;">per share for thirty consecutive business days (the &#8220;Bid Price Rule&#8221;). Under the Nasdaq rules, the Company had 180 days (or until May 4, 2022) to regain compliance by maintaining a minimum closing bid price of $</span><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000444" name="ttoo:RegainComplianceByIncreasingStockPrice" contextRef="C_0001492674_srtRangeAxis_srtMinimumMember_20220930" decimals="INF">1.00</ix:nonFraction> per share of the Company&#8217;s common stock for at least ten consecutive trading days during such compliance period. On May 5, 2022, the Company received a letter from Nasdaq informing the Company that its shares of common stock have failed to comply with the Bid Price Rule for continued listing and, as a result, the Company&#8217;s shares were subject to delisting. The letter further stated that the Company may appeal the Nasdaq Staff delisting determination to a Nasdaq listing qualifications hearings panel (the &#8220;Panel&#8221;).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company filed an appeal and hearing request to the Nasdaq Staff&#8217;s determination to stay the delisting of the Company&#8217;s shares of common stock from Nasdaq pending the Panel&#8217;s decision. The Nasdaq Staff informed the Company that the delisting action had been stayed, pending a final written decision by the Panel, and the hearing date had been set for June 2, 2022. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 9, 2022, the Company received a letter from the Nasdaq notifying the Company that the Nasdaq had granted the Company&#8217;s request to be transferred to The Nasdaq Capital Market, effective at the open of trading on June 13, 2022, and the Company&#8217;s request for an exception to the Bid Price Rule until November 1, 2022. </p><ix:nonNumeric id="F_000446" name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011_20221011"><p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 11, 2022, at the Company&#8217;s annual meeting of stockholders, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s restated certificate of incorporation to effect a reverse stock split of the Company&#8217;s common stock. Following the receipt of the stockholders&#8217; approval, the Company&#8217;s board of directors approved the reverse stock split at the ratio of 1 post-split share for every <span style="-sec-ix-hidden:F_000445">50 pre-split shares</span>, which was effective as of October 12, 2022. On October 31, 2022, the Company received a letter from Nasdaq informing the Company that it has regained compliance with the Bid Price Rule. </p></ix:nonNumeric>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;22, 2022, the Company received a letter from the Nasdaq (the &#8220;Nasdaq Staff Deficiency Letter&#8221;) indicating that, for the last thirty-five consecutive business days, the Market Value of Listed Securities, as defined by Nasdaq (&#8220;MVLS&#8221;) had been below the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000447" name="ttoo:MinimumMarketValueOfListedSecurities" contextRef="C_0001492674_20220722" decimals="INF" scale="6">35</ix:nonFraction>&#160;million minimum requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2).&#160;&#160;In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided an initial period of 180 calendar days, or until January&#160;18, 2023, to regain compliance. The letter states that the Nasdaq staff will provide written notification that the Company has achieved compliance with Rule&#160;5550(b)(2) if at any time before January&#160;18, 2023, the Company maintains its MVLS at $35&#160;million or more for a minimum of ten consecutive business days. The Nasdaq Staff Deficiency Letter has no immediate effect on the listing or trading of the Company&#8217;s common stock.&#160;&#160;If compliance is not achieved by January&#160;18, 2023, the Company expects that Nasdaq would provide written notification to the Company that its securities are subject to delisting. The Company will continue to monitor its MVLS and consider its available options to regain compliance with the Nasdaq minimum MVLS requirements, which may include applying for an extension of the compliance period or appealing to a Nasdaq Hearings Panel. On August 24, 2022, i<span style="color:#000000;">n a Compliance </span></p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000386_dcnt_205254b0-8b50-49a0-a993-fd131f5bae31">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">Notice, the Nasdaq notified the Company that, from August 10, 2022 to August 23, 2022, the Company&#8217;s MVLS had been $</span><span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000448" name="ttoo:MinimumMarketValueOfListedSecurities" contextRef="C_0001492674_20220824" decimals="INF" scale="6">35</ix:nonFraction></span><span style="color:#000000;"> million or greater and, accordingly, the Company had regained compliance with Rule </span><span style="Background-color:#FFFFFF;">5550(b)(2) </span><span style="color:#000000;">and that the matter was now closed.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These conditions raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern for a period of one year after the date that the financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include raising additional funding, earning payments pursuant to the Company&#8217;s contract with BARDA, delaying certain research projects and capital expenditures and eliminating certain future operating expenses in order to fund operations at reduced levels for the Company to continue as a going concern for a period of 12 months from the date these unaudited condensed consolidated financial statements are issued. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these financial statements.<span style="color:#000000;"> The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.</span></p></ix:continuation><ix:nonNumeric id="F_000387" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true" continuedAt="F_000387_dcnt_e0eebc13-fdda-47a2-b4a4-8939dac4e23f">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p><ix:nonNumeric id="F_000401" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as defined in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The Company&#8217;s condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, T2 Biosystems Securities Corporation. All intercompany balances and transactions have been eliminated. &#160; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000450" name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221012_20221012">On October 12, 2022, we effected a reverse stock split at the ratio of 1 post-split share for every <span style="-sec-ix-hidden:F_000449_2">50 pre-split shares</span>. All common stock amounts and references have been retroactively adjusted for all figures presented to reflect this split unless specifically stated otherwise</ix:nonNumeric>.</p></ix:nonNumeric><ix:nonNumeric id="F_000402" name="ttoo:UnauditedInterimFinancialInformationPolicyTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited Interim Financial Information </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted.&#160;Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying interim condensed consolidated balance sheet as of September&#160;30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2022 and 2021, the condensed consolidated statements of Series A convertible preferred stock and stockholders&#8217; deficit for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2022 and 2021 and the related financial data and other information disclosed in these notes are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual financial statements, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position as of September&#160;30, 2022, and the results of its operations for the three and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021. The results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022, any other interim periods, or any future year or period. </p></ix:nonNumeric><ix:nonNumeric id="F_000403" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Segment Information </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#8217;s chief operating decision maker is the Chief Executive Officer. The Company views its operations and manages its business in <ix:nonFraction unitRef="U_ttooSegment" id="F_000451" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001492674_20220101_20220930" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> operating segment, which is the business of developing and, upon regulatory clearance, commercializing its diagnostic products aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. </p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000387_dcnt_e0eebc13-fdda-47a2-b4a4-8939dac4e23f" continuedAt="F_000387_dcnt_0fb08a92-d119-4e64-acfb-7430d3bdf714"><ix:nonNumeric id="F_000418" name="ttoo:GeographicInformationPolicyTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true" continuedAt="F_000418_cnt_1">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Geographic Information </p></ix:nonNumeric><ix:continuation id="F_000418_cnt_1">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sells its products domestically and internationally. Total international sales were approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000452" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20220701_20220930" decimals="-5" scale="6">1.2</ix:nonFraction> million or <ix:nonFraction unitRef="U_xbrlipure" id="F_000456" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20220701_20220930" decimals="2" scale="-2">32</ix:nonFraction>% of total revenue and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000453" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20210701_20210930" decimals="-5" scale="6">0.6</ix:nonFraction> million or <ix:nonFraction unitRef="U_xbrlipure" id="F_000457" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20210701_20210930" decimals="2" scale="-2">9</ix:nonFraction>% of total revenue for the three months ended September 30, 2022 and 2021, respectively. Total international sales were approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000454" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20220101_20220930" decimals="-5" scale="6">3.2</ix:nonFraction> million or <ix:nonFraction unitRef="U_xbrlipure" id="F_000458" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20220101_20220930" decimals="2" scale="-2">19</ix:nonFraction>% of total revenue and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000455" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20210101_20210930" decimals="-5" scale="6">1.6</ix:nonFraction> million or <ix:nonFraction unitRef="U_xbrlipure" id="F_000459" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20210101_20210930" decimals="2" scale="-2">8</ix:nonFraction>% of total revenue for the nine months ended September 30, 2022 and 2021, respectively.  </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended September 30, 2022, one international customer represented <ix:nonFraction unitRef="U_xbrlipure" id="F_000460" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20220701_20220930" decimals="2" scale="-2">12</ix:nonFraction>% of total revenue. For the three months ended September 30, 2021, no international customer represented greater than <ix:nonFraction unitRef="U_xbrlipure" id="F_000462" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20210701_20210930" decimals="2" scale="-2">10</ix:nonFraction>% of total revenue. For the nine months ended September 30, 2022 and 2021, no international customer represented greater than <ix:nonFraction unitRef="U_xbrlipure" id="F_000461" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20220101_20220930" decimals="2" scale="-2"><ix:nonFraction unitRef="U_xbrlipure" id="F_000463" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20210101_20210930" decimals="2" scale="-2">10</ix:nonFraction></ix:nonFraction>% of total revenue.</p><ix:nonNumeric id="F_000419" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The following table shows customers that represent greater than 10% of revenue for the period presented: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer A</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000464" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001492674_srtMajorCustomersAxis_ttooCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20220701_20220930" decimals="2" scale="-2">28</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000465" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001492674_srtMajorCustomersAxis_ttooCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210701_20210930" decimals="2" scale="-2">42</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000466" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001492674_srtMajorCustomersAxis_ttooCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20220101_20220930" decimals="2" scale="-2">46</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000467" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001492674_srtMajorCustomersAxis_ttooCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20210930" decimals="2" scale="-2">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer B</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000468" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001492674_srtMajorCustomersAxis_ttooCustomerBMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210701_20210930" decimals="2" scale="-2">14</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000469" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001492674_srtMajorCustomersAxis_ttooCustomerBMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20210930" decimals="2" scale="-2">15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer C</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000470" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001492674_srtMajorCustomersAxis_ttooCustomerCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20220701_20220930" decimals="2" scale="-2">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2022 and December 31, 2021, the Company had outstanding receivables of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20220930" decimals="-5" scale="6">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20211231" decimals="-5" scale="6">0.6</ix:nonFraction> million, respectively, from customers located outside of the U.S.</p></ix:continuation><ix:nonNumeric id="F_000405" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies the two-class method for computing earnings per share because its Series A redeemable convertible preferred stock and the warrants issued with that preferred stock are participating securities. Under the two-class method, net income for the period is allocated between common stockholders and the participating securities according to dividends declared, if any, and participation rights in undistributed earnings. Because the Company incurred a net loss for the three and nine months ended September 30, 2022, and the holders of the participating securities do not have the contractual obligation to share in the losses of the Company on a basis that is objectively determinable, none of the net loss attributable to common stockholders was allocated to the participating securities when computing earnings per share.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing net loss attributable to commons stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Any accretion of the carrying amount of the Company&#8217;s Series A redeemable convertible preferred stock to its redemption amount is treated as a deemed dividend to the preferred stockholders and will increase the amount of the net loss attributable to common stockholders. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using either the if-converted method (for its Series A redeemable, convertible preferred stock) or the treasury-stock method. For purposes of the diluted net loss per share calculation, stock options and unvested restricted stock, restricted stock contingently issuable upon achievement of certain market conditions, and the warrants issued with Series A redeemable convertible preferred stock are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. In periods in which the Company recognizes gains due to changes in the fair value of its warrant liability, the Company will further assess whether the effect of adjusting its computation of diluted net loss per share to include the potential common shares and reverse the gain associated with the warrant would result in a more diluted net loss per share, and modify the computation if necessary. The Series A redeemable convertible preferred stock was not considered a common stock equivalent because exercise of the conversion option was contingent upon occurrence of the reverse stock split, which had not yet occurred as of September 30, 2022. Therefore, basic and diluted net loss per share applicable to common stockholders was the same for all periods presented.  </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000387_dcnt_0fb08a92-d119-4e64-acfb-7430d3bdf714" continuedAt="F_000387_dcnt_c0451b55-f22e-49ae-aac5-f85a4538d8aa"><ix:nonNumeric id="F_000406" name="us-gaap:MarketableSecuritiesPolicy" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s marketable securities consist of U.S. treasury securities, which are classified as available-for-sale and included in current assets. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported as a component of stockholders&#8217; deficit in accumulated other comprehensive (loss) income. Realized gains and losses, if any, are included in other income (expense) in the condensed consolidated statements of operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security&#8217;s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported as a component of stockholders&#8217; deficit in accumulated other comprehensive loss (income). </p><ix:nonNumeric id="F_000420" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001492674_20220930" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> marketable securities at September 30, 2022. The following table summarizes the Company&#8217;s marketable securities at December 31, 2021 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#160; </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000474" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001492674_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001492674_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20211231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001492674_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,996</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001492674_20211231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,996</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric><ix:nonNumeric id="F_000421" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the maturities of the Company&#8217;s marketable securities at December 31, 2021 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:50%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due in less than 1 year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000480" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000482" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,996</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due in 1-2 years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000483" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,996</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000407" name="us-gaap:DerivativesPolicyTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Derivative&#160;Warrant Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with&#160;ASC Topic 815,&#160;<span style="font-style:italic;">&#8220;Derivatives and Hedging</span>.&#8221;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the liability for the warrant issued in conjunction with the Series A redeemable convertible preferred stock is a&#160;derivative&#160;instrument.&#160; The derivative warrant liability is classified on the condensed consolidated balance sheets as current because cash settlement of the warrant could be required by the holder within 12 months of the balance sheet date. The Company has identified a single compound derivative liability related to its Term Loan Agreement with CRG, that is classified as non-current on the condensed consolidated balance sheets to match the classification of the related Term Loan Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the derivative liabilities meet the definition of a&#160;derivative, they are measured at fair value at issuance and at each reporting date in accordance with&#160;ASC 820, &#8220;<span style="font-style:italic;">Fair Value Measurement,&#8221;</span>&#160;with changes in fair value recognized in change in fair value of derivative warrant liability in the period of change in the condensed consolidated statements of operations and comprehensive loss. The Company does not designate its&#160;derivative&#160;instruments as hedging instruments.</p></ix:nonNumeric><ix:nonNumeric id="F_000408" name="us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies" contextRef="C_0001492674_20220101_20220930" escape="true" continuedAt="F_000408_dcnt_a8c3774c-fd58-4368-a1f2-eaf70145ebfc">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Guarantees </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while each such officer or director is, or was, serving at the Company&#8217;s request in such capacity. The term of the indemnification is the officer&#8217;s or director&#8217;s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited&#59; however, the Company has directors&#8217; and officers&#8217; liability insurance coverage that limits its exposure and enables the Company to recover a portion of any future amounts paid. </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000387_dcnt_c0451b55-f22e-49ae-aac5-f85a4538d8aa" continuedAt="F_000387_dcnt_2a8dab05-1a33-4a6e-b2be-7131119f9af6"><ix:continuation id="F_000408_dcnt_a8c3774c-fd58-4368-a1f2-eaf70145ebfc">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office, laboratory and manufacturing space under noncancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify the landlords against all costs, expenses, fines, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company&#8217;s leases. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company&#8217;s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements.  </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2022 and December&#160;31, 2021, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established. </p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000409" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true" continuedAt="F_000409_cnt_1">Leases</ix:nonNumeric> </p><ix:continuation id="F_000409_cnt_1">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Topic 842, <span style="font-style:italic;">Leases</span> (&#8220;ASC 842&#8221;), at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. The exercise of lease renewal options is at our discretion and the renewal to extend the lease terms are not included in the Company&#8217;s right-of-use assets and lease liabilities as they are not reasonably certain of exercise. The Company will evaluate the renewal options and when they are reasonably certain of exercise, the Company will include the renewal period in its lease term. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued lease payments. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. </p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the guidance in ASC 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). Then the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company made the policy election to not separate lease and non-lease components. Each lease component and the related non-lease components are accounted for together as a single component. </p></ix:continuation><ix:nonNumeric id="F_000411" name="us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Classification of Series A Redeemable Convertible Preferred Stock </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has applied the guidance in ASC 480-10-S99-3A, SEC Staff Announcement: Classification and Measurement of Redeemable Securities and classified the Series A redeemable convertible preferred stock as temporary equity in the mezzanine section of the balance sheet. The Series A redeemable convertible preferred stock was recorded outside of stockholders&#8217; deficit because under the terms thereof, in the event of stockholder approval of the reverse stock split or a delisting event, which are events considered not solely within the Company&#8217;s control, the Series A redeemable convertible preferred stock becomes redeemable at the option of the holders.</p></ix:nonNumeric><ix:nonNumeric id="F_000413" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true" continuedAt="F_000413_dcnt_6cb020c0-eaaa-4830-afe7-a011a0613dc8">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generates revenue from the sale of instruments, consumable diagnostic tests, related services, reagent rental agreements and government contributions. Pursuant to ASC 606, <span style="font-style:italic;">Revenue from Contracts with Customers</span> (&#8220;ASC 606&#8221;), the Company determines revenue recognition through the following steps:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.5%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Identification of a contract with a customer</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.5%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Identification of the performance obligations in the contract</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.5%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Determination of the transaction price</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.5%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Allocation of the transaction price to the performance obligations</span></p></td></tr></table></div></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000387_dcnt_2a8dab05-1a33-4a6e-b2be-7131119f9af6" continuedAt="F_000387_dcnt_1a2c6beb-5537-4bd0-8fcc-47eacd23edc1"><ix:continuation id="F_000413_dcnt_6cb020c0-eaaa-4830-afe7-a011a0613dc8" continuedAt="F_000413_dcnt_09f1fef7-cac2-4b41-b9eb-bd921854fea9">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.5%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Recognition of revenue as a performance obligation is satisfied</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of revenue recognized reflects the consideration the Company expects to be entitled to receive in exchange for these goods and services. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company's performance obligations are transferred to customers at a point in time, typically upon shipment, or over time, as services are performed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most of the Company&#8217;s contracts with distributors in geographic regions outside the United States contain only a single performance obligation, whereas most of the Company&#8217;s contracts with direct sales customers in the United States contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. Excluded from the transaction price are sales tax and other similar taxes which are presented on a net basis.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue is generated by the sale of instruments and consumable diagnostic tests predominantly through the Company&#8217;s direct sales force in the United States and distributors in geographic regions outside the United States. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors&#8217; receipt of payment from their end-user customers. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company either sells instruments to customers and international distributors, or retains title and places the instrument at the customer site pursuant to a reagent rental agreement.&#160;When an instrument is purchased by a customer or international distributor, the Company recognizes revenue when the related performance obligation is satisfied (i.e. when the control of an instrument has passed to the customer&#59; typically, at shipping point). </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When the instrument is placed under a reagent rental agreement, the Company&#8217;s customers generally agree to fixed term agreements, which can be extended, and incremental charges on each consumable diagnostic test purchased. Revenue from the sale of consumable diagnostic tests (under a reagent rental agreement) is generally recognized upon shipment. The transaction price from consumables purchases is allocated between the lease of the instrument (under a contingent rent methodology as provided for in ASC 842, <span style="font-style:italic;">Leases</span>), and the consumables when related performance obligations are satisfied, as a component of lease and product revenue, and is included as Instrument Rentals in the below table. Revenue associated with reagent rental consumables purchases is currently classified as variable consideration and constrained until a purchase order is received and related performance obligations have been satisfied.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from the sale of consumable diagnostic tests (under instrument purchase agreements) is generally recognized upon shipment. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shipping and handling costs billed to customers in connection with a product sale are recorded as a component of the transaction price and allocated to product revenue in the condensed consolidated statements of operations and comprehensive loss as they are incurred by the Company in fulfilling its performance obligations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct sales of instruments include warranty, maintenance and technical support services typically for <ix:nonNumeric id="F_000484" name="ttoo:MaintenanceServicePeriod" contextRef="C_0001492674_srtProductOrServiceAxis_ttooT2DxMember_20220101_20220930" format="ixt-sec:durwordsen">one year</ix:nonNumeric> following the installation of the purchased instrument (&#8220;Maintenance Services&#8221;). <span style="color:#000000;">Maintenance Services are separate performance obligations as they are service-based warranties and are recognized on a straight-line basis over the service delivery period. After the completion of the initial Maintenance Services period, customers have the option to renew or extend the Maintenance Services typically for additional</span> <span style="-sec-ix-hidden:F_000485">one-year</span> periods in exchange for additional consideration. The extended Maintenance Services are also service-based warranties that represent separate purchasing decisions. The Company recognizes revenue allocated to the extended Maintenance Services performance obligation on a straight-line basis over the service delivery period.&#160;&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fees paid to member-owned group purchasing organizations (&#8220;GPOs&#8221;) are deducted from related product revenues.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company warrants that consumable diagnostic tests will be free from defects, when handled according to product specifications, for the stated life of the product. To fulfill valid warranty claims, the Company provides replacement product free of charge. Warranty expense is recognized based on the estimated defect rates of the consumable diagnostic tests.</p></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000387_dcnt_1a2c6beb-5537-4bd0-8fcc-47eacd23edc1" continuedAt="F_000387_dcnt_f4a1d462-7a0e-4757-8431-76f8f58a0ed3"><ix:continuation id="F_000413_dcnt_09f1fef7-cac2-4b41-b9eb-bd921854fea9" continuedAt="F_000413_dcnt_be88d1a6-ce80-4979-bfbf-940f02682d6a">

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Contribution Revenue</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income under the government BARDA contract is earned under a cost-sharing arrangement in which the Company is reimbursed for direct costs incurred plus allowable indirect costs. The g<span style="Background-color:#FFFFFF;color:#000000;">overnment contract revenue is recognized as the related reimbursable expenses are incurred.&#160;&#160;The cost reimbursement that is reported as revenue is presented gross of the related reimbursable expenses in the Company&#8217;s consolidated statements of operations&#59; the related reimbursable expenses are expensed as incurred as research and development expense. The Company accounts for these contracts as a government grant which analogizes with International Accounting Standards 20 (&#8220;IAS 20&#8221;),&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="Background-color:#FFFFFF;color:#000000;">.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a significant development contract with BARDA and should BARDA reduce, cancel or not grant additional milestone projects, the Company&#8217;s ability to continue future product development may be impacted. Refer to Note 12 for further details regarding the development contract with BARDA. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:9pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Disaggregation of Revenue</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company disaggregates revenue from contracts with customers by type of products and services, as it best depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. <ix:nonNumeric id="F_000422" name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true" continuedAt="F_000422_cnt_1">The following table disaggregates our revenue by major source (in thousands):</ix:nonNumeric></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p><ix:continuation id="F_000422_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Instruments</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_ttooProductInstrumentsMember_20220701_20220930" decimals="-3" scale="3">814</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000487" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_ttooProductInstrumentsMember_20210701_20210930" decimals="-3" scale="3">522</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000488" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_ttooProductInstrumentsMember_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,528</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_ttooProductInstrumentsMember_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,427</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consumables</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_ttooProductConsumablesMember_20220701_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,822</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_ttooProductConsumablesMember_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">3,765</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_ttooProductConsumablesMember_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">6,442</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_ttooProductConsumablesMember_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">11,150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Instrument rentals</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_ttooInstrumentRentalsMember_20220701_20220930" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_ttooInstrumentRentalsMember_20210701_20210930" decimals="-3" scale="3">19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_ttooInstrumentRentalsMember_20220101_20220930" decimals="-3" scale="3">74</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_ttooInstrumentRentalsMember_20210101_20210930" decimals="-3" scale="3">57</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total product revenue</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20220701_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,641</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,306</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">9,044</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000501" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">12,634</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contribution revenue</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000502" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_ttooContributionRevenueMember_20220701_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,036</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_ttooContributionRevenueMember_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">3,122</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_ttooContributionRevenueMember_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">7,778</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtProductOrServiceAxis_ttooContributionRevenueMember_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">8,444</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_20220701_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">3,677</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">7,428</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000508" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">16,822</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000509" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">21,078</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Remaining Performance Obligations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, the Company is required to disclose the aggregate amount of the transaction price that is allocated to unsatisfied or partially satisfied performance obligations as of September 30, 2022. However, the guidance provides certain practical expedients that limit this requirement, and therefore, the Company has elected to not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. The nature of the excluded unsatisfied performance obligations pursuant to the practical expedient include consumable shipments, service contracts, warranties and installation services that will be performed within <ix:nonNumeric id="F_000510" name="ttoo:OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed" contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_20220101_20220930" format="ixt-sec:durwordsen">one year</ix:nonNumeric>. The amount of the transaction price that is allocated to unsatisfied or partially satisfied performance obligations, that has not yet been recognized as revenue and that does not meet the elected practical expedient is $<ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="C_0001492674_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-10-01_20220930" decimals="-5" scale="6">0.1</ix:nonFraction> million as of September 30, 2022. <ix:nonNumeric id="F_000511" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" contextRef="C_0001492674_20220101_20220930">The Company expects to recognize <ix:nonFraction unitRef="U_xbrlipure" id="F_000514" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" contextRef="C_0001492674_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-10-01_20220930" decimals="2" scale="-2">86</ix:nonFraction>% of this amount as revenue within <ix:nonNumeric id="F_000515" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" contextRef="C_0001492674_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-10-01_20220930" format="ixt-sec:durwordsen">one year</ix:nonNumeric> and the remainder within <ix:nonNumeric id="F_000512" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_20220930" format="ixt-sec:durwordsen">fifteen months</ix:nonNumeric>.</ix:nonNumeric>  </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Judgments</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain contracts with customers include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require judgment. Once the performance obligations are determined, the Company determines the transaction price, which includes estimating the amount of variable consideration, based on the most likely amount, to be included in the transaction price, if any. The Company then allocates the transaction price to each performance obligation in the contract based on a relative standalone selling price method. The corresponding revenue is recognized as the related performance obligations are satisfied as discussed in the revenue categories above.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.83%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Judgment is required to determine the standalone selling price for each distinct performance obligation. The Company determines standalone selling price based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as a range of selling prices, market conditions and the expected costs and margin related to the performance obligations.</p></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000387_dcnt_f4a1d462-7a0e-4757-8431-76f8f58a0ed3" continuedAt="F_000387_dcnt_ccba5af8-9413-4501-9e06-abe57e0e234c"><ix:continuation id="F_000413_dcnt_be88d1a6-ce80-4979-bfbf-940f02682d6a">

<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Contract Assets and Liabilities</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000516" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001492674_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentAssetsMember_20220930" decimals="-5" scale="6">0.1</ix:nonFraction> million of contract assets within other assets on the balance sheet at September 30, 2022. The contract assets represent revenue recognized for performance obligations in advance of cash receipt at the contract level based on the transaction price allocated to the respective performance obligations. The Company did <ix:nonFraction unitRef="U_iso4217USD" id="F_000517" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001492674_20211231" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction>t record any contract assets at December 31, 2021.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s contract liabilities consist of upfront payments for research and development contracts and maintenance services on instrument sales. Contract liabilities are classified in deferred revenue as current or noncurrent based on the timing of when revenue is expected to be recognized.&#160;<span style="color:#000000;">Contract liabilities were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000518" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001492674_20220930" decimals="-5" scale="6">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000519" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001492674_20211231" decimals="-5" scale="6">0.5</ix:nonFraction> million at September 30, 2022 and December 31, 2021, respectively. Revenue recognized during the nine months ended September 30, 2022 relating to contract liabilities at December 31, 2021 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000520" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001492674_20220101_20220930" decimals="-5" scale="6">0.4</ix:nonFraction> million and related to straight-line revenue recognition associated with maintenance agreements.</span> </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Cost to Obtain and Fulfill a Contract</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes commission expenses paid to sales personnel that are recoverable and incremental to obtaining capital purchase agreements within the United States. These costs are classified as prepaid expenses and other current assets and other assets, based on their current or non-current nature, respectively. The Company capitalizes only those costs that are determined to be incremental and would not have occurred absent the customer contract. These capitalized costs are amortized as selling, general and administrative costs on a straight line basis over the expected period of benefit. These costs are reviewed periodically for impairment. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="color:#000000;font-size:10pt;">At September 30, 2022, capitalized costs to fulfill contracts of less than $<ix:nonFraction unitRef="U_iso4217USD" id="F_000523" name="us-gaap:CapitalizedContractCostGross" contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20220930" decimals="INF" scale="6">0.1</ix:nonFraction> million was included in prepaid and other current assets. At December 31, 2021, capitalized costs to fulfill contracts of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000521" name="us-gaap:CapitalizedContractCostGross" contextRef="C_0001492674_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20211231" decimals="-5" scale="6">0.1</ix:nonFraction> million was included in prepaid and other current assets and less than $<ix:nonFraction unitRef="U_iso4217USD" id="F_000522" name="us-gaap:CapitalizedContractCostGross" contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentAssetsMember_20211231" decimals="INF" scale="6">0.1</ix:nonFraction> million was included in other non-current assets</span>. </p></ix:continuation><ix:nonNumeric id="F_000414" name="ttoo:CostOfProductRevenuePolicyTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost of Product Revenue </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product revenue includes the cost of materials, direct labor and manufacturing overhead costs used in the manufacture of consumable diagnostic tests sold to customers, related warranty and license and royalty fees. Cost of product revenue also includes depreciation on T2-owned revenue generating T2Dx instruments that have been placed with customers under reagent rental agreements&#59; costs of materials, direct labor and manufacturing overhead costs on the T2Dx instruments sold to customers&#59; and other costs such as customer support costs, royalties and license fees, warranty and repair and maintenance expense on the T2Dx instruments that have been placed with customers under reagent rental agreements.<span style="color:#000000;"> </span></p></ix:nonNumeric><ix:nonNumeric id="F_000415" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Costs </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs incurred in the research and development of the Company&#8217;s product candidates are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including activities associated with delivering products or services associated with contribution revenue, clinical trials to evaluate the clinical utility of our product candidates, and costs associated with the enhancements of developed products. These costs include salaries and benefits, stock compensation, research related facility and overhead costs, laboratory supplies, equipment, depreciation on T2Dx instruments used for research and development activities and contract services.</p></ix:nonNumeric><ix:nonNumeric id="F_000416" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses consist primarily of costs for our sales and marketing, finance, legal, human resources, business<span style="color:#000000;"> development and general management functions, as well as professional services, such as legal, consulting and accounting services. Other selling, general and administrative expenses include commercial support activity, facility-related costs, fees and expenses associated with obtaining and maintaining patents, clinical and economic studies and publications, marketing expenses, and travel expenses. We expense the majority of selling, general and administrative expenses as incurred.</span></p></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000387_dcnt_ccba5af8-9413-4501-9e06-abe57e0e234c">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000417" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Standards </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Accounting Standards Adopted </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the FASB issued ASU No. 2020-06, <span style="font-style:italic;">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40)&#8212;Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span> (&#8220;ASU 2020-06&#8221;), which simplifies accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. The standard is effective for smaller reporting companies for fiscal years beginning after December 15, 2023 and interim periods within those fiscal years. The Company adopted the standard as of <ix:nonNumeric id="F_000525" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202006Member_20220930" format="ixt:datemonthdayyearen">January 1, 2022</ix:nonNumeric>. The adoption did not have a material impact on the Company&#8217;s financial statements. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the FASB issued ASU No. 2021-04, <span style="font-style:italic;">Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#8220;ASU 2021-04&#8221;)</span> which clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after a modification or exchange. This standard is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply this standard prospectively to modifications or exchanges occurring on or after the effective date of this standard. The Company adopted this standard as of <ix:nonNumeric id="F_000528" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202104Member_20220930" format="ixt:datemonthdayyearen">January 1, 2022</ix:nonNumeric>. The adoption did not have a material impact on the Company&#8217;s financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In November 2021, the FASB issued ASU 2021-10,</span><span style="font-style:italic;Background-color:#FFFFFF;">&#160;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span><span style="Background-color:#FFFFFF;">. This ASU requires certain disclosures when companies (a) have received government assistance and (b) use a grant or contribution accounting model by analogy to other accounting guidance. A company that has received government assistance must provide disclosures related to the nature of the transaction, accounting policies used to account for the transaction, and the amounts and line items on the financial statements that are affected by the transaction. This ASU is effective for fiscal years beginning after December 15, 2021, with early adoption permitted, and can be applied either prospectively or retrospectively. The Company adopted this standard as of <ix:nonNumeric id="F_000531" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202110Member_20220930" format="ixt:datemonthdayyearen">January 1, 2022</ix:nonNumeric>. </span>The adoption did not have a material impact on the Company&#8217;s financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000388" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true" continuedAt="F_000388_dcnt_f18f8ae0-eca4-4596-b425-04d99f9b8e32">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Fair Value Measurements </p><ix:nonNumeric id="F_000423" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true" continuedAt="F_000423_dcnt_a7489a4b-dfb1-497e-a84c-65c46ff557d3">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures the following financial assets at fair value on a recurring basis. There were no transfers between levels of the fair value hierarchy during any of the periods presented. The following tables set forth the Company&#8217;s financial assets and liabilities carried at fair value categorized using the lowest level of input applicable to each financial instrument as of September&#160;30, 2022 and December&#160;31, 2021 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in Active</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets for</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identical Assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative warrant liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000533" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="C_0001492674_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220930" decimals="-3" scale="3">186</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000534" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="C_0001492674_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220930" decimals="-3" scale="3">186</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000535" name="us-gaap:DerivativeLiabilities" contextRef="C_0001492674_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000536" name="us-gaap:DerivativeLiabilities" contextRef="C_0001492674_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000537" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001492674_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,978</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000538" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001492674_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220930" decimals="-3" scale="3">186</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001492674_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000388_dcnt_f18f8ae0-eca4-4596-b425-04d99f9b8e32"><ix:continuation id="F_000423_dcnt_a7489a4b-dfb1-497e-a84c-65c46ff557d3">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in Active</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets for</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identical Assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US Treasury securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000540" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001492674_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,996</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000541" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001492674_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,996</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000542" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001492674_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,996</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000543" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001492674_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,996</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash equivalents and available-for-sale marketable securities were comprised of government securities. Securities are classified as cash equivalents when the original maturities are within 90 days of the purchase dates. The Company also maintains money market accounts classified as restricted cash for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000544" name="us-gaap:SecurityDeposit" contextRef="C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20220930" decimals="-5" scale="6">1.1</ix:nonFraction> million at September 30, 2022 and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000545" name="us-gaap:SecurityDeposit" contextRef="C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20211231" decimals="-5" scale="6">1.6</ix:nonFraction> million at December 31, 2021 (Note 4).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimated the fair value of the derivative warrant liability (Note 7) using the Black-Scholes Model, which uses multiple inputs including the Company&#8217;s stock price, the exercise price of the warrant, volatility of the Company&#8217;s stock price, the risk-free interest rate and the expected term of the warrant. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a single compound derivative related to its Term Loan Agreement with CRG (the &#8220;Term Loan Agreement&#8221;) (Note 6), which is required to be re-measured at fair value on a quarterly basis. The fair value of the derivative at September 30, 2022 is $<ix:nonFraction unitRef="U_iso4217USD" id="F_000546" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220930" decimals="-5" scale="6">1.8</ix:nonFraction> million and is classified as a non-current liability on the balance sheet at September 30, 2022 to match the classification of the related Term Loan Agreement (Note 6). As of December 31, 2021, the Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000547" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20211231" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction> derivative liability. </p><ix:nonNumeric id="F_000424" name="ttoo:SummaryOfContingentInterestPaymentsTableTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated fair value of the derivative at September 30, 2022 was determined using a probability-weighted discounted cash flow model that includes contingent interest payments under the following scenarios:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:50%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Probability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000549" name="ttoo:ContingentPaymentOfInterestPercentage" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220101_20220930" decimals="2" scale="-2">4</ix:nonFraction>% contingent interest beginning in Q1 2023</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000548" name="ttoo:FairValueDerivativeLiabilityDiscountRate" contextRef="C_0001492674_us-gaapContingentConsiderationByTypeAxis_ttooScenarioOneMember_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_20220101_20220930" decimals="2" scale="-2">50</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000425" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true" continuedAt="F_000425_cnt_1">The following table provides a roll-forward of the fair value of the derivative liability (in thousands):</ix:nonNumeric><span style="color:#000000;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000425_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000550" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="C_0001492674_us-gaapValuationTechniqueAxis_ttooProbabilityWeightedDiscountedCashFlowModelMember_20220101_20220630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,675</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at June 30, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000551" name="us-gaap:DerivativeLiabilities" contextRef="C_0001492674_20220630" decimals="-3" format="ixt:numdotdecimal" scale="3">1,675</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000552" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="C_0001492674_us-gaapValuationTechniqueAxis_ttooProbabilityWeightedDiscountedCashFlowModelMember_20220701_20220930" decimals="-3" scale="3">117</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000553" name="us-gaap:DerivativeLiabilities" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000389" name="us-gaap:RestrictedAssetsDisclosureTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. Restricted Cash </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to maintain security deposits for its operating lease agreements for the duration of the lease agreements. At September 30, 2022, the Company had money market accounts for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000555" name="us-gaap:SecurityDeposit" contextRef="C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20220930" decimals="-5" scale="6">1.1</ix:nonFraction> million, which represented collateral as security deposits for its operating lease agreements for <ix:nonFraction unitRef="U_ttooFacility" id="F_000557" name="ttoo:NumberOfFacilities" contextRef="C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20220101_20220930" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> facilities. At December 31, 2021, the Company had money market accounts for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000554" name="us-gaap:SecurityDeposit" contextRef="C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20211231" decimals="-5" scale="6">1.6</ix:nonFraction> million, which represented collateral as security deposits for its operating lease agreements for <ix:nonFraction unitRef="U_ttooFacility" id="F_000556" name="ttoo:NumberOfFacilities" contextRef="C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction> facilities. </p></ix:nonNumeric><ix:nonNumeric id="F_000390" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true" continuedAt="F_000390_dcnt_17041589-389c-40e2-bd35-0632e7ab65eb">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5. Supplemental Balance Sheet Information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inventories </p><ix:nonNumeric id="F_000426" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis and are comprised of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000558" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,195</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000559" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,591</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work-in-process</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000560" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,231</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000561" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="C_0001492674_20211231" decimals="-3" scale="3">953</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000562" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="C_0001492674_20220930" decimals="-3" scale="3">816</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000563" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,365</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventories, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000564" name="us-gaap:InventoryNet" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,242</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000565" name="us-gaap:InventoryNet" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,909</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000390_dcnt_17041589-389c-40e2-bd35-0632e7ab65eb" continuedAt="F_000390_dcnt_fd4d4346-749d-4b15-b679-ced39600512b">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment </p><ix:nonNumeric id="F_000427" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office and computer equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000566" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20220930" decimals="-3" scale="3">749</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000567" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20211231" decimals="-3" scale="3">749</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000568" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20220930" decimals="-3" scale="3">783</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000569" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20211231" decimals="-3" scale="3">783</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000570" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">5,573</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000571" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,507</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000572" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20220930" decimals="-3" scale="3">197</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000573" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231" decimals="-3" scale="3">197</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000574" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,445</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000575" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,445</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing tooling and molds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000576" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapToolsDiesAndMoldsMember_20220930" decimals="-3" scale="3">478</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000577" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapToolsDiesAndMoldsMember_20211231" decimals="-3" scale="3">478</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T2-owned instruments and components</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000578" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooT2DxInstrumentsAndComponentsMember_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">7,150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000579" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooT2DxInstrumentsAndComponentsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,668</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000580" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">3,785</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000581" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,768</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000582" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20220930" decimals="-3" scale="3">774</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000583" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231" decimals="-3" scale="3">512</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000584" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">20,934</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000585" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,107</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000586" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">16,200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000587" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,432</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000588" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,734</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000589" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,675</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress is primarily comprised of equipment that has not been placed in service. T2-owned instruments and components is comprised of raw materials and work-in-process inventory that are expected to be used or used to produce T2-owned instruments, based on the Company&#8217;s business model and forecast, and completed instruments that will be used for internal research and development, clinical studies or reagent rental agreements with customers.&#160;<span style="color:#000000;">At September&#160;30, 2022, there was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000590" name="us-gaap:InventoryWorkInProcessAndRawMaterials" contextRef="C_0001492674_20220930" decimals="-5" scale="6">1.0</ix:nonFraction> million of raw materials or work-in-process inventory in T2-owned instruments and components compared with $<ix:nonFraction unitRef="U_iso4217USD" id="F_000591" name="us-gaap:InventoryWorkInProcessAndRawMaterials" contextRef="C_0001492674_20211231" decimals="-5" scale="6">1.4</ix:nonFraction> million at December 31, 2021. Completed T2-owned instruments are placed in service once installation procedures are completed and are depreciated over <ix:nonNumeric id="F_000592" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooT2OwnedInstrumentsInServiceMember_20220101_20220930" format="ixt-sec:durwordsen">five years</ix:nonNumeric>.&#160;Depreciation expense for T2-owned instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of product revenue and was immaterial for the three months ended September 30, 2022 and 2021. Depreciation expense for T2-owned instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of product revenue and was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000594" name="us-gaap:CostOfGoodsAndServicesSoldDepreciation" contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooT2OwnedInstrumentsInServiceMember_20210101_20210930" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000593" name="us-gaap:CostOfGoodsAndServicesSoldDepreciation" contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooT2OwnedInstrumentsInServiceMember_20220101_20220930" decimals="-5" scale="6">0.1</ix:nonFraction></ix:nonFraction> million for the nine months ended September 30, 2022 and 2021. </span> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense for T2-owned instruments used for internal research and development and clinical studies is recorded as a component of research and development expense. <span style="color:#000000;">Depreciation and amortization expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000595" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001492674_20220701_20220930" decimals="-5" scale="6">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000596" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001492674_20210701_20210930" decimals="-5" scale="6">0.3</ix:nonFraction> million was charged to operations for the three months ended September 30, 2022 and 2021, respectively. Depreciation and amortization expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000597" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001492674_20220101_20220930" decimals="-5" scale="6">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000598" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001492674_20210101_20210930" decimals="-5" scale="6">1.0</ix:nonFraction> million was charged to operations for the nine months ended September 30, 2022 and 2021, respectively.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. <span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accrued Expenses </p><ix:nonNumeric id="F_000428" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000599" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">3,894</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000600" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,687</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000601" name="ttoo:AccruedResearchAndDevelopmentExpensesCurrent" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,482</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000602" name="ttoo:AccruedResearchAndDevelopmentExpensesCurrent" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,250</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional services</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000603" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001492674_20220930" decimals="-3" scale="3">392</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000604" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001492674_20211231" decimals="-3" scale="3">384</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000605" name="us-gaap:InterestPayableCurrent" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000606" name="us-gaap:InterestPayableCurrent" contextRef="C_0001492674_20211231" decimals="-3" scale="3">974</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000607" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,295</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000608" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,174</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000609" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001492674_20220930" decimals="-3" scale="3">468</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000610" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001492674_20211231" decimals="-3" scale="3">869</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000611" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">8,531</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000612" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,338</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000390_dcnt_fd4d4346-749d-4b15-b679-ced39600512b">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000391" name="us-gaap:DebtDisclosureTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true" continuedAt="F_000391_dcnt_4a3d0702-6500-43d3-8b64-2af7e0477c90">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. Notes Payable </p><ix:nonNumeric id="F_000429" name="us-gaap:ScheduleOfDebtTableTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future principal payments on the notes payable are as follows (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term Loan Agreement including PIK interest, before unamortized discount and issuance costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000613" name="ttoo:DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">51,597</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000614" name="ttoo:DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,364</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: unaccrued paid-in-kind interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000615" name="ttoo:DebtInstrumentUnaccruedPaidInKindInterest" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,233</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000616" name="ttoo:DebtInstrumentUnaccruedPaidInKindInterest" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,287</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: unamortized discount and deferred issuance costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000617" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="C_0001492674_20220930" decimals="-3" scale="3">176</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000618" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="C_0001492674_20211231" decimals="-3" scale="3">287</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total notes payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000619" name="us-gaap:NotesPayable" contextRef="C_0001492674_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">49,188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000620" name="us-gaap:NotesPayable" contextRef="C_0001492674_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">47,790</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Term Loan Agreement with CRG is classified as non-current September 30, 2022 and at December 31, 2021, as the Company has sufficient cash and cash equivalents such that the minimum liquidity covenant would not be triggered. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;The Term Loan Agreement includes a subjective acceleration clause whereby&#160;an event of default, including a material adverse change in the business, operations, or conditions (financial or otherwise), could result in the acceleration of the obligations under the Term Loan Agreement. As amended in February 2022, the entire principal payment, together with all other outstanding obligations, under the Term Loan Agreement are due and payable upon maturity<span style="color:#000000;">, <ix:nonNumeric id="F_000621" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220201_20220228" format="ixt:datemonthdayyearen">December 30, 2023</ix:nonNumeric>. There were no covenant violations at September 30, 2022. In November 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to <ix:nonNumeric id="F_000622" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221113_20221114" format="ixt:datemonthdayyearen">December 30, 2024</ix:nonNumeric>.  </span> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Term Loan Agreement </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, the Company entered into a Term Loan Agreement (the &#8220;Term Loan Agreement&#8221;) with CRG. The Company initially borrowed $<ix:nonFraction unitRef="U_iso4217USD" id="F_000623" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161201_20161231" decimals="-5" scale="6">40.0</ix:nonFraction> million pursuant to the Term Loan Agreement, which has a <span style="-sec-ix-hidden:F_000624">six-year</span> term with <ix:nonNumeric id="F_000625" name="ttoo:DebtInstrumentTermOfInterestOnlyPayments" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161201_20161231" format="ixt-sec:durwordsen">four years</ix:nonNumeric> of interest-only payments (through December&#160;30, 2020), after which quarterly principal and interest payments will be due through the maturity date. Interest on the amounts borrowed under the Term Loan Agreement accrues at an annual fixed rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000628" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161231" decimals="INF" scale="-2">11.5</ix:nonFraction>%, <ix:nonFraction unitRef="U_xbrlipure" id="F_000629" name="ttoo:DebtInstrumentDeferredInterestRateInterestOnlyPayment" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161201_20161231" decimals="INF" scale="-2">3.5</ix:nonFraction>% of which may be deferred during the interest-only period by adding such amount to the aggregate principal loan amount. In addition, if the Company achieves certain financial performance metrics, the loan will convert to interest-only until the maturity date, at which time all unpaid principal and accrued unpaid interest will be due and payable. The Company is required to pay CRG a financing fee based on the loan principal amount drawn. The Company is also required to pay a final payment fee of <ix:nonFraction unitRef="U_xbrlipure" id="F_000626" name="ttoo:DebtInstrumentFinalPaymentFeePercentage" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161231" decimals="INF" scale="-2">8.0</ix:nonFraction>%, subsequently amended to <ix:nonFraction unitRef="U_xbrlipure" id="F_000627" name="ttoo:DebtInstrumentFinalPaymentFeePercentage" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220930" decimals="INF" scale="-2">10</ix:nonFraction>%, of the principal outstanding upon repayment. The Company is accruing the final payment fee as interest expense and it is included as a non-current liability at September 30, 2022 and December 31, 2021 to conform to the classification of the associated debt in those periods. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may prepay all or a portion of the outstanding principal and accrued unpaid interest under the Term Loan Agreement at any time upon prior notice subject to a certain prepayment fee during the first <ix:nonNumeric id="F_000630" name="ttoo:DebtInstrumentPrepaymentFeeTerm" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161201_20161231" format="ixt-sec:durwordsen">five years</ix:nonNumeric> of the term and no prepayment fee thereafter. As security for its obligations under the Term Loan Agreement, the Company entered into a security agreement with CRG whereby the Company granted a lien on substantially all of its assets, including intellectual property. The Term Loan Agreement also contains customary affirmative and negative covenants for a credit facility of this size and type, including a requirement to maintain a minimum cash balance of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000631" name="us-gaap:RestrictedCash" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220930" decimals="-5" scale="6">5.0</ix:nonFraction> million.  </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000391_dcnt_4a3d0702-6500-43d3-8b64-2af7e0477c90">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, the Term Loan Agreement was amended to reduce minimum revenue targets, extend the interest-only period and extend the principal repayment. The final payment fee was increased from <ix:nonFraction unitRef="U_xbrlipure" id="F_000632" name="ttoo:DebtInstrumentFinalPaymentFeePercentage" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161231" decimals="INF" scale="-2">8</ix:nonFraction>% to <ix:nonFraction unitRef="U_xbrlipure" id="F_000633" name="ttoo:DebtInstrumentFinalPaymentFeePercentage" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20191231" decimals="INF" scale="-2">10</ix:nonFraction>% of the principal amount outstanding upon repayment. The Company issued to CRG warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000634" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">11,365</ix:nonFraction> shares of the Company&#8217;s common stock (&#8220;New Warrants&#8221;) (Note 10) at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000636" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF">77.50</ix:nonFraction>, with typical provisions for termination upon a change of control or a sale of all or substantially all of the assets of the Company.&#160;&#160;The Company also reduced the exercise price for the warrants previously issued to CRG to purchase an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000635" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231" decimals="INF" format="ixt:numdotdecimal">10,579</ix:nonFraction> shares of the Company&#8217;s common stock to $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000637" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231" decimals="INF">77.50</ix:nonFraction>. All of the New Warrants are exercisable any time prior to September 9, 2029, and all of the previously issued warrants are exercisable any time prior to December 30, 2026.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, the Term Loan Agreement was amended to extend the interest-only payment period until the December 30, 2022 maturity, to extend the initial principal repayment until the December 30, 2022 maturity, and to significantly reduce the minimum product revenue target for the twenty-four month period beginning on January 1, 2020. The Company did not pay or provide any consideration in exchange for this amendment. <span style="color:#000000;">The Company accounted for the January 2021 amendment as a modification to the Term Loan Agreement.</span> In June 2021, the Company satisfied the only remaining revenue covenant which was for the 24-month period beginning on January 1, 2020.  <span style="color:#000000;"> </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2022, the Term Loan Agreement was amended to extend the interest-only payment period through December 30, 2023, and to extend the principal repayment to <ix:nonNumeric id="F_000638" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220201_20220228" format="ixt:datemonthdayyearen">December 30, 2023</ix:nonNumeric>. The Company did not pay or provide any consideration in exchange for this amendment. As the effective borrowing rate under the amended agreement is less than the effective borrowing rate under the previous agreement, a concession is deemed to have been granted under ASC 470-60. As a concession has been granted, the agreement was accounted for as a troubled debt restructuring under ASC 470-60. The amendment did not result in a gain on restructuring as the future undiscounted cash outflows required under the amended agreement exceed the carrying value of the debt immediately prior to the amendment. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to <ix:nonNumeric id="F_000639" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221113_20221114" format="ixt:datemonthdayyearen">December 30, 2024</ix:nonNumeric>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Term Loan Agreement includes a subjective acceleration clause whereby an event of default, including a material adverse change in the business, operations, or conditions (financial or otherwise), could result in the acceleration of the obligations under the Term Loan Agreement. Under certain circumstances, a default interest rate of an additional <ix:nonFraction unitRef="U_xbrlipure" id="F_000640" name="ttoo:DebtInstrumentEventOfDefaultAdditionalInterestRate" contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220101_20220930" decimals="INF" scale="-2">4.0</ix:nonFraction>%&#160;per annum will apply at the election of CRG on all outstanding obligations during the occurrence and continuance of an event of default.&#160;&#160;&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000392" name="ttoo:RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true" continuedAt="F_000392_dcnt_3f560395-d1cf-4883-902b-3d338e3555a6">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. Series A Redeemable Convertible Preferred Stock and Related Warrant </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.9%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 15, 2022, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;), pursuant to which we entered into a private placement transaction an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000641" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815" decimals="INF" format="ixt:numdotdecimal">3,000</ix:nonFraction> shares of Series A Redeemable Convertible Preferred Stock with a par value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000642" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815" decimals="INF">0.001</ix:nonFraction> per share and a warrant to purchase up to an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000643" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815" decimals="INF" format="ixt:numdotdecimal">42,857</ix:nonFraction> shares of common stock of the Company at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000644" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815" decimals="2">7.50</ix:nonFraction> per share (such number of shares and exercise price adjusted for the reverse stock split described in Note 15) for an aggregate subscription amount equal to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000645" name="us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815" decimals="-5" scale="6">0.3</ix:nonFraction> million, before deducting estimated offering expenses payable by the Company. Pursuant to the Purchase Agreement, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock with the Secretary of State of the State of Delaware designating the rights, preferences and limitations of the Series A Redeemable Convertible Preferred Stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Series A Redeemable Convertible Preferred Stock</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Series A Redeemable Convertible Preferred Stock was issued at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000646" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815" decimals="INF">100</ix:nonFraction> per share (the Stated Value). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Conversion<span style="font-style:normal;"> -The Series A Redeemable Convertible Preferred Stock is convertible at the option of the holder, at any time after the date of the reverse stock split proposed by the board of directors, into that number of shares of common stock (subject to certain beneficial ownership limitations) determined by dividing the stated value of the Series A Redeemable Convertible Preferred Stock share by the conversion price then in effect, rounded down to the nearest whole share (with cash paid in lieu of any fractional shares). The initial conversion price was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000647" name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815" decimals="INF">7.00</ix:nonFraction> per share, adjusted for the reverse stock split that was effected on <ix:nonNumeric id="F_000648" name="us-gaap:PreferredStockConvertibleConversionDate" contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815" format="ixt:datemonthdayyearen">October 12, 2022</ix:nonNumeric> (the &#8220;Conversion Price&#8221;).&#160;&#160;The Conversion Price will be (1) adjusted proportionately upon occurrence of any subsequent stock splits or stock dividends and (2) lowered to a price per share equal to that of any common stock, convertible securities or option that is subsequently issued or sold by the Company for a price per share less than the Conversion Price in effect immediately prior to such issue or sale&#59; however, the Conversion Price cannot fall below the par value per share of the Common Stock nor exceed ten dollars ($<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000650" name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815" decimals="INF">10.00</ix:nonFraction>) per share, in each case, as adjusted for the reverse stock split that was effected on <ix:nonNumeric id="F_000649" name="us-gaap:PreferredStockConvertibleConversionDate" contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815" format="ixt:datemonthdayyearen">October 12, 2022</ix:nonNumeric>.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Redemption<span style="font-style:normal;"> - Series A Redeemable Convertible Preferred Stock do not contain any mandatory redemption provisions. Beginning on the date of the reverse stock split, as proposed by the board of directors (1) the Company may redeem in cash all or any portion of the Series A Redeemable Convertible Preferred Stock at a price per share equal to one hundred and five percent (<ix:nonFraction unitRef="U_xbrlipure" id="F_000651" name="ttoo:PreferredStockPricePercentageOnStatedValue" contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815" decimals="INF" scale="-2">105</ix:nonFraction>%) of the stated value and (2) each holder of Series A Preferred Stock may require the Company to redeem in cash all or any portion of the Series A Redeemable Convertible Preferred Stock held by such holder at a price per share equal to one hundred and ten percent (<ix:nonFraction unitRef="U_xbrlipure" id="F_000652" name="ttoo:PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock" contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815" decimals="INF" scale="-2">110</ix:nonFraction>%) of the stated value. In addition, if the Company&#8217;s common shares become delisted, the Series A Redeemable Convertible Preferred Stock will automatically be redeemed by the Company at a price per share equal to one hundred and ten percent (<ix:nonFraction unitRef="U_xbrlipure" id="F_000653" name="ttoo:PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares" contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815" decimals="INF" scale="-2">110</ix:nonFraction>%) of the Stated Value. At September 30, 2022, the Company determined that the Series A Redeemable Convertible Preferred Stock was redeemable and is being carried at its redemption value on the balance sheet, which is equal to its liquidation value under the terms of the certification of designation.&#160;&#160; </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Dividend Rights<span style="font-style:normal;">-Holders of the Series A Redeemable Convertible Preferred Stock are entitled to receive dividends on shares of Series A Redeemable Convertible Preferred Stock equal (on an as-converted to common stock basis) to and in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of the common stock.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Voting Rights -<span style="font-style:normal;"><ix:nonNumeric id="F_000654" name="us-gaap:PreferredStockVotingRights" contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220101_20220930">The Series A Redeemable Convertible Preferred Stock will have no voting rights other than the right to vote on certain matters. Each share of Series A Redeemable Convertible Preferred entitles the holder to 1,000,000 votes on a proposal to approve a reverse stock split of the Company&#8217;s outstanding common stock (the &#8220;Proposal&#8221;) and any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Proposal&#59; provided, however, that such shares of Series A Redeemable Convertible Preferred Stock shall be voted in the same proportion as the shares of common stock (excluding any shares of common stock that are not voted)</ix:nonNumeric></span> are voted on the Proposal. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Warrant</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the execution of the Securities Purchase Agreement, the Company issued a warrant to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000655" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815" decimals="INF" format="ixt:numdotdecimal">42,857</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;Warrant&#8221;) at an exercise price equal to $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000656" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815" decimals="2">7.50</ix:nonFraction> per share, subject to adjustments noted below. The Warrant will become exercisable on <ix:nonNumeric id="F_000657" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815_20220815" format="ixt:datemonthdayyearen">February 15, 2023</ix:nonNumeric> and has a term ending <ix:nonNumeric id="F_000658" name="ttoo:ClassOfWarrantOrRightMaturityDate" contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815_20220815" format="ixt:datemonthdayyearen">February 15, 2028</ix:nonNumeric>. At issuance, the Company determined that the Warrant should be classified as a liability because such Warrant could require cash redemption in certain circumstances. Recognition of the warrant liability created a day one loss of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000659" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815" decimals="-5" scale="6">0.1</ix:nonFraction> million. The Warrant is carried at fair value, with changes in fair value recognized in changes in fair value of the derivative warrant liability each reporting period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exercise price of the Warrant and the number of shares issuable upon exercise will be adjusted proportionately upon the occurrence of any subsequent stock dividend or stock split of the Company&#8217;s common stock. In addition, if at any time the Company </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000392_dcnt_3f560395-d1cf-4883-902b-3d338e3555a6">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">grants, issues or sells any </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ommon </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">quivalents</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or rights to purchase stock, warrants, securities or other property pro rata to holders of any class of shares of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ommon </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock (the &#8220;Purchase Rights&#8221;), then the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">older will be entitled to acquire, upon the terms applicable to </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Purchase Rights, the aggregate Purchase Rights which the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">older could have acquired if the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">older had held the number of shares of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ommon </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock acquirable upon complete exercise of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Warrant</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (subject to certain </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eneficial </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wnership limitations). Furthermore, after the issuance of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Warrant and while it</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> is outstanding, if the Company declare</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or make</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ommon </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock, by way of return of capital or otherwise (a &#8220;Distribution&#8221;), the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">older </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> be entitled to participate in </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Distribution to the same extent that the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">older would have participated if the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">older had held the number of shares of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ommon </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock acquirable upon complete exercise of this Warrant</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (subject to certain </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eneficial </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wnership limitations). </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the occurrence of a Fundamental Transaction, as defined, then, upon any subsequent exercise of the Warrant the holder will, at its option, have the right to receive for each Warrant that would have been issuable upon such exercise immediately prior to the occurrence of the Fundamental Transaction the number of shares of common stock (or its equivalent) of the successor or acquiring corporation or of the Company, if it is the surviving corporation, or such other consideration (the &#8220;Alternate Consideration&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of common stock for which the Warrant is exercisable immediately prior to the Fundamental Transaction. For purposes of any such exercise, the determination of the exercise price will be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of common stock in such Fundamental Transaction, and the Company will apportion the exercise price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of common stock are given any choice as to the securities, cash or property to be received in a Fundamental<span style="color:#000000;"> Transaction, then the Warrant holder will be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While any Warrant is outstanding, if the Company issues or sells, any common stock, convertible securities or options, for a consideration per share (the &#8220;New Issuance Price&#8221;) less than a price equal to the exercise price of the Warrant in effect immediately prior to such issue or sale (a &#8220;Dilutive Issuance&#8221;), then immediately after the Dilutive Issuance, the exercise price then in effect will be reduced to an amount equal to the New Issuance Price.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If at the time of a Warrant&#8217;s exercise there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares by the holder, then the Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221;.</p></ix:continuation><ix:nonNumeric id="F_000393" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true" continuedAt="F_000393_dcnt_89d54fc2-4a24-490d-b805-25f01634cfc3">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Stockholders&#8217; Deficit </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Shares Authorized</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, the Company&#8217;s shareholders approved an increase in the number of authorized shares of the Company&#8217;s common stock from <ix:nonFraction unitRef="U_xbrlishares" id="F_000660" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001492674_20210630" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction> to <ix:nonFraction unitRef="U_xbrlishares" id="F_000661" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001492674_20210701" decimals="INF" format="ixt:numdotdecimal">400,000,000</ix:nonFraction>.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Equity Distribution Agreement&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 31, 2021, the Company entered into a Sales Agreement with Canaccord (&#8220;New Sales Agreement&#8221;), as agent, pursuant to which the Company may offer and sell shares of its common stock, for aggregate gross sale proceeds of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000662" name="ttoo:ProceedsFromIssuanceOfCommonStockGross" contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20210330_20210331" decimals="INF" scale="6">75.0</ix:nonFraction> million from time to time from the effective date of the respective registration statement through Canaccord. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the New Sales Agreement, upon delivery of a placement notice based on the Company&#8217;s instructions and subject to the terms and conditions of the Sales Agreement, Canaccord is able to sell the shares by methods deemed to be an &#8220;at the market&#8221; offering, subject to shelf limitations if any, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company. The Company is not obligated to make any sales of shares under the New Sales Agreement. The Company or Canaccord is able to suspend or terminate the offering of shares upon notice to the other party, subject to certain conditions. Canaccord acts as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000393_dcnt_89d54fc2-4a24-490d-b805-25f01634cfc3">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company agrees to pay Canaccord for its services of acting as agent an amount equal to <span><ix:nonFraction unitRef="U_xbrlipure" id="F_000663" name="ttoo:PercentageOfAgentServiceFee" contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooOriginalSalesAgreementMember_20190730_20190730" decimals="2" scale="-2"><ix:nonFraction unitRef="U_xbrlipure" id="F_000664" name="ttoo:PercentageOfAgentServiceFee" contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20190730_20190730" decimals="2" scale="-2">3</ix:nonFraction></ix:nonFraction>%</span> of the gross proceeds from the sale of the shares pursuant to the New Sales Agreement.&#160;The Company also agrees to provide Canaccord with customary indemnification for certain liabilities. Legal and accounting fees are charged to share capital upon issuance of shares under the New Sales Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the New Sales Agreement, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000667" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20220101_20220930" decimals="INF" format="ixt:numdotdecimal">3,668,784</ix:nonFraction> shares for net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000670" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20220101_20220930" decimals="-5" scale="6">28.1</ix:nonFraction> million during the nine months ended September 30, 2022 and <ix:nonFraction unitRef="U_xbrlishares" id="F_000668" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20210101_20210930" decimals="INF" format="ixt:numdotdecimal">336,188</ix:nonFraction> shares for net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000671" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20210101_20210930" decimals="-5" scale="6">20.0</ix:nonFraction> million during the nine months ended September 30, 2021. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the New Sales Agreement, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000665" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20220701_20220930" decimals="INF" format="ixt:numdotdecimal">3,080,451</ix:nonFraction> shares for net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000669" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20220701_20220930" decimals="-5" scale="6">22.2</ix:nonFraction> million during the three months ended September 30, 2022 and did <ix:nonFraction unitRef="U_xbrlishares" id="F_000666" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20210701_20210930" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>t sell any shares during the three months ended September 30, 2021.</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p><ix:nonNumeric id="F_000394" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true" continuedAt="F_000394_dcnt_e8aa0e16-c6ac-4df5-a7da-1837c330bb19">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9. Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Incentive Plans </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2006 Stock Incentive Plan </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 2006 Stock Option Plan (&#8220;2006 Plan&#8221;) was established for granting stock incentive awards to directors, officers, employees and consultants of the Company.&#160;Upon closing of the Company&#8217;s IPO in August 2014, the Company ceased granting stock incentive awards under the 2006 Plan.&#160;The 2006 Plan provided for the grant of incentive and non-qualified stock options and restricted stock grants as determined by the Company&#8217;s board of directors.&#160;Under the 2006 Plan, stock options were generally granted with exercise prices equal to or greater than the fair value of the common stock as determined by the board of directors, expired no later than <ix:nonNumeric id="F_000672" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2006Member_20220101_20220930" format="ixt-sec:duryear">10</ix:nonNumeric> years from the date of grant, and vested over various periods not exceeding <ix:nonNumeric id="F_000673" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2006Member_20220101_20220930" format="ixt-sec:duryear">4</ix:nonNumeric> years.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2014 Stock Incentive Plan </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 2014 Incentive Award Plan (&#8220;2014 Plan&#8221;, and together with the 2006 Plan, the &#8220;Stock Incentive Plans&#8221;) provides for the issuance of shares of common stock in the form of stock options, awards of restricted stock, awards of restricted stock units, performance awards, dividend equivalent awards, stock payment awards and stock appreciation rights to directors, officers, employees and consultants of the Company. Since the establishment of the 2014 Plan, the Company has primarily granted stock options and restricted stock units.&#160;Generally, stock options are granted with exercise prices equal to or greater than the fair value of the common stock on the date of grant, expire no later than <ix:nonNumeric id="F_000674" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930" format="ixt-sec:duryear">10</ix:nonNumeric> years from the date of grant, and vest over various periods not exceeding <ix:nonNumeric id="F_000675" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930" format="ixt-sec:duryear">4</ix:nonNumeric> years.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares reserved for future issuance under the 2014 Plan is the sum of (1)&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000676" name="ttoo:ComponentOfCommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220930" decimals="INF" format="ixt:numdotdecimal">16,470</ix:nonFraction> shares, (2)&#160;any shares that were granted under the 2006 Plan which are forfeited, lapse unexercised or are settled in cash subsequent to the effective date of the 2014 Plan and (3)&#160;an annual increase on the first day of each calendar year beginning January&#160;1, 2015 and ending on January&#160;1, 2026, equal to the lesser of (A)&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000677" name="ttoo:PercentageOfCommonSharesOutstanding" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220930" decimals="INF" scale="-2">4</ix:nonFraction>% of the shares outstanding (on an as-converted basis) on the final day of the immediately preceding calendar year and (B)&#160;such smaller number of shares determined by the Company&#8217;s board of directors&#59; provided, however, no more than <ix:nonFraction unitRef="U_xbrlishares" id="F_000678" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930" decimals="INF" format="ixt:numdotdecimal">700,000</ix:nonFraction> shares may be issued upon the exercise of incentive stock options.&#160;As of September&#160;30, 2022, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000679" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220930" decimals="INF" format="ixt:numdotdecimal">52,676</ix:nonFraction> shares available for future grant under the 2014 Plan. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Inducement Award Plan </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Amended and Restated Inducement Award Plan (&#8220;Inducement Plan&#8221;), which was adopted in March 2018 and most recently amended and restated in January 2020, provides for the grant of equity awards to new employees, including options, restricted stock awards, restricted stock units, performance awards, dividend equivalent awards, stock payment awards and stock appreciation rights. The aggregate number of shares of common stock which may be issued or transferred pursuant to awards under the Inducement Plan is <ix:nonFraction unitRef="U_xbrlishares" id="F_000680" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001492674_us-gaapPlanNameAxis_ttooInducementAwardPlanMember_20180331" decimals="INF" format="ixt:numdotdecimal">192,500</ix:nonFraction> shares. Any awards that forfeit, expire, lapse, or are settled for cash without the delivery of shares to the holder are available for the grant of an award under the Inducement Plan. Any shares repurchased by or surrendered to the Company that are returned shall be available for the grant of an award under the Inducement Plan. The payment of dividend equivalents in cash in conjunction with any outstanding award shall not be counted against the shares available for issuance under the Inducement Plan. As of September&#160;30, 2022, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000681" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001492674_us-gaapPlanNameAxis_ttooInducementAwardPlanMember_20220930" decimals="INF" format="ixt:numdotdecimal">84,501</ix:nonFraction> shares available for future grant under the Inducement Plan.&#160;&#160;<span style="font-style:italic;"> </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Options </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the nine months ended September&#160;30, 2022 and 2021, the Company granted stock options with an aggregate fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000682" name="ttoo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember_20220101_20220930" decimals="-5" scale="6">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000683" name="ttoo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember_20210101_20210930" decimals="-5" scale="6">1.1</ix:nonFraction> million, respectively, which are being amortized into compensation expense over the vesting period of the options as the services are being provided. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000394_dcnt_e8aa0e16-c6ac-4df5-a7da-1837c330bb19" continuedAt="F_000394_dcnt_fc78663f-6e54-40a9-b13d-b2499d45d0f4"><ix:nonNumeric id="F_000430" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of option activity under the Stock Incentive Plans and Inducement Plan (in thousands, except share and per share amounts): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price Per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000684" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">197,171</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000691" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20211231" decimals="2">143.96</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000698">7.09</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000702" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20211231" decimals="-3" scale="3">51</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000685" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930" decimals="INF" format="ixt:numdotdecimal">33,520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000692" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930" decimals="2">21.50</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000686" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930" decimals="INF" format="ixt:numdotdecimal">25,608</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000693" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930" decimals="2">42.64</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000687" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930" decimals="INF" format="ixt:numdotdecimal">11,863</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000694" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930" decimals="2">119.60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000688" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220930" decimals="INF" format="ixt:numdotdecimal">193,220</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000695" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220930" decimals="2">137.64</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000699">6.78</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at September 30, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000689" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220930" decimals="INF" format="ixt:numdotdecimal">127,461</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000696" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220930" decimals="2">186.38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000700">5.90</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested or expected to vest at September 30, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000690" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220930" decimals="INF" format="ixt:numdotdecimal">182,864</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000697" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220930" decimals="2">143.27</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000701">6.66</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  <ix:nonNumeric id="F_000431" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true" continuedAt="F_000431_cnt_1">There were <ix:nonFraction unitRef="U_xbrlishares" id="F_000703" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> options exercised in the nine months ended September 30, 2022 and <ix:nonFraction unitRef="U_xbrlishares" id="F_000704" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20210101_20210930" decimals="INF" format="ixt:numdotdecimal">1,566</ix:nonFraction> options exercised in the nine months ended September 30, 2021. The weighted-average grant date fair values of stock options granted in the nine month periods ended September&#160;30, 2022 and 2021 were $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000705" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930" decimals="2">17.58</ix:nonFraction> per share and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000706" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20210101_20210930" decimals="2">54.77</ix:nonFraction> per share, respectively, and were calculated using the following estimated assumptions:</ix:nonNumeric> </p><ix:continuation id="F_000431_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000707" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930" decimals="4" scale="-2">2.27</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000708" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20210101_20210930" decimals="4" scale="-2">0.92</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000709" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930" decimals="2" scale="-2">106</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000710" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20210101_20210930" decimals="2" scale="-2">104</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected terms</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000711" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930" format="ixt-sec:duryear">6.0</ix:nonNumeric> years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000712" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20210101_20210930" format="ixt-sec:duryear">6.0</ix:nonNumeric> years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total fair values of options that vested during the nine months ended September&#160;30, 2022 and 2021 were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000713" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_0001492674_20220101_20220930" decimals="-5" scale="6">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000714" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_0001492674_20210101_20210930" decimals="-5" scale="6">2.1</ix:nonFraction> million, respectively. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2022, there was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000715" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember_20220930" decimals="-5" scale="6">2.1</ix:nonFraction> million of total unrecognized compensation cost related to non-vested stock options granted under the Stock Incentive Plans and Inducement Plan. Total unrecognized compensation cost will be adjusted for future changes in the estimated forfeiture rate. The Company expects to recognize that cost over a remaining weighted-average period of <ix:nonNumeric id="F_000716" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember_20220101_20220930" format="ixt-sec:duryear">2.1</ix:nonNumeric> years as of September&#160;30, 2022. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Units </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the nine months ended September&#160;30, 2022, the Company awarded restricted stock units to certain employees and directors at no cost to them. The restricted stock units, excluding any restricted stock units with market conditions, vest through the passage of time, assuming continued service. Restricted stock units are not included in issued and outstanding common stock until the underlying shares are vested and released. The fair value of the restricted stock units, at the time of the grant, is expensed on a straight line basis. The granted restricted stock units had an aggregate fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000717" name="ttoo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue" contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930" decimals="-5" scale="6">3.7</ix:nonFraction> million, which are being amortized into compensation expense over the vesting period of the restricted stock units as the services are being provided. </p><ix:nonNumeric id="F_000432" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of restricted stock unit activity under the 2014 Plan: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant&#160;Date&#160;Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value Per Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.76%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000718" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20211231" decimals="INF" format="ixt:numdotdecimal">142,434</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000723" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20211231" decimals="2">91.77</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.76%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000719" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930" decimals="INF" format="ixt:numdotdecimal">160,575</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000724" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930" decimals="2">22.79</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.76%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000720" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930" decimals="INF" format="ixt:numdotdecimal">50,352</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000725" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930" decimals="2">93.13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000721" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930" decimals="INF" format="ixt:numdotdecimal">28,355</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000726" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930" decimals="2">42.40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at September 30, 2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000722" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220930" decimals="INF" format="ixt:numdotdecimal">224,302</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000727" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220930" decimals="2">48.32</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000394_dcnt_fc78663f-6e54-40a9-b13d-b2499d45d0f4">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2022, there was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000728" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220930" decimals="-5" scale="6">8.5</ix:nonFraction> million of total unrecognized compensation cost related to nonvested restricted stock units granted. Total unrecognized compensation cost will be adjusted for future changes in the estimated forfeiture rate. The Company expects to recognize that cost over a remaining weighted-average period of <ix:nonNumeric id="F_000729" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220930" format="ixt-sec:duryear">1.7</ix:nonNumeric> years, as of September&#160;30, 2022.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the 2014 Employee Stock Purchase Plan (the &#8220;2014 ESPP&#8221;) participants may purchase the Company&#8217;s common stock during semi-annual offering periods at <ix:nonFraction unitRef="U_xbrlipure" id="F_000730" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20220101_20220930" decimals="2" scale="-2">85</ix:nonFraction>% of the lower of (i) the market value per share of common stock on the first day of the offering period or (ii) the market value per share of the common stock on the purchase date. Each participant can purchase up to a maximum of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000731" name="ttoo:MaximumAmountOfAnnualEmployeeCommonStockPurchase" contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20220101_20220930" decimals="INF" format="ixt:numdotdecimal">25,000</ix:nonFraction> per calendar year in fair market value as calculated in accordance with applicable tax rules. The first offering period began on August 7, 2014. Stock-based compensation expense from the 2014 ESPP for the three months ended September 30, 2022 and 2021 was approximately <span>$<ix:nonFraction unitRef="U_iso4217USD" id="F_000733" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210701_20210930" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000732" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20220701_20220930" decimals="-5" scale="6">0.1</ix:nonFraction></ix:nonFraction></span> million. Stock-based compensation expense from the 2014 ESPP for the nine months ended September 30, 2022 and 2021 was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000734" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20220101_20220930" decimals="-5" scale="6">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000735" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20210930" decimals="-5" scale="6">0.3</ix:nonFraction> million, respectively. &#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2014 ESPP, which was amended and restated effective August 6, 2020, provides for the issuance of up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000736" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200806" decimals="INF" format="ixt:numdotdecimal">90,478</ix:nonFraction> shares of the Company&#8217;s common stock to eligible employees. At September 30, 2022, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000737" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20220930" decimals="INF" format="ixt:numdotdecimal">29,181</ix:nonFraction> shares available for issuance under the 2014 ESPP. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense </p><ix:nonNumeric id="F_000433" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the stock-based compensation expense resulting from awards granted under Stock Incentive Plans, the Inducement Plan and the 2014 ESPP, that was recorded in the Company&#8217;s results of operations for the periods presented (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000738" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20220701_20220930" decimals="-3" scale="3">64</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000739" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20210701_20210930" decimals="-3" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000740" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20220101_20220930" decimals="-3" scale="3">309</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000741" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20210101_20210930" decimals="-3" scale="3">211</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000742" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220701_20220930" decimals="-3" scale="3">230</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000743" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210701_20210930" decimals="-3" scale="3">269</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000744" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220101_20220930" decimals="-3" scale="3">851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000745" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210930" decimals="-3" scale="3">707</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000746" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20220701_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,060</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000747" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,114</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000748" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,280</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000749" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">4,655</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000750" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_20220701_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">1,354</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000751" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">2,423</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000752" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_20220101_20220930" decimals="-3" format="ixt:numdotdecimal" scale="3">5,440</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000753" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_20210101_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">5,573</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three and nine months ended September&#160;30, 2022 and 2021, stock-based compensation expenses capitalized as part of inventory or T2Dx instruments and components were immaterial.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, a previous director of the Company resigned. In conjunction with his resignation, all of the director&#8217;s outstanding options vested in full and the exercise term was extended to the final expiration date for each respective outstanding option. Additionally, the non-vested restricted stock units granted to the director in June 2021 vested in full upon his resignation. These were accounted for as Type I equity modifications for the accelerated vesting and Type III equity modifications for the extended exercise period and resulted in an increase of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000754" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIModificationMember_20210701_20210930" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000755" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIModificationMember_20210101_20210930" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000756" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIIIModificationMember_20210701_20210930" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000757" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIIIModificationMember_20210101_20210930" decimals="-5" scale="6">0.8</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> million to stock-based compensation expense for the three and nine months ended September 30, 2021. Included within selling, general and administrative above for the three and nine months ended September 30, 2021 is $<ix:nonFraction unitRef="U_iso4217USD" id="F_000758" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIModificationMember_20210701_20210930" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000759" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIModificationMember_20210101_20210930" decimals="-5" scale="6">0.6</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000761" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIIIModificationMember_20210101_20210930" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000760" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIIIModificationMember_20210701_20210930" decimals="-5" scale="6">0.2</ix:nonFraction></ix:nonFraction> million related to the Type I modification and the Type III modification, respectively, from the director&#8217;s resignation.  </p></ix:continuation><ix:nonNumeric id="F_000395" name="ttoo:WarrantsNoteDisclosureTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Warrants associated with Term Loan</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Term Loan Agreement entered into in December 2016, the Company issued to CRG warrants to purchase a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000762" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231" decimals="INF" format="ixt:numdotdecimal">10,579</ix:nonFraction> shares of the Company&#8217;s common stock. The warrants are exercisable any time prior to December&#160;30, 2026 at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000763" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231" decimals="INF">77.50</ix:nonFraction> per share, with typical provisions for termination upon a change of control or a sale of all or substantially all of the assets of the Company. These warrants remain outstanding as of September 30, 2022 and December 31, 2021<span style="color:#000000;">.</span> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with a 2019 amendment of the Term Loan Agreement, the Company issued to CRG warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000764" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">11,365</ix:nonFraction> shares of the Company&#8217;s common stock (&#8220;New Warrants&#8221;) at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000765" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF">77.50</ix:nonFraction>, with typical provisions for termination upon a change of control or a sale of all or substantially all of the assets of the Company. All of the New Warrants are exercisable any time prior to September 9, 2029. The New Warrants remain outstanding as of September 30, 2022<span style="color:#000000;">.</span></p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000396" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. Net Loss Per Share </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies the two-class method for computing earnings per share because its Series A redeemable convertible preferred stock and the warrants issued with that preferred stock are participating securities. Under the two-class method, net income for the period is allocated between common stockholders and the participating securities according to dividends declared, if any, and participation rights in undistributed earnings. Because the Company incurred a net loss for the three and nine months ended September 30, 2022, and the holders of the participating securities do not have the contractual obligation to share in the losses of the Company on a basis that is objectively determinable, none of the net loss attributable to common stockholders was allocated to the participating securities when computing earnings per share.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The net loss attributable to common stockholders was increased by $<ix:nonFraction unitRef="U_iso4217USD" id="F_000766" name="us-gaap:TemporaryEquityDividendsAdjustment" contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesAConvertiblePreferredStockMember_20220101_20220930" decimals="-5" scale="6">0.3</ix:nonFraction> million to reflect the deemed dividend paid to holders of the Series A redeemable convertible preferred stock to accrete the carrying amount of that preferred stock to its redemption value.</p><ix:nonNumeric id="F_000434" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock or if-converted methods, because their effect would have been anti-dilutive for the periods presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three and Nine Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common shares</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000776" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20220101_20220930" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000767" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20220701_20220930" decimals="INF" format="ixt:numdotdecimal">193,220</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000777" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20210930" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000768" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210701_20210930" decimals="INF" format="ixt:numdotdecimal">186,352</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000778" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220930" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000769" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20220701_20220930" decimals="INF" format="ixt:numdotdecimal">224,302</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000779" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210930" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000770" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210701_20210930" decimals="INF" format="ixt:numdotdecimal">134,599</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000780" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20220101_20220930" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000771" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20220701_20220930" decimals="INF" format="ixt:numdotdecimal">64,801</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000781" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20210930" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000772" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210701_20210930" decimals="INF" format="ixt:numdotdecimal">21,944</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A redeemable convertible preferred stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000782" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_20220101_20220930" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000773" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_20220701_20220930" decimals="INF" format="ixt:numdotdecimal">3,000</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000783" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001492674_20220101_20220930" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000774" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001492674_20220701_20220930" decimals="INF" format="ixt:numdotdecimal">485,323</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000784" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001492674_20210101_20210930" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000775" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001492674_20210701_20210930" decimals="INF" format="ixt:numdotdecimal">342,895</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note that the net loss per share computations for all periods presented reflect <ix:nonNumeric id="F_000786" name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="C_0001492674_20220101_20220930">the changes in the number of shares resulting from the <span style="-sec-ix-hidden:F_000785_2">50 to 1</span> reverse stock split that was approved by shareholders on October 11, 2022 and became effective as of October 12, 2022.</ix:nonNumeric>&#160;&#160;The number of shares of common stock issued and outstanding immediately before the reverse stock split was <ix:nonFraction unitRef="U_xbrlishares" id="F_000787" name="ttoo:StockIssuedAndOutstandingDuringPeriodSharesStockSplits" contextRef="C_0001492674_20220101_20220930" decimals="INF" format="ixt:numdotdecimal">352,957,478</ix:nonFraction>&#894; the number of shares outstanding immediately after the reverse split was <ix:nonNumeric id="F_000788" name="ttoo:StockOutstandingDuringPeriodSharesStockSplits" contextRef="C_0001492674_20220101_20220930">7,059,144</ix:nonNumeric>, a decrease of <ix:nonFraction unitRef="U_xbrlishares" id="F_000789" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="C_0001492674_20220101_20220930" decimals="INF" format="ixt:numdotdecimal">345,898,334</ix:nonFraction> shares.</p></ix:nonNumeric><ix:nonNumeric id="F_000397" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. U.S. Government Contract</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, BARDA awarded the Company a milestone-based contract, with an initial value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000790" name="ttoo:CollaborativeArrangementInitialValueOfConsideration" contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20190930" decimals="-5" scale="6">6.0</ix:nonFraction> million, and a potential value of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000791" name="ttoo:CollaborativeArrangementAggregateConsideration" contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20190930" decimals="INF" scale="6">69.0</ix:nonFraction> million, if BARDA awards all contract options (the &#8220;U.S. Government Contract&#8221;). BARDA operates within the Office of the Assistant Secretary for Preparedness and Response (&#8220;ASPR&#8221;) at the U.S. Department of Health and Human Services (&#8220;HHS&#8221;). If BARDA awards and the Company completes all options, the Company&#8217;s management believes it will enable a significant expansion of the Company&#8217;s current portfolio of diagnostics for sepsis-causing pathogen and antibiotic resistance genes. In September 2020, BARDA exercised the first contract option valued at $<ix:nonFraction unitRef="U_iso4217USD" id="F_000792" name="ttoo:CollaborativeArrangementFirstContractOptionValueExercised" contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20200901_20200930" decimals="-5" scale="6">10.5</ix:nonFraction> million. In September 2021, BARDA exercised an option valued at approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000793" name="ttoo:CollaborativeArrangementOptionContractValueExercised" contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20210901_20210930" decimals="-5" scale="6">6.4</ix:nonFraction> million. &#160;&#160; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2021, BARDA agreed to accelerate product development by modifying the contract to advance future deliverables into the currently funded Option 1 of the BARDA contract for T2NxT, T2Biothreat, T2Resistance and T2AMR. The modification does not change the overall total potential value of the BARDA contract.&#160;&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;31, 2022, the Company announced that BARDA had exercised Option 2B under the existing multiple-year cost-share contract between BARDA and the Company and is providing an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000794" name="ttoo:CollaborativeArrangementAdditionalFundingAmountReceived" contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20220101_20220331" decimals="-5" scale="6">4.4</ix:nonFraction> million in funding to the Company. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The option exercise occurred simultaneously on March&#160;31, 2022 with a modification to the BARDA contract to make immaterial changes to, among other things, the statement of work. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2022, BARDA exercised Option 3 and agreed to provide an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000795" name="ttoo:CollaborativeArrangementAdditionalFundingAmountToBeReceived" contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20220901_20220930" decimals="-5" scale="6">3.7</ix:nonFraction> million in funding for the multiple-year cost-share contract. The additional funding under Option 3 will be used to advance the U.S. clinical trials for the T2Biothreat<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;Panel and T2Resistance<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;Panel, and to file submissions to the FDA for U.S. regulatory clearance. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded contribution revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000796" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srtProductOrServiceAxis_ttooContributionMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20220701_20220930" decimals="-5" scale="6">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000797" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srtProductOrServiceAxis_ttooContributionMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20210701_20210930" decimals="-5" scale="6">3.1</ix:nonFraction> million for the three months ended September 30, 2022 and 2021, respectively, under the BARDA contract. The Company recorded contribution revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000798" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srtProductOrServiceAxis_ttooContributionMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20220101_20220930" decimals="-5" scale="6">7.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000799" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srtProductOrServiceAxis_ttooContributionMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20210101_20210930" decimals="-5" scale="6">8.4</ix:nonFraction> million for the nine months ended September 30, 2022 and 2021, respectively, under the BARDA contract.&#160;&#160;&#160;&#160;   </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000800" name="us-gaap:AccountsReceivableNet" contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20220930" decimals="-6" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction> outstanding accounts receivable at September 30, 2022 and accounts receivable of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000801" name="us-gaap:AccountsReceivableNet" contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20211231" decimals="-5" scale="6">1.9</ix:nonFraction> million at December 31, 2021, respectively, under the BARDA contract. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000398" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13. Leases </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Operating Leases </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases certain office space, laboratory space and manufacturing space. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. The Company does <ix:nonFraction unitRef="U_iso4217USD" id="F_000802" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeSpaceLaboratorySpaceAndEquipmentMember_20220930" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000803" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeSpaceLaboratorySpaceAndEquipmentMember_20220930" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction></ix:nonFraction>t recognize right-of-use assets or lease liabilities for leases determined to have a term of <ix:nonNumeric id="F_000804" name="ttoo:MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities" contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeSpaceLaboratorySpaceAndEquipmentMember_20220101_20220930" format="ixt-sec:durmonth">12</ix:nonNumeric> months or less. For new and amended leases, the Company has elected to account for the lease and non-lease components as a combined lease component.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2013, the Company entered into an operating lease for additional office, laboratory and manufacturing space in Wilmington, Massachusetts. In August 2018, the Company entered into an amendment to extend the term to <span style="-sec-ix-hidden:F_000807">December 2020</span>. In October 2020, the Company entered into an amendment to extend the term to <ix:nonNumeric id="F_000808" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoMay2013Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeLaboratoryAndManufacturingSpaceMember_20201001_20201031" format="ixt:datemonthdayyearen">December 31, 2022</ix:nonNumeric>. In September 2022, the Company entered into an amendment to extend the term to <ix:nonNumeric id="F_000809" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoMay2013Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeLaboratoryAndManufacturingSpaceMember_20220901_20220930" format="ixt:datemonthdayyearen">December 31, 2024</ix:nonNumeric>. This amendment resulted in an increase to the operating lease right-of-use assets and lease liability accounts on the balance sheet of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000813" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoMay2013Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeLaboratoryAndManufacturingSpaceMember_20220930" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000812" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoMay2013Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeLaboratoryAndManufacturingSpaceMember_20220930" decimals="-5" scale="6">0.2</ix:nonFraction></ix:nonFraction> million at September 30, 2022.&#160;&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2014, the Company entered into an agreement to rent additional office space in Lexington, Massachusetts. In April 2015, the Company entered into an amendment to extend the term to <ix:nonNumeric id="F_000805" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001492674_srtMortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_srtOfficeBuildingMember_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20150401_20150430" format="ixt:datemonthdayyearen">December 31, 2017</ix:nonNumeric>. In connection with this agreement, the Company paid a security deposit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000810" name="us-gaap:SecurityDeposit" contextRef="C_0001492674_srtMortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_srtOfficeBuildingMember_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20141130" decimals="0" format="ixt:numdotdecimal">50,000</ix:nonFraction>, which is recorded as a component of other assets in the condensed consolidated balance sheets. In May 2015, the Company entered into an amendment to expand existing manufacturing facilities in Lexington, Massachusetts. In September 2017, the Company entered into an amendment to extend the term to <ix:nonNumeric id="F_000806" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001492674_srtMortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_srtOfficeBuildingMember_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20170901_20170930" format="ixt:datemonthdayyearen">December 31, 2021</ix:nonNumeric>. In June 2020, the Company vacated this office space and determined that subleasing it to a tenant was unlikely due to the impact of the COVID-19 pandemic on the local commercial real estate sub-lease market. The lease terminated on <ix:nonNumeric id="F_000811" name="ttoo:LesseeOperatingLeaseTerminationPeriod" contextRef="C_0001492674_srtMortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_srtOfficeBuildingMember_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20141130_20141130" format="ixt:datemonthdayyearen">December 31, 2021</ix:nonNumeric>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2014, the Company entered into a lease for additional laboratory space in Lexington, Massachusetts. The lease term commenced in April 2015 and extended for <ix:nonNumeric id="F_000814" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20141130" format="ixt-sec:durwordsen">six years</ix:nonNumeric>. The rent expense, inclusive of the escalating rent payments, is recognized on a straight-line basis over the lease term. As an incentive to enter into the lease, the landlord paid approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000816" name="us-gaap:IncentiveFromLessor" contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20141130" decimals="-5" scale="6">1.4</ix:nonFraction> million of the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000817" name="ttoo:SpaceBuildOutCosts" contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20141101_20141130" decimals="-5" scale="6">2.2</ix:nonFraction> million space build-out costs. The unamortized balance of the lease incentive as of January 1, 2019 was reclassified as a reduction to the initial recognition of the right-of-use asset related to this lease. In connection with this lease agreement, the Company paid a security deposit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000815" name="us-gaap:SecurityDeposit" contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20191231" decimals="0" format="ixt:numdotdecimal">281,000</ix:nonFraction>, which was recorded as a component of both prepaid expenses and other current assets and other assets in the condensed consolidated balance sheets at December 31, 2019. In October 2020, the Company entered into an amendment to extend the term of the lease to <ix:nonNumeric id="F_000818" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20201001_20201031" format="ixt:datemonthdayyearen">October 31, 2025</ix:nonNumeric>. In accordance with this amendment, the Company paid a replacement security deposit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000819" name="us-gaap:SecurityDeposit" contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20220930" decimals="0" format="ixt:numdotdecimal">130,977</ix:nonFraction>, which is classified as restricted cash at September 30, 2022 and December 31, 2021 and received the initial $<ix:nonFraction unitRef="U_iso4217USD" id="F_000820" name="ttoo:SecurityDepositReceived" contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20211231" decimals="0" format="ixt:numdotdecimal">281,000</ix:nonFraction> security deposit in return.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2021, the Company entered into a lease for office, research, laboratory and manufacturing space in Billerica, Massachusetts. The lease has a term of <ix:nonNumeric id="F_000821" name="ttoo:TermOfLease" contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoSeptember2021Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeResearchLaboratoryAndManufacturingSpaceMember_20210901_20210930" format="ixt-sec:durmonth">126</ix:nonNumeric> months from the commencement date. At September 30, 2022, there is <ix:nonFraction unitRef="U_iso4217USD" id="F_000823" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoSeptember2021Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeResearchLaboratoryAndManufacturingSpaceMember_20220930" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000824" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoSeptember2021Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeResearchLaboratoryAndManufacturingSpaceMember_20220930" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> effect on the operating lease right-of-use assets and lease liability accounts. The Company opened a money market account for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000822" name="us-gaap:SecurityDeposit" contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoSeptember2021Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeResearchLaboratoryAndManufacturingSpaceMember_20220930" decimals="-5" scale="6">1.0</ix:nonFraction> million, which represents collateral as a security deposit for this lease and is classified as restricted cash at September 30, 2022. Occupancy of the building has been delayed due to disagreement between the Company and the landlord as to the parties&#8217; obligations under the lease agreement. Negotiations are on-going. The Company believes that a liability is reasonably possible but not probable. An estimate of the possible loss or range of loss cannot be made at this time.     </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases are amortized over the lease term and included in costs and expenses in the condensed consolidated statement of operations and comprehensive loss. Variable lease costs are recognized in costs and expenses in the condensed consolidated statement of operations and comprehensive loss as incurred. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000399" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true" continuedAt="F_000399_dcnt_7448f958-f7cc-4410-8f6b-295bab554d77">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14. Commitments and Contingencies</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">License Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2006, the Company entered into a license agreement with a third party, pursuant to which the third party granted the Company an exclusive, worldwide, sublicenseable license under certain patent rights to make, use, import and commercialize products and processes for diagnostic, industrial and research and development purposes. The Company agreed to pay an annual license fee ranging from $<ix:nonFraction unitRef="U_iso4217USD" id="F_000825" name="ttoo:LicenseFeesPayable" contextRef="C_0001492674_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20061231" decimals="INF" format="ixt:numdotdecimal">5,000</ix:nonFraction> to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000826" name="ttoo:LicenseFeesPayable" contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20061231" decimals="INF" format="ixt:numdotdecimal">25,000</ix:nonFraction> for the royalty&#8209;bearing license to certain patents. The Company also issued a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000827" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="C_0001492674_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20060101_20071231" decimals="INF" format="ixt:numdotdecimal">1,693</ix:nonFraction> shares of common stock pursuant to the agreement in 2006 and 2007, which were recorded at fair value at the date of issuance. The Company is required to pay royalties on net sales of products and processes that are covered by patent rights licensed under the agreement at a percentage ranging between <ix:nonFraction unitRef="U_xbrlipure" id="F_000828" name="ttoo:PercentageOfRoyaltyOnNetSales" contextRef="C_0001492674_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20220101_20220930" decimals="INF" scale="-2">0.5</ix:nonFraction>% - <ix:nonFraction unitRef="U_xbrlipure" id="F_000829" name="ttoo:PercentageOfRoyaltyOnNetSales" contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20220101_20220930" decimals="INF" scale="-2">3.5</ix:nonFraction>%, subject to reductions and offsets in certain circumstances, as well as a royalty on net sales of </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000399_dcnt_7448f958-f7cc-4410-8f6b-295bab554d77">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products that the Company sublicenses at </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000830" name="ttoo:RoyaltyOnNetSalesSublicensingGrossRevenue" contextRef="C_0001492674_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20220101_20220930" decimals="2" scale="-2">10</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of specified gross revenue. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalties that became due under this agreement for the three</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">months ended </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 30</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2022 and 2021</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> were </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">immaterial</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalties that became due under this agreement for the </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nine</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> months ended September 30, 2022 and 2021 were </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000831" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" contextRef="C_0001492674_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20220930" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000832" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" contextRef="C_0001492674_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20210930" decimals="-5" scale="6">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million.</span></p></ix:continuation><ix:nonNumeric id="F_000400" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_0001492674_20220101_20220930" escape="true">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15. Subsequent Events</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Equity Distribution Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subsequent to September 30, 2022, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000833" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20221001_20221109" decimals="INF" format="ixt:numdotdecimal">256,628</ix:nonFraction> shares for net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000834" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20221001_20221109" decimals="-5" scale="6">0.7</ix:nonFraction> million under the New Sales Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Reverse Stock Split</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 11, 2022, at the Company&#8217;s annual meeting of stockholders, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s restated certificate of incorporation to effect a reverse stock split of the Company&#8217;s common stock. Following the receipt of the stockholders&#8217; approval, the Company&#8217;s board of directions approved the reverse stock split at the ratio of 1 post-split share for every <span style="-sec-ix-hidden:F_000835_2">50 pre-split shares</span>, and the amendment to the Company&#8217;s restated certificate of incorporation became effective as of October 12, 2022. As a result of the reverse stock split, every <ix:nonNumeric id="F_000836" name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011_20221011">50 shares of issued and outstanding common stock of the Company were automatically reclassified and combined into 1 share of common stock</ix:nonNumeric>, with any fractional interest in shares being paid out in cash. Immediately after the reverse stock split became effective, the Company had approximately <ix:nonFraction unitRef="U_xbrlishares" id="F_000838" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000839" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011" decimals="INF" format="ixt:numdotdecimal">7,059,144</ix:nonFraction></ix:nonFraction> shares of common stock issued and outstanding. As a result of the reverse split, there was an adjustment of <ix:nonFraction unitRef="U_xbrlishares" id="F_000837" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011_20221011" decimals="INF">50</ix:nonFraction> shares for rounding. All common stock amounts and references have been retroactively adjusted for all figures presented to reflect this split unless specifically stated otherwise.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Securities Purchase Agreement</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="color:#000000;">On October 26, 2022, the private investor in the Company&#8217;s Series A redeemable convertible preferred stock redeemed all </span><ix:nonFraction unitRef="U_xbrlishares" id="F_000840" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20221026" decimals="INF" format="ixt:numdotdecimal">3,000</ix:nonFraction> shares<span style="color:#000000;"> of the Series A redeemable convertible preferred stock for an aggregate amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000841" name="us-gaap:PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable" contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20221026" decimals="-5" scale="6">0.3</ix:nonFraction> million.</span></p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This Quarterly Report on Form&#160;10-Q contains forward-looking statements about us and our industry within the meaning of the Private Securities Litigation Reform Act of 1955, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section&#160;27A of the Securities Act of 1933, and Section&#160;21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report on Form&#160;10-Q, including, without limitation, statements regarding our future results of operations and financial position, business strategy, prospective products and product candidates, their expected performance and impact on healthcare costs, marketing clearance from the FDA, reimbursement for our product candidates, research and development costs, timing of regulatory filings, timing and likelihood of success, plans and objectives of management for future operations, availability of raw materials and components for our products, availability of funding for such operations and future results of anticipated products, are forward-looking statements. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward looking statements are subject to numerous risks, including, without limitation, the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">our ability to continue as a going concern&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">our ability to regain and maintain compliance with Nasdaq listing requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">our status as an early commercial-stage company&#59;</span><span style="font-size:10pt;color:#000000;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">our expectation to incur losses in the future&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">the market acceptance of our technology&#59;</span><span style="font-size:10pt;color:#000000;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">our ability to timely and successfully develop and commercialize our existing products and future product candidates&#59;</span><span style="font-size:10pt;color:#000000;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">the length and variability of our anticipated sales and adoption cycle&#59;</span><span style="font-size:10pt;color:#000000;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">our relatively limited sales history&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">our ability to gain the support of leading hospitals and key thought leaders and publish the results of our clinical trials in peer-reviewed journals&#59;</span><span style="font-size:10pt;color:#000000;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">our ability to successfully manage our growth&#59;</span><span style="font-size:10pt;color:#000000;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">our future capital needs and our ability to raise additional funds&#59;</span><span style="font-size:10pt;color:#000000;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">the performance of our diagnostics&#59;</span><span style="font-size:10pt;color:#000000;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">our ability to compete in the highly competitive diagnostics market&#59;</span><span style="font-size:10pt;color:#000000;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">our ability to obtain marketing clearance from the U.S. Food and Drug Administration or regulatory clearance for new product candidates in other jurisdictions&#59;</span><span style="font-size:10pt;color:#000000;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;font-size:10pt;">federal, state, and foreign regulatory requirements, including diagnostic product reimbursements and FDA regulation of our products and product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;font-size:10pt;">our ability to protect and enforce our intellectual property rights, including our trade secret-protected proprietary rights in our technology&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">our ability to recruit, train and retain key personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">our dependence on third parties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">manufacturing and other product risks, including unforeseen interruptions in supply chain&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;font-size:10pt;letter-spacing:-0.2pt;">the impact of cybersecurity risks, including ransomware, phishing, and data breaches on our information technology systems&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;font-size:10pt;letter-spacing:-0.2pt;">the impact of short sellers and day traders on our share price&#59;</span><span style="color:#000000;font-size:10pt;letter-spacing:-0.2pt;">&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">the impact of the COVID-19 pandemic on our business, results of operations and financial positions&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">the continued market demand for SARS-CoV-2 testing and our ability to convert T2SARS-CoV-2 customers to our other test panels.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">These forward-looking statements represent our estimates and assumptions only as of the date of this Quarterly Report on Form&#160;10-Q. Unless required by U.S. federal securities laws, we do not intend to update any of these forward-looking statements to reflect circumstances or events that occur after the statement is made or to conform these statements to actual results. The following discussion should be read in conjunction with the financial statements and notes thereto appearing elsewhere in this Quarterly Report on Form&#160;10-Q. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under Part I, Item 2, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of this Quarterly Report on Form 10-Q, and Part I, Item 1A and Part II, Item 7A, &#8220;Risk Factors&#8221; and &#8220;Quantitative and Qualitative Disclosures about Market Risks&#8221;, respectively, in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021, as updated by Part I, Item 3, &#8220;Quantitative and Qualitative Disclosures about Market Risks&#8221; and Part II, Item 1A&#8212;&#8220;Risk Factors&#8221; in this Quarterly Report on Form&#160;10-Q. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form&#160;10-Q and the audited financial statements and notes thereto and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2021. </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Business Overview</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an <span style="font-style:italic;">in vitro</span> diagnostics company and leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. We are dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. We have developed innovative products that offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. We are developing a broad set of applications aimed at improving patient outcomes, reducing the cost of healthcare, and lowering mortality rates by helping medical professionals make earlier targeted treatment decisions. Our technology enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter, or CFU/mL. We are currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role &#8211; saving lives and reducing costs. Our current development efforts primarily target sepsis, which is an area of significant unmet medical need in which existing therapies could be more effective with improved diagnostics.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary commercial products include the T2Dx<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> Instrument, the T2Candida<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> Panel, the T2Bacteria<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> Panel, the T2Resistance<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> Panel, and the T2SARS-CoV-2&#8482; Panel. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never been profitable and have incurred net losses in each year since inception. Our accumulated deficit at September 30, 2022 was $524.1 million and we have experienced net cash outflows from operating activities over the past years. Substantially all of our net losses resulted from costs incurred in connection with our research and development programs and from selling, general and administrative costs associated with our operations.&#160;We have incurred significant commercialization expenses related to product sales, marketing, manufacturing and distribution of our FDA-cleared products, the T2Dx Instrument, T2Candida Panel and T2Bacteria Panel. In addition, we will continue to incur significant costs and expenses as we continue to develop other product candidates, improve existing products and maintain, expand and protect our intellectual property portfolio. We may seek to fund our operations through public equity or private equity or debt financings, as well as other sources. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements, if and when needed, would have a negative impact on our business, results of operations and financial condition and our ability to develop, commercialize and drive adoption of the T2Dx Instrument, T2Candida,&#160;T2Bacteria, T2Resistance, T2SARS-CoV-2 and future products.<span style="color:#000000;"> </span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to a number of risks similar to other early commercial stage life science companies, including, but not limited to commercially launching our products, development and market acceptance of our product candidates, development by our competitors of new technological innovations, protection of proprietary technology, and raising additional capital.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has impacted and may continue to impact our operations. Although we did not see any material impact to accounts receivable during the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">three and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nine</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> month period </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ended </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 30, 2022</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, our exposure may increase if our customers continue to be adversely affected by the COVID-19 pandemic, including as a result of the spread of variants of the virus. Customers may reduce their purchases of products, depending on their needs and cash flow, which could negatively impact revenue. Our customers may cease to comply with the terms of our sales agreements and this may impact our ability to recognize revenue and hinder receivables collections. We have a significant development contract with BARDA</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, as described further below, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and should BARDA reduce, cancel or not grant additional milestone projects, our ability to continue our future product development may be impacted. Our shipping carrier&#8217;s ability to deliver our products to customers may be disrupted. We have reviewed our suppliers and quantities of key materials and believe we have sufficient stocks and alternate sources of critical materials should our supply chains </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continue to be</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> disrupted, although raw materials and plastics for the manufacturing of reagents and consumables are in high demand, and interruptions in supply are difficult to predict. </span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 9, 2022, the Company announced it was exploring the potential to develop a rapid molecular diagnostic test for detection of the monkeypox virus, including technical and commercial feasibility. While the Company believes it is&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technically feasible, it&#160;has concluded that the current market opportunity does not currently support the investment of time and resources in developing a rapid molecular diagnostic test for detection of the monkeypox virus.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the third quarter of 2021, we signed a lease for the purpose of consolidating our existing operations into a single 70,000 square foot, state-of-the-art life sciences facility in Billerica, Massachusetts, to accommodate current and future growth. <span style="color:#000000;">Occupancy of the building has been delayed due to disagreement between Management and the landlord as to the parties&#8217; obligations under the lease agreement. Negotiations are on-going. We believe that a liability is reasonably possible but not probable. An estimate of the possible loss or range of loss cannot be made at this time.  &#160;&#160; </span> </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our cash, cash equivalents, and restricted cash of $21.5 million at September 30, 2022 will not be sufficient to fund our current operating plan for at least a year from issuance of these financial statements unless additional funds are raised. Absent any reductions in current operating expenses, the Company believes it will require additional financing during the first quarter of 2023. Certain elements of our operating plan cannot be considered probable. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Term Loan Agreement with CRG Servicing LLC (&#8220;CRG&#8221;) (Note 6) has a minimum liquidity covenant which requires us to maintain a minimum cash balance of $5.0 million. There can be no assurances that we will continue to be in compliance with the cash covenant in future periods without additional funding. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2022, CRG amended the Term Loan Agreement extending the interest only period and maturity to December 30, 2023. In November 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2024.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;31, 2022, BARDA, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services exercised Option 2B under our existing multiple-year cost-share agreement with BARDA and the Company and is providing an additional $4.4 million in funding to us. The total potential BARDA funding if all contract options are exercised is $69.0 million. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The option exercise occurred simultaneously on March&#160;31, 2022 with a modification to the BARDA Contract to make immaterial changes to, among other things, the statement of work. The modification does not change the overall total potential value of the BARDA agreement.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2022, BARDA exercised Option 3 under our existing multiple-year cost-share agreement and agreed to provide an additional $3.7 million in funding. The additional funding under Option 3 will be used to advance the U.S. clinical trials for the T2Biothreat<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;Panel and T2Resistance<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;Panel and to file submissions to the FDA for U.S. regulatory clearance. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 5, 2021, we received a letter from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) indicating that we were not in compliance with the requirement of Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market as a result of the closing bid price of our common stock being below $1.00 per share for thirty consecutive business days (the &#8220;Bid Price Rule&#8221;). Under the Nasdaq rules, we had 180 days (or until May 4, 2022) to regain compliance by maintaining a minimum closing bid price of <span style="color:#000000;">$1.00 per share of our common stock for at least ten consecutive trading days during such compliance period. On May 5, 2022, we received a letter from Nasdaq informing us that our shares of common stock have failed to comply with the Bid Price Rule for continued listing and, as a result, our shares were subject to delisting. The letter further stated that we may appeal the Nasdaq Staff delisting determination to a Nasdaq listing qualifications hearings panel (the &#8220;Panel&#8221;).</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We filed an appeal and hearing request to the Nasdaq Staff&#8217;s determination to stay the delisting of our shares of common stock from Nasdaq pending the Panel&#8217;s decision. The Nasdaq Staff informed us that the delisting action had been stayed, pending a final written decision by the Panel, and the hearing date had been set for June 2, 2022. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 9, 2022, we received a letter from the Nasdaq notifying us that the Nasdaq had granted our request to be transferred to The Nasdaq Capital Market, effective at the open of trading on June 13, 2022, and our request for an exception to the Bid Price Rule until November 1, 2022. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 11, 2022, at the annual meeting of stockholders, our stockholders approved an amendment to our restated certificate of incorporation to effect a reverse stock split of our common stock. Following the receipt of the stockholders&#8217; approval, our board of directors approved the reverse stock split ratio at the ratio of 1 post-split share for every 50 pre-split shares, which was effective as of October 12, 2022. On October 31, 2022, we received a letter from Nasdaq informing us that we regained compliance with the Bid Price Rule. All common stock amounts and references in this Quarterly Report have been retroactively adjusted for all figures presented to reflect this split unless specifically stated otherwise.  </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;22, 2022, we received a letter from the Nasdaq indicating that, for the last thirty-five consecutive business days, the Market Value of Listed Securities, as defined by Nasdaq (&#8220;MVLS&#8221;) had been below the $35&#160;million minimum requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), we have been provided an initial period of 180 calendar days, or until January&#160;18, 2023, to regain compliance. The letter states that the Nasdaq staff will provide written notification that we have achieved compliance with Rule&#160;5550(b)(2) if at any time before January&#160;18, 2023, we maintain our MVLS at $35&#160;million or more for a minimum of ten consecutive business days. The Nasdaq Staff Deficiency Letter has no immediate effect on the listing or trading of our common stock.&#160;&#160;If compliance is not achieved by January&#160;18, 2023, we expect that Nasdaq would provide written notification to us that our securities are subject to delisting. We will continue to monitor our MVLS and consider our available options to regain compliance with the Nasdaq minimum MVLS requirements, which may include applying for an extension of the compliance period or appealing to a Nasdaq Hearings Panel. On August 24, 2022, i<span style="color:#000000;">n a Compliance Notice, the Nasdaq notified us that, from August 10, 2022 to August 23, 2022, our MVLS had been $35 million or greater and, accordingly, we had regained compliance with Rule </span><span style="Background-color:#FFFFFF;">5550(b)(2) </span><span style="color:#000000;">and that the matter was now closed.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These conditions raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that the financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include raising additional funding, earning payments pursuant to our contract with BARDA, delaying certain research projects and capital expenditures and eliminating certain future operating expenses in order to fund operations at reduced levels for us to continue as a going concern for a period of 12 months from the date these unaudited condensed consolidated financial statements are issued. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least 12 months from the date of issuance of these financial statements.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financial Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generate revenue from the sale of our products, related services, reagent rental agreements and government contributions. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grants received, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue is generated by the sale of instruments and consumable diagnostic tests predominantly through our direct sales force in the United States and distributors in geographic regions outside the United States. We do not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to our customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors&#8217; receipt of payment from their end-user customers. We either sell instruments to customers and international distributors, or retain title and place the instrument at the customer site pursuant to a reagent rental agreement.&#160;When the instrument is placed under a reagent rental agreement, our customers generally agree to fixed term agreements, which can be extended, and incremental charges on each consumable diagnostic test purchased. Shipping and handling costs are billed to customers in connection with a product sale.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fees paid to member-owned group purchasing organizations (&#8220;GPOs&#8221;) are deducted from related product revenues.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct sales of instruments include warranty, maintenance and technical support services typically for one year following the installation of the purchased instrument (&#8220;Maintenance Services&#8221;).&#160;Maintenance Services are separate performance obligations as they are service-based warranties and are recognized on a straight-line basis over the service delivery period. After the completion of the initial Maintenance Services period, customers have the option to renew or extend the Maintenance Services typically for additional one-year periods in exchange for additional consideration.&#160;The extended Maintenance Services are also service-based warranties that represent separate purchasing decisions.&#160;&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We warrant that consumable diagnostic tests will be free from defects, when handled according to product specifications, for the stated life of the product. To fulfill valid warranty claims, we provide replacement product free of charge. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current sales strategy is to drive adoption of our test platform installed base in hospitals, to increase test use by our existing hospital customers, and to expand T2SARS-CoV-2 customers to sepsis testing. Accordingly, we expect the following to occur:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">recurring revenue from our consumable diagnostic tests will increase&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">become a more predictable and significant component of total revenue&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we will gain manufacturing economies of scale through the growth in our sales, resulting in improving gross margins and operating margins.&#160;&#160;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe the COVID-19 pandemic hindered our U.S. and international sales growth. Our customers may cease to comply with the terms of our sales agreements and this may impact our ability to recognize revenue and hinder receivables collections. We have a significant development contract with BARDA and should BARDA reduce, cancel or not grant additional milestone projects, our ability to continue our future product development may be impacted.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of Product Revenue </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product revenue includes the cost of materials, direct labor and manufacturing overhead costs used in the manufacture of our consumable diagnostic tests sold to customers and related license and royalty fees. Cost of product revenue also includes depreciation on the revenue-generating T2Dx instruments that have been placed with our customers under reagent rental agreements&#59; costs of materials, direct labor and manufacturing overhead costs on the T2Dx instruments sold to customers&#59; and other costs such as customer support costs, warranty and repair and maintenance expense on the T2Dx instruments that have been placed with our customers under reagent rental agreements. We manufacture the T2Dx instruments and part of our consumable diagnostic tests in our facilities. We outsource the manufacturing of components of our consumable diagnostic tests to contract manufacturers. We expect cost of product revenue to decrease as a percentage of revenue as a result of the cost of product revenue improvement initiatives.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development expenses </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development expenses consist primarily of costs incurred for the development of our technology and product candidates, technology improvements and enhancements, clinical trials to evaluate the clinical utility of our product candidates, and laboratory development and expansion, and include salaries and benefits, including stock-based compensation, research related facility and overhead costs, laboratory supplies, equipment, depreciation on T2Dx instruments used in research and development activities and contract services. Research and development expenses also include costs of delivering products or services associated with contribution revenue. We expense all research and development costs as incurred.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate our overall research and<span style="color:#000000;"> development expenses to remain consistent or increase in support of increased activity under the BARDA agreement. We expect to continue developing additional product candidates, improving existing products, and conducting ongoing and new clinical trials. We have a significant development contract with BARDA and should BARDA reduce, cancel or not grant additional milestone projects, our ability to continue our future product development may be impacted. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Selling, general and administrative expenses </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses consist primarily of costs for our sales and marketing, finance, legal, human resources, business development and general management functions, as well as professional services, such as legal, consulting and accounting services. Other selling, general and administrative expenses include commercial support activity, facility-related costs, fees and expenses associated with obtaining and maintaining patents, clinical and economic studies and publications, marketing expenses, and travel expenses. We expense the majority of selling, general and administrative expenses as incurred. We expect selling, general and administrative expenses to decrease as a percentage of revenue in future periods. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest </span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">income</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income consists of interest earned on our cash and cash equivalents.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest expense </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense consists primarily of interest expense on our notes payable, the amortization of deferred financing costs and debt discount.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Change in fair value of derivative instrument </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="color:#000000;"> change</span> in fair value of the derivative consists of the change in fair value of the derivative associated with the CRG Term Loan Agreement. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Change in fair value of derivative warrant liability</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="color:#000000;"> change</span> in fair value of the derivative consists of the change in fair value of the derivative warrant liability associated with the Securities Purchase Agreement. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other income (expense), net </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net, consists of dividend and other investment income. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Use of Estimates </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have prepared our condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States.&#160;Our preparation of these condensed consolidated financial statements requires us to make estimates, assumptions, and judgments that affect the reported amounts of assets, liabilities, expenses, and related disclosures at the date of the condensed consolidated financial statements, as well as revenue and expenses recorded during those periods.&#160;We evaluated our estimates and judgments on an ongoing basis.&#160;We based our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.&#160;Actual results could therefore differ materially from these estimates under different assumptions or conditions. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The items that we disclosed as our critical accounting policies and estimates in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021 remained materially consistent. For a description of those critical accounting policies, please refer to our Annual Report on Form&#160;10-K filing for the year ended December&#160;31, 2021. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations for the Three Months Ended September&#160;30, 2022 and 2021 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,641</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,306</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,665</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contribution revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,036</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,122</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,086</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,677</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,428</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,751</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,085</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,720</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,365</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,375</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,384</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,017</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,536</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,519</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total costs and expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,477</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,640</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(163</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,800</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,212</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,588</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,560</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,919</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">359</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative instrument</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(117</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(117</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative warrant liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(78</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(241</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,575</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,750</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,375</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,962</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,413</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Product revenue</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue was $2.6 million for the three months ended September 30, 2022 compared to $4.3 million for the three months ended September 30, 2021, a decrease of $1.7 million, which was driven by lower consumables sales of $2.0 million mostly due to a decrease in sales of <span style="Background-color:#FFFFFF;color:#000000;">T2SARS-CoV-2</span>, offset by higher T2Dx sales of $0.3 million.  </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contribution revenue </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contribution revenue relates to our BARDA agreement and was $1.0 million for the three months ended September&#160;30, 2022, compared to $3.1 million for the three months ended September 30, 2021. The decrease of $2.1 million was due to timing of the contract activity and the option amounts.   </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of product revenue </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product revenue was $6.1 million for the three months ended September&#160;30, 2022, compared to $4.7 million for the three months ended September&#160;30, 2021, an increase of $1.4 million. The increase was driven by $2.4 million of higher costs due to the effect of a change in build plan and manufacturing inefficiencies and $0.3 million of costs related to higher instrument sales, partially offset by $1.0 million of decreased costs related to lower consumable sales, $0.1 million of lower service and repair costs, $0.1 million of lower royalties, and $0.1 million of lower shipping and other costs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development expenses </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $6.4 million for the three months ended September&#160;30, 2022 and 2021. Clinical-related expenses increased by $0.9 million primarily for our T2Resistance Panel 510(k) Study and T2Biothreat Panel, and internal usage for our T2Resistance research and development projects increased by $0.8 million. These increases were offset by decreased lab and facility expenses of $0.9 million primarily due to BARDA and less IT support services, decreased materials costs of $0.4 million, decreased consulting expenses of $0.2 million for BARDA, and decreased stock based compensation expenses of $0.2 million. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Selling, general and administrative expenses </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses were </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.0 million</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the three months ended </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30, 2022</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compared to </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.5 million</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the three months ended</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30, 2021</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">de</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">crease</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">de</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">crease was driven by </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lower stock based compensation expenses of $1.1 million</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">primarily due to the $0.8 million equity modification recorded in the third quarter of 2021 upon a previous director&#8217;s resignation</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lower consulting expenses of $0.3 million</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> due to the timing of the annual meeting</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and the 2021 payments associated with a previous director&#8217;s resignation, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and lower payroll related expenses of $0.2 million</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> due to lower 2022 quarter-to-date average headcount</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, partially offset by $0.1 million of increased travel expenses due to increased </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tradeshows</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and conferences</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest income </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income was immaterial for the three months ended September 30, 2022 and 2021. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest expense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense was $1.6 million for the three months ended September&#160;30, 2022, compared to $1.9 million for the three months ended September&#160;30, 2021, a decrease of $0.3 million, primarily due to amortization of the debt discount and the final fee interest associated with the CRG Term Loan Agreement (Note 6).</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Change in fair value of derivative instrument </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The change in fair value of the derivative instrument associated with the CRG Term Loan Agreement (Note 6) was $0.1 million of expense for the three months ended September 30, 2022. There was no derivative liability recorded at September 30, 2021 as we had achieved the only remaining revenue covenant in June 2021 and had sufficient cash and cash equivalents that the minimum liquidity covenant would not be triggered, relieving the derivative liability. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Change in fair value of derivative warrant liability  </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The change in fair value of the derivative warrant liability associated with the Securities Purchase Agreement (Note 7) was a $0.2 million reduction of expense for the three months ended September 30, 2022. There was no derivative warrant liability recorded at September 30, 2021. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other income (expense), net </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net, was expense of $0.1 million for the three months ended September 30, 2022 primarily due to the loss recorded upon issuance of the Series A redeemable convertible preferred stock and warrant compared to income of $0.2 million for the three months ended September 30, 2021 primarily from a one-time payment.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5%;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations for the Nine Months Ended September&#160;30, 2022 and 2021 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,044</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,634</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,590</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contribution revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,778</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,444</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(666</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,822</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,078</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,256</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,371</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,341</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,030</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,056</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,448</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,608</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,071</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,983</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,088</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total costs and expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,498</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,772</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,726</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,676</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,694</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,982</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,556</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,642</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,086</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative instrument</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,792</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,010</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,802</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative warrant liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">211</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(276</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,228</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,403</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,825</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,904</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,097</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,807</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Product revenue</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue was $9.0 million for the nine months ended September&#160;30, 2022 compared to $12.6 million for the nine months ended September&#160;30, 2021, a decrease of $3.6 million, which was driven by lower consumables sales of $4.7 million mostly due to a decrease in sales of <span style="Background-color:#FFFFFF;color:#000000;">T2SARS-CoV-2</span>, offset by higher T2Dx sales of $1.1 million. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contribution revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contribution revenue relates to our BARDA agreement and was $7.8 million for the nine months ended September&#160;30, 2022 compared to $8.4 million for the nine months ended September 30, 2021. The decrease of $0.6 million was primarily due to decreased contract activity and the amount of the options.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of product revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product revenue was $17.3 million for the nine months ended September&#160;30, 2022, compared to $15.3 million for the nine months ended September&#160;30, 2021, an increase of $2.0 million.&#160;The increase in cost was driven by $4.2 million of higher costs due to the effect of a change in build plan and manufacturing inefficiencies, $1.7 million of costs due to higher instrument sales, $0.6 million of higher service and repair costs, $0.2 million of higher shipping and other related expenses, partially offset by $4.5 million of decreased costs related to lower consumable sales, and $0.2 million of lower royalties. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $21.0 million for the nine months ended September&#160;30, 2022, compared to $16.4 million for the nine months ended September&#160;30, 2021, an increase of $4.6 million.&#160;The increase was driven by clinical related expenses of $1.8 million for our T2Resistance Panel 510(k) Study and T2Biothreat Panel, internal usage of $1.3 million primarily for T2Resistance research and development projects, higher payroll related expenses of $0.8 million and stock based compensation expenses of $0.2 million due to a higher 2022 year-to-date average headcount, higher materials costs of $0.6 million and consulting expenses of $0.3 million primarily for BARDA, partially offset by a decrease of $0.1 million in lab and facility expenses related to less IT support services.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Selling, general and administrative expenses </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses were $24.1 million for the nine months ended September&#160;30, 2022, compared to $22.0 million for the nine months ended September&#160;30, 2021, an increase of $2.1 million. The increase was driven by a $1.5 million increase in payroll related expenses due to higher year-to-date average headcount, $0.5 million of increased travel primarily from higher average sales headcount, tradeshows and conferences, $0.4 million of increased marketing expenses primarily for tradeshows and conferences, and other expenses of $0.1 million for software, professional dues and equipment to support the higher 2022 year-to-date average headcount, partially offset by lower stock based compensation expenses of $0.4 million primarily due to the $0.8 million equity modification recorded in the third quarter of 2021 upon a previous director&#8217;s resignation, partially offset by the higher 2022 year-to-date average headcount. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest income </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income was immaterial for the nine months ended September 30, 2022 and 2021. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest expense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense was $4.5 million for the nine months ended September&#160;30, 2022, compared to $5.6 million for the nine months ended September&#160;30, 2021. Interest expense decreased by $1.1 million primarily due to amortization of the debt discount and the final fee interest associated with the CRG Term Loan Agreement.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Change in fair value of derivative instrument </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The change in fair value of the derivative instrument was $1.8 million of expense for the nine months ended September 30, 2022 due to the probability of triggering a violation of the minimum liquidity covenant associated with the CRG Term Loan Agreement (Note 6). The change in fair value of the derivative instrument was a $1.0 million reduction of expense for the nine months ended September 30, 2021 as we achieved the only remaining revenue covenant in June 2021 and had sufficient cash and cash equivalents that the minimum liquidity covenant would not be triggered, relieving the derivative liability.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Change in fair value of derivative warrant liability </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The change in fair value of the derivative warrant liability associated with the Securities Purchase Agreement (Note 7) was a $0.2 million reduction of expense for the nine months ended September 30, 2022. There was no derivative warrant liability recorded at September 30, 2021.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other income (expense), net </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net, was expense of $0.1 million for the nine months ended September&#160;30, 2022 primarily due to the loss recorded upon issuance of the Series A redeemable convertible preferred stock and warrant compared to income of $0.2 million for the nine months ended September 30, 2021 primarily from a one-time payment.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred losses and cumulative negative cash flows from operations since our inception, and as of September&#160;30, 2022 and December&#160;31, 2021, we had an accumulated deficit of $524.1 million and $472.2 million, respectively. Having obtained clearance from the FDA and a CE mark in Europe to market the T2Dx Instrument, T2Candida Panel, and T2Bacteria Panel, we have incurred significant commercialization expenses related to product sales, marketing, manufacturing and distribution. We may seek to continue to fund our operations through public equity or private equity or debt financings, as well as other sources. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements, if and when needed, would have a negative impact on our business, results of operations and financial condition and our ability to develop and commercialize T2Dx, T2Candida, T2Bacteria, T2SARS-CoV-2 and other <span style="color:#000000;">product candidates.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historically, we have funded<span style="color:#000000;"> our operations primarily through our August 2014 initial public offering, our December 2015 public offering, our September 2016 private investment in public equity (&#8220;PIPE&#8221;) financing, our September 2017 public offering, our June 2018 public offering, our</span><span style="Background-color:#FFFFFF;"> July 2019 establishment of an Equity Distribution Agreement and Equity Purchase Agreement (Note </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">8</span><span style="Background-color:#FFFFFF;">), </span><span style="color:#000000;">our March 2021 establishment of an Equity Distribution Agreement (Note </span><span style="color:#000000;">8</span><span style="color:#000000;">), </span><span style="Background-color:#FFFFFF;">private placements of redeemable convertible preferred stock and debt financing </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arrangements.</span><span style="Background-color:#FFFFFF;"> </span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, our shareholders approved an increase in the number of authorized shares of our common stock from 200,000,000 to 400,000,000.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Equity Distribution Agreement&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 31, 2021, we entered into a Sales Agreement with Canaccord (&#8220;New Sales Agreement&#8221;), as agent, pursuant to which we may offer and sell shares of common stock, for aggregate gross sale proceeds of up to $75.0 million from time to time from the effective date of the respective registration statement through Canaccord. Under the New Sales Agreement, we sold 3,668,784 shares for net proceeds of $28.1 million during the nine months ended September 30, 2022 and <ix:nonFraction unitRef="U_xbrlishares" id="F_000668_2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20210101_20210930" decimals="INF" format="ixt:numdotdecimal">336,188</ix:nonFraction> shares for net proceeds of $20.0 million during the nine months ended September 30, 2021. Under the New Sales Agreement, we sold 3,080,451 shares for net proceeds of $22.2 million during the three months ended September 30, 2022 and did not sell any shares during the three months ended September 30, 2021. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subsequent to September 30, 2022, we sold 256,628 shares for net proceeds of $0.7 million under the New Sales Agreement. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We agreed to pay Canaccord for its services of acting as agent 3% of the gross proceeds from the sale of the shares pursuant to the New Sales Agreement.&#160;Legal and accounting fees are reclassified to share capital upon issuance of shares under the New Sales Agreements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Plan of operations and future funding requirements </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2022 and December&#160;31, 2021, we had unrestricted cash and cash equivalents of approximately $21.5 million and $22.2 million, respectively.<span style="color:#000000;"> Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, costs related to our products, clinical trials, laboratory and related supplies, supplies and materials used in manufacturing, legal and other regulatory expenses and general overhead costs.</span> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time as we can generate substantial product revenue, we expect to finance our cash needs, beyond what is currently available or on hand, through a combination of equity offerings, debt financings and revenue from existing and potential research and development and other collaboration agreements. If we raise additional funds in the future, we may need to relinquish valuable rights to our technologies, future revenue streams or grant licenses on terms that may not be favorable to us<span style="color:#000000;">.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has impacted and may continue to impact our operations. Although we did not see any material impact to accounts receivable during the nine months ended September 30, 2022, our exposure may increase if our customers continue to be adversely affected by the COVID-19 pandemic, including as a result of the spread of variants of the virus. Customers may reduce their purchases of products, depending on their needs and cash flow, which could negatively impact revenue. Our customers may cease to comply with the terms of our sales agreements and this may impact our ability to recognize revenue and hinder receivables collections. We have a significant development contract with BARDA and should BARDA reduce, cancel or not grant additional milestone projects, our ability to continue our future product development may be impacted. Our shipping carrier&#8217;s ability to deliver our products to customers may be disrupted. We have reviewed our suppliers and quantities of key materials and believe we have sufficient stocks and alternate sources of critical materials should our supply chains continue to be disrupted, although raw materials and plastics for the manufacturing of reagents and consumables are in high demand, and interruptions in supply are difficult to predict. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Going Concern</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our cash, cash equivalents, and restricted cash of $21.5 million at September 30, 2022 will not be sufficient to fund our current operating plan for at least a year from issuance of these financial statements. Absent any reductions in current operating expenses, we believe we will require additional financing during the first quarter of 2023. Certain elements of our operating plan cannot be considered probable. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Term Loan Agreement with CRG Servicing LLC (&#8220;CRG&#8221;) (Note 6) has a minimum liquidity covenant which requires us to maintain a minimum cash balance of $5.0 million. There can be no assurances that we will continue to be in compliance with the cash covenant in future periods without additional funding. In February 2022, CRG amended the Term Loan Agreement extending the interest only period and maturity to December 30, 2023. In November 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2024.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 5, 2021, we received a letter from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) indicating that we were not in compliance with the requirement of Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market as a result of the closing bid price of our common stock being below $1.00 per share for thirty consecutive business days</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(the &#8220;Bid Price Rule&#8221;)</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 11, 2022, at the annual meeting of stockholders, our stockholders approved an amendment to our restated certificate of incorporation to effect a reverse stock split of our common stock. Following the receipt of the stockholders&#8217; approval, our board of directors approved the reverse stock split ratio at the ratio of 1 post-split share for every 50 pre-split shares, which was effective as of October 12, 2022. On October 31, 2022, we received a letter from Nasdaq informing us that we regained compliance with the Bid Price Rule. See the discussion under &#8220;Liquidity and Going Concern&#8221; in Note 1 in the notes to the condensed consolidated financial statements for further information. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;22, 2022, we received a letter from the Nasdaq indicating that, for the last thirty-five consecutive business days, the Market Value of Listed Securities, as defined by Nasdaq (&#8220;MVLS&#8221;) had been below the $35&#160;million minimum requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), we have been provided an initial period of 180 calendar days, or until January&#160;18, 2023, to regain compliance. The letter states that the Nasdaq staff will provide written notification that we have achieved compliance with Rule&#160;5550(b)(2) if at any time before January&#160;18, 2023, we maintain our MVLS at $35&#160;million or more for a minimum of ten consecutive business days. The Nasdaq Staff Deficiency Letter has no immediate effect on the listing or trading of our common stock.&#160;&#160;If compliance is not achieved by January&#160;18, 2023, we expect that Nasdaq would provide written notification to us that our securities are subject to delisting. We will continue to monitor our MVLS and consider our available options to regain compliance with the Nasdaq minimum MVLS requirements, which may include applying for an extension of the compliance period or appealing to a Nasdaq Hearings Panel. On August 24, 2022, i<span style="color:#000000;">n a Compliance Notice, the Nasdaq notified us that, from August 10, 2022 to August 23, 2022, our MVLS had been $35 million or greater and, accordingly, we had regained compliance with Rule </span><span style="Background-color:#FFFFFF;">5550(b)(2) </span><span style="color:#000000;">and that the matter was now closed.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These conditions raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that the financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include raising additional funding, earning payments pursuant to our contract with BARDA, delaying certain research projects and capital expenditures and eliminating certain future operating expenses in order to fund operations at reduced levels for us to continue as a going concern for a period of 12 months from the date the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q are issued. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least 12 months from the date of issuance of these financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash flows </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of cash flows for each of the periods set forth below: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,300</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,032</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,695</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,990</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,306</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,296</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net change in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,299</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,254</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net cash used in operating activities </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities was approximately $40.3 million for the nine months ended September 30, 2022, and consisted of a net loss of $51.9 million adjusted for non-cash items including stock-based compensation expense of $5.5 million, a change in fair value of the derivative of $1.8 million, non-cash interest expense of $1.6 million, non-cash lease expense of $0.9 million, depreciation and amortization expense of $0.8 million, a change in fair value of the derivative warrant liability of $0.2 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">loss on issuance of Series A redeemable convertible preferred stock and warrant of $0.1 </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and a net change in operating assets and liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The net change in operating assets and liabilities was primarily driven</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> by a decrease in accounts receivable of $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million due to </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BARDA payments and the timing and volume of instrument and consumable sales,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a decrease in prepaid expenses and other assets of $0.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> due to timing of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deposits</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for goods and services,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an increase in accrued expenses of $0.1 million primarily from </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">accrued clinical for our T2Resistance 510(k) Study</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">partially offset by </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a decrease in operating lease liabilities of $0.9 million, a decrease in accounts payable of $0.8 million primarily due to timing of invoices and payments</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an increase in inventory of $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.8</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million due to</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> securing raw materials and bulk materials purchases for favorable pricing</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a decrease in deferred revenue of $0.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million due to </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">timing of our </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ratably recognized service agreements.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities was approximately $29.0 million for the nine months ended September 30, 2021, and consisted of a net loss of $37.1 million adjusted for non-cash items including stock-based compensation expense of $5.6 million, non-cash interest expense of $2.8 million, non-cash lease expense of $1.0 million, depreciation and amortization expense of $1.0 million, a change in fair value of the derivative of $1.0 million, amortization of bond premium of $0.1 million and a net change in operating assets and liabilities of $1.4 million. The net change in operating assets and liabilities was primarily driven by an increase of $1.9 million in inventory to support the 2021 build plan, a decrease in operating lease liabilities of $0.8 million, an increase in prepaid expenses and other assets of $0.7 million primarily related to an increase in insurance, increased software subscriptions and the security deposit receivable for one of our operating leases, partially offset by a decrease in accounts receivable of $0.9 million primarily due to the timing and volume of consumable and instrument sales partially offset by an increase in accounts receivable for our BARDA agreement, an increase in accrued expenses of $0.6 million primarily due to the timing and volume of increased research activities, consulting and the employee stock purchase plan, and an increase in accounts payable of $0.5 million due to timing of payments<span style="Background-color:#FFFFFF;color:#000000;">.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net cash provided by investing activities </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by investing activities was $9.7 million for the nine months ended September 30, 2022, and primarily consisted of proceeds from sales of marketable securities of $10.0 million, partially offset by equipment purchases of $0.3 million. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by investing activities was approximately $15.0 million for the nine months ended September 30, 2021, and primarily consisted of proceeds from maturities of marketable securities of $15.3 million, partially offset by equipment purchases of $0.3 million. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net cash provided by financing activities </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities was approximately $28.3 million for the nine months ended September 30, 2022, and consisted primarily of proceeds from sales of our common stock under the New Sales Agreement, net of issuance costs, of $28.1 million, proceeds from issuance of Series A redeemable convertible preferred stock and warrant of $0.3 million, proceeds from issuance of shares under our 2014 Employee Stock Purchase Plan of $0.1 million, offset by payment of employee restricted stock tax withholdings of $0.2 million. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities was approximately $20.3 million for the nine months ended September 30, 2021, and consisted primarily of proceeds from sales of our common stock under the Sales Agreement, net of issuance costs, of $20.0 million, and of proceeds from issuance of shares under our 2014 Employee Stock Purchase Plan and stock option exercises of $0.3 million.  </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Borrowing Arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Term Loan Agreement </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, we entered into a Term Loan Agreement with CRG. We borrowed $40.0 million pursuant to the Term Loan Agreement. Interest on the amounts borrowed under the Term Loan Agreement accrues at an annual fixed rate of (a) prior to the Approval Milestone (as defined therein), 12.50%, 4.0% of which may be deferred during the interest-only period by adding such amount to the aggregate principal loan amount and (b) following the Approval Milestone, 11.50%, 3.5% of which may be deferred during the interest-only period by adding such amount to the aggregate principal loan amount. In addition, if we achieve certain financial performance metrics, the loan will convert to interest-only until the maturity date, at which time all unpaid principal and accrued unpaid interest will be due and payable. We are required to pay CRG a financing fee based on the loan principal amount drawn. We are also required to pay a final payment fee of 8%, subsequently amended to 10%, of the principal outstanding upon repayment. We are accruing the final payment fee as interest expense and it is included as a non-current liability at September 30, 2022 and December 31, 2021 on the balance sheet. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Term Loan Agreement with CRG is classified as non-current at September 30, 2022 and December 31, 2021 as we have sufficient cash and cash equivalents that the minimum liquidity covenant would not be triggered. <span style="color:#000000;">We have assessed the classification of the note payable as non-current based on facts and circumstances as of the date of this filing, specifically as it relates to the </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">probability of triggering the </span><span style="color:#000000;">minimum liquidity </span><span style="color:#000000;">covenant. Management continues to reassess at each balance sheet and filing date based on facts and circumstances and can provide no assurances regarding the probability of meeting its</span><span style="color:#000000;"> minimum liquidity </span><span style="color:#000000;">covenant in future periods.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may prepay all or a portion of the outstanding principal and accrued unpaid interest under the Term Loan Agreement at any time upon prior notice subject to a certain prepayment fee during the first five years of the term and no prepayment fee thereafter. As security for our obligations under the Term Loan Agreement, we entered into a security agreement with CRG whereby we granted a lien on substantially all of its assets, including intellectual property. The Term Loan Agreement also contains customary affirmative and negative covenants for a credit facility of this size and type, including a requirement to maintain a minimum cash balance of $5.0 million. The Term Loan Agreement also requires us to achieve certain revenue targets, whereby we are required to pay double the amount of any shortfall as an acceleration of principal payments. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, the Term Loan Agreement was amended to reduce minimum revenue targets, extend the interest-only period and extend the principal repayment. The final payment fee was increased from 8% to 10% of the principal amount outstanding upon repayment. We issued to CRG warrants to purchase 11,365 shares of the Company&#8217;s common stock (&#8220;New Warrants&#8221;) (Note 10) at an exercise price of $77.50, with typical provisions for termination upon a change of control or a sale of all or substantially all of the assets of the Company.&#160;&#160;We also reduced the exercise price for the warrants previously issued to CRG to purchase an aggregate of 10,579 shares of our common stock to $77.50. All of the New Warrants are exercisable any time prior to September 9, 2029, and all of the previously issued warrants are exercisable any time prior to December 30, 2026.<span style="color:#000000;"> </span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, the Term Loan Agreement was amended to extend the interest-only payment period through December 30, 2022, to extend the initial principal repayment to December 30, 2022, and to significantly reduce the revenue covenant for the 24-month period beginning on January 1, 2020. We did not pay or provide any consideration in exchange for this amendment. We accounted for the January 2021 amendment as a modification to the Term Loan Agreement. In June 2021, the Company satisfied the only remaining revenue covenant which was for the 24-month period beginning on January 1, 2020. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2022, the Term Loan Agreement was amended to extend the interest-only payment period through December 30, 2023, and to extend the initial principal repayment to December 30, 2023. We did not pay or provide any consideration in exchange for this amendment. As the effective borrowing rate under the amended agreement is less than the effective borrowing rate under the previous agreement, a concession is deemed to have been granted under ASC 470-60. As a concession has been granted, the agreement was accounted for as a troubled debt restructuring under ASC 470-60. The amendment did not result in a gain on restructuring as the future undiscounted cash outflows required under the amended agreement exceed the carrying value of the debt immediately prior to the amendment.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2024.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Term Loan Agreement includes a subjective acceleration clause whereby an event of default, including a material adverse change in the business, operations, or conditions (financial or otherwise), could result in the acceleration of the obligations under the Term Loan Agreement. Under certain circumstances, a default interest rate of an additional 4.0%&#160;per annum will apply at the election of CRG on all outstanding obligations during the occurrence and continuance of an event of default.&#160;CRG has not exercised its right under this clause.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We assessed the terms and features of the&#160;Term Loan Agreement, including the interest-only period dependent on the achievement of the Approval Milestone and the acceleration of the obligations under the Term Loan Agreement under an event of default, of the Term Loan Agreement&#160;in order to identify any potential embedded features that would require bifurcation. In addition, under certain circumstances, a default interest rate of an additional 4.0% per annum will apply at the election of CRG on all outstanding obligations during the occurrence and continuance of an event of default, we concluded that the features of the&#160;Term Loan Agreement&#160;are not clearly and closely related to the host instrument, and represent a single compound derivative that is required to be re-measured at fair value on a quarterly basis.&#160; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Securities Purchase Agreement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.2%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 15, 2022, we entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;), pursuant to which we issued in a private placement transaction an aggregate of 3,000 shares of Series A Redeemable Convertible Preferred Stock with a par value of $0.001 per share and a warrant to purchase up to an aggregate of 42,857 shares of our common stock at an exercise price of $7.50 per share for an aggregate subscription amount equal to $0.3 million, before deducting estimated offering expenses payable. The Series A Redeemable Convertible Preferred Stock was issued at a price of $100 per share (the Stated Value). Pursuant to the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase Agreement, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock with the Secretary of State </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the State </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of Delaware designating the rights, preferences and limitations of the Series A </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Redeemable Convertible </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> On October 26, 2022, the private investor in our Series A Redeemable Convertible Preferred Stock redeemed all 3,000 shares of the Series A Redeemable Convertible Preferred Stock for an aggregate amount of $330,000.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the execution of the Securities Purchase Agreement, we also issued a warrant to purchase 42,857 shares of our common stock (the &#8220;Warrant Shares&#8221;) at an exercise price equal to $7.50 per share, subject to adjustments noted below. The Warrant will become exercisable on February 15, 2023 and has a term ending February 15, 2028. At issuance, we determined that the Warrant should be classified as a liability because such Warrant could require cash redemption in certain circumstances. Recognition of the warrant liability created a day one loss of $0.1 million.&#160;&#160;Accordingly, the Warrant is carried at fair value, with changes in fair value recognized in other income (expense), net. See Note 7 in the notes to the condensed consolidated financial statements in this Quarterly Report for additional information.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations and Commitments </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no other material changes to our contractual obligations and commitments from those described under Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021.&#160;<span style="color:#000000;">&#160;&#160; </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a smaller reporting company, we are not required to provide this information.  </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_CONTROLS_PROCEDURES">Item&#160;4. Controls and Procedures </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;Evaluation of Disclosure Controls and Procedures </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Management of the Company, with the participation of the Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of the design and operation of the Company&#8217;s disclosure controls and procedures (as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;of the Securities Exchange Act of 1934, as amended) as of September 30, 2022. The Company&#8217;s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported on a timely basis and that such information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, as appropriate, to allow timely decisions regarding disclosure. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Based on the evaluation of our disclosure controls and procedures as of September 30, 2022, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, the Company&#8217;s disclosure controls and procedures were effective. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;Changes in Internal Control over Financial Reporting </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;There have been no changes to the Company&#8217;s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f)) that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="PART_II">PART&#160;II. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OTHER INFORMATION </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_LEGAL_PROCEEDINGS">Item&#160;1. Legal Proceedings </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be from time to time subject to various claims and legal actions during the ordinary course of our business. There are currently no claims or legal actions, individually or in the aggregate, that would have a material adverse effect on our results of operations or financial condition. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS">Item&#160;1A. Risk Factors </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the other information set forth in this report, you should carefully consider the factors discussed in &#8220;Risk Factors&#8221; in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021. Aside from the risk factors below, there have been no material changes from the risk factors previously disclosed in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash, cash equivalents, and restricted cash at September 30, 2022 was $21.5 million, which will not be sufficient to fund our current operating plan for at least a year from issuance of these financial statements. <span style="color:#000000;">Absent any reductions in current operating expenses, the Company believes it will require additional financing during the first quarter of 2023. T</span>here can be no assurance that any financing by us can be realized, or if realized, what the terms of any such financing may be, or that any amount that we are able to raise will be adequate. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Term Loan Agreement with CRG Servicing LLC (&#8220;CRG&#8221;) (Note 6) has a minimum liquidity covenant which requires us to maintain a minimum cash balance of $5.0 million. As security for its obligations under the Term Loan Agreement, the Company entered into a security agreement with CRG whereby the Company granted a lien on substantially all of its assets, including intellectual property. We intend to continue to evaluate options to refinance the Term Loan Agreement, which becomes due on December 30, 2024. There can be no assurances that we will be able to refinance on terms favorable or at all. The amounts involved in any such transactions, individually or in the aggregate, may be material.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These conditions, as well as those described below under &#8220;<span style="font-style:italic;">Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our common stock,</span>&#8221; raise substantial doubt regarding&#160;our&#160;ability to continue as a going concern for a period of one year after the date that the financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include raising additional funding, earning payments pursuant to&#160;our&#160;contract with BARDA,&#160;delaying certain research projects and capital expenditures and eliminating certain future operating expenses in order to fund operations at reduced levels for&#160;us&#160;to continue as a going concern for a period of 12 months from the date these unaudited condensed consolidated financial statements are issued. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly,&#160;we have&#160;concluded that substantial doubt exists about&#160;our&#160;ability to continue as a going concern for a period of at least 12 months from the date of issuance of these financial statements.</p>
<p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our common stock.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to satisfy or maintain compliance with the continued listing requirements of The Nasdaq Capital Market, Nasdaq may take steps to delist our common stock. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the reverse stock split discussed below, our stock had been trading under $1.00 since September 27, 2021. <span style="color:#000000;">On November 5, 2021, we received a letter from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) indicating that we were not in compliance with the requirement of Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market as a result of the closing bid price of our common stock being below $1.00 per share for thirty consecutive business days (the &#8220;Bid Price Rule&#8221;). Under the Nasdaq rules, we had 180 days (or until May 4, 2022) to regain compliance by maintaining a minimum closing bid price of </span>$1.00 per share of our common stock for at least ten consecutive trading days during such compliance period. On May 5, 2022, we received a letter from Nasdaq informing us that our shares of common stock had failed to comply with the Bid Price Rule for continued listing and, as a result, our shares were subject to delisting. The letter further stated that we may appeal the Nasdaq Staff delisting determination to a Nasdaq listing qualifications hearings panel (the &#8220;Panel&#8221;).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We filed an appeal and hearing request to the Nasdaq Staff&#8217;s determination </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> stay the delisting of our shares of common stock from Nasdaq pending the Panel&#8217;s decision. The Nasdaq Staff informed us that the delisting action had been stayed, pending a final written decision by the Panel, and the hearing date had been set for June 2, 2022. </span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 9, 2022, we received a letter from the Nasdaq notifying us that the Nasdaq had granted our request to be transferred to The Nasdaq Capital Market, effective at the open of trading on June 13, 2022, and our request for an exception to the Bid Price Rule was granted until November 1, 2022. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 11, 2022, at the annual meeting of stockholders, our stockholders approved an amendment to our restated certificate of incorporation to effect a reverse stock split of our common stock. Following the receipt of the stockholders&#8217; approval, our board of directors approved the reverse stock split at the ratio of 1 post-split share for every 50 pre-split shares, which was effective as of October 12, 2022. On October 31, 2022, we received a letter from Nasdaq informing us that we regained compliance with the Bid Price Rule. However, there is no assurance that the market price per share of our common stock will continue to remain in excess of the $1.00 minimum bid price as required by Nasdaq, or that we will otherwise meet the requirements of Nasdaq for continued inclusion for trading on The Nasdaq Capital Market.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;22, 2022, we received a letter from the Nasdaq indicating that, for the last thirty-five consecutive business days, the Market Value of Listed Securities, as defined by Nasdaq (&#8220;MVLS&#8221;) had been below the $35&#160;million minimum requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), we have been provided an initial period of 180 calendar days, or until January&#160;18, 2023, to regain compliance. The letter states that the Nasdaq staff will provide written notification that we have achieved compliance with Rule&#160;5550(b)(2) if at any time before January&#160;18, 2023, we maintain our MVLS at $35&#160;million or more for a minimum of ten consecutive business days. The Nasdaq Staff Deficiency Letter has no immediate effect on the listing or trading of our common stock.&#160;&#160;If compliance is not achieved by January&#160;18, 2023, we expect that Nasdaq would provide written notification to us that our securities are subject to delisting. We will continue to monitor our MVLS and consider our available options to regain compliance with the Nasdaq minimum MVLS requirements, which may include applying for an extension of the compliance period or appealing to a Nasdaq Hearings Panel. On August 24, 2022, i<span style="color:#000000;">n a Compliance Notice, the Nasdaq notified us that, from August 10, 2022 to August 23, 2022, our MVLS had been $35 million or greater and, accordingly, we had regained compliance with Rule </span><span style="Background-color:#FFFFFF;">5550(b)(2) </span><span style="color:#000000;">and that the matter was now closed.</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.46%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The delisting of our common stock from Nasdaq may make it more difficult for us to raise capital on favorable terms in the future. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. Further, if we were to be delisted from&#160;Nasdaq, our common stock would cease to be recognized as covered securities and we would be subject to regulation in each state in which we offer our securities. Moreover, there is no assurance that any actions that we take to restore our compliance with the&#160;minimum bid&#160;price requirement would stabilize the market price or improve the liquidity of our common stock, prevent our common stock from falling below the minimum bid price required for continued listing again, or prevent future non-compliance with Nasdaq&#8217;s listing requirements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be adversely affected by fluctuations in demand for, and prices of, raw materials and other supplies.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use various raw materials and other supplies in our business. Although there are currently multiple suppliers for these materials and supplies, changes in demand for, and the market price of, these raw materials and supplies could significantly affect our ability to manufacture our diagnostic instruments and, consequently, our profitability. The prices of these raw materials and supplies may fluctuate and are affected by numerous factors beyond our control such as interest rates, exchange rates, inflation or deflation, global and regional supply and demand, and the political and economic conditions of countries that produce rare earth minerals and products. &#160;&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.8%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our agreements with our third party suppliers are non-exclusive. Our suppliers may dedicate more resources to other companies. We may in the future experience shortages and price fluctuations of certain key components and raw materials required in the manufacturing of our products, and the predictability of the availability and pricing of these components and raw materials may be limited. Current or future supply chain interruptions that could be exacerbated by global political tensions, such as the situation in Ukraine, or the COVID-19 pandemic and government responses could negatively impact our ability to acquire such key components or materials. Component and raw material shortages or pricing fluctuations could be material in the future. In the event of a component or raw material shortage, supply interruption or material pricing change from suppliers of these components or raw materials, we may not be able to develop alternate sources in a timely manner or at all in the case of sole or limited sources. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Developing alternate sources of supply for these components or raw materials may be time consuming, difficult, and costly and we may not be able to source these components or raw materials on terms that are acceptable to us, or at all, which may undermine our ability to meet our requirements or to fill user orders in a timely manner. Any interruption or delay in the supply of any of these parts </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or components, or the inability to obtain these components or raw materials from alternate sources at acceptable prices and within a reasonable amount of time, would adversely affect our ability to meet scheduled product deliveries to users. This could adversely affect our relationships with our users and could cause delays in our ability to expand our operations. Even where we are able to pass increased component or raw material costs along to our users, there may be a lapse of time before we are able to do so such that we must absorb the increased cost initially. If we are unable to buy these components or raw materials in quantities sufficient to meet our requirements on a timely basis, we will not be able to have sufficient ability to meet user demand, which may have a negative impact on our operations and financial results.</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Approval, clearance and certification by the FDA and foreign regulatory authorities or notified bodies for our diagnostic tests takes significant time and requires significant research, development and clinical study expenditures and ultimately may not succeed.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The medical device industry is regulated extensively by governmental authorities, principally the FDA and corresponding state and foreign regulatory agencies. The regulations are very complex and are subject to rapid change and varying interpretations. Regulatory restrictions or changes could limit our ability to carry on or expand our operations or result in higher than anticipated costs or lower than anticipated sales. The FDA, other U.S. governmental agencies and foreign regulatory bodies regulate numerous elements of our business, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.75%;"></td>
<td style="width:6.75%;"></td>
<td style="width:86.5%;"></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product design and development&#59;</p></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pre-clinical and clinical testing and trials&#59;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.75%;"></td>
<td style="width:6.75%;"></td>
<td style="width:86.5%;"></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product safety&#59;</p></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">establishment registration and product listing&#59;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.75%;"></td>
<td style="width:6.75%;"></td>
<td style="width:86.5%;"></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">labeling and storage&#59;</p></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketing, manufacturing, sales and distribution&#59;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.9%;"></td>
<td style="width:6.9%;"></td>
<td style="width:86.2%;"></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pre-market clearance, approval or certification&#59;</p></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">servicing and post-market surveillance&#59;</p></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">advertising and promotion&#59; and</p></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recalls and field safety corrective actions.</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before we begin to label and market our product candidates for use as clinical diagnostics in the United States, we are required to obtain clearance from the FDA under Section&#160;510(k)&#160;of the Federal Food, Drug, and Cosmetic Act, or FDCA, approval of a&#160;<span style="font-style:italic;">de novo</span>&#160;classification request for our product, or approval of pre-market approval, or PMA, application from the FDA, unless an exemption from pre-market review applies. In the 510(k)&#160;clearance process, the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a device legally on the market, known as a &#8220;predicate&#8221; device, with respect to intended use, technology and safety and effectiveness, in order to clear the proposed device for marketing. Clinical data is sometimes required to support substantial equivalence. The PMA pathway requires an applicant to demonstrate the safety and effectiveness of the device based, in part, on extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing and labeling data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices. However, some devices are automatically subject to the PMA pathway regardless of the level of risk they pose because they have not previously been classified into a lower risk class by the FDA. Manufacturers of these devices may request that FDA review such devices in accordance with the&#160;<span style="font-style:italic;">de novo</span>&#160;classification procedure, which allows a manufacturer whose novel device would otherwise require the submission and approval of a PMA prior to marketing to request down-classification of the device on the basis that the device presents low or moderate risk. If the FDA agrees with the down-classification, the applicant will then receive approval to market the device. This device type can then be used as a predicate device for future 510(k)&#160;submissions. The process of obtaining regulatory clearances or approvals, or completing the&#160;<span style="font-style:italic;">de novo</span>&#160;classification process, to market a medical device can be costly and time consuming, and we may not be able to successfully obtain pre-market reviews on a timely basis, if at all.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and other regulators or bodies can delay, limit or deny authorization or certification of a device for many reasons, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.75%;"></td>
<td style="width:6.75%;"></td>
<td style="width:86.5%;"></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or notified body that our products are substantially equivalent to a predicate device or are safe and effective for their intended uses&#59;</p></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the disagreement of the FDA or the applicable foreign regulatory body with the design or implementation of our clinical studies or the interpretation of data from preclinical studies or clinical studies&#59;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.75%;"></td>
<td style="width:6.75%;"></td>
<td style="width:86.5%;"></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the data from our preclinical studies and clinical studies may be insufficient to support clearance,&#160;<span style="font-style:italic;">de novo</span>&#160;classification, approval or certification, where required&#59;</p></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our inability to demonstrate that the clinical and other benefits of the device outweigh the risks&#59;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.75%;"></td>
<td style="width:6.75%;"></td>
<td style="width:86.5%;"></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the manufacturing process or facilities we use may not meet applicable requirements&#59; and</p></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the potential for marketing authorization or certification policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for marketing authorization or certification</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any delay in, or failure to receive or maintain, clearance or approval for our product candidates could prevent us from generating revenue from these product candidates and adversely affect our business operations and financial results.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining FDA clearance,&#160;<span style="font-style:italic;">de novo</span>&#160;classification, or approval for diagnostics can be expensive and uncertain, and generally takes from several months to several years, and may require detailed and comprehensive scientific and clinical data. Notwithstanding the expense, these efforts may never result in the receipt of FDA marketing authorization. Even if we were to obtain such marketing authorizations for our products, it may not be for the uses we believe are important or commercially attractive, in which case we would not be permitted to market our product for those uses. Any delay in, or failure to receive or maintain, marketing authorization for our products could prevent us from generating revenue from these products and adversely affect our business operations and financial results.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The EU regulatory landscape concerning in vitro diagnostic medical devices recently evolved.<span style="font-size:12pt;color:#000000;"> </span>On May 26, 2022, the EU In Vitro Diagnostic Medical Devices Regulation, or IVDR, entered into force, which repeals and replaces the EU In Vitro Diagnostic Medical Devices Directive (<span style="font-style:italic;">See</span>&#160;&#8211;<span style="font-style:italic;">&#160;International Regulation -&#160;Regulation of Medical Devices in the European Union</span>) and these modifications may have an effect on the way we conduct our business in the EU and the European Economic Area, or EEA, which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland.&#160;&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the transitional provisions (i.e., a tiered system extending the grace period for many devices (depending on their risk classification) before they have to be fully compliant with the regulation) and in order to sell our products in the member states of the EU our products must comply with the general safety and performance requirements of the IVDR. Compliance with these requirements is a prerequisite to be able to affix the European Conformity, or CE, mark to our products, without which they cannot be sold or marketed in the EU. All medical devices placed on the market in the EU must meet the general safety and performance requirements laid down in Annex I to the IVDR including the requirement that a medical device must be designed and manufactured in such a way that, during normal conditions of use, it is suitable for its intended purpose. Medical devices must be safe and effective and must not compromise the clinical condition or safety of patients, or the safety and health of users and &#8211; where applicable &#8211; other persons, provided that any risks which may be associated with their use constitute acceptable risks when weighed against the benefits to the patient and are compatible with a high level of protection of health and safety, taking into account the generally acknowledged state of the art. To demonstrate compliance with the general safety and performance requirements we must undergo a conformity assessment procedure, which varies according to the type of in vitro diagnostic medical device and its (risk) classification. A conformity assessment procedure generally requires the intervention of a notified body. The notified body would typically audit and examine the technical file and the quality system for the manufacture, design and final inspection of our devices. If satisfied that the relevant product conforms to the relevant general safety and performance requirements, the notified body issues a certificate of conformity, which the manufacturer uses as a basis for its own declaration of conformity. The manufacturer may then apply the CE mark to the device, which allows the device to be placed on the market throughout the EU. &#160;&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with applicable laws and regulations, we would be unable to affix the CE mark to our products, which would prevent us from selling them within the EU.&#160;&#160;The aforementioned EU rules are generally applicable in the EEA. Non-compliance with the above requirements would also prevent us from selling our products in these three countries. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From January&#160;1, 2021 onwards, the Medicines and Healthcare Products Regulatory Agency, or MHRA becomes the sovereign regulatory authority responsible for Great Britain (i.e. England, Wales and Scotland) medical device market according to the requirements provided in the Medical Devices Regulations 2002 (SI 2002 No 618, as amended) that sought to give effect to the three pre-existing EU directives governing active implantable medical devices, general medical devices and in vitro diagnostic medical devices whereas Northern Ireland continues to be governed by EU rules according to the Northern Ireland Protocol. Following the end of the Brexit transitional period on January&#160;1, 2021, new regulations require medical devices to be registered with the MHRA (but manufacturers will be given a grace period of four to 12 months to comply with the new registration process) before being placed on Great Britain market. The MHRA will only register devices where the manufacturer or their United Kingdom Responsible Person has a registered place of business in the United Kingdom. Manufacturers based outside the United Kingdom will need to appoint a U.K. Responsible Person that has a registered place of business in the United Kingdom to register devices with the MHRA in line with the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">grace periods. By July&#160;1, 2023, in Great Britain, all medical devices will require a UKCA </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UK Conformity Assessed mark but CE marks issued by EU notified bodies will remain valid until this time. Manufacturers may choose to use the UKCA mark on a voluntary basis until June&#160;30, 2023. However, UKCA marking will not be recognized in the EU. The rules for placing medical devices on the market in Northern Ireland, which is part of the United Kingdom, differ from those in the rest of the United Kingdom. Compliance with this legislation is a prerequisite to be able to affix the UKCA mark to our products, without which they cannot be sold or marketed in Great Britain. Under the terms of the Northern Ireland Protocol, Northern Ireland will follow EU rules on medical devices and devices marketed in Northern Ireland will require assessment according to the EU regulatory regime. Such assessment may be conducted by an EU notified body, in which case a CE mark will be required before placing the device on the market in the EU or Northern Ireland. Alternatively, if a UK notified body conducts such assessment, a &#8216;UKNI&#8217; mark will be applied and the device may only be placed on the market in Northern Ireland and not the EU.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A public consultation by the MHRA was opened until end of November 2021 on the post-Brexit regulatory framework for medical devices and diagnostics. The consultation proposes amendments to the UK Medical Devices Regulations 2002 (which are based on EU legislation), in particular to create a new access pathways to support innovation, create an innovative framework for regulating software and artificial intelligence as medical devices, reform in vitro diagnostic regulation, and foster sustainability through the reuse and remanufacture of medical devices.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 26, 2022, the MHRA published its long-awaited response to its consultation on the UK&#8217;s post-Brexit regulatory regime for medical devices and in vitro diagnostic medical devices. The MHRA confirmed that the new regulatory landscape will mirror many of the provisions of the EU regulatory regime. However, the response also highlighted that in certain areas, medical devices regulation in Great Britain is likely to deviate from the EU framework. The UK government now needs to translate its proposals into legislation, via amendments to the UK Medical Devices Regulations (SI 2002 No 618, as amended).</span><span style="color:#231F20;font-family:Arial;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regime is expected to come into force in July 2023 subject to appropriate transitional arrangements.</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if granted, a 510(k)&#160;clearance,&#160;<span style="font-style:italic;">de novo</span>&#160;classification, PMA approval, or similar authorization or certification from other regulators or notified bodies for any future product would likely place substantial restrictions on how our device is marketed or sold, and the FDA and other regulatory authorities or bodies will continue to place considerable restrictions on our products and operations. For example, the manufacture of medical devices in the United States must comply with the FDA&#8217;s Quality System Regulation, or QSR. In addition, manufacturers must register their manufacturing facilities, list the products with the FDA, and comply with requirements relating to labeling, marketing, complaint handling, adverse event and medical device reporting, reporting of corrections and removals, and import and export. The FDA monitors compliance with the QSR and these other requirements through periodic inspections. If our facilities or those of our manufacturers or suppliers are found to be in violation of applicable laws and regulations, or if we or our manufacturers or suppliers fail to take satisfactory corrective action in response to an adverse inspection, the FDA and other regulatory authorities could take enforcement action, including any of the following sanctions:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.75%;"></td>
<td style="width:6.75%;"></td>
<td style="width:86.5%;"></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adverse publicity, untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties&#59;</p></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">customer notifications or repair, replacement, refunds, detention or seizure of our products&#59;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.75%;"></td>
<td style="width:6.75%;"></td>
<td style="width:86.5%;"></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operating restrictions or partial suspension or total shutdown of production&#59;</p></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">refusing or delaying requests for 510(k) clearance or PMA approvals or foreign regulatory authorizations or certifications of new products or modified products&#59;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.9%;"></td>
<td style="width:6.9%;"></td>
<td style="width:86.2%;"></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">withdrawing 510(k)&#160;clearances, PMA approvals or foreign regulatory authorizations or certifications that have already been granted&#59;</p></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">refusing to issue certificates to foreign governments needed to export products for sale in other countries&#59;</p></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">refusing to grant export approval for our products&#59; or</p></td>
</tr>
<tr>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pursuing criminal prosecution.</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these sanctions could impair our ability to produce our products and product candidates in a cost-effective and timely manner in order to meet our customers&#8217; demands, and could have a material adverse effect on our reputation, business, results of operations and financial condition. We may also be required to bear other costs or take other actions that may have a negative impact on our future sales and our ability to generate profits.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, the FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, over the last several years, the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products. For example, in November 2018, FDA officials announced steps that the FDA intended to take to modernize the 510(k) premarket notification pathway, including plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway. In September 2019, the FDA also issued revised final guidance establishing a &#8220;Safety and Performance Based Pathway&#8221; for &#8220;manufacturers of certain well-understood device types&#8221; allowing manufacturers to rely on objective safety and performance criteria recognized by the FDA to demonstrate substantial equivalence, obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA has developed and maintains a list of device types appropriate for the &#8220;safety and performance based&#8221; pathway and continues to develop product-specific guidance documents that identify the performance criteria and recommended testing methodologies for each such device type, where feasible. Some of these proposals have not yet been finalized or adopted, and the FDA announced that it would seek public feedback prior to publication of any such proposals, and may work with Congress to implement such proposals through legislation.</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, FDA and foreign regulations and guidance are often revised or reinterpreted by the FDA and foreign regulatory authorities in ways that may significantly affect our business and our products. Any new statutes, regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any future products or make it more difficult to obtain clearance or approval for, manufacture, market or distribute our products. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require: additional testing prior to obtaining clearance or approval&#59; changes to manufacturing methods&#59; recall, replacement or discontinuance of our products&#59; or additional record keeping. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance as a result of a changing regulatory landscape, we may lose any marketing authorizations that we have already obtained or fail to obtain new marketing approvals or clearances, and we may not be able to achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We currently develop, manufacture and test our products and product candidates and some of their components in two facilities. If these or any future facility or our equipment were damaged or destroyed, or if we experience a significant disruption in our operations for any reason, our ability to continue to operate our business could be materially harmed.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently develop our diagnostic products exclusively in a facility in Lexington, Massachusetts and manufacture and test some components of our products and product candidates in, both, Wilmington and Lexington, Massachusetts. If these or any future facility were to be damaged, destroyed or otherwise unable to operate, whether due to fire, floods, hurricanes, storms, tornadoes, other natural disasters, employee malfeasance, terrorist acts, power outages, or otherwise, or if our business is disrupted for any other reason, we may not be able to develop or test our products and product candidates as promptly as our potential customers expect, or possibly not at all.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacture of components of our products and product candidates at our Wilmington facility involves complex processes, sophisticated equipment and strict adherence to specifications and quality systems procedures. Any unforeseen manufacturing problems, such as contamination of our facility, equipment malfunction, or failure to strictly follow procedures or meet specifications, could result in delays or shortfalls in production of our products. Identifying and resolving the cause of any manufacturing issues could require substantial time and resources. If we are unable to keep up with future demand for our products by successfully manufacturing and shipping our products in a timely manner, our revenue growth could be impaired and market acceptance of our product candidates could be adversely affected.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2021, we entered into a lease for office, research, laboratory and manufacturing space that will consolidate our existing operations into a single 70,000 square foot, state-of-the-art life sciences facility in Billerica, Massachusetts.&#160; <span style="color:#000000;">Occupancy of the building has been delayed due to disagreement between Management and the landlord as to the parties&#8217; obligations under the lease agreement. Negotiations are on-going. We believe that a liability is reasonably possible but not probable. An estimate of the possible loss or range of loss cannot be made at this time. </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain insurance coverage against damage to our property and equipment, subject to deductibles and other limitations that we believe is adequate. If we have underestimated our insurance needs with respect to an interruption, or if an interruption is not subject to coverage under our insurance policies, we may not be able to cover our losses</span><span style="font-size:12pt;color:#000000;">.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have any unregistered sales of equity securities during the quarter ended September 30, 2022 other than the issuance of Series A redeemable convertible preferred stock and related warrants to purchase shares of our common stock that had been previously reported in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the SEC on August 16, 2022.  </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES">Item&#160;3. Defaults Upon Senior Securities </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">Item&#160;4. Mine Safety Disclosures </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_5_OR_INFORMATION">Item&#160;5. Other Information </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_EXHIBITS_FINANCIAL_STATEMENT_SCHE">Item&#160;6. Exhibits, Financial Statement Schedules </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;Number<span style="font-weight:normal;">&#160;</span></p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;Description</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:12.12%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;3.1</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1492674/000110465914059947/a14-18838_1ex3d1.htm"><span style="text-decoration:underline;">Restated Certificate of Incorporation of the Company, as amended (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Form 8-K (File No. 001-36571) filed on August 12, 2014)</span></a></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;3.2</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1492674/000119312521222976/d92089dex31.htm"><span style="text-decoration:underline;">Certificate of Amendment of Restated Certificate of Incorporation of the Company dated July 23, 2021 (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Form 8-K (File No. 001-36751) filed on July 23, 2021)</span></a></p></td>
</tr>
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;3.3</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1492674/000119312522261285/d409744dex31.htm"><span style="text-decoration:underline;">Certificate of Amendment of Restated Certificate of Incorporation of the Company dated October 12, 2022 (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Form 8-K (File No. 001-36571) filed on October 12, 2022)</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;3.4</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1492674/000156459022029526/ttoo-ex33_437.htm"><span style="text-decoration:underline;">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.3 of the Company&#8217;s Form 10-Q (File No. 001-36571) filed on August 16, 2022)</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;3.5</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1492674/000156459022029526/ttoo-ex34_436.htm"><span style="text-decoration:underline;">Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.4 of the Company&#8217;s Form 10-Q (File No. 001-36571) filed on August 16, 2022)</span></a><span style="text-decoration:underline;"> </span></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;4.1</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1492674/000156459022029526/ttoo-ex41_435.htm"><span style="text-decoration:underline;">Form of Warrant (incorporated by reference to Exhibit 4.1 of the Company&#8217;s Form 10-Q (File No. 001-36571) filed on August 16, 2022)</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;10.1</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1492674/000156459022029526/ttoo-ex101_433.htm"><span style="Background-color:#FFFFFF;text-decoration:underline;">Securities Purchase Agreement, dated as of August 15, 2022 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 10-Q (File No. 001-36571) filed on August 16, 2022)</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;10.2</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1492674/000156459022029526/ttoo-ex102_318.htm"><span style="text-decoration:underline;">Amendment of Solicitation/Modification of Contract, dated as of July 26, 2022 by and between the Company and Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Form 10-Q (File No. 001-36571) filed on August 16, 2022)</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;10.3</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1492674/000156459022029526/ttoo-ex103_434.htm"><span style="text-decoration:underline;">Registration Rights Agreement, dated as of August 15, 2022 (incorporated by reference to Exhibit 10.3 of the Company&#8217;s Form 10-Q (File No. 001-36571) filed on August 16, 2022)</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;10.4*</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ttoo-ex104_892.htm"><span style="text-decoration:underline;">Amendment of Solicitation/Modification of Contract, dated as of September 29, 2022 by and between the Company and Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;10.5*</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ttoo-ex105_1066.htm"><span style="text-decoration:underline;">Amendment No. 8 to Term Loan Agreement, dated November 10, 2022, between T2 Biosystems, Inc. and CRG Servicing LLC</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;31.1*</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ttoo-ex311_11.htm"><span style="Background-color:#FFFFFF;text-decoration:underline;">Certification of principal executive officer pursuant to Exchange Act Rules&#160;13a-14(a)&#160;and 15d-14(a), as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;31.2*</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ttoo-ex312_12.htm"><span style="Background-color:#FFFFFF;text-decoration:underline;">Certification of principal financial officer pursuant to Exchange Act Rules&#160;13a-14(a)&#160;and 15d-14(a), as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;32.1**</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ttoo-ex321_14.htm"><span style="Background-color:#FFFFFF;text-decoration:underline;">Certification pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;32.2**</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ttoo-ex322_7.htm"><span style="Background-color:#FFFFFF;text-decoration:underline;">Certification pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH*</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL*</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF*</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB*</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE*</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104*</p></td>
<td valign="top" style="width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document) </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Furnished herewith </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment pursuant to Rule 406 under the Securities Act of 1933, or the Securities Act. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.66%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T2 BIOSYSTEMS, INC.</p></td>
</tr>
<tr style="height:12pt;">
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:46.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 14, 2022</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ JOHN SPERZEL</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.66%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Sperzel</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.66%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Chairman of the Board</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.66%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(principal executive officer)</p></td>
</tr>
<tr style="height:12pt;">
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:46.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 14, 2022</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ JOHN M. SPRAGUE</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.66%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John M. Sprague</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.66%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.66%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:46.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(principal financial and accounting officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>2
<FILENAME>ttoo-ex104_892.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ttoo-ex104_892.htm
</title>
</head>
<!-- NG Converter v5.0.2.73 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 10.4</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g1b2xf54kzm3000001.jpg" title="" alt="" style="width:720px;height:854px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#FFFFFF;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGE 1 &#921; 53 2. AMENDMENT/MODIFICATION NO. P000l0 3. EFFECTIVE DATE See Block 16C 6. ISSUED BY CODE ASPR-BARDA 200 Independence Ave., S.W. Room 640-G Washington DC 20201 [****] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. 4.&#160;&#160;REQUISITION/PURCHASE REQ. NO. 15" PROJECT NO. (If applicable) OS301992 ADM INI STERED&#160;&#160; BY (If other than Item 6) CO DE I ASPR-BARDA ASPR-BARDA us DEPT OF HEALTH &amp; HUMAN SERVICES BIOMEDICAL ADVANCED RESEACH &amp; DEVELOPMENT AUT 200 INDEPENDENCE AVE, s.w. Washington DC 20201 NAME AND ADDRESS OF CONTRA CTOR (No., street, county, State and ZIP Code) 9A. AMENDMENT OF SOLICITATION NO. T2 BIOSYSTEMS , INC. 1512719 Attn: Alec Barclay T2 BIOSYSTEMS, INC. 101 HARTWE 101 HARTWELL AVE LEXINGTON MA 02421 CODE 1512719 I FACILITY CODE 9B. DATED (SEE ITEM 11) 10A. MODIFIC ATION OF CONTRACT/ORDER NO. X 75A50119C00053 10B. DATED (SEE ITEM 13)&#160;&#160;09/30/2019 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS 0 The above numbered solicitation is amended as set forth in Item 14.&#160;&#160;The hour and date specified for receipt of Offers 0 is extended. 0 is not extended. Offers must acknowledge receipt of this amendmentprior to the hour and date specified in the solicitation or as amended, by one of the following methods: (a) By completing Items 8 and 15, and returning cosi of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted, or (c) By, separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. tf by virtue of this amendment you desire to change an offer already submitted, such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opning hour and date specified. 12 ACCO UNTING AND APPROPRIATION DATA/If required) Net Increase: $3,690,810.00 2022.1992022.25106 THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14. CHECK ONE A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A. B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHOR ITY OF FAR 43.103(b). X C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: FAR Part 43.103(a) - Bilateral Modification D. OTHER (Specify type of modifIcation and authority) E. IMPORTANT: Contractor D is not 00 is required to sign this document and return 1 copies to the issuing office. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) Tax ID Number: 20-4827488 DUNS Number: 803126320 UEI: QVYNQM9WLJG3 The purpose of this modification is to: 1) Exercise Option Period 3 - CLIN 0005, 2) Revise sections B.3, B.4, F.2, J, and Attachment 1. See Block 14 Continuation Sheet. BARDA Share Price for Option Period 3 decreased by $6,926,391 from $10,617,201 to $3,690,810. T2 Biosystems Share Price for Option Period 3 decreased by $5,234,359 from $8,566,423 to $3,332,064. Total contract value including BARDA plus T2 Biosystems Shares decreased by $12,160,750 Continued Except as provided herein, a ll terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect. 15A. NAME AND TITLE OF SIGNER (Type or print) Alec Barclay Chief Operations Officer 15C.&#160;&#160;DATE SIGNED 09/28/2022 15B.CONTRACTOR/OFFEROR Signature of person authorized to sign Previous edition unusable 16A. NAME AND TITLE OF CONTRACTIN G OFFICER (Type or print) RICHARD A. HALL Digitally signed by Richard A. Hall S Hall S Date 2022(Signature of Contrading Officer 16 DA E SINGNE 09.28 16:35:45-04&#8217;00&#8217; STANDARD FORM 30 (REV 11/2016) Prescribed by GSA FAR (48 CFR) 53.243</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5.5pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:19.6%;"></td>
<td style="width:68.05%;"></td>
<td style="width:6.9%;"></td>
<td style="width:5.45%;"></td>
</tr>
<tr style="height:10.5pt;">
<td rowspan="2" valign="top"  style=" border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-top:7pt;margin-bottom:0pt;margin-left:8.85pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">CONTINUATION SHEET</p></td>
<td rowspan="2" valign="top"  style=" border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:2pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REFERENCE NO. OF DOCUMENT BEING CONTINUED</p>
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:2pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75A50119C00053/P00010</p></td>
<td colspan="2" valign="top"  style=" border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;letter-spacing:-0.15pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PAGE&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;OF</p></td>
</tr>
<tr style="height:14.5pt;">
<td valign="top"  style=" border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:5.6pt;;text-indent:0pt;;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="top"  style=" border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:2pt;;text-indent:0pt;;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NAME OF OFFEROR OR CONTRACTOR</p>
<p style="margin-top:1pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T2 BIOSYSTEMS, INC. 1512719</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:10%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:9.5pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM NO.</p>
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:13.75pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(A)</p></td>
<td valign="top"  style="width:50%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;margin-left:112.7pt;;margin-right:19.44%;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUPPLIES/SERVICES</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:112.7pt;;margin-right:18.89%;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(B)</p></td>
<td valign="top"  style="width:10%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">QUANTITY</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(C)</p></td>
<td valign="top"  style="width:10%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UNIT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;letter-spacing:-0.35pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(D<font style="letter-spacing:-0.05pt;">)</font></p></td>
<td valign="top"  style="width:10%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.93%;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UNIT PRICE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.93%;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(E)</p></td>
<td valign="top"  style="width:10%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMOUNT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(F)</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12.5pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.6pt;;text-indent:0pt;;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="top"  style="width:50%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.75pt;;text-indent:0pt;;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from $106,922,207 to $94,761,457.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.75pt;;margin-right:1.3%;text-indent:0pt;;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appr. Yr.: 2022 CAN: 1992022 Object Class: 25106 Period of Performance: 04/01/2022 to<font style="letter-spacing:-3.8pt;"> </font>03/31/2025</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.75pt;;text-indent:0pt;;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Add Item 11 as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.75pt;;margin-right:3.33%;text-indent:0pt;;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASPR-22-02198- Option 3 funds to T2 Biosystems under</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.75pt;;margin-right:11.11%;text-indent:0pt;;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract Number 75A50119C00053 Obligated Amount:<font style="letter-spacing:-2.9pt;"> </font>$3,690,810.00</p></td>
<td valign="top"  style="width:10%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12.5pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:38.95pt;;text-indent:0pt;;font-size:9pt;letter-spacing:-0.05pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,690,810.00</p></td>
</tr>
</table></div>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.34%;text-indent:0%;font-family:Times New Roman;font-size:5.5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:79.25%;"></td>
<td style="width:20.75%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NSN<font style="letter-spacing:-0.65pt;"> </font>7540-01-152-8067</p></td>
<td valign="top" >
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OPTIONAL FORM 336<font style="letter-spacing:-0.5pt;"> </font>(4-86)</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sponsored by GSA</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FAR (48 CFR) 53.110</p></td>
</tr>
</table></div>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.34%;text-indent:0%;font-family:Times New Roman;font-size:5.5pt;">&nbsp;</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-right:8.89%;text-indent:0%;font-family:Times New Roman;font-size:5.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5.5pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.85%;">
<tr>
<td style="width:28.53%;"></td>
<td style="width:43.69%;"></td>
<td style="width:27.64%;"></td>
</tr>
<tr style="height:40.35pt;">
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.2pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Continuation_Page_Block_14"></a>Contract No.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75A50119C00053</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modification No. P00010</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuation Sheet</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Block 14</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:13pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:3.33%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">**<font style="Background-color:#FFFF00;">Yellow Highlights</font> denotes applicable changes</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;margin-right:13.33%;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning with the effective date of this modification, the Government and the Contractor mutually agree as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">SECTION B - SUPPLIES OR SERVICES AND PRICES/COSTS,</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;margin-right:13.52%;text-indent:0%;font-weight:bold;color:#2C2E2E;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE B.3 OPTION PERIODS <font style="font-weight:normal;">- </font><font style="color:#1C1C1D;font-weight:normal;">the table included in this Article is hereby modified to </font><font style="font-weight:normal;">reflect </font><font style="color:#1C1C1D;font-weight:normal;">the following</font><font style="color:#525252;font-weight:normal;">:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-weight:bold;color:#2C2E2E;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">B.3.<font style="margin-left:36pt;">COST REIMBURSEMENT</font><font style="letter-spacing:-0.05pt;"> </font>OPTIONS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:2.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;">I.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;color:#000000;">The contract includes optional, cost reimbursement CLINs 0002 through 0007. The Government may exercise Option Periods in accordance with FAR 52.217-9 Option to Extend the Term of the Contract (March 2000), as set forth in Section I of the</font><font style="font-size:12pt;letter-spacing:-1.75pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">contract.</font></p></td>
<td valign="top" style="width:9.81%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.19%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;">II.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;color:#000000;">The contract includes optional services, cost reimbursement CLIN 0008. The Government may exercise Option Services in accordance with FAR 52.217-8 Option</font><font style="font-size:12pt;letter-spacing:-1.5pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">to Extend Services, as set forth in Section I of the</font><font style="font-size:12pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">contract.</font></p></td>
<td valign="top" style="width:10.56%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;">III.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;color:#000000;">Unless the government exercises its option pursuant to the option clause contained in ARTICLE 1.2, the contract consists only of the Base Work segment specified in the Statement of Work as defined in SECTION C and F, for the price set forth in ARTICLE B.2 of the</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">contract.</font></p></td>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.82%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;">IV.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;color:#000000;">The Government may modify the contract unilaterally and require the contractor to provide supplies and services for Option Periods listed below, in accordance with</font><font style="font-size:12pt;letter-spacing:-1.95pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">FAR 52.217-9.</font></p></td>
<td valign="top" style="width:10.93%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.32%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;">V.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;color:#000000;">If the Government decides to exercise an option(s), the Government will provide the Contractor a preliminary written notice of its intent as referenced in the</font><font style="font-size:12pt;letter-spacing:-2pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">clause. Specific information regarding the time frame for this notice is set forth in the OPTION CLAUSE Article in SECTION G of this contract. The estimated cost of the contract will be increased as set forth</font><font style="font-size:12pt;letter-spacing:1pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">below:</font></p></td>
<td valign="top" style="width:8.7%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 3</a> of 18</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.85%;">
<tr>
<td style="width:28.53%;"></td>
<td style="width:43.69%;"></td>
<td style="width:27.64%;"></td>
</tr>
<tr style="height:40.35pt;">
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract No.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75A50119C00053</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modification No. P00010</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuation Sheet</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Block 14</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:13.5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.91%;">
<tr>
<td style="width:9.24%;"></td>
<td style="width:6.23%;"></td>
<td style="width:14.84%;"></td>
<td style="width:25.48%;"></td>
<td style="width:14.34%;"></td>
<td style="width:14.27%;"></td>
<td style="width:15.5%;"></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:6.2pt;;margin-right:0.93%;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Option</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.2pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">CLIN</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:8.2pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Period of Performance</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Supplies/Services</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;line-height:11pt;margin-bottom:0pt;margin-left:4.1pt;;margin-right:0.74%;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">BARDA</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.93%;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Estimated Not to Exceed</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:1.8pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">T2 Estimated Not to Exceed</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.05pt;;margin-right:1.11%;text-indent:-0.05pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Overall Total Estimated Not to Exceed</p></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0002</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.9pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/14/2020 -</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:10.6pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/15/2021</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:5.4pt;;margin-right:2.41%;text-indent:0.05pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option 1 Period: Optimize the T2 Biothreat Panel to meetrequirements on the T2Dx device.</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Design, build,</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.4pt;;margin-right:2.22%;text-indent:0.1pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and optimizeT2Nxt subsystems, and integrate those subsystems into a working device.</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Optimize the T2AMR Panel</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.37%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$10,495,783</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3,925,669</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.3%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$14,421,452</p></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2A</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0003</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:13.45pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/30/2021-</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:15.05pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03/31/2022</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:5.4pt;;margin-right:4.26%;text-indent:0.05pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option 2A Continue T2Biothreat verification testing and</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:5.4pt;;margin-right:0.74%;text-indent:0.05pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">initiate validation testing. Produce a functioning Beta instrument. Complete initial optimization studies and demonstrate required sensitivity with a manual process. Initiate T2Resistance Panel verification and clinical</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">validation studies</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:4.1pt;;margin-right:0.37%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$6,357,371</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2,087,418</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:10.1pt;;margin-right:1.3%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8,444,789</p></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2B</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0004</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:13.45pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">04/01/2022-</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:15.05pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/30/2022</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0.05pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option 2B Continue T2Biothreat verification testing and initiate validation testing. Produce a functioning Beta instrument. Complete initial optimization studies and demonstrate required sensitivity with a manual process.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:4.1pt;;margin-right:0.37%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4,389,160</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2,960,502</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:10.1pt;;margin-right:1.3%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7,349,662</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 4</a> of 18</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.85%;">
<tr>
<td style="width:28.53%;"></td>
<td style="width:43.69%;"></td>
<td style="width:27.64%;"></td>
</tr>
<tr style="height:40.35pt;">
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract No.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75A50119C00053</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modification No. P00010</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuation Sheet</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Block 14</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.91%;">
<tr>
<td style="width:8.52%;"></td>
<td style="width:6.42%;"></td>
<td style="width:14.88%;"></td>
<td style="width:24.83%;"></td>
<td style="width:14.73%;"></td>
<td style="width:14.68%;"></td>
<td style="width:15.85%;"></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:2.05pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.19%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0005</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.8pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">09/30/2022</font> -</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.55pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">03/31/2023</font></p></td>
<td valign="top"  BGCOLOR="#FFFF00" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0.05pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Option 3 Period: <font style="font-weight:normal;">Complete validation testing of the T2Biothreat panel on the T2Dx instrument under</font><font style="letter-spacing:-0.65pt;font-weight:normal;"> </font><font style="font-weight:normal;">BSL-3 and prepare and submit a 510(k) application to the FDA for the T2Biothreat panel for use on the T2Dx instrument. The contractor will also complete verification and validation testing and prepare and submit a 510(k) application to the FDA for the T2Resistance Panel for use on the T2Dx instrument. In AIM 1, the contractor will complete contrived sample verification studies of the T2Biothreat panel, prepare a 510(k) application and submit to FDA for clearance. In AIM 6, the contractor will complete verification and validation testing of the T2Resistance panel and prepare a 510(k) application and submit to FDA</font><font style="letter-spacing:-0.35pt;font-weight:normal;"> </font><font style="font-weight:normal;">for</font></p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clearance.</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:4.1pt;;margin-right:0.37%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">$3,690,810</font></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">$3,332,064</font></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:10.1pt;;margin-right:1.3%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">$7,022,874</font></p></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:2.05pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.19%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0006</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****]-</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0.05pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option 4 Period: [****]</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0.25pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0.25pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0.25pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0.25pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0.25pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0.25pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0.25pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0.25pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0.25pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0.25pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0.25pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0.25pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.37%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[****]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[****]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:10.1pt;;margin-right:1.3%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[****]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 5</a> of 18</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.85%;">
<tr>
<td style="width:28.53%;"></td>
<td style="width:43.69%;"></td>
<td style="width:27.64%;"></td>
</tr>
<tr style="height:40.35pt;">
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract No.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75A50119C00053</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modification No. P00010</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuation Sheet</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Block 14</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.91%;">
<tr>
<td style="width:8.81%;"></td>
<td style="width:6.53%;"></td>
<td style="width:14.5%;"></td>
<td style="width:25.02%;"></td>
<td style="width:14.68%;"></td>
<td style="width:14.62%;"></td>
<td style="width:15.75%;"></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.19%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0007</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****]-</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:10pt;line-height:8pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option 5 Period: [****]</p>
<p style="margin-top:10pt;line-height:8pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;line-height:8pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;line-height:8pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;line-height:8pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;line-height:8pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;line-height:8pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;line-height:8pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;line-height:8pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;line-height:8pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;line-height:8pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;line-height:8pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;line-height:8pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:4.1pt;;margin-right:0.37%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[****]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[****]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:10.1pt;;margin-right:1.3%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[****]</p></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.19%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0008</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****]-</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0.05pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option 6 Period: [****]</p>
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0.05pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:4.1pt;;margin-right:0.37%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[****]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[****]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:10.1pt;;margin-right:1.3%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[****]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 6</a> of 18</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.85%;">
<tr>
<td style="width:28.53%;"></td>
<td style="width:43.69%;"></td>
<td style="width:27.64%;"></td>
</tr>
<tr style="height:40.35pt;">
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract No.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75A50119C00053</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modification No. P00010</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuation Sheet</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Block 14</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.91%;">
<tr>
<td style="width:9.44%;"></td>
<td style="width:6.44%;"></td>
<td style="width:14.58%;"></td>
<td style="width:24.49%;"></td>
<td style="width:14.98%;"></td>
<td style="width:14.4%;"></td>
<td style="width:15.56%;"></td>
</tr>
<tr>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.5pt;;margin-right:0.37%;text-indent:-1.15pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Optional Services</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0009</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TBD-TBD as</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:10pt;line-height:10pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option 7 Period: [****]</p>
<p style="margin-top:10pt;line-height:10pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;line-height:10pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;line-height:10pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:4.1pt;;margin-right:0.37%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[****]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[****]</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:10.1pt;;margin-right:1.3%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[****]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTALS</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Only option years</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;margin-left:4.1pt;;margin-right:0.37%;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">$</font><font style="font-size:10pt;font-weight:normal;">[****]</font></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.37%;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">$</font><font style="font-size:10pt;font-weight:normal;">[****]</font></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;margin-left:10.1pt;;margin-right:1.48%;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">$</font><font style="font-size:10pt;font-weight:normal;">[****]</font></p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTALS</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base+ options</p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;margin-left:4.1pt;;margin-right:0.37%;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">$62,024,574</font></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.37%;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">$</font><font style="font-size:10pt;font-weight:normal;">[****]</font></p></td>
<td valign="middle"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;margin-left:10.1pt;;margin-right:1.48%;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFF00;">$</font><font style="font-size:10pt;font-weight:normal;">[****]</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:3.33%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">B.4 ESTIMATED COST - COST SHARING</p>
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:3.33%;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This is a cost-sharing contract. The total estimated cost sharing for performing the work under this contract <font style="Background-color:#FFFF00;">is $</font><font style="font-size:10pt;">[****]</font> (Base $2,875,256, Option 1 $3,925,669, Option 2A $2,087,418, Option 2B $2,960,502, Option 3 <font style="Background-color:#FFFF00;">$3,332,064</font>, Option 4 $<font style="font-size:10pt;">[****]</font>, Option 5 $<font style="font-size:10pt;">[****]</font>, Option 6 $<font style="font-size:10pt;">[****]</font>, Option 7 $<font style="font-size:10pt;">[****]</font>). For further provisions regarding the specific cost-sharing arrangement, see the ADVANCE UNDERSTANDINGS Article in SECTION B of the Contract</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">SECTION F &#8211; DELIVERIES OR PERFORMANCE</p>
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:3.33%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">F.2. DELIVERABLES</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:11.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Successful performance of the final contract shall be deemed to occur upon completion of performance of the work set forth in the Statement of Work dated July 22, 2019<font style="color:#FF0000;">, </font>set forth in Section<font style="letter-spacing:-0.2pt;"> </font>J<font style="letter-spacing:-0.05pt;"> </font>-<font style="letter-spacing:-0.15pt;"> </font>List<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>Attachments<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>this<font style="letter-spacing:-0.15pt;"> </font>contract<font style="letter-spacing:-0.1pt;"> </font>and<font style="letter-spacing:-0.15pt;"> </font>upon<font style="letter-spacing:-0.2pt;"> </font>delivery<font style="letter-spacing:-0.1pt;"> </font>and<font style="letter-spacing:-0.15pt;"> </font>acceptance,<font style="letter-spacing:-0.15pt;"> </font>as<font style="letter-spacing:-0.15pt;"> </font>required<font style="letter-spacing:-0.2pt;"> </font>by the Statement of Work, by the COR, of each of the deliverables described in Section C, Section F, and Section<font style="letter-spacing:-0.2pt;"> </font>J.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All deliverables and reporting documents listed within this Section shall be delivered electronically (as defined in Section F.3 Electronic Submission) to the CO, CS, and the COR unless otherwise specified by the CO.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:3.33%;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise specified by the CO, the deliverables identified in this Section F shall also be delivered electronically to the designated eRoom along with a concurrent email notification sent to the CO, CS, COR, and Alternate COR stating delivery has been made.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Upon the written request of the CO, CS, or COR, all <font style="font-weight:normal;">paper/hardcopy documents/reports submitted under this contract shall be printed or copied, double sided, on at least 30 percent post-consumer fiber paper, whenever practicable, in accordance with FAR 4.302(b). Hard copies of deliverables and reports furnished to the Government under the resultant Contract shall be addressed to the Contracting Officer and Contracting Officer Representative. The address for delivery of the hard copy documents, shall be provided in the written request from the CO, CS, and/or COR.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 7</a> of 18</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.85%;">
<tr>
<td style="width:28.53%;"></td>
<td style="width:43.69%;"></td>
<td style="width:27.64%;"></td>
</tr>
<tr style="height:40.35pt;">
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract No.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75A50119C00053</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modification No. P00010</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuation Sheet</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Block 14</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Contract Data Requirements List (CDRLs)</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:7.5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">CDRL#</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Deliverable</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Reporting Procedures and Due</p>
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.04%;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Dates</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.5pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:2.78%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kickoff Meeting</p></td>
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.4pt;;margin-right:1.48%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor shall complete a Kickoff meeting after contract award</p></td>
<td valign="top"  style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;margin-right:3.33%;text-indent:-13.5pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Within 10 calendar days after contract</font><font style="letter-spacing:-0.05pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">award.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;margin-right:1.3%;text-indent:-13.5pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Materials: Contractor shall provide itinerary and agenda to CO and COR at least 5 business days in advance of meeting. CO approves and the COR distributes itinerary and agenda within 3 business days. &#x2022; Due out: Contractor provides meeting minutes to CO and COR within 5 business days after</font><font style="letter-spacing:-0.4pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">the</font></p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:14.5pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">meeting.</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:14.5pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.5pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:7.22%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarterly Meetings</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:5pt;margin-bottom:0pt;margin-left:5.4pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the discretion of the government the Contractor shall hold recurring teleconference or face-to-face Project Review Meetings up to four per year either in Washington D.C or at work sites of the Contractor or subcontractors. Face-to-face meetings shall alternate between Washington DC and Contractor, sub-contractor sites.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:3.7%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The meetings will be used to discuss contract progress in relation to the Program Management deliverables described below as well as study designs, technical, regulatory, and</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ethical aspects of the program.</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:18.9pt;;margin-right:1.48%;text-indent:-13.5pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Materials: Contractor shall provide itinerary and agenda to CO and COR at least 5 business days in advance of site visit. The COR approves and distributes itinerary and agenda within 3 business</font><font style="letter-spacing:-0.1pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">days.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;margin-right:2.04%;text-indent:-13.5pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Due out: Contractor provides meeting minutes to the CO and the COR within 5 business days after the</font><font style="letter-spacing:-0.1pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">meeting.</font></p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:2.78%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biweekly Teleconference Meetings</p></td>
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:2.04%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor shall participate in teleconferences every two weeks with the CO and the COR to discuss the performance of the contract.</p></td>
<td valign="top"  style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:0.93%;text-indent:-9pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Materials: Contractor provides agenda and slides to the CO and COR no later than 2 business days in advance of meeting. The COR approves and distributes agenda prior to</font><font style="letter-spacing:-0.1pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">meeting.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:14.4pt;;margin-right:2.78%;text-indent:-9pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Due out: Contractor provides meeting minutes to the CO and COR within 5 business days following the</font><font style="letter-spacing:-0.25pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">meeting.</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 8</a> of 18</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.85%;">
<tr>
<td style="width:28.53%;"></td>
<td style="width:43.69%;"></td>
<td style="width:27.64%;"></td>
</tr>
<tr style="height:40.35pt;">
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract No.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75A50119C00053</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modification No. P00010</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuation Sheet</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Block 14</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:11.5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">CDRL#</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Deliverable</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Reporting Procedures and Due</p>
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:12.2pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Dates</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Monthly) 05</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Annual)</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.93%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Monthly &amp; <font style="letter-spacing:-0.15pt;">Annual </font>Technical Progress<font style="letter-spacing:-0.15pt;"> </font>Reports</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:3.33%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Monthly and Annual Technical Progress report shall address each of the below items and be cross- referenced to the Work Breakdown Structure (WBS), Statement of Work (SOW), Integrated Master Schedule (IMS), and Contract Performance Report (CPR).</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:0.93%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.An Executive Summary highlighting the progress, issues and relevant manufacturing, non- clinical, clinical and regulatory activities. The Executive Summary should highlight only critical issues for that reporting period and resolution approach; limited to 2-3 pages.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:1.11%;text-indent:2.25pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.Progress in meeting contract milestones &#8211; broken out by subtasks within each milestone, overall project assessment, problems encountered<font style="letter-spacing:-0.7pt;"> </font>and recommended solutions. The reports shall detail the planned and actual progress during the period covered, explaining occurrences of any differences between the two and the corrective<font style="letter-spacing:-0.05pt;"> </font>steps.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.The reports shall also include a three- month rolling forecast of the key planned activities, referencing the WBS/IMS.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:0.74%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.A tracking log of progress on regulatory submissions with the FDA number, description of submission, date of submission, status of submission and next<font style="letter-spacing:-0.1pt;"> </font>steps.</p>
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:15.3pt;;text-indent:-9.95pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.Estimated and Actual<font style="letter-spacing:-0.3pt;"> </font>Expenses.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.This report shall also contain a narrative or table detailing whether there is a significant discrepancy (&gt;10%) at this time between the % of work completed and the cumulative costs incurred to date. Monthly and actual expenses should be broken down to the appropriate WBS level. This section of the report should also contain estimates for the Subcontractors&#8217; expenses from the previous month if the Subcontractor did not submit a<font style="letter-spacing:-0.5pt;"> </font>bill</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the previous month. If the</p></td>
<td valign="middle"  style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;margin-right:1.11%;text-indent:-13.5pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Due: Monthly Reports shall be submitted on </font><font style="font-weight:bold;font-family:Calibri;">the 15</font><font style="font-weight:bold;font-size:6.5pt;font-family:Calibri;">th </font><font style="font-weight:bold;font-family:Calibri;">day </font><font style="font-family:Calibri;">of the month after the end of each month with an Annual Report submitted on the 30</font><font style="font-size:6.5pt;font-family:Calibri;">th </font><font style="font-family:Calibri;">calendar day of the final month of each contract year for the previous twelve calendar</font><font style="letter-spacing:-0.05pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">months.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;margin-right:1.3%;text-indent:-13.5pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;When the 25th or 30th falls on</font><font style="letter-spacing:-0.65pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">a weekend or a US Holiday, the reports will be due the next business</font><font style="letter-spacing:-0.1pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">day.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;margin-right:2.22%;text-indent:-13.5pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Monthly progress reports are not required for the periods when the Annual Report(s)</font><font style="letter-spacing:-0.75pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">and Final Report are</font><font style="letter-spacing:-0.2pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">due.</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:10%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:0.93%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subcontractor(s) was not working or did not incur any costs in the previous month, then a statement to this effect should be included in this report for</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">those respective subcontractors.</p></td>
<td valign="top"  style="width:35%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 9</a> of 18</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.85%;">
<tr>
<td style="width:28.53%;"></td>
<td style="width:43.69%;"></td>
<td style="width:27.64%;"></td>
</tr>
<tr style="height:40.35pt;">
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract No.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75A50119C00053</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modification No. P00010</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuation Sheet</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Block 14</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">CDRL#</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Deliverable</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Reporting Procedures and Due</p>
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Dates</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:0.93%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk Management Plan</p></td>
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:0.93%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor shall provide a Risk Management Plan that outlines the impacts of each risk in relation to the cost, schedule, and performance objectives. The plan shall include risk mitigation strategies. Each risk mitigation strategy will capture how the corrective action will reduce impacts on cost, schedule and performance.</p></td>
<td valign="top"  style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;margin-right:1.85%;text-indent:-13.5pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Due: Within 90 days of</font><font style="letter-spacing:-0.65pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">contract award.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;margin-right:1.3%;text-indent:-13.5pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Due out: Contractor provides updated Risk Management Plan in Monthly Progress Report.</font><font style="letter-spacing:-0.7pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">The COR shall provide Contractor with written comments in response submitted plan. Contractor must address, in writing, all commercially reasonable concerns raised by the COR within 20 business days of Contractor&#8217;s receipt of</font><font style="letter-spacing:-0.45pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">COR&#8217;s concerns for CO approval.</font></p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.4pt;;margin-right:2.41%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deviation Notification and Mitigation Strategy</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Process for changing IMS activities associated with cost and schedule. Contractor shall notify BARDA of significant changes the IMS defined as increases in cost above 5% or schedule slippage of more than 30 days, which would require a PoP extension.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:3.89%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractor shall provide a high-level management strategy for risk</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mitigation.</p></td>
<td valign="middle"  style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;margin-right:2.22%;text-indent:-13.5pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Due: As needed and communicated by the</font><font style="letter-spacing:-0.55pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">COR/CO.</font></p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:0.74%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Go/No-Go In- Process Review (IPR) or Decision Gate Presentation</p></td>
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:0.74%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractor shall provide a presentation detailing technical progress made towards completion of Go/No-Go decision gate milestones following a prescribed template provided by BARDA prior to the IPR.</p></td>
<td valign="top"  style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:13.8pt;;margin-right:2.41%;text-indent:-13.5pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Materials: Contractor shall provide presentation materials to the CO and COR 10 business days prior to the In- Process Review (IPR). Contractor shall submit written justification of progress towards satisfying Go/No-Go criteria. After reviewing, the CO and COR will provide a written response within 10 business</font><font style="letter-spacing:-0.15pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">days.</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 10</a> of 18</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.85%;">
<tr>
<td style="width:28.53%;"></td>
<td style="width:43.69%;"></td>
<td style="width:27.64%;"></td>
</tr>
<tr style="height:40.35pt;">
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract No.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75A50119C00053</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modification No. P00010</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuation Sheet</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Block 14</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">CDRL#</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Deliverable</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Reporting Procedures and Due</p>
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Dates</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.96%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Incident Report</p></td>
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:2.78%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractor shall communicate and document all critical programmatic concerns, risks, or potential risks with the CO and COR.</p></td>
<td valign="top"  style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.15pt;;margin-right:1.11%;text-indent:-9.75pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Due out: Contractor shall submit, within 5 business days, a Corrective Action Plan (if</font><font style="letter-spacing:-0.6pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">deemed necessary by either party) to address any potential issues. If corrective action is</font><font style="letter-spacing:-0.1pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">deemed necessary, Contractor</font><font style="letter-spacing:-0.5pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">must address in writing, its consideration of concerns raised by the CO, within 5 business days of receiving such concerns in writing.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.15pt;;margin-right:1.48%;text-indent:-9.75pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Due: Within 48 hours of activity or incident or within 24 hours for a security activity or incident via email or telephone, with written follow- up to the CO and COR. Additional updates due within 48 hours of</font><font style="letter-spacing:-0.15pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">additional developments.</font></p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Draft and Final Reports for Clinical and Non- Clinical Studies</p></td>
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:1.48%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractor shall provide Draft and Final Clinical/Non-Clinical Study Reports to the CO and COR for review and comment.</p></td>
<td valign="top"  style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:0.93%;text-indent:-9pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Draft - within 45 calendar days after completion of analysis and at least 15 business days prior to submission to FDA. Subcontractor prepared reports received by the Contractor shall be submitted to the CO and COR for review and comment no later than 5 business days after receipt by Contractor. The CO shall provide written comments to the Draft Final Report for Clinical and Non- Clinical Studies within 15</font><font style="letter-spacing:-1.1pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">business days after the</font><font style="letter-spacing:-0.25pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">submission.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.11%;text-indent:-9pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Final - due 30 calendar days after receiving comments on </font><font style="letter-spacing:-0.3pt;font-family:Calibri;">the </font><font style="font-family:Calibri;">Draft Final Report for Clinical and Non-Clinical Studies. If corrective action is recommended, Contractor must address, in writing, all reasonable concerns raised by the CO in writing. Contractor shall consider revising reports to address CO&#8217;s recommendations prior to FDA</font><font style="letter-spacing:-0.2pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">submission.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.11%;text-indent:-9pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Final FDA submissions shall be provided to the CO and COR concurrently or no later than 5 business days after</font><font style="letter-spacing:-0.65pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">submission to the</font><font style="letter-spacing:-0.25pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">FDA.</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 11</a> of 18</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.85%;">
<tr>
<td style="width:28.53%;"></td>
<td style="width:43.69%;"></td>
<td style="width:27.64%;"></td>
</tr>
<tr style="height:40.35pt;">
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract No.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75A50119C00053</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modification No. P00010</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuation Sheet</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Block 14</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">CDRL#</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Deliverable</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Reporting Procedures and Due</p>
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Dates</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:5.93%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Standard Operating Procedures</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:1.3%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor shall make internal and, to the extent possible, subcontractor Standard Operating Procedures (SOPs)</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">available for review electronically.</p></td>
<td valign="middle"  style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon request from the CO.</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="middle"  style="width:15%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Correspondence</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.4pt;;margin-right:0.93%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor shall memorialize any correspondence between Contractor and FDA and submit to the CO and COR.</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All documents shall be duly marked as</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">either &#8220;Draft&#8221; or &#8220;Final&#8221;.</p></td>
<td valign="top"  style="width:35%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:16.7pt;;margin-right:4.07%;text-indent:-11.3pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Due: Contractor shall</font><font style="letter-spacing:-0.7pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">provide written summary of any FDA correspondence within 5 business days</font><font style="letter-spacing:-0.15pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">of correspondence.</font></p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA Meetings</p></td>
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:0.74%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor shall forward the dates and times of any meeting with the FDA to the CO and COR and make arrangements for appropriate government staff to attend the FDA meetings. Government staff shall include up to a maximum of four people (COR, CO and up to 2 subject matter experts).</p></td>
<td valign="top"  style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:16.7pt;;margin-right:1.48%;text-indent:-11.3pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Contractor shall schedule upcoming FDA meetings, so at a minimum the CO, COR, and RQA persons from BARDA can</font><font style="letter-spacing:-0.65pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">attend. Additionally, a pre-meeting needs to be held with BARDA to review slides and discuss meeting</font><font style="letter-spacing:-0.05pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">strategies.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:16.7pt;;margin-right:3.7%;text-indent:-11.3pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Contractor shall notify the CO and COR of upcoming FDA meeting within 24 hours of scheduling.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:16.7pt;;margin-right:0.93%;text-indent:-11.3pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;The Contractor shall forward initial Contractor and FDA- issued draft minutes and final minutes of any meeting with the FDA to the CO and COR within 5 business days of receipt. All documents shall be duly</font><font style="letter-spacing:-0.45pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">marked as either &#8220;Draft&#8221; or &#8220;Final&#8221;.</font></p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:7pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA Submissions</p></td>
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:0.93%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor shall provide the CO and COR the opportunity to review and comment upon all draft submissions before submission to the FDA. Contractor shall provide the CO and COR with an electronic copy of the final FDA submission. All documents shall be duly marked as either &#8220;Draft&#8221; or<font style="letter-spacing:-0.9pt;"> </font>&#8220;Final&#8221;.</p></td>
<td valign="top"  style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;margin-right:1.11%;text-indent:-13.5pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Due: Contractor shall submit draft FDA submissions to the CO and COR at least 15 business days prior to FDA submission. The CO and COR will provide feedback to Contractor within 10 business days of</font><font style="letter-spacing:-0.3pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">receipt.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;margin-right:2.41%;text-indent:-13.5pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Due out: If corrective action is recommended, the Contractor must address, in writing, its consideration of all concerns raised by the</font><font style="letter-spacing:-0.15pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">CO.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;margin-right:2.04%;text-indent:-13.5pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;The Contractor shall consider revising their documents to address CO&#8217;s concerns and/or recommendations prior to FDA submission.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.9pt;;margin-right:0.74%;text-indent:-13.5pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Final FDA submissions shall be submitted to the CO and COR concurrently or no later than 5 calendar day of its submission</font><font style="letter-spacing:-0.35pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">to CDER.</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 12</a> of 18</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.85%;">
<tr>
<td style="width:28.53%;"></td>
<td style="width:43.69%;"></td>
<td style="width:27.64%;"></td>
</tr>
<tr style="height:40.35pt;">
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract No.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75A50119C00053</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modification No. P00010</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuation Sheet</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Block 14</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">CDRL#</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Deliverable</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Reporting Procedures and Due</p>
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Dates</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA Audits</p></td>
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:0.93%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of an FDA inspection which occurs as a result of this contract and for the product, or for any other FDA inspection that has the reasonable potential to impact the performance of this contract, the Contractor shall provide the Government with an exact copy (non- redacted) of the FDA Form 483 and the Establishment Inspection Report (EIR). The Contractor shall provide the COR and CO with copies of the plan for addressing areas of non- conformance to FDA regulations for GLP, GMP, or GCP guidelines as identified in the audit report, status updates during the plans execution and a copy of all final responses to the FDA. The Contractor shall also provide redacted copies of any FDA audits received from subcontractors that<font style="letter-spacing:-0.95pt;"> </font>occur as a result of this contract or for this product. The Contractor shall make arrangements for BARDA representative(s) to be present during the final debrief by the<font style="letter-spacing:-0.25pt;"> </font>regulatory</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inspector.</p></td>
<td valign="middle"  style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.95pt;;margin-right:0.74%;text-indent:-9.55pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Contractor shall notify the CO and COR within 10 business</font><font style="letter-spacing:-0.65pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">days of a scheduled FDA audit or within 24 hours of an ad hoc site visit/audit if the FDA does not provide advanced notice.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.95pt;;margin-right:0.93%;text-indent:-9.55pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Contractor shall provide copies of any FDA audit report received from subcontractors that occur as a result of this contract or for this product within 5 business days of receiving correspondence from the FDA or third</font><font style="letter-spacing:-0.15pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">party.</font></p>
<p style="margin-top:0pt;line-height:12pt;margin-bottom:0pt;margin-left:14.95pt;;margin-right:0.74%;text-indent:-9.55pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Within 10 business days of audit report, Contractor shall provide CO with a plan for addressing areas of nonconformance, if any are</font><font style="letter-spacing:-0.05pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">identified.</font></p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">QA Audit Reports</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.4pt;;margin-right:0.74%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BARDA Quality group and /or their qualified representatives reserves the right to participate in QA audits.Upon completion of the audit/site visit the Contractor shall provide a report capturing the findings, results and next steps in proceeding with the subcontractor. If action is requested of the subcontractor, detailed concerns for addressing areas of non- conformance to FDA regulations for GLP, GMP, or GCP guidelines, as identified in the audit report, must be provided to the CO and COR. The Contractor shall provide responses from the subcontractors to address these concerns and plans for corrective action<font style="letter-spacing:-0.05pt;"> </font>execution.</p></td>
<td valign="middle"  style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.05pt;;margin-right:0.93%;text-indent:-14.65pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Contractor shall notify the CO and COR 10 days in advance of upcoming, ongoing, or recent audits/site visits of subcontractors as part of weekly</font><font style="letter-spacing:-0.05pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">communications.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:20.05pt;;margin-right:0.93%;text-indent:-14.65pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Contractor shall notify the CO and COR within 5 business days of report</font><font style="letter-spacing:-0.15pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">completion.</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 13</a> of 18</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.85%;">
<tr>
<td style="width:28.53%;"></td>
<td style="width:43.69%;"></td>
<td style="width:27.64%;"></td>
</tr>
<tr style="height:40.35pt;">
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract No.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75A50119C00053</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modification No. P00010</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuation Sheet</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Block 14</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:9.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">CDRL#</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:15.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Deliverable</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:39.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:34.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:51.7pt;;text-indent:-51.7pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Reporting Procedures and Due </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:51.7pt;;text-indent:-51.7pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Dates</p></td>
</tr>
<tr>
<td valign="middle"  style="width:9.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="middle"  style="width:15.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BARDA Audit</p></td>
<td valign="top"  style="width:39.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractor shall accommodate<font style="letter-spacing:-0.9pt;"> </font>periodic</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or ad hoc site visits by the CO and<font style="letter-spacing:-0.95pt;"> </font>COR.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:1.3%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractor shall also accommodate any &#8216;for cause&#8217; audit if and when there are potential issues identified in the program during the period of performance. Such issues include but are not limited to stability failures, GLP issues etc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:1.67%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the CO, COR, Contractor, or other parties identifies any issues during an audit, the Contractor shall capture the issues, identify potential solutions, and</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provide a report to the CO and COR.</p></td>
<td valign="top"  style="width:34.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:5pt;margin-bottom:0pt;margin-left:18.5pt;;text-indent:-13.1pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;If issues are identified during</font><font style="letter-spacing:-0.3pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">the audit, Contractor shall submit a report to the CO and COR detailing the finding and corrective action(s) within 10 business days of the audit.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.5pt;;margin-right:1.48%;text-indent:-13.1pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Due out: The CO and COR will review the report and provide a response to the Contractor with 10 business days. Once corrective action is completed, the Contractor will provide</font><font style="letter-spacing:-0.25pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">a final report to the CO and COR.</font></p></td>
</tr>
<tr>
<td valign="middle"  style="width:9.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="middle"  style="width:15.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:5.93%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Technical Documents</p></td>
<td valign="top"  style="width:39.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:1.48%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon request, Contractor shall provide CO and COR with deliverables from the following contract funded activities: process Development Reports, Assay Qualification Plan/Report, Assay Validation Plan/Report, Assay Technology Transfer Report, Batch Records, SOPs, Master Production Records, Certificate of Analysis, Clinical Studies Data or Reports. The CO and COR reserve the right to request within the PoP a non- proprietary technical document for distribution within the</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government.</p></td>
<td valign="middle"  style="width:34.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.5pt;;margin-right:1.3%;text-indent:-13.1pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Contractor shall provide technical document within 10 business days of COR&#8217;s request. Contractor can request additional time on an as needed basis.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.5pt;;margin-right:2.22%;text-indent:-13.1pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;If corrective action is recommended by the COR, the Contractor must address, in writing, concerns raised by the COR to the COR and CO in writing.</font></p></td>
</tr>
<tr>
<td valign="middle"  style="width:9.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="middle"  style="width:15.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.4pt;;margin-right:1.3%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw Data or Data Analysis</p></td>
<td valign="middle"  style="width:39.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:0.74%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractor shall provide raw data and/or data analysis to the CO and COR upon request. Contractor shall address and adjudicate all concerns from BARDA review of the data/analysis and amend the reports as required.</p></td>
<td valign="top"  style="width:34.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.5pt;;margin-right:1.48%;text-indent:-13.1pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Contractor shall provide data or data analysis to the CO and COR within 20 business days of request.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.5pt;;margin-right:5%;text-indent:-13.1pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Contractor shall amend the reports if required</font><font style="letter-spacing:-0.1pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">and adjudicate all comments.</font></p></td>
</tr>
<tr>
<td valign="middle"  style="width:9.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="middle"  style="width:15.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Publications</p></td>
<td valign="middle"  style="width:39.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:2.04%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any manuscript or scientific meeting abstract containing data generated under this contract must be submitted to the CO and COR for review prior to submission.</p></td>
<td valign="top"  style="width:34.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.5pt;;margin-right:1.3%;text-indent:-13.1pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Contractor must submit all manuscript or scientific meeting abstract to the CO and COR within 30 days for manuscripts and 15 days for</font><font style="letter-spacing:-0.1pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">abstracts.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.5pt;;margin-right:3.7%;text-indent:-13.1pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Contractor must address in writing all concerns raised by the CO and COR in</font><font style="letter-spacing:-0.2pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">writing.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.5pt;;margin-right:3.33%;text-indent:-13.1pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Final submissions shall be submitted to the CO and COR concurrently or no later than five (5) calendar days after its submission.</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 14</a> of 18</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.85%;">
<tr>
<td style="width:28.53%;"></td>
<td style="width:43.69%;"></td>
<td style="width:27.64%;"></td>
</tr>
<tr style="height:40.35pt;">
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract No.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75A50119C00053</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modification No. P00010</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuation Sheet</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Block 14</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">CDRL#</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Deliverable</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Reporting Procedures and Due</p>
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Dates</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="middle"  style="width:15%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Press Releases</p></td>
<td valign="middle"  style="width:40%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.4pt;;margin-right:1.3%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractor agrees to accurately and factually represent the work conducted under this contract in all press releases.</p></td>
<td valign="top"  style="width:35%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.45pt;;margin-right:1.67%;text-indent:-14.05pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;With the exception of ad-hoc press releases required by applicable law or regulations, Contractor shall ensure that the CO and COR has received and approved an advanced copy of any draft press release to this contract not less than 10 business days prior to the issuance of the press</font><font style="letter-spacing:-0.3pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">release.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.45pt;;margin-right:1.67%;text-indent:-14.05pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;If corrective action is</font><font style="letter-spacing:-0.55pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">required, the Contractor agrees to accurately and factually represent the work conducted under this contract in all press releases.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.45pt;;margin-right:0.93%;text-indent:-14.05pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Any final press releases shall</font><font style="letter-spacing:-0.85pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">be submitted to the CO and COR no later than 1 (one)</font><font style="letter-spacing:-0.5pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">calendar</font></p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:19.45pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">day prior to its release.</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:19.45pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Integrated Master Schedule (IMS)- Gantt</p></td>
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.4pt;;margin-right:4.07%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Contractor shall provide an IMS including WBS, critical path, and milestones.</p></td>
<td valign="top"  style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.45pt;;margin-right:0.74%;text-indent:-14.05pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Due: Contractor shall provide the draft IMS-Gantt within 15 days of contract award with final due 30 days after award and updated monthly as part of the Monthly Progress</font><font style="letter-spacing:-0.4pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">Report.</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:19.45pt;;margin-right:1.48%;text-indent:-14.05pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Contractor must address, in writing, all concerns raised by the COR in writing and</font><font style="letter-spacing:-0.55pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">provide response to the CO and</font><font style="letter-spacing:-0.3pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">COR.</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 15</a> of 18</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.85%;">
<tr>
<td style="width:28.53%;"></td>
<td style="width:43.69%;"></td>
<td style="width:27.64%;"></td>
</tr>
<tr style="height:40.35pt;">
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract No.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75A50119C00053</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modification No. P00010</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuation Sheet</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Block 14</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:11.5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.11%;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">CDRL#</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Deliverable</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:11.48%;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.04%;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Reporting Procedures and Due</p>
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.04%;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Dates</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:6.45pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.4pt;;margin-right:2.41%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Draft and Final Technical Progress Report</p></td>
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:1.48%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Draft Final Technical Progress Report containing a summation of the work performed and the results obtained for the entire contract PoP. The draft</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:1.3%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">report shall be duly marked as &#8217;Draft&#8217;. The Final Technical Progress Report incorporating feedback received from the CO and COR and containing a summation of the work performed and the results obtained for the entire contract PoP. The final report shall document the results of the entire contract. This report shall be in sufficient detail to fully describe the progress achieved under all milestones. The final report shall be duly marked as &#8217;Final&#8217;.</p></td>
<td valign="top"  style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.5pt;;margin-right:1.3%;text-indent:-9.15pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Due: Contractor shall provide a draft Technical Progress Report 30 calendar days before the end of the PoP and the Final Technical Progress Report on or before the completion date of the PoP.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.5pt;;margin-right:1.11%;text-indent:-9.15pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Subcontractor prepared reports received by the Contractor shall be submitted to the CO and COR for review and comment no later than 5 business days after receipt by the</font><font style="letter-spacing:-0.35pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">Contractor.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.5pt;;margin-right:1.85%;text-indent:-9.15pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Due out: the CO shall provide feedback on draft report within 15 calendar days of receipt, which the Contractor shall consider incorporating into the Final</font><font style="letter-spacing:-0.1pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">Report.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.5pt;;margin-right:3.7%;text-indent:-9.15pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Contractor shall submit, with the Final Technical Progress Report, a summary (not to exceed 200 words) of salient results achieved during</font><font style="letter-spacing:-0.3pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">the</font></p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:14.5pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">performance of the contract.</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:14.5pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:6.45pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:2.78%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Draft and Final Study Protocols</p></td>
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.4pt;;margin-right:0.93%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractor shall provide all Draft and Final Study Protocols to the COR for evaluation. (The CO and COR reserves the right to request within the period of performance a non-proprietary Study Protocol for distribution within the US Government.</p></td>
<td valign="top"  style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.5pt;;margin-right:0.93%;text-indent:-9.15pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;The Contractor will submit all proposed protocols to the CO and COR at least 10 business days prior to study start. If corrective action is required, the Contractor must address in writing all concerns raised by the CO and COR to the satisfaction of the COR before study execution and provide the CO and COR a revised draft protocol that addresses the CO&#8217;s comments and requested changes.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.5pt;;margin-right:0.93%;text-indent:-9.15pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;After receiving the revised Study Protocol that satisfies the COR, the CO will approve the revised Study Protocol and will provide a written approval to the Contractor that provides authorization to the Contractor to execute the specific</font><font style="letter-spacing:-0.45pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">study.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.55pt;;margin-right:1.48%;text-indent:-9.15pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;Contractor shall not proceed with any study protocol until</font><font style="letter-spacing:-0.75pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">the COR gives its approval and the Contractor has provided the CO and COR with a final and approved Study Protocol.</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 16</a> of 18</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.85%;">
<tr>
<td style="width:28.53%;"></td>
<td style="width:43.69%;"></td>
<td style="width:27.64%;"></td>
</tr>
<tr style="height:40.35pt;">
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract No.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75A50119C00053</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modification No. P00010</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuation Sheet</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Block 14</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">CDRL#</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Deliverable</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="middle"  BGCOLOR="#C0C0C0" style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Reporting Procedures and Due</p>
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Dates</p></td>
</tr>
<tr>
<td valign="middle"  style="width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:7pt;margin-bottom:0pt;margin-left:6.45pt;;margin-right:1.11%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="middle"  style="width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.4pt;;margin-right:3.89%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical Study Status Update</p></td>
<td valign="middle"  style="width:40%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.4pt;;margin-right:0.93%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractor shall provide COR with a status update of clinical studies that are actively enrolling patients to include by study site: cumulative enrollment; new enrollments; screen failures; patients dropped from study; AE and SAEs; activation or inactivation of study sites; investigator appointments or changes; and status of IRB/IEC review/approval/renewal. Contractor will provide proposed format for the COR&#8217;s review and approval.</p></td>
<td valign="top"  style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.45pt;;margin-right:1.85%;text-indent:-14.05pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Update will be submitted by e-mail or other electronic format to be provided by the COR by the end of the 25th business day of each new month.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.45pt;;margin-right:1.85%;text-indent:-14.05pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;When the 25th falls on a weekend or US Holiday, the update will be due the next business</font><font style="letter-spacing:-0.1pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">day.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.45pt;;margin-right:1.85%;text-indent:-14.05pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;Updates, to the extent they are available, will be presented during biweekly teleconferences.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.45pt;;margin-right:1.85%;text-indent:-14.05pt;;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:Calibri;">&#160;&#160;&#160;&#160;If no changes have occurred since the prior update only a simple statement that there</font><font style="letter-spacing:-0.5pt;font-family:Calibri;"> </font><font style="font-family:Calibri;">is</font></p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:19.45pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no new data is required.</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">SECTION J - LIST OF ATTACHMENTS</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following documents are attached and incorporated in this contract:</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.71%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">Statement of</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">Work</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statement of Work, <font style="Background-color:#FFFF00;">dated 9/30/2022, 34 pages</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.72%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">Reserved</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.72%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">Sample Invoice, 1</font><font style="font-size:12pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">page</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.71%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">Financial Report of Individual Project/Contract, 1</font><font style="font-size:12pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">page</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.72%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">Instructions for Completing Financial Report of Individual Project/Contract, 2</font><font style="font-size:12pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">pages</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.72%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;">6.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="font-size:12pt;color:#000000;">Inclusion Enrollment</font><font style="font-size:12pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:12pt;color:#000000;">Report</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inclusion Enrollment Report, 5/01 (Modified OAMP: 10/01), 1 page.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.71%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;">7.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">Research Patient Care</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">Costs</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research Patient Care Costs, 1 page.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.71%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;">8.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">Report of Government Owned, Contractor Held</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">Property</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-right:25.56%;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Report of Government Owned, Contractor Held Property, 1 page. Located at: http://rcb.coancer.gov/rcb-internet/forms/Govt-Owned-Prop.pdf</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;">9.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;font-family:Calibri;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">Go No-Go Success Criteria, 2</font><font style="letter-spacing:-0.2pt;color:#000000;"> </font><font style="color:#000000;">pages</font><font style="font-weight:normal;color:#000000;">.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 17</a> of 18</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.85%;">
<tr>
<td style="width:28.53%;"></td>
<td style="width:43.69%;"></td>
<td style="width:27.64%;"></td>
</tr>
<tr style="height:40.35pt;">
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.2pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract No.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75A50119C00053</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.2pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Modification No. P00010</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Continuation Sheet</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Block 14</p></td>
<td valign="top"  style=" border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">ATTACHMENT 1</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-right:16.48%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Biomedical<font style="letter-spacing:-1.05pt;"> </font>Advanced<font style="letter-spacing:-1pt;"> </font>Research<font style="letter-spacing:-1.05pt;"> </font>and<font style="letter-spacing:-0.9pt;"> </font>Development<font style="letter-spacing:-1.25pt;"> </font>Authority<font style="letter-spacing:-0.9pt;"> </font>(BARDA)<font style="letter-spacing:1.1pt;"> </font>Broad<font style="letter-spacing:-0.9pt;"> </font>Agency Announcement (BAA)(Solicitation<font style="letter-spacing:0.5pt;"> </font>#BAA-18-100-SOL-00003)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advanced<font style="letter-spacing:-1.2pt;"> </font>Research<font style="letter-spacing:-1.15pt;"> </font>and<font style="letter-spacing:-0.95pt;"> </font>Development<font style="letter-spacing:-1pt;"> </font>of<font style="letter-spacing:-0.95pt;"> </font>Chemical,<font style="letter-spacing:-1.2pt;"> </font>Biological,<font style="letter-spacing:-0.9pt;"> </font>Radiological,<font style="letter-spacing:-1pt;"> </font>and<font style="letter-spacing:-0.9pt;"> </font>Nuclear<font style="letter-spacing:-1pt;"> </font>Medical Countermeasures</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:15.74%;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">RAPID,<font style="letter-spacing:-1.35pt;"> </font>HIGH-THROUGHPUT,<font style="letter-spacing:-1.1pt;"> </font>MULTIPLEXED<font style="letter-spacing:-1pt;"> </font>DETECTION<font style="letter-spacing:-1.05pt;"> </font>OF<font style="letter-spacing:-1.05pt;"> </font>BIOTHREAT<font style="letter-spacing:0.85pt;"> </font>SPECIES<font style="letter-spacing:-0.55pt;"> </font>ID<font style="letter-spacing:-0.75pt;"> </font>AND RESISTANCE GENESUSING<font style="letter-spacing:-0.9pt;"> </font>T2MR</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Topic<font style="letter-spacing:-0.65pt;"> </font>Area<font style="letter-spacing:-0.5pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>Interest<font style="letter-spacing:-0.75pt;"> </font>No.<font style="letter-spacing:-0.65pt;"> </font>[7.2.4<font style="letter-spacing:-0.5pt;"> </font>&amp;<font style="letter-spacing:-0.55pt;"> </font>7.3.3]<font style="letter-spacing:1.3pt;"> </font>Statement<font style="letter-spacing:-0.65pt;"> </font>of<font style="letter-spacing:-0.65pt;"> </font>Work<font style="letter-spacing:-0.75pt;"> </font>DATED<font style="letter-spacing:-0.3pt;"> </font>September<font style="letter-spacing:-0.25pt;"> </font>30,<font style="letter-spacing:-0.3pt;"> </font>2021 (<font style="text-decoration:underline;">Diagnostics/Devices</font>Product<font style="letter-spacing:-1.3pt;"> </font>Development)</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STATEMENT OF WORK</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:10.93%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[****]</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;line-height:12pt;margin-bottom:0pt;margin-left:0.19%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 18</a> of 18</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>3
<FILENAME>ttoo-ex105_1066.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ttoo-ex105_1066.htm
</title>
</head>
<!-- NG Converter v5.0.2.73 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.5</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_1_36"></a><a name="_cp_text_1_45"></a><a name="_cp_text_1_51"></a><a name="_cp_text_1_57"></a>AMENDMENT No. 8 TO TERM LOAN AGREEMENT </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS AMENDMENT NO. 8 TO TERM LOAN AGREEMENT, dated as of November 10, 2022 (this &#8220;<font style="font-weight:bold;font-style:italic;">Amendment</font>&#8221;) is made among T2 BIOSYSTEMS, INC., a Delaware corporation (&#8220;<font style="font-weight:bold;font-style:italic;">Borrower</font>&#8221;), the other Obligors party hereto, CRG SERVICING LLC, as administrative agent and collateral agent (in such capacities, &#8220;<font style="font-weight:bold;font-style:italic;">Administrative Agent</font>&#8221;) and the lenders listed on the signature pages hereof under the heading &#8220;LENDERS&#8221; (each, a &#8220;<font style="font-weight:bold;font-style:italic;">Lender</font>&#8221; and, collectively, the &#8220;<font style="font-weight:bold;font-style:italic;">Lenders</font>&#8221;), with respect to the Loan Agreement described below.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">RECITALS</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_4"></a>WHEREAS, Borrower, Administrative Agent and the Lenders are parties to the Term Loan Agreement, dated as of December 30, 2016, with the Subsidiary Guarantors from time to time party thereto (as amended by Amendment No. 1 to Term Loan Agreement, dated as of March 1, 2017, as further amended by Amendment No. 2 to Term Loan Agreement, dated as of December 18, 2017, as further amended by Amendment No. 3 to Term Loan Agreement, dated as of March 16, 2018, as further amended by Amendment No. 4 to Term Loan Agreement, dated as of March 13, 2019, as further amended by Amendment No. 5 to Term Loan Agreement, dated as of September 10, 2019, as further amended by Amendment No. 6, dated as of January 25, 2021, and as further amended by Amendment No. 7, dated as of February 15, 2022, in each case, by and among Borrower, Administrative Agent and the lenders party thereto, and as further amended, supplemented or modified to date, the &#8220;<font style="font-weight:bold;font-style:italic;">Loan Agreement</font><a name="_cp_text_1_4"></a>&#8221;); and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Borrower has requested that Administrative Agent and the Lenders, and Administrative Agent and the Lenders have agreed to, amend the Minimum Required Revenue covenant in <font style="font-weight:bold;">Section 10.02(e) </font>of the Loan Agreement and make certain other changes as more fully set forth herein.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the mutual agreements, provisions and covenants contained herein, the parties agree as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">SECTION 1.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Definitions; Interpretation</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk61432393"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Terms Defined in Loan Agreement</font><font style="color:#000000;">.&nbsp;&nbsp;All capitalized terms used in this Amendment (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Interpretation</font><font style="color:#000000;">.&nbsp;&nbsp;The rules of interpretation set forth in </font><font style="font-weight:bold;color:#000000;">Section 1.03</font><font style="color:#000000;"> of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_2_10"></a><a name="_cp_text_1_9"></a><font style="Background-color:#auto;text-decoration:none;">SECTION 2.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Amendments to Loan Agreement</font><font style="font-weight:normal;color:#000000;">. Subject to </font><font style="color:#000000;">Section 3 </font><font style="font-weight:normal;color:#000000;"><a name="_cp_blt_2_10"></a><a name="_cp_text_1_9"></a>of this Amendment, the following definitions in </font><font style="color:#000000;">Section 1.01</font><font style="font-weight:normal;color:#000000;"> of the Loan Agreement are hereby amended and restated in their entirety:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:13.46%;margin-right:7.69%;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Interest-Only Period</font>&#8221; means the period from and including the first Borrowing Date and through but excluding the thirty-second (32nd) Payment Date following the first Borrowing Date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">277220955 v2</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:13.46%;margin-right:7.69%;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Stated Maturity Date</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">&#8221; means the </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">thirty</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">-</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">second</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> (</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">32</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">nd</sup></font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">) </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Payment Date following the first Borrowing Date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_2_24"></a><a name="_cp_blt_2_25"></a><a name="_cp_blt_2_28"></a><a name="_Ref_ContractCompanion_9kb9Ur013"></a><font style="Background-color:#auto;text-decoration:none;">SECTION 3.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Conditions of Effectiveness</font><font style="font-weight:normal;color:#000000;">. The effectiveness of </font><font style="color:#000000;">Section 2 </font><font style="font-weight:normal;color:#000000;">of this Amendment shall be subject to the following conditions precedent:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Borrower, Administrative Agent and each of the Lenders shall have duly executed and delivered this Amendment pursuant to </font><font style="font-weight:bold;color:#000000;">Section 13.04(a)(i) </font><font style="color:#000000;">of the Loan Agreement; </font><font style="font-style:italic;color:#000000;">provided</font><font style="color:#000000;">, </font><font style="font-style:italic;color:#000000;">however</font><font style="color:#000000;">, that this Amendment shall have no binding force or effect unless all conditions set forth in this </font><font style="font-weight:bold;color:#000000;">Section 3 </font><font style="color:#000000;">have been satisfied; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">no Default or Event of Default (in each case subject to any cure period provided under the Loan Agreement) under the Loan Agreement shall have occurred and be continuing; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Borrower shall have paid or reimbursed Administrative Agent and the Lenders for their reasonable out of pocket costs and expenses (including the reasonable fees and expenses of Administrative Agent&#8217;s and the Lenders&#8217; legal counsel) incurred in connection with this Amendment pursuant to </font><font style="font-weight:bold;color:#000000;">Section 13.03(a)(i)(z) </font><font style="color:#000000;">of the Loan Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">SECTION 4.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Representations and Warranties; Reaffirmation</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Borrower hereby represents and warrants to each Lender as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Borrower has full power, authority and legal right to make and perform this Amendment.&nbsp;&nbsp;This Amendment is within Borrower&#8217;s corporate powers and has been duly authorized by all necessary corporate action and, if required, by all necessary shareholder action.&nbsp;&nbsp;This Amendment has been duly executed and delivered by Borrower and constitutes a legal, valid and binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability affecting the enforcement of creditors&#8217; rights and (b) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).&nbsp;&nbsp;This Amendment (x) does not require any consent or approval of, registration or filing with, or any other action by, any Governmental Authority or any third party, except for such as have been obtained or made and are in full force and effect, (y) will not violate (i) the charter, bylaws or other organizational documents of Borrower and its Subsidiaries or (ii) any applicable law or regulation or any order of any Governmental Authority, other than any such violations in the case of this clause (ii) that, individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect and (z) will not violate or result in a default under any Material Agreement or agreement creating or evidencing any Material Indebtedness, or give rise to a right thereunder to require any payment to be made by any such Person.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No Default has occurred or is continuing or will result after giving effect to this Amendment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The representations and warranties in </font><font style="font-weight:bold;color:#000000;">Section 7</font><font style="color:#000000;"> of the Loan Agreement are true and correct in all material respects (taking into account any changes made to schedules updated in accordance with </font><font style="font-weight:bold;color:#000000;">Section 7.20</font><font style="color:#000000;"> of the Loan Agreement) (unless qualified by materiality or Material Adverse Effect, in which case they are true in all respects (taking into account any changes made to schedules updated in accordance with </font><font style="font-weight:bold;color:#000000;">Section 7.20</font><font style="color:#000000;"> of the Loan Agreement)) on and as of the date hereof, with the same force as if made on and as of the date hereof (except that the representation regarding representations and warranties that refer to a specific earlier date is that they were true and correct in all material respects (taking into account any changes made to schedules updated in accordance with </font><font style="font-weight:bold;color:#000000;">Section 7.20</font><font style="color:#000000;"> of the Loan Agreement) (unless qualified by materiality </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">277220955 v2</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">or Material Adverse Effect, in which case they are true in and correct in all respects (taking into account any changes made to schedules updated in accordance with </font><font style="font-weight:bold;color:#000000;">Section 7.20</font><font style="color:#000000;"> of the Loan Agreement)) on such earlier date).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">There has been no Material Adverse Effect since the date of the Loan Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Each Obligor hereby ratifies, confirms, reaffirms, and acknowledges its obligations under the Loan Documents to which it is a party and agrees that the Loan Documents remain in full force and effect, undiminished by this Amendment, except as expressly provided herein.&nbsp;&nbsp;By executing this Amendment, Borrower acknowledges that it has read, consulted with its attorneys regarding, and understands, this Amendment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">SECTION 5.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman Bold;color:#000000;">Release</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;In consideration of the agreements of Administrative Agent and the Lenders contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Borrower, on behalf of itself and its successors, assigns and other legal representatives, hereby fully, absolutely, unconditionally and irrevocably releases, remises and forever discharges Administrative Agent and each Lender, and their respective successors and assigns, and their respective present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives (Administrative Agent, each Lender and all such other persons being hereinafter referred to collectively as the &#8220;</font><font style="font-style:italic;color:#000000;">Releasees</font><font style="font-weight:normal;color:#000000;">&#8221; and individually as a &#8220;</font><font style="font-style:italic;color:#000000;">Releasee</font><font style="font-weight:normal;color:#000000;">&#8221;), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which Borrower or any of its successors, assigns or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Amendment, including, without limitation, for or on account of, or in relation to, or in any way in connection with the Loan Agreement or any of the other Loan Documents or transactions thereunder or related thereto (collectively, the &#8220;</font><font style="font-style:italic;color:#000000;">Released Claims</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;Borrower understands, acknowledges and agrees that the release set forth above (the &#8220;</font><font style="font-style:italic;color:#000000;">Release</font><font style="font-weight:normal;color:#000000;">&#8221;) may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of the Release.&nbsp;&nbsp;Borrower agrees that no fact, event, circumstance, evidence or transaction which could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the Release.&nbsp;&nbsp;Borrower acknowledges that the Release constitutes a material inducement to Administrative Agent and the Lenders to enter into this Amendment and that Administrative Agent and the Lenders would not have done so but </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">277220955 v2</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">for Administrative Agent&#8217;s and each Lender&#8217;s expectation that the Release is valid and enforceable in all events.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">SECTION 6.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-family:Times New Roman Bold;color:#000000;">Governing Law; Submission to Jurisdiction</font><font style="font-variant: small-caps;color:#000000;">; Waiver of Jury Trial</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Governing Law</font><font style="color:#000000;">.&nbsp;&nbsp;This Amendment and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; </font><font style="font-style:italic;color:#000000;">provided that</font><font style="color:#000000;"> Section 5-1401 of the New York General Obligations Law shall apply.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Submission to Jurisdiction</font><font style="color:#000000;">.&nbsp;&nbsp;Borrower agrees that any suit, action or proceeding with respect to this Amendment or any judgment entered by any court in respect thereof may be brought initially in the federal or state courts in Houston, Texas or in the courts of its own corporate domicile and irrevocably submits to the non-exclusive jurisdiction of each such court for the purpose of any such suit, action, proceeding or judgment.&nbsp;&nbsp;This </font><font style="font-weight:bold;color:#000000;">Section 6</font><font style="color:#000000;"> is for the benefit of Administrative Agent and the Lenders only and, as a result, none of Administrative Agent or any Lender shall be prevented from taking proceedings in any other courts with jurisdiction.&nbsp;&nbsp;To the extent allowed by applicable Laws, Administrative Agent and the Lenders may take concurrent proceedings in any number of jurisdictions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:433pt;color:#000000;"></font><font style="font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;color:#000000;">Waiver of Jury Trial</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="font-variant: small-caps;color:#000000;">Borrower, Administrative Agent and each Lender hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any suit, action or proceeding arising out of or relating to this Amendment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">SECTION 7.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Miscellaneous</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">No Waiver</font><font style="color:#000000;">.&nbsp;&nbsp;Except as expressly stated herein, nothing contained herein shall be deemed to constitute a waiver of compliance with any term or condition contained in the Loan Agreement or any of the other Loan Documents or constitute a course of conduct or dealing among the parties.&nbsp;&nbsp;Except as expressly stated herein, Administrative Agent and the Lenders reserve all rights, privileges and remedies under the Loan Documents.&nbsp;&nbsp;Except as amended hereby, the Loan Agreement and other Loan Documents remain unmodified and in full force and effect.&nbsp;&nbsp;All references in the Loan Documents to the Loan Agreement shall be deemed to be references to the Loan Agreement as amended hereby.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Severability</font><font style="color:#000000;">.&nbsp;&nbsp;In case any provision of or obligation under this Amendment shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Headings</font><font style="color:#000000;">.&nbsp;&nbsp;Headings and captions used in this Amendment (including the Exhibits, Schedules and Annexes hereto, if any) are included for convenience of reference only and shall not be given any substantive effect.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Integration</font><font style="color:#000000;">.&nbsp;&nbsp;This Amendment constitutes a Loan Document and, together with the other Loan Documents, incorporates all negotiations of the parties hereto with respect to the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">277220955 v2</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">subject matter hereof and is the final expression and agreement of the parties hereto with respect to the subject matter hereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Counterparts</font><font style="color:#000000;">.&nbsp;&nbsp;This Amendment may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Amendment by signing any such counterpart.&nbsp;&nbsp;Executed counterparts delivered by facsimile or other electronic transmission (e.g., &#8220;PDF&#8221; or &#8220;TIF&#8221;) shall be effective as delivery of a manually executed counterpart.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Controlling Provisions</font><font style="color:#000000;">.&nbsp;&nbsp;In the event of any inconsistencies between the provisions of this Amendment and the provisions of any other Loan Document, the provisions of this Amendment shall govern and prevail.&nbsp;&nbsp;Except as expressly modified by this Amendment, the Loan Documents shall not be modified and shall remain in full force and effect.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> [Remainder of page intentionally left blank]</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">277220955 v2</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment as of the date first above written.</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BORROWER:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">T2 BIOSYSTEMS, INC.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By <font style="text-decoration:underline;">_/s/ John Sperzel</font>_______________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:  John Sperzel</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp; Chairman &amp; CEO</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:50%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[Signature Page to Amendment No. 8 to Term Loan Agreement]</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADMINISTRATIVE AGENT:<font style="margin-left:216pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CRG SERVICING LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">/s/ Nathan Hukill</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Nathan Hukill</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Authorized Signatory</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LENDERS:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1636"></a>CRG<font style="text-transform:uppercase;"> PARTNERS III</font><a name="_cp_text_1_1636"></a> L.P.<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1637"></a>By CRG PARTNERS III GP L.P., its General Partner</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:40.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By CRG PARTNERS III GP LLC, its General Partner</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By <font style="text-decoration:underline;">/s/ Nathan Hukill</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Nathan Hukill</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Authorized Signatory</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:41.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:41.24%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CRG<font style="text-transform:uppercase;"> PARTNERS III </font>&#8211; PARALLEL FUND &#8220;A&#8221; <font style="text-transform:uppercase;">L.P.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By CRG PARTNERS III&#160;&#8211; PARALLEL FUND &#8220;A&#8221; GP L.P., its General Partner</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:40.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By CRG PARTNERS III&#160;&#8211; PARALLEL FUND &#8220;A&#8221; GP LLC, its General Partner</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By <font style="text-decoration:underline;">/s/ Nathan Hukill</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Nathan Hukill</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Authorized Signatory</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:21.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CRG<font style="text-transform:uppercase;"> PARTNERS III </font>(CAYMAN) UNLEV AIV I <font style="text-transform:uppercase;">L.P.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By CRG PARTNERS III (CAYMAN) GP L.P., its General Partner</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:40.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By CRG PARTNERS III (CAYMAN) GP LLC, its General Partner</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By <font style="text-decoration:underline;">/s/ Nathan Hukill</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Nathan Hukill</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Authorized Signatory</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Witness:<font style="margin-left:54pt;"></font><font style="text-decoration:underline;">/s/ Sean Scanlan</font><br />Name:<font style="margin-left:54pt;"></font>Sean Scanlan</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[Signature Page to Amendment No. 8 to Term Loan Agreement]</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:53.85%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CRG<font style="text-transform:uppercase;"> PARTNERS III </font>(CAYMAN) <font style="text-transform:uppercase;">LEV AIV I L.P.</font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By CRG PARTNERS III (CAYMAN) GP L.P., its General Partner</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:40.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By CRG PARTNERS III (CAYMAN) GP LLC, its General Partner</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By <font style="text-decoration:underline;">/s/ Nathan Hukill</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Nathan Hukill</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Authorized Signatory</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Witness:<font style="margin-left:54pt;"></font><font style="text-decoration:underline;">/s/ Sean Scanlan</font><br />Name:<font style="margin-left:54pt;"></font><font style="text-decoration:underline;">Sean Scanlan_</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CRG<font style="text-transform:uppercase;"> PARTNERS III</font> PARALLEL FUND &#8220;B&#8221; (CAYMAN) L.P.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1660"></a>By CRG PARTNERS III (CAYMAN) GP L.P., its General Partner</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:40.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1661"></a>By CRG PARTNERS III (CAYMAN) GP LLC, its General Partner</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By <font style="text-decoration:underline;">/s/ Nathan Hukill</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Nathan Hukill</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;margin-right:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Authorized Signatory</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Witness:<font style="margin-left:54pt;"></font><font style="text-decoration:underline;">/s/ Sean Scanlan</font><br />Name:<font style="margin-left:54pt;"></font>Sean Scanlan</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[Signature Page to Amendment No. 8 to Term Loan Agreement]</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ttoo-ex311_11.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ttoo-ex311_11.htm
</title>
</head>
<!-- NG Converter v5.0.2.73 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;31.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO 17 CFR 240.13a-14 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PROMULGATED UNDER </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, John Sperzel, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this quarterly report on Form&#160;10-Q of T2 Biosystems,&#160;Inc.; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.53%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.53%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.53%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.53%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="letter-spacing:-0.1pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.53%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.53%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="top"  style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ John Sperzel</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Sperzel</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Chairman of the Board of Directors</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(principal executive officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 14, 2022 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ttoo-ex312_12.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ttoo-ex312_12.htm
</title>
</head>
<!-- NG Converter v5.0.2.73 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;31.2 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO 17 CFR 240.13a-14 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PROMULGATED UNDER </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, John M. Sprague, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this quarterly report on Form&#160;10-Q of T2 Biosystems,&#160;Inc.; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.53%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.53%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.53%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.53%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.53%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.53%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="top"  style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ John M. Sprague</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John M. Sprague</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(principal accounting and financial officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 14, 2022 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ttoo-ex321_14.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ttoo-ex321_14.htm
</title>
</head>
<!-- NG Converter v5.0.2.73 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;32.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION&#160;1350, </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Quarterly Report of T2 Biosystems,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the period ending September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;I, John Sperzel, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that: </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended; and </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="middle"  style="width:100%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ John Sperzel</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Sperzel</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(principal executive officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 14, 2022 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This certification accompanies each Report pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of &#167;18 of the Securities Exchange Act of 1934, as amended. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A signed original of this written statement required by &#167;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ttoo-ex322_7.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ttoo-ex322_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.73 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;32.2 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION&#160;1350, </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Quarterly Report of T2 Biosystems,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the period ending September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;I, John M. Sprague, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that: </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended; and </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="middle"  style="width:100%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ John M. Sprague</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John M. Sprague</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(principal accounting officer and financial officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 14, 2022 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This certification accompanies each Report pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of &#167;18 of the Securities Exchange Act of 1934, as amended. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A signed original of this written statement required by &#167;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g1b2xf54kzm3000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g1b2xf54kzm3000001.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 9R!/L# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBO%OC;^TC^SM^S/H.D>*OVC_CW\%OV?\
MPQK^K_\ "/Z#XC^-OQ2\#?"G0=;U[['<ZC_8FD:QX[UW0=/U+5_[/L[N_P#[
M-L[B:\^QVMS=>3Y$$KJ >TT5YBOQL^#+?">'X]+\7/ABWP,N?"UMXXM_C.OC
MWPJ?A//X*O+>.[M/&$/Q%&K'P?+X6NK6:*YMO$":PVDSV\L<T5VT;JQ].!!
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M$GAW7+&#4]%U[0-;TN>ZTS6-%UC3;JVU#2]4TZZN;'4+&X@N[2>:"6.1MJ@
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MQEKU];:9H?A+PG;ZYJ%C-XC\3:SJ5[9Z?I6@Z.EYJNHWUW;6EG:33SQ1OW=
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MTC0/B!X@FMO#WA3Q=X4U;PCIVM:+=:S=V6GR7%Q'J5W)JJ: GA3Q( >ER?\
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M_GUX._8+_P""@%K\'O\ @GS=>-/V)(?$?[6/[/'_  4Z^&_[47[;?[0^K_M
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MPAIGC>#P9J^BE6\=ZAXSBLGTKPI/X0N]0\5:)]B_%;]GC]M+QMXF_P""6_\
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M_;D_:E_:]\"_L@_$'XQ?!;_@H[X*^!/Q#^(7P/T_XN_LU^'OCS^R?^TA\'_
M;_#N_P##_B:?Q=\:-&^#_COX;^,]$EM;_5/%'PT^+'C36-"U73C9Z1X4U+3+
M:VDU+Y(_:&_X)V_MC?"K_@FWH'P(^#'[-]]^TA^T?\>?^"CUI_P4'_:$TGX9
M_%3X*^"?AO\ "O5YOVEO#O[0>O>!M(\3?'3X@?"B^\2PV7AW0_#_ ,,?"NH:
M#H%]'K6K:'K?BG7+;PEIUWI.G7@!^ROP@_;A\>^)OVYO&?["GQL_9]LO@]XZ
MA_9KLOVM/A3XG\-?%^V^+&C^-_A#_P +-B^$_B#3O&MJGP_\"#X=_$[PIXJU
M'0(]5\+Z'J/Q-\)W=IJKW6B_$+4X+19+OT[]IW]K*;X(>.O@9\"?AO\ #V+X
MQ_M*_M*WWCQ/A'\--0\91_#?PC#X9^%6@V/B+XF_$CXF?$8^&_&MWX+^'W@V
MUUCPWI-S>Z%X%\=>*M7\4>+O#&AZ!X/U3[;J%YI7YXZ3X;_;#\1?\%M?AO\
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M_P '_"FI?LI^*/B1^SGX3\/^*OBUX)_:$_;F^%W[(OB_6;KQ3X37Q[HOP_\
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M_8G^"W[;'AWX+?\ !4GP3\:_^";]@I_:L_X*&_$7]ISP3\)OVB_B[^S+XO\
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M/PW\2O Q^$5W\1]"U/Q#X=N=!\*>*M'N-6U/1?G'X$_L _\ !3#1_P#@D/\
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M9],^$OP;\8^,]%^-G[2'@CP]J>774],T?]HJ_'P0N9#-.;2?]F>&TC9(T(8
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M-"T/Q@POQHOBNQ@^+,'@#2Y]:\9>!P#]8?C-_P %-?&/[*'@KX3Z?^V9\/\
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M\'^?I?Q3UOQ?X&^)&E6]W;'6_ 7@_P $>*/!J7VM)XLL]7@M/!^K@%SX0?\
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MC>'XE?LC_L__ +4O[:<GQ;U[P?\ &#0?"/Q+\#?"O2OVLOB?#K7C#X1? Y?
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MZ1[VV?2_"6I6T6H7%C\F:S_P4^^,'A+XQ_L8?#KQ=^Q3J-MX7_;[\&^*[O\
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MU.RT;1=)L(%W3WNIZKJ,]M8V%I"OS2W-U/%#&O+NHJGX.\9>$/B'X5\/^.O
M'BOPWXY\$^+-*L]=\+>,?!VN:7XF\*^)=#U&%;C3]9\/^(=%NKW2-9TJ^@=)
M[/4=.O+FTNH666"9T8,?GK]N3X>> OBI^QS^TYX'^)G@OPK\0?!NJ?!#XCWN
MH^%?&F@:5XF\/WE]X>\,:CXE\/:A/I&LVM[82:AX?\2:1I/B'0KYH#=Z/KVE
M:;K&G36VHV%I<Q?A?^P;_P % _B3^Q;_ ,$P?^"4GB[XS_LO?9OV-?&/P?\
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MK'X4U'QU8?LQ:9;^'-0^*$WB70K/X&W/AGPE\2]#^)=]KV@1#6M AU"YN=.
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MO6_'FO\ A;P=I-UJ4X2!=0\1^(-*TNU5FFN+H! C@"?#[XC?#WXM>$=*\?\
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M]*\CS_WE;%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2$!@58 J000
M0""",$$'@@C@@\$4M% 'FGPI^#OPR^!WAFY\%?"/P=I/@#P;<>(=>\41>$?#
MHN;3PQI.K^)[]]5UW_A&] -Q)I/A72[_ %2:YU1_#_AJTTG0(=2O=0O[;3(;
MO4+Z:X;X(^#?PP^'/BCXD>./!O@[2]'\:_%_7[3Q+\3/&!-WJ/BGQGJ>FV9T
M[18M:\0:M<WVK3:-X;TYI-/\*>&H[N+PYX3L9[JS\-Z5I=M=7,4OIM% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7Y ?\%&O@/^T)\6_P!I3]A#Q/HOP/N_VL/V-_ASKOQEOOVEOV9['QU\-/"<
M&N>/]6\-^'(OV?/BOXM\*_%WQ;X)\"?&#P?\+?$%GXGNKCP/JVMW4VC:QJ^F
M>-=*\*>*M;T72XM,_7^B@#^.SXE_L7?\%,=!_9$_:2_9\\+?L :CXW\6_%#_
M (+2^+/V[/#L_P //VC_ -F"R\!6OP7C_:0\"_'[2X=*U#XB_$GX8ZZ?[3L/
M#UQX0T&UU/P=X<UR*\A:]UWPIX;L/LHN/THN/ ?[7/Q$_P""S/A#]I/7/V%O
MC=X+_9<\2_\ !-76_P!C?Q=\2M<^+_[(']N>"?'OQ-^*O@_X[:IJFH^#/!_[
M2'B[Q7=^'?!-OHTWPTUS5/"NG^(M0N?'BWNI^%-+\1^!+33?%VM_O710!_(?
MXB_86_X*9>'?^"*7QY_X(RV?[*5K\3O%/@[3[SX>? #]J30/C?\  WPQ\(/B
MY\))/CSIGQ,\/ZKKOAGQ5X]L/BQX%^)NBZ!<W.DZMX3U3P#_ ,(?=KHLMW8_
M$6:\FM+/4OZ+?C5\(_B#^UW^PC\:/@1\7?#7AGX2?$K]H[]FCXI_"?Q;X=\.
M>-+KXC^&?A_XD^*'P^\0>$0-/\;2^$?!]QXD@T"YUBWOGU%/".G*UQ;R1VUM
M>0Q175U]AT4 ?S]?!;Q#\7_BY_P;^WWP#^&GP4\3_%']J_P+^QGXI_X)X^/O
M@'I/BCX9^"?%G@W]H?X?_"VX_9J\3VOC75/BQXX\ ^%/#FDZ1>06/Q+O9[C7
M7U#6_AUJVE>(/!.E>)TUWP_;ZE\Z?&;X*_\ !0?7/V"?^"(GPB\+_P#!._XO
MZ]\5_P!B/]H;]A[XJ_M$^#T^.W[%FFQ>'O#7[%'A2/P3XCMO#?B/4_VF+70/
M%>L?%>2?^WOAG;:;>_9+71[6\B^(=[X'U@66F7W](ND?!SX8^'_BCXM^-.@^
M#=(T3XG^/O#^A^&/'?BW1UN-,O/&VD^&'D/AH^+[.RG@TOQ+JOAR"6;3M \0
M:U8WOB#1M%GGT+3=3MM&GEL7]+H _$#_ (*<>$KW]K/]IS_@D]^R;X8L;J'Q
M'X(_;%^'_P#P4;^-5E*]E>W7PR^"7[)V@^*'TT>-FT:^U.PTUOB3\7_&_A3X
M:^%I+>^O+7Q!K%EXE?1+R^TWPWKE_8_MCJFEZ;K>F:CHNL6-IJFD:O87>EZK
MIE_!'=6.HZ;J%O):7UC>VLRO#<VEW:RRV]S!*C1S0R/'(K*Q!X#P1\&_AA\.
M?%'Q(\<>#?!VEZ/XU^+^OVGB7XF>,";O4?%/C/4]-LSIVBQ:UX@U:YOM6FT;
MPWIS2:?X4\-1W<7ASPG8SW5GX;TK2[:ZN8I?3: /YE-)_P""2W[3GA#]AF_\
M#Z9=>&?%/[3_ .P]\?\ P]XG_P""7]YJ_B2V6VM?@K^R_P#M#^,_B;\!O#WC
M/7+RZN;+P]XE^,WPK\<>(?@I\1@M]9Z0W@73_AM:>)H#>^&-0EE^R/\ @H'_
M ,$_?C+\1OV;/V.KO]F+5?#GB']IG]@3]IGX2?M<>#-'\:ZF_A+PO^T7XT\'
M-X@/QB\*^+/$'E:E%X5UCXV2>,O%OB)O$]U!<PV_BV^$&HWNFZ=JVHZS8_M'
M10!^*&L_LN?'+]N+]KSX;_M7_&WX&Z]^R3X?_9Z_90_:0^!WPO\  ?Q"\<_"
M?Q_\3?%7Q8_:GTG0/"_C7QCK+_ SQQ\3O .F_##P%X.\/3:;X6CE\<2>,/%F
MM>*;[4M2\+^#K70X(-<_.;_AD;_@IT?^">W_  2G_9CT/]BG1(?BS_P3B_;'
M_9.^(GCF;QE^TM\&M%\!?%GPE^S5<^.6M_%GPX\1>%-6\>Z]I_@KQ3ILNDC6
MKSQKX0\/_$SPMJ^M6%IHWP>\<:=%K.K:+_6110!^$>L?"W]KGQ)_P6TC^/FO
M?L;?$2W_ &6-=_X)PW7[$GB7XY^'_C+^S=<Z3I?Q \4?%^P^-NL^,='\)7_Q
M=T7XQW_PTT6V%QX#BUJ7X8:9X[N_%,3:K;?#H>&?(U:;\Z_$7["W_!3+P[_P
M12^//_!&6S_92M?B=XI\':?>?#SX ?M2:!\;_@;X8^$'Q<^$DGQYTSXF>']5
MUWPSXJ\>V'Q8\"_$W1= N;G2=6\)ZIX!_P"$/NUT66[L?B+->36EGJ7]>%%
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M/XV_L_?\%(C^PC_P11^"UC^P=J/Q$^+/[$?[2?[$_P 6_CCHGPI_:1_9UN-
MT;X<_L7>%HO!US;0^(_C'X[^"2:A\3?BI!=+K.@^$_"UEXM\$>&OL.J:=KOQ
M4>1-*NM7_I3\5>*_$>A?#K6O&>A_#+Q?XV\5Z=X5N-?TWX1Z'JGP]T[QQX@U
MN+3C>0>![#6?%7C?P_\ #&S\07-WC21J&K_$'3_",-YNGD\2_P!G!;U^YHH
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MS_PKO6C=7,3:#_PL;PA:V7AKQ;LMHK>[_M31[6&T;[5Y 3S(')]=HH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M /P_5_X)U?\ 0T?M/?\ BOK]OO\ ^AIH_P"'ZO\ P3J_Z&C]I[_Q7U^WW_\
M0TT ?L!17X__ /#]7_@G5_T-'[3W_BOK]OO_ .AIH_X?J_\ !.K_ *&C]I[_
M ,5]?M]__0TT ?L!17X__P##]7_@G5_T-'[3W_BOK]OO_P"AIH_X?J_\$ZO^
MAH_:>_\ %?7[??\ ]#30!^P%%?C_ /\ #]7_ ()U?]#1^T]_XKZ_;[_^AIH_
MX?J_\$ZO^AH_:>_\5]?M]_\ T-- '[ 45^/_ /P_5_X)U?\ 0T?M/?\ BOK]
MOO\ ^AIH_P"'ZO\ P3J_Z&C]I[_Q7U^WW_\ 0TT ?L!17X__ /#]7_@G5_T-
M'[3W_BOK]OO_ .AIH_X?J_\ !.K_ *&C]I[_ ,5]?M]__0TT ?L!17X__P##
M]7_@G5_T-'[3W_BOK]OO_P"AIH_X?J_\$ZO^AH_:>_\ %?7[??\ ]#30!^P%
M%?C_ /\ #]7_ ()U?]#1^T]_XKZ_;[_^AIH_X?J_\$ZO^AH_:>_\5]?M]_\
MT-- '[ 45^/_ /P_5_X)U?\ 0T?M/?\ BOK]OO\ ^AIH_P"'ZO\ P3J_Z&C]
MI[_Q7U^WW_\ 0TT ?L!17X__ /#]7_@G5_T-'[3W_BOK]OO_ .AIH_X?J_\
M!.K_ *&C]I[_ ,5]?M]__0TT ?L!17X__P##]7_@G5_T-'[3W_BOK]OO_P"A
MIH_X?J_\$ZO^AH_:>_\ %?7[??\ ]#30!^P%%?C_ /\ #]7_ ()U?]#1^T]_
MXKZ_;[_^AIH_X?J_\$ZO^AH_:>_\5]?M]_\ T-- '[ 45^/_ /P_5_X)U?\
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M /P_5_X)U?\ 0T?M/?\ BOK]OO\ ^AIH_P"'ZO\ P3J_Z&C]I[_Q7U^WW_\
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M/VGO_%?7[??_ -#30!^P%%?C_P#\/U?^"=7_ $-'[3W_ (KZ_;[_ /H::/\
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M#1^T]_XKZ_;[_P#H::/^'ZO_  3J_P"AH_:>_P#%?7[??_T-- '[ 45^/_\
MP_5_X)U?]#1^T]_XKZ_;[_\ H::/^'ZO_!.K_H:/VGO_ !7U^WW_ /0TT ?L
M!17X_P#_  _5_P""=7_0T?M/?^*^OV^__H::/^'ZO_!.K_H:/VGO_%?7[??_
M -#30!^P%%?C_P#\/U?^"=7_ $-'[3W_ (KZ_;[_ /H::/\ A^K_ ,$ZO^AH
M_:>_\5]?M]__ $-- '[ 45^/_P#P_5_X)U?]#1^T]_XKZ_;[_P#H::/^'ZO_
M  3J_P"AH_:>_P#%?7[??_T-- '[ 45^/_\ P_5_X)U?]#1^T]_XKZ_;[_\
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M)8WCT34#>S>&XM5ATIEMDU1[-[^P6Y /K>BBB@ HHHH **** "BBB@ HHHH
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MJ]ERI:KF44[/JG>ZWNK+= JC;225[:W;T?*Y-:?*S[.Y_2G\1_C[\"?@Y?\
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M)OBYX2G^.7ACP+J+W-]:OHNC:[I7ABT2UL;M[2VM(],N(C,-0,[BI)M*[O\
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MXPFU_1M.M;>WBTO3K)+>$)\U_P##HF?_ *2C?\%@/_$R]/\ _G44?\.B9_\
MI*-_P6 _\3+T_P#^=12YI;<SMZOS_P#DG][[L++LON]/\E]R[&%-_P &]O\
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M ,ZBC_AT3/\ ])1O^"P'_B9>G_\ SJ*5W:UW:UK7Z-W:]&U?U"R[+>_SVO\
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MU<:<D=HOYY?\.B9_^DHW_!8#_P 3+T__ .=11_PZ)G_Z2C?\%@/_ !,O3_\
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M3_\ YU% '[ 45^/_ /PZ)G_Z2C?\%@/_ !,O3_\ YU%'_#HF?_I*-_P6 _\
M$R]/_P#G44 ?L!17\MW_  3<_8)^(O[1?P\_:5\2_$/_ (*E?\%<7U'X>_M[
M?MH_ ?P\NF_MG7;6\?@?X&_'#Q'\-?!QF77/ 6N31ZC<:'X?M;S5TT^>PT1M
M6N;V71M%T73Y(-.M_P!$?^'1,_\ TE&_X+ ?^)EZ?_\ .HH _8"BOQ__ .'1
M,_\ TE&_X+ ?^)EZ?_\ .HH_X=$S_P#24;_@L!_XF7I__P ZB@#]@**_'_\
MX=$S_P#24;_@L!_XF7I__P ZBC_AT3/_ -)1O^"P'_B9>G__ #J* /V HK\?
M_P#AT3/_ -)1O^"P'_B9>G__ #J*/^'1,_\ TE&_X+ ?^)EZ?_\ .HH _8"B
MOQ__ .'1,_\ TE&_X+ ?^)EZ?_\ .HH_X=$S_P#24;_@L!_XF7I__P ZB@#]
M@**_'_\ X=$S_P#24;_@L!_XF7I__P ZBC_AT3/_ -)1O^"P'_B9>G__ #J*
M /V HK\?_P#AT3/_ -)1O^"P'_B9>G__ #J*/^'1,_\ TE&_X+ ?^)EZ?_\
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MO^"P'_B9>G__ #J* /V HK\?_P#AT3/_ -)1O^"P'_B9>G__ #J*/^'1,_\
MTE&_X+ ?^)EZ?_\ .HH _8"BOQ__ .'1,_\ TE&_X+ ?^)EZ?_\ .HH_X=$S
M_P#24;_@L!_XF7I__P ZB@#]@**_'_\ X=$S_P#24;_@L!_XF7I__P ZBC_A
MT3/_ -)1O^"P'_B9>G__ #J* /V HK\?_P#AT3/_ -)1O^"P'_B9>G__ #J*
M/^'1,_\ TE&_X+ ?^)EZ?_\ .HH _8"BOQ__ .'1,_\ TE&_X+ ?^)EZ?_\
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MO^"P'_B9>G__ #J*/^'1,_\ TE&_X+ ?^)EZ?_\ .HH _8"BOQ__ .'1,_\
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MX\K2O>\8RU_O1O;3L3%\ROMK)?<VC]@**_'_ /X=$S_])1O^"P'_ (F7I_\
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M,_\ TE&_X+ ?^)EZ?_\ .HH_X=$S_P#24;_@L!_XF7I__P ZB@#]@**_'_\
MX=$S_P#24;_@L!_XF7I__P ZBOT>^ ?P@;X#?"?PM\*6^*?QB^-3>%VUQC\2
M_CYXTC^(7Q8\1_VYXCU;Q$%\4^+XM)T./5ET<:M_86AA=+MOL'AS3-)TT^<U
MF;B4 ]BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M *$*C_AJ[_@L?_TB!^!?_BTOPO\ _0A4 ?L!17X__P##5W_!8_\ Z1 _ O\
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M?_Z$*C_AJ[_@L?\ ](@?@7_XM+\+_P#T(5 '[ 45^/\ _P -7?\ !8__ *1
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML.B>$O@?X=^'.F^.[.XU?10ZZ+K1GOM),KR6SY//_A[_ )-:KU%S^7_#6O\
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M -K5M2@^&.C2ZIJM[X:U;6;B2_B\'1RZW?7^FZU>Z=-)J\MU$U\5\1_M&?\
M!.WX3Z)X*^(G[-/@+P?XW^*?PG^&_CBV\"Z%\#-+@T35?ALFK^$6T/P_\/?V
M@[31M3\.WWA2'XC_ !"G\#_#/0O /Q2L=2\1W?Q:\0>&-9M?"D6I>'=2\6>&
M5R]KN]K62TNKZ^7_  ?0?/O>RLW>[>MG;335];:]/4_6R[\>^!;#1M=\1WWC
M3PG9>'O"^H7>D^)M>N_$>CVVC>'=5L+F*ROM,UW5)KQ+'2-0LKR>"TN[+4)[
M>YMKF:*":-)9$0\QH7QT^"7BA]3C\,_&+X6>(I-$T:_\1ZS'H7Q"\):N^D>'
MM+$1U/7=333]7N&L-&TX30F_U2[$5C:"6(W$\?F+G\L_V,?AO\2OV7OBZG[/
M_P"T+X-\#0>'_P!J[X?MXZ-]IWQ!N?BMI'Q#_:I^%5EITWQW\6:Y;:W\,?AY
M;Z'KGQK\(ZMH7CFR\-1V7B&"W7X1>*[[^VY)2L=5]'\'>$-&_P"">'_!375=
M'\*^&])U1/$/_!5W14U+3=#TRQOTT>U^(7QTBM=)6\M;6*X73;:*SM(H+ 2"
MUACM;9(XE6"(*<J[MZQLU:SYG;\'?\ YW:]K:3;3NFG%<WXIK\?(_7S6O'G@
M;PU/H=MXC\9^%- N?$TRV_ANWUKQ%H^E3^(;A_*V0:'%?7D$FK3/Y\.V*P6X
M=O.BPI\Q,[$>M:-+K%UX>BU;3)-?L=.LM7O=#CO[5]8M-)U&XO;33]3NM,64
MWMOIU_=Z;J-K97LL"6UU<6%[#!+)):SK'^-'@;7/V5/ GC?]I*/]NVV^%EIX
MP\=WG@+_ (5?J'QQT'2-5M?B'^S5_P *(^&.G^&O OP7'B+3KP>*H-(\=P?$
MNW\3_#7P+#?^)W\>:CJNN:AH=R?%&B7M]X[^ROX#^-'AOXDZE\5WT/QK<?&W
MX%_L4_L>WME\/?$T]Y+X\\9? 'Q/\</V^I[CX(>*8]6N/MC?$67X5Z'\.-1T
MD:W<V^J0?&;X>>%++Q-J=OID_BB*[.3?5^K6C?D^W1OI^ >TU2LG=ZI/6*5]
MUW:5TM+KOHS]_--U;2M8L4U/2-3T_5=-D>ZCCU#3;VVOK%Y+*YFL[U$N[666
MW9[2\MKBUNE60M;W,$T$H26)U6C!XJ\,76EZ/KEKXCT&YT3Q#+I\.@:Q!K&G
MS:7KDVK,J:5#H^H1W#6FIRZF[*FGQV4T[WK,JVPD) KXG_X)VZUIOB7]B/P!
MXBT:=[G2-?U3X[:UI5S);W-G)<:;JOQQ^*-]8SO:7D-O>6KRVL\4C6]W!!<P
M,QBGACE5T7\V/ VG^+_A3^R!_P $X_ 7AM+B3PA\:+G]AKQ_\*=6N89[W3/
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MB7X+>!?C3X"T'1;4V/\ 8>JZ;\;KSX57OB"\U<2VDE^;W29/A+HJ:.;*\M8
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MEYK>I:EJ.J0ZA86OE:39_6VE_L<>!=&^"/A'X Z?XG\50^ ?A_\ '7P1\:O
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M_$OQ'>>-/ DU[XTU72;_ %OQ-JDWA[[MU[XS_#N'XS_LO?M)_''XU? OXU?
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MPR\._%;X9^!/A)\0/CSI/@?QYI.N_ S5_B+\0KJ#Q#^Q9^R_INO7_A/QE/\
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M+OVO?_GG4?\ #EKX ?\ 1T__  5 _P#%EW[7O_SSJ /V HK\?_\ ARU\ /\
MHZ?_ (*@?^++OVO?_GG4?\.6O@!_T=/_ ,%0/_%EW[7O_P \Z@#]@**_'_\
MX<M? #_HZ?\ X*@?^++OVO?_ )YU'_#EKX ?]'3_ /!4#_Q9=^U[_P#/.H _
M8"BOQ_\ ^'+7P _Z.G_X*@?^++OVO?\ YYU'_#EKX ?]'3_\%0/_ !9=^U[_
M //.H _8"BOQ_P#^'+7P _Z.G_X*@?\ BR[]KW_YYU'_  Y:^ '_ $=/_P %
M0/\ Q9=^U[_\\Z@#]@**_'__ (<M? #_ *.G_P""H'_BR[]KW_YYU'_#EKX
M?]'3_P#!4#_Q9=^U[_\ /.H _8"BOQ__ .'+7P _Z.G_ ."H'_BR[]KW_P">
M=1_PY:^ '_1T_P#P5 _\67?M>_\ SSJ /V HK\?_ /ARU\ /^CI_^"H'_BR[
M]KW_ .>=1_PY:^ '_1T__!4#_P 67?M>_P#SSJ /V HK\?\ _ARU\ /^CI_^
M"H'_ (LN_:]_^>=1_P .6O@!_P!'3_\ !4#_ ,67?M>__/.H _8"BOQ__P"'
M+7P _P"CI_\ @J!_XLN_:]_^>=1_PY:^ '_1T_\ P5 _\67?M>__ #SJ /V
MHK\?_P#ARU\ /^CI_P#@J!_XLN_:]_\ GG4?\.6O@!_T=/\ \%0/_%EW[7O_
M ,\Z@#]@**_'_P#X<M? #_HZ?_@J!_XLN_:]_P#GG4?\.6O@!_T=/_P5 _\
M%EW[7O\ \\Z@#]@**_'_ /X<M? #_HZ?_@J!_P"++OVO?_GG4?\ #EKX ?\
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M^#6\4:SHR;;?5-.M+Z>UM+@%=??L?N]17X=^,?\ @E=^R?X'U*PT35OVK?\
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M[2VL-/M5BM;2"*")$"M^#M^?^0T[M::-73^[I\S]N**_ W7/^">/PR\ V?Q
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MM>__ #SJ/^'+7P _Z.G_ ."H'_BR[]KW_P">=0!^P%%?C_\ \.6O@!_T=/\
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M^>=1_P .6O@!_P!'3_\ !4#_ ,67?M>__/.H _8"BOQ__P"'+7P _P"CI_\
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M&+4;:2.\C29?SR_X<M? #_HZ?_@J!_XLN_:]_P#GG4?\.6O@!_T=/_P5 _\
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M54CN%51P !3NET[=O^&L^PG%OKW_ !_&ZMOOYGZ'?&6Z\3:W\;=&\*^(]-\
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M$G7_ (\#3R]O\-M7\%OJ\2L;SQNI\.:S\&I]&L_#>AV9N]'30M"L],CN=/\
M=?'2>&_$GQIM/!OQ<U..Q\&2?#;0]7\ ^&=0UZZT/POXT\;3>(?%D'Q%COEB
MN]/MO%^H^#M#L/A]<:3HFI^=%IMMXEU36K;3+B??>:1^62WO_!P\FO/XI3]F
M;_@BZGB>6W%I+XC7XJ?M2KKTEJ$$8MGU<?#,:@]N(U""%K@QA %VX %3ZWJW
M_!Q/XEL)-*\1_LW?\$9/$&ERNDDNFZW\6OVJ=5L))(CNB>2SO_AK/;N\9)*,
MT99"<J0:=_7KZJ_;T_JP<OITTUL[7WUW=_\ AS]:_A(GPL\'V7Q.E\&_$NX\
M1>$[?QD-3U1];\;WOBGPO\-[F/PKX:T>Z\':#XEUO4-0MM,T:S?1O[<N/#B:
MQ-#X<U'Q!=6J6VEV4UA8Q?'O[+=UI^F67[/5[^T#XAB\.^*=6^!/PMM?V>K+
M3?'.KZ/\,=8\*:7X*\,7.HZ?_9KWFBQ:]\8K:^U".?Q%:^*+&^MKGP[-I<GP
M]B-I;>.(;3Y;BU[_ (.+H-,CT6#]G7_@C3#H\5N+2+28OB]^U9'ID=JHPMM'
M8)\-EM4MU' A6(1@<!<4V?6_^#BRZ%B+G]G+_@C/<#3-O]FB?XN_M5S#3]GE
M;/L(D^&S?9-OD0[?(\O;Y,6,>6F%??S]+[6[6]=/\PY=MM.EG;>_?[O/7R7[
MS5C:YXC\/>&+--1\2Z[HWA[3Y+A+5+[7-4L=)LWNI$DDCMDNK^>W@:XDCAFD
M2$.9'2*1E4JC$?B+_P )K_P<B?\ 1"/^"/7_ (>O]K7_ .=W5*_\1_\ !QGJ
ML MM3_9Y_P""-NHVPD646]_\8?VKKR 2J&59!%<?#>2,2*KNJN%W ,P! 8Y1
M1^J/[)?BCPUK_P"SG\"[+0O$6A:U>:+\$_A);:Q::3J^GZC<Z3<-X%T:);?4
MH+.XFEL)C+:W,0BNDBD,EO.@7=#(%^9O!&J>+/A[\.]1O[CXR2)\4O"GQ@U[
MPJGP6L[7PI9Z+XBU;6?BIJ 70M3T&]TFY\;ZEXC^+VFZM_PL*/QFNMVKQ2>)
M[+Q5I-O;^#;>]T_4OD+3M<_X.+-(\[^R?V<_^"-&E_:/+\_^SOB[^U79>?Y6
M_P KSOLWPVB\SR_,D\O?NV;WVXW-F.35_P#@XGEUB#Q%+^S=_P $9)/$%K:O
M96VN2?%K]JE]8M[*4L9+2#4V^&IO8;60NY>WCG6)R[;D.XY=]_/7IY_Y^I/*
M[+75*W7LE?UTZZ'ZO:'K>B>#/CK\4K3QGJ&GZ'JGQ#M? ^J> -4UFYM[&#Q'
MX7\,^'&TK4?"VC7]V\4=YJ'A+Q._B/Q#J.@02/<6-IXWMM96$PZK<R1^H>"/
M$?P_\42>+=4\ 76CZFK>*'MO%6NZ#98T[6O%6G:'HFE7$S:_#;1Z=XIO]*T?
M3]%\-WVHZ??:HNER:(OA>\N;:^T"XTVQ_%+6M8_X.*/$EA)I7B+]F_\ X(R:
M_I<S(\VFZU\6OVJ=4L)7B;=&\EG??#6>W=HV^9&:,E&Y4@U>M?%?_!QW8VT%
ME9? #_@CG9V=K#';VMI:_&7]K&WMK:")0D4$$$7PY2*&&)%"1QQHJ(H"JH
MHO\ IZ:#MZ6U?GJ?NU17X6?\)K_P<B?]$(_X(]?^'K_:U_\ G=T?\)K_ ,'(
MG_1"/^"/7_AZ_P!K7_YW=(9^Z=%?A9_PFO\ P<B?]$(_X(]?^'K_ &M?_G=T
M?\)K_P '(G_1"/\ @CU_X>O]K7_YW= '[IT5^%G_  FO_!R)_P!$(_X(]?\
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M=^#/B!>2>-M-U2V\(R:IJ'B&&RG\17NM6NGV5I;N\?RZ>GX?=Z.^BM+O^/\
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MO^+K^TM%+WVHQZ'IMQ?QZ5IL*K))<ZKJTT,6F:7:0QRSWFHW=M:P12S3)&W
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MJ#YMEMWTUT^^]]]#VA?VSO!=MI?B&WU+X>?%JW^).@_%/1/@S8?!S^P/"/\
MPLCQQXX\2>!+3XG>'AX2LK;Q]J'A&UTC6/AU/=^.);SQ=XW\.'PCX?TC6W\>
M#PS=Z3=VPD\&_MF^"_'_ ([\+_#+PG\-/C#JGCO6+#6-2\8>'VT7P78O\(+/
MPU\1M4^%OBJ7XG:EJ/CVTT6S?0?%6BZJ(X/"&I>,;CQ9I5C+JOP_B\7VC1-)
MYC\6OV M"^*I\2ZSK&O?#OQ+XMUK]H_6/V@K:+XP?!'2OC!\+YUU'X/Z/\#=
M/\$^+OACK'C#1E\46OAWP-X?T2?0]?L?%'AG4+#Q/I-EK%M;PV;:CH^H>I_L
MS?LD>&_V:]9\6ZWHNI>&KR;Q5X*^'7@L6'A+X5^!?A'H&D6?@;6OB7XKO)-,
M\+?#JSTCPK9PZYXJ^*OB6_$5CH=E>Q6,&E0:]JGBK6K>\\1WY[ENM^VN^GX;
ML/>NNW?3S_'I^)XI\9/VW/B)X$^,'Q!^&?AGX-ZK=Z3X1^(/[*OPRT/QA>P:
M#XAM_&/C#XP>+H]>^)VA:-H'AWXCV_BPZEI'P*E;7_ B:EX?TFS7Q3IVM7OC
M.]TWPY#X=B\5]YK?[>_@?0O 5S\0KGX-?'V;2/#1^)@^*4$7A[X=VP^#Y^$7
MB?5?"?CNW\8^(M4^)^G>!/$.L:9J.B:G=6WA;X2^+OB7XMU72+==5TS0;JTN
M;1Y]VP_9-U2/X_7_ ,8=7^)5CK'AN3X^S?M#Z9X(/@2:UUBV\7M^S-'^S)8Z
M=J?C,^-;JQU71- \-(^N>'K>#P5I4]CJ5S<BYGO[IXM3A^2?'/\ P2D;QII7
MC+2+CXQ>!;[_ (61HWB2S\8^(_&_[.FD^/\ QOI&J>,?BM\3/BMXTNOA'XDU
M?XE6R?"W2O'NI?$W4M,\<:?:Z9K^MZK;V%G?:/XI\.W\-G+8'N:7TVN]==K_
M -=_(/?UMKO;;3M_EZ'U]XL_;:^&?A7QUKG@H>#_ (I>(;/PCKGP7T3QWX\T
M#P]H)\">!F^/EUHUA\.[W7M0UKQ5HNM7,=W>^(_#\.J:5X<T#7O$^E0:Q::I
M<:"=&2[U*VZ;]I_X_:E\ M(\":MI'A]/%4FM>(/%]YXCT:/[$NJGX?\ PX^$
M?Q%^*_C*[T*?5_$?A70;/6Y(/!.GZ%I5[XAUJWT2WU'7[0Z@#$V^/G-3_9+@
MU>7QM)>^.%D7XA?M8_"W]IOQ3&/"P"WNG_!NT^%EOX#^&:9\0D1V&ES?!SP1
M=/KK+)!*]M?A?#41OW>/4_:9_9BE_:-L=4T^7Q]+X/M;SX%_'?X/V*0>'/[:
M-CJOQPT_PEH5UXTF?^W]':Z70/#>@:YH::# =/GU&W\6ZA-'XBTF6UA\U>[=
M=NN[[?YO;L-\UGWTMMW=_P $OO/*OAA^W;!KGA7P'-\2/@]\3O#GB4Z?\)-*
M^.^MZ'I?@W4?AK\#/B3\7[;PW)X5\(^)M7A^)&IZW?KJZ>,/"6N12>$-,\97
M/A/PCXP\+:U\48? 4][?Z?I>WKO[?/P]TGQB?!NF_";X]>+[B?XS^,OV>=%U
MKPGX3\(7VA>)/C+X+\-:KXJO/!>B37_C_3-2D^V:9X?\2#_A*;_2]/\ !/AF
M7P]JLGQ \3>#K&.VO+KAK?\ X)V^%+CXYR_&7Q*WP#\2RZWXT\'_ !.\62:K
M^R;\-]?^)<GCCPOX3\+>'KC2O OQ:\>:SXXU/P#\*]3U+PG9^([+PC!H&M^.
M/"EY?:G!X6^*VEB2TN+/UKP#^R6?!.J?!S5Y?'T>MW?PI\6?M.?$N[:;PD;4
M>+/BC^TEXHU[7[KQ?.1XGNI-+B\)V/C3QUH,6E[]2FUBQ\00&/5M$BTPVM\W
MR?\  N_Z\O02Y_ZM_7GZZ'OGP=^*GA_XV?#?PU\3?#%CK>E:3XDCU-1I'B2W
ML+77]&U+0]9U'P[KNBZQ%I6I:SI)U#1]=TC4M,N9M(UC5M(N9+5KG2]4U"PE
MM[N;XB_9L_;0\5?M+?%*X@\*ZW\*]*^&VO0_%"Z\!^$-=\"?&/1_B/J_A#P!
MKW_"(Z9\4_#_ ,3-26V^$'Q6LM6\0MIUQXL^&W@:&TU3X:Z#XGT%O$/CNX\1
M+=>'6^S?@'\*(/@9\%OA?\(8=:D\2R?#WP5H7AK4/%$U@NE3^*];L;*,:_XK
MN-+6\U!=-N?$^N-J&O7%@NH7RV<^H26XO+H1B>3Y.\)?LF_$OX/:)X6M_"GQ
M&LO'LGP;^&VN_!']E[0CX)TOP59_"GPUXXN_#NF7'CKXH:R_B[59OBKXC\#^
M'?#>B6L-WH.F>"O[7TC3=5M1X5N_$GB6Y\06R7+[WX-]M?\ @;[+ST&^;3TU
MMWT_X/S^]:?@W]N[2?$_@?1=>TCX.?&#XHZSHGP\\$>+?CA+\&O#WAG5_#7P
MDUKQ/X.TSQC>>';N;QCXZ\)ZQXKUFTTC4;?78O"7PXL/'_C.+P[J6@WUYHJ2
M:YI4=[ZSXI_:L\):?JOA;PY\-_ ?Q/\ C[XJ\5^ -$^*T'AOX1Z3X46ZT3X:
M>)GN(O#'C+Q3K'Q0\9?#/PIX?L_$\]CJD'AK1K_Q#'XKU^71=<&D>'[Q=&U)
MK7YW^&GPW^,W[&#_ !3^'/P8^ VK?'+X?>-M8\->+_A9XBT_XA_#GPN?".N:
M=\(OAW\*]0\-?&0>.O$OAO73HD=]\-K/Q+;>+OA]HWQ!UBYTOQ!<:5-X7BOM
M$@EU3L(O#?[1/P8^+NK_ !F'PQ@_:$NOC#\%_@SX.^+&C_"37?!W@?5?"WQ8
M^$?_  FYN-?\(Z7\9?''A71[WX6^+D\?7BQV%WX[G\6>%;C0HITT_P 2?V]=
MMIS:C?2UNGO6OMOVMKU6UO,2<K:WOU]W;T[W^>]_(]:UO]K;X5Z+^S%\4?VK
M?LWB_4/ ?P<\%?%#QAX_\*V^A1:=\2]#O/@Y9:W<?$#P+>^%?$>HZ%!I_CO1
M;SP]J>CG2=7U;3M.GOTM[B+6#HUY:ZK+XGXM_P""B?A+X5:'XTUCX]_L\?M(
M? *Z\,?!CXL_'+PWHGC^S^!/B*Z^*OA?X)^$9_'/Q!T#X=:_\'?CS\4O K^/
M=-\,P/JUGX/\;>+O!.IZII\=[J=B)M)T?7=0TOA_B)^S7\:O$?[ '[>O@(^&
M])N_CY^UGX0_:C\4Z3\--"\1Z4^D:'XM^+'P[O?!W@'X=0>,==E\/>'[F_MM
M*TOPO9>)/$U[+H_AR;Q5=:[J$-U'HODWTGA'[:WPB_:D_;I^%NJ^'-'_ &6_
M'GP5B^%WP$_:SG\):5\7OB'^SU-XU^*_QI^+O[*/Q:_9O^'W@7PM!\(OC1\5
M/!FA>%V@^+?B+6/$7BKX@>.O"L%MJ-CX:M8M*GM)=2U?1W%1;UM;FLWS6LK+
M;OJVKV\]+ W*VF]MK;N[^[2SM<_2[X2?'#XB?$O7CI?B?]D;]H?X&Z*VB3:Q
M;>-?BIXD_91U7PW>3I-8I;:'!9_!3]IWXP^,H]6OX+R:]M9;OPE:Z)';:=>I
M?:S9WKZ?:7WAG[3?C?\ X*#)\7_AQ\+?V2_#O[&^@>'/$MGJOBOQ%\3OVBO$
MOQL\9:VGA'PI?^#M'\:6&B_!SX:>%_ =A;^(]/N_'6CZAX7N;[XX7FF>)[>Q
MU+3M6M_!DLEKJ=9/[)'A.\\'>-Y(V_9@_P""@WPI-[X.GTR^\7_M1?MJ:9^T
M;\-(VM[C2KK^S]*\$7/_  4%_:?N]&\17]Q:*-,\0Z/\-=/EM-/BU'3+CQ#I
MEAJ4]EJ'K7Q \8?%+2_VG_AA_87[,'QJ\=> =+\'>+O!^M_%WPQXE_9JLO ^
MBW7Q+\3?">\35;O1?&W[0?@_XK76D>#;+P7K%UXN.D?#34]5DC:SC\'Z5XNN
M9W@A32N[);=7Y?XWK\_D.^F[W[?_ &OZ?,\2\::3_P %9/#OA?6==T;X]_\
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MU3_]%K1_P@W_  7D_P"CD?\ @E5_XB7^U3_]%K7Z_P!% 'Y ?\(-_P %Y/\
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MGP;_ .C,?^"KW_BLK]K+_P"=_7[ 44 ?C_\ \/G/@W_T9C_P5>_\5E?M9?\
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MH]-DL/[7T?6=)^T_VEH^IVMIZU2VW'>^VH4444 %%%% !1110 4444 %%%%
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M,PL=5>2%_(OBTJOHM-K=.WZ_UJ/EU>N]]WW[Z=.FOI8\I\/_  \\-_"3X]>
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MWK>-=,;PQX)7^Q8-62VOC>^)-(VV@N_K*OS3_:R^!GQ=^)'Q+O/$FC>"-?\
MB'_8OA7P-J'[-FNZ)XY\(^'=!^ WQK\,>)=:UK6_%_Q \(^,-;TNT\4Z!XHV
M^#;;4=4TG1/B!KZ^&M(USPSIOAO2)-1_M6_44F]=ON_K_*^[LFY-I:;^6O\
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M^&6I->WFW3](U*UTW6M2FM]/TZZN(H_BW?>']1^*'[.^G:'<V5Y\2K?QO?\
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MTU/IL_%_X9)\/8?BM<>-="L/AW<1)+#XKU2Z.DZ8YEU$Z/!; ZFEI<"_N=7
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M[P)XPTG0_%G@2WDTJWTO^P;B:^NYM8D?6IK>XMCI_E1W-"^#'Q:\.?"7X,>
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M>>PU"2PU37].\036LL3^('NM'N=3:>YTFWD;N6\ ^)/$OPWO_!GQ*\96FO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH _'_\ X(Q_\D;_ &SO^TKW_!3;_P!:R^(%
M?>G[5N@Z7KGP1\1S:S!+<:;X8UCP7XVU"**\O;$R:1X0\9Z#KOB*VFN-/N+:
MX^QZAX:L]9TW4(Q*$EL+VYC?AMR_!?\ P1C_ .2-_MG?]I7O^"FW_K67Q K]
M5?'G@[3/B'X'\9^ -;FOK;1O''A3Q#X/U:YTN6"#4[?3?$ND7FC7T^G3W5M>
MVT-_#:WLLEG-<6=W!%<+&\MM/&K1,T[-/LT)JZ:[I_U]]C\RO$%];_$6\N/
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MM&?'/P6_CF32?[8\.^&;#X OH<%KHEB^GZ?8Z7=>)?@3XC\5V4,-O-<9NO\
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M /AQ5_P3L_Z%G]J#_P 6"_M]?_1+4?\ #BK_ ()V?]"S^U!_XL%_;Z_^B6H
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MJ#_Q8+^WU_\ 1+4?\.*O^"=G_0L_M0?^+!?V^O\ Z):@#]@**_'_ /X<5?\
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MB6H _8"BOQ__ .'%7_!.S_H6?VH/_%@O[?7_ -$M1_PXJ_X)V?\ 0L_M0?\
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MM1_PXJ_X)V?]"S^U!_XL%_;Z_P#HEJ /V HK\?\ _AQ5_P $[/\ H6?VH/\
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MXN:[XAT[P+X_\*+\5_'?C[_@K?X7\4^//@SX^^*'B7P1X..N?$__ ((Q?\-
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MVF8K3X?:CXE_M[XFMK-UXMM=7L],ET^SU^R^*,MYX6FT[Q#>Z=X9A\5_9O&
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MUEBUK]:OV;]?U?Q+\+1JFKZC?:OM^)'QRTG0]5U*ZGOKS4O!?A[XW_$3P_X
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MX=T62>WOWB0VIR7V?WJVJM?KMK>_DP]I:UUH];IWLK/RWNDK>:L?O-7Y ?\
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MJ*?5V]-=I/9O^Z_ZN-S:Z)]?BNMXI;+?WD_3Y'] M%?A!^T9\1O'OA#X_O\
M%/X/?#GXPZE\"?\ @G*G@/P5*_P\O/"4GPM?1;C0H-=_:^T_QGIVL_$G1?%O
MB9_ O[/GB3P"? <.A^!O',NF_$KP?JMBMU::HE^EI]"_%_\ 9V^ 'C3]N+]F
M6:;P3HVN:#\8/@_^UE\0/&!M=7UI](\;ZWHNK_LT3>%?$MVEEJZ65Y+86WB_
MQ!)I-S;JL*0ZY>-""EQ1R[7>Z;T2=K*]GKO:S^?S#GWLMFEJVKW=KK35<R:Z
M[7ZV/U:HK\0_B5XAOKS]JSXJ?"[QEXR\2^$_@!\0/VZ?A/X"^*6JZ5XPUSP?
M'_97_#N_P3XM^'WPTN?%VCZGIFI^#_"OQ)^+6GZ!I^L?V5J6DGQ7J<MKX&N;
MN2/QQ=V6I\+^U+X8TSPA\2/%G[,GP2\<^._#WP<\1Z[_ ,$^[GXD:+X2^(?B
M74)/@C\2?'W_  4#^#O@+2AX&UW4-6UB_P#AQKGQ+^&M[XJU/5/"-A=6FE-_
MPAVC^*XM @N/$&JW^N')MKNK[:):?CKMU^:$ZEDW;9\MKZMW:73;3?I\F?OM
M17Y@?!+XI^,?%O[<UC\//B+>_9_BA\*OV3_'?A?XI:18^=8:!KVO6OQ@^&$W
MAGXJ:!HIF>WB\._$OPG?6OB?0S$UZ?#L^HZ]X"N=2GUOPEK\4-+]K:Q^*MY^
MW+^R[JWP@U?5V\8_#;]E#]LKXLZ/\/H=;DTOPQ\6KKPS\7OV'?#FJ_#KQ1;2
MSPZ3-)XJ\#^-/&>@^#];U99+7P3XZU/PWXTD2>'09[*[7+K:Z7N\U^FS?W/3
M7SOT97-=7L][6Z]/R[>1^IE%?SV^&?C-I7QIEL(KSXB>+M"_9;^/_P#P5%^)
M7A3XF>)K7Q5XD^'VI?\ "._\,I:5XK^&7P8\2^)+'4M'\2_#72/&/QCTK0O"
M7BWP_%J&@7][XEMS\)M6>"?QAJ6CZA]U? ?3-!^$W[<GQ.^ ?P1UK6+KX*6'
M[./A+XA_$/P!+XOU[QMX8^#GQEU#XA:IHGA"U\/OK^KZY/X#OOBEX#@\1:SK
MW@2RN[#2ID\#:-XPM="LKWQ%JFJ:ZW"U[O5)NUM+*R:;Z.[V_P T"E?II=+?
MO=_=I_5C]*****@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "N.\=_#OX?_ !2\/3^$?B;X%\'?$7PI=3P75SX8\=^&
M-$\7>'KBYM6+VMQ/HOB"QU#39I[9F9H)I+9I(68F-E))KL:* .0T#X?> ?"E
MW;W_ (6\$>$/#5]:>&-(\$6M[H'AK1=&N[;P7X>N]1O] \(V]SIUE;30^&-#
MOM8U:\TC0(W72M-N]4U&XLK2":]N7ET[;POX:L_$>L>,;3P[H5KXN\0Z/H'A
MW7_%-MI-A!XCUSP_X4N_$6H>%M"UC7(K==3U/1_#5_XO\67N@:9>W4]EHUWX
MH\17.G06TVMZD]SN44 ><_#GX/?"3X/V6I:;\)/A;\.?A;IVLW5O?:Q8?#GP
M1X9\$66JWMI:1V%K>:E:^&=,TR"^NK:QABLK>XNHY98;2*.WC=845!B1?L\?
M "#1_$'AZ#X&_!Z'0/%EEI&G>*M#B^&?@J/1_$VGZ!XN\2_$#0K#Q!IB:(++
M6;+1/'GC/QAXVTBUU&"Y@TWQ=XK\2^)+..'6==U2]NO8:*=WW?WO_,++LON7
M^1XK\0/V;/V=/BS9:QIOQ4^ 7P5^)>G>(?&.G?$37[#X@?"SP-XRLM<^(&D>
M$+3X?:3XYUBU\1Z%J4&I>,=+\!6%AX(T[Q->QSZU9>$+*T\-6U[%HUM#9)K?
M"GX%?!'X#Z5J>A? [X.?"OX-:)K>H)JVLZ-\*?A[X1^'>E:OJJ6T=FFIZGI_
MA#2-'M+_ %!+2&*U2]NH9;E;:*. 2")%4>J447=K7=NUW;[KV_ 5EO97[V5_
MOM<X5OA=\,W\ CX4O\.O K_"X:6FACX;-X1\/MX!&BQR++'HX\'G3SX>&EQR
MJLB:>-.^R)(JNL(8 AE_\*OA?JOA#4OA]J?PW\ ZCX!UK6=3\1:QX'O_  ?X
M>O/"&K>(-:\77'C_ %C7=2\-7&G2:+?ZSJWCR\N_&VIZG=64M[?^+KJX\274
M\NLSRWK=[12N^[[[O?OZCLNR[;+;MMMY;>1X/KO[+'[,7BGX@3?%GQ-^SC\!
M_$7Q4N+[3=4N/B7KOP@^'VK_ ! GU/1;*RT[1]1F\9:AX>N/$<M]I.GZ;IUA
MIMV^I-<6-E865K:R106L$<?KUWX;\.W^N:-XGO\ 0=%O?$GARUUBQ\/>(;O2
M[&YUS0K'Q#_9_P#;]GHVK30/?Z7:ZY_9.E?VQ;V-Q!#J7]F:?]M2?[%;>7M4
M4[ON_O?^8K);)+T2_P CR[QO\#_@K\3-.\7Z/\1_A!\+OB!I/Q!B\+P>/=+\
M;_#_ ,)^*].\;P^"+]M5\%P^+[+7M)O[;Q+%X0U-WU'PO'K,5ZF@7[M>:2+2
MX8R'C+#]DC]E/2OASX@^#VE_LR?L]Z;\)/%E_IVJ^*OA;8?!CX<6?PY\2ZIH
M]]9ZGI.I>(/!%OX;C\,ZS?Z7J6G:?J&G7FHZ9<W%E?6-G=VTD4]M!(GT)11=
M]WWW>_??<++LON7^1XKX3_9L_9T\!>!/%?PM\#? +X*^"_AEX[L]1T[QQ\.?
M"?PK\"^'? GC+3]8T^72=6L?%?A#1]"L_#_B*SU32IY],U&UU?3[R"^T^:6R
MN4EMI'B/H.M^!O!7B6_\*:KXC\'^%O$&J> ]5GUWP-J6M^'])U6_\&:W=:-J
M/ARYUGPI>7]I/<>'=5N/#VKZMH4^H:1)9W<NC:IJ.ER3-8WMS!+U-%%WW?WO
M_,=EV7W(^7_!'[$/[%WPR\4:+XW^&_[(7[+_ ,/O&GAJX:[\.^+_  1\ ?A1
MX4\4:!=O;S6C7.BZ_H/A.PU;2KAK6XGMFFL;N"1K>::$L8Y'5O2_#/P(^!_@
MKQEK'Q&\&_!KX4^$OB%XA^U?V_X[\,_#SPCH/C+7/MTHGO?[8\3Z5H]IK>I_
M;)@)KK[;?3_:)0))=[@&O5:*+M[MOIJV].VK>GD*R[+[E_D>5>&?@1\#_!7C
M+6/B-X-^#7PI\)?$+Q#]J_M_QWX9^'GA'0?&6N?;I1/>_P!L>)]*T>TUO4_M
MDP$UU]MOI_M$H$DN]P#6E\1?A%\)_B_IUCI'Q:^&'P\^*.DZ7=F_TS2_B+X*
M\-^-M.TZ^*JAO;&R\2Z9J=M:79154W-O%',555+X  ]#HHN^[^]_YCLNR^Y?
MY','P1X,:#PC;-X1\,-;?#^]BU+P';G0-*,'@G4;?0=5\*P7_A&(VGE^&[V'
MPQKNM^'(KK1ELIX]!UC5='21=/U"[MYNGZ]:**0'EW@CX'_!7X9:WKGB;X;_
M  @^%WP^\1^)]W_"2^(/!'P_\)^$];\0[YQ=/_;FJZ#I-A?ZMON0+EOM]Q<;
MIP)CF0!J++X'?!73?B#=?%K3O@_\+K#XJWWGB]^)EE\/_"=K\0;P7,1@N1=>
M,X-(C\1W'VB!FAG\[4G\V(F.3<A*UZC13N^[^]_YA9=E]R_R//-0^$7PGU;P
M7JGPWU7X8?#S4_AWKFMZIXEUKP%J'@KPW>^"]8\1ZYXRN?B+K?B#5/"USIDF
MAZAK>L?$&]O/'>J:K=V,U_J'C*[N?$]W/-K<\M\_2WGA7PQJ'B+0_%]_X<T&
M^\6^&=.UW2/#?BB\T?3[GQ%X?TGQ3)HTWB;2]#UN:W?4])T[Q'+X=\/RZ[96
M%S;VVKR:%HSZA%<-IED8-ZBE=]W][Z[_ ']0.!N?A3\+KSP7XD^&UW\-O -U
M\._&=QXMNO&'@&Y\'>'9_!?BNZ\?ZSJ?B/QW<^)/"TNG-H>NW'C7Q#K>LZ]X
MMFU2PNI/$FLZOJ>J:RU[?7]W/+>T?X>^ ?#VA:UX7T#P/X/T/PSXEOO$.I^(
MO#NC^&=%TS0M?U+Q;/<77BK4=:TBRLH-/U6^\37-W=7'B&[OK>>XUJ>YN)M2
MDN9)I&;L**+ON_O?^8'&7/PX^'E[X%A^%]YX#\&7?PSM]"T_PM;_  [N?"^A
MS^!8/#.D6]M9Z5X<A\(RV+Z!%H6F6EG:6NGZ0FGKI]E;VMM!;6\44$2JG@+X
M;_#OX5^'X_"?PP\!>"_AQX6AN9[R+PUX"\+:'X/\/Q7=SL^TW4>C>'K'3M.2
MYN/+C\^=;82R^6GF,VU<=I11=]WW^8'#Q?#'X:V_@&#X4P?#WP/#\+K718/#
M5M\-HO">@1^ ;?PY;(D=MH$'@Y-/7P[%HMO''&D&E1Z<MC$B(L<"JJ@8FC?
MSX)^'?A]KWPE\/\ P=^%FA?"KQ38ZQI?B?X9Z-\/O"6F?#[Q'IGB&R?3-?T[
M7O!EEI$'AS5['7--=]/UBTU#3;BWU.R=[2]CG@8QGU.BG=]WO?=[]]]_/?S"
MR[+MLMON.7UGP1X+\1ZCX2UCQ#X0\+Z]JW@'5IM?\"ZIK.@:3JFH^"M=N-'U
M#P[<:UX2O;ZTGN?#FK3^']7U70IM1T>6SO)='U/4-,>9K*]N8)<'4/A5X*U;
MQW<?$'5])MM8UFYT;P5I+6NKV6F:GI,,_P .?$7B?Q3X&\06=M?6%Q/8^)?"
M^L>,O$EQI&KV5W!+:'4Y)$07$-M/#Z-12N^X67ZG :Y\*/A;XGC\:P^)?AKX
M \0Q?$FQT?3/B+%KG@WP[JT?C[3?#R31Z!IWC5+_ $ZX7Q38Z''<W$>CVFN"
M_M],2>9+*.!97#9-]\$?A7<^$8_ VG^!/"/AOPS;^&KCP39Z9X:\*^&-)MM-
M\#ZAJ6GZGK7@S2+:/1WM-'\-Z]-IEJNIZ?I=O:#?%#J%A)8ZS9:=J=GZK13N
M^[^\5EV7W'#?$#X8?#3XLZ)#X:^*GP\\#?$OPY;ZA;ZM!H'Q \):!XRT2#5;
M-94M-3ATKQ'I^I6,>H6J3S);WJ0+<P+-*L4BB1P:VA_"/X4>&=?F\5^&_AC\
M/?#WBBX,;7'B30_!?AO2=?G:+1;#PW$TVL6&FV^HRF+P[I>F:#&7N6*:+IUA
MI:XL;2W@C]"HI7?=CLNR^Y'D-U^S[\!+V;Q_<7GP1^$-W<?%=43XI3W7PU\&
M7$WQ*2.X2[C3Q_++HKOXQ5+N..Z1?$3:B%N(TF4"1584O$7[.OP3\1^'-*\+
MS?#'P%IFE^'_  WJ'@KPW_8_@?P=:7'A;P/KLU@WBCP9X4DET&Y7POX<\56>
MGP:9KMCH$>G--:!)[.:RU2ST[4;+VNBG=]W][_S%9=E]R_R.!\=_"GX7?%)-
M$C^)OPV\ _$6/PUJ:ZUX<C\=^#O#OBY/#^LH%5=6T1/$&G:@NE:FJH@6_L!!
M= (H$H"C$4_PB^%%SX_@^*]S\,/AY<?%*VTXZ/;?$J?P5X;E\?V^D&WDM#I<
M'C&336\11:<;666V-C'J*VQMY)(3%Y;LI]#HI7?=_>QV79?<O\CQOPU^SK^S
M[X+DM)O!WP*^#?A.:PU.+6K&7PU\,?!.A266L07O]IPZM:/I>AVK6VIPZD3J
M$5_"4NH[T_:TE$_[RJ_C3X ?#GQ5%<7VCZ/IOPW\>?:]>U#2/BW\/_"?P^LO
MBEX6U#QA/I__  GFI>%_%'B+P=XF72-5\?:;IZ:'XNUB*P?5M4TR9G2^MM5M
M=,U.P]LHIW>]W]XK+LON/*O#7P6^'?@[1_A+X;\+Z#;Z+X9^"&G'3OAQH%I'
M;M9:$J>%[GP9;72W-S!/JTM[;>&M1UC33.=24:@=:U"]UB/4M0%G=V>IXU^$
MOPJ^)-SI%[\1?AG\/O'UYX?E:?0;OQKX,\.>*KG1)G=)&FTB?7=-OY=-E:2*
M.1I+)X79XT8DLBD>@T47?=_>%EV7W=M$>,>)_P!G#]GGQLVM/XS^ WP8\7/X
MD\2Z-XS\1/XG^%W@?7VU_P 8>'=*_L+P_P"*]:;5=#NSJOB70M$_XD^C:[?&
M?5-,TK_B7V5U!:?N:=/^SE^SW<Z9J&BW/P(^#5QH^K^"M)^&NJZ3/\+_  1+
MIFI_#G0+^35-"\ :A82:&UK>^"M%U.674=)\*W,4NA:=?R27=G80W#M(?9:*
M+ON_O?\ F%EV7W+_ "\W][[LY_PWX3\*^#?#FE^#O"'AKP_X5\(Z)8)I6B^%
MO#>C:=H?AS2-,C5ECT[2]#TNVM=,T^PC5F5+.TM8;=59@L8!->=^$OV=/V?/
M ,RW'@3X$_!OP5<)J5AK*S^$OAAX)\.3+J^ESZC=:9JJRZ/H=FXU+3KK6-7N
M;"^#"ZLY]4U&:WECDOKEI?9**5WW?WL=EV7W+_(\D\4? 'X$>.+*QTSQK\%/
MA)XOTW3-6\7:_ING^*/AOX.\066GZ[X_OKW4_'FM6-IJVC7<%IJWC;4M3U'4
M/%VHV\<=YXDOM0O;O69KVXNYY),#QU^RM^S!\4/$=SXQ^)G[.'P%^(GBZ\MK
M*SO/%/CKX/\ P]\6^([JSTV!;73K6YUS7_#NH:G/;6%JBVUE!+=/%:P*L,"1
MQ@*/>J*=WW?WO_,5EV7W+_(\]T[X1_"C1].BT?2/AC\/=+TFW\1>'O&$&EZ=
MX+\-V.G0^+?".FZ'HWA3Q1%96VFQ6T?B+PQH_ACPUI/A[6TB74]%TWP]H=CI
MMU;6NDV$5OZ%112&><6OP=^$=CK7BGQ)9?"SX<6?B+QQ97NF^-=?M? _AFWU
MKQAIVI KJ-AXIU6+2TOO$%E?J2+VUU:>[@N@2)XY 36%'^SI^SY%X(L/AG%\
M"?@W'\-]*UV+Q1I?P^C^&'@E/!&F^)H&=X/$5AX470QH-GKL+R.\6KV]A'J$
M;.[)< L2?9**=WW?WOI\Q679?<O\CQ;7OV>/@OK<?AJ:'X:^!- \0> _"Q\&
M?#/QIX?\#^"[+QE\*/#JV;V%KIOPPUVX\/7L_@:UTZT=HM,M=!2TM-/&TVMO
M&R(5]1\.^']%\)Z!HOA?PWIMMH_A[PYI6GZ'H>DV2&.TTW2=+M8K+3[&V0EF
M6&UM8(H8]S,Q5 79F)8[%%*[[CL@HHHH *\LB^!GP2@UKQUXCA^#OPLA\0_%
M#2[_ $/XEZ]%\/O"4>M?$31=4B,&IZ/XZU1-(%]XMTO48"8;_3]?GU"TO(B8
M[B&1"17J=% '.:EX.\(ZS8:'I>K^%?#FJZ9X9U30]<\-Z=J6AZ9?6'A_6O#$
M\5SX:U?0[2ZM9;?2=4\/7$$-QH>H6$=O=Z3/#%+836\D:,*,_P .OA]<^$;+
MP!<^!?!MQX#TTZ*=.\$S^&-$E\(V!\-ZG8ZWX=-EX;DL6T:U.@:SIFFZOHOD
M64?]EZGI]C?V/D7=I!+'V-%%P.'\;?#'X:_$NWM[3XC_  ]\#_$"UL[/Q#IU
MI;>-O">@>*[>UT_Q=H5[X7\5V-O#KNGW\<%GXG\,ZEJ/AWQ#:Q*L&M:%?WND
M:DESI]U/;R,OOA;\,M3OO$&IZE\.O FH:EXLU?P1K_BK4+[PCX?N[[Q+KOPS
MU'3]7^'&M^(+N?3Y+C6=7^'^K:3I6J>"-2U&2YO/"FHZ9I][H,UA<V=M+'W=
M%%WW8K+LON7^1\UW/[&7['UYXON?B%=_LH_LUW7CZ\\33^-+OQQ<_ OX7S^+
M[KQC=:J^NW/BRY\2R^%FUJ?Q-<:W(^LSZ]+>MJDNJN^H2737;&8^KW_PJ^%^
MJ^$-2^'VI_#?P#J/@'6M9U/Q%K'@>_\ !_AZ\\(:MX@UKQ=<>/\ 6-=U+PU<
M:=)HM_K.K>/+R[\;:GJ=U92WM_XNNKCQ)=3RZS/+>MWM%.[[O[W_ )A9+9)7
M[)+]#\-/^"/7P7^#OB#1/VN_C+KWPF^&FM_%_1/^"I?_  4AT31OBKJ_@3PM
MJ7Q)TC1M"_:C\?Z7HFD:9XYO-*F\3V&F:/IBC3M*L+75(K73[ "SM(H;<".O
MV0NOA;\,KZ\FU"]^'7@2\U"X\=Z7\4KB^NO"/A^XO)_B;H>A:9X7T3XBS7,V
MGO-+X[T?PUHNC^'=+\7.[>(-/T+2=,TBTU"'3["UMXORZ_X(Q_\ )&_VSO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU?5)HXXXYM2U*:ZOIDCC62=E10*7QR\)7EW\0O WC;5O@I<_M!>"]%\+>*]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_E3>6.]EVZ:+T["7*F[;]=7UU>C;7GHCTAP65E#,A92 ZA2R$@@,H=70LIY
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M>OEI_P #7\0M'5:=GKLOOT7W'G^J_![5-=^$/B'X2:Y\9/BCJA\2Z=?:+?\
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M[N\U76=9U2[O-5UC5;R\U/4[R[O[NXN).HHHI#"BBB@ HHHH **** "BBB@
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M_BC/X-T[P#KW@[3O@_XN\$^%_B7H7C:U\/WD_AG5M'DL?B3X3\1>&-:T_2=
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MGZ5X?OK=K/Q3IVIP:HL>GWD*<=]5I?OLK7>J\P4TW:SZ:Z-:WML_)^A\I?\
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M_P $P?\ Q,3]I/\ ^A)H_P"%C?\ !=W_ *-4_P""8/\ XF)^TG_]"37[ 44
M?C__ ,+&_P""[O\ T:I_P3!_\3$_:3_^A)H_X6-_P7=_Z-4_X)@_^)B?M)__
M $)-?L!10!^/_P#PL;_@N[_T:I_P3!_\3$_:3_\ H2:/^%C?\%W?^C5/^"8/
M_B8G[2?_ -"37[ 44 ?C_P#\+&_X+N_]&J?\$P?_ !,3]I/_ .A)H_X6-_P7
M=_Z-4_X)@_\ B8G[2?\ ]"37[ 44 ?C_ /\ "QO^"[O_ $:I_P $P?\ Q,3]
MI/\ ^A)H_P"%C?\ !=W_ *-4_P""8/\ XF)^TG_]"37[ 44 ?C__ ,+&_P""
M[O\ T:I_P3!_\3$_:3_^A)H_X6-_P7=_Z-4_X)@_^)B?M)__ $)-?L!10!^/
M_P#PL;_@N[_T:I_P3!_\3$_:3_\ H2:/^%C?\%W?^C5/^"8/_B8G[2?_ -"3
M7[ 44 ?C_P#\+&_X+N_]&J?\$P?_ !,3]I/_ .A)H_X6-_P7=_Z-4_X)@_\
MB8G[2?\ ]"37[ 44 ?C_ /\ "QO^"[O_ $:I_P $P?\ Q,3]I/\ ^A)H_P"%
MC?\ !=W_ *-4_P""8/\ XF)^TG_]"37[ 44 ?C__ ,+&_P""[O\ T:I_P3!_
M\3$_:3_^A)H_X6-_P7=_Z-4_X)@_^)B?M)__ $)-?L!10!^/_P#PL;_@N[_T
M:I_P3!_\3$_:3_\ H2:/^%C?\%W?^C5/^"8/_B8G[2?_ -"37[ 44 ?C_P#\
M+&_X+N_]&J?\$P?_ !,3]I/_ .A)H_X6-_P7=_Z-4_X)@_\ B8G[2?\ ]"37
M[ 44 ?C_ /\ "QO^"[O_ $:I_P $P?\ Q,3]I/\ ^A)H_P"%C?\ !=W_ *-4
M_P""8/\ XF)^TG_]"37[ 44 ?C__ ,+&_P""[O\ T:I_P3!_\3$_:3_^A)H_
MX6-_P7=_Z-4_X)@_^)B?M)__ $)-?L!10!^/_P#PL;_@N[_T:I_P3!_\3$_:
M3_\ H2:/^%C?\%W?^C5/^"8/_B8G[2?_ -"37[ 44 ?C_P#\+&_X+N_]&J?\
M$P?_ !,3]I/_ .A)H_X6-_P7=_Z-4_X)@_\ B8G[2?\ ]"37[ 44 ?C_ /\
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M_P $P?\ Q,3]I/\ ^A)H_P"%C?\ !=W_ *-4_P""8/\ XF)^TG_]"37[ 44
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MN)HH2PDDB@>XMTFD12D33PJY4RH& )J*IZAJ.GZ397.I:K?6>F:=9QF:[O\
M4+J"RLK6($ RW-U<O'!!&"0"\LBJ"0"<D5+;75M>VT%Y9W$%W:74,=Q:W5M+
M'/;7-O,@DAG@GB9XIH98V5XY8V9'1@RL5(- $]%0K<VS7$EHMQ UW##%<36J
MRQFXB@N'FC@GDA#&1(9GMYTBD90DCP3*C,8G"S4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^%^@^&-;MK;3+JVO_%6I6?ARQO6U+3_!6@^(?%VN^(?#/P^TV_8*EUIWP_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1I&@>$?%*>.#XC>6Y\6Z9I/B+1/&7BO3[C0#H\MB-9\,Z396^H6MEKEUZO\
M&[Q)\3O!]KH'B'PAJW@RP\,Q^,_A5H&OV6L^&M6USQ%JT7C7XJ^%?!NJP:3J
M-OXFT72O#T=OHVNO-!?7>D>)9IKLNBV=F(H[A_&].\&_%UO O@3]FNX^&UW8
M>%O!&K?#W1KSXSR>)O!L_@[5_A=\+O$NB:MI$6EZ!;>('^(G_"?^*O#?AG2O
M#FJZ;J7@S2_#.@:QJFKZO:>*M;L=*L+;6?0/VE-2^(-UH6F>$_ _P1^(WQ,>
M7Q5\+/%]QKGA/7/@QI&BZ?!X)^*_A7Q=JVD7:_$;XM> ];DUB;1O#=U)8?8-
M%O=(FN+RP@GU>V9KPV3ZJUNO;;I?6U_Q%KROXKV7>_-;6VFU_EV/IVBN9\(:
M]JGB70+/6-9\%^)OA]J-R]RL_A3Q?=>#KW7].$%S+!%)>7/@+Q9XW\+NE[%&
ME[;#3_$E\Z6T\27B6EXL]I#TU26?-/A;QW\:?%/Q"_:+\*06OPOM-*^&E]IO
MAWX=W4J>*Y-0U#Q!KO@3PQXVTNZ\:*ER+8:/;Q>)8[&_BT-8KV22U>6W=5=5
M'#VGQP^+]W^R#X6_:!?3_AA9^-;_ ,%0?$'6M :/Q9=^'+G2]2T^]U#1?#/A
ME(KN+6KKQ9JDMQX=T6RCNIC:WNLW5S!;H!/9A?,)/@3X7^(/QF_:A\<_&;]B
MO6?&@DU/2=2^&'B;Q*_[/VMS_$71?!_@'POX2C\.>#$;XQS:IH5YX@US1-5U
MCP_%\2+/P!I$>G:G:S>(=4T#4I;W3K/D/#_@3X]:Q\!_V0O@)-\%/C+\(=+\
M#R_#@_$[Q)H^M?LL:]<>$)_A.MNG@R&'3K_XN^,-%U7P_#XTTOPYX_N[G3?#
M_B_4(O#GANVTRW\-2^(]3>QTF[+3;=7VVM?^;6_73?[B&WKOL[;[WLNFGW[>
M6I]L_"WX@^-_'_@'Q5'JNE>%_#OQC\$Z[XH\"^*- 6YU/4/"6E^,M*CBU'P]
M=>>%M]8G\.>)O"^L>$O&5H (]071?$5O"6%TC-7BOASXY_':Q^'G@+XP>/=!
M^#=UX&\8R^"([S1?"^M>+=(\:V*>.M4TW1M/7P_#KMKJ6D^+=;MKW5;9H_#"
M7&C7FM11W$.DWLNIFTTZ\I>$O#/QK^#?Q^\<ZLN@?&KX^^"OB#\/[&Z\2^-+
MU_V8?#$4'C[P):7!\)6?AW1]*\6_"J_O+CQ-H%]?^$-;U/7O!UFEKJVB> TD
MUZ;PP-3U7PYP'PN_9H;1/AGX(^)GAKX )\)?VH/A1;;K:W\57'PRNW^)]R-/
ML)?%VDW^K^"/&7CWP_;:9X_B:^T32/%NH7VE>+?">OQIKK6,6B"]T_Q$:>5G
M;\5MO=:];.PKRTWNKWOY-6>BLW;I=)ZZGM7Q5^*?[07AK5?&MYX.\.?#2#P;
MX9\?_"SX?:5<>-[;QK'JWB*Y^(]U\.=*FUZPN-*E@TN?2-%UGQ^]C,MNLLCS
M:!J%JTRW64BS_&/Q;_:+\'?#7XA:O?\ AKX6Q^-?!WQB^&/@73]0N+?QQ;>
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M)+C2&%UXLM_#6C7GAFYTB\>X2"\@N(-:DCU.665+6XBMSY=RDJCZ TL>-/\
MA$XQK3^%SXZ_LNZ\U]+CU9?"?]M;)_L1CBNY6UC^RQ)]F^U*TOVLH)_*96,>
M/E3XA:Q\=/$_P#>PU#X#_$+7_'OB[QIXGN?^$4T?7O@18ZCX*\'Z+\7[K6?
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M1KN"28EH@_OU?(OP#MO&GA;6?#_P\T+X$_$?X._!?0O#WQ<UNZ_X6'JWP)U
M/XQ\8?$GPWXK\)^'_#,'PG^*OC_4K31]%T_7/B5;0PWVFZ;8V^F0:%;7.HZA
MJ,44DGUU2>_3Y?\  ;U^94=NOS_2Z6G;0****0PHHHH **** "BBB@ HHHH
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M9:;Z^7>S7Y]S]DZ*_-B]_;GOOAE_PMZ_^*G_  KSQWX3^#G[%'@7]K2[\:?
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M.ZU/4_#>G^(KFXT32$LM-O-4^I]'^//[0GPW^,'P9^&/[1/ASX/:IH7[0_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>UE_X)W7DMM!)*&>*"2[NI(8RL;W,[*96_+?_@FA^RQ\:/$?Q$_X*KV^D_\
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M^.#\9O\ @L1^U3\1/B=X[^$'C#X%:UXP@^#7[/GA[P7KGPJ\6R3WUSX&\3>
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M\=?%1_A[?^.;_P +:GXX^%VMZ7I=AXO?X9:)>^(_#^O:9XXU@1^'/"-GX/\
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MY_\ _#&7[0'_ $E8_P""@'_A$_\ !,O_ .ES4?\ #&7[0'_25C_@H!_X1/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\?\ _@C'_P D;_;.
M_P"TKW_!3;_UK+X@5^P%?C__ ,$8_P#DC?[9W_:5[_@IM_ZUE\0*_8"@ K\@
M/^"4G_)3O^"Q'_:77XO?^LJ_L=U^O]?D!_P2D_Y*=_P6(_[2Z_%[_P!95_8[
MH _7^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE
MO%/CCP5X'7P^_C7QAX6\'IXL\4Z+X'\+/XI\0:3X?7Q+XU\22R6_AWP?X?;5
MKNT&L^*=?GBEAT7P_IQN=6U26*2.QM)W1E'4U^77_!47_D&_L!_]I1?V+_\
MU*]?II7=OZV?^0F[*_\ 6Z_S/U%HHHI#"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /Q__ .",?_)&_P!L[_M*]_P4V_\ 6LOB!7[
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M;PEXU\;>+O&'Q%OM"^,>IW'A-D\&ZAXAUR'PO>^'=:U7PU;:5I>JW=@O-_L
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M(:BNI/$OQ=TC4['XK113LITVZCB\9HEWX<DF\*72S>&)Y](DX;PI_P &]?\
MP1D\%RZW/H7[ OPD^T:_X=U'PS=76MZQ\2/%5WIUCJC6[S:EX6NO%/CC6;CP
M5XMM'M89-%\=^#Y-"\;>'9/-DT#Q!ICSSM*^>+Z?;<MNEXM+1I;)JS36NFXN
M5_\ DMM^MI:[7ZK9HQ/%'C'X5_LU:Y^Q/\0O@Q^TIXGU&]^)OQL^'?PB^,WP
M^\??M:_$/XV^#_&/@+XB_#[Q;>>(-?G\.?%WXH>/+?P3XE^'VMZ-IOC>R\6^
M$?\ A&KG[#I6K^'=??5-'U1+.V^A/'_[1/A[XF_%CXQ>%_"/[3'PS^$^A_!7
MX86OA_P)XGU'XA>&+/P_XB_:3^-'AG68?#6O:_%)K$-KXK\+_";1=1\(2:3X
M7E>_TG7_ !CX^NY=0TN;7O!OA6>V\S^'G_! _P#X([_"^YU6Z\,?L!_ Z_\
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M4%GVK_PO;X(?]%D^%7_AP_"/_P N*/\ A>WP0_Z+)\*O_#A^$?\ Y<5\5?\
M#FO_ ()-_P#2-_\ 8K_\1R^%O_S-4?\ #FO_ ()-_P#2-_\ 8K_\1R^%O_S-
M4 ?:O_"]O@A_T63X5?\ AP_"/_RXH_X7M\$/^BR?"K_PX?A'_P"7%?%7_#FO
M_@DW_P!(W_V*_P#Q'+X6_P#S-4?\.:_^"3?_ $C?_8K_ /$<OA;_ /,U0!]J
M_P#"]O@A_P!%D^%7_AP_"/\ \N*/^%[?!#_HLGPJ_P##A^$?_EQ7Q5_PYK_X
M)-_](W_V*_\ Q'+X6_\ S-4?\.:_^"3?_2-_]BO_ ,1R^%O_ ,S5 'VK_P +
MV^"'_19/A5_X</PC_P#+BC_A>WP0_P"BR?"K_P .'X1_^7%?%7_#FO\ X)-_
M](W_ -BO_P 1R^%O_P S5'_#FO\ X)-_](W_ -BO_P 1R^%O_P S5 'VK_PO
M;X(?]%D^%7_AP_"/_P N*/\ A>WP0_Z+)\*O_#A^$?\ Y<5\5?\ #FO_ ()-
M_P#2-_\ 8K_\1R^%O_S-4?\ #FO_ ()-_P#2-_\ 8K_\1R^%O_S-4 ?:O_"]
MO@A_T63X5?\ AP_"/_RXH_X7M\$/^BR?"K_PX?A'_P"7%?%7_#FO_@DW_P!(
MW_V*_P#Q'+X6_P#S-4?\.:_^"3?_ $C?_8K_ /$<OA;_ /,U0!]J_P#"]O@A
M_P!%D^%7_AP_"/\ \N*/^%[?!#_HLGPJ_P##A^$?_EQ7Q5_PYK_X)-_](W_V
M*_\ Q'+X6_\ S-4?\.:_^"3?_2-_]BO_ ,1R^%O_ ,S5 'VK_P +V^"'_19/
MA5_X</PC_P#+BC_A>WP0_P"BR?"K_P .'X1_^7%?%7_#FO\ X)-_](W_ -BO
M_P 1R^%O_P S5'_#FO\ X)-_](W_ -BO_P 1R^%O_P S5 'VK_PO;X(?]%D^
M%7_AP_"/_P N*/\ A>WP0_Z+)\*O_#A^$?\ Y<5\5?\ #FO_ ()-_P#2-_\
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M-4?\.:_^"3?_ $C?_8K_ /$<OA;_ /,U0!]J_P#"]O@A_P!%D^%7_AP_"/\
M\N*/^%[?!#_HLGPJ_P##A^$?_EQ7Q5_PYK_X)-_](W_V*_\ Q'+X6_\ S-4?
M\.:_^"3?_2-_]BO_ ,1R^%O_ ,S5 'VK_P +V^"'_19/A5_X</PC_P#+BC_A
M>WP0_P"BR?"K_P .'X1_^7%?%7_#FO\ X)-_](W_ -BO_P 1R^%O_P S5'_#
MFO\ X)-_](W_ -BO_P 1R^%O_P S5 'VK_PO;X(?]%D^%7_AP_"/_P N*/\
MA>WP0_Z+)\*O_#A^$?\ Y<5\5?\ #FO_ ()-_P#2-_\ 8K_\1R^%O_S-4?\
M#FO_ ()-_P#2-_\ 8K_\1R^%O_S-4 ?:O_"]O@A_T63X5?\ AP_"/_RXH_X7
MM\$/^BR?"K_PX?A'_P"7%?%7_#FO_@DW_P!(W_V*_P#Q'+X6_P#S-4?\.:_^
M"3?_ $C?_8K_ /$<OA;_ /,U0!]J_P#"]O@A_P!%D^%7_AP_"/\ \N*/^%[?
M!#_HLGPJ_P##A^$?_EQ7Q5_PYK_X)-_](W_V*_\ Q'+X6_\ S-4?\.:_^"3?
M_2-_]BO_ ,1R^%O_ ,S5 'VK_P +V^"'_19/A5_X</PC_P#+BC_A>WP0_P"B
MR?"K_P .'X1_^7%?%7_#FO\ X)-_](W_ -BO_P 1R^%O_P S5'_#FO\ X)-_
M](W_ -BO_P 1R^%O_P S5 'VK_PO;X(?]%D^%7_AP_"/_P N*[_0]>T/Q-IE
MMK?AO6=)\0:->^<+/5]#U&SU;3+LVUQ+:7 MK^PFN+2?R+J">VF\J5_*N(98
M7VR1NH_.O_AS7_P2;_Z1O_L5_P#B.7PM_P#F:K[>^#WP8^$G[/GP[\/_  C^
M!?PV\$_"+X7>%#JS>&?A[\.O#>E>$?!^@MKVMZCXDUHZ3X?T2VL],L#JOB#6
M-5UK4#;6\9NM3U&\O9M\]Q*[ 'IE%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %?+/[2/C_ ,?:/K_P&^$/PSUZV\%>
M*/C[\2-;\)7/Q#N=&T_Q#<>!_"G@WX:^-?B;XFU'P[HFL)/H>I>,=5M_"-MX
M=\.IKUEJ>B::VKWOB'4=(UB'1/[(O_J:O)/C%\&O#/QIT+1-+UW4O$OAG6?"
M'BC3_''@/QUX)U2#1O&G@/QEIMEJ6E6_B+PUJ%Y8ZKIAN)M$UK7/#^J:;K>C
MZSH&N>'];U?1=;TC4=-O[BW=JU]?\_33K9V=NHG>SM_E^/2ZZGR1XWU;]I[X
M:^*OAQ\ HOCMI_BJZ^/OQ,;0O OQN\4^!?!7_"T_A]X-\+?"WQ[\1OB3#K7A
M?POX9\)?"3Q-XGNI_!&FZ/\ #35H_!MEIUM;^)-=U'Q7X9UP>#8(O$/S_P#M
M/_&3]I7X"WL_P!L?VA/%&LZOX_\ $W['M_X#^/3>!/@K!\7?!7ACXJ?MM_!C
M]G'XR>&]6T8_#*Z^"6MWL_A?XD0:A\//$5S\(;<Z?<W6O1:II.LW&C:?J)^R
M'_8D^'>H6FMZIXI\??%WQC\6]8\3^$?&$'[0>L^(_#>F_%_PWKO@#3O$.D>"
M6\(3^$/!WACX?>&M'\.Z5XQ\;:<GA72_A]#X3URS\<>,H?%.AZ\OB;6!=\]X
MR_8)\$^/_"GB[3_%OQF^.^M?$WQ=XE^"/B>7]H&^U/X57/Q5\/3_ +/'Q5T/
MXS_"K1_"6CW/PDF^">@>&=$\?Z&FL:EX>MO@^VF>)9-1U.;Q%!J=[-;7EI2<
M;J]O/W=WW]%VZ]M26I>?E[VR[>K[_CIK\(_MB?'C]IW]C_4[GX/O^T[\5_B%
MI?Q*T#X&>._"?QG;X-?!3Q-^T+\,=+B_;G_95_9X^.'AG1/!GPQ^ 0^''Q)O
M/&'P\_:,M;GX7Z8G[/NO^,+7Q-HNNVME9^+[Z\T2ST[]"/V1/$,GB7_A/+K_
M (7W^VC\:(;/_A'+?[-^UW^RK:?LQ_\ "/23_P!MR>?X#A_X8P_9'OO&7]IK
M#Y?B.3=X[M-"^P:(NWP[-JP.M</XK_X)W>$/B!I/BNY^(G[0?[1WCOXL>)+K
MX-S:9\?=?O?@;#\1_ -C\"OC)X5^/7@71/ 'A?0O@5HWP'T/1Y?B9X-T/6_%
MEO<_!C4KCQHEI:VOB:ZU*+2]$_LOZ7^$?PE\??#>\UJZ\9?M/?'+]H"#5+6T
MM['3OBYX?_9JT:S\-RVTLTDU[HK_  '_ &>?@GJ$]U?I*D%VGB*_UZS2*WA-
MA:64[3S3MN+C96OU=K7>FJ]W]8][:@D[ZWMTUO;\?T?KH>Y4445F6%%%% !1
M110 4444 >.?$7XUZ!\-==\,Z#JWACXA:N_B37O F@OK>@>#[^X\(^'Y?B+X
MZTOX<>&KG7?&6IOI7A</)XJUC3[:^T#1]5UCQC8Z?<PZS-X:_LF>WO)MSXG_
M !%7X::#I^KQ^#_%GCW4=8\1:/X7T;PKX*D\(0:]JFJZU)*ELD%QX[\6^"/"
M]M!#'!-/<S:EXDL0L496$3SM'"_S3^VA\?O@1\,O#?A/PA\2/C7\)/A]XMO/
MB]^R[XQM/"_C?XD>#O"?B*Z\(:+^T_\ #"_UCQ5;Z)KVLV&IS^&])L?#VOWN
MIZY%;-IEA::'K%Q=744.F7KP>D?$_P :_LX?$+X3>'?%_B[XAV>I?![7M:T_
M5O#OQ5^''Q"\7:1X9L]0TF6^DL=?A^,?P?US3AX4TN"ZL;W3I/$,_BW1]#FO
MF_L&YOY;N_AL+BK?"[/5OOKMM_P&2WOJKKS6GK_P4>M^ ?%NO^,=+N]0\1?"
M_P =?"F[MK][.'0_'VH?#/4=4O[=;>WF&JVDWPN^(GQ)T1+"22:2T2.^UBRU
M07%I<-)IJ6C6MU<XW@3XM:+\0/$/B?PYIWA[QQH5WX9T?POX@:7QIX6O?"+Z
MOHOBZ_\ %VEZ3J&G:-K;6OBBT0:AX(U^WN(/$>@:#>+Y-O<06UQ:W4<Y\@_9
MKUW0M5U[XE6GPQ\>^*OB?\#-/LO S^"_&7B7QGXA^)MG)XVO)/&*_$+0O"?Q
M-\6:AK7B#QKX:TO2K3X?7PO9O$7B:PT[7]:U[2K'6M]I=Z/H_,^!_P!I3]G/
MQ)^TWXZT[P[\?O@IK^H>)_A=\"O#'AJPT7XJ>!=4O/$/B73_ !O^T+-?^'M#
MM;'7IY]6URQAUK1Y;S2;!+B_MH]6TQYK=%O[4REM]'HK]=/71_CL%_AU6KMT
MUWV=U^!ZWXP_: TWPKX@\0Z-8?#7XK^.M-\$&V7XA^+? _A[0]1\.^!9+G2K
M+7_LU_!JWB?1/%'BK4+7P_J6G:W?:3\-?#7CG5;*QO[-;FRCO+B*U:U\0?C-
MKOA2;PBG@/X#_&'X^6GB[1-0\0PZQ\)+SX+66@Z-IEFVB"R;6-;^,/QB^$NF
M-<^((]<CNM LM$N=:N[VST[5KN6&VM[+S)/!/BM^U7\%M7\9>+/@GJ/[0/PE
M^$&E^&9WT+XK^(O%WQ3\%^#?'$TL]I%/>^!OAYH.M:YI^N6=]=:?=1QZ]\1I
M[.&ST*WNAI_@<:QXJDO=8\"_4%YX\\#>#/@S<_$[2@K?#;PK\,I?'6F+I%C/
M"'\$:)X6;7[%-+TV6&"YCWZ%;1+8V$EO%<*3%;M"D@,8+6M=;^NO;73[ETW!
M.[>JT]--7?2[T\VM[V./\$?'^R\6_#_Q=X\U;X7_ !<\#3^"/%VH>"=<\"ZI
MX>T#Q]X[;7-.ETBVE72-.^!/BOXNZ+K]G]KUJWM+J\T77[Z+0Y[/6O\ A)O[
M$BT+5Y;/OOAA\1--^*G@^#QCI>C^(/#\#Z]XT\,W>B>*;;3K37M+UKP#XT\0
M> O$5EJ$&DZIK6G*T&O^&=32![74[J.:U$$Q:-Y&AC\Y^'D^@?L\_L^Z!K/Q
MK\7^$/  TO3F\7?%OQEXM\1Z1X8\'Z?\1OB3XBF\2^.[ZZ\0ZY=V&DZ=8ZM\
M2O%VJ6^DBZO(T=[^PT^!Y)I(4?RW]B[X\? [XG^%/&'ACX:_&7X4_$/Q)IWQ
MC_:<\5ZAX>\#?$3PAXMURQ\+^(OVG/BKJ?A_Q)>:3H&L:A?VN@:[INL:3J&C
MZQ/;IIVIV6J:==V5S/!>VTDI;1M)V36NMNOE^O5#3V3:NUMHG]U_T[GJGB']
MHSPYX=\3ZSI,_@GXCZAX0\*ZO9>'O&OQ<TS1]!G^&O@S7+V*QF:QUJYN/$UK
MXPN[72DU.P_X2;Q%X<\':]X3\(M-<IXIU_1WTC6UTSX^_P""HO\ R#?V _\
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M_P#8X_:/_:M@UGQS\4_"W[,\?BS1=)^$/@[P!\")/B#XX\:?"+7O!6@?M3?
MS]H?XU6/Q/\ BGKWP$TW5[W_ (6?I/P,\,>"M-T6R^ VI:-HMM;7+ZQ_PD4&
MN3II7UC^RK\'-0^$$_C.U7]D']CO]EC2O$$6BSRO^RKXRG\03^,]0TM]2CMT
M\9Z</V5?V<[:&+1+;4+DZ+>M?>*)P^IZE EIID;R378^6VEK];/KIM=_E?KJ
M.+GS._-R]+JW?>RW]6NA]B4445!H%%%% !1110 4444 %%%% !1110 4444
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MZ"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/_\ /^K]?Z* /R _X<=_L._]![]M7_Q8G^W/_P#/^H_X<=_L._\ 0>_;5_\
M%B?[<_\ \_ZOU_HH _(#_AQW^P[_ -![]M7_ ,6)_MS_ /S_ *C_ (<=_L._
M]![]M7_Q8G^W/_\ /^K]?Z* /R _X<=_L._]![]M7_Q8G^W/_P#/^H_X<=_L
M._\ 0>_;5_\ %B?[<_\ \_ZOU_HH _(#_AQW^P[_ -![]M7_ ,6)_MS_ /S_
M *C_ (<=_L._]![]M7_Q8G^W/_\ /^K]?Z* /R _X<=_L._]![]M7_Q8G^W/
M_P#/^H_X<=_L._\ 0>_;5_\ %B?[<_\ \_ZOU_HH _(#_AQW^P[_ -![]M7_
M ,6)_MS_ /S_ *C_ (<=_L._]![]M7_Q8G^W/_\ /^K]?Z* /R _X<=_L._]
M![]M7_Q8G^W/_P#/^H_X<=_L._\ 0>_;5_\ %B?[<_\ \_ZOU_HH _(#_AQW
M^P[_ -![]M7_ ,6)_MS_ /S_ *C_ (<=_L._]![]M7_Q8G^W/_\ /^K]?Z*
M/R _X<=_L._]![]M7_Q8G^W/_P#/^H_X<=_L._\ 0>_;5_\ %B?[<_\ \_ZO
MU_HH _(#_AQW^P[_ -![]M7_ ,6)_MS_ /S_ *C_ (<=_L._]![]M7_Q8G^W
M/_\ /^K]?Z* /R _X<=_L._]![]M7_Q8G^W/_P#/^H_X<=_L._\ 0>_;5_\
M%B?[<_\ \_ZOU_HH _(#_AQW^P[_ -![]M7_ ,6)_MS_ /S_ *C_ (<=_L._
M]![]M7_Q8G^W/_\ /^K]?Z* /R _X<=_L._]![]M7_Q8G^W/_P#/^H_X<=_L
M._\ 0>_;5_\ %B?[<_\ \_ZOU_HH _(#_AQW^P[_ -![]M7_ ,6)_MS_ /S_
M *C_ (<=_L._]![]M7_Q8G^W/_\ /^K]?Z* /R _X<=_L._]![]M7_Q8G^W/
M_P#/^H_X<=_L._\ 0>_;5_\ %B?[<_\ \_ZOU_HH _(#_AQW^P[_ -![]M7_
M ,6)_MS_ /S_ *C_ (<=_L._]![]M7_Q8G^W/_\ /^K]?Z* /R _X<=_L._]
M![]M7_Q8G^W/_P#/^H_X<=_L._\ 0>_;5_\ %B?[<_\ \_ZOU_HH _(#_AQW
M^P[_ -![]M7_ ,6)_MS_ /S_ *C_ (<=_L._]![]M7_Q8G^W/_\ /^K]?Z*
M/R _X<=_L._]![]M7_Q8G^W/_P#/^H_X<=_L._\ 0>_;5_\ %B?[<_\ \_ZO
MU_HH _(#_AQW^P[_ -![]M7_ ,6)_MS_ /S_ *C_ (<=_L._]![]M7_Q8G^W
M/_\ /^K]?Z* /R _X<=_L._]![]M7_Q8G^W/_P#/^H_X<=_L._\ 0>_;5_\
M%B?[<_\ \_ZOU_HH _(#_AQW^P[_ -![]M7_ ,6)_MS_ /S_ *C_ (<=_L._
M]![]M7_Q8G^W/_\ /^K]?Z* /R _X<=_L._]![]M7_Q8G^W/_P#/^H_X<=_L
M._\ 0>_;5_\ %B?[<_\ \_ZOU_HH _(#_AQW^P[_ -![]M7_ ,6)_MS_ /S_
M *C_ (<=_L._]![]M7_Q8G^W/_\ /^K]?Z* /R _X<=_L._]![]M7_Q8G^W/
M_P#/^H_X<=_L._\ 0>_;5_\ %B?[<_\ \_ZOU_HH _(#_AQW^P[_ -![]M7_
M ,6)_MS_ /S_ *C_ (<=_L._]![]M7_Q8G^W/_\ /^K]?Z* /R _X<=_L._]
M![]M7_Q8G^W/_P#/^H_X<=_L._\ 0>_;5_\ %B?[<_\ \_ZOU_HH _(#_AQW
M^P[_ -![]M7_ ,6)_MS_ /S_ *C_ (<=_L._]![]M7_Q8G^W/_\ /^K]?Z*
M/R _X<=_L._]![]M7_Q8G^W/_P#/^H_X<=_L._\ 0>_;5_\ %B?[<_\ \_ZO
MU_HH _(#_AQW^P[_ -![]M7_ ,6)_MS_ /S_ *C_ (<=_L._]![]M7_Q8G^W
M/_\ /^K]?Z* /R _X<=_L._]![]M7_Q8G^W/_P#/^H_X<=_L._\ 0>_;5_\
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M[_UE7]CN@#]?Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCKPO\0?#UEX@L_!OP4U&[T*[UKPEJNKZ;;:Q:Z?JVE7]QIDURE[!9:GI]U+
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MPE^T)\,/BW\.++_@I!^S]XRU3XG^*_BKJ7PWO;'Q=^WUX1U?XD_&;7M6T%O
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MW:_8"B@#\?\ _APE_P $F/\ HTNU_P##T_M%?_/=H_X<)?\ !)C_ *-+M?\
MP]/[17_SW:_8"B@#\?\ _APE_P $F/\ HTNU_P##T_M%?_/=H_X<)?\ !)C_
M *-+M?\ P]/[17_SW:_8"B@#\?\ _APE_P $F/\ HTNU_P##T_M%?_/=H_X<
M)?\ !)C_ *-+M?\ P]/[17_SW:_8"B@#\?\ _APE_P $F/\ HTNU_P##T_M%
M?_/=H_X<)?\ !)C_ *-+M?\ P]/[17_SW:_8"B@#\?\ _APE_P $F/\ HTNU
M_P##T_M%?_/=H_X<)?\ !)C_ *-+M?\ P]/[17_SW:_8"B@#\?\ _APE_P $
MF/\ HTNU_P##T_M%?_/=H_X<)?\ !)C_ *-+M?\ P]/[17_SW:_8"B@#\?\
M_APE_P $F/\ HTNU_P##T_M%?_/=H_X<)?\ !)C_ *-+M?\ P]/[17_SW:_8
M"B@#\?\ _APE_P $F/\ HTNU_P##T_M%?_/=H_X<)?\ !)C_ *-+M?\ P]/[
M17_SW:_8"B@#\?\ _APE_P $F/\ HTNU_P##T_M%?_/=H_X<)?\ !)C_ *-+
MM?\ P]/[17_SW:_8"B@#\?\ _APE_P $F/\ HTNU_P##T_M%?_/=H_X<)?\
M!)C_ *-+M?\ P]/[17_SW:_8"B@#\?\ _APE_P $F/\ HTNU_P##T_M%?_/=
MH_X<)?\ !)C_ *-+M?\ P]/[17_SW:_8"B@#\?\ _APE_P $F/\ HTNU_P##
MT_M%?_/=H_X<)?\ !)C_ *-+M?\ P]/[17_SW:_8"B@#\?\ _APE_P $F/\
MHTNU_P##T_M%?_/=H_X<)?\ !)C_ *-+M?\ P]/[17_SW:_8"B@#\?\ _APE
M_P $F/\ HTNU_P##T_M%?_/=H_X<)?\ !)C_ *-+M?\ P]/[17_SW:_8"B@#
M\?\ _APE_P $F/\ HTNU_P##T_M%?_/=H_X<)?\ !)C_ *-+M?\ P]/[17_S
MW:_8"B@#\?\ _APE_P $F/\ HTNU_P##T_M%?_/=H_X<)?\ !)C_ *-+M?\
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M?N[=%>UWKM?U/T8_X>L?\$V?^CX/V:?_  ZWA;_Y.H_X>L?\$V?^CX/V:?\
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M_H^#]FG_ ,.MX6_^3J_0"B@#\_\ _AZQ_P $V?\ H^#]FG_PZWA;_P"3J/\
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M$7R:#-X7U30M=U'3O$%YI>B^+'TGPAJ=[:^)M?T/2M0+,+GS'_P]8_X)L_\
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M;^%H_%UT^I06DFEV!TM_&GAM5M]1O+6YO_M['3HKH6EZ;?N: _3?^OF?G_\
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M?"SXRZ9>7_Q3\,?"]KBW\(ZKH^I"^T0RQV.BW4=A])?L[>#)X/VD?VA_%WP
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M/PM^%'BOX9>!?&VO:E:>,OC'J^K:+\-_#&A>#_&OC76_$MUH$-A=>(;I-/\
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M,+R#QC<^'];3^DF218HY)6#E8T>1A'')-(512Q$<,*/+*Y (2.)'D=L*B,Q
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MX\D]YK%I:7'TU\(OC=\+_COH_BK7_A3XG_X2K2?!/Q'\=_"3Q/=_V+XAT/\
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MJ6K^ -8\3:5HVK)<Z#K%[8Z[9WFG0=72 **** "BBB@ HHHH **** "BBB@
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M\7?V6_$-[XF_;G^.'PO_ &<?B/IGC;3?VJ?^"<GB']E?6]&^#WCKPWXE\/\
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M$^DE3;WD^A:%XA\ 6\CZ#HU[9?//BK]CW]KKPOX*_9[A^#?P3^,_ANS\>?\
M!-K]DGQ!^VQ93?"WXH:_>?%+QWX:_:E\ :S\6_"7Q-\-6VL^!O$?Q,^,%A\/
M=3\1CQ%\)&\<^&?BCXH^$>F^(/AQH]]IND3VEI#_ &ET5:K2716UTN[:WZ>K
MOZI/=![-6W?KI?I_E]US^4+X+?L/>)_'O[1W[/UA\5?A#\4/B)^S-<)_P4@U
MC2?"GC7]DGQU^SA\%_AKHOC;PU^SY:>"O _AGX,^*_BW\;-?^'GPL\1>.-"\
M9>-_@UX)^+^I^!/%EOXECU#5- ^&NB1>'O#>IO\ .$W[/'[16M_LFZQ:_M0?
MLP?M2_&;X@>(/^"2_AOX3?LEVMO\(OBIXT\2_!KXXZ!J_P 4]/\ B%X7\2:5
M:Z5/J_PG^(&N:-<_#O4+C7/%MEH5SX_^'.ES_#?3=5\0W-T/!FH?VF44>V=]
METZM6L[Z-;7TOW6CW8>S7?OT773YVZ=OD?QYQ?L+_$/Q-I_CCQ1XF_9G^,$G
MC>Y_;U_X)FZ=I.NM\.OB-IWB6R^!:_ OX(>"/V@[_P -WUKIMKJ.D^ TL?\
MA)/#7QBU_19+;28QH":=XSOE?PK91:;R_C/]DW]I/1OB?\9/".J?!;XD:?\
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M7Q+\26%S^T3<>-;K3-(\0^&+&]^,FB_";PQ>&T^'/P[T;P!JFIZ#8WWZP?\
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M'9W+^']:@TJ0P_GU\!_V6/&DG[4G[%OCSQW^S_KA^''A_P",/[?_ (F^%_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/[8$>G^/?^"9/B/QI^TQ;:_\9?VFM"67]JG0H?V6[;P)H/CUQXRTZ3PAX_\
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MX;3PG_\ *NC_ (8G_9!_Z-E^!W_AM/"?_P JZ6GG^'^96OE^/^1]/T5\P?\
M#$_[(/\ T;+\#O\ PVGA/_Y5T?\ #$_[(/\ T;+\#O\ PVGA/_Y5T:>?X?YA
MKY?C_D?3]%?+LG[%?['L2/)+^S1\"XXXU+O))\-O"2(B*,LSNVF!551R6)
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M'PM\97/PS\=_\(OXWMM6_8S^&&GPZAX>^(EOX?G\$7=[I_Q \-?M(6^OV?\
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MM=^"OP6N?%?C3PQK4MI\'?#EG'XN^+]SXD\+^,O%&J2F'RI/&]E_2@  , 8
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MUZGX^MX/^-^CZ[^RY\$O'VK:IJGC7]K7X&_!/1OVEY!XAAO[_P +>)OV5_\
MA&?%WQ?\1ZC);7GG7/\ PN?P3K]Y\&O$_B728VT^37;3PE,OV>35X)9O<OVQ
M/#UEJ/QG\#:I\8_AS\<_BK^SU#\&?B%INA^'/@?X=^*7C&ZTCX\W7B3PQ-I6
MK:]X<^$+-XCL==U'P?%>Z=\-/B%K4,'A7P!J<'B>>^\2^$+S6[+4+S] HO"7
M@RT\777C:'PSX8MO'FKZ+;^'KWQ=%HNE0^+M3\.Z;<O?6NAW6OI;+K-[HMA>
M7$EW;Z9-=RV-K<SO<1P1RR%VZ571]VQU?8Q1]K!MKK]Y&P3M9<C*G!&>12YM
M4[='Y;]K;65DO(.71J_5>>W>^]W=OS9^5G[&GP*\?^&OV@HOBG\=/ U^WQIN
M?^">O[$?A;X@?%'4K*:^?7/C'IVM_M$:9\7=)F\:6Z'0?$'C*QTO2_ALGC8:
M5=3D0GPUJ310Z?JVES77CG[8'[.D/C?]L/Q=J<?PA^(>K+\4]#_X)F6;?$#P
M/X/^(;V<NB?#/]MGX@7WQ^LK_P")O@VP^P>"=0T3X?7WP>UG6!>>(?#^NOX2
MTL>(M"D>Q\)>(=1T?]LA<0&)9Q/"8'V%)A(GE.)&5(RLF[8WF,RJF&.YF4+D
MD"HDO[&2<VT=[:/<JSHUNES"TZO&2'4Q*YD#(00ZE<J000,&CF=[^5MVOZ]!
M.FG%1O\ :YM;7?KWO;??<_"7XM_!WXT>%].\1>!?"/ACQO9?LS^"?VY/&-[=
M^"KWX8?'CXU:#/\ ";7/V7OA[K/A.XT[X7_"SQGX2^*WQ(^#6F_'O7O&TCZ#
MX#U3Q#X>T?QW)97=]X8O='\(:JFC?7GA#PC^T#:_\$XO$/A72-4^)6J_%V7P
MM\3%\(#4M$U?X7_%-/!=]\0/$M_X6\(Z!I_BOXB>//%OA3Q!I_PKGLO"7PVO
MO&_CYOB#80V_A;4/'%SX>\;1ZS;:;^E!(4%F("@$DD@  #)))X  Y)/ %(CI
M(JNC*Z.JNCHP971@"K*P)#*P(*L"0000<4.3=M%H[^OKZ]1J%FW=ZJUNV^WI
M?3T/P/U/]G;0_B5^UE^R_P"*O 7[/WQ<L_V9O O[0GPXU*TTSXI_#[XK: /"
M?CRV_9C_ &X+GXH>.M.\*_$JSM_%?@SP9>^([7]E;0]>\8:O8:3X2\8?%+2/
M#;:%>:MK%S=ZEK?E&C_LQ>._A?:RV>F_"GQ)X-^#FI_&_P#X*(WTGAK3O@'^
MT3\3?-\9ZI^V+XVC^"GC*Y\"? CQ]\.O'=G)JGP,M=&'P2^*NI+JO@C0?#WV
MO5+36/#\GB/1-=O_ .D5IH4225Y8UCA#F:1I%5(A&-TAD<D+&$7ERQ&T<M@4
MR:ZM;95>XN8($?=L>::.)6VHTC;6=E#;8U:1L$X168_*"17M'MTM;=]V[^NN
M]@Y%WZWT2\M/338_,']F#X'>,I/VH-8^)WQSTSXA^*/&'@+]D']C#PYX0^('
MCO3]5T'3[CXDS:3^T1I/QPU6TT;2O$GB/X>M\1]0MK[PQ%\1HM&U_P 72Z"=
M0TFVMM;;3]1L[O4><_:G\*^/8?VKO"'CGP=X8^)WC[5(IO@=9Z1X0NOAM\9)
M?"<5GI?Q"N[KQ%KOPO\ VC/A5XOM_ ?P8NK2PO9[CXL>%OCMX:.B_$71--LM
M*5]4T2\6V7]96EB7R]TD:^:P2+<ZCS7*LX2/)&]BBLX5<DJK,!@$A?,3?Y6]
M/,V>9Y>X;]F=N_9G=LW?+NQC/&<U/,[WMTM;I:W]/2P^72UWO>_4_F(_:B\/
M?'[QA^S?%^S=H_P'_:I\0^/? GQ'_P""G=]XZO-&^%'Q(?PKJWA[XG>$/VQ;
M_P"!\7A/XA2:2?"GCZ/Q_8^.O!H\&OX4U/Q!9^&M;&E>&_%7_"+^*+KP_HNH
M^_ZU\']>\<)\0]#^"7PQ_:C\#?LN^+?C3_P37TNY\%^--+^/'@?QQ>>.=#_:
M7UBZ_:W\=:+I?C.YMOBGX=\'3_""_P#ACIGQ-^)MI+8>&?%FH^'?%/C#2?$%
M\ECK/C'6/WS:ZMDCEF:X@6&%F2:5IHQ'$Z-L=)9"P6-D;Y65B"K<$ \4LMS;
MPLJ33PQ,_*++*D;./,BARH=@6_>S0Q< _O)8D^](H->T?\JW;W>[W=K?=V%R
M>?9;+I_6O<_!_P -?LR>+?AGXM\.^*/ ?@'XTZ;J/A[_ (* _'_P)H+?;/BO
MJVF^'_V2=?\ V<OC9>Z/X;TK2=2O[[2+#X%W/Q1OM!U'PXT=F/"D/CZZT.31
MKJ/6/[+C3PF]_95\1^(?@/\ M#:/XA_9Z^(FK?&?XP_\$!OV9?A[X3O]3^&7
MCJYU#6/C[\,_ ?[0\'CKX<:[XEGT=M)\._%ZP\1WO[.AC\$^+=2TCQ=KMWI>
MG3:1IFI#PQXE?3/Z5;BZM;-!+=W,%K&6""2XFC@0N0S! \K*I8JK$*#DA6(&
M :@35-,>*6X34;%X("@GF2[MVBA,C;8Q+()"D9=B%0.PW-PN31[1]EO>]WWB
M[>EX_BPY%KK^"[-?K^"/YU_"GPS^.4O[4.D:SX;TKXL^!]-D_:"^ NN_ &^M
MOV3_ -J%;GPS^Q]HWA_X61WOPUG^('B+XP?#7X"_!#X?-X1L?'O@[XN?"+XM
M_#?2_B];^);_ ,4>*])\!>-O'$W@.]/H/P0^&/B2V_:K_9*U;Q=\'?VDO^&A
MO!W[0O[7&L_M0?&+Q%X3^+<WP:U;1O$OPR_:%TWX7:]:>/M627X3^)/#FK:;
MK'A31_A!'X,O+U?A?X>NY?ASK=OX)US7K?PWK'[X07$%S&)K::*XB;(66"1)
M8V(." \;,IP00<'@\&GAT+M&'4R*JLR!@757+!&9<[@K%6"D@!BK $X.!U-]
M-U;=]K=M5UL]+ZCY?/K?9?Y_*_;0PH_$^BR^*+SP9'<S'Q%I^@:9XGNK,Z?J
M26Z:+J^HZMI5A<QZJ]HND7$TE]HFI13:?;W\NI6:107-Y:6]K?6$US^/_P :
MO!GQ)O/B!\5QIW@+X]ZE^TSJ/[2/@'6/A#\3=!TGXD7'PJTS]F"VN/AT_C#0
MQXTTUF^%6A>&/^%;6GQ.\,^*/A?JUQ:>-O%WQ&U*36]*\-:KJ.JZ%XF@_87[
M5X=@U&YO/M.BPZM/!;:=>77G6,>HS6VG3WLMG87,^Y;F2"QN=1U&2VM96,=M
M/?7KQ1I)=3E]:*:&;S/)EBE\J5X9?*D63RYHSB2*3:3LE0D!XVPRDX8"H3MT
MO_7Y>0-76_?;^MUW/BK]@WX02_!W]BCX#^&[+P_K?A3XDZY\#?ACXF^)">.6
M\0S^,+GXS:G\*O"=IXMU/QU%XJFN-<MO$2:YIZVNMZ5>QVW]F363Z:FG62V_
MV5/B/PGX:TK4OA)^QK+\8/ 'QO\ B+\&]"_9,U+P7XC\-?"S0/BAXQU[P[^U
MQI-_X*T;QS?>/=!^$AE\3V_CY=:TCX@:1H_Q U>W30O!7C&T\9W.H^(O#&IZ
MW9WUW^TKZOI,80R:GIT8D4O&7O;9!(@=XRZ%I1N421O&67(#HZYW*0*^E6>@
M:<DRZ':Z/81ZO?:CK5PNE065JFIZE>W FU;5IA9JBWM]=W4@EU&_<2W$]Q('
MN97D?)?-JWU;;W[WZ^5]/0.79=E;[K=-NFI\B?#&.]N/VMO%UYI%IXCT[1M-
M_9,^ ^B>/K/Q/>P:GK=MXT?QG\4-6\%Z+XGU6UU+6;/4_'F@>%[WQ'-XLGM]
M9U>0V_B'P_>S:C>66IZ3=W/Y(_M+>"_C)J.O_P#!4+X>>&M4_:RT_6OC%\;=
M*\3_  K^"/AK]BWQ?\3?V>/VCX8OV2_V6_#6G6'C#X]M\$Y_#_ACP?X[\:>"
M=:^%?Q O;;]HOX=6WA?1- U34)9M&NC=7FI?T2PP^&M#N=6N;>+0]'N]<U)-
M3URXA2PT^YU?5TTO3=+CU#5I4$,NH:DFBZ;I&G)=WC372Z7I^FVBR"TM;6./
M1AO[&Y266WO;2XC@&9I(;F&5(1@MF5XW98QM5FRY PI/0&G&?*[VOHEKY._9
M]?PV:>H.-U:_5_BK?UY]S\Q]*T7QO=?MDQ? RZ=QX&N=5\*_MV>,DTO6FO\
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M<'CF]\"61\1_L_P:-\2/#?COQQX2T#]E#6M-TKQSHVI0:3K/A#4]'U+Q3?\
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MUS1/VR;SPMXKNOAWX4FT5]5T"3]ESXO_ !%T?PI\5/"!\>:Y!I^LV[Z1//\
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M3_B-I.I>'/#MK=ZUIZSZ*MAHE[/HR_=W[%/[0L/Q]\'?L]?$S3O@'^P+\*_
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M3XS?'CXN_L=?LGQ^&_A)^U1\&/V9_B1XEC^-^M^)?&-]XG\$?M'?#CP=\/\
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M_LU_$?4#X0\)_&?XZ:!XV@\)_!OX#^&-'\5ZWXGT'X;S>+SX8^#'Q;U#Q?\
M$;Q=?^!O&=SX<T:'X<W4>G:1X:O-7UOQ+HD=YHD&K#MS6Y4K7;^%)*[M=[*U
MTO-H$VU=2=G9)M.[NELM;WU?2R^9]!?LT?$WXH?&;X-^([_QM:Z3X/\ B-HG
MBWXB_#R/6]/L] NK.XN?#>HW.G:#XNOO!FC>//'EGX<U=8I;-O$_@"]\<ZI<
M:7X@T_5=.DOXK.2V,?Y0_LH?M.?M2S_LMVL@^-GPJTRY_9W_ &(O@Q^T3K6N
M_&KP5KGBGQ'\89?'_A;QSXFE3Q)XB3XH>&[O0O!N@Q>!V\&ZKX]C@\0^)-<\
M:7FL:S?&T&CQ^'];^E]4_;MMO@SX$\#?#'P3^SY\*?A)\3="_:MT7]D'QS\'
MO&'Q0LOA9\%OA'J?B+X(>./VA- \=>'_ (A^#_A;X@MM;^&GB_P?H&D7GA"^
MM_AOX8O;^[\3W-CKNC^&_$&@ZQHR>-^-/B!X(\-^-OV=?AIJ/[&__!*[4M0^
M($O[0WQ!\"^+O^%W:0_PC\!7WPKOO@UJ7B.ZT[QE/^QZ9].^)'C/Q#\54U.Z
MM-'T"WF9M 76+_7+N^OA#9BB]?=T;;6SVW_#;7K=)V0GK9J6J5G\2NV]-NS6
MOI9VNSZT_;-\>_$3Q=^Q%\//B7\/_$FL_!3Q-XW^(W[$FM7R_99KW6=$TWXF
M_M!_!32]5\)ZBT=[H4WDVA\5I:^)K9VAM_$&CV&K^%]2M8M-UZ]:#Y0_9^^+
MOQ]_9^^&?P[\4OK?@CQW\*/B!^W?^WG\*YOA?IGP\U?3_B#,H^.W[9_C]/$N
MG^/%\<7MC-XENO'OP\N-/MO#Z>"%T>3PKK=O8B0:[9'6+KW?X[?M3>+G?X!?
M KXA?"#]BKQ]%^U!X)_:!\5>(1\1/VEM3O/V;AX:^!VN_!VSLM)A\5:Y^S7K
M*^/M4\52_$^WO#I5]X#TFPT:[\+W:17NK,4G@I1_&+QOH_BK]E[X!_#;]E[]
MAWQ!K_CX_M.?&WP</!7QWU=_@G\-KWX-ZS\+(=;\4>%/$6@_LI7=ZGQ.\:Z]
M^TAXMN=;N-+\$Z+-82/KMY=^)=6O?%NIPVXD[6Y59W>ZV5^MKZ6]=-KL&KRY
ME*UDH]=]-;;6?;S\B#]C?]L7]H_XS>,O@5-\2_"FBCP)^T3\)/$'Q*L9K;PU
MX/\  T/@G4=/TSP[XATNS\ ZI%\??B-XF^,?@[[!K5SX<\0ZS<^ O"6JZ9KL
M6B:]>P:)8Z[/X8T?J?VLOVJ/CG\#/BQKE]IK>&M-_9Y^'?A'X=>)/''C#2O
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MV??@Q\,QHFI^+O%/_"P/$\/BSP7"NIQ^$OBWJ4OA[P?<Z#X\6!M)GTVRNY-
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M4L+R36-.L+7Q/J7A^+^TX'NK9I/BJQ^)GBGP;^R9\6_V<M7M/'WPDTK]G_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/O\ P2$^'OBBU;_@JC]J^-GQ-U:_O_\ @I;^U7X"BUC4-&^"L>I:;X@T?2/
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M3XMZ]\6/"4?B'3H/AU\,/!OV+P7H2OJ6I>(7N;[5_<+K]DWXV>"_"'C[X(>
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MK^(-+T'6M?\ "NOWEK=7OB6?09=7D_,G]D7X\_%K]G+QW\2/@_\ !K2_@D?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.J:)\/O"5G]@C;D?B?\ 'KXQ_%'_ ()@_M$?&/QO^T=\+]3U;XT?\$ZOCO\
M%_1_@SX5T#3/"'CWX<:[;^&=726^\!:QIOBV;Q/JG@WP5]L3P?XFN/$.DZOK
M%MXS@LKU/%6DF6309JY)75VM;+=O=VM\NJ=D+FCK9;7>R6RW^?EK\C]8KG]B
M?]C.]\77'C^\_9'_ &8[OQY=^(Y?&-UXVN?@)\*Y_%USXNGU-M:G\4W'B27P
MH^LS>(YM9=]6EUR2];4Y-39K][IKIC*?1[SX$_!#4/!OB[X<W_P;^%5]\/OB
M!K^I^*_'G@2\^'GA&Y\&^-O%.MZM!KVL^)?%WAB;2'T3Q)K^KZY:VVLZGK&L
MV-[J-_JUM!J-W<RWD,<R_FE^P1\</C[#\>T_98^+OC[1/BAX>L_V"?V6OVE?
M"OB&V\%VG@_5_"^K>.K_ ,4^!O$W@L266I:B_B'P\C^%M/U32-3U^:\\30RR
MW46I:OJ?G+)'^4?PP_;<_:H^'/B7XJ_ CX-RZQ#-J_[0W_!5KXUR^.[W3_A9
MXGFN[CX.?'>UT3PMX$FO/CU\6/A3X*\._"[PK#K<GB3XJ7>CZ]?^,].\)-I1
M\+VOA^P@UG7+>E"3;7-LHM.[M9MV=V]+6[>@KQ23Y4KMIV2O>RNM%K>_];']
M6'@OX?\ @/X;Z9>:)\._!/A'P%HVHZUJWB34-(\%^&]&\+:9?>(M>NFO==U^
M\L-#LK&UN=:UJ]9KO5M5GB>^U&Z9KB\GFE)>N(\*_LY_L]^!-4T'6_ _P(^#
M7@W6O"NK^--?\,:OX5^&'@CP]JGAS7?B3:Z;8_$36]!O](T.SN]'U?Q]9:-H
M]IXTU+3Y;>\\4VNE:;;ZY-?Q6-JD7\YO[0WQL_:K\:^.OVH/B1!\>_'7P:U-
M?^"!>B?M267PT^&7BCP=XF\#>"?B+KK_ !'N/%L'PV\6:,_B&PGCEUCPDMWI
MWQ?\&>(+CQ9>Z=)I;Z3XR;1]'\-)I^SK'[?7[:GPLT_P_P##/X9W4?C6/]GG
M]B?]C[XU7>O_ !"3]GSPMX>^-6J?&F]G36?^%M_$CXJ?%OX/#P/\/]+T;2X?
MAGX6\2_##2=?\1-\1I6U;QQJ5_+<Z?H6LGLY6TDM=]6EMU>S[==[[;OG79Z;
M:+OT73O_ ,$_H:\;_LZ?L^?$WQ%%XP^)'P)^#?Q!\6P1Z)##XH\;_##P3XK\
M10P^&KK4;[PY%%K>O:'?ZG''X?O=8U:\T2-+H+I5UJFHW%@();ZY>7A]$_95
M\#:?^T[KG[6FN^)O''CGXI7GP]D^%'@^W\5S^#U\*_"KX>76N1^)-4\-^ -+
M\,>#?#5__P 3?6XQ=ZAKWC35_&7BDPO+I=IKEKH\TNGM\R_LN?%_]H'XR_MH
M_MT>&?%?Q+M;+X+_ +-/Q2^'O@'P+\+K#P-X4BO[]/'/P(\%>.M4F\4>-A%<
M:Y<#1-?UI[O1HM-FM6:2ZU*VU2^U33AI=KIOA_QN_;9^/_@[Q'^UIX\\-:_X
M0TS0_P!E'X__  "^#&A?LXW_ (3M;_Q5\;-(^*4OP[34]<G\2R:DGB33?$'B
MZ/Q[J,WPH_X1FQ32((_",[:YI7B6.6_FLYY97Y;]%U>TK-+7O=7M9=V#<=&U
MU?1;QOKTVUM>[[:GZ]>(_ 7@7QCJ/A;5_%W@OPGXIU;P-K0\2>"=4\1^'-'U
MS4?!WB)8'M1KWA:]U.SNKGP_K0MI)+<:II,MI?""1X1/Y;,IX[7?V??@+XID
M\=R^)O@C\(?$4OQ2U;P=K_Q-DUWX:^#-7D^(NN_#M;!?A_K7CM]0T6X;Q=JW
M@5=+TQ?!VH^(#J%YX973K :)-8BSM_+^*_\ @G%\6_V@/V@-+_: ^)OQB^)]
MEXAT#PU^U!^TI\#_ (?^ -(\"^&/#MAH/A;X3_%S5_#7AW6=4U_3[?\ MW7/
M$3:;9RZ3<-+<6NERZ=!87$NGRZTM]JM_\Y? /]MK]ISXP_%71QXA\/:?IOPO
M^(WQ"_:U^&>I>%]6F^#WA:3P#9_!*#Q3;^$Y_ 4C?%>7XU^/_'%G<>&+>#XN
M:5J_PUM]/TZ#Q7#XCT*TT3P]I,%WJQRR3:O\.]F_6RV_X?[Q\RT=OBVT7I=_
M>?KMXE^#?PA\:>,/#WQ"\8_"OX;^+/'WA'2]9T3PIXX\2^!_#&N^,/#&B^([
M*[TWQ#I'A[Q-JFEW6M:+I>O:=?WUAK-AIM[;6FJ65[=VM]%/!<S1OYWX=_8]
M_9(\(6^IVGA/]EK]G/PO::WX8UOP3K-KX=^"/PST2WU?P9XEU'3=8\1^$=3A
MTWPQ;1W_ (8U_5]&TC5-;T"[672M5U'2M-OKZTGN;&UEB_G*^ O[;7[4WP\_
M9!_X)Q?!CX.OJZ:KXQ_83^-O[0NO?$B_T[X5^*=2\0^(?A9XEM=)T7PUK.J_
M'OXK_"KPAIG@'0QK;^*?B_K-CXAU3Q[;^%CI4GAV/0K*WUG7;?\ 2[]E_P#:
M\_:!_:,U;4O'7C_XJ?!#]FS3OA]XQ_9I\&>(/@KJT'A'QGH'CBY^+OP>\">/
M]?31/BM;>.4.J:EXX\2>-+_1/@1KW@?6=4\,ZK8:!97?]F>/_P"T)IGJ4)1O
M[VB;7Q/HVEHK[M.W;RW$I1?373HNJ3>NFUUZ]#]5_AO\*_AA\&_"]OX(^$/P
MX\!?"KP7:W-S>VOA#X;^#_#W@;PO;7EX4-W=V^@>&-.TO28;FZ,<9N9X[199
MRB&5V*KBBOP8^#R?$-OBXGPG^&J?%=[?[(_Q.7P)X77XAO:FV-D;9O&@TH>)
M&MS9DVGDG4C']F)@V^4=E?SA_!KX^?MB>%!8>#O#_P"T]XCU77OCG_P6V_::
M_98\0^*/B'X/\&^.=2\)_#7P1IWQ5ED'A:SU'3H(=+O)(/"/A^?P[HK,?"?A
M-M$TW2M$\/P^&'U#0[[W_P"-G[?/[4GPWU3]L/QUHOCCP;+I_P"Q)^T+^R_^
MSWIG[-VL^ =)D\<?M,6/Q97X56WB#QK?Z_:ZA::]X?\ %?Q%?XBZQJ7P;M?
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MXD>)/&EWX4^$?CS0?B?I7PNTZ?PG:^ O$_CWPG/<77A/Q#XR:X\(WOC;4?\
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MXI_L'PIJ'_"#^#?$OCBQT'P/KMEJ45[I_@WXB>*O'/C6WDT0/KNMVLUW>Z-
MN63OK\+[OK;;[TWU'SPBD[?$K[+9)[K;HTDM/O/WP\0?LV?LZ^+;3P_8>*O@
M%\%?$UCX2\/7OA'PK9>(/A9X&UFT\,^$]2MI++4?#'A^WU'0KF'1?#VH6<LM
MI>Z+IJ6VFW5M+)!/;21.R&BG[+'[,4?C33?B1'^SC\!T^(FCZK8Z]I'CU/A!
M\/E\::5KFEZ-I7AS3-9TWQ2OAX:Y8ZKIWA[0M#T*QU&UOHKRTT;1M*TNWFCL
M=.M((?Q3^(O[?O[8'P9O=>\":]X]^'OBO5_'7P*_84^*6A_$_4?AI9Z!X?\
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MP/\ #B3PUJVIR6%LVGOXA3P/')KFF6=K1^/W[:/[3W@GQ!\%_@O\+_B9\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %?D5^U9^R]_P5T^)7QQ\5^,/V4_^"I/PY_9G^!^
MIVGAN+PI\'/$'[$GPQ^,NJ^&;NP\.:78>([FX^(7B37['6-:77_$=MJFOP0W
M-M&NE0:E'I4&^"SC=OUUKX!_X*6?$W]I+X/?LH_%'XD?LW:M\/\ PGK/@GP;
MXG\5^*/'7C.VO=>UKPWHVAZ>ES;V_@#P7_95QX=U[Q3KMTQL8M5\7ZM:Z!X3
MMTDU>;P]XRG,.BEI7:2MJTM=M=!-V3?8_/W_ (8C_P""_P!_TG"^#_\ XK3^
M"G_S4UYQ>?\ !,'_ (+1:C\0;#XM:A_P5O\ V6+[XJZ7:"PTSXF7G_!)S]FV
MZ^(.G6*PR6RV5AXSGU9_$=G:"WFFMQ;V^I1PB&62()Y;LI_6C]L?5?B5X \&
M^*OB?X3_ &AO%W@#4K#PU!H/P;^$'@[X?_##Q,WQ3^-EY_;$OAGPGK$/C/PA
MXO\ &'C23QOJ9T70;?PWX#U7X=3Z+HEMK^NW>O(%;Q!X<^M8O$$FA^!X_%7Q
M!DTOPU+H_A1/$'C>5+HR:+H$FGZ0-1\2R)>N6,FEZ4T-ZRW3%BUI )B3DDFR
MNGOII?\ I_ET#=M-;:ZV_I?GU/YR=-_X)/?\%@=&\;O\3-'_ ."J7['^E?$B
M36]0\2O\0=-_X)$?LP6/C=_$>K6%]I6J^('\5VM_%KS:WJ>EZIJ>FZAJIOS?
MWEAJ-]9W,\EO=W$<D4'_  26_P""O5K#\0K>V_X*E_L=6UO\6]/U'2?BM!!_
MP2$_9=AA^)VE:PLZ:OIGQ"BCO53QII^JI<W*ZC9>)%U*VOEN)UN8Y1+(&^D?
MA!_P4J\9Z5\/_P!I?Q[\1/$O@_XCZI<_L\^+_P!M;]G[P1H^J>$_M'@_P'#K
M?B;2;/X#^-6\*^5J%AK'@C0_^%/>(O%%YX@6[\3"X^(7BUY)Q;>'(].T[]$M
M-\#_ +1WP\_X1+X@>(OVE=0^)=O817>H_&;X?^(O 'PUTGP3?Z0OAO4[W4!\
M$V\$>"= \?>'M9TK78;%O#EKXZ\<_$&UU3P^E]I^MS2ZO/;:]:4U);NW1:O6
MVMEZ/3UV[DIQ>R]=%IT_'?O;[C\B='_X)J_\%M/#OB4>,_#_ /P6 _9GT+Q@
M/!NB_#H>*]'_ ."4_P"SKIGB4?#[PW=75]X=\"C7;+6H-4'@W0+V^O;S1?#
MNO[$TNZO+JXL;&"6XE=_/?$'_!'G_@J]XMT4>&O%7_!3+]B3Q-X=7QMKOQ*7
M0/$'_!'/]E'6M%'Q&\47C:AXF\?C2M2GN;$>-O$5^[WVN^*A!_;NKWCM<ZA?
MW$S%S^MGP27]J#XS?!CX-?M,6?[0RZ-XB^*^A_#OXM'X*WW@OX<S_ ;2_A[X
M\&D>)'^'RZI:^!_^%T2>)=.\#ZL-.@\;_P#"T)8+CQS;KJLGAD>&YF\,(OPN
MO/V@OVG_  KXW^,_AC]HCQ!\&[1OB5\9/ _PD^&_AWP%\*O$/@RQTWX/_$WQ
M;\*[34_B\WC+P5XB\>^)M6\6:UX)OM<U[3O!OCOX>1:+HNJV^@Z0]OK%A+XA
MN59K[5K:-IRT=VDM/G9K3?YNZ?V;W5TM-59.^ORTWV^7Y?:__P $M_\ @LQX
MK\2:3XR\4?\ !6?]E'Q)XOT'PKK/@70_%6O_ /!);]FK6/$FC>"?$5E=:;X@
M\':3KFHZI<ZIIWA77=.OKVPUGP]9W4.D:G97EU:WMG/!<2QOQR_\$<O^"K"I
M\.HU_P""EO[$"Q_!\N?A+&O_  1O_9/"?"XR:G+K<A^'2B8+X),FLS3:NY\,
MC3-VIS2W[9NI'E/Z@W7[6/Q&\>?#C_@EW\3O#DT/@<_M/?M&^&/!_P 7O#NG
M6VGZQI>HZ!=_LP_M,^,]>\,Z;J&L6-[>P:"?B+\._#FKZ+KFFRZ=K=UIVEV$
M4E\MGJ6I6=WXS^WQ^T=^TGX ^,'Q<^&_P6^*P^'1@^$'_!.J\\%ZA/X-\)>+
M++PKXS_:%_X*+ZC\ ?'OB6YL-<TF:XUJ'6OARMOH-SHUWJ4=I#;6DEYH3:+K
MLKZPK49-I<UM^KLK/E>WJ]NE^]FG*-KVOMT6MU=;^GWV/GC0?^"<_P#P7&\*
MZUXO\2>&/^"R'[.GASQ%\0=4LM<\>Z_H/_!++]GS1]:\;ZUINE6FA:=K'B_5
M=/UVWOO$NJ:?HEA8Z-9:AK,][=VNE6=II\$T=I;PPIB:M_P3"_X+1:_XZT;X
MH:[_ ,%</V6=:^)GAR%+?P]\1-6_X).?LW:CXZT&WC,AC@T;Q;>:M-K^EPQF
M64I%8ZA BF60JH+MG[ZOOV@?B?\ &;XW?LP?!_2_''BCX#:KXT^'7[7OA_\
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MW\9+KQ?^T1H'QMTSX*>--8M[_P")>H>"KOX9>-]%\ ?\(3X>\>:<GQN\*_\
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MO&AFE*J#(^?T2D_:2^+U@/V3_AOXF\16^E_%^+]JCP%\)/CNUEHVD067Q/\
MAQXG^!'QO\<^$?B#HMA>65T-&\._%"3P7HNNSMX?:V/AGQWX9\=?#FRUB\A\
M*:L]YX-\.?BQ^TQX._8$_9Z_;MUS]ICXD?%'7M7\'? /QY\6?A)XY\'_  )B
M\ >,M ^)?B+P?X?\<:5X4N/ GP@\$>/?"GB73K+Q1=:MX$O(_&6K:?\ VSI]
MGI7B#1==LK]WMCEEH^;?1:O6_2_9V].Z[+GC>W+LN9[:;.]NK5_7MY_+\?\
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M=W<T/C;5].>>=K'4O$J:G>6C32M;S1F1R?3?"G_!/;_@NGX#\.:1X/\  _\
MP6<_9^\&>$O#]FFG:!X6\*?\$NO@%X=\.:'I\19H['2-$TCQ!9Z9IMG&SNR6
MUE:P0(68J@+'/]$%%3=]W][]._;3TTV+L?S0>%_^"3W_  6!\$:CI^L>"_\
M@JE^R!X0U;2;CQ==Z5JGA?\ X)$?LP:!J.F77Q 73%\>7.GWNDW]I<V5QXV7
M1=&7Q=-;2QR>)%TG3!K+7HL+419K?\$AO^"M3K\/4?\ X*>_L7.OPDCCA^%*
MM_P1Z_969?AE##>'4(8OAZ#=$>"XXK\F^CC\-C352\)N5 F.^OZ<:*+ON_O?
M^8K+LON7^1_.)\1?^":'_!;#XO\ AX^$?BU_P5\_9C^*/A0WEOJ)\,?$7_@E
M+^SGXV\/'4+195M;XZ+XEUG4]--Y;+-,MO=&V\^%991&ZB1P>>\2_P#!*/\
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MD63R'\2:?!#<:&\I=V>K]+Z?/7S[/S#2Z5E;OY^6ENG5I]C\-?B+_P $E?\
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M_L^Z[J_B7X(_"S6M?U*?6M:O/!&@C4]<NBAN=>O+6QCLYM>N6C5(FGUMK?\
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M?_A%=7EO-"\[4]0D^P;[VY:7%MO^#?7_ (*K66K6NOV?_!:O0[37;'Q'X?\
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MOMI;R_+MI^/NI?\ !.G_ (+D:SX.F^'FL?\ !9+]G;5?A_<Z)'X9N/ VI?\
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M;:-%J'AW5_$MWH]Z="\9Q)XOT)[BSD?1O% /B#3C;:L3=G[O_P"&(_\ @O\
M?])PO@__ .*T_@I_\U-?;_P-O?!VH-\*_BU\3_@=XH\2>)/'UQX=ET3]I[XD
MZ9X,U:\7QCXO@C;1O^$2\-ZAKNI>._@W\.O$&JWJ:!\-].TW0-"AC2[T9/$6
MG66H:RVM:I^D-$KWU;?FW?\ 5_CJ$;6T27DOPOHOPNNS/Y__ /AB/_@O]_TG
M"^#_ /XK3^"G_P U-'_#$?\ P7^_Z3A?!_\ \5I_!3_YJ:_H HJ2C^?_ /X8
MC_X+_?\ 2<+X/_\ BM/X*?\ S4T?\,1_\%_O^DX7P?\ _%:?P4_^:FOZ **
M/Y__ /AB/_@O]_TG"^#_ /XK3^"G_P U-'_#$?\ P7^_Z3A?!_\ \5I_!3_Y
MJ:_H HH _G__ .&(_P#@O]_TG"^#_P#XK3^"G_S4T?\ #$?_  7^_P"DX7P?
M_P#%:?P4_P#FIK^@"B@#^?\ _P"&(_\ @O\ ?])PO@__ .*T_@I_\U-'_#$?
M_!?[_I.%\'__ !6G\%/_ )J:_H HH _G_P#^&(_^"_W_ $G"^#__ (K3^"G_
M ,U-'_#$?_!?[_I.%\'_ /Q6G\%/_FIK^@"B@#^?_P#X8C_X+_?])PO@_P#^
M*T_@I_\ -31_PQ'_ ,%_O^DX7P?_ /%:?P4_^:FOZ ** /Y__P#AB/\ X+_?
M])PO@_\ ^*T_@I_\U-'_  Q'_P %_O\ I.%\'_\ Q6G\%/\ YJ:_H HH _G_
M /\ AB/_ (+_ '_2<+X/_P#BM/X*?_-31_PQ'_P7^_Z3A?!__P 5I_!3_P":
MFOZ ** /Y_\ _AB/_@O]_P!)PO@__P"*T_@I_P#-31_PQ'_P7^_Z3A?!_P#\
M5I_!3_YJ:_H HH _G_\ ^&(_^"_W_2<+X/\ _BM/X*?_ #4U<T[]BC_@OE!J
M%C/J/_!;CX0WVGPWEM+?6*?\$VO@M;/>6<<Z/<VJ7,?BDO;M<0!X5G0%XBXD
M4$J*_?2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "O)?CQ\&O#'[0WP;^)'P/\:7^O:7X3^*'A35/!^OZAX7NM/LO$-G
MIFK1>3<SZ/=ZMI>MZ;;WR+S!+>Z3J%NK<R6L@XKUJOC3XB_L0_#_ .)?C7Q!
MXZU;XT?ME^'-1\1W<=Y=:)\.OVT_VFOAQX*T^2.UM[00^'_!'@OXF:+X7\/6
MC);K+)9Z/I=G;274EQ=/&9[B:1Q.S36ZU7J@.@^(O[+D_C[XRV'QOL/V@OCA
M\/\ Q/HOA,^#_#6C^%;'X!:_X5\)V%U-+/KNH^%=,^*_P)^)5YH/B'Q67@M_
M%.O:?JD.HZSINGZ9H\\RZ/I]K81^H_%GX/Z/\9_@_P")_@OXR\1^+%\/>-?#
M]MX6\7:UHMUHFE>)O$&A-+9CQ%I]W<1Z!)HMM!XTTV"]T+Q/'IFA6"-H^M:K
M!HBZ)</975C\L_\ #N?X7_\ 1P?_  4 _P#%A/[8/_SWZ/\ AW/\+_\ HX/_
M (* ?^+"?VP?_GOT[O37;;;3\!66OGO\SVWXH?LG?!7XKWO@*]USPS;Z-_P@
M5[XI5+/PMI_A_2=/\6^$O'7@/Q%\.?&_PV\:6<NB7L6L> /%GAOQ%(-6TBV&
MG7Z:CI.A:CINK:?/IP,O->&OV0/#>DZO\.;CQ3\7/C=\5?"OP>U6UUWX5?#K
MXD^(?!NI^$O!NN:7IUUI/A[69[[0/ /AKQWX_P!4\+Z=>7$/AR]^*_C7Q]/I
M=VT6M1.VOVMKJL'F_P#P[G^%_P#T<'_P4 _\6$_M@_\ SWZ/^'<_PO\ ^C@_
M^"@'_BPG]L'_ .>_1=[7"R[(ZR#]AOX>PZ/8?#[_ (6/\8Y?@#I7B.R\2:=^
MS7+KO@UOA':OIFO1^)]+\."^7P$GQ;G\ Z;KT%O>67PYN_BG<>!8K.WM_#Y\
M/OX9@BT5-S7/V0?#UWJ/CP^#?B_\<OA+X0^*FN:QXF^)/PV^&GB3P=IOA'Q1
MXA\3<^+=:L;[Q#X!\3>/?AYJ7BZ5I;WQ)=?";QMX DU+6+J^\0L8_$.H7VJW
M'F__  [G^%__ $<'_P % /\ Q83^V#_\]^C_ (=S_"__ *.#_P""@'_BPG]L
M'_Y[]',^_P"7KVWOUW\PY5V_K;OMY;>1[G\1?V7/A?X_^%OP[^%&GIKOPRTC
MX-:QX)\1_!77OAE?6.B>)/A)XA^'>GSZ+X1U7P=)K.E^(=!E.G^'[S4O#=WI
M/B?0/$?A_7/#VK:KH^O:/J=CJ%Q$_DMY^P1\//$=CXTN/B/\4?C1\4_B#\0/
M%O[.'B7Q/\7/&6I_#>S\<SZ5^RK\8]+^.GPB^'^E:7X&^&'@WX9>&O =AXZL
MM5N-=TSPW\.])U;7X/%GB6ZOM<.O7.FZWI>-_P .Y_A?_P!'!_\ !0#_ ,6$
M_M@__/?H_P"'<_PO_P"C@_\ @H!_XL)_;!_^>_1S26EW_P /J];7U>K5[-ZV
M"R['M.I_LH_"_4?VI_"G[7L<_BC2_BCX6^'/BSX9R:9I>J64'@?Q/I?BV?PX
M\^O^)O#\VE7-S<^,=)L_"^FZ+IOB+3-5TFYN=!BM-'\01ZY9:%X7BT'E=8_8
MG^%>M_##XT?">[U_X@Q^'/CI\?4_:+\6WMOJOAQ-:T[QLGQ \#_$<:7X<N9/
M"DMC:>%3KG@#1K4V.IZ;J^K_ -E7.IP#7!>36M]9<!_P[G^%_P#T<'_P4 _\
M6$_M@_\ SWZ/^'<_PO\ ^C@_^"@'_BPG]L'_ .>_1S2TU>EDODVU]S;MZA9:
MZ;WO\]'^1[<_[*WPNNF_:A75F\1ZU9_M:^*]%\9?$BPOM3M((M$UKP]\(?AM
M\&M&N/A_>Z3IFF:QX9N--T/X5^%_$NF:K+J>IZ_H_CE;GQ#HVKZ<L6E6.E^.
M>$O^"?/PX^&WA#X+:+\)?BO\<OA5XX^!WPFT_P"!_A_XT>$M9^'%[\1/%GPP
MTV_DU>U\+_$K1_&?PO\ %GP?\<6]MK=Q>ZWI-SJGPK%YX7U35-;N?"-QX?\
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MO[ U'0/>?%?[''PJ\8>%OC#X9U74?&*3?&7XS^%/C[JGB>UOO#Z^(_"?Q)\
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M&@W.C1IX>U.PO] 7^S*\:_X=S_"__HX/_@H!_P"+"?VP?_GOT?\ #N?X7_\
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M)^'_ !5XX\0^&_#$UOI<VB:192:#H+:9X)_P[G^%_P#T<'_P4 _\6$_M@_\
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M.["RUTWW_K_*Q]8?#OX76?@&[\0ZW>>*_%WQ"\9^*QI,'B'QUXZE\.-X@O\
M2_#ZWX\.Z##9^#O#?@_PGI&A:$^KZS<V&FZ%X9TN%M0UK6=5O?M>J:I>WDWR
M?^Q]^R[XQ^&7QA_;%_:8^,=TM[\7/VF_C?K,FAV$.LOK.G>!OV>OAF[^!O@;
MX7T_$DEA8ZKKOA/2;;QMXN&F"$27VM:5HVI))?>&/.8_X=S_  O_ .C@_P#@
MH!_XL)_;!_\ GOT?\.Y_A?\ ]'!_\% /_%A/[8/_ ,]^B[LUWLGZ)WMZ;?<%
MEIY7MZL^H?'7P@@\7^(K3QGH'CSQ]\+?&D&BIX:O/%'P^N/";W6N>&H;VZU*
MST/7M%\>^$?'?A+4[?3-1O\ 4;W1;^;PZ-<T.;5=871]6L8-8U2&\W?"WPXT
MKP1X$G\#>$]6\0:1Y\?B*X?Q;)>6>N^,&\2^*;W4=7UKQI=7_B;3]:TS5/$M
MUK^J7FO,VL:/J.B&^=+5]%?1HH]*7Y!_X=S_  O_ .C@_P#@H!_XL)_;!_\
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M>$W_ &;OVDO%3Z#J:[6\_3F\1>%?#NKF'Y<WNCV4F[]W@^[_ !F^"OPZ^/\
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MZ+NM'J^_FPY7Z[7U>N^OENM/^ ?CQIW[77[1_B+X!?MU>)M7^*6L-XM^#O\
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M;02AOL4!7PZZ^*'Q]\ _%&W^(WQ+^)GQUM/!6K_M7P>'/"OQT\ :O\(/C/\
ML*Z]\#_$GQU_X5WX4^#OC'P#X3U*U^+'PH\=1>&=2TGX;:W\3-4\,:C'X>^/
M=M/XDUSXD:CX+_M'PLG[$:O\,O!&O?$3P1\6-6T3[7X_^''AWQWX4\&:_P#V
MEJ\']C:!\2[CP==>-K#^RK:_AT74?[:G\ >$9/M6JZ=?7NF_V3MTBYL$O]36
M]\*/[#_[,Q\=R?$#_A ];2_F\>I\5)_!\?Q2^+D7P9N/B='KR^*T^(ES^S_%
MX[3X%7'CE?%R)XQ_X2R?X=2:[_PF"+XL-^?$(&I4*:LKK:-MEO>7Z.*UOMKL
MF#B];=[[O:R_6[^?R/BK3/B-\7/VA?VHT^#Z?&7Q_P#"CX._$J]_:D^*NA7W
M@.^TC2?&7B/PG^R]XX^"'[+NF_#CP5XIU31]6/AWPEKWCZ;XB_'3Q5K?A>*#
MQAK.G^*_ MEIGB#3O#$^I1WWEWQ]^,GQO^&7P[_:P^!5A\5?B]\1'^"O[3'_
M  3I\->#/B/X:U+PWHOQ]OO '[3_ ,=O@YI?C?X(R^+M/C\&>'=2\>67A[4-
M<TOP_P"*]4?P_J=SX2^)/@]/%VLSZE:WGBW4_P!2/$O[)/P \5_#[X;?#+5/
M!-]:>'?@[!:0?"O5?#7CKXB>"_B+\/VM-).AO>>%?B_X.\6:%\6='U75-*:2
MS\1ZS:>-8]7\4I-</XEO=5FN)Y)#2/V2/V>M#^'2?"K3OAZJ^#F^)_@KXU:D
MEWXI\:ZGXG\3?%GX>>.O"?Q)\)?$'QMX_P!3\1WGC[QWXIT_QCX%\(:C=ZIX
MS\3:[/KEEH%AX?UXZGX=1])<4HZ::*VEET?Q7WNU9->O9!RO775WUN^JVMV3
MU/QQ\0_&_P".OA_X9?\ !3W6/AKXK_:E^'7A3]G?]B/XE7DWAW]JGQS\/?$/
MQP\$_M*1>"_$_C/P+X_^&D7AGQ)XU\6Z5\.Y_!5O).OB?Q%XAE\)>+?$UE9+
M\/[:67PMXPN7] _;Z\0_&+]B7X5WVM_"/]H?XW^(X_BW^SM^V9I6H:-\2O&D
M/CS5? ?BWX7_ +'WQ=^/?@+XU?#_ ,2ZIIB>+/#>J>%O%/PVM/".IV(UB]\,
M:B/'FCW,VD0:QI>G7DGZM?%3]E;X"_&K5_%VN_$GP)_;NK>/_@AXP_9P\;WM
MEXH\9>&'\5_!;QU,USX@\#Z^GA/Q%H<.IVR7,U]<^'=8NHY/$?@NXUC7Y_!N
ML:!+XAUQ]0\\C_8'_9@ETGQUHWB#PGX_^(</Q%^%_C/X+>)-1^+W[0'[0WQH
M\30?"WXBZ>NE^.O!?A'QA\6?BIXS\5_#S2?%=E%;1ZV?A]K7AB[OI+'3;F6Y
M-UIMA-;-3C=-KJKJR=]$M_57O97V[W.5ZZ][.[5M7TUZ:?B? _Q&U[XC_#7]
MDC]M#XJ>&]/_ ."A'PR\:^!?V*?CWXO\(>,OVB_B[X$\7>$+#Q;H_P /[S6-
M&U3PGIOA3XO?$2^L_&NF:C9PZMHNIW>B65K:6%KJ<9OHYYXK2YU/@!\1?B5#
M^U_X/^'V@ZA^UQ\//"?A3X-^-/B1^T-X<_;<^)/PN\1Z+XB\':II\&F_#GQ7
M\'+;3?'GCOQ9J-WX>\>VLO\ PG/B?0-8TGP/X5\/2S:%XR<^)?$7A6"#[JC_
M &%O@ _AOQSX,UFY_:$\:>#OB3\//%OPJ\:>$?B3^V3^V'\4?"VL>!O'&D2Z
M#XETM/#WQ%^._BC1]+OKO2)Y[*R\1Z/9Z?XFT1)II-"UC39I7D;V[Q7\%OAE
MXV\8_"[X@^)/#"7WC/X,W'B2;X<>(;?5M=TK4-!@\8>'W\,>*M(N6T?5+"+Q
M%X:\0Z1]F36/"OB>/6?#5_J&EZ#K=QI4FM^'M"U'3ES1LU:][ZVV]VRT>^OF
MK;J[T9RO1[6MI??777_@>7F?DW^S7\1_VA/!?Q5_9EM/VA_'_P ?M.\2_%^_
MU;PYXP\8Z]J/PC^,O[%?[3NMZQ\,/%OC/P_=?LV^*_A9?1:]\"+FXU+P]'XR
M^&^F^-O"/@NQU[X<Z?KO@[5H_&?BW4-!\3Q_H_\ MI>*_$?@/]CG]K+QSX.U
MB]\.^+O!G[-'QW\5^%?$&FR^3J.A>(_#OPM\5:QH>L:?-AO*O=,U.SM;VUEV
MMY<\$;X.,5D?#O\ 8C_9I^%7BSPWXQ\$^!M=L;WP/<:C=_#OP[J_Q4^+WBWX
M:_"RZU72]0T.]N?A'\(?%_CS7?A3\)KAM!U;5= @F^''@SPQ)9:!JFI:'9-;
MZ5?W5G+[%K'P@\">(OA#KOP*\2V>O>*/AKXH\!:[\,O$NF^*/''CGQ+XBU_P
M9XFT2\\.:[IVL_$'7/$FH?$/4K_4M'U"\M+CQ'>>*IO$P>;[7'K"7J1W")RB
MY1:6B:NK)77-?;TTL[]D[#2:37>]M;]+;^NNGYGYG>,/AKXHUS]JS]DSPG_P
MT7^U#HWACX]? ?\ :-^)_CS0?#OQN\3Z/I@\4?#]_P!FK_A&#X>M[;CP_I=D
M/B7XL$FEV!2UN1=6OG*WV*#;V/\ P4^^)/QP^%^D_LFZC\"/$_B32M?B_:#\
M6^*O$OAC09XQ/\7O!WP2_9._:4_:#U/X/:HD\;I=6/Q)NOA)I_AMUW6\B7E]
M;7,5W:2PI<1_H'+\(?AW-XS^''Q!E\/;O%_PD\(>,/ ?P^U?^UM<7_A'_"GC
MX^"CXMTK[ NIC2]5_M8_#OP=_IVMV6I:E8?V/_Q++RS_ +0U3[=>\6?#/P1X
MY\1?#3Q7XJT,:KK_ ,'_ !;JWCGX=WS:AJMHOA_Q3KOP^\:_"O5=3:SL+ZUL
M-8%WX"^(GC'038:]:ZIIL(UC^T[>SBUC3]+U"R.97B[744[JRU^+R[-+Y:;(
M.5V:ONUK=[+EO^3^\_#?X]_M\?%+2OCA\4?CQ\$/&A\2? +PC^P?^UYJ_P ,
M/"\YDO/AKXR^)?P-/[&?C(_'35(+18K^_P!&\,7/[26M^ M=ACN[:2UL_AEX
MNA@-H]X]Z_UI\2M-^*O[)E_^S;XXTK]I_P",/QPD^+7QP\"_!/XF^%OBE>>"
M-7\/?$&V^)^C>(1)XZ^'VD>&/"&@)\-=>\!ZAIT?CRUT[P1<VO@Z?P%I'BC2
MM:T'4YAI?B#1OK/X;_L:?LR?"+1OAQX<^'GPET3P_P"'?A-X!^,'PO\  7A\
MZCXBU?0M'\ _'WQ9X3\<?%[PU=Z/KFLZGIOB&R\:^)_ _AG4;Z7Q+;:Q>6,>
MGS:=H]SIVEZGJUE?9_PY_8E_9I^%7B?1/%_@_P ":U_:WA+3]4TGP#;>+/BA
M\6OB)X;^%FF:W82:3JMA\'?!GQ#\=>*?!_P=M+W1I9M#F@^%^A>$H_[!FFT-
M%729I+-GS1Z+1*VR]Y6:5WTU:;:Z^B%9]7^+TU3=N^UK?YL_-?X(:_\ &#X=
M?LD_\$W?VKHOVAOC?X_\:?'S4/V'_#7QF\ ?$WQI#XZ\%_$2S_:E;P+X2\<W
M^B:3K6F2:GX.UWP3?^-)_BAHM[X0U?2XH=/\(ZEHVK6>I:%>W,,/G?AWXR_&
MOXC>#?\ @E-::[K_ .UG\17^+O[$W[0'Q.^)VF?LV^/?#7@WXA^,O''A35OV
M0;+P_P"-/%FK^*?&_P /--U#2M#M_B!XOM)8(M<DNS?^*()8M+N(EGN+/]5/
MA-^P7^S%\%+[X=7G@CPKX_NXO@_8V^G?"/1/B/\ M ?M"_&CPE\*[>ST"7PK
M8O\ #7P5\8_BGX\\(>!+S3_"]Q<^&]-U+PKH>DZCIV@W-UH]C=6^GW,]O)Z;
MX#_9F^"/PRF^#=QX(\$_V)-^S_\ ##Q9\&?A$_\ PDGB[4O^$2^&WCF]^'VH
M>*?#>W5]>OUU[^U+SX5^ IO[8\3+K6O67]@^7IVJ6D6J:RFHMSCK97=Y-.R6
MCYK+2^UU_20<KTUTLDU=O:UW\[/^KGX\?M3_ !8^,GPQG\7> O"'C/\ :9TC
M2K;X,?\ !+[4K7PCJ/CO2+SX^VFI?'O_ (*1>+?AQ\4]%B\7'Q-<:#'\2_%7
MP]EA^&K:FOC5M$MX+/3+2+Q'#I]HNIK]):K!\9]$^ ?Q;_X5+<?M8?"7XJ>(
M?$WP7\,>$E_;'^-_PDN]6\7VFH_$2Q'C3P;\!?$-WX\^,7@_PI\5_&7@/_A)
M_"/@W4_%>DK9CQYK7@BZ-A?6VG75SIWV]\7?V3/@+\=+[Q1JWQ*\(:OJ>L^,
M?#_PF\,:WKF@?$/XE^ =>&E? SXI7_QK^$S:)KGP^\8>%]6\+:OX*^*.IW?B
M[3?$7A>\T?Q#/>-#::EJE[I=I9V,&%:_L7? 9?"OC#P1KL'Q@^(OA7QS!H<>
MN:+\9?VG/VFOCA;6MSX9UB#Q%X=UKPFWQA^+_CB?P#XHT+7[2QUO2?%O@2;P
MWXGT_5M-TO4+75XKO2]/EMES1LM-59O2]]O1/Y[ARN[[/;78\+_8E^(7BFY^
M)7QK^$OC77/VC-$U3PWX6^%WC?2/@K^U?IO@S6?BQX%M?$=]X_\ #^O^)?#O
MQG^&_B3QAX(^+?PK\7:KX6LX- 6W\4:YXA\%>)=#\56VKW=MH_B'PQH^E\;\
M;?A1KUW^W+\ / =C^T)^T]X<\%_&OX9_M7_$+QCX8\,?&WQ/HNCVVO?#76_V
M=H/"$'AFUMN/#NCZ;#\2/%,1TFP9;6X2XM!,&^Q0;?M[X/?LX?"3X%7GB75O
MA_I'BB7Q'XPM]%L?$_C3XA_$WXH?&;X@:UI7AMM3?PYH-[\0OC'XR\>>-Y/#
M?AZ76]:N-"\-+KZZ#H]SK.KW6G:=;7&IWTD_;ZO\,O!&O?$3P1\6-6T3[7X_
M^''AWQWX4\&:_P#VEJ\']C:!\2[CP==>-K#^RK:_AT74?[:G\ >$9/M6JZ=?
M7NF_V3MTBYL$O]36]7,N9M;.+6RWY;7U3ZZ]^]V.SLD][WW>U]5]WR]#\0O&
M7[9W[0&A?L6?M87%C\/?VE=2\4>#OVDOVR/!GA;]I/3+CX3MX(\->&_!_P"V
MO\4/!7A*"'4+_P"*MC\0XM*\#^#M,TWP.5B^'<]U FD&"PM]0LD@OY_0K_Q#
M\1_'O[5W[;N@:GI?_!03QQX>^'/Q[^'7@GP0W[-'Q:\!^"OAKX*\.:C^R9^S
M7X[O_#]WH_B?XO?#[4SK;^+/&OB;Q3J=W::)J-O-;^(;58M1FN(YK*T_4"[_
M &9O@C??";QS\#;KP3YOPM^)'BKXA^-?&GA?_A)/%R?VSXF^*WQ'UOXM^/M3
M_MN/7D\1:=_;WQ!\1:SX@^Q:3J]CI^E_;/[*T6TT[1+>UTV#@/$_[$7P%\4^
M/_'_ ,3I)_CWX3\7_%+6])\2_$"?X5_M>?M;_!C0?$_B+0_!OACX>Z;KM]X,
M^$7QP\$>#(]7A\&>"_"V@2ZA:>'[:[O;/1+)KV6YN$>9VI1UTM?9VO\ R_=L
M]M-1<KTUO\[=_P#-?<<U^UIXP\>V7BK]E#X%>"?'.N?"ZR_:+^,VO^ O&7Q3
MT*+1[GQAH_A;P/\ !'XH?%RX\,>#KWQ'I>LZ-I?C/XA7?P_M-"C\07>F7U]I
M/AO_ (2S4- @@\2Q:/JFF^$?&OQ#\3/V8O _C+P!X,_:QU7QIK/C_P",?[)'
MPX\-7GQ'@\%^,_BS^RGX6_:/^+ME\(M>^(6MZS<*/^$ST+7I8];N/@PWQ1\'
MS6>G?$33-4TW5-?\<^%H1X8\.??WQ,^"GPS^,7@:V^'7Q)\.R^*/#-A>:'JN
ME/<:]XDL?$^AZ]X:ECFT#Q5X>\=Z5K%AXZ\/>,M(GC\^P\9:)XCL/%,$\EQ,
MFKB2ZN6EX#PU^R%^SMX7\"_$?X<Q_#J/Q1X:^,3(_P 6)?B?XH\:?&'Q7\2F
M@L8=,L&\<_$#XK^(_&?C[Q2=%L;>"W\.G6O$UY_PC20QG0/[-=%8)2BDK]-U
M9.^M[W>NBTMY6V;&TW?\'=Z:6M;]?U2/R_\ V\?&'QI_8A\ ^.-+^&_[1GQE
M\>6WQ4_9"_;;UVV3XFZ[H7B?QM\,/B-\"O@3??$GPI\:? 7B[3O#>AZUH]E'
MJ<:>%O%'AV^DU#PI%KGB3P-?>&-.\,7%MJ-OK_N(^,7Q3N_CO^R_^RUX\\>>
M(M+^(6B>*?C?\/?C-?\ A^[7PY=?%KP(_P"SSXZUWX-?''3A811+I_\ PF T
M5]:FDTF&'3O"?QD\)?$'PKH[W5MX/BN[GZBLOV#/V7+;P]\3/#6H>!/$WB^S
M^+WPQ\0_!;QSJWQ(^,?QM^*7C*Y^$GBJTEL_$'PX\._$'XD?$7Q5X[\!^#=3
MBE$LV@> O$?AG3TO;;3]1@@BU#3-.NK7V7Q+\"?A-XP^+GPT^._B+P997_Q;
M^#^F>,-&^'GC9;W5['4="TGQYIJZ3XHTV>VT[4+33->LKZQ#I:VWB.QU>+19
M[B\O=#73;V^O+B=\T;6M=V?O62;=FEIVUL_1/<5G??332[VOK_7FT?C#\3=-
M^)7PR^'O_!83QGX>_:6_:>N]8_9#^'_C/_A2">(/C/XBUO3M!NM3_8)\$_%-
M-2U2PO T&O:EI/CWQKJ_B/0[S41+)I=[!I1@^33+=1ZQ^SGX]^)\W[9?@3X9
M^&I_VP?!'AKP_P#"3Q9\0/V@/"'[9_Q%^&'B>Q\6^$];M+;2?AKXB^"-EI7C
MCX@^+]5U71?']O)%XQ\2>'M3T[P3X8T.>30/&(D\3>(_"EM#^EOB3]FOX*>+
MM#_:(\.>(?!?]H:+^U=87&E_'VS_ .$C\66G_">V-U\,=&^#<\'VBQUZVN_"
MWF?#?P_I'ASS?!<_AR9?LG]KI(NO7%UJDTGQ5_9P^#?QKN?"=_\ $7PI=:IJ
MO@;2/'GA_P *:WHWBWQIX*\0:/H/Q.\'7?@/QYH</B#P/XB\.:U/H_B7PW=I
M%?:9>7]Q9)J^F>'O%%K!;^*/"_AS6=*.=.Z:W5KV6GN);:7]Y-[K>^^@<K[_
M "N_YF]^FEEL]K>9^2W[+'[>OC?Q=^TGXY\1>)-8^)?BSX3_ +4GAOXK^)_V
M;? ^N?"WXF>$/"?A"\^ 4NMWGPR\._#OQUXI\!:%X.\:W?[5O[/MA??'0Q^$
M?%'C2*QOO!VL/ \%O=#[1]%?LZZ=\2?&'P5_97_:_P#&G[;7B?0_$WQFL/@E
M\0O'?ASQ._@.3]G?Q/I_QPM]#EMO@'X$\$7%KX:D\+WSZEXNTGP1\*/%VF>*
M+OXDWGBVST*?Q2_Q#GU76/"^M?>>L_ GX3Z]X<^%/A+4?"$ \/? _P 2^!_%
M_P *-/T[5-<T0>"=>^'&GS:/X/N=+NM%U33[V2UTW1+F\T&[TF^N;O1]=T"_
MU'0M?L-4TC4;ZSN/*_#?[#_[,?A/QQH_CW0OAYJ-M?\ AKQ5J7COPEX4NOB/
M\4]5^$/@GQOJTE_-?>,? ?P)U?QM??!/P+XJDN-5U.ZB\0^$?A_HNK6EWJ%[
M=V=W!<W,TKCE%WLN7Y)W2326MK75FW;=-ZZ!9]=?FUJ[-OSL[V\F?*?AKX8Z
MIH_[?/Q!\"ZG^T=^TS-\-OAS^S9\"OC_ &?A_7?CGXDG\/+XK\1_&?\ :!T?
MQ.-?2Y98K[P?=:#\-?#=E=>'[R0:7%8V]^,*M[<L>#_9[\0_&;]K;XD>(?!W
MCOXY_&#X2^$-!^#'PS_:9T+PO\/-7TKP?XZ\4VW[7OQ'^/?B_P "6OB/Q+J'
MA_4M>L_!_P #?AGX/\%_##1/#'AQ](L=1\6V?BZ]\=/KDT&D65I^G'BGX"?"
MGQIK_P 1?%/B/PQ/>>(/BQ\'[3X">/=4MO$GBO2;G6OA387OCG4;/PQ;_P!C
MZY81Z%/;7OQ(\:7$7B3P\FD^*UDUA<:YMTS2!8<U\4OV5_@?\8;_ ,,:UXN\
M,:YI?B3P;HESX7\->,/AA\1_B;\$?'.E^$[Q[:6[\')XY^"_C'P!XNN/!ES-
M9VMQ/X0O-:N/#4MS!%<OI;3J)*.9?/E2O9.S2U:76[^=A\K^5V[7>JZ+Y'Y*
M_$#X]?'36/"?P.^&>I^,_CM\1KWPI_P4T^-7[*GBKQ7^S]JOA#X=_&/X]_#C
MX:_LR?M#?$3P_)-?)JWPY\"VOB+P]XAT?POI_P 2I-)O_">BZOXC^&'B6[TO
M2-/EO(O#28.E_%[XX>)OV??CGJV@?$G]HOP1\+]0_;F_8>_9]^'MM\7O'7A!
M_P!J_P"'!\2?M0?!3X4_M.>%_%6K^!]1UW6?!6FZ_9^*VM_!&D>-M<U#QY#H
M^JZCXHC:T\*^)?""#]F=%_9G^!?AO2/@MH'AWX=:1H&B_L\^+M4\>_"#3-%N
M]8TJS\*>,]=\'>/O >N^))H;'4H%\3:IKOAOXH>/HM;N/%W]O'5]8\37WBG4
M1<^*4M-9M^5^(G[&_P"SM\4[WXGZEXN\$ZN-2^,E_P#![6OB+J7A/XD_%+X=
M:AKGB3X ^)+#Q9\(/&%K??#SQKX6NO#GCGP3K>D:))8^.O#$NC>+[[3] \.Z
M'K.MZEH7A_1M-L7SQ[6UO>R_FOMMMV>FUK;+E??RW?;OZ^7G<_*;]MKQO\:_
MV6/$P^"'P_\ C;^T+\0O!WQ6\._L]>.$@E\9Z/JOQO\  >I6W_!07]D;X$>,
M/"GPZ^).HCPSJD4'QZ^'7QT\1:#I=CXT\1RV6C:[X,O[O2->T*PU+6!!W?QR
MUWXC?#3]EKX@^(_"VG?\%"/A_P"(=7^/G[$/@,0_&#XN^!/$'Q%\0^&_B!^U
MC\+_  /XTT'X)ZIH/Q>\8:7X:U_Q+X3\2ZOX5U&^US6_"5O-/KFB9U%+>VNK
MW3_O6Y_8&_9?U#PIXS\):QX3\?\ B%?B!J'PVU/Q3XT\4?M ?M#>*?C%>77P
M=\;:?\1_A:MA\=_$/Q4U/XU^'[+P%X[TRT\5>&-,\.^/]*TW2]8^U75O:*VH
M7XN=[3?V,O@;8Z7=Z)J+_&WQQI%WXK^&'C?^S?BQ^U3^U+\9;.R\5_!OXA:#
M\5/AUK6C0?%CXR^,TT&YT/QWX8T'6KM-$&GV_B.+38=&\40ZUH+SZ7*<\=/)
MW>EN;;MHOGZ[ARO7S6FNW^9\B_L0>.OB5XH_:;^.WA2QO?VE-#^#WPO\ ^%?
M#WC3X<?M@>,_A[XI^+>D_'#7-7?7M \2^!;/PSXF\:>+;#X6ZU\.7O8KCQ%X
MB\1R>$O&/B""VC^']O)+X7\873;'Q$^.7Q5^%W[?'Q;UV_\ %NH7W[,/PM_9
ML_9)N_BKX!G2%M+\#V_QL^*7[7VB:O\ M"V$WE?:;<^ KOX4>!K+XB1O<V^D
MP_"B^\6^,K\RWG@+2;2Z_0";X/\ PZG^+MC\>#X=\GXKV'@"]^%P\666KZ[I
M[ZAX"O==MO$P\.Z_HUCJ=OX>\2VVF:];/J?AVZ\1:3JFH>%KC4]?_P"$:N])
MC\2^($U.=?A/\/!XX\>_$:3PQ:77B[XG^ _!/PR\>W]_<ZAJ-CXE\"?#O4?B
M/JOA'PY>^'[^\N?#D=IIM[\6_B$]S-::3;7NM0^(GM-=N=2L]-T>#3YYE=NV
M\;6\]+N_WM.R>VFCN[.UK];W\M?ZMZ_+\=_V._'7QF_;(\2>)OAMX^_:#^+G
M@#P[\&/ _P#PEL<?PXUW1O#/CKXK:Y\2OVE/VJ_"&G^)O$7C*]T#5==/@CX;
M^&?@UH7@_P *^'_#<VEZ;?ZW)XBE\82ZW%8Z!I]E^@?[%'Q)\>>.O!7Q<\+?
M$3Q3)\0M;^!/[17Q9^ UG\4+G3M(TG4?B1H/@2]TRXT;Q#KUCX=L-*\-IXMT
MJTUP>"/&UQX>TG2-&O\ QEX1U[4++1=%2Z.DV4=K_P $_/V3M+\&?#GP+X:^
M'?B'P-I'PET77_#/P_U?X;?&'XV_#/Q]H/A7Q3K]UXI\0^$6^*?P_P#B-X;^
M)NK^$-6\0WMQJUWX4UWQ=J?AYKQD==-400+'[WX!^"WPT^%>C>"O#?PW\./X
M(\,?#_2_$&D^&O"_AO7/$6E>%UA\4WUIJNO7^O>&[75DT3QAXAU#5K5]6?Q5
MXPL-=\30:MJ?B'5+75X+_P 3^([C5'*46G;RLK)6M>[NM?>TNNGR0)-6O\]7
MK>WY?C\V?DG^U[^W!XN^%_[8NDW_ (=\5_$'3O@=^R7=_#/2OVA/#?AWX6_$
MOQ1X"\?'XZK*_P 5+OQU\0?#?@;7/ G@L_LL?"'6?A=\?+9O%'C/PI<3VGB'
M6+.2"[@N($N+'[4_Q$_:'\'_ !!_:2^*,?Q"^/-O\)OAW<Z7<_"GXL?LUZI\
M'_BG\&?V=[7P?\-/"&N^/="_:Y_9QDU/2_C%XRN$\7'Q5XL\;W?ANQ\>:A%\
M(?$7AB/PM_PKS7M/&HW/ZLV'P'^$VF^$?BKX$@\'V\WA3XX:Y\0/$?Q7TG4M
M3US6%\:ZM\4;5]/\<2ZI>:MJ=[J$=IJ^ELFBVVEV-W::5H6@VNGZ%X>LM*T?
M3=/LK;P_6?\ @GY^RCKTI.H^ /%(L;WP[X7\*^*_#VG?&KXZ:+X/^*&A^#?#
M6E^#= MOC=X*T7XE:?X1^.]S!X2T32/#6H:I\9=$\=:KKNAZ=::7KU[J=G"D
M(%**MILK;)W6C;];W6MU9I/034M==]=VK/5?=:W;5:'$_MB:OKOBKQ7^P5X'
M\)_$SQWX'\)?'+]IO6?#OC#7/A3XMO?".M^)/!EC^Q_^T_\ %32=.MO$6FC[
M9%I5SXK\#>$M:<0%?M2:=#%(3%)(K?$G[1?Q0^-WP7\._M9? 30OBW\;/B'I
M/PW^*/\ P3!U;P%XRTWQ#H$7Q^LO#/[5O[5FD?#3XI_ O3/'RCPC:ZKK,V@>
M#;^Y\*:[XLOK/6[/3?BY9Z;KGBIM,T_3=1M_UN^-'[.OPI^/VF^!=-^(VF^+
M5'PR\7#QW\/]6^'GQ2^*GP7\4^$?%7_"(^*? 3ZIHGC+X->-/ /BVS6?P;XU
M\4^';K3TUK^S+O3-:NX;JRF(A:+@9_V)/V;+KX5^*_@Y<>#/$TWA+QUXX\'_
M !,\9:S)\7?C*WQ6\3?$3X?^(_"?BSP/XXUKX[GX@?\ "\+_ ,5^%-=\"^#[
MG0==G^(;ZEIMKX=TS2K:XCTFW%B2,HI*^MMU9?S7O?>]M+?H-IN]NO6[[6M;
MUU/D'58/C/HGP#^+?_"I;C]K#X2_%3Q#XF^"_ACPDO[8_P ;_A)=ZMXOM-1^
M(EB/&G@WX"^(;OQY\8O!_A3XK^,O ?\ PD_A'P;J?BO25LQX\UKP1=&POK;3
MKJYT[Q _M'_&/X=:)\4/A1IWCG]HGX8^.O$WQ&_8L\!Z)X;_ &L_#?PY\8_%
M;]G?0_VD?CI=_!/QQ\8?"GQ3\):UX\^%7QI\#:J8TM/AG:ZQKOBAO!?Q6T^Z
MM_&<=SX3\0:'X5MOTPM?V+O@,OA7QAX(UV#XP?$7PKXY@T./7-%^,O[3G[37
MQPMK6Y\,ZQ!XB\.ZUX3;XP_%_P <3^ ?%&A:_:6.MZ3XM\"3>&_$^GZMINEZ
MA:ZO%=Z7I\MM8\/?L8?LW^'_  O\1_",W@+4?&VF?%W1=+\-?$F_^+_Q#^)W
MQR\7>+O#F@/J,_ASP]J?CWXR^,_'?CD:#X7O-7U74_"FC6OB*WTWPMK&HWVL
M^'[;3=5NIKQQ2CK=7U3V7EW?2ST^5[-BY7TT^;\^W?O^%TCX\_:ITOX@_LK?
MLY_MDZ]X._;(^(?B#7;?]AK]HOXD> ?A[\4-;\+>(_BSX>^('PS\)377_"[/
MAMXPM(M \467AO0[K7-"TKQ9X=F\/>(/"NF>)-5\$7^@WW@J2:\TCQ9\7_$/
MXR_'7P;<?'31_A+KO[:/PJO?A?\ L'_M0_&CXJ:;^US\2/ACXCFU.&+X1^(!
M\%_''[/]MI/C?XA^,-2\2>$_BIID$_B7Q/X=U&P\%>%M+(T+Q@DOB?Q'X4M8
MOU^T[]A?]F2Q\+_%CPE>>"?$_BRP^-_PVU3X._$O5_B/\8OC7\4O'.N?"G6;
M'4M.U#X=Z=\2?B1\1/%7Q$\)^#Y+?5]0DM]!\'>*- TZQOIUU.P@MM2@MKN'
MN_C/^R]\"_V@[?0K?XM^!_\ A)O^$:\-_$;P=HUU:>)O&'A34[;PC\7/ ]_\
M.OB3X6FU?P;X@\/ZI?\ AWQ?X2U!K/5M%U&\N]-?4M/T#Q)!;0^)O#/AW6-+
M:G%;J^NKY4NBZ;/9[M/6^NP.+>VFFUWW?7ITV7D?DW\<?B'\;M?_ &@_B[X<
M\.)^W%XY7P9^PQ^RI\0_ ^B_LG>./ &@6OAOXE_$#6/VJH-=\1^,]!\?^,_#
M=CXFU'Q=+X"\'1:9;0^'O'$,D7A?4K>]T4"YMK35>9\*_'#XD_'SXL>!;F7Q
M#^V+\;O#&H_\$ZOV(OBT]U^QSXN\,?!WP]+\2_B9XK_:;TWXE>.O$GA3Q[\0
MOA/>Z=)XVN/ FA6^D:,EM?7>@0^&KO3-1LM(DBB2[_5?QS^Q/^S_ /$'QG/\
M0-7L/BSH/BJ]\ >#OA;J]]\,_P!I7]I7X-V7B+P#\/[KQ9>>#?#?BO0OA'\7
M/!&@>+;7P_<>.O&!LKCQ+I>JW_E>(M4MYKN6WN&B&;K/[!_[-6J:YH?B+2=
M^)WPUU+P[\+/ ?P4TI?@5^T?^TE^SQI4?PM^&%[XIU#X>^#KO0/@3\6_AUH.
MJ:?X0NO&WBM]$GU73;W4;./7+VW6]-N8XHSGC9*VMK7MMI_6WS#EEWZ]]SYC
MT/P-XN^+_P"UE\0OA3J7QN_:J^&7A3X8?L4_L:^+?"_A_2?BS_8_C#2?&7Q+
M\=_M;:1XOUGXAS6;>*_#GB_QVUC\-?!NGZU>:A-XET6>_P!#F,4NJ65S)+<Z
M&E_'OXN>(_\ @E!\??C/K'B^5_C%\//@A^VSH>G?%#0K.QT.[\0^(OV>-9^-
MOPV\(?%_3;+2XH])TK4/&4?PYT;XB10:1;6^CVE]K&-)L[;34M;>/Z+\0?L)
M?L\^)O$%KXKU,?'B'Q/%\.O"?PGU+Q!H?[7O[77A?6/%_@'P-JGC#6?"NA?$
M?4?#/QQTB[^*$FD:E\0/&D\>L_$67Q1KURGB/4K:]U2YM95A3VZ[^!_PHN_@
MKJ7[.J^"-(T[X*:K\.-4^$=U\/=!-YX;T:/X=:UX>N?"FI>&-.E\/W6F:EH]
MM/H%Y<V"7FD7UCJ=MYINK2]@O52Y5<T=.MG%[+1)^]Z\WG\QV>O2Z?5]=O2Q
M^2W@W]I3XW^"_%G[:OB7Q[\0-:UOX.77CSP[\$O -[>M K? ;XLO^P;^S!\5
M_ EW:7Z0I)'X9^-GCSXI>*M!N9M0N'CTCXLI\.-+T>UFG^)&JS6?T)\2?BU\
M2=*_X)L?L^?%73O&>N6?Q%\36?\ P3R?7_%\%R%UK57^)OQN_9ST#Q^UW<["
M)#XKT7Q1XATW6/D'VBUU>\0;?,R/KVZ_9>^ ]]X)^-7PXO\ X>V6H>"?VB+L
M7_QBT#4-7\27]MXOOE^&/@3X.0W?GW>LS7OA^YM?AY\,_ VBV,WA:YT22PO?
M#]OXFLV@\57-_K=WO:M\!?A/KGPE\+_ S5?"GVKX6>#(_A;%X:\+_P!N^)8/
M[-3X+>(?"GBOX9K_ &W;:Q#XBO/^$:U_P1X8O\W^KW1UG^S/LNOG5;*]U"VN
MSFC=.VTE?1:I1M]]]^CT>XK.S5]T[:O1MGP;\;?A1KUW^W+\ / =C^T)^T]X
M<\%_&OX9_M7_ !"\8^&/#'QM\3Z+H]MKWPUUO]G:#PA!X9M;;CP[H^FP_$CQ
M3$=)L&6UN$N+03!OL4&WQ/\ 99UKXC?$SQOXKUWQA8?\%"O%DFF_MK_M3>#;
M/QWX6^+_ (%T_P#9RL/"/PU_:Z^*G@?PAIEYX3O/B]H_BM_!GA#PGX9T?PUX
MITZ+X?7%UJ$>D:HMC8ZS'<0W%Y^P.K_#+P1KWQ$\$?%C5M$^U^/_ (<>'?'?
MA3P9K_\ :6KP?V-H'Q+N/!UUXVL/[*MK^'1=1_MJ?P!X1D^U:KIU]>Z;_9.W
M2+FP2_U-;WY\T;]ACX ^&O$NI^*?"]S^T)X4N=8^(GBKXK:CH'A/]LG]L/PO
M\/;CQUXY\:ZI\1?&.J_\*LT#X[Z=\-(;'Q/XTUO6-=UOPY;^$XO#&HSZI?6]
MSHTEC=36KBDK6>_*E>RWO*^UGJG%?(.5WOTN]+]++];_ 'GYB? O]JSXY0^'
MOVGO@[XN^)?B'7_BE\=OVC/C1HG[(_B;5)K>YU?P?X?UW]MSXY?L>:YH/A6-
MK<+=Z5^RWH/PKT/XX7UM=0W30:#XK6W$MY#"EC;^EW_Q:_:@U;_@DQ^R#\=?
M"?QGA\.^+]4^!O[*?C7XS^-M7\/2>)OB/X^N/&?_  J6TU:PT'6I]5L='\+W
MGBF]\0ZQ<>+O$]]HOB/4&TYI=.T"QTG4]23Q'HWZ/Z/^R)^SIH/BWX6>.],^
M&>GQ>+O@IXL^/_CCX6Z]<:WXIU"^\(>*/VH_$FN^+OCOJ=D=0UVZBNAX^\0^
M)=:OI['4X[[3M 2\%CX5L]"T^VL[2WZ"W_9O^"]I\!_#'[,MOX,\OX(>#/"O
M@;P5X;\$_P#"1>*W_LWPS\-I=#F\%:9_PDCZZWBZ\_L63PYHK?;;_7[K4-1^
MQXU:[OUN+L3G/&Z:C]I-Z+9+ELODD[;7;8*+M9O[-MWO>]_OO\M#\R_B7^W[
MHFO_ /!0W]FWX/>#?VB?A9X.^%O@S]HSQW\ /BQ\/[CQ[X,M/'7Q6^*%]^S7
M\;M7B@U;0+S5X_$.A^ _AU\4-+^&_P ._"QFLH/^%B?&WQ-J6A6T)F\'^%)?
M$_[25YWXG^$WP[\9>*/ASXT\2>%[/4?$_P )O%NJ>.O &JB>_LI="\5:UX'\
M7?#C4M6D@T^[M+366N/!OCOQ5I(M->M]4L+>74TU:VM8=:T[2]1LNOTC1K/1
M(;R"SFU69+[5=5UF9M7U[7/$$R7FL7TVHW<-G<:]J.I7&GZ5#<7$D>E:#82V
MVAZ%8K#I>B:=I^FVUO:12VFHV5K*SVU=[WNOU]-D4DU>^MW^G]?GU-6BBBI&
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117RO\9?V&?V,?VBO%
MT?C_ ./G[*?[/7QG\<PZ/9>'HO%_Q0^$/@7QQXECT+3I[RYT_1DUKQ'H>HZ@
MFF65QJ%]/:V2W MX);RYDCC5IY"P!]445^?_ /PZB_X)B_\ 2/G]C7_Q'#X3
M?_,K1_PZB_X)B_\ 2/G]C7_Q'#X3?_,K0!^@%%?G_P#\.HO^"8O_ $CY_8U_
M\1P^$W_S*T?\.HO^"8O_ $CY_8U_\1P^$W_S*T ?H!17Y_\ _#J+_@F+_P!(
M^?V-?_$</A-_\RM'_#J+_@F+_P!(^?V-?_$</A-_\RM 'Z 45^?_ /PZB_X)
MB_\ 2/G]C7_Q'#X3?_,K1_PZB_X)B_\ 2/G]C7_Q'#X3?_,K0!^@%%?G_P#\
M.HO^"8O_ $CY_8U_\1P^$W_S*U^8/PV_X)]?L)ZQ_P %@/VK?@QJO[''[,FI
M?"3P1^PE^R-XY\'?#:^^"'PXN?!/A?QCXU^,7[3VF>+_ !/H/AN;PZ^E:5KG
MB;3_  QX=L]=U*RMH;K4[?1-+BNY)5LH @!_1]17Y_\ _#J+_@F+_P!(^?V-
M?_$</A-_\RM'_#J+_@F+_P!(^?V-?_$</A-_\RM 'Z 45^?_ /PZB_X)B_\
M2/G]C7_Q'#X3?_,K1_PZB_X)B_\ 2/G]C7_Q'#X3?_,K0!^@%%?G_P#\.HO^
M"8O_ $CY_8U_\1P^$W_S*T?\.HO^"8O_ $CY_8U_\1P^$W_S*T ?H!17Y_\
M_#J+_@F+_P!(^?V-?_$</A-_\RM'_#J+_@F+_P!(^?V-?_$</A-_\RM 'Z 4
M5^?_ /PZB_X)B_\ 2/G]C7_Q'#X3?_,K1_PZB_X)B_\ 2/G]C7_Q'#X3?_,K
M0!^@%%?G_P#\.HO^"8O_ $CY_8U_\1P^$W_S*T?\.HO^"8O_ $CY_8U_\1P^
M$W_S*T ?H!17Y_\ _#J+_@F+_P!(^?V-?_$</A-_\RM'_#J+_@F+_P!(^?V-
M?_$</A-_\RM 'Z 45^?_ /PZB_X)B_\ 2/G]C7_Q'#X3?_,K1_PZB_X)B_\
M2/G]C7_Q'#X3?_,K0!^@%%?G_P#\.HO^"8O_ $CY_8U_\1P^$W_S*T?\.HO^
M"8O_ $CY_8U_\1P^$W_S*T ?H!17Y_\ _#J+_@F+_P!(^?V-?_$</A-_\RM'
M_#J+_@F+_P!(^?V-?_$</A-_\RM 'Z 45^?_ /PZB_X)B_\ 2/G]C7_Q'#X3
M?_,K1_PZB_X)B_\ 2/G]C7_Q'#X3?_,K0!^@%%?G_P#\.HO^"8O_ $CY_8U_
M\1P^$W_S*T?\.HO^"8O_ $CY_8U_\1P^$W_S*T ?H!17Y_\ _#J+_@F+_P!(
M^?V-?_$</A-_\RM'_#J+_@F+_P!(^?V-?_$</A-_\RM 'Z 45^?_ /PZB_X)
MB_\ 2/G]C7_Q'#X3?_,K1_PZB_X)B_\ 2/G]C7_Q'#X3?_,K0!^@%%?G_P#\
M.HO^"8O_ $CY_8U_\1P^$W_S*T?\.HO^"8O_ $CY_8U_\1P^$W_S*T ?H!17
MY_\ _#J+_@F+_P!(^?V-?_$</A-_\RM'_#J+_@F+_P!(^?V-?_$</A-_\RM
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M?_$</A-_\RM'_#J+_@F+_P!(^?V-?_$</A-_\RM 'Z 45^?_ /PZB_X)B_\
M2/G]C7_Q'#X3?_,K1_PZB_X)B_\ 2/G]C7_Q'#X3?_,K0!^@%%?G_P#\.HO^
M"8O_ $CY_8U_\1P^$W_S*T?\.HO^"8O_ $CY_8U_\1P^$W_S*T ?H!17Y_\
M_#J+_@F+_P!(^?V-?_$</A-_\RM'_#J+_@F+_P!(^?V-?_$</A-_\RM 'Z 4
M5^?_ /PZB_X)B_\ 2/G]C7_Q'#X3?_,K1_PZB_X)B_\ 2/G]C7_Q'#X3?_,K
M0!^@%%?G_P#\.HO^"8O_ $CY_8U_\1P^$W_S*T?\.HO^"8O_ $CY_8U_\1P^
M$W_S*T ?H!17Y_\ _#J+_@F+_P!(^?V-?_$</A-_\RM'_#J+_@F+_P!(^?V-
M?_$</A-_\RM 'Z 45^?_ /PZB_X)B_\ 2/G]C7_Q'#X3?_,K1_PZB_X)B_\
M2/G]C7_Q'#X3?_,K0!^@%%?G_P#\.HO^"8O_ $CY_8U_\1P^$W_S*T?\.HO^
M"8O_ $CY_8U_\1P^$W_S*T ?H!17Y_\ _#J+_@F+_P!(^?V-?_$</A-_\RM'
M_#J+_@F+_P!(^?V-?_$</A-_\RM 'Z 45^?_ /PZB_X)B_\ 2/G]C7_Q'#X3
M?_,K1_PZB_X)B_\ 2/G]C7_Q'#X3?_,K0!^@%%?G_P#\.HO^"8O_ $CY_8U_
M\1P^$W_S*T?\.HO^"8O_ $CY_8U_\1P^$W_S*T ?H!17Y_\ _#J+_@F+_P!(
M^?V-?_$</A-_\RM'_#J+_@F+_P!(^?V-?_$</A-_\RM 'Z 45^?_ /PZB_X)
MB_\ 2/G]C7_Q'#X3?_,K1_PZB_X)B_\ 2/G]C7_Q'#X3?_,K0!^@%%?G_P#\
M.HO^"8O_ $CY_8U_\1P^$W_S*T?\.HO^"8O_ $CY_8U_\1P^$W_S*T ?H!17
MY_\ _#J+_@F+_P!(^?V-?_$</A-_\RM'_#J+_@F+_P!(^?V-?_$</A-_\RM
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M?PE^*^D6_P ,K6V@CO)_!WP_M?"7BGPB=8U_Q%HFO7-O#X>UF/2);O5M1M=
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MX(_ ;Q%9?&F^^)J_#[Q-K/[0OQ"\.W4.E_#/P_:>);VY\9:)8_LU^(XM%O\
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M$?XYZU\)-)N/!^GA?"NLZ(;>R^'/B2YO/%5_X1\-::MYJ'B0?V?\TZ+^P?\
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MM*^+_B#X]^&?PR^(OBCQ[X/\4_"?Q3^RW\?/@K?0:3?W7P!^"^/&.L^*OC-
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M=XC^&_@]_B9=+'HVO?VQJ>D^)_C!\.=*M?!CMHSZL=3UN8:[9#P[=QR[NO\
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MI<FI7S*][J#Z?H]I9VCWMXZ(UU=M"9[AE5II'*@CIJR+"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%7_@G_\ ^' _:+_^=I1]O_X*G_\ 0J_\$_\ _P .!^T7_P#.TH _0"BOS_\
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M ,$__P#PX'[1?_SM*/M__!4__H5?^"?_ /X<#]HO_P"=I0!^@%%?G_\ ;_\
M@J?_ -"K_P $_P#_ ,.!^T7_ /.TH^W_ /!4_P#Z%7_@G_\ ^' _:+_^=I0!
M^@%%?G_]O_X*G_\ 0J_\$_\ _P .!^T7_P#.TH^W_P#!4_\ Z%7_ ()__P#A
MP/VB_P#YVE 'Z 45^?\ ]O\ ^"I__0J_\$__ /PX'[1?_P [2C[?_P %3_\
MH5?^"?\ _P"' _:+_P#G:4 ?H!17Y_\ V_\ X*G_ /0J_P#!/_\ \.!^T7_\
M[2C[?_P5/_Z%7_@G_P#^' _:+_\ G:4 ?H!17Y__ &__ (*G_P#0J_\ !/\
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M ?H!17Y__;_^"I__ $*O_!/_ /\ #@?M%_\ SM*/M_\ P5/_ .A5_P""?_\
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MY_\ V_\ X*G_ /0J_P#!/_\ \.!^T7_\[2C[?_P5/_Z%7_@G_P#^' _:+_\
MG:4 ?H!17Y__ &__ (*G_P#0J_\ !/\ _P##@?M%_P#SM*/M_P#P5/\ ^A5_
MX)__ /AP/VB__G:4 ?H!17Y__;_^"I__ $*O_!/_ /\ #@?M%_\ SM*/M_\
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MM*/M_P#P5/\ ^A5_X)__ /AP/VB__G:4 ?H!17Y__;_^"I__ $*O_!/_ /\
M#@?M%_\ SM*/M_\ P5/_ .A5_P""?_\ X<#]HO\ ^=I0!^@%%?G_ /;_ /@J
M?_T*O_!/_P#\.!^T7_\ .TH^W_\ !4__ *%7_@G_ /\ AP/VB_\ YVE 'Z 4
M5^?_ -O_ ."I_P#T*O\ P3__ /#@?M%__.TH^W_\%3_^A5_X)_\ _AP/VB__
M )VE 'Z 45^?_P!O_P""I_\ T*O_  3_ /\ PX'[1?\ \[2C[?\ \%3_ /H5
M?^"?_P#X<#]HO_YVE 'Z 45^?_V__@J?_P!"K_P3_P#_  X'[1?_ ,[2C[?_
M ,%3_P#H5?\ @G__ .' _:+_ /G:4 ?H!17Y_P#V_P#X*G_]"K_P3_\ _#@?
MM%__ #M*/M__  5/_P"A5_X)_P#_ (<#]HO_ .=I0!^@%%?G_P#;_P#@J?\
M]"K_ ,$__P#PX'[1?_SM*/M__!4__H5?^"?_ /X<#]HO_P"=I0!^@%%?G_\
M;_\ @J?_ -"K_P $_P#_ ,.!^T7_ /.TH^W_ /!4_P#Z%7_@G_\ ^' _:+_^
M=I0!^@%%?G_]O_X*G_\ 0J_\$_\ _P .!^T7_P#.TH^W_P#!4_\ Z%7_ ()_
M_P#AP/VB_P#YVE 'Z 45^?\ ]O\ ^"I__0J_\$__ /PX'[1?_P [2C[?_P %
M3_\ H5?^"?\ _P"' _:+_P#G:4 ?H!17Y_\ V_\ X*G_ /0J_P#!/_\ \.!^
MT7_\[2C[?_P5/_Z%7_@G_P#^' _:+_\ G:4 ?H!17Y__ &__ (*G_P#0J_\
M!/\ _P##@?M%_P#SM*/M_P#P5/\ ^A5_X)__ /AP/VB__G:4 ?H!17Y__;_^
M"I__ $*O_!/_ /\ #@?M%_\ SM*/M_\ P5/_ .A5_P""?_\ X<#]HO\ ^=I0
M!^@%%?G_ /;_ /@J?_T*O_!/_P#\.!^T7_\ .TH^W_\ !4__ *%7_@G_ /\
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M?CK\'-(FMQ=6]IY&GZY\5/A[X0T?5-2\RY20:3IU]=:F;5+B\%K]EMKB:/\
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MOA+PEK7B'_A&]-U+7K;PY9ZX^O7^D:;J6HZ?IUU::?>2P9?PD_;J^!OQRMO
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M/J>E7VI:=K%UI2RV<LT=Z]L!,?G;]AGXIZ=\+]/^)OP4\>_#O]H[PWXZU_\
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M-]=O?C_XS\-0_"'ROAWX.L=8U'P'JGPI^)?B&\O?$&B>&[SPO97.HML@\H^
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M?@;_ (3"W_:FT?5/!WC']KG1?"WPZUSX9_MK>-/#FM>&M7^*MMK/P@AB\8?
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MTKP<P\<:!:^"C+9>'?K?XUWGQ5UK]L#XY?LW^&I_B"_P[^)_PF^ ?[0OQ/\
M$WA2_P!9FU'P?\+?!\_Q=\%?$?X9^ DTNZ_M/2/B!\=+_P"''PZ\&:/9:%%9
MZA=>&?$7Q,\5Z'<_\)+X8A+')_>6S?R5OT>G?87/O[KW2^;3\NZ:>]M^U_U?
MT77+37HK^:TM=9M4T[6=6T.9=:T'6O#\LUWHU[+875U80:Y8Z?/J6C7$\+R:
M3KUA'<:+KED8M1T>^OM/G@N9-FOYSOAA\"/VHO$?[-7Q3\:^/Q^T_I/QO\0>
M-?V5OAO\)O#,'B+XS>%IOA]XD\9W/PP\6_&#XSIX>TB_T==0\/?#SXF?'GXN
M6MUKOBJTU+PGH?@SX/31K%8:4^IVL_H>K/XL\6_&+X)>#?'TG[4NA?M-_$K]
MO;Q0?$^K_P!J_&/PC\"8OV</@[XJ^(7Q=\-^"O!5PNH6/P6\:?#'Q-\%OAGX
M,L[JS\'+KGB63QAKNH:I\0[C1O%6HS6-X<BU][:_3LK]]O/\.H<[LO=>MM]-
MW:VV_EVW:V/WNKQCQQ^T%\*/ASXRM_ 7BWQ#J-CXD?P3K?Q)U&.Q\(>,]>T?
MPOX \/1:E)J7C'QSXGT#P_J?AGP%X?+Z1J=IIVI>,]7T*#6M0L+K3]':_O8)
M8$^*_P!IU/$VI?&KQ_9>/_!W[37C+P';? [PM#^S;X8_9^'Q>TWP_P"(/C'J
MNJ_$%/'MYXS\9_">\TK2_!OC'3%MOAE:>$=>^,/B'PUX%\-:1=:IKFAZD=3G
MU^6R^3_$?[*GQ+\>^ OVDM1^*_@OQ_XK^-WQ)T[]BG]C;4O%UE_PG\,'B;2X
MO#GP=B_:#^,NE6UC<6NFM\.;'Q+\2OB1?ZEX@BL5\+!/AUK6 B7>JI?BBM+O
M>WXV\^FM]M5;S&Y/6R_I?+KI;?>Y^S_PL^+7A/XQ^'AXJ\%VGCB#0I?LS6=W
MXW^&7Q'^%]QJ=M>6R7EKJ&DZ7\2_"OA/5M3TNYMI8Y8-4LK&;3Y5D41W#,2!
MZ97XE:!X3\=>%++P7%\1_ '[3LG[/'B7QI^U]XO;X8?#'3OC=J/C5==\.>/_
M  =\-?V3?A]XPMO!MU'\0/#G@?5?@AX:U_QA9-K]_I'P[;QK>:9JWCG7+&2#
M3+R_X#4?AW^UOJOQ USPEJ%W\<? WB6WD^$&@_L]K-;_ +1_QBT[X6>%8_!'
M@?5]<\2WWQQ\,_$3P'\ ?%VL:%\0;_QQI7Q)N?CC=7WC3QGHGA>'18=*\4^&
MM3T'3=7.57W27W_KTZZ?>'.[:IM^EO/:VE^FOW'[Z45QUOXUTW5AX[M?#4%]
MKNM_#^_ET/5]'^PW^C>=XD_X1G2/%EEHMAJFMVECI-^;W2?$&B.-4T^[O=)M
M9M0^S7=Y%=VE[;V_\X&O?$7]J'P8=3^.,&A?'KPEJ9_9M_:=\=?$2Q\3_#[]
MKGPII=K\;_%WAO0O"'P<^ .M>.OCG\0#\.?B!J6E_%3XF:1/X)UCX;_!GX>^
M$+6T\"2)\,M8OM$.N:):*,>:^J6V_6X2FHVT;O?;I;Y'].%%?SA?%"S\>^ /
MAV^F_"0_MH:)X(\:?"GX#?LO>--5^)5Q\;;/XL?$OXW^,/C'\.SXN\4?"KP/
M\5;O_A((_%_PO_9_\+_&F:[\2?#_ $#3_!'BJ]\4>%_#O@J\\1Z=X5BCT3Z"
MT[X9?%7Q_P#%*Q\)_#NU_:N\!_LJ_%3]HCX0ZFU[XZU_X^Z!X[L?#7P3^$_Q
M9\=?%[QI<:C\2=17XN_"7P[\:_B:GP1^%]AI_B.Z\%Z_K^J:'XP\::#86L^L
M6FN:J^3^]^';?KOV6OR%SZVY>VS[[/;;N]+=GN?MW17X@?#OP)\55\6_#_0-
M-\-_M3Z+^T?X<_:YN;CQ;XDUR_\ CCIO[.7P_P#V1?!/Q:UD6?A;P]K^O:DO
MP*^(_A?QW^SII>A^&-,TG0[GQK\4-6^*'C$_$#QW#IGB;1-5U?0^'^%^O>./
MBSXD7XO^!M+_ &L;_P").M?MP>./BQ_PE!;XTVOP*T+]CGX>^.-4T-M$\*1K
M=6_P3\?CXO?"+P/8>%M.\!>'[?Q/\1Y?B/XSM=9OM+T_2/"6EZUI9R;Z_AZV
MZ[.V_P" <_\ ==^U_2_3=7V_$_=[5]<M-%ET6&ZM=9N7U[68=#LVTC0=:UN*
MUNYK*_OUNM:GTBQO8/#^C)!IT\<VO:Y)I^BPWLMAITE\NH:GIUM=1>*O%'A[
MP/X8\2>-/%VKV7A_PIX0T'6/%'B?7M2E$&G:)X>\/Z?<:MK6KZA.01#9:;IM
MI<WMU*01'!#(Y!VU^(WA#X>?M(?##PU\#OB1;^"OC[\0_C#I'[('[0/[2GQ?
MTC4O%?Q#\G6OVA/'MKX<M?AQ\ -(761JOAGP]>^"$^*7QC>R\&:'X;75C/X1
MT?6Y_#>M^)IK:XD^9O%'PU^-OBWPQ^T)X*O/#G[2OB[X'^*_A#^S?X$\42'X
M*_MRZ!=^-M0^)O[3>@:5\7?'D'@CXV?$+XI_%OQ]XH^#_P (/#/BW5/%=YX;
M\&>#M=\2Z=XKMXM1\":YX;D\.ZE(U!?S+?7[[::_=W!U&OLN]M-^UU?3OOV/
MZ2/#7C#1_%HO)-&BUS[-:0Z+<+?:IX9\1:#8:C;Z_HECX@T^XT6]UW2].M];
M@73]1MH]0ETJ2[32=46[T/5&L]:T^_L+;J*_"SPQX6\?^'Y_ [?&;P=^UA:?
MLQ>*_&W[7?BV3X>_"[0_VAO$'C2TUSPU\2?!WPL_9/\  _Q%TGX9)>_&+1_
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MP)HOQ/\ #?AGXS?$'X:^!_A+%\>-8TO5/C?XC\1ZM\4/BE=:-=MX+N=8\(?
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MKOA;P1XDM+7P3K2>(_ O@+4/B]\9_$/P8\ :] 9SI^K_  ^^ WB/XA:M\%/
ME_HC7,\GARY\(^ -&D\-2RO+H#:;(=U.\7_L.?LR>.O%7B?Q7XE\!:W<MXYU
M^S\5?$#P;I_Q3^+WA_X0_$?Q+91:= FN_$KX&>'O'FE?!CXBZI<PZ1I4>J7O
MC;P%KT^M+IMC_:[WWV6#8.<6]4]XO9=)7LE?2ZTW:[*V@<K_ #6[ZJU[^6^U
M^^NI^.?[6'[97Q&\(_%SP+XF\'>._BQ#I7[ WP;^!GCSXK?#_P *^'OBKX@T
M?X_^/?B[<>"M>^-/@'X@:CX3T/6?"T^K?"[]E*SU3QCX<B^(5]:V]IX\^+_A
MO7EB^UZ/%J=A]6_!SX[>,]"_:_\ VR/BY=?$O7/'G[*NO?M _ #X3?V=?:[=
MZSX0^#MCX[_8V_98\;_"KXK^ X;B62V\.^ O&/CGXBZYX?\ BC!IL:Z?/J'C
MSP5\1KTZ/I/A7QQJNH?J-X)^#GPV^'=I\0['PGX7M[&U^+'COQ7\2OB+'?W^
MK>(#XL\9^-8+*R\1ZIJDGB+4-6E-O=Z;INF:+::);O!H.C:!IFFZ!HFF:=HM
MA:6,/F/PD_8X_9N^!WPZ\=?"7X;_  U@TSX=?$S3M)T;QUX5U[Q/XU\>:?XB
MT70OA9X4^"6D:+=R>/O$GB>\BT:Q^%7@?PKX*ATFSN;;3O[*TB)GMGO9[RZN
M$Y1M;EZ);+5-IM^33O;?32Z6@*+OOY]=[67RMO\ ?OJ?C5H'A"Y\=?L;?\$M
M?BWXC^*/[1TWQ!^-GQ>_9<^'GQ3U_2OVJ?VEO#0\9>$O$6E^*[?7K#4M)\,_
M%C2-#BO-832K!]2UZPTVT\07EQ ;J?5'NIIYI?W&U;X!?#[6OAIHWPEO;WXI
MIX0T&YAN]/N=.^//QTT;QX\T$M]-&-4^*^C_ !'L/BIKL!?4+D2VFN>,]1M9
MXUM(9H9(=/L([;$T7]E7X"^'?AK\$OA!I'@5K7X=_LZ>(/!GBGX-^'W\5>-;
MM_"&O?#Z&]M_".H-K-[XCN-?\1MI,6HWJM;^+-4UVUU$S%]5@OG2)D^A*4I7
MVNM9/HM'*ZV[+3RZ#2MOV7X+7\3^?+X3:EXJ^%__  3:^%'QK\+_ !1^,]I\
M5_CO\6?A7\ ?'?QJ\??&_P"+OQ:7X:>!_BQ^V/IGP;U_XCZ1X:^+GC7QMX \
M/>(_"W@[4%L_#WB1/#EK%INM/I=]K$EYIZ:C:WOV7\1/"-U^R#\:/V-I?A+\
M3_C?XDL?CO\ 'F;X#_$[X8_%OXX_%?X\6?C?PUJOPA^*7Q N/B-H:?%[Q?XW
MU3P/XK^'.L?#_3M?U+4O D_AWPW?^%+OQ!HFOZ/.LWAR?1_MK0/V=_@IX;^"
MTG[.MA\/=$O/@G/I&OZ!=_#OQ&U_XPT/4-&\4:EJ6L:]INIGQ9>:W?:I:ZAJ
M6KZA<O'J%Y<^09UCMC!#!;QQ<C\,OV0_@)\)/%]EX_\ "OAKQ5JOC31]$OO#
M7AGQ)\3/BW\8/C5JO@CPYJAMO[3\/_#NX^,GCWQX?AUHFII964&HZ3X&'AZP
MO[6SM+2[MYK:U@BC;FG??5R=K+5->ZGVY?+Y:BY7IZ+6[TMO;O?_ (?0^7/^
M"J?@6R/[+GQ'^,&D^+?B_P"#?B%X)LO &E>&]:^&WQW^-GPNM+2TUGXL^$-+
MU-KOPY\.?B!X7\+ZS>W6G:WJ=D=3UO1M1U.*UN$AANXTMK00>=Z/=_%']G_]
MOWXF?"7X$>"/BA\:_A^G[&?[/_CFX\'>/_VHO&NN6OA3Q5X@^.G[46CZGXGL
M=1^.WBKQYJ$^H>(],\-Z+I-V--O(/)LO#FG0R+Y*0(OZ>?%/X6> _C7X#UWX
M9?$W0O\ A)O!'B4Z4=:T3^U-9T;[:=%UK3O$.F'^TO#^HZ5J]M]FUC2=/O/]
M$OX/.^S_ &>X\VUEG@D6U^%O@2R^*FN?&NVT+ROB;XD^'_A7X6ZUXF_M/67^
MV^!/!/B/QEXL\,:%_8TFH/X?MO[,\0?$#Q=J']IVFE0:S>_VO]EU#4+NRL-,
MMK)*24;-7^+1[:\MMK/2SZ]?-C:;=UIJOPO?RZH_G5\*>-/CS\8?C5\$_"GB
M72/C=XYFUKXX_P#!92;Q/\&O#'[7OQ%^#9TI?AG^TE\ =$\#Z5>?$3P+XS\+
M+XAT7X1Z=XAUGPOX/T1+DZ'8:;K%V-"T^SLV:.OWM_9Q\(W?@;X9IINJ>"O&
M7PZO)M:U?4[SPWX^^._C+]HC6;3?]GMTNA\1O'?B?Q7JQT^ZM;.&XAT2'5(]
M.TIS.\5I#/<W4DWG.O\ [!G[,FOZQH_B/_A%OB#X6\2:!XN^.7CG2O$GPT_:
M"_:'^$GB.V\1_M)^*M \;?&VX?7OA=\5/!^KW6F^.O%/A?P_JUUX>O+RX\.Z
M/+I=O;^'-*T>S\RW?U[PS\!O /A7X<>+OA3:WOQ0U_P=XX@\06OB+_A87QU^
M./Q3\62V?B?0X/#NKV6E?$7XF?$3Q;\1/#5B^F0+]@LO#7BG2+71=1FO-;T6
M'3]:O[[4+ASE&25E;Y>?K;\+^8HIK=W^?EZ7/QZ_9F_;-USQ%^V+I?Q-UOX@
M>/M6^"W[9_COXH_##P#X*U_0/B1I_P //A=I_P -8-(M/V6/%?A+5M>T2'X>
M*W[0WA[PE\5?$^MMX5U>XOO$&O?$;X=V=Y->#1X+?3??;+XB>.(?^">O_!2+
MQ?>>.O%<?BSP)XX_X*G0>%_%%QXGU<>(O!UGX+^)'QT'P_@T#6WOO[2\/V_A
M+1K/04\'PZ;=6D>@:=::5'HRVEO;6BI^A?B+X _"+Q5\,/"?P:UCP;;M\-_
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ME^,+@1>,O!6@'P_?#Q#K_P YVF@WOQC_ &.O^"BGC+QU\0_CB_BGX'?M)_\
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M7_A=\<O&FEZ3XQ_9V@LM)\/?MH_%_P" ^A_":+Q5^R5\"/&7B+PE8^ _"7Q
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *_(#X2_\IS?VU?^T='[#W_J
M[_VNZ_7^OR ^$O\ RG-_;5_[1T?L/?\ J[_VNZ /U_HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O@/]I?X#?M^?$GXBP>(?V:/^"@?@W]F3X=)X;TS3I_A
MQKW[&/@WX]WT_B2VNM2EU/Q*/'.O?%OP3?10:I:W.FVL>A#1F@L&TV2XCO9V
MOY(X?ORB@#\?_P#AD;_@L!_TF*^&?_BL;X9?_1%4?\,C?\%@/^DQ7PS_ /%8
MWPR_^B*K]@** /Q__P"&1O\ @L!_TF*^&?\ XK&^&7_T15'_  R-_P %@/\
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MUZ33]0L(;?3;%U_J;K\@/A+_ ,IS?VU?^T='[#W_ *N_]KN@!/\ AD;_ (+
M?])BOAG_ .*QOAE_]$57S/\ $&S_ ."G'P^\3>*O"C?\%;G\<ZA\/+"PU7XH
M77PR_P""/OAGQWIGPST_4],77;$^+;W1?C]*G]K3>'WB\1?\(IX?37O&4?A^
MYT_69?#T>G:MI-Q??T,5\&6>G?'?]G[Q_P#M&-X#^ ^K?'+0OCE\2$^,/@?Q
M%X?\>?#7PI:^%O%&I_#7P%X!UGPG\6(O'_BOPQKMKX?L=4\ 6^LZ5XG^'^C?
M$346\.:TNC/X8AOM A.JM).]_DKVOKKKY+43OI;YNU[:=O7^M3Y:\/?LS_\
M!67Q;H&A^*O#7_!9[X3:YX<\3:/IGB#P_K6G?\$S/AA<Z?J^B:S90:CI6J6%
MPG[192XLM0L+F"[M9D)66"9'4X85\<Z+XJ_X*PZW\9)?@4G_  4&^*FG^.K'
M2O"GB;65U3_@D%\"[?1] \$^-/%7B+P?H/CO5]1B_;)N##X6N-8\(^)Q+<6U
MO=:C#:Z'>SMIA_T=)_Z)_ 5]XWGT.RT_XB:/9VGB_1])\.6GB/7?#\5I:^!?
M%7B.?PYI=[XEU/X?Z=+XE\0^*M-\*V>OW.HZ196GC9-,UY&L)&5-3L&M-9O_
M )]TOX8>.;;]N3XJ_&*;0]GPY\2?LC? WX8:+XB_M/1V^V^.?!WQ?_:-\4>(
M]#_LA-0;7;;^SM"\>>%+[^T[O3(-'N_[5^RV&H75Y8ZE;V;5O>OT3:UMKI;;
M??\ #U!WTMW2>GKKKZ?B?E#I-O\ \%)M9^#/[/?QWLO^"R'A4^ _VFM0^#.F
M?#&27_@E9\,X]7ENOCQ%I\O@(:]IW_#2C?V1'(FIVO\ :[^?<_V<?,&)]G/%
MZCXN_P""C\,UII'AS_@K9<_$/QKJ/CSX\> M,^'?P\_X)#> O$WC.^F_9J\>
MVOPU^,7BHVD/[24&DZ9X(\+^+M3T#2T\1:[K.E1:K=>)O#MEI<%WJ>J0V%>]
M_"G_ ()W?$CP'^R]_P $XM,D?XX77QA^"GC+]B[7?C+\-O$?[37BSQ5\-/ U
MO\.8O#S?%+^R?!&K?$K4OA-<6G@Z6TO8]#T_P/;:E'##;Q1>"K>YA%LIV-2_
M9;^+6FVL]SXY_9=\6_%;1HOVF_V[?B+X=U7X ?';1_@G^UE\-X_C5^T3J?CC
MX:^,_AS\2X/CO\&O#3_#GQ]X#E6X^(G@+5/B+H7B&#5]/\$'6O#6N&PU+1]'
MOEA=ZWLW;5*ZYFEN]=$GNK]-R;RTTZ*^E[:)O\;]&9OPF^$7_!47XV_#S1/B
MC\/?^"S_ ,.]0\):X=:MXY=4_P""6/@;P[JVE:MX8US4_"_BOP]XCT#7OC_I
MVL^'?$GA+Q1HFM>&O$VAZQ96FH:+KFD:CIU[!'/;2 >)?#C6_P#@H]\3M>\#
MZ3HO_!7M='TCXM6&J:G\%?'7B[_@D!X5\,^ OC/8Z1X>O/%]Q-\//$6H_M!(
MEX][X-TW4O&6@VFN6V@WOBCPCIVH^)/#5MJVCV%Y>0_L/^R+X-^.7@G]GNT\
M._&/4KB?XB'Q'\4=2\/+XRU+0_&/BK0O!VN^.?$VK?"_1/BKXG\&1Z1H7COQ
M]H?A&^T&S^(/B/09W37]<AU&7_A)O$E\T_B[6/B_X&? 'XV^$OB=\$X_"GP-
M^(W[-FA>%];U:Z_:"T8?'KPU\1?V.?$^CW/@'Q=H]];?LS?![4?B;\0/&WPY
MO]1\=ZIX?U7PG/9?#SX#Q>&_",&M:?KJZV]S-H&L3:-Y:[-VUZ:_?T5[?+6X
M-R]VRWWT]/N[[I^?0^<;/3?^"E=]\'/@9\=(/^"R'A/_ (07]H>Y^$EI\.W?
M_@E=\,UU:2;XUV]A<^"1K6G#]I0_V6LD6HVW]JMY]P-/8N/WVS)\Q^&7CO\
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M2708(?#UEIMWJT>CH)X;;L?BS_P3K^'GC#X'_'OPOX=UKXCZ_P#&+XH_LO\
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M4 ?C_P#\,C?\%@/^DQ7PS_\ %8WPR_\ HBJ/^&1O^"P'_28KX9_^*QOAE_\
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M /%8WPR_^B*H_P"&1O\ @L!_TF*^&?\ XK&^&7_T15?L!10!^/\ _P ,C?\
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M"P'_ $F*^&?_ (K&^&7_ -$57[ 44 ?C_P#\,C?\%@/^DQ7PS_\ %8WPR_\
MHBJ/^&1O^"P'_28KX9_^*QOAE_\ 1%5^P%% 'P?^R_\  O\ ;P^&7C_5]>_:
M@_;W\'_M2^ +OP?J&D:1\/O#_P"QWX/_ &?+S2/&%QK.@7FG^,9?&?A_XK>.
MKW4[73]&L-?T5_#$FD6]M>R^((=5?489=%AMKO[PHHH **** "BBB@ HHHH
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ML:Q+H?AE\NK2:=NNO>W8+Z+1Z]-.U^Y^I%%>1? ?XC:M\6?A-X/\>Z]X;O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUY>=^M^UK]=!*4TM8W?DGY]DU;2W=NVV[U]5^)/_  6=T_XF^/O@[9_M3?\
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MZ273MV6N^UW;OWV8^:76+^2?=Z+3=)7W2?35H]HT[P[_ ,%QM7>6+2?VM?\
M@D_J<D-M87DT>G?LJ?M*7KQ6>JP?:M,NI4MOVNY6CMM1M@;FPG<"*\@_?6[R
M1_-3KSPU_P %R-.O-/T_4/VLO^"4-C?ZO))#I5C>?LI?M*VMYJ<T05I8M/MI
M_P!KM)KV2-65I([9)60,I8 $9^C/@)^R)HWP*_:877? 7P\T7P5\)_A[^R)\
M._@KX9\4:<GAVWUKXH^,]2\>:YJ_CO4?& TVYD\3:SJWA70_ ?PWGC\1^,H/
M.U#4/'7B$:->WKKKKI\9_MB?LL_M+_'KXL?%8VOP:OKR'Q+\1/@;X6\%?$WP
MQ'^R8GAK3OV?-%U_P#>>+M:U;Q7\5I/$/[26F_%+P?=:I\4=?TSP_P#"^R^%
M7AZV>TTK5O#OBC6_%!>#Q"E&+?Q65KW=ONM?Y_\ !&Y22ORW=VK*_3KMUV71
M[WL=[_PC_P#P7#^W1Z7_ ,-;_P#!)[^TY;NXL(M._P"&5?VD_MTE]9V4&HW=
ME':?\->?:'N[73[JVO[BW6,S065Q!=2HL$T<C>:_$;QA_P %K?AKJWP^T#4O
MVGO^"8.MZ]\2/BGX9^$>C:)X;_9'_:*OM3L/$?B?0O$7BJ&]URTN_P!LJPDT
M_1=-\*^$O$7B34YU%Q?C2-+N9]/T[4'"Q'U.V_8K^(.LM\/_ ![J7PP\/Z3\
M;O'O_!0/X@_M&_%#XB:O=>"M=\1?"7X6^$=2^*>L_ W1=+U^+5[W4[K3-1T[
MPA\!/"&M>%? UU=V\I\5^+[G6[&UL7U^9<;]EK]DOX@:3\7_ -C;Q-\0?V6;
M/X7:]^SE\*/C#J?QB^/>J^+OA1XH\6?'#]I7QIH7A/P'JOBA;_P7XHU[QIXF
MT'Q[;^*?BYX_L?%'C^ST;7;*>:?1=1\,>#WDT^UUQ\L?YMD]--TM.NS>FEW\
MA<TMN6UVM;/9M>5KI:O6W3<U;OPQ_P %RK"ZL+&__:P_X)1V5[JLCPZ99W?[
M*/[2UM=:E-&%:2*PMYOVNDFO)(U96=+=)&0,I8 $4DGAK_@N3$EW)+^UE_P2
MBCCL+^VTJ^DD_92_:51++4[PV2V>FW;M^UV%MK^Z;4M.%M9S%+B<W]D(HW-U
M!YF)^UI^S/\ M%_'#XH_$\VOPCOKN+Q%X_\ @MX:\'?$?PW'^RVOARP^ VCZ
M[X&N_%>KZKXG^)\NO_M#Z=\2_"=SJ7Q+UW3="^&MG\,=!MGM=,U30/$NL^)2
M\.N^DZ/\'?VB-<\1Z/\ #[Q'\%K_ $CPCKG_  4%\8?M)?&/XI:CXX^&UWX=
MUOP%X+\6>*?B!^S^?!OA[1_%VI^-=75/^%>_ 'PQXBC\4^'/"NK:%J]GFST#
M6=!CO]>T-<JM?F7FM/\ /\-[CYG>W*_)Z_Y?CM8^&]5_:K_X*U:?\6Y?@M9?
MM6?\$RO$'C*Q^.NA?L]:T=%_9#_: ETK0/'>K? CQ3^T=JESJMY>_MK6,\7A
MOP;\+_"=]?\ C'68;2=-)U>YM]!B@O-2M=9ATKZNGT7_ (+?6MAI^JW/[7?_
M  2:M]+U9[./2M2G_98_:1AL-3DU%0VGQZ?>2?M>K;WKWRLK6:VTDK7*L# '
M!%<%\'OV#/$GBO\ ::/C_P"/O[+V@Z;X*\._&G]O3X[^(9-7G^#/B/P_\8/B
M#\1/B+X-\(?LJ7%IHF@>+]9U'6M"\-_LW2>-)V'Q/T#PU<:+\2K_ %FXN-$T
MV2:PUK6/-_AM^Q-\<_A_X&T#1?BE^QEX4_:4O_$7[(V@>"_AMX&USQ;\$9?A
M%^RA\;OB1XY^,WQ(_:!\->*]%\7^*K>+3?"-]K?Q)\!Z OC_ . GAGXJ:Y<^
M#_AC;^%-$T2UT72]#.MVX0Z2ULKZQ=V^SNEIOKTTWT#FEV[]'IZJS?E_P#VO
MQ>O_  6_\&Z7K5]??M5_\$H[C4M)TNXU"#PV/V9/COHVLZQ<+I^J:AIVD6$O
MBO\ ;2\/:):W^MIH^HPZ7/KNL:/I!>TNKB^U2QT^ROKRV\_^'7Q+_P""R?Q/
M\<_%?X=>&_VL_P#@ED/%7P5\4^%? OC^SO/V3_VA?)T_QQXK\#:5\0H?"5A<
M6/[9E\NJZOH_A[6K#^VS9+)86VI&]TNTO;Z\TC6(["W9_P#!.GXJ7GP^\;:/
M\0_!UC\3OB?XB^)?[#?[/%G\5_%&K>#]5\1VO['7[/WA#X!Z!\=/B-IM]J^N
MW=_HFI?&:\T?]H2?6]"T^>#QKKMMXS\.6VO:-J$6G*J;6O?#/Q?\"/@?\5?B
M1>_!32?#7[3OBC_@IPOQD\!>$TU;X;V][\?]-U+]I+3O#_PRL_".N>#==U_5
M)=,O/V=O%+Z9J2>,].\-^(O#'B-/'^LZWX7TWP]+_P )%JZY8ZVE=W26W7K:
M^WY;O1!S/M9;O?\ J_\ 6X_4-9_X+:Z;\5/"OPAG_:A_X)>/XG\7^&?'/B33
M+FW_ &1OVD)M)MW^'\W@'^V?#^IRI^V)_:%CXCN]-^(FC:_I&GR:<8K[0[+6
M+\W4(LX8[KTS_A /^"\/_1SG_!+3_P 1$_:?_P#HMJ]/^#GP?OM$_:+^%WA\
MZHGBKQ%\$/!7Q8^*G[3'Q,MH'AM?&/[2/[2Y\'06.B6V\L8(;'PCH7BC5K7P
MS)/-=>!OAS%\%-(>)-+U#19I/TPJ&DK6[?Y_FM?2W<I.]_7^ONV^_L?D!_P@
M'_!>'_HYS_@EI_XB)^T__P#1;4?\(!_P7A_Z.<_X):?^(B?M/_\ T6U?K_12
M&?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[
M3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.
M<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1
M_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\
MB(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7
MA_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4
M ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[
M3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.
M<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1
M_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\
MB(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7
MA_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4
M ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[
M3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.
M<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1
M_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\
MB(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7
MA_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4
M ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[
M3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.
M<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1
M_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\
MB(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7
MA_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4
M ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[
M3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.
M<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1
M_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\
MB(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7
MA_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4
M ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[
M3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.
M<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1
M_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\
MB(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7
MA_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4
M ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[
M3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.
M<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1
M_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\
MB(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7
MA_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4
M ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[
M3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.
M<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1
M_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\
MB(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7
MA_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4
M ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.<_X):?\ B(G[
M3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1_P (!_P7A_Z.
M<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M1
M_P (!_P7A_Z.<_X):?\ B(G[3_\ ]%M7Z_T4 ?D!_P (!_P7A_Z.<_X):?\
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MEQ*L,2R2,(T OT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5^0'PE_Y3F_MJ_\ :.C]A[_U=_[7
M=?K_ %^0'PE_Y3F_MJ_]HZ/V'O\ U=_[7= 'Z_T444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGT/X0^+)=&_X)Q>'?%?B+5=;?Q'I:V7QJMO!U[\6M'U=O!A&G%=(LCKWP?\
M$6E6FI7DFI6]PTD<Z#;#(C=1H7_!4_PIX9U>PL/VF_A'K'[/FD^)/V3/$/[9
M7@GQ?!XWT+XH>&O$7PK\'VVCW_BS1[G^Q-.T3Q!HWC[2].\0:/>V?AZ;0+JR
MUL7$MEINM2ZHEO8W;Y)ZZ;6TTOJE+:]WHT].XN:/?_+1M?FFCUO_ (=P_![_
M *+C_P % /\ Q9)^W7_\_P#H_P"'</P>_P"BX_\ !0#_ ,62?MU__/\ ZX_P
MY_P46N[34_V?)_C?^S5\2?@+X#_:PG72O@'XX\2^*O 7B9+[Q=J?A.^\<^#/
M /Q2T#POJ]YJ/PQ\:>/O"^G7MUX8TU)?%E@-2M+K0M:U72-5@>WKQKX=?\%9
M=?\ &/PP_9.^-&O?LJ:UX8^&O[:GQ!TSX1? W5K'XQ>%?$NLO\3O%%EXQD\%
M:/XY\-IX;T?4?#7AW6]3\%:EI^J>*]+/B:#PQ;R0ZIJ6G/;$(QR2[?BO/1:Z
MM<LKKI9_,YH]_P 'Y>76ZMWN?2O_  [A^#W_ $7'_@H!_P"+)/VZ_P#Y_P#1
M_P .X?@]_P!%Q_X* ?\ BR3]NO\ ^?\ UG?LX?MI?%GX]?'[XU? W4OV9K+P
M"O[.?B[P]X+^,/BY_C=I'BB#2-7\7_#F#XB^&&\,Z+:>!=*N?%%K>V>H:3IU
M_*;W2&TVYN[B;9=1V96>E\%_^"E7PG^-?[<?QS_8BT+PQX@TW6_@];:]!HOQ
M.O[JT/@SXG^*OA\O@B'XQ>"_"B"&.X7Q#\*]3^(&A:=K]G)<7,\QBU2\2""S
ML?-F7)+739*3LT[)VL]/5>=M1\RTUW=ETN^WX&]_P[A^#W_1<?\ @H!_XLD_
M;K_^?_7*6_\ P2E_9BL_&NJ?$NR\;_MEV/Q)UWPWH_@W7_B+8?M[_ME6/C[Q
M#X1\.ZCK&K^'?"WB'QI:?&V'Q+KWAWP[JGB'7]0\/Z+K&J7NG:'=ZWJ\VE6U
MH^I7AF\'LO\ @M?\#-0\$?MP:W;> ?$2^/OV'/CQIWP<\9?"^Y\0Z3;:SXV\
M/ZU\==%^ NC_ !3\*:DUFUN?#DOBC4=0DU/3Y+2XO=$DTRVL-0F1]>T>YN/H
M#PK^VW\;/$/[76K_ +(5[^RIIND>*_"WP_\ !7Q?\6>)U^/VBZAHNE_"OQKX
MYU?P1;:]I]K'\/+:ZU?7[*;0=4U&?PN)+(RPQV\":NLEP7B?));JUE?5I:63
MOOKI*/WBYHNUG>^UD_-?H_N.C_X=P_![_HN/_!0#_P 62?MU_P#S_P"C_AW#
M\'O^BX_\% /_ !9)^W7_ //_ *^M_AO\7_AM\7O^$]_X5OXKL?%7_"L/B3XI
M^$'CW[#!?P?\(W\2?!7V'_A*?"EY]OM+3SK[1_[3L?M$]E]JL)/M"?9KN;#[
M?2:C;?0H_/\ _P"'</P>_P"BX_\ !0#_ ,62?MU__/\ Z/\ AW#\'O\ HN/_
M  4 _P#%DG[=?_S_ .MSQ-^V3K=Y\5_C'\)_@/\  #QM\?\ 4_V=K;PR/C/J
MFA>+? W@NQTOQ%XMT+_A*=(^'W@4^,M5L4\=^/D\-&#5M4TXW'A[PYI!U'2]
M+OO%<6L7<MA:^G?$']KW]GGX02^%=/\ C#\1]'^%?B+Q5X3LO&Y\*>,6>+7_
M  KX7O+FUTZ37O'T6CC6-/\  _A_3]:NU\/ZAXK\1ZC8>$HM<ANM.AUZ>6WD
M(?*^V_3=[7V5WMKL3S1UUVTN]%O;=V3UTT9XK_P[A^#W_1<?^"@'_BR3]NO_
M .?_ $?\.X?@]_T7'_@H!_XLD_;K_P#G_P!>J:S^W%^R=X>^(NH_"?6OCAX0
MTWQ]H_C'P?X!UG0KH:LB:-XM^(6E:;K/@/2=7U@:8="TO_A,[#5[ ^%[^_U.
MWTS7;QY],TR\N=3LKVSM_'/ 7_!4#]D_QEH?BWQ)K/BCQ'\.-*\._M">+/V;
M-&/COP3XNL+[QO\ $+PI!J\QM?"VGZ?HFI3WL^O#P[K[:'H/'BG_ $.QT_6=
M$T;Q'K%AH#G++L_N[[!S1_F77JNFY?\ ^'</P>_Z+C_P4 _\62?MU_\ S_Z/
M^'</P>_Z+C_P4 _\62?MU_\ S_Z]H?\ ;&_9FC^(VB?"6?XN>'[;X@>(-3\,
M:#IV@7=IKMIY?BCQKX?7Q7X1\&:MJMSI,6B:!XZ\2>')(M9T7P+KVI:;XOU"
MQF@EMM%D$\(?S;XO_P#!1?\ 9'^#.G_%=]>^*=CX@\1_"#0O'VJ^(/!7@^RO
MM<\0:QJWPST?^V_&G@?PI=>1;>&-=\=>&[)HY?$_ANW\0I=^#+3[3JWC4^'=
M#TS5M3L#EEV?W/T#FBM>9:;ZKU[F!_P[A^#W_1<?^"@'_BR3]NO_ .?_ $?\
M.X?@]_T7'_@H!_XLD_;K_P#G_P!>FI^VS^SQIOPC^#_QA\;^-X_ &C?&[PXO
MB+P1H'B+2/$0\9:C#::,FN>)$M?"%IHLWBF]LO"%DSW/B/7K;1&T'3=-%OK5
MSJ$6CW]A>W&_8?MA?LTZO\0O"'PKT'XM^'O$WCSQ]X0\*?$#P=HGA2VUKQ4F
MO^ _&]QJ%IX8\:V6K^'=+U/0_P#A$]3N=,N;?_A(IM3BTBRF>QCU"\M'U33!
M>%GV?7H^F_W#YH]UTZKKM]YXG_P[A^#W_1<?^"@'_BR3]NO_ .?_ $?\.X?@
M]_T7'_@H!_XLD_;K_P#G_P!?H!7S'^TC^T!X@^"%Y\#/#G@WX8M\5?&WQ\^+
M=[\)?">@2>,]/\!Z?9:AI?PB^*?QDU'5]5U_4=(UN**TA\._"C6K.&WCL'EN
M-1O;% \<?F,!*[LOZZ_H-Z'C?_#N'X/?]%Q_X* ?^+)/VZ__ )_]'_#N'X/?
M]%Q_X* ?^+)/VZ__ )_]>W_ C]H2;XM^(?B?\./&'PZU[X1?&+X-W7A3_A._
M &MZQH/B>T;P_P"/M-U#4_ ?CCPCXM\-W,^F>)/!_BE-$\2:9:7<]MHNM6/B
M#PIXFT;5M!L)=.BFO/2/BC\2M+^%VC>&]9U8V @\2?$GX8?#6U_M'4I-+B_M
M3XG^.]!\":4+>:+3M3:YO_[0UZW_ +/TUH;>/4[SR;&74=-CG:^@+.]NO]/\
MM175KGR1_P .X?@]_P!%Q_X* ?\ BR3]NO\ ^?\ T?\ #N'X/?\ 1<?^"@'_
M (LD_;K_ /G_ -?3?@S]H3X,?$/QIJ_P\\&?$#1=>\8Z(FOS76C6JWT1NX/"
MFLVWASQ5<Z#?7=G;Z9XGM/"_B&\L]"\2W?AN]U:VT#6;JVTS5I;.]GB@;CY?
MVP_V9H/BY/\  B?XO^&8/BO:>+K#P!>^$YX]6A>P\<:OX?M/%.A^$-0UB734
M\/6'B3Q%H%];:CX:T:\U:#4/$D;2Q:%!J%S;W,,19]GHKO1[=_0+KNNV_4\4
M_P"'</P>_P"BX_\ !0#_ ,62?MU__/\ Z/\ AW#\'O\ HN/_  4 _P#%DG[=
M?_S_ .M3XV?\%&OV6/@SX/\ CMKK_$33?&GBGX#^!?B?XOUCP!X734;G5_%&
MI_"6PFG\8>"O"6KG3G\.Z[XF\.ZDD.D>-+/2=2U!_AU*]W?^/(_#^F:3JUU9
M_9WA;Q)I7C'PUX?\6Z&]W)HOB;1M-U[29+_2]4T2^?3M6LX;ZS>\T?7++3=9
MTNY:WGC,VGZKI]EJ%I(6@O+2WG22)1II7::3VOZ7_)A=/1-?UH?#O_#N'X/?
M]%Q_X* ?^+)/VZ__ )_]'_#N'X/?]%Q_X* ?^+)/VZ__ )_]?H!12&?G_P#\
M.X?@]_T7'_@H!_XLD_;K_P#G_P!'_#N'X/?]%Q_X* ?^+)/VZ_\ Y_\ 7W+X
MFUI/#7AOQ!XBDMY;R/0-$U;6I+2 XFNDTJPN+Y[>$[7Q+.L!BC.Q\.P^5NA_
MBI^!_P"UO\;=&^#G_!,K]OR^\>^-M7^./[5'_!2GQY\*/CW++XO\47F@>._@
MYXR\82^$S\+SX.N]5NO#%IX8\&Z1I]JWPVTJST>.W\&:K;PZCH\<%Y)<23W"
M#FFT[6:2\VU)V\E:+U[VTWM,I*-O/7Y72_-K\3^G'_AW#\'O^BX_\% /_%DG
M[=?_ ,_^C_AW#\'O^BX_\% /_%DG[=?_ ,_^OYCOCQ^UO\;-7^"W_!2?_@H!
MIWC[QMHWQQ_9A_X*;>#?A#\!)X/%_BBST'P-\&O!'B&#PRGPO/@ZVU6W\+W?
MA?QEI.HW4OQ(TFZT9X/&6KW$^I:TD]S';M!_4A\9?VV? 'P,\0_">;XC:BGA
M;P9XX^!WQ:^-NO--X:UG6]7T_1/ACHG@O6KR*SOM,U&)+>[A7Q9%:?V4_AW5
MKS7+N2""QETUX9/M#E3<;=;W5ET:49->>DEKWOIM=*:=^B5M?)MI?C%_+4P/
M^'</P>_Z+C_P4 _\62?MU_\ S_Z/^'</P>_Z+C_P4 _\62?MU_\ S_Z]]^#_
M .TCX,^,_A7Q5XLT+PY\0O#=EX1@M;Z_@\9^%7TH:II.H:&OB'3-;\)ZY87N
MK^$/&6CZAIQD"7WA?Q+JR6-_!/IFL#3=0B:VKY-^'_\ P5:_9X^)?@3P=\0O
M"W@3]H6YT7X@>"/$GQ0\'63_  K\S7]<^%G@>*,?$#XE0:+8Z_>W=OX0\%ZG
M-!H%]>WPM;SQ'K4\-MX!L/&$$@NJCED[Z/1V?J_F5S+NM=3M?^'</P>_Z+C_
M ,% /_%DG[=?_P _^C_AW#\'O^BX_P#!0#_Q9)^W7_\ /_JK\8_^"F_[,OP>
MCO[H'XD_%/3M"_9ZL/VJ/%VK?!SP#J'C;2?!/P*UZ*[D\(>./%>H&XTNWTVW
M\9FPOFT'38WN=6BTZRO/$6O66B>%K2YUR*!_^"G?[-,?@CXJ_$!H?B,= ^#O
MCC]G+X?^+@/"MC]N;7OVH]*^'&L?#)M)MCKX2]L$L_BEX8'B2XEFM7TF9=22
M"#4!:1M</DEORO7R#FCW1H_\.X?@]_T7'_@H!_XLD_;K_P#G_P!'_#N'X/?]
M%Q_X* ?^+)/VZ_\ Y_\ 7!>+_P#@IK\,/A?\:OBG\(/&>C^-_%VN^'_VBOAG
M^S;X"\,?"[X<7FJ^)M3^('Q(^!@^-&D:3J%UJ/C%=/U>/4K&WO+>WUZUM/#F
ME:++-:6NN1QV5OJ'B*'TK4/^"CG[.&B_$IOAKXAF\>>'FT[Q]X'^#WC'Q]JW
M@ZXC^%OP\^.'Q%\)VWC/PK\%?&WCFVO+K3--\?W>CW^F07ZV*ZGX6T37=6TK
MPYK/B>PUW4+73Y3DEI[KU5UZ?T_^'#FCW6]OF4O^'</P>_Z+C_P4 _\ %DG[
M=?\ \_\ H_X=P_![_HN/_!0#_P 62?MU_P#S_P"O(_AW_P %/O#OQP_:C_9/
M^$'P@\ >+F^$W[2/PW_:#^)%E\3/B+X*\2>"I?$OAOX50^%/^$)\5_"X7TJ6
MVL>%O&-UJ7B(W:ZY9Z?XDL].L]"U6?1--TWQ#HUYJO8Q_P#!2/P;X>^*G[9_
M@_XJ_#KQC\/O!'[)7BCX4>"+3QG'!!XJU#XG^+OBKI.A7?AGP[X>\*>'YKK7
M6\2>,M2\5:':^ /#^GV6K'5-&,FO>(-5\.333Z'I(X26ZUM>VE[7Y=N]]+?D
M+GCWT;M?IHN;MV.K_P"'</P>_P"BX_\ !0#_ ,62?MU__/\ Z/\ AW#\'O\
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MYH;>'M-T;28O$FN')*S;BTDF];+1?/[N_2X<T>ZWM_7]:=;'=?\ #N'X/?\
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MMU__ #_Z_0"B@#\__P#AW#\'O^BX_P#!0#_Q9)^W7_\ /_H_X=P_![_HN/\
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MU?4]'LM)FUSQ==>&--NM?N/#=M9VUT\*Y7VZV^:'S+OTO\GL2?\ #N'X/?\
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M9H4^\?@G_P %,OA3\2OA1\)?& TGXB?$/Q+XX^$OA_XQ^,;7X._"#Q9K=O\
M#_P-XG\5:KX1T/Q-XF\-6^K^*-?TJVU35-&U0V?AS2+_ ,9>+GT_2=2UO^R?
M[(B6Z-.G..Z^YI]6NGFG]PE.+Z_>K=G^J.U_X=P_![_HN/\ P4 _\62?MU__
M #_Z/^'</P>_Z+C_ ,% /_%DG[=?_P _^O2-2_;9^!FE_%B;X2SWGBN6YLOB
M3X3^"^L>/;3PKJ%Q\,-"^,OCO18-?\(?"W5O%Z'RX?%NMZ??:4D:V]G<Z+8:
MKK.CZ#J^L:=KNH0::WUQ4M-;K<::>SV/S_\ ^'</P>_Z+C_P4 _\62?MU_\
MS_Z/^'</P>_Z+C_P4 _\62?MU_\ S_Z_0"BD,_/_ /X=P_![_HN/_!0#_P 6
M2?MU_P#S_P"C_AW#\'O^BX_\% /_ !9)^W7_ //_ *_0"B@#\_\ _AW#\'O^
MBX_\% /_ !9)^W7_ //_ */^'</P>_Z+C_P4 _\ %DG[=?\ \_\ K] ** /S
M_P#^'</P>_Z+C_P4 _\ %DG[=?\ \_\ H_X=P_![_HN/_!0#_P 62?MU_P#S
M_P"OT HH _/_ /X=P_![_HN/_!0#_P 62?MU_P#S_P"C_AW#\'O^BX_\% /_
M !9)^W7_ //_ *_0"B@#\_\ _AW#\'O^BX_\% /_ !9)^W7_ //_ */^'</P
M>_Z+C_P4 _\ %DG[=?\ \_\ K] ** /S_P#^'</P>_Z+C_P4 _\ %DG[=?\
M\_\ H_X=P_![_HN/_!0#_P 62?MU_P#S_P"OT HH _/_ /X=P_![_HN/_!0#
M_P 62?MU_P#S_P"C_AW#\'O^BX_\% /_ !9)^W7_ //_ *_0"B@#\_\ _AW#
M\'O^BX_\% /_ !9)^W7_ //_ */^'</P>_Z+C_P4 _\ %DG[=?\ \_\ K] *
M* /S_P#^'</P>_Z+C_P4 _\ %DG[=?\ \_\ H_X=P_![_HN/_!0#_P 62?MU
M_P#S_P"OT HH _/_ /X=P_![_HN/_!0#_P 62?MU_P#S_P"C_AW#\'O^BX_\
M% /_ !9)^W7_ //_ *_0"B@#\_\ _AW#\'O^BX_\% /_ !9)^W7_ //_ */^
M'</P>_Z+C_P4 _\ %DG[=?\ \_\ K] ** /S_P#^'</P>_Z+C_P4 _\ %DG[
M=?\ \_\ H_X=P_![_HN/_!0#_P 62?MU_P#S_P"OT HH _/_ /X=P_![_HN/
M_!0#_P 62?MU_P#S_P"C_AW#\'O^BX_\% /_ !9)^W7_ //_ *_0"B@#\_\
M_AW#\'O^BX_\% /_ !9)^W7_ //_ */^'</P>_Z+C_P4 _\ %DG[=?\ \_\
MK] ** /S_P#^'</P>_Z+C_P4 _\ %DG[=?\ \_\ H_X=P_![_HN/_!0#_P 6
M2?MU_P#S_P"OT HH _/_ /X=P_![_HN/_!0#_P 62?MU_P#S_P"C_AW#\'O^
MBX_\% /_ !9)^W7_ //_ *_0"B@#\_\ _AW#\'O^BX_\% /_ !9)^W7_ //_
M */^'</P>_Z+C_P4 _\ %DG[=?\ \_\ K] ** /S_P#^'</P>_Z+C_P4 _\
M%DG[=?\ \_\ H_X=P_![_HN/_!0#_P 62?MU_P#S_P"OT HH _/_ /X=P_![
M_HN/_!0#_P 62?MU_P#S_P"C_AW#\'O^BX_\% /_ !9)^W7_ //_ *_0"B@#
M\_\ _AW#\'O^BX_\% /_ !9)^W7_ //_ */^'</P>_Z+C_P4 _\ %DG[=?\
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ME]FWU>^NO<3BG9.^GG_P#\9?@K_P2*^.GPG_ &?/VT/A-+XZ^$NJ^)OVGOV
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MH]]=_$C4HS>P2?=7_#5/[,'_ $<A\!?_  \'P]_^:*C_ (:I_9@_Z.0^ O\
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M/^CD/@+_ .'@^'O_ ,T54I.-[.U]_P 5\G9M771L32=KK;_@?Y+[C\U_B?\
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M .'@^'O_ ,T5'/+O^"#V<'T_%_U_3[GS?\>OV#O^%W?$']J?QW_PM3_A&/\
MAI?]BL?L??V7_P (-_;7_"%8U;X@ZI_PL/[=_P )AI/_  D>?^$[$'_")?8]
M!_Y!7F_\)-_IWEV=30OA-_P4I\$Z)HW@SP7^T;^PX/!WA'2M/\,>$QXH_8Y^
M/>I^)1X:T"TATK0AXBU+2?VYM$TO4-=_LNTM?[7OM-T72-/N]0^T3V>EZ?;R
M1VD7TW_PU3^S!_T<A\!?_#P?#W_YHJ/^&J?V8/\ HY#X"_\ AX/A[_\ -%2N
MVK=%_E;\BE%)MI:O?YN_YGSS_P (;_P5/_Z.-_X)_P#_ (A7^T7_ /1]4?\
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MET[= /GG_A#?^"I__1QO_!/_ /\ $*_VB_\ Z/JC_A#?^"I__1QO_!/_ /\
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M;TZ)/\3/V?\ 4-.N+VU?3O&#'2KA=7_3;_AJG]F#_HY#X"_^'@^'O_S14?\
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M ,-4_LP?]'(? 7_P\'P]_P#FBH_X:I_9@_Z.0^ O_AX/A[_\T5 'O5%>"_\
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M2YDLO#_A;XC>#_$&MWB6=O+>7;VNE:3K-W?W"6MI!-=7+0P.(+>&6>4K%&[
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MK5= =])L+W1=!T75+SQ#?ZY;<6G96;DWMTULD^BU6G=.[V)2=]7=6M\]+O\
MKY=3\D_#7[&_A/X\_M(_M[^'=$UWPU\'-)^!GQ>^%?@#X3>&/!?[,7[%NO\
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MT5K*[LM[2V5NK<;MM[+:P[/O^+[KK?R?1;GX>_M&>&_!G[-?QRD^!GA/X8?
MKX@7GB/X)_LH>"_ 'B7XN?LZ_L_WD6E?&3]IC]LWQ'\!9/BYXZ3X??#+X<V^
MK6_A+PQJ&G7$7A31X?#VB:W+X:TK2A;6>I:UJ.M3>]^+OV8/ W[)_P 3_P!F
M-?%&E_"[]HWX>?M!_&%/@!XST+XI_LQ_LGZ!XD\)>+?$7PZ^('CKPCX]^&>I
M_!GX&_"R--(M=6^'\VA>*_!WC&T\8L?#FM)KVE:[IUYX;ODU_P"_OBQ^QQ\&
M?C=XW\>>-OB1;^)-<E^(?P7\)?!#6M!@UL:/I&GZ'X%^(^L?%CPEXN\-W^CV
M=CXN\/?$7P]XXU:+6M$\5:9XHA?1KW1-!U#2+.QU73SJ$V=X-_9!T?2/B'X*
M^)WQ+^-?QS_:(\3?"V'6D^$J?&;5?AJ-&^&=[XBT6Z\,:SXAT+1/A5\+OA;I
M^O\ C&[\+W^I^&D\;_$*'QKXOLM$U?7++3];M%UW66OSFC9;;>][JU=G:SZ6
M?IWUV%:5WZZ:[*_;K=?Y:;GX:_"3Q/HLG_!.;X6^)OBE\'OV<W_:6\5>&?V(
M_BYX:^*5K^S=\#-.A^*OP>^/_P ?_@7X1\>7$'AI/ /_  BEIXF\"MX]\0?"
MCQ[9:-I"_P!F:7JWPX^($/\ 86H_$72+33/U#_:G^"?P0\.:[^SK\&/A;\ /
MV;O!'C+]I7XMZO\ #[_A9-[^SY\)O$3?#_PMX.^%/Q"^+_B_6- T/6/"\^A:
MKXVU+2?A^WAOPE;Z_8ZIH-C?ZU+X@U;1]:LM#ET;4/3M?_X)U? ?Q'^S?^SC
M^S+J.K?$=?"O[+<WP@D^&7C2RU[0;/XCRV_P;O\ PW?Z3I?BC5X/"J^'M;T3
MQ8_A31D\<:(OA:RTO5)K.PU?2K30_$&A^&]8T7Z6^-'P3\&?'3PUI7A_Q;+K
MVE7OA?Q1I/COP+XR\(:O)H'C7X?^.M!CO(-(\7>$=:2*YCL]5MK/4M4TNZMK
M^RU+1=;T+5M7\/>(=)U;0=6U+3;H;BVFE;WIMZ:6?PZ=4M';IJ@M*UK](J]]
M7MS:]&]5?S3/QB_:=^$OA#]D/3?B;X.7PE\'_BY!XY_8M_;$^+WPH\=^/?V:
M?V8;/XF_"KXN?LW?#[1/$EI<3_\ "N_@SX#^'_BSP/KMOXMM]0M[;7/ $NH:
M'XE\/VUC>ZAKFB^)H]/TCWW]D?\ 99^!GBF\TS7O%?PE^)&N"3P)I^IWFE?'
MW]E+]D#PA\/-2U#5H-,>2ZT"_P#AY^S]X/\ $EUJ-K+)+-IUL^O"R.GRSRW=
MM=ND1C^J]2_8@\$>+=(^+</Q4^*7QE^,/C+XO?!'QW^SO?\ Q-\=ZG\.K/Q;
MX(^%7Q(TV2P\6:%\-]$\ ?#3P/\ "_PK=ZM.-.U?4]9'P[OM5U[4] \.GQ-=
MZW8:)86$/TWJ7@>&\^&VH?#73?$7B;PS;W7@>Z\#V'BWP]=Z;;^,O#\,^@R:
M!:^(M#OK_2=1T>#Q-I*-'J>F7=YH=]IL6JV\$UQI-U:J]FZ;5K=>KM;IOM_E
M>UQ*+YKN]ELKWL[^O;UM>W0_GV_9J^*W[-?Q*_;FUOPQKGP]_8Y\1_L^?M$>
M,OCE\*?V9_ 6C_"W]GZ?Q5X \4?LK+H>E3Z_X@@TSPU#XS;3_P!I1]+^.GC;
MPS<^*9+FRAT#X?\ @6U\/VMB?$CS:OC? CQY\-_"\'[=]A\9/@'^SG\1O$VA
M_%']H[7_ -CS3+W]G[X+^'_[9T_PK^V%\4_V-_!7[/ML_AOP+HYU4^'?B7X>
M^!UH^OZPFI>(KI_CWI::CK6H&UBCM?V2U/\ 83^ -Q\&?@[\%O#NC7W@#3?@
M)J_P4U[X6>./!$/AG3?B/X;UCX$ZKH&H^%;_ /X2'4/#.K66I3:[::%)X?\
M'"ZGHUW%XG\/^(/$ME<1P3ZF+NWY%O\ @G+^S_/XL^"WC2_O/B!J6M? K]HK
M]H/]I?PB;O7=$2TU+QE^TA\2=;^+_C'PQXIM[+PQ:'5_ /A[XEZAX=\9^"-%
MADL=5TO7?AUX O\ 5]>UZ?2+]]6KFIZZ/9):?RMM/3^964NNK':>FO5]>ZV^
M3NUZ*Q^#'[.7A^3XD>-]$^'WQ/T'QMXMD\+_ +.][KVL:S^R]^QA^Q+J6J>)
M/'6E_MS_ +;WP0O/%OC:Q\5_LY^)K+1+?4/ GP8\ Z5I&F^'8-(TT2Z+?74M
MK-J-U?7EU]P?%OX<>&_A/\7_ -B/2? GP%\%^.O!%Q\!?VL?C1\?/AW\5?V7
M/V>H?C5\5O"_PR\9?LPZ.D;VG@CX5>&H-"^)7PY\-?%[QAXG\(^&?!.D:1:>
M/+_0M.\#:Q:7-[K\&OZ9]R>$/^"<?ASX7>+Y?&_P8_:;_:9^#^NWO@O4_ >M
MOX6C_9H\36NO:%J/QZ^.7[1,9U"W^*_[-GQ&%K>Z9XX_:"\=:?87&AOI"OX9
MM_#]AJ46H:EI]WK&H_1FA_LXZ?:?$3X-?%OQ?\4/B=\3OB1\%?AY\:_AKI'B
MKQDGPQTN;Q7H?QT\5?##Q5XBO/&&C_#;X9_#_P -/J_AUOA'X1T/PE/X4T3P
MI90:*-3;Q%I_B36[T:U 2E"]TEL]+-:M-;6LM7NG=:.V@)2MJWOWZ77]6M^9
M^('Q$\/_  X^(_[1,?PS^&>D?!KPC\+O''[?O[//PI\*>,?AG^S[^R[JVI1_
M!+X@?\$Q_&W[2][8^%M8\;?!?QWHE]8^*OB1HVC^+8]>U+2=9U-;&5]-TG4;
M+1YUM%P_VOOAC>_L_2_%W]FCP):?!SQ#XP\5^'OV-/&WP/\ V@O&O[+/[*LW
MQ%^&;_&7]N#X=?LR?$SP=XNTKPO\$/#WPM\8:)-H_BFRU?P5J]Q\-K#Q!:P7
MOBNPU*YUJ]TS2-9M_P!1KG_@F)\'+#6=8\1_#KXH_'/X0Z_??M1:7^UIH.I>
M!]3^%.K1^!/B%I?P4\7? :+PQX-T7XG_  C^(OARS^&;^"O&_B"6W\(ZOHVM
M'0M2EL+;PMJ>@^&M)TSP[:]U>_L#?#;Q);>++_XC?$KXR_%+XC>-O%W[._B;
MQ#\8/&FK?#Z'QW)I7[+_ ,8]!^.GPK^'FC:9X.^&WA+X9>$_A[!X[T6ZNO$6
MB^$?AWH5_P"(D\2>(;Z_U<^(I].UW3'S036S26J<=6[QU;^3NKZWVLP:E9]W
ML^;I9Z?TOGH?DY\2_B!\)_B':_\ !/F;X/\ [/O[._P]U#QO\1_V;]=_:WT:
MW_9_^#&MW.AP_$/]H+P_^S9K7P!U$Z]X)U<:.NM>/[+X_P!I<Z]H;V/B*RU#
MX#3VNFZO;P:A>&5?^"=OPB\!?'3X6?LK?$SXG?#_ ./?B#Q+\0_!O@KQAXSN
M+W]C7]AK1?V<]<U*^TN/5=3B.OZ'^S+IWC"S\!:G(CVUM=:;XELM9-O/"L&J
MP3N+A?U3TG_@G+^S]H7B#XF>)M'O/B!I^J?%7]J[X:?M?^(FBUW1)8++X@?"
MSQE;?$;0_"&@0W/AB==+^&6I_$"7Q7XTU_0,W&MW7B/XB>.]0L/$VFMJ]HFF
MWO@'^Q/K_P"SEX2^%/PW\!?MF_M4WGPK^$%AX8T'PW\-?$NB?L>:AH6H>$?"
MS6R6WA#7M>L/V2=*^(=SI.H6%M_96I:CIWC72O%9LYYIM/\ $>GZF(-0A3E#
ME:22=W:Z=[.[W2>S=E>VB6H)2O=O\?3IIVO\S\E=#U/PMX<^ ?[?NK_$3X+_
M +.4VNV>L_\ !3W4/V/?B1#^SE\$;$^&-0_92^(/QX\*:9\&=5L4\"#0-=\1
M>"/"_P //#/Q+\$7VNV.HZKX^\,I\1(-<M+^'X9:KJNL^H>.OV/O"-S\>_V)
M?"^E>+O^$9\-?M/^&/BWXE\<Z'HG[.O["LMKX?N?!?PH\.>-=&LO!-UKW[)6
MN:II^GG6-4NDNTU_4/$EY/9>7 EY%(GG']*/&G[ WP2\??LW?%[]F#Q#J7C^
M3P1\8OB/\</BKJ?B6RUS1;#X@^$/&?Q[^)?C3XH^*[_P)KUOX:73])@TK6?'
MOB#0M"M-3T36XKOP7<S>%O&7_"7:;J>O+J_L&H?LZ^"=1\<_L[^/Y]4\4IK/
M[,^B>,] \"6T5[I*Z9JUGXY\&Z9X'U:7Q;"^B/=7]S;Z3I-O<:<^C7N@Q0ZB
M\\MS#=VS1VD:YH]$OM?97\B4>_VM7YZ]1V?Y=?[UW^'X:=#\*_V_?"O_  JO
MQG\.]-_9Q^$_P2N['X:_&#X<?#SQCH=Y^S?^SOK&L?'7Q)X+_9-_:@_:W^*/
MPWUNZN?A9Y.D:E\1?!O@#X%Z);ZEX,A\)2Z5J7C75Y])&BQ?9S'WOCKQ/^S[
MXH_;6_9=L_@]\&OV>[S]E6?POXEN?B7::'^SU\&-5_X6OXG\9_LD?%#]I_PM
MI2:IJ/@BYUW1KGX>_#_PW\'O&NF6_AS5-'778_C+%;ZY]NMK"UA3]=]0_92^
M'>J>(/ASXGO=8\9RZU\-OVE/&G[4NG79U#0RVO\ Q \:?#KXG_"B31O$X/AP
M_;/!GASP%\4;SP_X9T[3CI.MVEIX2\&+J7B'5?L&L#7?)/@;_P $Y?V?_P!G
MBT^"MA\.;WX@06GP*^+7Q=^,/A.'5]=T34O[4UWXO> _$OPNNM \2R#PQ;S7
M?A'P'\.=?L/!7PXTO2I-&O-"\/>#/!NGZEJ>N1Z9>_VFU*%E=:I26V]T]7YI
M[/I?R%:5]]&T]]K?UKWMYGYNV/P&N]3_ &%U_P""BD%M\ 8/%-]^SX/VNM/_
M &:W_9<_98/[-D'P^?P&?BW:_!R^\0?\*9?X[/J[^"63PW?_ !2A^,D21>,-
MWBBW\*)X:B;P=-U'PE_9>\$?M8_%_P#;*U+PKJFB?!#PW\._''P-TCX,^#?#
M'[,'[%FM^&/#>D_$']C7]GCXU3CQAIGQ"_9N\7^+?$DMQXT^(^O7>MVD?CO1
M[@V5R^E:+J6A&WL[VU^\)?\ @G9\,'\+7/PB3XL?'NW_ &7KS4)[JZ_9*M_%
M'@=/@G+I%WJ;:Q>>!$U9OAP_QSM?A;=7LDD,WPKLOC-;?#T:%+)X1B\-Q^#W
M.@5T.L_L3";XE?'/XB^!_P!J']ICX0VW[16O>%O$?Q+\"?#2;]GVS\,3ZGX4
M^$_@;X,6<WAG7_%7[/OBSXK>#GN_!/P]T".YN?#/Q*TR^LM6-YJN@7>BW$EO
M]E.:.NR>O*^39732:L[NU]=?7702>F_G[V[L]?+7I^&A^!OQ ^*NG>+_ (/Q
M>/-$^!_P-^'&M:M^RQ^QEXFU?2OAC^S9\!=?NM.^*'CG_@HR/V9?C-XD^&MO
MX\^&OBDWH\:>#M,U73O ^C^)1KNFV%G?Z1=QVTFLK+JLWV1\2_@I\-OA5^S!
M\8/BGX;^'7CT>*M(\;_LY^&M';]J7]DO]C?PTVFV7C+X^_#SPIXHN?!VG> O
MV>?!\.J#5O#&OZKH>KW&O'5DTY;JTN-'AT[4E6^'Z'^)/^";W[.FMV>CZ/HY
M\;^!/#/ASX6?LZ?![P[X6\&ZQHD.C:+X-_9B^/>F?M$_#U;9_$'AKQ#J]UJV
MI>--)M],\8ZKJFJZA<:[X<ENQ#_9WB2YD\2GZ:^/'P4\*_M#?#'6/A/XTU#Q
M!I?AW6M;\"Z]=7OA>ZTZRUJ.\^'WC[PQ\1=&CM[G5M*UNQ2VNM;\*:=:ZFDF
MG2RS:5->P6DUE=R07UL.4/=M'2]WIT[;._W_ 'B49:W>MM->OZ'Y(_"W]ENT
M_:T^'WQ.^/O@)/@?\#)(/BS\?O 'P,^%%A^RE^RWXA^%MKI?P%^+7C?X.:;>
M_'N7Q?\ !OQ)\5?$5_X[\1?#W5-?\6V_P^^)/PU_X1OPYK=EHGAU(-;TBY\0
M:IX%^VY\4/@+\ OVC?!&D:9\-?V+_"W@']F+P)\,/B?^V5X%F^%?P(75/BA8
M_'?X@Z/X#B\,_#^#Q7X6C\7W$WP8^&FE_$OX_P![:^$WLM8U.%/AUINKS/9Z
MR^E:E^LOBW]@WP3XAG^*>E>'OC/^T#\+_A9\<]?\0^)_C'\$/AOXI\"Z7\._
M'.N>-<GXA7T&JZ[\-_$?Q7^'+?$:22ZN_&T7P>^)GPZAUK5=2UC7&C@US6M6
MU*\[7X=_L4?L]_#O0?BUX;B\%V/B_2OC/XHUCQ!XMB\;Z7X<U:2VT:_\%^'/
MAKHGP\\/R6.@Z4=(^'G@7X;^$?#7@3P5H2B>ZTOP_I$!O-4U+59[[4[I<T+W
M:NND5%*R:2=WU:5VGKJT[WT3M*V]GU=][7>BZ7TOY:>9^>G[<'[(OPP\.>(O
MV=O%?PKO]!^'6B?&K]ISX)_!G6?"O@[X ?L8ZSX0LO!OC6PU\:QK'A>Z\<?L
MS>-?$L>N:B=(M;^#4-0\4ZSI<<MQ<&UTM+62&"'QCQ-X;\&?!34OVO?AG8_#
M#X%?%#Q1X8_:._8;_9G^!7C/XO?LZ_L_R)X.UK]JW1?A+H>I^-O&]K\-/AE\
M,M-\2V?AK7?B'JGBN+1X[+2QK%SINF>&(+G3X-0>Y3]<;+]C[P';_"+]F3X-
MZAXV^*'B+1/V4_%WPK\9?#_Q)K^M>&;OQEX@OO@[IM]HW@ZQ\>ZI;^$+33];
ML!I5ZMGJ\VF:1H6L:F+.UN9-6COFO+J[L>)OV./@SXVN/VEV\96_B3Q)8?M4
MZG\.=:^(.DW6MC3(-!UGX4^%?#/ACP/K7P\U3P]9Z-XE\*:YH4_A#P_XMTW7
M5UV^UG2/&>GVVN:)?Z6;:TMK<4HI)-7M?[*U]]-/O\/2_EUN#4GMI\_[KO\
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M%\7@RQ$]EI4'@)O#Y\+?\(W;&UFBN;:R70"=-C>"XCN8X</'.LP$@^?/A_\
ML9^&/!VO?"O5O$_Q?^-_QCTGX$Q,/@GX*^*>M?#Z?PE\-K]?#=YX,L=>M+?P
M)\-O >L^-O$VC>#]1U/PYH7B3XJZWX_UK1K+4]2O-.O;?6;^ZU25)Q_&Z5KW
M23LK^MF^GX U+3S5FT[6;:N[;Z*Z77\3\_O '[./A?\ :+^"OB/]JW1U_9W_
M &?-!UR?QOK7P/\ A[=_LS_LOW?P?TGP'X4\0ZSHG@[6OV@]>\:_"76OB)K$
M_CN#1(O$7C-O GQ!^&]OX3T778]#\/[M7T:;Q'JOG]M\)/AU\4OCM^T;9M\&
M_'GAOP'\/_BKH'PC\!V?[-'[(_[(OB?X?+?>&?AIX"N/B?J>K>*_B?\  +QC
MK]S?0_%77?%VB^4]]:V^GZ5X?M97LX9KF6*+],+#]A;X;V"#PJ/B!\7KOX$Q
M^.IOB-;?LR7FN^$)/@K:^)9O%<GCP6ZF/P+%\5;KP7!XUE;Q);_#'4?BC>_#
M**Y$6FCP>?#\$&CQ^_\ P;^#WAKX(^%-6\*>&+_7M7AU_P"(GQ3^*.MZSXGN
MM/O-<U3Q7\7?B+XF^)?B::[N-+TO1K$VEIJ_BBZTK0K>+3XGL?#NG:1I\\U[
M<6LM]<MN.MM>VB5EZV=WIKOUL]1<LG:^G=\S=W;LFK*[\MDFCXX_:"\%_L=?
MLR>%? ]_XA_9&^#7C!?$NMP^$%\17GPN^ '@[PWI5Y;:'>ZD=:^(OC[Q;IOA
M#P+X0BUIM-;3M-DN);*'5O$VHV6EZ?8VT$LLEG\Z>*/C]_P3I\*:EJECJW['
M'P@TY/ ^C^"]5^,$>N> ?V5= UWX9W'C72-+\0Q>'QX5U+Q-'KWQ&U_PSX<U
MC3O$?BR'X7V?B[2[;2+NWC\/ZOXDUR:/0S^DOQC_ &>-+^+NMZ3XGM_B/\3O
MA=XET[PGXI\ 7NL_#>]\%M_PD?@3QE-I5UKWA;Q#H?Q%\#_$+PM=VLUWHUC=
M6&L6N@V/BG19?M:Z-K]A#J%_%<^1^$_V!O@_X U?3W\">)OB5X1\$6LGP_NM
M1^%NDZKX2E\*>(-1^&G@[PCX"\-7^I^)=5\%:E\7[,3>&/ GA/3_ !'I'AOX
MGZ!X;\5G2YI_$6BZE+K7B!M5%R6UO?Y_UZ?CV&^>^EK?+^O4\'\17G[*%C9?
M$7Q3X2_X)X>!O'?PM^&FI_$OPSKOQ9TOX4?LYZ5X1?Q5\)['7_\ A,XK:RUJ
M\L_%K^$M"\4>&]5\!:OXV'AQM-L?%EE>"*VO= LKG7H_%?A[?_LX^&O 'P9U
M3]HK]D[X:6'Q8N?V>O#7Q4\<>!O _P "?V?]2L/%/B_XT?$CP_\ #3X1>!-,
MT:'PD-4;Q9XP\47-_8?#G3K7Q)H.G:?8V^KGXCW\]W92WVD?;?B3]@+X5>*]
M#\=^#=8\??&63X=^,(?CC)HOPXM?%'AJQ\)_#37?VBH?%L/Q4\5>!C:>"XO$
M-UK>K+X^\;C1X?B%K_CW0/"D7BO6[3PQH>E6-T+6/L/$?['/@'Q<WB?4_$?C
M3XDZEXS\2:)^S[ID/Q!CO?!6D^*/"^J_LSZ]KGB[X9^*_"=MH7@;2_"6EZRG
MC/Q+KWBO7M+G\+WO@K5=0U2[TU/"5IX8E.@47C_5[[?\/>WE8+3_ *:MOZ>E
MK^=SY'UCQ3^Q[X5OK_PAXS_X)[>"_#_Q9L_'?P5\%6WPH@^$/[.WB+7]?A^/
M-QXP3P/K_A_6_#U[J/A&YL5A^'7Q#;7(M4UW1GT.3P7K%SJ4MMX?:Q\0W?I?
MA#0_V,_$'PI^.'Q.\1?L9?!KX?\ _#/>L?$;0_B/X?\ $?PD^">H2V-[\-?"
MUEXSUB?3];\+V.NZ%J>G2:#J=DYNK>]WV6HKJ.EWEO%=:;.&]P\,_L=^ =$\
M>^%OBKKOC/XE_$/XE^'?'EQ\1]1\:>-]4\*3:AXP\2)\,?%OPB\-KX@TOPUX
M,\,^&-,T3P-X,\=>+8O!WA[P+H/@W1M,UCQ!K&OW5EJ&KZIJ-W=Z^J_LH?#W
M6?@+\8OV>KS7?' \)?';5_C%K'Q%\00:IHD7C/4W^.7B[7_%7CBQM]2'APZ1
M;:<UMXBN_!VD0G0I9=/\&VNGZ:T]S?VQU61>[Y[J[U[ZV7IMUU'[VNVSMMVT
MO\]^ED?D_P#"#XN_LL?#'X"?#S4/VP_V,/ GAGX@_P##+_P\^.&L>*=6^!G[
M,]HWQ)UOQ?XE\%> )?#VA^&O#\]HO@S5]9^)'Q T#0O!6G^.K3P;!>:(]SK/
MB6X\,?V#XE73?9]$^,7_  3_ -6\%?$_Q%-^QU\ ;;Q'\*=6^'&F>(?#%KI?
M['&L:&UO\5VU9?!VNGXM:=XQD^$>E:)&_AWQ/%XE.O>,M+UC1)_#6IQV^C:M
M]O\ "[>(_N'XM_L9?"?XS^(_&7BSQ7J'C&UU[Q1X1^"GA/0[O1+WP]:Q_#0_
M /XD>*/BSX#\0^ +*^\,:E8P:W)XW\3)?^);?Q7;>+/#/B/3_#OA[0M0\.MH
MD&IZ?JO(ZE^PCX+U/2?"#2_%_P"-4?Q"\$?$JX^*FA?%U6^#=QXJMO$=UX)U
MGX=S6L/@?4/@W>_ 33-$7PGK^IV=KI^A?!O27T_4;NZ\1Z=<VGB6_P!2U>]=
MX/5IIOHKV^7ET_(FU1:732T3=KOIKY]5]SU/DWP!\6?V&?BUIVAZ=\)_V$_A
M9\3/BAKGB[XE>%HOAUX*\!?LMZ[81:?\(K7P5=^/?B OQ3L]<D^%U[\.M//Q
M'\":-IVNV'B>YU+5/%GBG3_"Z:';ZE9>(!HGSMIWQ3_9:\(_!#P;\=?BG^RS
MX5GC^+OQF_:6\;_#?X=^'?V?/V=;7Q1IOP6^$OB[4OAEX$\ >+-/7P/K37Z^
M*]?U#X=QQGPQJEWXHG\;>/M"M(?%USH*7&GWOZ2^&_\ @GO\/_!2>';[P3\9
M_P!H;PGXVT74_CM<ZM\3M-\6>!;[X@^.-%_:+\>:;\1_B1X6\9:OX@^&NM6%
MYI[^)M$\/S^&O$.CZ3HGQ#\+0:%IZ:/XUMYWO[B]F'_!.[X(&P_9NTJ7Q#\3
M;G2OV7O!'P]\"> ]-NM<\,3VNO:?\/OB=\)OC!'JOCGS/!QFUC7O%_CWX)?#
MK6/&UYI<VA6NKG16BL['2UNIBSO#L[7\[VL]/F[;:VW"U1]KV[JW37Y:^6UC
MYWN?&W['.G>*O%/PQU?_ ()W^$].^-&G^,/AYX-\$?"1/A'^S/JOB/XB7WQ.
M\*>-O'&@W%AK.C:YJ'@WPW;^'_!_PX\:^*?B&_BCQ'IT?A#P_HT-XLNKW.MZ
M%8ZEQ^K?&/\ 8ST'PQXCUWQ%_P $Z_ WA.[\*_'G4?V=]?A\:?#G]F'PIX5T
M#QMH7P]T3Q_K.J>)OB?JVJQ?#CP_X/G&N6?ACPEKU[XC_P"*M\2S6UC9V=KO
MNVL/HK]H7]EW6K/QB?B[\(_#?Q2\6_$OQ/\ '.'XR:MXW\"_%'X3>"_B5\+]
M5TCX":?\!M$TCX>Z-\6/AYK?PJ\5_#C5O!^GZCI7BSPKX_:^U"RO_%NM>+]'
MFU?5ETRUT3&^#?\ P3^U32?A+X2'CKXQ_%7P+\=M4_X7KJ'Q:\:?#/Q1X.\2
MR^,++]HKXA7/Q!\7> O%#_%/X:>-/"_BJS\.1Q^'?#&C^,K/P5X;\46L/AQ[
MKP[?^'[+5[S3I#W+)ORTN[WZZ7V_'Y;'OWLNE];*UNFK5F_32WFM?H;P#^SC
M^REX[\%>%O&3?L?_  8\(OXFT/3M:?PQXJ^"7PBC\1:"]_;I.^EZQ_8>G:YH
MDE[9LYAEN-%UK5](NMHN=,U.^LI8+J7Y!\[]CVU^(-WX3\-?L6^#OB;XB\:_
M&KXL?";P;X5TSX-_L[6NFVLWP!\$Z-+\0_$.CZEJ&@>&(=+\%0>,+E_#NKW_
M (S\1:CJ,/BR6]@TUEMY]!\.2_HE\*?AC/\ "BSTWP/X>U-[3X/^ _AO\,_A
MC\*_ K20ZE+X?TKP!I%[I$^KZCKUWI<7B*]U#5-,;P_HAM-1US7+6*W\+1:Q
M'-#J.OZE;P<%\-_V4?A]\,/$WASQ?H6O>-]0UWPMX;^.>@:5=:]J'AZ] O/V
MBOBYI_QJ^*/BRXCMO#-BLWBO6/&6DZ9'#>_)I\&BV46GR:7<.\]U+/NZ_A^.
M_P"!7O:?B]/+;IKK^&A\5>&/%7[(7Q$T?0W^%7_!.WPC\2/&4_@K4_'_ (T\
M":'\)/V;-.U'X?Z!IGCOQG\-K>+5-=\0ZMI'AC6]8\7^+/AWXYM_A[I_AO5M
M3C\4:9X9O];N+O1=,DLI[JAX<T7]FK5?VW=>^"\O[+?P7D\(WW@KP%X=T#PT
MWP&^#MHWA/QWIW@/Q;\:?BIXJ\67$GA;^VQ)!X3\;_L^>"XM%MKZZM-/U;Q#
M'=FW3[9/<O\ 3&G?\$_OA-HFA>'?"OA_QS\8/#_A:U^$?PY^"/Q%T'2/$OAB
MWM_CIX!^&%WXAO\ P_9_%/49/!4VO1:E?WGC#QA)XIU?X9ZO\-[WQ/;>*=8T
MK6)+G1GM-.M-K4OV(_ \_P 2=5^+7A_XH?&?P-XX\0Z_\3=6\1:OX1UOP-;S
M:QI'Q7T;X.>'_$OA 2ZU\/=;NM T:TT7X#?#33O#NN>$;GP[\0M#M=$>*T\;
M[;F0!^YKZ.V^_G_P/GU%[^GJKZK;[OSZ_(^,KSXN?L2W5IXAN/ 7_!/?PC\4
M7\">%_B'\3OB3#X0^#_[.EFG@3X-^"/B9\3?AIH/C[4;WQCJ'A:QU/4/BO<?
M"/QUXF^&/@C0[C4?$6L>&- U'4-730RMA'J/SQX(^(G[.GP\\(_L5:3\9OV4
M/#7Q+^.OQP^#/PS^(FO>"/A]\ OV:;2SU'Q)^U#XSM8/A]X-UNPU#P3H$UMK
M/@71-*^(3:+>Z?XA\)>&H] ^''C'4_'>HZBR6VL:7]]^(/\ @F!\(M1\!W_P
MW\*?&+]HOX6>%_%/[-7A/]E?XG0_#GQ;\/K"_P#BS\._ UAXOL_"VL>--4\1
M?"[Q-?Z?XYL)/'WC*[OO$/P_G\#P^)#XAOM*\5:9KGAP6VB0>RW7[$?PAN_V
MC_"7[3<NI^-O^$P\"P>![7PKX374?#P^'ND6?PX^&WQL^%_@RSMM(/A=M;6V
MT/1/VAOBMJ=HG_"297Q#XC^W[OL]G;V*.]/LWN^M[V:2OT3>NG3?4+3[]NUM
M]?PTU/D+P?XV_9#\<WM]X%\._P#!.OP5??'72OB+\3?A]J_P;A^%_P"S1)>:
M1%\)+#P)JGC+QQJ/CQ-4/@"+P59P_$WP)HMO>Q:[-K%WXTU\^%+?1)+G2=;N
M].^@O@A\/?V/OCA\'(_C/IG[%OPN\,:1<7_Q!L[7PMK_ ,!_A3/XUE7X>^+?
M$?@^_P Z/H6DZM;O?:GJ7AF^?2K"RU"]:[BELS!/,MS$[>6?$K]DWQY\,=;L
MM5_9LT/XH:GXPU2?]I7Q-?\ Q<T;XQ_"SPGXEN_%O[2?Q57XI>*O!GQ/T3QK
M\+]2T>X^$=KK2:$OAGQ/\.;-_BSX'T3P=IFB^'T:\DO-<U?ZW^'_ .S/X:\.
M_LF>$/V5?%6H:CKFB:9\']'^&7BKQ#I6IZCHVMZWJ<>A067B+Q?8:Q;S)JFF
MZYJVOF^\30:BDWVNVU2Y6X)9U(*?+TZM=7=+KIV[=>XTY7=^B?I?I\^_0^!?
M!7Q5_8B\<:/IMUI'[ /@*\\2>+O$FA>#?ASX(T;X9_LN>(O$7BKQEK.C^(_$
MFI^"-=32/$%Q:?"[QE\/?"WA76/%7Q/T3XFW'A=/"F@01W-K?:Y=S1V)PO&F
MM?LM7OBGX=Z99?LI_!WX43_#7XA?'W5OVH_".O?!'X#ZSK&F^ /V>_V>_P#A
M8FN:/::OIFC^(] N=(U[5_B[\ O$MEXDT/5;6]72-432KU](U*?5=+M_L\_L
M*>$I?$LGQ*O?C5\=K_XYQZUX4U?2OCU/>_".#X@Z);>#/"GCOP3HOA^UT+3_
M (/V7PCU/0SX9^)OCG3]3C\3?#'7M2UA]=6_U/4[K4='T"[TJ"^_X)]?!?4]
M*\9Z=J/B7XI7U[\1?AK\4/AIX]\27OB30KOQ'XMM/C7XF\)>)/BOXGU6_N?"
MDL*^)_&\/@7PIX4OA86EEX8TCP3H6E>&?#'AG0K'3=.%H>YY_C^O3MUOKH+W
M[=/P7IMKZ]+:'@?@/3/V9-8M-'\/^$?V ])^+L_A32/A;'\8O%G_  IO]F&V
MU/P%XD^)OA;PWXUB\,ZW9+:^!XO%WC#PEX4\7:!XF\=V'P_\+#3M(T/5-/;3
M!J.LW']AIX%IGB?]GV^\?^ M;\.?L=?"[7_@1<_!3XW_ +1/C[5-9^%'[+]O
MXE;09_B5-X%^"&C:";C0_".E:;X4U3^P_$%[H%WK6IV=[=Z?JWAR]\5>+S8>
M'?&.JO\ I7XD_8Z\#>(?&?B[Q1%X_P#BQX<T+QSXST/XG^)_AGX9UWPQIW@#
M4OBOX6\+>'/"7A;XD.D_@V\\81ZSX?L_!O@S4[3P['XP7X=WOB+PGHFO:UX)
MU74(;F6ZX#4_^">/P@N]/T72=,\;?%3PYI?ASX1?L[?"+0=.TN[^'-_9:7:?
MLL>,+SQO\&_&$5KXJ^&OB."Z\4:)K&JZV-7TO4H[WX<^*(=9N)_$/@'4-4T_
M0=2T@3C]_D]/^#>]K=D%I_=Y_P# VM:]SX0\:?%7]F?QWX+OM"_9Z_8M_9UU
M3XOI\<_@%\)FBTSPQ^RCX_\ #,6G?%;5K[7M4U#0_%_A*]\4^#M2UVT\ >"_
M'=I<Z+J%Q!>>%-8&G:]K-A<>&EBO+[UO2]9_9(U7XC?'+P;\./V$O#_QH\0?
M"[Q!J_\ PF&AZ)\(OV8-*\,^"/#OA!9?",]YH6N>);/P0;RY\8^.?"?Q&TG0
MO#.IZMXB\17NO^"?%MY=W/A7PJNB(?K#P_\ L,^"M"\6:;X^D^+?QM\0>.['
MX]Z!^T+=^+/$>J?#74+[6_%.A_!VZ^!9\,:CID7PNM?#=KX#U#X?ZGKEFNB:
M!H>BZAX7U#7=0O\ P!K7@]XM+CT[+LOV /ASHB>)H?"7Q6^.W@JW^(VG^(=*
M^,D?A?Q/X*L[CXQV'B7XB_$GXFZB/%VJWGP\O];\/:F/$'Q;\>VD/B7X5:G\
M.?%7]BZQ'I]QKEPVFZ9<6A>']7\M^MK)V\WJ%I_TUY[=+ZZ^FA\MZM\6OV$5
MT3Q9XS\%_L)>!OB'\.O OP^^"'Q0\6^.="^"GP'TK3=)\)_'3P[!XO\ #4,5
MAXK;0=5UCQ7;^%=3T#6I?"6AVFI:I)%K=G;RBRN+K2DU7IOC=X>_9B\'_'#P
M)\//"'[*OP<\21:-J]CI'B3PGX,^!7P1N?$/Q,^*?C[PIXEU7X=_!FQU+Q9H
MNG:%H%AX?\!Z%XS^/WQ4UZ;6]"O_  KX6\+?#T_:;W3O'$NDZE]=Q?L:?"*U
M\&>-/A_I\WBC3/"OCSXP?"KXOZ[IEA>:%!$)?@TOPBL_ _PZL0?#KK:_#*ST
M#X)>"/"MUH.V35YO#BZM91>(;>?43=PVM9_9+\%ZEH^@QZ9XV^)'A7QWX:^+
MWB[XY:/\8-!OO!MQ\1H?B%XXTCQ1X6\0W]X/$W@CQ%X%UC2YO GBV_\ A]8Z
M%K/@?4-)TCP;I_AW3-*M;.?PYHU[9KW>SZ[W?3=_.^P6EW73MWV7X;GR5-/^
MS6=3U7P;IO\ P3)T+5_BCX.\,7'C?XE_#^V^%'[+]J_@3PDVKZ_H_AK59_%N
MI>(++PAK\_Q&E\*^([OX>:1H.KWFIZI8:+J%UXCM_"<<(+\3JWQ:_8171/%G
MC/P7^PEX&^(?PZ\"_#[X(?%#Q;XYT+X*? ?2M-TGPG\=/#L'B_PU#%8>*VT'
M5=8\5V_A74] UJ7PEH=IJ6J21:W9V\HLKBZTI-5^LC^P=\.[&/4K?PG\4/CK
MX$M?&7@RV\#?%]/#'C/P_)?_ !MTF'Q!XS\476H^/O$?B7P;XB\5Z3XIU76O
MB+XYNM3\6_"[7?ASXCFC\27-G#J5O9Z?H=OI77Q?L:?"*U\&>-/A_I\WBC3/
M"OCSXP?"KXOZ[IEA>:%!$)?@TOPBL_ _PZL0?#KK:_#*ST#X)>"/"MUH.V35
MYO#BZM91>(;>?43=POW.S_'Y_P# _'4/?_JWRZ??^!\#:#J7P,TOQ/\ 'C5_
M&/["7P>USP=;?M8^%?V6_P!GGPSX.^$/P#O/$/C+6[70;2R\;7"27%AIT"3V
M7B;3_&&O:I>^(M8TO1-&\/:?;:?-=6$^A>*-0BZF\^(G[#.@?%3PM\)?&G[%
MGP&\+>(_$/CGPM\,KJTDT/\ 9*U7Q!I/C3Q7;V;6Y'P^T[Q!)\1]2\':1J%Z
MFCZ[XRM?":V-I<VU_J]I:7_A"U_X2:3[:\&?LE>!O!FJ^$-1C\8?$/Q#;^ _
MCQ\:/VA_">C^([WP?-IVE^.OCI8^/;/Q7;S3:3X+T?6=9T;2IOBA\0=1\+2:
M]JVJ>)-,N?$]S:7GB/4]&T[0M*TK@]'_ &"OAMI'BOPIK9^(WQ?U+PIX'^,'
MCCXW>&/A/J.H_#H?#RU\:_$.W^($?B5]7.G_  UL/'7C*U:\^)/B#5=)N/''
MCCQ+KV@7\=@FBZW8Z<E[I]\>Y^'2_:R_*[[ML+3_ !ZOSN^GG9>B/B_XN>,/
M@-;?L[^//C)\'_\ @G#X O\ 0=;^'NJZI^S_ /%#Q#\(/V=(?!?C3Q!K.I:7
MX6^&^LZCX>2_G\9:1X=\8ZMXBTGQ'X,AUK0;*\\7Z!%]DF@T'5M4TJRN_J#X
ME?#+]EWX#? ;1OB=\1?V-/@]K>M6EEX&TSQ5I&C_  <^")DT?7O$4NF:3J>K
M^*O$;:/I/@KPYX5T#4;N:_\ %GBR2]M_#NCZ=;W-U:?:(OLEO/MG_@GM\-V\
M':+X,G^+7QXN['P-I?PT\._!^]OO$/P^OKKX,>$OA-\0O!'Q-\'^%?!>FW?P
MSF\,:_IJ>)OAMX#76M1^*_A[XD^)_$.D>%='TC6?$%Y9VVQOI;XM_!NQ^*Z^
M#+V/QOX]^&WB[X>^(;CQ+X-\=_#J]\-P>(=(OK_0M4\,ZM:SZ9XS\+^-?!&O
MZ3J^B:Q>VE]I/B?PAK=DLOV74;**SU2PL;ZW7NZ+I=WWO;I_P;=1^]KWLK;6
MOU[?+R/B+X<R?L2>/M4ATVZ_8S^#/A..V^#7B;XW>(-6U'X7_ +Q!H&D>$-#
M\82>$]&U&P\1>!QXG\/>)M&\<PZ=XD\3>#_$&A:K=:?>^'_#]V]Z-/U-I=-M
MOAZ'XR_ .T^*/Q?^+.H?L#>$]0_98^$_[+7[*GC_ .(=AI'P2_9CCD^#_BOX
MPV?C?XK_ !#U_P 5SZZ-!\4>*-?\'?"#7?A#>:CX,\"2>)H[/2X/$6H"U35]
M0\,V?B7]$KS_ ()M_"EO#'BWP=H/Q8^/W@SP_P#$;X3:C\(/B9:^%?%'@.TN
MO'^C:GXR^+7Q#NM=U35]1^&NJ:QX>UV7QM\;_B-KUU8^ +_P=X+U,:TFA:QX
M0U'PO9V^AI2\9_L!> K&[^+?BO2/$OQZ\;>&?BCXU\)?%#XC?LQ:=XO^%>D_
M#/XM^(_AUHG@OPOX!\.:C>>(/ ^F>*-&\*:!X;^'W@O09?"^F_%#PSX8\6Z'
MX;M-)^(5MXML9[VVO*7L[N^J>FS[Z]=';9[+KU%[_I;M;Y=-N_?[CP;Q-XY_
M8&\">)O$6D3_ +,?P>\0>)/$7Q?^)'PW\$^%-?\  /[+7@?PU':_ K2_"FC?
M$_Q9IWBWQ?I_@K3-%\&Z?XQU@Z!/'XG\0^(_%^K>-YKNR\.:6=%1K;1.F\.>
M+OV+?B7I&@77P._8%\"?&?7K[P'=_$;Q7X5\*_"7]FNPO/ .@V7C3Q=\.QIV
MM:YK^L:;X2UCQ1K?C7X?>/\ 0O"6E^$=?\0:=XC/@W6]7@UNVT Z7JNI>O?#
M_P#8;AG^&7P:N_&_C'Q+\/\ X\>%=%^*%YXV\7_#%O &O1ZAK/[0?CT?%[XP
M^&9X?BG\._B!X;UG29?B&\5UI/B6/PQIOBFR.G"YT35M'AU34K2Y])U[]B7X
M:ZS>;[+QK\7/#.BZU\//!7PJ^)WAC0?%VFR:=\:/ G@#5?$VL>'M&^)&M>(/
M#FO>-_-:Y\:>+H-<UCP/XL\$ZYXFTSQ'J6D>(=2U/2S;6ELO<\[_ #MIZ='T
MM\] 7/Y6^5]=>NS[_@?/O[+OPP^#OQL\:_M-:CXI_8T^ ?A7X;^"/B[%\-_A
M-'?_  <^##:A=6WA+PMHUKX\?5X-,T&ZU&/68_'<VM+>QW\XM=-M?[.T"U0Z
MKH_B"5^;^,/BO]C/X1^+/BUH'_# /@KQUHGP/E^#D'Q)\8>$/@M\!FTO2;WX
MS:A!8Z%H.EZ?KIT76O$_BRVCU;PQ?_\ "->';#4M0O+3Q#9A?L]S/I=OJWZ'
M?!?X-:+\#] \4^&?#OB/Q5K^D>)OB;\2/BDD/BN3PW<7'A_5?BGXNU/QWXHT
M32+[0?#7AZ]O= 7Q7KFN:KIC^*I_$OB2T35)-,?Q%<:/8:-I^F\)J7[*?P[U
M=_&$FHZQXSNF\>?M'_#W]ISQ7YNHZ&PU?QK\+(OAS%X&\,W&?#I+> -#_P"%
M4>!I(-%).JM+I&YM?_TB8.KQN]--+)7\O^#\W<=I66NNMWIY_P!>A\):Y\0_
MV+_"TGC/1_&'[!/PB\"^,/!7CC0_!FJ:)X]\.?L?>#]#LAXC^']A\2=*U76/
MB!K'BZ'P1I[_ /"/ZGI]K>^'[/6-7\20ZQJ&GQV>EZAHUQ)KEOYM;^/_ -G#
MQ[XR^'GBOX7_ +$GP,N_@;8?LN_'']HCXJ7&I?#3]G6VU19_!GB*]\%>#]%B
MU2&VUK2QHTGB#P3\0%A\0^'M4O\ 2?$\<V@Z]I.J7'AG2]:DG^]]9_87\ WW
MQ1\0_&?0?B;\8_ _Q)\6>(?&^L^(_$_A?4OAU/?W^F>/-#^%OAO5/"ED_BWX
M:>*3X9TG3]$^#O@;3]!UWP@?#_Q"TNVT^:)/&TB3(L.-HG_!/;X2^'_ OBOX
M<:=X[^+R^$O&_P"R?H/['_B:QEUKP1)=ZCX"\-/XV?2O&"ZN/A^NKV'Q%S\1
M_'#:I>Z;>VG@WQ!/XAN+WQ!X(U._M-,NK%^YYW^?97_5H5I_+U5]W;IZ7/SP
M^&?[0/['?AGX;>&(/C_^R%^S^OQ,\(>"O 7B#]HV]T[P+^RIH5IX$UCXA:5I
M_BRUT_PYX/U;5=$\6^-Y=$\'Z_HOBK6-%\&:!KVIZ#X;OK#2KJZUKX@IJ/AQ
M/O?X6?#_ /94^+?CKXE^&O#G[#GPCM?"'PO\<^*_AQJWQ/U;X2?!6U\,ZWXP
M\(#18-7TGPOID>G3^*-4^Q:EJ&I:9J.I2Z-9Z%9WNB7=E'JUYJBWFFZ?W^G_
M +$_@?3_ !E<^+X_B3\5G37M:\(>+/B!X:B;X6Z5H?Q(\<>#_#7ACPK#XP\0
MWN@_"W2?%_AVZ\0:;X.\/-XK\*_#'Q5X ^'&NS6EPD_@E++5=6L[[Z"^$WPM
M\/\ P=\'?\(7X;N]8U*RD\5>/_&E_JGB"XLKO6]5\2?$SQ[XD^(_BO4=1N=/
MT_2[266[\3>*M5EA\JQA\FT-O;MYC0F5QN/1:OULN_\ P/+S!*6EWHO1M_/S
MZ^9^<%UXW_8 T_QSX$^'^H_LC?!FQUOQE\8_C?\ "?4)[CX._!^+3/!-G\$-
M9UW0]2\>^+;^31TBT[PWXKO-,TQO"T)SJ5[;ZQ/<O;K#X?UR2T^<]/\ B;^S
MO<?$#XO?$T?L&^#=3_9Y^&_P8^!&N7^CV?P,_9UTZ]\/:I\3?$7C[Q+-XOU1
MO$=MH7B'4?$FO?";4?@WKNA_#31)=5U.RM=;N[36;/2-?N-/@U7]"?%O_!/+
MX"^-KOXK7NOWOC^XF^,GQ8\*?%/QEY6NZ-$K0>%XM4CE^&6E?\4TSZ?\,O%/
M_"3>-Y/%NEJ\OB34Y?'GBAK;Q78"32%TCT[5OV3_ (;ZUH_Q-T2^U7Q@UG\7
M?CK\._CWXX,=]H4<VI:W\,+KX42>&?!,3CPX5@^'/]F?!KP?X=O]$"-JUQH+
M:S:0^(+:?4C=0EX=G^/=7_5(+3[KRV\[7_-GP[;_ !6_X)T7WQ97X;:=^RO\
M [_2/^%RQ?L_-XYA\"_LSJDOQ4EUP^$FL+'X=R:HOQ7U#PM;>-BG@BZ\8V_@
MHZ8/$+/<VL=WX3MKOQ1;\D_QO_85&G>!=1;]A7X0:;%\6Y_&DGPBD\5^#_V6
M? MEX[\-_#[7;O2/%7C\:GXQU;1+#PWX&M4?PXVDW_B*:PU_Q7?>*]*@\(>&
MM?TF*\U^#[J\-?L7> _"'B;4]:\.^/\ XJ:5H%SXE\>^--#^']C?> [+PMX1
M\8_$>_U[6O$/B#1M6LOA];?$75U@\0>)M:\0Z%X9\<^//%_@C0-7N;6;2_"]
MO!I&BVVG1ZQ^Q-\-;GP_\$-%\)^+/'_PXU#X!?"T?!;P7XI\*)\-]6UN]^&D
MEAX0L[SPYXCL/B-\./'O@^_>]F\"^&]4_MRQ\+:7XBTS4[2ZFT'5M(@U/4[:
M[/<\_P >W^>_EL'O^7IIW_R/-?"_A?\ 8C\<_LV:A^TOX0_9.^!.H^&K#P=X
MZ\4/H%[\)_@K9:BE]\.KCQ!IGBKP]<ZW;6&I^$A-INO>&-9TB37-/UW4_#5S
M]D.IZ9JVH:5+;W<_Y;?L]_M%?LG^"?ANUW^TW^SA\)_$WQ#LM.\%_$/XXG4/
M ?[#?AK2_@E8_%?0=#\9>'/ OPZ\&:;IWP[^('Q"T_PGX#\0:%XN\0:5:Z-\
M1?'&CZ=J1L+_ ,3:_P"-7D\&:?\ O5XR^ ?A#QG^SYXJ_9LN=7\8Z1X&\8?#
M37?A5JVM:5KPN/'(\.>)=$NM UR\A\2^(;/7FE\0:C87UZUQK-_9WTYN[N:[
M"";8R>1W'[$'PR'Q-UWXA:)XN^(WA/1_%OBSPQX[\9?"SPS<^!+'P%XH\6^$
MO#_ACPOIFJ7.K7'@"\^+.@V=UH?@SPO8:]X7\&?$_P ,>#?$<6E2#7?#M_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^+_A[XM:M\1M2+^&_CGXP\#SZ;HL?@6V^"OQ=\$_"7P_H%\L$@U^Y^)=W?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS3-<M=-NY'AL]7?1-8M=/U9M&O9HY(;/68[-]+NYHY(K>[EDC=1\F^(O@_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW5_!5QX:B@\=KJUHNERS6MOH;:D89S]DU>SOU==0"M9F20'=&8S\0?M-^.O
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^!UQ=IX\DC6XTW_A._B3?Z<DAO\ PM=)'[)\9/#'Q&\"^$_VC(!:_!V3X/\
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MM \<*DNNW>B6>B:KXSU;6+#5_!EQ;ZY/I,&F:5-'?:K!<:AJG46NJ_'SX/\
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MGAO0?%_A75;/7?#/BC1].U_P_K>GR>=8ZMHNKVD5]INI6<N%\RUO;.>&X@?
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MCPIX=N3>:26>FVNW]>77]1<R5]'IJ_3IUZ]/G>Q]O45\0?"3XW>++KXF^&_
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M8Z5-;ZEX:@TR%7G2&].M-&^;B.T!2;;6O]6]'?[F#44F[::?GZZ:N^C2/5O
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MT_X71_#VQ?5;K4KS7;;6WU;5!>4/$'[.WBG7O'%MX]7]J+X_:-JNEP>*]/\
M#UEI.B_LROI7AS1/&.H:)J&K:%IT6L?LY:O?7EBC^&]"@L[KQ!?ZUK4-OIJ>
M9JTT]UJ$]W].447?Z;+;[A\J[=;[O?ON>)_%;X-W_P 5O#.@^%YOC!\3_!5I
MI%QI-]J=[X-LOA&^H^+M2T'5-#US1=1\0-XT^%7C*RM9].UO0;?5(X/"ECX8
MT^YFN[VVO[*[TTVEC:=!HO@/Q3I7@S7_  O??&KXF^)-<UE=1&G?$?6M*^#<
M'C/PH;VPAL[9M L?#OPET#X>7+:1<1/JNG#Q3X#\2K+?W,T>K+JFF+;Z;!V7
MB.PU?4]#U*PT#76\,ZS=6S1:=KZ:;9ZPVEW!92MT-,U#_0KTJ R^3<?NSNR>
M0*^?O@<_Q9N?&WQAL_'OQ5'C?1O 'C.#P'I.F+X%\-^&6GDO/AS\+O'ZZ]=7
MVD$W#7,$WC'5-(6Q7%G):I;W+@W,9).FZTZ6_P"!^HM+K1W>E[]EZ_H9GP]_
M9E\5_#_QQK'C<?M9?M%^+7\4^)=-\5>-?#?BG0_V5H_#WC+4-*\,Z)X/M(=5
M;PG^S)X5\1Z79CP]X<T6QDC\)>(?#4[FQ%W]H%Y<WEQ<=OXF^!:ZGXJUGQCX
M+^*OQ3^$&J^*GLI_&=O\/+GP#=Z-XNO].TZUT:RU?5-$^)/P_P#B'IFG:['H
MUAIVD3Z]X8MO#^L:AINF:5::G?7D>E:<+;W>BB[W_1?Y6_ =E^N[_P [_B>'
M:W\#;+4M(\(6VE?$;XI>%_%7@>37'T/XDV.OZ-XG\<&+Q.ROXEL]2D^)7AOQ
MWX7U73M8EBM)#IM]X7FL=&&G:9!X:M]$M=/M((HO 'P*A\ >/M;^(<7Q1^*W
MBS5O%/A70_#/BO3O&FK>$]8T?7[GPWJ>O:CHGB3R[?P9IVI>&]3L$\2ZOI\6
MA^"=3\+^ #;73W3^"WUEY=5E]CUF[U&QTN]N])TE]=U*" O9Z0E[:Z<U_/D!
M8/MUZ1;6JG)9YI=P5%;:DC[4;RCP1\5/$>L>-+CX>^/_ (;W_P ._%$OAR\\
M7^'G3Q)HOB[P]XF\/:7JFFZ-KDEAJVE_9+VSU70+_7/#ZZMINJZ-8QF#7M,G
MTF^U55U%=.-;/\=O^'^X5E=::Z6W^7E<P]0_9[AN-9UVXT?XP?&CP=X1\3ZY
MJ'B77OAQX.\0^%=$\-W>MZU<&]U^^T_Q*O@N?XL^%SKVHO<:IJ-OX/\ B3X?
MM!J=Y?7UE;V=Q=SN_2?&/X2ZC\7] NO"Z?%OXE?#;0-6T/Q!X<\3:;\/[+X4
MW"^*-)\1V2Z=>0:I=_$?X7_$/4+%[>R:[@LY_#=WH,R"_N)+A[F:.QEL_'$_
M:D\7#0O&?BN?X >+SX6^%FN^-=(^)^N6?BCPU)%I5OX%U;4;77=0\%V6HG2=
M1^(*Z;HNGCQ!J::=::;;J)SX>T6]U_Q58:IHMC[!X]^*^H>']<T?P;X#\"ZM
M\3_'&LZ/+XE;2--U;1_#VB^'O"\=RME#X@\5>)M;G6WTRUU6_,FG>'[#3[+6
M=;UR[M-3ELM+.EZ)KNI:8]=/PV_'\-P]VS[/??S6GXK33<ET+X1F'P;XF\"?
M$/XB>./C7X>\4Z>^CWEO\1[#X9Z;+9Z--926%UIE@_PI^'7PR017,4@E:\OH
MK[5;6YCBGT_4+-T%<UH/[/5K8:YH&J^+/BS\8?BEI?@^_@U7P;X2^(FN^%+S
MPYX>U:R5DTO5[A_#7@OPQXB\;ZKHP<S:/J/Q-\0>.+S3]22WUVWF7Q!:6FJP
M<K^S[XV\0^*?B5\?-,UZ#X@:'-H&H>!)KKP1X_O-.U.3P9KFO:;K^H:GI_A?
M5-&DNM&U+PCJ%A'HFJ:'=Z5J6H6_V:Y%O>'3]9M]5TC3_J^D[K2_Y=5^'RL"
M2=G;[[]'_GKK<\;\-?"*\\,>*/BQXJM_BM\1]1N?BO=_VA+IVI6GPM.F>"-0
M@TJWT+2KWP6-.^&>G:B\FBZ-8:9I]C#XVU'QG:7$>FV]SK%MJE]/J-W?=!\)
M_AW#\)_A[X8^'5KXI\3^,;#PGIT>D:9KGC!?"ZZ_)IELS+I]G>-X/\,^$-#E
M33;3RK"VGBT."[FMK>*34;B^OFGO)OE[XZ?$;XQ_#_XH7^I^#/&UOK/@3P#X
M#@^,GQ5^'LW@K2+NXTGX=:?XAT/0[O3])UZU9-?G\0^*]"TKXM^*O#.X3JVI
M> )=#^SR07T31^I?M(^/_B#X1^'7A_Q%\*-$LO$TVJ>/?A-93Z@GBNQT**/1
M_$/Q-\$Z8(;6:YTC6;?4K3Q7::G+X?GGB$7V"QU1]4C:<0K&79Z:K7^M=%T"
MZ5]'[M_Q>MM7U^X^D)%+HZ+(\3,C*LL80R1E@0)$$J21%T)W*)(Y$) WHRY4
M_+^G_LX>+;#QE<>.O^&K/VAKS7;_ $G0/#^J&ZT/]EL6FIZ!X;U77-8TS2+B
MWM/V:;3R(%O/$FMF:[TZ2QU6:*_,9U ?9K)K;UGP;XC^)FKZ9KMSXS^&FF>#
M-3L8U;0=,L_']IXJBUV0V]Q(T=QJ%OX>TI-&5;B.VMQ));WNY;AY]@$!23P7
MX$_%#]H/Q7!>+XJ^$FDG25^+7Q6T#4/$S?%;2[JZT#2-%^*/BO1H]/M]$M_!
M]M)JT7A>RLH]%LW%Y;2:K;Z?#=,\!G(1*ZOMY[?A>_X VKJ]];VWZ>ENYZIX
MQ^"L_B3QK?\ C_PY\7?BS\,/$FJ^&O#GA/4V\#WW@2^T>]T;PQJ7BG5=.63P
MW\1_ /Q \/0ZB]UXNU,7.LVFF6^KM;Q65M!>V\,4R7'=^ / >C_#KP\OA_2+
MK6-3,VH:EK6KZ[XBU!M6\0^(M?UJ\DO]7US6]0:.%)[Z^NI6*PVEM9:9IUI'
M:Z5H^GZ=I%C8V%LOC?6_&6B:?!-X*\#Q^.=2EE=9+"?Q1IWA2VMHE4$2S:A?
M6M^S&1B42.WLIR"K&0QC:6XGP]\;=%N_ 7CSQMXST75_A[-\*KS7=-^)'A_5
MFL]:OO#U_H&BZ?XDF%A<>&Y]4M_$=KJWAS6-%USPZ^D^9J&IV>L:?:2Z99:V
MUSI%L:M>6W2_^?H/1/SU[V[OR]3VJO"_%7P.;7?%6M>*O#7Q9^*_PPE\5IIO
M_"::1X O? BZ3XMNM)L(M(LM3O'\9> ?&.LZ!JZZ+:V.CS:KX'UCPI?75AIV
MFK<SRSV%K/%A0_&GXGV]WH$VO?LV^/M'\.^*/$?A;0+#4[;Q-X(U_6/#L7B;
M7=.TD:MX_P##>BZO<W'A[3]+M;Y]1U.;0KWQ?#8"V:'4IM/A,M[!XGX=^*7Q
M@\&_%S]I7P!X-^&WQ2_:!MO#/Q&T/Q+;WNN>-/"'AO0_!^@>+?A;X#\2'P)X
M2\0>*IM,AUG5FUV]\07>B>$H(QI^@:9)9OXI\5>'X-7\/MJK2?E]Z[V\U]_R
M$VGT;U[.ZT;71/5=OF?4_B_X0>'O%_A?PMX>EUGQEHNH^!9-/N_!/CO2/$]]
M+\0?#>J:=I4VAKJR>)]?_MV;7[W4=(NKS3_$,?C"W\1Z?XIM[Z\7Q+8ZL;AV
M-?X??""R\$:UJ?BS6/&OCKXH>.M5TZ+1)O&WQ%O/#DNJV7A^&Y%ZN@:'HW@O
MPQX*\%>'-,GOECO=3&@>%=-N]>N[;3Y]?N]4?2=*-EY??_M,ZIJ9^#%Q\,/A
M)XB^)&E_';X;W7Q$\'7B^(-$\)W&EV]G:^'-5N;/QE8Z^$_X1^"'2/$MCYM[
M'<ZE<IK[P^'QI3R3&]AVOA)^T2_Q4UGPS:S?#+Q?X'T/Q_X(UOQY\/-:\3WW
MAN2Y\0:1X7U#PII?B%-2T31M5U*Z\/3"Y\9:-=: ;BXO(M=TD7FH,^G-%;VU
MT6=O+Y?\/NMO+8+QOY_/LK>6S5GYK4ETC]F'P-HO[4GBS]K6V\2?$6;X@^,?
MA;I?PEU+PM=^*S/\,[7P_I6JZ?J]OJ>E^$S8+-::^]QIL$<ERVK3:=&L^HW%
MKI5MJ&JZE>W7T?7RW_PT5XGU*TO_ !EX0^!7COQA\(]-N-04^.]+UGPG!K7B
M+2M)N)[;4_%7@;X>W>J1^(?%'AB%K:ZGTZ9Y=)U_Q58VQO\ P9X=\1VNH:#+
MK&UXU^/-]H/B3X<Z%X+^'FJ?%&S^+'A#6/$O@?6?"^NZ7;6EY<:2= N]NJRZ
MI%;Z?HOAF70?$%OKK>++S5/+9(AH^FZ5JOB#4-&TO4DT^O:W32W3RMY@G'IZ
M[/6[WVUN^J/:_%&CZCX@T'4='TGQ7K_@?4+V.)+;Q5X7MO"UWKVCM'<0S/-I
MUOXU\->+_"\LD\<3VDHU;PWJD(M[B9H8H;I8+F#R;X2_!+5_A1>:C(?CE\6_
MB#H^IW_BG6[CPSXZT[X)PZ.OB+QEXCN?%6N>((KKP!\&_ ?B1;Z;5[_4Y(+)
MM??0K>'4KB"/2 D&G_8K_A/XH^)?%_ACQS):?#B[TKXE?#_7&\,:W\.]:\3:
M3#:RZW)HF@^)].;3O&>FPZIIEWH>K^&_$ND:G9:K]@CGBEEN-+U+3+#4[&]M
M8/-OV9/B1\<?'/P^^%&H>/\ X;:=::9KGP^\/ZKJ?Q!'Q'TW5]2U2\N/#]M=
M1:A-X6M/"VG-%-K%TRM/$FH*MB9W<F;R]KFMGMY[?AU^YA=-K>]G;?O9_P#!
MNO4]5\/?#J^MOC!\0?BSXAO+&\O-9T#PKX \#65EY[#P_P" ] 6ZU_4S>M/%
M"O\ ;_B;QOKVL3ZJ;7SK1M"\/^"X%F-U:7@KUVBN7\6Z)KGB#2X].T'QEJ_@
M6Y:\AEN=<T'3?#FI:Q]AC282V=BGBS1O$.AVLMQ*T#/>76B:BT<,4D<,*2S+
M<0K?\A[;>OS9I:_IMYK&AZOI.G:_JWA6_P!2TV]L;+Q-H,.A7&N>'[JZMY((
M-9TBW\4:+XD\-S:EILKK>646O>'];T>2XAC74=)O[0RVLOQ.?V(=<;X67/P4
M?]LO]JE_AG>>"-0^'%UX;;1/V/ 9O!FJ://H.H:,=:3]DE/$$8N=)N)K0ZA#
MJT>JQ[Q<07T5TD<R_1W[/FN:SXF^!7P>\0^(M3N=:U_6_AKX,U76M8O1 MWJ
MFJ7V@6%Q?:A=+:PVULMQ=W,DD\PM[>" 2.PBAC3:@]@IW:V[]ET]4PTDD^Z[
MO9Z]&CQI?@W"_P :I_C5??$#QWJUT/"TGA'1OA_JD7P_NO 'A73KE;1]2NO#
M"CP%'XWTO5-;O+1+[7[W_A-YCKCK9V&J1W6BZ)X=TO1^3\&_LS^'?"WPWU/X
M7:IX^^)7CGP_/X@7Q+X;O/$-[X-T#6OASJ,%_'JVF1_#B]^&'@GX>0>%=/T+
M5HQ?:!IUM9S6>C1%M&L(H?#C'1J^D:Y;QSKFJ^&/!7C#Q)H6@77BK6_#WA;Q
M!KFC^%[%G6]\2:KI.DW=_I^@6;1Q3NMUK%W;PZ=;LD$SB6X0K%(0$8N]K]ET
MZ;?G_G<++>W?OUWZ^2^Y6L<%X-^$FL^&M>MM>\0_&_XS_$Q]/2Y32M*\9:EX
M"TC0K'[5;26CO<Z5\+_A[\.;?Q*\=O-(+8^,O^$D%K<^7J-N(]4M[:]AXX?L
M\^)XOB!K_P 1;/\ :<^/5AJOB2VT'2M2TNWT;]FN713X;\+ZSXIUOP]X8@CO
MOV=[O5(M,TNX\:>(K:.^.JOXCN[2^0:EKM[<VEG<P<)\+?'WQ$\=:YX3OO"?
M[2WP%^,.F3:M'/\ %'PAX;\,0:%K/A71O[+U$W$7AF*U\<>(/$6CWFGZ\VEZ
M;?Z#X_TNYU@12327&IZ/>V,VF:AZ/JOQO\6WNO\ B;3?A=\%?%'Q0T7P1JUS
MH'B;Q/;>*/!GA'3[OQ'IR1OK7AOP1#XIU6SE\5:OH,DBZ?J]U>/X<\*VVMBX
MT*/Q//JFEZY;:4]4WMMKHE^:5OU%>-EH]]-W?3I:3V]=-CM_B/\ "C3?B%=:
M!KEOXG\8?#_QKX535+?PYX]\!7VCVGB/3-.UW[ =<T6>T\2Z'XH\)Z]H6L2:
M5I-U>Z+XH\,ZYIAU#2-*U2"V@U/3;*[@N^!?A[=^#(M6EU'XC?$?XA:UK*6T
M=WK_ (ZU?19I8([,7(M5TGPSX5\/>%/A_H3H;N5[F?1/!VGW.J%;8:Q-J"65
MDEOQ.K?M :(?"_@/5_!'A?Q/X^\3_$V74K;P?X"L(;'0?$"7/A\2KXP;Q?-X
MDO--T_P79> [N&32O&<^KW'VK3-=-MX;L;#5?$>HZ7I%]N?#_P"*6J^)/$&H
M^"/'/@'5_AGX[T_24\16NCW^K:-XCT7Q-X;:[33[C7/"7B;1)V@U.#2-1FM-
M.\0Z=J5AHNN:)=:AI$UWI7]EZYH>I:DM;>7R[_?:_P @O&_F[=[:K3RO;YGG
MNG_LX>+;#QE<>.O^&K/VAKS7;_2= \/ZH;K0_P!EL6FIZ!X;U77-8TS2+BWM
M/V:;3R(%O/$FMF:[TZ2QU6:*_,9U ?9K)K;L_&/P5G\2>-;_ ,?^'/B[\6?A
MAXDU7PUX<\)ZFW@>^\"7VCWNC>&-2\4ZKIRR>&_B/X!^('AZ'47NO%VIBYUF
MTTRWU=K>*RMH+VWABF2X]PKX=^*?Q"\2>&?CEX@\*ZY^U1X)^"?A&3X?^$O&
M7AFP\8:%\-[=I[O4=8\5:#KEA:ZIXNU+3KC5;:T;PU9ZI,T3F>T?63;R.D"V
MA+3;>_3MT]%'] =DMMWWZZ]7)6^\]^A^!?@E/A[+\.[F?Q-J-O<ZU)XKN?%U
MWXAOD\?3>.)-6&O#QRGBFQ-G=6/B6#6%CNK*73(['2]/M(8-!L-+MO#4,>C*
MWP;\)-9\-:];:]XA^-_QG^)CZ>ERFE:5XRU+P%I&A6/VJVDM'>YTKX7_  ]^
M'-OXE>.WFD%L?&7_  D@M;GR]1MQ'JEO;7L.#\'?%6K_ !J^$%[>:MXEANEU
M#4_%?AO1OBA\-DN?#-AXVT#2]6NM-TCXB^"H[R[UV32K;6;:(26MS!J&LZ3>
M7-O<:MX>O[_P]?Z5<R7_ -G:?5W^'^IV6M>(M>\5W6@?%+XT^%K;7/$]ZFHZ
M[=:1X6^+?C/0-$BU"^2"V6ZEL](TZRLEF\A&>.W0N"V6*UUUZ_UTT_ %;W;+
M=:?+OKK^)[K7F?CKX8:=XUU#2/$%GXC\5> _&>@6]Y8Z3XV\$7>D6VN0:5J4
MEO-J.B7UEXCT7Q+X5\0:+=W%G9W9TSQ+X<UFUM+ZU@U#3X[.^3[0?+[C]H'Q
M7>_VKXA\$_ CQWX[^&.B:AJ6GW/C72-:\(V>K>(8]$O)[#6]9\ >!=2U:WUS
MQ;H5A=VEY%:W4DVBZAXG6RENO!6E>)K"\T2[U?OO%/QCT#2/"O@CQ'X5T_4O
MB-=?%&33(?ACH7A5[".Y\8G5] NO%5MJ$6H:W=Z7I.C^'[3PQ8WGB'5=;U>\
MM;>TTVV\BVBOM:O=*T?42S7]+\?^"#<7OZ]>^C7SV:ZGD_Q?^'FF>"/@#\=[
M2W@^(7Q/\9_$_P  ^*/#&J:Q-HFH^._&_B_5=5\*:SH'AS3;C2O!GA^&PTCP
M]8R:C+#;Z=H7A[0?".B'4-3U)[.TN=4U2\O-GP#\(?#FO6?A3Q!+XV^..N^!
M_#^IV^K^#/A;\4[=O#^G>&M2\.:@RZ%<ZAI>M^!_#/Q1U[_A'KVRAU'PRGQ*
M\1^*+>WN+72?$%DDMY::5J4/7^#/B5XZU[Q</ _C?X->*?A]=S^%];\1Q^*(
MM>T#Q7X)N(]-U3P]I<&D6'B'1Y8[R+Q#<#7)[TZ=K&B:.Z6NESW&GOJT'GRV
MG@W@CXQ^,_"6EZ-\-?#>C:]\>_B'=?%7XX:1+!KOC2RTO6_#7PW\&?$KQIH>
ME>,?&>OSZ)=6<.CPG3-/\*:6]Q!:W^MZF5MM'M]2?3]7:Q=W9KK>^Z[->BLE
MT:["M&]^EK6L]T[^KNWV:Z^9]0^/?AS#XWGT+5++Q9XL\!>*/#+:DNB^+O!<
MGATZQ:V.M16T6M:3/8^,/#GB[POJ>EZH;#39[FUU;P[?&*\TS3[VRDM;JUCF
MJM9_#?4M-\'ZEX:TWXJ_$^VUO5=135;KXAWFH>$_$/C".[S8I,FFV/BOP=KW
MP_T;3KFUL([-]%T?P-8Z+;"XOK_3]/L]9O;C4W]/^O\ G^58OB+3]5U71K[3
MM%U^Y\+:G=)'';:_96&F:G>:8//B:>>TLM9MKW2I;IK99H;=M0LKVT@FD2XF
MLKM(C;R*[_JW^7X%66KMKZM?JOO_ !/*OAK\&]7^&]_/.OQL^*WC+2+O4_$N
MN7GACQ;I_P &(]&N];\6:K>Z[J^J277@_P"$'A'Q)%,VL:C>7UO;6OB"WTV!
MYOLXL6LHXK9,W4?V>M+N;C5[32/B5\6/"7@CQ%J.HZIX@^&GA;Q!H-AX3U"Z
MUJYFO=>6QU.[\+7_ ,0?"-GKE[<W=YJ.G>!/''A:P-W>WMS:VUK-=W#R:?[/
M^H^(-0\"ZO'XF\3:OXPU31OBE\:/#"^(=>CT>'5K_3?"WQ9\9>'M&^VQ>'])
MT+14EMM)TVSM0NG:1I]J%A7R[:/I7CGQO\>>-]6\::+8^ ?$NI>&O"/PH^+/
M[/VD?$/4=)-L&\9>+?B;\8?AIX<?X93S3P7!&AZ)\-_%E]XA\900+;SW5]XO
M\ QV6H)_9NOV3-7OO\[:>6EONTN3[O*M-.BN[^?7;2[UMY:GO%]\)K6;QQX
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MA?#OP3\/_#%O/K$^DZ4=3UR]T._\27D&G6ME)K/V%9+:3Y?^('[*_BSXQ?\
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M68+ ^,/$6DW6C:?>OK-YX>\-V>HVUCIFD3Z!%;V,EQ>_3M%%WHK[>O3;K;\
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M*&[MON^FP)625V[)*[U;MU?FSQ'Q]X;^*-GXTTWXB?"U/!7B&]C\+W'A#6O
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MKVW^+W@TW^F"QAN;2RNH9[FX^HZ*+^2].GY_J.VVKTOK?77?I^A\J_'KX/\
MB[XA>*/#VM67A3X>?%CPKI^A76DW'PQ^*GC_ ,:> O".GZU/?K<_\)K'#X6\
M%?$32O&&IRV)&D_V5XJ\+J=)@M5G\/Z[I;:KKD-_R/PT_9Q\9Z+X&^/WPK\5
M6_PX\*^%/B;KJ>)O!6N?"F]\0"?PQJ&H>!/!_AZ6T/@CQ1H36.FKX-UWPA::
MEH]]'XS\0VGBX2-<7OAWP=;,-!C^V**+NUOZT=^_Z"Y5>_77\59]/U]+'@'A
MVY_:EGU#2M-\5Z+\ M*TFSO+/^V_&6@>*?B'XBU/Q%I]O+&;\:9\-M0\&^%+
M3P??:M LJ6KW/Q4\;V_A^>6.66'Q)';M!<\_\/\ PS\=O#'CW]IWQ/JO@[X2
MOIGCWQ):^*OA-'I_Q<\8W-]K5UX>^'WAKP%HNE_$2"Y^!UE;^ ;?64\'Z?J^
MJ:GX:N_B?)H+:U>Z=::9XA&C07^M?3]%%_)?UKW';S>GGY6['PQ\#/A/^T+X
M(A_9ATWQOX8^#-M8?!WX5>+/AIXSOO"OQ=\;^(;NX;4X_!]OI&M>&-.U?X$>
M$H=4$L7@>QEU'3]5U/P^;"36[J&VO=371H9]9[+X8_"CXK>#Y/V<6UFP^'KK
M\+?A]\1?ACXS_LSQIXDNBVE:W/X#F\,>)_# N_ASIXUC4+O_ (0"V77O#>JG
MPW;:)_;<YT_Q+XC_ +(C&K?6M%%_3^K^?F+E7G]_IY?W4?F]%^QC!X0:3PQX
M:_9V_9)^(GAF*ZN1H7CGXA2Z[X8\;Z3H\]Q++8Z=XB\,Z/\ "[QEI_CO4=$@
MD2Q.OKXX\&7/B""VAN-1L[349;N]G^C'^'WQ(T;XD_ :Y\,^&OA4/AS\-?AS
MKG@KQ!-9>)/$7@J_T^;78/"EGY/@/X;VO@7Q?I"^'=$MO!FGII&FZG\2K"=;
M;5)-/>=!H<5[K?TK10Y-[Z_?U^?Y6] Y4MM-NW1WMMMZW]3Q+X;>&/B'H?Q%
M^.6M^*M)\&67A?QSXQT+Q#X+O/#_ (PUS7=>GL]*\$>&_!,T7BC0]2\!^&=/
MT"ZDC\*VNJQ)I7B/Q3%OU2XT]YE738[_ %/B?AGX5_:)\ Z7X*^&,=E\%U^'
MG@5=(T"'Q])XC\<:QXS\1^"="EBMK:TD^&J^$?#NA^&O%%]H,$=C-K:_%+Q1
MI5CJK/K*>'K^T T(_4=%%_)?UIW_ *[#MZZ7Z]W>VVW]7"N.\<7OQ L-&2?X
M;>&?!WBSQ";V".32_''CG6OA[HRZ:T<YN;M->T'X=_$V^>]BE6V2#3V\.1P7
M$<L\LFIVK6\<-SV-%(9\]_LX>'_C!X)^'?ACX?\ Q4\+_#71D\"^$/"OAC1M
M8^'_ ,2O%'CMO$4FCZ<-.O[S4]-\1_"/X:#PXA6UM)[.&UU#Q*TYN;B*:2T%
MI'+>W-+T/]H6+]HGQ+X@U;QKX%N?V:+GX=Z?I_A;P';:/<1_$#3OB3'J-C)J
M&N:CJYTU(9]%FTY-2B1!K=PKM<6$*:'92V5QJ>H>\44[[Z+7R_+LQ)625WI:
MVO;H^Z"N1\?6?C34/!GB2R^'6L:1X?\ '%UI=Q#X7UO7K!]4T;2]7< 6U[J6
MFQCS+ZT@.6EM$:-IP/+6:$MYJ==12&?)=W\-?B[\0?'/@/7/B'X-^!7@^/X?
M^*]/\4Q^/_ _B'Q/XO\ B/K_ /9$-Q"FBZ5%KGPY\$I\.]+\1).UAXHC_P"$
MM^((O/#%QJOAA$<ZF-;LO-?&'[)-M:>-/&6O^&_@/^S+\8-.\=^)]6\8W-W\
M7KS5_!GC#PSK?B.Z;4?$4']N:)\,/BA'XYTB[UJ>^U?2[>_@\*7^C)?R:*-1
MO]/M;![7[^HI\SZ:=-+K];_C\B>5===;W=GTMVMMY?,^*?&'[*&E^(/ 'PKL
M(O /P&O?$GPIF\6S:;\/[WP=>V'P6U#3_'=^-2\3>'[.T(U[6/#%]-?VNCZG
M#X[M-.U2\DUK3M0O9_"IT[Q'?:';]1\!O@A-\/\ Q1J?BR[^"/[./P=N+C0+
MG0(;?X.2ZWXK\0WT-WJ6F:A,-0\<ZMX'^%J6VC,VE6[S^'8O!=ZUY?1:??-K
MEN-,%K>_5U%%W:W^?^=OO3]1\JO>WY=/E?[F@KY)\9>$?CN?C5XG\=>&OA5\
M _''A._\"^$?!6BCQW\9?&/A;7Q_8&J^*->O]3O-(L/V</B'INGFZO/%<VFQ
M65IKVH>9::1;ZE-=I+J#:7IOUM10G;L_7_AT#5^^COI\_)]SYD^'?@3XI_#;
MPM\1M9T;PA\)%\;>.?&EOXKT[X5:+XT\2>%/A/X6B;2/#V@ZG!;^-X/A?K.L
M7FK:H-)O_%6L:O:?"?0[76]=OUM9=%L9VU#Q)J"? G1OV@?"4FIZ%\1/ GP<
MTOPUJ_C/XG>-YM>\%_&CQKXPURTNO'GC?Q!XUL]'C\,ZY\ ? 5A=06#Z[_9=
MSJK>*[621;7[?%I69_L,/TY11??1:_UW#E6F^E[?/?I_EY6/D[2_!?[2OP^T
MA_AG\-[CX-WW@2SDO++P3\0?%^K>,+;QEX!\-75Q--INCWWPUTOPI?\ A_XC
M77A&VG73-(U-_B7X 76+"QT_^V; 7JWU[?\ 3:W\&-:\.^"_@SIWPCU;38/$
MOP$L=+TCPC%XY-Y-HGBWPY:>#I/ ^I^'/%>H:/;OJ.F2:MI9M=3A\2:5IM]<
M:5XBTO3[V31=7TMM0T6_^BZ*+OR^[?U_I!RKS[;[:WT^?J>3>![KXZ7^H75Y
M\2=#^$WA32HM.FBLO#O@?Q7XP^(&H7NK-+;O!?W7C+7O!OPTMM,TZ&%+J";2
M(O FKW-Q+<V]VFMVJ64EE?\ S?X:^!?QB^'^FWGQ,\ Z%\*='^/_ (M^)_BW
MQ-\2= E^(_C ?"[QMX$\3^.O$.OVOAW7O%:?"677]4\0>$]"U6"+P;XC@^'F
MB76@:W+J49DU#PU?ZYHGB/[IHHOZ:].GY_UH%K]7ZWU]=OZ5^Y2TV349=.L)
M=7M;*QU:2RM9-4LM-OY]5TZSU%X(VO;6PU2ZTW1KG4K*WN3+%:W]QI&E3WD"
M1W$NFV,DC6L6;XHN?%-IH.HW'@K1] \0>*(HXCI.C^*/$NH^$-!O9C<0K,FH
M^)-)\*>.-0TN..U:>:*6V\*ZPTUQ%#;/#!'.]W;[]%(9\U? 31/COX3_ +=T
M/XE^"OA)HV@:IXL^)GCB#6O OQ?\9>-M8CU+QY\0-8\96VA2^'M?^!?P[LA8
MZ=;Z_=64^N)XE>>>;3[>6/0D34)%T_QCXY_LC:GK%FA^#">(9;W7OBSI7Q2\
M7V'BG]K;]H7X9^%;6_M/BCH?Q0UM_#GAKPCHWQ#T5=0\1ZA9ZM;65Q;Z;X<7
MP1?W.F^(-!^TW>EVEI;_ 'Y13YFG=67Y?G^I/*K6=WV[K\AJ@A5!&"% (W,^
M" ,C>P#/_O, S=2,DUQ7Q&\$6WQ$\':MX3GU*\T2>[DTK4M(U[3D@EO_  ]X
MF\-ZSI_B;PIXCLH+I)+2YNO#_B;1])UFWM;R*6SNI;%;:[BDMI94;MZ*11\]
M:3%^U'J>I:-I/B@_!;PMH.FZEI]UK_CCP9K'B[Q'XD\8Z=I]S'<76EZ7\//$
M_@[3-%^'7_"0B(6E[?7/Q!^)L^D:=<7D&F++J;V6MV">)O"?QA\)>._$GC?X
M.6OPZ\56/CZ#1I/%_@GXC^)?$G@6.S\2Z!IT>AV?BWP]XR\->#/B).RW_AZU
MTG2=9\+ZCX2,$SZ%IVHZ;K^F2SZG;WOT-13OY+TM_P ']16\WWO?7MV_0^._
M%'P@^,C?"[Q5;Z/_ ,*W\7_%OXE_%SP5\3O' UKQ+XF^'G@'2H_"5QX$2ST;
MPM>:=X'^)6O74>G>'/ACX3\,1R:GI%H^M7MSK7C&YDTF22'PN_I^N^&_B;J/
MQJ^$OC2TT/P)_P (?X;\#^/= \9SW/CGQ!#XEL=7\;7'@Z^ \,:%%\.+C2_$
M>G:;<>"K6V-YJOB?PE<W<.L3W0TZV?2H[35/=:*+^G7\?^&T"R\^GX-OMU;=
M_P!#YNU7PS\<O"'CSX@:W\+=(^%'B;0?B=J>A>(M0G\?^,O%_A'5O!WB#2?"
M&@>"+DV>E>'?A_XTL_&ND7>E>%M&U"&SGUSP->6M^^I6SZA<V\]M/:2?&W0O
MCOXH^%.I_#[P7H'PD\5ZWXV^'/B;P?XT\2>*/'GC'X6Z7I.M:[X<.B-K'A?P
MUI/PT^,MWJ.ERW=]J-^-)U7Q-I]WIMO;V5@=7U>2YGU"V^C:*+[:+3^M=?\
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M> O@K\/-0\):%XDTNQUK1[#5_B7XS^+FG>--8CTO4X+FRDU2YTOX<>$M+AU
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M^)'@*\O;VXAM+.SM/&'AZXNKNZN)%AM[:VMX=1>6>XGE=(H88D>261U1%9F
M/7:: VF:>" 0;"U!!&00;>,$$'@@C@@]:^4OB#\)/A5:>)/@5\,?"/PV\!Z#
M+=^-M+\9W,VB>$]"T[4=$\#? \Z=XOCN["\M;".YBMV\?P_"WPE?*LR&72_%
M%U%(TB,T,PAMNR:MT[];?YGUY2$@ DD  $DDX  Y))/  '4TM<KXV\'^'?'O
MAC4O"?BVV>]\-:J;$ZUI_P!KGL[;5+#3]1M-3FTG5#;RQ?;-!U460T[Q#I%R
MSZ?KFAW6H:-JD-QIM_=V\J&:^DZWHNO6\EWH>KZ7K-I%<2VLMUI-_::C;QW4
M! FMI)[.6:)+B$LHEA9A)&2-ZC(HGUK1K;4[/1;G5M,M]9U&*:?3])GO[6+4
M[Z"W!:XFL["25;JZB@56,TD$3I$%)=E -?+WPF\,>"]5^+,WQ+^#?A'P_P"#
M?A;8> ]:\#W>N>%]'L?#NB_&37;G7_#-_HFN:1INDV]G9ZUX8^'%EH?B'2O#
MWC2Y@DBUR;QMK$7A*YD\.VL]_K7FNI?#SP=XM^!_[1_Q0\3Z1I%Q\2#XN_:2
MU33OB)=Z?83>*_!EU\&_&_COPC\++_PSKES!+?\ A\>"M$\"^&]4TB&RG@M(
M]5_M'5F@:;6=2>Z=OT];OOZ=?\R;NVRZ]=&DKZ>O3I\C[XN+BWM()KJZGAMK
M:WBDGN+BXE2&""&)2\LTTTC+'%%&BEY)'941068@ FI000"""" 00<@@\@@C
M@@CD$=:^6?VD/"?A?X@_LS_$#7_''A31-=U31_@?X_\ $.E0ZUIT.HV^AZ]=
M_#Z^NWU"QLKY9[:WU.RN8(S8:@83?Z<Z,;.X@>28R?3.E_\ (-T[_KQM/_2>
M.C_-COK;R37WV+U1-/"LT=LTT2W$T<TT4#2()I8;=H4GECB)WO' ]S;I-(JE
M8VGA5RIE0-+7QQ\5O!WQ%US]ICX63>&/C#JO@BVNOA3\93965IX,\&:ZFF"Q
MU[X)1ZFL4^NZ;=3W0UN6ZLKB8W;R-8MIJ1V)BBNKE7%KUL#=NE]4OO=C['HK
MPKQQK_CSX>^!?"'A[2]=T[QA\3O&/BG3/ 6A>+O%^D6^GZ%'JVJKJVL7?B3Q
M#H7AB31XI[3P_P"&M(U:[M= TF[T>3Q)J5AINA#5]'EU>36+/G=,U+XO?#/Q
MY\/?#_Q \>Z'\4O"WQ4US5O"%A?1>"[7P1XG\)^,--\$^+/B#;S*-*U:^TC7
M?"&IZ'X)\06#VDUC:^(-$U4Z1.^JZ[87E^=*+>:Z_.WR"_D^E_*^U_\ @'TO
M1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% #7!964,R%E(#J%+(2" RAU="RGD!T9<@;E89!^5M!_9H\5^&[34=/TK]K'
M]HZWT[5]=\0^(]4LUTO]F&(W>J>*]7O-<\03IJ%O^S9!K%A_:&I:A>3J=*U&
MQDT_S@NER6(A@\KZKKY[?]J#X3)XYD\"BX\:W,J^(M*\%0^,=-^&/Q%UGX87
M/CO5/$5SX5D\#I\3=&\,:AX(MO$NC:[%;:;KUIJ&M65KI=]?Q6$UX=0L=;M-
M):OK;\D_S0G;2_RU:WWV:*F@_LT>'/#7Q!\'^-M)\;^/%T;P)X"'PW\.?#/4
M(?AUK7@BT\,/;V7VZ-M3UKX>ZA\3VU36=8TK1_$VOZROQ&34M>UO1M+_ +7N
M;S2;1=*./K_[+5OKFM?&/5[;XU?%WPU;_&SPK8^#?$N@>&]-^!=KH>DZ-ITE
M[':MX?CO_@GJ6H_VJNCZOKGAJ76O$6I>(M5N="U807-W+>Z!X1OO#OK?COXN
M^!_AQ=6&G^([CQ)=ZKJ5O+>6NA^"_ /C_P")7B :?#((9-4NO#_PX\,>*]:T
M_2%G)@_M:_L;;33.KPK=&6-T7K/"OBKP[XW\/Z9XJ\*:M::YX?UB%Y]/U.R=
MFAF6*:6UN8G218Y[:[LKR"XL=0L;J*"]T^_MKFQOK>WN[>:&,N]_E>R]>WS_
M %%:.VE_^!;OV_X9'FFJ_!:'7OAYX<\$:[\1/'^JZ_X/UC3O$/A;XM21?#S3
M_B3H/B#2+VYETS5[ :+\/],^'ZSV^DWEWX3N[2;P#-I6O>$[W4M%\2:?K,>K
M:M)?<QJ?[/GB"[\:>+_&FC?M(?'7PC+XV.C+K.A>';#]GYM'2VT*P;3K"TT^
MY\0? ;7O$UBB02W+/<Q>(CJ/G7,DL=[&8K46_P!)5R'C?Q[X/^'&B'Q%XVUZ
MRT#2C=V^G6TER)I[O4]5O2RV.BZ)I=E%<ZKKVNZ@Z/'IVAZ+97^K:A(K1V5G
M/("M%WT_)?Y#:77IYM;:=UT/&+G]F#PR-9^$U_H?CKXA>&M%^$6I:IKFE^#K
M3_A7WB30?%7B+Q'/JDGB[Q3XVU'X@_#[QGXUU;Q7XOM==U_3M>\36'BW2-=:
MVU_7;G3;_3=6UC4=2N.GE^"%I_PNG2?C38>/O&VC76E>%]0\'MX!TC3OAA:^
M!-6T+5)K&^NK?6I6^&\OC^_D36-,L-:T^<^/(WT>^CO(-(^PZ3KGB'3=6[31
MOB3X3UGP;?\ C]I]<\->%=*M=4OM5O\ XA>#_&'PPNM+T_18'N=3U/4M&^(V
M@^%M<T_2[6VBEN3J5WIL-A+;QR3PW$D2,XQ_ 'QH^'GQ,OKS2_"VI:Y'JUE8
MQ:LVC^+/!'CGX>ZQ>Z)-,+:+Q#HVD?$'PWX8U'7_  W)<LENOB/0[74=#-Q+
M!#_:'FSPHYK]VFW?Y?UW%:.FW1KY;?UMY,]3KQWQ_P#!^/QOXETGQGIGQ&^)
M7PX\6:'H&I>&].UCP%JGAP0C3-7U'3M3OUO_  WXS\*^,O!^MSR3Z7:)!-KG
MAW4C81K(VGBUN)7G-GQS\</AK\.=670_%.L:M'J::7%KNI0:#X,\;^,HO#7A
M^XGO+>W\1^-;SP;X<U^R\"^&[B;3=32W\0^,;C0]%G_LK5FBOG32]0:V]2M;
MJUOK6VO;*Y@O+.\@ANK2[M9H[BUNK6XC6:"YMKB%GBG@GB=)89HG:.6-E=&9
M6!)JM1Z/3>WX'@-S^SOI=WX ^)7@RY^)'Q.N=?\ BWIZZ3XX^*MW>>"K_P"(
M=_I2VK:;_96GP:AX&NOAWH&DKHUQJ>E6^DZ%\/\ 3],T]=;UK6-,L[+Q/J,^
MNF]XB^"%[XDM?@_#<?&7XJ6-W\'M;C\0VNJZ?9?!\7WCC5HM&O/#L=QXVBOO
MA+?:6JKH6JZ[IGD>"=.\%0&/7+RZ:,ZC::->:5[O7D?CCXY_#3X=ZP- \3:O
MK1U:/3H=9U*T\-^!_'?CD>&]#N9;F&VU[QE<>"/#7B*U\$Z#<R65^+;6_%TV
MB:5.NGZC)#=O'I]XT!=O\]EZ=O\ @!:*WTZ;OO?OWU.8U#]GVWN=9\07&E_%
MGXP>%?"'BO6=1\0^(_AMX5UOPEI'AG4=9UIQ-KM];>)!X)G^+/AXZU>>9?WU
MMX5^)6A62WMQ=3V=M:&YF5\C4/V:OMWP%TC]GN+XV_&'3O"VG>%KGP)?>([*
MU^"S^,?$7@2?0[KPW%X3UBYU#X-W_AN"QLM#GAL+;5/#_AC0O%#BQM;F\U^[
MO7O;F\]IUSX@^"?#?A[3_%>L>)M)M_#^L&P70]2AN1?Q^(9=5MGO-+MO#D.G
MBZN?$-YJEI')=:;9:+!?7=_;QO-:0S1HS#2\*^*-#\;>&= \8>&;UM1\.^*-
M'T[7]#OWL[[3WO-*U6UBO;"Y:QU.VL]1LVFMIHY&MKZTMKN L8[B"*5612[T
M]=-%NOEN*T=5I=K57>S^>W]=3F/!/@36O#6G:QIOBWXH^.OC!#JY5-_Q'TGX
M46IL+,P2V]UIUK;?#/X9?#C3[JROUE)O$UJRU:9MJQPS00-+%)YM8_LZ/I1M
M=)TGXZ?'O2_A]8^7#I_PRL/%'A"#0].TV$J(-&L/&P\!M\;+32K:)5MK."#X
MK)+8V:1V=E/;VT442=?KOQZ^%GAOQ5/X.UCQ#?P:I8W^EZ3K.HV_A+QGJ7@[
MPSJ^MQV4VD:/XQ^(6F>'KSP#X,UC4X-4TJ>QTGQ7XET?4;FWU;29XK9HM4T]
M[GV"B[^_R7^5ONL/1^=O-_YW^^X5E:[IUYJ^C:GI>GZ]JOA>]O[&XM+3Q%H4
M.AW&LZ)//&R1:GID'B;1O$7A^6^LV(FMX]9T+5]-:15%WI]U"6B;5HI#/&?@
MM\(;SX,^&K'P>GQ7^)'Q'\.:)H/AWPUX5TWX@6GPLA'A71O#5BVFV5KI=Y\.
M_AC\/M0U!KBQ6S@O;CQ/=^(+A_[/MI+>6VFEOY+WF/%_P"\0^*?B+%\2;']H
MWXW^#-3L-&U[P[H6C>%])_9YN= \/:%XHN?"=_X@TS3D\8_ /Q;K5W'J>I>"
M?#^H/=:]K6LZC:3VTT&GWMG874]F_P!&T4[N[?5[Z+_(5E9+HMM7_F>>^+?!
M?B3Q'X=TC1-'^+?Q"\ ZEILEH]YXO\):;\*;SQ%X@6VLI;2:+5[;QU\,?&GA
M.&/4)Y$U.[.@^%]$E2^@BCL);+33-I\W(_!OX+W_ ,'M&L_#/_"XOBA\1_"N
MD>'M/\-:!X<^(%A\'X['0=/TR.."V>SO/A]\)O .N7US]DB6SE;7M7UB"2$L
MYM_M1^T#W"BB[M;]%_E?\0LKWZ^K_P [?@?-6F_LUPZ'%%H/AWXU_'7P[\-;
M3$.F_"K1/$OA&Q\-Z+IBDF+0=!\7KX$;XS:%H5G&5MM+TS2/BE9P:)816^F:
M)_9VFVMM:0]?XU^#4/B;7SXN\+?$3XB_"3Q=<Z;9Z-K/B#X=7?A"=_$FE:;)
M<R:9:^(- ^(W@WX@^#]1NM,:]O%T_7&\.1^([6WNI;*+618E+9/9J*+O^K?Y
M:_.X67;\_P -=/E8X_P1X0/@K1FTJ3Q3XP\97=Q>S:C?^(?&^M#6-9OKR>*"
M%V6.UM=,T/1K)8K:(0Z-X:T70]"MY3/=0:9'=WE[/<=A112&?//COX#Z[XT^
M(-A\1+#]H/XT> [W1=-U/2?#^@^$-+^ 5UX?T*RUV#08]?2S'CGX&>-==O'U
MJX\.:;J%S)K6NZJ]I=B>/2#IMA+]B7L/%_PFT[QOX8\+Z-KGBKQDOB?P;-8Z
MEX<^*.D7NBZ#\0=.\1VFESZ/=>)8YM'T&R\(M>:Y87FH6_B#0G\(MX*U:VU&
M[L+CPJ=-,%E!ZM13N]/+T_R_.XK+73???_/\K'CG@7X.6O@W4]9\3ZIX\\?_
M !'\>ZSI(T!_'_CZ[\*SZYI6A),;N/1_#NB^%/"7A/P%X=L6OQ%J-^FC^#;.
M77[VTTV;Q)+K/]E:8MGR'@?]GWQ)X'\5:MXIC_:5^.OB,>)?%-IXN\7Z!XAT
M?]G%=$\5ZK9^&O#WA"--2?P[^S[X>U[3K1_#WA70=/EA\,:YH$A^P?:TFCOK
MJ\N;CZ2HHN]?/R7^7Y6"RTTV\W_G^=PKD_&W@K0?B!X?N/#GB&&[:TDN;+4+
M.]TV_N])UG1=8TNZBO\ 2-=T+6+"6"_TG6=)OX(;NQOK29)(Y(S'();:6>"7
MK**0]]&>/^%_@_!HOB'3_%?BCQ]X_P#BEK^A6][:^%[WQ]<^$H[?PM%J5N;/
M4)M'T;P-X0\$Z$^K7EBTFG2^)-7TO5/$RZ9<7VFP:S%8ZGJ=O>?.G@_PI'XY
M^,?QXU/1/$/[1GP<UGQ/XST_4&UK2O FJ>&?"_C7PIX<^&7PP\&QL]U\5_AE
MXD\&IJEMXATWQ':Z;J/AY-&\97^E0F\M]1N]$M=.EMONNBGS/7S5O36^UK?A
MY[DN*=O)M]=;JV][[>?EL>8_\*B\&I\-C\++6'5++PYL,T=Y;ZO?/XDBUS^V
MO^$H_P"$M/B&[EN=1NO%K>+/^*KGUR_DN[F]\0F34;\73S3)(WP=\-]1\,:E
M=ZSK/Q4^*'Q"U2?39M)MIO&.I>%;33M,LYY[:X=[3POX#\(>"/"%QJ0EM(!%
MK>K>']3URW@%Q:0:C%::AJ,%WZA11=_>.R[;?IMU/G&Q^ ?BBR\5S^,O^&EO
MCK=:S>Z9HFB:B;G1OV<!:ZAHGA_4M8U73M+G@M?V?+;R85NO$&L&6YL'L]2E
MCO2AOA]GM#;]GXR^$EOXF\0_\)?X>\=>//AAXLGTNVT/5M>\ 77A=F\0Z-8S
MW5SIUCKNA^./"GC;PK?2:7-?Z@VEZO\ V!%K^G1W]Y:V>K0VEP\!];HHN_Z2
M_P OS#E6UO/=[]][W]&CP?6/@%HM_P##P?#W1_&_Q \)I<>*M.\::]XQTF\\
M*ZYXW\5^(M.U*VUE;_Q'JOC_ ,(^--/O'N-6T_2+J06VD61M+71=*T#2CIWA
MBU_L1^KU'X;2ZCX_\#_$"3QYXSANO!'A_6_#J^'X(/ H\/>);?Q$=-DUB]\1
M>=X)GU]+^ZN=$T6Z!\-Z_P"';*WFTN!+:RBM;G4K>^]-HHN_S[==^G]=+!RK
MMV[]-5UZ?\/<*\I^+_PMD^+GAS3?#8^(7CGX=1:;XJ\+>+_[2\!0?#^;4[W4
MO!>OZ=XJ\.07G_"PO ?C_318V'B71]'UEHK/3;.XNYM-ALKRZGTFXU#3KSU:
MBEMJ-J^C.4\->&KS1_#$/AOQ)XKU[XE3B*^M]1\1>-K#P9#J^MVU]/<.;;5;
M#P1X2\%^$F@@M9QIL<5CX8L5FL8(OM_VR\>YN[CQNQ_9T?2C:Z3I/QT^/>E_
M#ZQ\N'3_ (96'BCPA!H>G:;"5$&C6'C8> V^-EII5M$JVUG!!\5DEL;-([.R
MGM[:**)/H^BG=_U;_(5E]WK_ )_G<^;/B[^SWKOQ7\9>#/&-I^T9\</A>? &
MIMK_ (5\.?#S2OV>;K0-.\33^%O%W@F^\1N_Q-^ GQ(\0WM]J'A7QQX@TBXL
M;[Q!<:!$D]O?6&C6>J6L5\/3&\#^)V^'MMX+'QC^)">)((;>*7XMKI?PB/Q"
MO7AOQ>27%SIK_"M_A2DUW;@Z5<+9_#*TMUL&,EI!:ZIMU)?1Z*+O3R\E_E^=
MPLM?/S?^?Y6/G_X5? S6_A9J-Q<+\?/C'XYT6]U;Q7X@O_"?C33/@3%H=[K_
M (RUB_\ $.M:O+=^"/@EX*\4Q3MK>IWNH6UI:>)+;2[=YOLPT]K&.*U3+U/]
MF?2;JYUNST7XJ?&7P7X \3ZGJ>K>)/A3X0\2^'=.\&:E=Z]=SW_B)=/U:\\(
M:C\2_!5EX@O[J\OM3TSX>?$'PAIQO+Z^NK.ULY[VYDE^E**+O?\ 1?Y?COYA
MRK:WY_Y_A>WD>,>,/@CH/B%O"U[X5\1^+/A%XB\%:*_A?PUXG^%\OANPO;#P
ME(MD'\)W.@^*_#7B_P #ZUX>C;3;"6PT_7O">J#1+BV%QH,FESSW<EQE_##X
M :3\*_&OBOQQI/C_ .)/B'4/'FEZ7!XWL?&&H^%M:L_$_B31W>.Q\=7]_'X0
ML?$UIXA@TISX>MM)T;Q!IG@#3M CL]-TKP58)INF/9^]T47>U_Z_KS"RO>VO
M]+O;;38*\F\=_"_5/%^KV^N:!\7_ (L_"_4(["+2[Q? FI^#K[2-3LH9[FXB
M%QX9^)7@GXA^&+&_#W<Z2ZYH6C:1K]U!]FMKO5;B"PT^.U]9HI#:OO\ U]S1
MQ?@#P%H/PW\.1>&O#YU.XA-]J>KZGJNN:G=:UX@\0:]K=]-J6M:]KVKWKO<Z
MAJFJ7]Q+/,Y\NVM8O)T_3;6QTNSLK&V[2BB@#YAUK]ECPUK$'B#P['\2/BWH
MWPL\53ZQ<Z]\&-%\0^'+;X?WDGB&>YN]<MK>\N?"-Y\1='T#5;Z\NKJ_\&:'
MX^TSP1<I=76F2^&VT2\N]+GU8?V=K*T\*> M%T_XI_%73/&'PXT&;PKX>^+>
MFW/P^LO'T_A>:6!D\/>(--@^'B_"[Q)I-K!8Z7;VEKK?PWO1;OI=KJB-_;TV
MHZM??1-%.[[_ -?=K\[WZBY5V_/U[Z:]K'DFA?"#3K7PSXM\+^-_%_CKXP6O
MCK3)M$\4S_$S5-)NH]1T6XL[VPN-+M?#WA'0O!_@K0;:ZM=0NX[Z3PYX7TB[
MU+? VHW-VUCIYM>;\._ G4M#U#2GOOCW\??%7AS0KRSO-'\&Z_XH\(6^F6_]
MG2QS:?:ZGXI\,> _#?Q0\66,#0QI=6OC3X@>)(M<A$EOXC&L0SW$<OO]%%W]
M_I_EI\K!9?=Z_P">OSN?.7B_X!>(?%/Q%B^)-C^T;\;_  9J=AHVO>'="T;P
MOI/[/-SH'A[0O%%SX3O_ !!IFG)XQ^ ?BW6KN/4]2\$^']0>ZU[6M9U&TGMI
MH-/O;.PNI[-_4_%7P_T?QOX0B\(>*;S6=26 :1<P>)+>^30O%=IK^ARV]WIG
MBS3=5\.6^CQ:/XBMM1MH]22XT:ST^P$S36@TX:5/-IS]U11=Z>6VWZ(++7SW
MW_S/&?!OPDUGPUKUMKWB'XW_ !G^)CZ>ERFE:5XRU+P%I&A6/VJVDM'>YTKX
M7_#WX<V_B5X[>:06Q\9?\)(+6Y\O4;<1ZI;VU[#YKKG[)FD:[X3\0_#F?XS?
M'*P^&&M:/KFB:;\.]&U[P+I.B>$[36H;R-(]%UNS^'<?CS5K/2)+QY=-T#QS
MXP\8>%YHX8-,UK0M7T17TN3ZPHHN_P"K?Y!9;6_%_P"9X9XH^"=UXFN? ^MI
M\8OBYX=\;>!?"VN^%+3QUX<N_A];:IKMMXFNO"EYK>I>*/#&H_#S5/AGJVIW
MEQX/TV2$+X#M=,TQ[C4'TC3+!Y;=K70T#X(>%--\,>-/#?B74?$GQ)F^([.W
MC[Q)X[U"SG\0^)A_9L.D6D3-X9TWPQHOAVUTK3[:&/1K'P;HOANQTF[$NKV%
MM!K5W>ZC<^QT47?]?\,%EV_/T[]O(\&\/_!#5]&UG3+[4_C[\>?%^AZ+>6U[
MI7@[Q!X@\#V>C0O8RK+90:GKOA#X>^%OB'XKLX61!<VGC+QOXBM]9C5H=?35
MH9KB.:'Q%^S_ &6K>(M?USPW\4/BW\,[+QE=)?\ COPM\/=>\.:?X?\ %VH_
M8[;3KC5'DUWPEXB\1>#-7U#3[.UM=3UGX8>(/ FK7\D":E<WLFL[M2;W^BB[
M_JW^067;\7_G?\3RKX-_"72?@EX+C^'_ (<\0>)-:\+Z?JVK7OAFP\1KX8SX
M1T?4[IKV+PAHDWAOPSX;DN?#VDW,MT^F3>(SKWB4+=2PZAXBU"&*TCMN[\1Z
M5>ZYH>IZ1IWB/6O"%]J%J]M;>)O#L'AZYUO1I7(Q>Z9!XLT'Q1X<ENHP"$76
M/#^K69#-OM'(4KM44O,=K*W38^1/#/['/@_PKX3\/_#*P^)WQFNO@UH.DZ5H
M\OP<U'Q)X7N/!6OVFFVT$%Q;:YJ4?@J#X@MHFN2PO<Z]X)TGQQI/P^U".[O=
M&'A*'PU=2Z&=W]J?QMIVC_"_QIX);P'\3?'6N>,O!'B"Q\/V'@/X:?$?Q?8P
MZM<6[V6D7.I>)? _AO6;?PI<:;JDMKJ\%XUS#KEE'8'4]%M;F^M[2.3Z>HIW
M=TWK;7MY]$3RJS2TOIWT^;_KL>=_"7PSIGA#X:^"M TB76+JUMM L;N;4O$>
MFWFC>)=;U75T.LZ[XB\4:5J%M9:AI_BGQ'K=_J&N^);2_L[2]AUW4=02[M;>
MX$D2>B444BEHK=CY9^(O[*_@GQG\0++Q_IDWBSPUJ?B;Q=9:E\9SX9^+/Q=\
M$6WQ)\+:3\.=5\':1H>K:+X+\8:/H6I-9ZA9^!Y52\LH(SI6CZI;O/*FK:I9
MZO[7KGPU\&ZYX!7X9OI$>D^$+;3M&TW1].\.R/H#>&H_#,]A>>%;KPQ<:6;:
M70;_ ,*:AI6E:EX;N].,,FD7^F6%S:;'MH\=W13N]-=MOZ_K3385EKIOO_7]
M:Z[GD7P^^$<?@G6]4\4ZUX_\?_%+Q;J.F6V@P^)OB)<>$3>Z-X<M;E[Y=!T+
M3/ O@_P-X:TZTNKYTO-6OTT)]>U^>TTPZ]K&IIH^DI9?*7[&O[*_BSX8_&7]
MLW]J#XQ)#)\8_P!J+XZ:TVD6T>JQ:S#X/_9W^%KOX"^!'ANVFMYKFRL]1U[P
MEI%OXX\30Z?*G[_6]%T7581J7AAMOZ%44<SLU_,DGZ)WMY*]ON"RT\KOYOJ<
M+X]\'ZSXRTZSL=$^)?COX8W%K>FYGU;P%!X"GU'4K9H)8)-+O%^(/@7Q[IL=
ME(95G$^G:=8:M#/#$]MJ<"^8DG'Q? OPQIOPQ\7_  S\,Z_XW\)-XZCU6?Q+
M\1-%\1FX^*6H^(-;M;>RU+QA/XP\0VFNR7/BB6SM+6RM;Z\LKJUTK3K/3])T
MBQL-)TO3+&S]JHHN_P"OZ_,++]/ZUT^5CYR\ _L_ZWX"O/!J0?M"?&?6_"?@
M<E=*^'5WHO[/'ACP3=6B:+J.B6>F:E:_#/X"> M<FTG3H]1_M"STRVUZSLAJ
MMCIMY<0W'V-(SUOC[X01>,M=M_%>@_$'X@_"KQ<NCQ>&]2\2?#JY\)"\\0>&
M;>\O-0LM"UW3?'7@_P <^'+R#2[_ %+5;O1-3BT2W\0Z#+K&LC1=9T^+6-2C
MNO8**+N]_P!%_EK\[A96MT^?^?Y6/A;]LG]G_P"(?CC]A_XD_LP_LW3+HGB7
MXE>'M!^#T?B+6=;?S_#W@?XA>,-$\/?&/Q[K&KZC=IJ6OZY8?#K6?'7BF\Q<
MSZ_XKU_=%$\^IZGO;Z@^$'PH\&_ [X4_#[X-?#^QETWP1\-/!VA>"/#=K+.T
MUZ-)T#38--@N=0O@(YKW5[X0M?:KJDF+K4-3N+J_G=KBXD<^DT47=K=+M^K:
MMK\MO5A97OY)>B1\YK^SG;75W86WB;XP?&KQOX&TO5=-UFP^&7BWQ'X7O_"_
MVW1;^#5-&36?$%EX+T[XI^,;#3]1M;2\.E^./B+XETS4Y;:)=<M-4AWQOWWQ
M!^'>L>.I=.&G_%KXG?#FPMH+JVU73/A]-X$LHO$EO=/"VS4=5\2^!/%/B72)
M[98GCM=0\&:[X5U.%+B9OMK2K;R0>G447?\ 5O\ (++M^+_SO^)Q/A[P!H'@
MOP1'X"\"K<^#=(M-/U.TTN\TIX-1U?3+[5I+N[O/$?VSQ1;>((M:\27&KWUU
MK]_JOBFVU^36]=GN-1\0QZO+>7HN?*_A_P# 3Q!X#\9:OXPD_:*^-OC+_A)=
M9BU_Q9X<\5Z5^SY#H'B;4[;PMIG@^QFOW\'_  &\)>(M/2QT?0]%\F'P[X@T
M.*6ZTR&>\6Z%SJ,=[]%447>OGOL_S3866FFVV^GW-!7FOQ9^'4_Q6\$ZMX&3
MQ[XS^'MCKUO>:=K>J^!8/ L^LZGH6I:9?Z5JF@2M\0/!/CS2K:PU"WOS)-=Z
M=I-EKD$]K;-8:O9QFZBN?2J*0]SRWX>_#OQ%X&T_4].U;XS?$SXE175G866D
MR^.=,^#]E/X6CL8+J#S-$/PY^%'P_ANI;I9[=KD^)H?$48?3K3[+';+)J"WW
MG_@?]GWQ)X'\5:MXIC_:5^.OB,>)?%-IXN\7Z!XAT?\ 9Q71/%>JV?AKP]X0
MC34G\._L^^'M>TZT?P]X5T'3Y8?#&N:!(?L'VM)H[ZZO+FX^DJ*=WKY[Z+_+
M_(5EIY;:O_,\6\<_!:V\5^)?^$U\,_$/XB_"3QE<:3:Z!K7B+X;WGA%G\3:'
MI\]Y=:7I_B+0/B!X.\?>#]1ETB?4=2;2-:_X1R'Q)ID6HWMI9:S!9W$EN>?;
M]G#0;>U^'EMH7C[XD>')? GQ"N?BCJ.J6M[X/U_6_B3XQO\ 3;O1M2U'XBZS
MXX\%^+-1U!;W1]2U+2!'X<N/"YTW2KJWTW1'TNRT/PU!HOT311=_U_PW_#=
MY5V_/R??R6UK]3P1?@#IL+V<EK\0?B%:'2_C?J_QTT00CP!(-&UGQ'#XC@\2
M^#[3[5X!N3=>"M>C\8>)Q=IJYU/Q?9'6)#HGC#2OL6E?8/>Z**0));*W]?\
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M_$3^%M!6."699]8C\.^(/%+0S/&K"VB_LCPQJTHGEVQ>=%%!N#SH#^;?Q/\
M _\ :<?QH^.&C>.?A7\6_ ^EZQ\0;7Q%_P )+X\^+7PK^(?@9/"LVH>&O&7P
MX\/?$[PWXZU'PUX9.BWNCZKI6@6D/PY\+VES(]O)K=UK$M]=^*=2]X_:$\ _
M##XD:M^S!XH\=^$[6>VO?BAI^DRMXF-QI]U8:3XC^$_Q.GT[0M4Q>1);75UX
MHET&R6WDE:>77)+33X9))KA(I79::^OD[7M9V#F=GIM:VNZ;M?3^ON9]G45\
M??%9M!^$WP'^+OA?]G67P[H7BGPG::-J^OZ+X=\00IK/@G2/%.M65AXB\87X
M%IXLU+PW=6?@W3?%&MZ-JMYX<UA$N/#<UW::)K)TZ>PE\3\(^$O%_@_Q)\*_
M%_@[PE\,/AI8ZWXO\*V&J^+O^&R_'/Q)M/BCX5\0:A;Z?K.FW^B>+?A]!8?$
MSQ7JEA=R7_@W6'UV'Q/'XK@TPVNO-I5]K>E:N6TO?TOZ7_K?[@<K.UK][:];
M:>G7;[S]+:*_+G2/@CX,>X\+2P7OCC3_ /A+OVP/C)X UF'2OB%XTTRT;X;Z
M9-\:-1;X;V5G9:W#:Z=X*U/4?"NFZAJ^D6<,+7UY+>SO<JTZ>5[1IPTJP_9A
M\=>%=2^)]W\*](@^+/Q2^%?A;QSJ>J:W>-X8M[C]H?Q#X&^'_AV74X]=TGQ"
M-%9I]$\$1?8_%7A_4[#P_/';:9XG\.RVMKK%@67?K;;_ (<2E?IT;W[*_D?;
MU%?!?P8\(ZE\(OC9X<\&^)M'^'4NH^*/ 7CB]T#5OA/XR^)MC9Q6=CJ7@RYU
MO4/%_P 'O&WB;Q?IUI%JDD>CP:9\0K+Q)JM]#J"OX>NU5=<AN)/O2DU;S\RD
M[]+:VL<3X[^)'@3X8Z5;:UX^\4Z1X6T^^OX]*TZ34[D)<:MJLT,]S%I>CV$2
MRW^L:F]K:W5T-/TRUN[S[):W5UY/V>VGDCX2\_:*^%9^'?C'XG^&->/Q$\->
M H6G\5Q_#V%?$VL:.L$$5YJ$5YI4$T-Q:W>D:?(VH:O877D7VG6UO<_:;9)X
M6AK"^+-K;ZE\3_AM'X/^)WA#P/\ &[2?#/CV?P?H7C?PW+XOT/Q5X,UJ\\'P
M>,XFT"U\1^#=5:_L]1T?PLUEK&@^*+34])BDODN-.U;2-1U&T?R;5O%%WK'P
MK_;.T+Q#H/P]M_'7ASX?>)/^$U\7?#&[NKSP]XMU#4/A-J4.F)K U"VCU31?
M&F@:+I=C9:OX7U#4->FTO0+CPGJ$>LS6^M0V5@TEI\ON;MV_%-Z]!-M7VV=N
MNJBWWW\FMNNI]PVUQ'=VUO=0DF&Y@BN(BPVL8YHUD0LIY4E6&0>AXJ:OBF#X
M5^'?A)XG_9Q\1^%-2\7R>)_%WCL^$?'WB+7/&/B+6KWX@Z/J?P?^)/B&ZC\6
MV5[J#Z'=R0^(_#VB:UHXL-)TZ#PS)IT6E>&(-&\/2W.CS<;\:-1\.?$&^^('
MB-?A)I.H:#\.-1U/P?KGQ:\6?M!7'P7U#0M>T*W1-0N/!(T6/6-0T2XT:XGC
M2QU?6KCP+<:C>Q?VCIHO='N-.UG4E:_73T\[;7#FTU6NG7ROV_KN?H117PO\
M2XF^)O\ P3[N/%_B]_[3\5I^RZ/B?8Z\^^&[T[XAP_!NYUBS\66@M)+98]1L
MM5O)[Z!5VP+*Y'EA0 /?_ 'P,\,_#_6T\6VWB#QYXB\:7FG7UCXJ\4>*/&.L
MZM/XTEU">QNGO=<T1YX_"]H^FW%B/^$:L?#FAZ%I/A.SO-1TKPYI^F:5J%W9
M3%M+WZM6MV'>[6FC2=[]_*Q[317Y%^$_#OQ*^(?A'7?'WB/P3X5NOBE;:IX@
M'BGXH7'[9'COP/XM^%?B^PU"\270;+PO!\*;[PW\.]*\%S10V-KX)ECU'PQK
M>EV4=YXF_P"$U@UW5-7US]1/A[J.LZOX!\#ZMXCOO#VI^(=3\'^&=1U[4O"-
MZ-2\*:AK-[HME<ZI?>&-1"1B_P##UW?2SW&BWHCC%UILEM.$42;0-6ZW$I7Z
M-:7_ !M]YMZ[K>F>&M&U/Q!K5PUII.C6-QJ.HW2V]U=M;V=I&TT\JVME#<W=
MP4C5F$5M!-,^-L<;,0#XYX._:=^ WCW4]$T?PO\ $G1+W4/$XC_X1B"]@U;0
ME\3/-:O?PP^')]?T[3+;7KF:PCDOH;729KRYELHY+N.)K>-Y%]XK\[?@UX=^
M-?Q4_9X_9X\#ZOX,^&GA#X;6?@WX">(G\<K\0-<\6^-;_2/ D7@WQ;H;:'X(
M_P"%<^'=*\.^(]:ET*Q#:M<^.=27P9+/)=V%MXENK6 EI)IM][;VZ-]M=M@;
M:=EVOLWU76^F^[/T2IKL41V"ERJLP1<;G*@D*N>,L1@9XR:^,?BC\'?#WC']
MIWX?J=5\3^&;'QA\'_C#J/Q*M/!^O:AX;N/B3:^$?%7[/>E>&="\2:QILT.L
MV>C:;'K-V\R>&[[0]0U*W,FCZAJ,^@:CK6E:I[U%\%?AW_P@/_"K]1TBYU_P
M-'?W%]::%XAU?5=92P275)M7M=-L[Z\O'U*/2=)N9FAT73WO)(=*TZ.VTNS$
M>G6EM;1*RTUWUV]?/R'=ZZ;:;[[>7F=AX*U[4?%/@_POXEU?PUJW@S5=?\/Z
M1K.I>$==:V?6_#%]J5A!=W6@:NUG)-:-J6DS2O8WK6TLD!N()#%(Z;6/35\[
M_L]W&IVW[+7PDNM*MSJFL6OP7\*S:7:7=Q(YO]1M_"=JUA:W%S-(96%S<)##
M)-)+OPY=I,Y:O!/#'PJ^!'Q!^!&F_$SQ5\3O$5CXF\3>#HY?''QRD^*^O^$O
M%&D>)]2T]8O%VGZE//X@M=#\)V^DZO+J&C7OPTO=,M/#7AI+:3PU+X<M$LC;
MQEM_6VBOW%?1=6XWU:71?Y^B/T#HKX*_:+'C#Q3\<?!7@*?PSX?\9?#Z_P#A
MY<:YX;\'>)/C7XB^#.A>-_'::_=VWB$7;^&O!WBB3X@W'A'PXGAN[TWPGJ-U
M::9:)XFU'Q VC:[=Z?9ZAX9]%_9GL/&/AW5/B9X0UX>$M&\.://X4U#POX T
M;XUZO\;-=\!SZQ!KD6O:=>ZMXA\,>&=?\/\ A/49-*TW4/!^@:FNII8WC^*[
M;2+NST"VTK1=++:7OYV#FUM9[VO\K_<?6%>;_$+XH^'OAP-$M]3T_P 4Z_K?
MB:YO+;P]X7\%>&=6\5^(M5_LVW2ZU2[2PTNWE2QTO2X)8&U#6-6N-/TFVGN]
M/L7O?[0U+3K2Z](KXS^+?P.^$_CG]I/X3ZEXM\$:3KE]KG@/XMMJUS=M>K)?
M-H,OPKM=(,WD74*YL;>[N(H2BIE)6W[R%(%;K?Y#=[:6O=+7S=CZK\+>(H_%
M6B6FMQ:1XAT);HS+_9?BG1[K0=;MF@F>%A=Z;=@2Q"0IYD+@O'-"R2QNRL#7
M0U\I?&+2/#&DS_ [X5:KJM[X!^"NMZIJOAW51HOB#4O"=OK&KZ3HD4GP_P#A
MCJ7BC3[ZQU32M"\3N-:O9;>VU;3YO$^H^&=*\'7%U>V7B.]T36(OA]HGA;X<
M?'V;X;?"K5;YO!]Q\,-?\4?$3P/_ ,))JWBC1/A_XMM?$W@O3_AU>:?#J^HZ
MI+X(NO'FBZC\1&NM LYK/3?$">#8M;ATRVO;#4;W5BW7U>W2]MQ7UMYI/7JU
M?;L?65%? _P]_9L\">(O''[1ND:CJ?C:W\%>&/BWIVE^!? /A_QEX@\+>&/!
M.I:G\!O@KX@U;Q=I">'K_3]2N_%ESK.N7.H:=J6M:AJ=MX8NXS>>%;#1M0U#
M6KW5/O2&,PPQ0F268Q11QF:9E::4HH4R2LJHK2R8W2,J(I<DA5& !JW6_P N
MZ3_4:;?2WSOLVNWD+))'#&\LKI%%$C2222,J1QQHI9W=V(5$1069F(55!)(
MKR[PG\</A%XZUI?#WA#XA^%M?UF:&YN;&RT_4X9'UFTL@#>WOAZ5MEOXCL;,
M%6N[[09=1M+971IYHUD0MB_M%0K/\(]?6[M[F\T"/6O 5UXXM+:&:Z:Z^&=G
M\0?"UW\4;:YM+97N;W39_AW!XGBU>QMXY;B^TIKRT@BDEG1#SOQMUCP?K'@7
MP+!X?U'1=4\0Z]XW^'E[\&7T*[LKV>ZUVQ\2:5>1:WX;?3Y)?.T+2?#2:O?>
M*KRP9M/'@1/$%OJ+2:3=75O.))]];K3I;O\ UM=B;:;VT2>N[N[:?EL]6D?2
M%87B/Q)I7A338]6UF:2"QDU?P[H:R1027#?VAXI\0Z7X8TA#'$K.(Y=7UBQB
MFEP5@B=YY,1QL1\1>!OAK\&_$GQ@_:;\*^*=8OISX-^(F@ZIH?P\E\9>(/#N
MB>$-#\1?!GX7:_JGC31]+TO6=,,MWKOBF]\0/=^)YI;B71KFP>TTJ31C)?/J
M<'B31O#/Q$_9HTG4_&TQ\=>&_"OQDT2W\(>-?$U]<75SJGPSTS]H31="L/%.
MH:V\\3:K97/@*V*3>+KR:5?$>B6\?C"6\E_M0WKNRTWZ7T[JZMW%SNS=E>TF
MM;_"[.^FGE]Q^@-<Y;:W?S^+=8\.2>'=4MM,TSP_X>UFT\5RM;_V-K%]K6H>
M)+.^T"Q59#=#4O#\&AZ??ZFTT20-;>(]+%N\DBW"Q\CX'\*_"7X<ZK>^$O M
MOX9\/:[K-@OB&\\.6&JQOK5]I6FRPV(UHZ7<7T^H-IMG<:K;6CW\<(M(Y]0M
MH9)1+<0JW#^!?"'ASP=\??B=:^&=+BT>VUOX:?#7Q%JEO;2W+07>N7_C3XP1
MWNIO#--+''=7,=O DSPK&'2&)2-L: +OZ:#;?N[?%9V=^^FWW[,^B:*^6=;\
M.^$/B;\9O&?A+XJ:A>7,7AO0/#6H?#[P!+XDU?0=$U'P]?V4TFO_ ! 33-+U
M+3%\3:Q%XD6]\-7-W>G41X.L]$TJ6PBT:?Q/=76L<E']AUO]GS]ICP_;:UJ'
MC/X>^%F^(>C?#?Q%J>M7VOW=]H6B?#O0M<G@A\77%U/J7B2+P;\29O%?A?3M
M;NM0O+^)?#,.FWE_?W>ES7UR[>?:^G=Z6?7_ (?LQ<V^G\UM=?=75=$[:/T[
MH^TZ*^1;?X=Z-\.O$'P"\3Z!J7BF;Q1XK\7KX<\;Z_J_BG7-3NO'&F:G\*O'
MNN7,/B2PN+TZ),L.NZ)I&K:/%8:5I]MX<DT^'3O#L&E:(\^ES?75)E)WOI:U
MNM]U?R//OB-\4_ 7PETBRUWXA>((_#FDZCJMGH=E>RZ?JNH)/JVHOY6GV 32
M;"_F2>^G*6UH)(T6XNY8+2%GN9X8I*?@'XR?##XH7.I6/@7QEI6NZIH\%O=Z
MKHJ_:M.U_3K*\DEBL[^\T#5K>PUFWTZ\F@GAM-0EL5LKJ:">*">22&15X;]J
M*;5+;X3V]QH=A::KK4'Q>_9QFT?2]0U*31[#4M4B_:*^%;Z?87NKQ:?JTNE6
MEY=K#;W.I1Z5J<EC#(]RFGWK1"VDX?6]%_: U>_UWXOZOX,^'GA;QC\.?A#\
M5-%^%G@WPAXKUCXBZKXL\6>*K+0]4LU\2>(M2\%?#ZWT[0TU3PAI%K;>%-/T
MS6%U6_N8-9O=:LI-*M-/D=E:_77JNEK:6\][Z";=[;K1[/9WOK>W3YGU]17Y
M&Z)X?\=+\.]#^+G@[1?AOI?BQ+;3M<3]H7Q+^VQXZO9-;UJ-X9]2B^(VEZM\
M);'PWJ7A_5;D7.F>(?AM>VNDZ5X<M[B;2O#&G^$-4T?1;G1_K7]H_P"&FG>+
MOB+^SC?6>M>(O!?B'6_B=K/@K6?%W@S4I-&\577@)/@?\<_$^I>$;75E$K:5
M::QJ.FVYFU;38K?Q!I;'^T/#VJZ/K=OI^JV)RZVOW_"_^7KY!S.U[=NO=VW[
MK[O,^O:Y;PAX@U+Q+I=YJ&J>%]7\(W-MXD\7:'%I>MM;-=W>G^&_%&KZ!I?B
M.$VDDL0TOQ;IVFVOB?15=A<+I.K62W<<5R)8TY'PY\%/A]X7\*^)? NG:=J=
MSX+\52R2ZEX9UOQ#KWB'3X?M&GV>GW\.G3:WJ-]J5C;ZI]B34=2@AO\ R[K6
MKG4=9=1J6IW]Q<\A^S'I.G^'_AUKV@:1;_8]'T+XQ_'G1](L1+/-'8:7IWQE
M\;VMA80/<2S2BVL[:*.WMXVD810QI&F$50%IKZ_UU'=W7FG^%O(^AJ*_/CPW
MX3^#?C?X<>*/C#\7OB'KVB?$K1=4\3GXA>-_^%H^)/"NL? WQ1H^J7T+^$/#
MUA::Y:Z3X0TOP<L%K9Z-HS:*]CXZTZ*TU_Q#9^+F\4WM[J_5:WJVL>.?#G[*
M&@?'+4M4\&Z'\3?!2:C\3;6TU+4? (\1_&*/PAX3U+0?A7KE[I=[IVHZ1IFN
M37_Q!UVY\,V^I6G]M:EX(T_PO>R:CIEW?:/JSM_P=.ROIW_KH+F_)-:]W;7M
MK_5SZ@M?B'I%U\1M3^&+:=X@M->T[PW%XKAO[W2G@\/ZQI#W5G8W+Z+J_FM'
M?3Z=>:A:VNH0>5$UO-)MRX!-=[7PU\,- \ ^#?VN?$7@OX=^)-1O-)T/X%//
MJ7@F77]1\3Z-X US4_'6CO<6.DWVJW>IW>@S:SIMMI6HW_@F+48[#1HUT_7K
M31M-/BR>ZU7[EI-6^Y/[QIWO?NUIY'G?C;XEZ1X(N;*PGT'QUXEU.^@DO(].
M\$>"/$7BN6VL89!%)>:C=Z78RZ7ID9DREK;ZAJ%M?:DT<XTNTO3:W7D]%X3\
M5Z%XW\/Z?XG\-WDE[I&I"Z6&2>SO=-O(+FPO;G3-3T[4M+U.WL]3TG5M)U2S
MO-+U?2-3L[34M*U.SN]/O[6WN[::%,7QC<?VY:ZMX+\-?$>U\"^.3I=IJ\-Y
M81^&-;\0Z+IDEY*D6K2>&?$4%_;3:7?/87]@+N\L/L[M#=BVN([FV9XO/?V:
M;B)_A@MA%?VWB!]%\9?$#2K[QKI\LDVF?$/6D\8ZS>^(O'NGM)-<)"/$WB&]
MU2]U+3[*XN=)T;7?[5T71+FZT;3K"XE+*U^MU^/RM^/X"N^:VZ:?;1JVFC;]
M;I+MKH>_5S7C'Q/;^"_#&M>*KO2]<UFUT.R:_N=-\-Z<VK:W<6\;HLQL-.66
M%KIX(V:XE02*5MX9I.=FT]+7YF77A_X7^(/V=?&GQQ\??$+Q'HGQIMM"\5MX
MQ\8P>/\ Q#;Z_P##;XJV\=_;7/PHT+PE'K']B1:;X;\0K'X,T;X9-X>NM/\
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MU)H]-T+4[L6NB>(=1N;&QT'4]2NM2TV*[ZOX9?$SP5\8OAUX-^+'P\U:;6_
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M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIZ=K?GVM[<P:9%:7T$']I5]03Z;IUUITVCW.GV5QI-Q9/IL^ESVL$NG3Z=+
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M/AG\./B;966F_$GX?^"/B%IVFW@U#3M/\<>%-!\665A?JNQ;ZRM=>L+^"UO
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M-UX>M=&U?6);C4AI?T]12OI]_P".XVM;W[77>VWH?FUX[^&OA;POX\^,T_Q
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MXL32^(+ZPUR/Q(=>TK4+7%IIVEZI9^$]0>Y\3>&O$%Y<;'P8^//C[XH?%_\
M:/\ AKXI_9V^)?PD\-?!'Q1X9T'P/\4O&* >$_CSI^NZ?J=W?>(? +_V=:12
M6&AS:?;Q7GV*_P!=ACCU;3DO[O3-8%]HEE].44F[MNV^VNVWW]M1I-65]M]%
MKOOV[Z!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/1Y++2M-T_#'A7XFZ;\)?V<-;@^'M[;>._@MHNEZ/X@^&7B+7O!\.IZS9P>
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ME\2:I+XK\-K<>';GP?J$FJZ7;ZK?:KJ6D>(;272=.34-%6'0OA?XI^(GA?\
M:*G\?Z$/AI-^T+I=UX;@\)1ZAH^OZSX9T$?#R/P!#K?BJ^T&ZO/#E[XUU)'G
MGO;?0]7UK2K'1=.\-:1%KNHRV,\RI9#XR?$WQ3\*[#QW\+)_AUIWPR\1MXT\
M:^)[GQ3X.UWP_P"./$.G^$O$/AK2=*^&=IX=U_4_% T&XUSQ$/$]SK'C_0/
M^I6FFZ):Z.F@7EWK%Q<Z.]-?QV[=/GV%KIOY;[\W7UCWV]3ZJHHHJ2PHHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***_)K_ (*M>+?&WAVU_8=T7P?>?&R6S^(/[;G@/P1XT\&? +XL:O\
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MB#P\_P /)-'T&P\!:9XQMD^)[>:_M1_'']K'2M4_X*66^D_&PVVF_"7]H?\
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M^'/@OP+XA\2:?=-\+?&.I:CXQU#P+:7OB2X\7Z8+G2%O_&?#?_!53]H/P?\
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MACI/CSP9X)^)6L>./A+8:W:>+/$=CXD^)2ZI\3K:P?08I=&^'&KLUW!#]_\
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MET[C4DVDKZWUZ:6OY]>Q^C%%%%24%%%% !1110 4444 %%%% !1110 4444
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M#OQOU[5=;LY-)@EN[J+PII6OZC;;/L[V)NF6%O.IOAM_P30F\#?!?XE^'O\
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M_P#PDV?$7]K_ -LLU\?G?_AU/_P3:_Z,@_9K_P##5^&/_D*C_AU/_P $VO\
MHR#]FO\ \-7X8_\ D*B[[O3;4++LM?(]0T3]AW]ES0O"?Q;\$V_PO&J>'?CM
MJ&A:Q\6K?Q9XT^(?CC4/&NN^&;:UM]"\1ZCK_C/Q9KWB"V\3Z=)8VFI0^)=,
MU2QUY]>MH?$<VH2Z^@U*L>[_ & /V3K[2[?3KCX::J;^#6_$GB&7QM!\4_C!
M:?%?5=4\8Z+8>&_%C^(OC+:^/H?BQXHLO$WAW2M*T#7M(\1^--4TC5=%TK3-
M*OK&>QT^S@AX?_AU/_P3:_Z,@_9K_P##5^&/_D*C_AU/_P $VO\ HR#]FO\
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M;6MG%;_B+_P4I_8#_8F^%'B+_@FM:_#?]ECX&>"[?XK?\%._@)\(_B1#X?\
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MZ?J<5M>PI-'J.F:I862]Y]W_ ,'1??L#Y4];)ZM;=-7]R>I^DGP;_9)_9[^
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M.OW$VJ20:I^PG^RMJ]M%;7?POEB>#Q]\4/B9'J&E^//B7HFN+XJ^-=V;SXM
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MO?&]W\//B'<V?CF"]^+'@&7Q9J6H:Z/!7Q2N?&/AB*^O;EH=*C29T;X3UGX
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M_P -7X8_^0J/^'4__!-K_HR#]FO_ ,-7X8_^0J /T HK\_\ _AU/_P $VO\
MHR#]FO\ \-7X8_\ D*C_ (=3_P#!-K_HR#]FO_PU?AC_ .0J /T HK\__P#A
MU/\ \$VO^C(/V:__  U?AC_Y"H_X=3_\$VO^C(/V:_\ PU?AC_Y"H _0"BOS
M_P#^'4__  3:_P"C(/V:_P#PU?AC_P"0J/\ AU/_ ,$VO^C(/V:__#5^&/\
MY"H _0"BOS__ .'4_P#P3:_Z,@_9K_\ #5^&/_D*C_AU/_P3:_Z,@_9K_P##
M5^&/_D*@#] **_/_ /X=3_\ !-K_ *,@_9K_ /#5^&/_ )"H_P"'4_\ P3:_
MZ,@_9K_\-7X8_P#D*@#] **_/_\ X=3_ /!-K_HR#]FO_P -7X8_^0J/^'4_
M_!-K_HR#]FO_ ,-7X8_^0J /T HK\_\ _AU/_P $VO\ HR#]FO\ \-7X8_\
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MV::%^SA\<?CC\7?'/Q/^-G@Z?X-^)?&O[$G[&OAS1_&&DZ]X(\27WPT_:O\
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MPJ\6_&?X!^$;'P/HR>#/B'X*\6_ OXV>"?!'Q!U'3_LEKXL^#OCGPC\2M/\
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ML\_$_P"'7[07B'1]56W\2?"_X/Z'\1/A/XEM_$-NMJ6N],U[QKH^N_$GX:^
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MZZ?G<_&T?LB_M*P):_M;Q>(/&$O[2*?M+S?M(S_LVE_@.GA]]!U.YC^#5_\
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MMYWN_/4_-+4?V+=0\7?MC^.O'^O^(?CSX<^%EI^R'^S'\)?!?C3P-^TG\2?
M_B+Q7XQ\ ?%/]JG7O&FF>-;SP;\0-,\<>+;[1- \>^ -2B\0^.(+RTNKGQ)J
M/]C:K=ZF/$L=MQ?Q*_93^-?B77_VP?%/AG0-+;6;S]L']C?]I_X$V'B?Q1IT
M&B?%BV_9H^&?[-+:YX8UG4;*;6]3\*2>(M?^&'C#P9I>L>)=*MYM*\2)I'C!
M[&_T*&&ZO/UAHH4VNVR7R3O^/7UZ!RK\6_O5OZ_4_+W]HP?M?_M3?LY_M@?#
M#3/V9;KX0^'O&W[&WQY^&_@KPG\3O'/PDU7XO_$SX\>/O!>HZ%X/L?#NI?#/
MXM^-?A1X+^&FG6\FHV&H:MXZ\56NO>(-<\0Z'=O8>"=%\,:O-K_B'C;X+?%C
MQS^S#^US\'_!G[-'[?>@^._BQ^Q]\<_AAX1F_:;_ &M?@U\5OAOJ?C/Q-X O
M])\.>'=*TJ+]MKXRCPWX@UW6YK6QTWQ1=>%]'TC3-/;4(-8\2Z-I]U*MQ^V-
M%-3MLDK--:O=6\]=NH.-^KVMTVU^[<_,7PI^R'XJ^"_[7?P=^+>ACXI_'_X<
MZAX#\5> ]3F^,OQZ\9?$;Q!^RAXKN=(2\;XB?#.T^)WC^YL-3\*_%>QL7^'?
MQ$M-'TO7/B+HM^GA&[\-7J^!+_QQIMK]4VEI<2?M>Z_?:JCM:V?[-_@^U\!R
M2J3%%<:C\3O',OQ96R8_*LD\6F?!8ZF(\%DM])\W(6''TC12<F]^UK_._IY:
M)7ZZZCLNG>Y^4?Q9\*:S\._V3OVO-:^(]O:>'OBW\=_C_P#%/Q[\*/!\VJZ9
MJ6O^.?'GA?6M/TW]EKP=X=&A76K+JOBWQIX)^"'PVU'3=#TU[S4]&CN;B/4[
M6RFT35H[+RR[^&'CG2_VD_AH/$WP&M_VE_B+X4^#_P 2OVA?C=HNG:YX"LM)
ML/V@/VGO$>A>!?AS=M=_$S5]"T+4/ 7PI\!_!#QQ\(?#=Q;2:AXLTWP)9Z1K
MFG^%O$6KQ7,+_M?11S>6]_+HETUM9?>+EVUVM^;?IK?ML?A)XF_8*^/-BO@S
MP#=VGB;X@>'I/V2OA9^SG;ZKX$O/V;['X?\ @"YM+WQB?B_9ZFWQ\\$>.OB'
MX+\*ZB-<\.W/A/Q#\%?!WB?Q3J>E>&-#T7Q'HUE-X/\ "]VOZ6_'SX?>)]2M
MO@//IW@K5/C;X5^&'CF/7?&OP\;5O"%OX@\9I8^ /$_A_P *^()!X[UGPKX*
M\0W_ (8\7:CI/BF?2]>US1[9M0MX?$6G-+K6@:79S_5U%#DW:_3];K]>GKN'
M*E??6WX6_P OTV/S:^&'[+GBR;XM_"'Q+\3_  !X9L_!'@2T_:>^*]AX3MKO
M0=:\,>"/BM\=OB?X/O\ P7X6TO3D9!=7WP_^'FG>,9-3URQT2'P]-XN\7ZC?
MZ%>LT5LU>+?'OP#XR_:!_:1_:[T;P]\!-*^*BV_[/_@;]D+P/\0/$FI>!X_!
MGP9\:^.?#_B3XH_$?Q;XLTKQ3JUEXDO=.?PS\7?A5?E_AKHWBKQ+<S^#HM!E
ML-&AU4ZS'^QU%',[W\K+?36_?]?4.56MYW>VNC7Z_P"70_*'QO\ LK?$J\T[
MXY>(;;X=1>,?'7Q"_:%_9RTS2M2U/7/!J^(KG]F3]G[3_@Q=:E;-K6I:Y%%8
M#XEZUX!^(2ZEI8O;?5I7^(5O+JFF11:<9[7SAOV*OB[X-^#/A?P[X%^'>C/\
M1/#O_!//]H'P)XCUZVU/P39:E\0?VKOV@8?AB=9@U?5+O5[>34X-"U+PAXFU
M/3KK7+Z'P@#JVA64?B"&#2(7L?VEHHYGY?CV2[[:?BPY5Y_U=_K^"/CK]G/P
MS;77CKQ9X^\/^%[SP3\/="^%WPH^ G@3P[?+HZWC2?#6\\;:]XVO99/#NH:M
MH%Y;:1XC\;IX!CO=&U/4=)O-?\$^*]3T;4]7T/4]+U:]^Q:**3U&E9!1112&
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5;Z^LM,L
MKS4M2N[>PT[3K6XOK^^O)H[>TLK*TA>XNKNZN)62*"WMX(Y)IYI&6.*)&=V"
MJ2/S*_X)]?\ !6W]EC_@I/XE^+OA+X!6/Q/T+6_@[%H=_JMI\4/#_A?P[)XJ
MT'7K_6-,M_$O@R+P[XV\7W-]HMG=Z3#%JC:U!H&H6#:YH*RZ?YE](EMXM_P7
MY_:Q_P"&5_\ @F[\7(M&U/[!X_\ V@&M_P!GSP1Y,WEWD<7CRSU!_'VI1"-A
M<PK8?#73?%L-OJ,!3[!K=_H9,T<T]N)/YL/V8_VLOV'?V/OV_?\ @F)XS_9(
M^-6F^-?!WB+]G3PI^R/^VO'9>!?B7X L+?QIXBU.W&H?$G5+GXB>"O"$6I:;
MJ'Q#\2:'XJGFT5]:%AI?PQECOFMGU"RGO=H4N:$I6DV[\EMO=7,[^OPKS,Y3
MY9)75M.;O[SLK>F[\C^Q_P"+/[>7PA^#G[8?[.G[$OB?PY\2+[XJ_M.:#XI\
M0^ O$&@Z/X8NOA]I%EX2T_Q%J6I1>+]5U#QAI?B.PNIX/#-^EBFC>%-?BDEF
MM%GGMDDFDM_MBOYI/^"B.N6_AC_@O+_P2K\2W<4]Q:>'O@K^T#KEU!;*'N9K
M?2? OQAOYHK="0&GDCMV2)20&D903S7XR>"?VXO^"AO[5/PY^)'[6/@+7_\
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M[=K:=KWNTEM]S/ZP****Q- HHHH **** "BBB@ HHHH **** "BBB@#\?_\
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MHES<W.D65C:>*)O%+17,UY^Z9U:X4;VGMRHP3B>WZ'_MCFD;7&XQ- .N<W$
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MJ^)NM? S_@L1\>?@#H'Q1^(/B3XA:YX0^$OPW^(/@;29]4U_4;F[1]43P?\
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MYK*_6W74_&KP1_P2=^*MM^TE^PI^TW\9OVU;SXV^./V+/"/C_P &3/??L_\
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M_"X?^$"_X82^+$?Q0_X1W_A7W_"4_P#"T]FL_"W5O[#_ +6_X3?PY_P@^?\
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M_A<?]N_\-D^"O#?@_P#X5U_PKW^S/^%<?\(_X>T?0?[1_P"$N_X3C4/^$O\
MM?\ 9/VK[)_PC'A?[/\ :/(^U3>5YTGAOPA_X(^_\*J_X)9?%7_@FC_PT/\
MV]_PLVX\83_\+J_X5)_9?]B?\)7XAT77MO\ PKC_ (6;J/\ :7V#^Q_LN[_A
M/+#[5]H\_%MY/DR_M314<\N_6+V6\%:/3HOOZW-N6/;^;O\ :^+[_P#AC\0?
MB!_P1CM=8\"_L/ZO\(_VHO&/P'_:W_86^#_AOX+?#_\ :A\'_#S1-9@\5^$=
M$T&?1;NP\6_"7Q!XEN=/N])O&U'Q%/9Z(_C*YL[>T\6>)=(UIO$EAJ");]%\
M./\ @C?X2F^#7[77PW_:O_:4^,O[6/BW]M.XTF^^+/CW7/L7P^TC0]7\,W<&
MJ>$_$GPR^&.E7OB#PAX.\2:!K5AHNHV]^XU>S,'AS0- M],L_#-I=:-??LY1
M1[2=K<W6^RO\3E:]KVYG>U[7#DCO;\[;6VO:]M+VN?C'^S/_ ,$NOVD/@SXT
M^"DOQ3_X*A_M+?&7X(_LY06EG\)_@-X:T.T^!.A7FE:-#:6WAKP]\9O%/@7Q
MC?:W\;_#&@V^GV,4.@^,85LKBWLTTJ0+X=NM5T/4O?/V/?\ @GU_PR?^U'^W
ME^TI_P +<_X3[_AMOXA>%/'?_"%_\(%_PBW_  K+_A&-3^(NH_V5_P )'_PF
MGB/_ (3/[=_PG_D_;O["\)_9O[)\S['<?;]EE^D%%#G)WNUJK.RBKJ_-T2UO
MJWNP44K66SNM6^ENK?32P4445!04444 %%%% !1110 4444 %%%% !1110!^
M/_\ P5J_Y&G_ ()*_P#:8#]FG_U3G[2U?;'[9/B[PKX2^"-W)XI^(7A_X9KK
M'COX4Z7HWB;7]8\.:0+35(_B;X3U=[K3/^$I;^Q]0O\ 1M*TO4O$3V5W;WML
M-/T>^O+^TDTVTO"OQ/\ \%:O^1I_X)*_]I@/V:?_ %3G[2U?L!36Z$U=-=U8
M^%_#ES+X!^*O@+QQ\6/C1)\9/ /Q)TQ=$^ _Q5U*X\#^'_"?A3Q)XIL=/NH_
M"\MKX%TG0O".OWWQ6TVU^T_#WXAS/=7%V;>\\ ::+*Z\1Z6?&-OX@?M)?L[>
M'?VEOAU9>(/CW\%M"O/"GP_^.OAWQ1::S\4O VF7/AOQ!=>)?@D;;0]?@O==
M@ET?6+D:1JI@TS44MKV;^S-0\N!OL5SY7V[11==;[6TLOT_+KJ+ETLGU3UN]
MM>]]^^RT/G'XM:Q9>"?B)\*/B_K\-Q<_#KP]X;^)/A+Q%K=C97&KVW@V^\>W
M/P\U+P[X\U6"QANKBV\-VEOX+UOPQJOB*V@DBT&+QC#?ZK+9>&3KNIV6[X;_
M &AO@QXVO]6N?!OC/P_XO\.^%/#&K^(O%7Q0\/:CI6J?"_PAIMD]I+=Z?K/Q
M(AO#X:M]3GMH;C5KO2;+4;R?2]+T.ZU/Q(FCVW]E27_N-%&G]?\ #>H[.^ZM
MOMUMZ^GZ;GXYZ=XHT+3OV3O@Y\1-1_;'TA_AT/'7P'TS_A%;V]^ ]IX+BU'1
M_BCX(US5O!7_  ED7AZW\2?;?"VBV%[K&H6S^)CK]GI>C76H:O,;2WO9J]\\
M8?%M_B_^TY;^"O@\GP2^,]E\%?AWKU[XB\'ZY\<-.\,W$GC/XC-!X<O]6M]&
MT/P7\2M3U6W\#^!OM?AK5;VXTS2](MI/C#/I$E[>ZDEQ9V'Z(44[K>W?MU]$
MA<KVOVOO?3U;7X'Y$:9^T'X ?]D+5OACXR^-_P )_"?CWX,_%+X8?!W4-:TS
MXM>!_%T&F6VC?$[PIJ_P_P!>L/$.MK9V7BF^L_AOIJ7NKW^LZ# ESXD\%>/8
M=9TF)_#NOVEG]'^'+F7P#\5? 7CCXL?&B3XR> ?B3IBZ)\!_BKJ5QX'\/^$_
M"GB3Q38Z?=1^%Y;7P+I.A>$=?OOBMIMK]I^'OQ#F>ZN+LV]YX TT65UXCTL^
M,?NBBB^^F]^W7MI=:^>VC!1VUO9)+?I??6ST_'4^$_AC^U'^SGX7O?C3INJ?
M&[X8R:^/C=X[EM?"&C^,]"\0^.-7=8M&M4L_#_@?0;W4?%GB'4KB\MKBRM=-
MT31[^_NKV&6TM[>2>-XQ]$_L_P"@:MX9^$'@S2M;TJ?P_?FVU351X:NC";GP
MI8>(-=U37](\(W(MI)K6.X\*:1J=CX=GALYIK*"73'ALYI;:.)V]CHI-I].W
MX*PTFMVM$TK+N[]SFO&/C#PQ\/\ POK?C/QGK>G>'/"_ARPEU+6-9U6ZALK&
MRM8BJ@R3SO'&99YGBM;2 ,9KN[F@M+=)+B:*-OR_3XD^-?#_ ,*?!'[2VNZ;
M\%[/P[;_ !=U'XSZW\0K'X_6&J:AJ^B^+IM7\+>*?A[9:1%X&M_#>O\ B+PW
M\,IU\"Z5X7T[X@:A+-XF^'>A):7&JZKID$4GZRT4T[=+]_373\?/TT%*+EUM
M9.VG737\%IIUUU/F']HW]KGX0_LR?!6Q^/WC.;Q%XM^'.J:UX1T72M0^%ND1
M>.Y]4;QM=QVNAZI8"POH+&YT682+/_:*7YBN5>WM=-6_U*^TZQN_IQ'61$D7
M=M=5==Z/&^U@&&Z.15D1L'YD=5=3E64," ZBEI^?_ _KJ/7J^W3KU^_\ K\A
MM;\4:%XH_9Z_:X\<>%OVQ](T?P-IOB3]HJ#4?#>@7OP'UKPI:3>)_$'C"#PY
MI5[XEU7P]JVOVDGQ$GN;<:(DGB".\U2;5X8_#3@262+^O-%"=OP[='YI@U?\
M>_5>31^<_P 3?CMH?Q&^(_[.7PC^"WB?X*_%'5[>*W^-NN^%-1^-NA^%K?Q+
M9^%_#YN/AQI6E7.BZ'X_U37;LZ[>_P#"V+:VTGP[<I;6/PRMM5O]0L+"[L_[
M1T?V<?CSX-\ :G\=_@[\6_''P6^'FK_"WQ=K'Q&@T.P^,_ASQ+HW@_X>?$G6
MY]7O-+U3Q!JMAX+N=,F\'?$74?$.BWFD:IX>T?\ X170=;^'NG,GV35]$FO?
MT'HIW5K6_P [WO\ UI\Q<KO>^O:VEK6]?Q^1^<GPL_:_^ OA;]G_ ,%6/ASX
MU_!+Q%X^^U:9HVG>!8?BEX-NO$6HWGB#X@)I7V2VT&QUU]:N+W[%J;WEK;06
MCRR[(W\MH6.>_P!<_:0_9W\)_M/Z[:>*?CU\%_#5UHWPEM_#>KVVO_%+P/HU
MQI7B*T\=:E/=Z!J4.HZ[;26.M6L#+-<:7=+%?0Q,LDD"H03]N4475V[/6_5=
M?D%GIJM+='TOY]3R+X,?%C1OC)X<U[Q9X<U3PYKWART\=>+_  QH'B#PGK%K
MKVA:]I7AS5'T^VU:RU:PN;NPO/M.QQ-)97$EL)D=8R-I4>NT45)2\PHHHH *
M*** "BBB@ HHK!\3ZC+I/A_5M0@(6>WLY# Q (2>3$,+X((;9+(K[2"&Q@\$
MU,Y*$)3EM",I/TBG)_.R^\UH49XBO1P].SJ5ZU*C3N[+GJU(4XW>MES33;L[
M)-V;LGO45RV@:=>6T.E74FHWUR)M&7^T8KRZGNEEOY3;7"7,(GD?[.5,EW$4
MBVQF(PIM!B5CU-$).45)Q<&[.S:>C46G=:?:L^S379NL32A0K3I0K1KQ@Y1=
M2,)TUS0J5:<ERU&Y+6ES)W:E"=.6C<HQ****HP"BBB@ HHHH **** "BBB@
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M_P 48,JDDT:N2 J;LL0%8CKYOVGO%OCOXQ_&+X*_ +P/X5\4:]\ M/\  O\
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M_P"#'PJ_:)\6?LU>#K'X+_%CXJ?#[X::4=#^,DFO_$NQ7XF?%*V^$NEZ_?\
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MA2Y<3A,#F,\1/$WYG4A/-ZLL1B72JPE*E4IX..&I2IU)TTH/FF?AO^S!K_\
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M:=>^IQ8#$K&*M+1.CB9T6HWM[C33=];M:L_6ZBBBO//9"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /Q__ ."M7_(T_P#!)7_M,!^S3_ZI
MS]I:OV K\?\ _@K5_P C3_P25_[3 ?LT_P#JG/VEJ_8"@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N3\=1--X2UU%SD6?F\#/RP313M^&V,Y/8<UUE4]1M!?Z??6+$!;RSN;4D]
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M>D:!X<T?Q'XVT3X7Z3X@U6_M](\3>)K*%-&N[F36=/MY/SS\07WQ3\2>'?\
M@IOX+^*WAW]HCPS_ ,$S?$G_  4Y_:3^.G[1?CSX)_LD?#?X_$>'/@W\=/#G
MB[Q=KW@/]I_2/VO=-\7:7X3D'PMTG6/B/?6_['WQ"\2?!*_TOQ;\/O#^OF\\
M%WD/AL _J.LOVU?!FB_$/]ISQ3XP^/7P2U7X _"#X'?L]?&/3/!_A/P-\2XO
MC?\ #WP]\7]-\5WUEXO^*E_<ZCJFDZYX<^)']D6\OPYTOPQX(T76]%M].U:/
MQ5YL@AG?R/\ 9@_X+2?L)_M&_LHZ1^UEJ_Q8T3X'^%!8>!!XW\/?%6XNM%U+
MP-XJ^)5UXCM/!G@4ZI+IMOH_C7Q3K\GA/77TW3/ 5QXBNKF*PF<0)MQ7%?LO
M>$_$WC+_ (*=?\%)OCMHOASQ+)\#OV@OV0_^"=C_  7^,%UX;UZQ^'7Q+BM_
M"_[1U[J;>#/%5[IUOI7B*?0K'Q7X:N_$%CI=Q<W^A0Z]H_\ :UK9MJ5DLWYB
M?LR?&+]O+X _\$DOV4_V;/A/^R=^UA\(/CG^RG\2O@O\#OVL?&?B7]D/6?B=
MXH\!_!_6=7^,-KX]^,W['G@C4FNM _:?UOPU+H/A""6^\$:;X^TO1?#'Q%AU
MC_A&_$DJ3V-F ?O5_P -L? G]H+]E_\ :8^*G[)7QS\&_$;4?A'\-_B9_:&H
M>$KV*XUWX>^.M&^'^L^(M"@\4>%M:LX-8\/:D&@M=5TZS\2Z);1:E;1^?##=
MV@D-?EI^P[^W%\?O&?QD_P""9%M\9?C!JFL?#[XJ_P#!!^__ &P/CK%?:+H"
M6_B?XRZ3XJ_9LCU+XIZE_8N@0ZG#J=MHGBKQ:K:9H1M=)=-5NO)T:2X^S^7Y
M1^Q5\,_VDM=^./\ P6M^)7C70/VTO'>@_M ?L;_LX:'\(_BG^U7^S9X-_9]^
M(/QOU[PA\/\ ]J[PE>:5X?\ AM\+OAC\*]-COO#4^HZ+H-AX<\3>!=%^+MKI
M.J>&KKQ7I":=XB\)WFI]A_P3B^ 'QR\#_M'_ /!(G7/'/P8^*/A'0/AK_P $
M 4^"_P 2=6\5?#_Q3H6E> OB\?'?[*UXWPH\;7NK:5:VOA?XC&RT'7[EO VN
MR6/B7[-H>MRG2_+TG4&MP#]S[[]KO]FC3?@#X0_:EO/C-X+C_9^\?P?#^?P5
M\4H[Z:X\.^*/^%J:[HWACX?6VBBVMYM0OM0\4>(?$&D:/8:9#8MJ*:A=FWN[
M6W>VNA!L_M#_ +2_P0_93\ P?$SX]^.8/ WA*^\2Z'X*T1XM#\3^+?$7BKQI
MXEDG30/!O@KP/X'T7Q+XW\<>+=8%I>SZ?X9\(>'=;UNYM+#4+V.Q-G87D\'\
MQ'[-7P#^)'_#QKPE_P $@M7\,W9_8Y_X)N?M/?$C_@IWX(UTR0MX>U7X4?$^
MVL_$W[$?P)MRLDU^]U\(/VA_BG\=M;GM=8@@T^]TGX*^&?[-20:?;W,7[=_\
M%2?!OPL\:_!;X9P_%'P)^V;KDOA#XY>%?B+\,?BE^PGX#\0_$?XZ_L[?%GPK
MX<\81^&/B]8>%?"6E>+M?U#1TTO5?$7@?4X/^%:_$KP_>0>,VTSQ/X8&E7TF
MIV(!N)^V)\+?C#\3_P!A/6/@[^U7!X2\$_'KQM^T3X:T[X.Z[^SMX[D\4?M(
MZO\ "GX8>+-4\1^![O7O&ND>%?%'[-.O?!6_\,:OXYUR/QMX;TW4?%QT-O!2
M6D4^H6_G[W[0O_!4G_@GA^RCXVU'X:_M"_M@?!#X8?$'1;;3+OQ!X+UOQ=;W
M?B?PU!K=NEYHK>*=%T6/5+_PP^L64D5]I,.OP:=-J5C/;WME'/:W$,TGY/?!
M73/V]?C-\=_^",OQ7_:A^&OQ5UO4/A3^T[_P4GAU3XG>)O@P/AKXQ3]GW5/V
M9/BWX%_9U^*7[3'@#P?!<>$/@1\0_BE;W.C:?=>%;E?#5FWB"_TS3;?1M.UK
M47TB/\G-9\2_M'>.[O\ X+1_L_\ @7P!\1#^QA^U-^W9^U)8_&_XP?#C]ACQ
M+^VKKNBZ#%9>%O!?CK6?@]\:O 'Q^\&^'/$.JRZ%X::]M/".O_"+Q%J7[./B
MV2_\-:=J'B/Q'X?F6Q /ZR/%O_!4+_@GSX!\)>$?'7CG]K3X.^#/"GC_ .'&
MH?%OP/K'BKQ"_A^+Q?X TOQCIWP_O-;\-V^K6MI>:U./&>JV'A^WT+3[:X\0
MWU],WV'2;F&"XEB]C\$_MA?LM?$?]GF^_:R\#?'WX6>)?V;-*T#7_$^L?&K3
M?%^E/X T31?"BW!\3W6NZY)/'!HDWAYK2XAUK3]5%GJ.F7,3VMY:0W.(C^07
MP7\#_#3]H+_@I=_P3D_:D^"7A;7_ (W_ +(W@[_@DG\4M-^"O[1WB/P-KNM>
M']&\9R?%_P"!NA>#/MOC3Q%X<L8_"OQIU;X>Q^-H+G2M130?'4EA_P )O#)I
M=O;PZY!#\"_M(?LU?&Z[_8=_X+-_LU>!OA)\3M!^(_[5/_!9"_\ 'W[+OPPT
MKPU:^"]0^._A3PWI/[)O[0GQ#U7X8W7CW2D\$7?A/Q+X=^#7QAO?^$RO;/5_
MA_J7BW2=1T74X=:O+N]T.] /Z-_V:/\ @H5^R%^UYXG\0>"?@-\6+CQ%XU\-
M>%K#QY?^#?%_PX^*_P 'O%M]\/\ 4[X:78?$3PQX:^,O@;X?ZUXT^'5QJ3P:
M>OC[P=8Z[X/6^O=.M)-:2?4K".Y_.W]M3_@KI\#)K_\ 9D^'W[#O[:?[/_CK
MXL:[_P %)?V)/@+\:?!WPX\:_"OXG^)9?@Q\5?C=IG@;XK:-_8MT/$<EOINH
M6-V/#^H^,O#$$>I>&+^[@CT_Q!HVKS6LA^#?A-\"OBO^VK+\=_%"?\/I=%_:
MK\*_L'_MF? /X/\ C7_@H+\/?V??@E\#/!/B?]I'P)H/AK2]&\/^*/!/[-W[
M.7Q!^(NOZAXLT;P[KEAJ>A:?XA\(>"I_ NL:Q>7]@FK>%K[Q3YKK>F>)_B_^
MSA_P1L_9Q^'W_!)_]K;X5?%']B?]M#_@FYJGQJ\9^,_V68?!_@GX(:1\*_B;
MX$\._&GQ!X'^)4AEU/XG^%_%6JI>>+O$?COX9VVN>&Y?!MEJOQ ^*VN^''M1
M#<@'[P?\%6/VF/B;^RO\(/V;O'/PR\<Z?\/6\8_M^?L5_![XBZ]JNE^%=2TZ
M7X._%'XUZ%X9^*.D7TOB_3-3TW0[35?"=Q?VMUXDM!I^LZ#;M+J.DZQI5Y#'
M>Q?07P?_ &_?V)_VA;#XGZC\ _VI?@C\;H?@SI.H:]\3;;X1^/\ 0OB-JOA/
M0],@N[BXUJ[T3P?=:QK-YI,R6%Y'IFHZ787UGK-S;R6>D37UV/(/PQ_P74^%
M'COXP_LH?!+P]X#_ &>_%O[4DNA_MX_L:>.?&'P0\'^&=/\ %5UXX^'/@WXN
MZ=K/CK1]:L=>:#PE9>%]1\/P76E^(-9\<W^D^!=+L+][CQ=J^FZ&+R[B^6?"
M.I?&#]H[_@J/\'/VOOV9?^"?OQ\^"OPZ_9R_9!^*_P "_BQJO[2?P\'['6H?
M&G5_BCXP^']YX!^$OAW2O$^E:CJOC/PI\&H?!VO>+/\ A(M.T?4?!$&J7]MI
MN@ZS+'-8W5X ?MC+^V/^S-%\'/@G^T /BYX?G^$/[1OB#X1^%/@?XRLK37;^
M#XD>)OCKJ&GZ7\*M \/Z38Z3<:^^K^*K_4[:!;"[TFUN=%\N_E\11Z1#I6IR
M6?S[_P %._VHOC7^RE\"?ACXG_9\M?A;+\4?BW^UA^R_^S3H>H?&7PUXM\8^
M ?#D7[07Q9T+X;WWBC5O#'@GQU\-O$6MR:!;ZP=0M;"S\9:.LTT06:5TS&W\
M[_\ P20L_B9^T3^U]\*/V3-<^%U]X*_8W_X)H>-/BU_P4$^"EIJ/B"Q\4V%W
MI7[;.CRZQ^P]\+-2-A:V\<.J?L_Z/\5?VH;G2K^>3<9/"?A>ULM.TZVT-&O/
MV\_X+3_ ?6OVD/V;_P!GSX66'PFUKXU>'-5_X*$?L*WOQ1\#:3X/U+QQ8W'P
M=L?V@/"S?%'4_&.BZ=8Z@$\ :9X.EU2X\;:IJ<*:'I?AW[==ZS<VVGQSS*-6
M=GNM!)W2:V>J]&<U\(/VVOVF4^.7[;G['7[4'B_]F^T\=_LY?LG^'OVD[']K
M+]F#P+\0;OX<?#S2_'1^)&A1:#\6/@3XZ\=?$SQ!H_Q.\#3^!)?B/I_@JW^)
M>MK\0O DD$\-KHKSHD_T</\ @H7^R3^SK^RI^RS\7OVI?VU_A,VF_&[X/_#G
MQ-X*^,_B[1U^#5S^T2=7\!>&_$=]\3O"/P3N'N_%/ABQ\2VFM:?XLU+PE;6%
MV/A_#XBT_1-9FM)1 )?S?\/?LB:]^PO\9O\ @H[^RC^S)^S[XML/V+/VP?V&
M_'W[0OP:L/AUX#\0:Q\/_A)^U9X:\*Z[\(?BE\#=)U73-/U/^Q[KXSZ!JWP]
M^)'P^\$ZCJ<5K-JVD^-]-\!Z3;0QW=DWSQ\!?"?QJ_8?^,7_  3)_:W^+_['
MO[47QF^&EE_P0T_9>_8OO=-^"7P/\2_%_P",_P"RQ^T=X*.A>,_'>E^-?@EI
M=M'\0_!^G>._#M[;>$?$'BG3]#N=1T?Q'X,;PGXLBTW3I%:$&?H7^VE_P4-\
M'_#+XU_\$E/BCX'_ &H?AOX=_8R_:$^)_P"T;>_&+XH0^+? L_PB\<_#'P?^
MR=\4/''A:\U#X@:A]JT^QTK2O'6C:3?6]QH^LZ;=3:Y9PZ1<O/,7T]_N#X?_
M /!13]B#XK? GQ[^TQ\-?VF/A?XZ^"'PMOWTCXB>.?"VL3ZS%X/UOS[&UMM
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M^U/J/Q@_:9U32CX6UK]I?X@_M$_%KPQXY^(G@[P#X'U34KR:U\(6_BW08)-
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MY[>]$@&-YX"#=C''RY..HX]LCCN.M9TM[';K(\TBP #S&:6011QKC(W;]JH
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MN>Q\S]S:3:Q>QS:JEO$J)*EJ+LVHE=S'!!EH(_2I0RC"1?U^>(S;$>SFX8#
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M&T5-3M-.N-&CU\ZQ]B?Q?:VVHZ9K]QX8&-33PQJ5GKRQO8/))%Y9I'_!./\
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M\211&R\.Z?JOB6TN]:NQ+/!&;;38;F;S)HDV;I$#4[K_ ((W?\$'+'XAZ?\
M"*]_9!_8TL_BQJVER:WI7PPNK_2[?XAZGHL4<\LNKZ?X*F\4IXDO=+BBM;F2
M2_MM,EM$CMYW:4+%(5+/L^^S%==UVW6_;?<_:W[=9?\ /Y:_^!$7_P 71]NL
MO^?RU_\  B+_ .+K\E/^'"7_  1R_P"D>G[.W_A-:A_\MJYQO^"(?_!$1-$U
M#Q*_[#O[*:>'-)N]3T_5-?:V1=$TV_T35;C0M9LM0U4^(!8V=WI&MVEWH^IV
MUQ/'-8:K;7&GW217<,D*@S]COMUE_P _EK_X$1?_ !='VZR_Y_+7_P "(O\
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MU^19QSM<$1T6?9_<PNNZ^]'[,_;K+_G\M?\ P(B_^+H^W67_ #^6O_@1%_\
M%U^&^A_\$E/^#?CQ/_:X\-?LQ?L,>(3X?T+4?%&O#0_$OAW5O[$\-:0(CJWB
M+5_L'C"X_LW0M,$\)U'5KWR;"R$T1N;B(2)F]X._X) ?\$"_B)JLNA?#_P#9
M0_8G\<ZW#93:E-HW@[6=$\3:K%IUO+!!<7\NGZ+XLOKN.R@GNK6&:Z:$012W
M,$;R*\T89V?9_<_\@NNZ^]'[=?;K+_G\M?\ P(B_^+H^W67_ #^6O_@1%_\
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M_L:_L?Z9X7\=:AX9TGP1XDU">QLM!\8ZKXU\H>#=,\*ZQ<^)HM.\0ZAXM-Q
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M@#X>>#/!UI::;IJZ%X.\-Z0VJ7UKID[ZE>3:[XAU_5+O4IY+Y8X?IG[=9?\
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MO2]%TK5+YHM.3RX9);F"%Z?B?_@G5_P;U>%O!GP&^(5S^Q-^S[J/@_\ :/\
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M_4U\.>"]!O\ Q'K3:?8_VW#]LO1ING7)M;7SHOM$X2+S$W[APWPP_P""0_\
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MZ?L[?^$UJ'_RVH_X<)?\$<O^D>G[.W_A-:A_\MJ /UK^W67_ #^6O_@1%_\
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MM[%"G)7C"<MM(TVV_.S2VW>M_EJ9RKT8.U2M2I_WISBH^E[O5[+35]C6%X2
M?.'('!\O//8D\Y]R,Y[4&Y)!'F9Z?Q#L03]U">F1TQ7,V^MZ1<3;;7Q#HUT1
M)L\F"XM)9O,#;1$S12RJDA?]W^^\K#YWE"& J:OXS\.:#>0Z=J_BGPUINH36
MMQ?16>I:UHFE7L]G;L TL-A?:G;WKH &#3+$T&X#]X"55DXOF484*]WT=&2Z
MV[M_AIL[ JU&47*G5HU8Q=I.G7H>ZVKI-5*]!W:U5E)6ZIZ';K=D;OWI +9
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M;/">IVFJ^)+W6O#'Q/N/%7Q?^%_AWQM\-EGU+3=;\(VY@\=VVE:CJ'C"/4/
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M?V(?B7^R;^S/^Q[\:/VZ_P!M/XG?M6_$3XMZ'\&?AI'/X8\'^#/A1_PI_P"
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MM?#VIZ3K/BC6-9\:>!?"GA&+6] TJ76]9\1ZI=:)H[<[WT>KONNT5;77[-]
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MV_QP_;?^ %W^S/\ V!<LHM[I?AM^SGK7COX=ZPEJT@BN]0MO-6Q<"VD_.O\
MX-F_&&O_ +&/[5W_  4V_P"")OQ,U:[EU']G/XR:]\;_ ("/J\F+WQ!\,M5O
M=%\+:_JENDPC^S66M^%[_P"!WQ#TS3+52KR>.?$VI&")OM,LW]D5/G\M=_G:
MU_NT%R>;MM\KWM]^I^(/_!,GXG_#F7X5_LA^%9?V@?V M4U__A2?P^TF'X9^
M$=.T*R_:;@UJ'X:6L0T._P!1;XSZO>S>,]*FCD3QDB?#VVN[Q;768O[-T=Y6
M-I^>'[<G[0^D_L7_ +&'BGX[_'7PYX+UK]F;QC_P48_:8^'OBG4_A1\%-/\
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M%X"\$:SXDT>Q\0VVCZEHVJW&BW-_I\$6IV^FZOI=]-9M-%:ZC93,EQ'\X_\
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MBJN5Y<OM1H-1_M/%QZK]W*G@:4EO4KUU%MQ=NF(!!!&0>"#T(]#7YB?M[?\
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MRI5*U'$*IAJDE6HXBG0_<M2<INE.I"?Z0^%_^#NW_@F5J&N:)9_$?X3?MS?
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M"."Q2^M+G5;*&[,%S]OT44F[_P!?YC2LK!1112&%%%% !1110 4444 %%%%
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MT36/#UM#$DY#0VMSH[PB&.-6$_E+.?$O#.M_''_@E)XQ\5>'/&^F?$'XY?\
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M?%?XI_$W6/$$[6\E[+JOB;_A+;QH[LWMX==N9\W7[1'X5_\ !0J:/_1_VO\
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M'-4U:!%CO;[0['XNW26FF7-P@$LMI;KXJ\0K%"[-&@U:]"J!<2AOUH_X+/\
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M^$T\*RV>D^%=2U/P#XB\.-K.G^(/[(F:>3XH7-L+>UN7AU>YD$7F_;EFS/\
M\&>[EF+$?\$R[]06))"I9W"(N3V5%55'0* !P!7&_M$?\$>O^"\__!0_X%>/
M/@Q^WY_P4N_9TM?!=IX+UZ[\#?"7]FCP=KOA3P;\8/BUI^EW$OPUO/VA?'/_
M  J#P3KUEX TGQ?%I'B#Q'H&@^#/&^GSK8"70_#>FZ];Z3KNF?J);_\ !-+X
MU0_\$'V_X)<-XR^%Q^.[?L=W7P _X30:IXL_X5)_PG$]E,JW_P#;)\'CQC_P
MBBW<@B.I?\(-_:_V<&Y'A_S?]$H ['_@@#H^DZ'_ ,$;/^"?5KHVF:?I-M=?
M ;3=8N;?3K.WLH;C5M=U_7]8UK4YX[>.-)=0U?5KV\U/4KQPUQ>W]U<7=S))
M/-([?A!_P;]26M__ ,%\/^#@#4/'JQM\7(/C'\4[#PVU]Y1U2#X=1_M2>/K?
M5[;36E NCH,=OI_PGBA:'-L]G;Z$TI8_9&/]0'_!-+]F+QO^QA^P5^RQ^RQ\
M2=:\*^(O'OP/^$VA>!?%FM>![K5[[PAJ&M6$MW/>3^'KW7M&\.ZS=Z6'N?+M
MKG4M"TF[F5/,EL+8MY:_C5^WY_P0S_:=UG]O=O\ @J+_ ,$F_P!JWPC^R;^U
MEXJTB+1/C!X4^)VB7VH_"+XF@:;IFBW^J7\FE>&/'4<,/B/2-#T1/%OA36?A
MYXFTG6?$6D:9XZTZ^\/^+K1M1N #NO\ @[!72&_X(E_M%G4ETYKQ/B#^SPWA
M\WPMC=)JY^-W@I)FT<SCS5U$Z"^MI*;+%S_9#:HKG[&UV#^FG_!(_P#Y15_\
M$UO^S#/V1_\ U0O@*OYY_P!K7_@W]_X*C?\ !1_X'?$36?\ @H/_ ,%"_AM\
M7?VD= \/V%K^RE\%_A[IOB+X6_L;?"KQA+XET)_$OCWQQ=^'OAQ:>+?&OB#4
MO R>*/#^DWTGPL;6-(O-5@^U:WK&AI%I%A_4!^P_\#O$W[,?[%_[)/[-_C75
M-"UOQC\ OV:O@=\&/%FL^%YM0N/#.J^)/AE\,_#/@S7-1\/7&K:=I&J7&AWN
MIZ+=7&E3ZEI.EW\UC)!)>:=97#26T0!M_M;_ +1O@_\ 9#_9A^/7[3WCUXSX
M6^!GPK\9?$>_LGG6VDUNY\.:-=7FC>&+*5@5&J>*];73O#6D(0?.U35;.$<R
M"OX2_P#@A5\=?^"N?[.OPF^/G[5_PJ_X) >*?VT]:_X*&_&/6?CYXF_:2N_V
ME/A]\'#XML;+6?$]I#I%CX/\0:#X@UT:=8>/]9^)^O6^LWUW:1ZLGB>,V-@=
M/M+/4]3_ *F_^"[G[!?[6'_!2K]B.+]DG]E;XC?"'X9R^-_BWX$UWXS:M\8-
M:\;Z-I6M_"OP8=3\11^'-%/@?P1XXO+S5W^(5GX%\1"TU&STW3Y[?PW+ ^J0
M23I7Z>?LZ_!#PC^S1\ O@M^SQX!A$7@SX(?"WP+\*_#1,*0S7.D^!?#6F^'+
M74+Q4+!]1U--/_M'4IW>26YU"ZN;F>66:621P#_/A_;!_:M_;D_9>_X+._L2
M_P#!7_\ :X_X)X>)?^">_@;Q%K7A']G+XU/+\9/"/QG\/?%+PO/8^(?"WCCQ
M#J%_X5TS1Y+'Q)HOP;\0PSZ3HNKV;VE]-\+O#NH:==Q76F7;P?Z/T$\%U!#<
MVTT5Q;7$4<]O<02)-!/!,@DBFAEC+1RQ2QLKQR(S(Z,&4E2#7Y/_ /!:[_@F
M]>?\%3OV!/B'^R_X7UCPCX8^*Z>)_!7Q)^"WB[QW)JT'A+PU\1/!VK&*2?7K
MG0=&\0ZW::=KO@;6?&O@^XO=+T74[NQ3Q)]N2PO5MFM9OD3QI_P3Y_X*W^(/
MV4?^"2?PB\%?MN^"/@U\6/V./&G@.V_;%U[X<_$/XP:9X3^/OPL^'DFB:!H&
MGV%_9>!=)UGXF7[>!O#L47B+P7\3="\+^#O%_B/Q!JUWK-\L=A97%R ?T05_
M*3_P>/?\HB]%_P"SN/@Q_P"HE\5Z_JVK\5/^"]O_  3;^-/_  50_86M/V9/
M@+XO^%_@KQ[9_&_X??$Y=6^+VJ^*]&\(3:-X4TCQCI6I6+:AX,\'>.M9BU.7
M_A)K>>Q0>'Y;6;[--%<75KN22@#B/V8/^"'?_!)#Q=^S3^SQXL\3?L"?L]:U
MXC\3_ SX2^(?$&L7WA6XDO=6UO6O /A_4M5U.\D&H*)+J_O[FXNKAPJAI978
M 9Q7\^?_  62_8;_ &1OV)_^"P?_  ;\Z9^RA\ /AY\![#XA?MC?#6^\;6OP
M_P!*DTN+Q+>>'/VH/V:+?0[C5%DN+@S2:9#K&IQVI!78M[."#NX_N;^!?@/4
MOA9\$O@[\,=8O++4-7^'/PL^'O@/5;_3#.=-OM2\(>$M(\/WUYIYNH;>Z-E<
MW6GRS6AN;>"<P/&9H8I-R+^*G_!5O_@D_P#'K]N[]O?_ ()._M4_"OQW\(O"
M_@+]A'X[:/\ $[XMZ)\0-5\9V'B[Q'X?TGXP?!GXD?9/AS9^'/!/B;1M6UBX
MT[X;ZQIWV;Q-KGA&RBO;W37_ +1D@>Z>U .Y_P""S_\ P5Q\6_\ !-VQ_9K^
M#7[/?P1MOVBOVSOVT?']S\-_V=OAIK6J3:1X-AU.UU3PIX>?6O%UQ9W>G7]^
MMYXG\<^$_#^A>'H-9\+Q:M+?ZKJ-YXMT.R\/W)N_P@_X*W^$?^#DG6_^":G[
M5'C/]LWXB_\ !-+P[^S5+\/=)U/XO_![X3:=\3;KXK6>A_\ ":>%9;/2?"NI
M:GX!\1>'&UG3_$']D3-/)\4+FV%O:W+PZO<R"+S?W8_X+3_\$@O$O_!3#3?V
M;OBS\!OCDO[.'[8G[&WCVZ^(7[/_ ,3[_3+K5/#)OKW5/"FOOI?B-=-2;5=*
MN=+\4>!O"?B7PSXHLM/\0_V)=Z=J=E/X8U:V\03RV/YH_M$?\$>O^"\__!0_
MX%>//@Q^WY_P4N_9TM?!=IX+UZ[\#?"7]FCP=KOA3P;\8/BUI^EW$OPUO/VA
M?'/_  J#P3KUEX TGQ?%I'B#Q'H&@^#/&^GSK8"70_#>FZ];Z3KNF 'M7PQ9
MG_X-%=2+,6(_X))_%Q06))"I\*O&B(N3V5%55'0* !@ 5[__ ,&XK*/^" /[
M(0+*#_PK_P#::;!(!VK^TA\>\MC^Z.,GH,C)YKU_PS^P+\7_  U_P1(7_@E4
MOBGX::E^T!>_L.^,_P!FZ^\96FI^*&^$>E>+?%'@G7O#\.NW6M2>$X?%_P#P
MBL>HZO"J77_"%KKDMHKWB>'FD"64O5?\$R_V,/BK^PI_P3/^ '_!/[Q[XD\!
M^)OC)X+\+_%72/&OBOX<WWB'5? L4'C_ .*OQ'\=V<NE:EXE\.^%/$$]G::3
MXSL;"[>^\.:5*;BUU 6UHPN+2>XQJ5X0C.2]YPDH<JO>527PTX:6E-R:4DM(
M:N35FEZ6%RROB:U"E*U"->C/$^UJ-*-'!TFW5Q==-J5.A&G"I.G*23Q#4(T5
M)5(2E^-?_!F3H%SJ?_!-;XIZI-(4L-'_ &U/BH+,,HD']IW/P:_9Z\V6)'S&
M)((%A=GD1U$GV5@C%"5_J0_:@TW]H%/@)\3KK]D_3/A5XC_:6A\/^9\([+]H
M";Q%+\)I_$XU"RWCQ=#X7N+35+>R&E?VBUM_9#63-J:V*W,R6AN''YA?\&_?
M_!,;XX?\$G_V*/&_[-WQ_P#&?PI\<>-_%'[1_COXQ6FK?!W5O%VM>%;?PYXE
M\!?"OPAINGW%[XU\%^ ]7_MM+GP#J%Y?01Z&]C!!>V<=OJ%W()_+_<FG&C"+
MF[<SJ3=27-K=M)+1W5HQBE'1V7J95<PQ56.&A[1TXX7#0PM%4OW;C3A*I.3Y
MX<L^:I4JSJ5&IQYI-7O9'\WO@;Q!_P '4H\8>$8/&_P]_P""/-MX$/B708_&
M#:%>?M$1ZM#X3;5+4>(7T<-XQN(EU--(-XVG[[:>,78A+P2KF-OZ"OB3\,_A
MS\9/ _B/X9?%KP)X0^)OPZ\8:>^E>*O OCWP[I/BSPEXBTYY$E-GK/A_7+2^
MTO4(%FBBN(TNK:00W$,-Q%LFBCD7N*_G[_X*!?\ !,#_ (*)>.?VL=1_;?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %8UV9/M$FT''R8Z_W%SW]:V:^*OVAOBU^UOX$\96NF?
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M'UA;?''XNZ99:+X$^-7Q5\-:EX^\4Z?^P'XGTJQT_P .#PVUC\4O&_QFEO\
MXE> ]!TCP]%>ZUKOAQ/#'AC2=5NH]0N+B[L9M2N[:2Z6PU,BP^S/'\_[1?BO
MQK_8/@:\\*^!OAW!_9LL_CN[LI/$WB75?ML$MS>/HECJ=O'X3L$L7*6$$8FU
MZ[U.15OU&DVTXB@_-VR\>?M0+\1M$^+FO?\ !)7XJ:WXLM;B>ZT_^T?VI/V=
M+[3?"U[)%;:9;ZEINCKJ<&D/X@@L?M4=AKRJ-6TNSO+NUMKM8Y_+&_\ &/\
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M?_@H'^UE\)/^"FVOZ9^SY\&?AQ^S+H?_  [[^*VJ6UOX+L-4\0ZO:>&_$/Q
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MJ*** "BOR]F_X*K?"WPY\9OA#\)_BY^SA^V5^S]X?_: ^*UM\#O@C\=/C?\
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M:GX=^"*S>*'T'X=:)YGB_3M'M_'VN7.H:4 ?%W[;O[3?Q3^#U_\ \$X?%/\
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M)OAU\.]9O/B;X-U/P;/I&D:SX*\8:'\--4U.?P=I&IV7BSP\-6U'3K4 ^MO
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MT^-4W[0FO^.O$G[(&SX=Z+=64L?PVFUW5_&<B7]I:PR2+*MI;7S1>P_ME?\
M! ?]FGXI_!34/!/[,&F>//A=XUUK]H;X5_&'6+;Q3^VI^W+%\)Y-.A_:+\+_
M !>^.UUI_P .K7XP^,O!&D^-/%^BQ^-[WPKJ6D^ ]/N-)^(6K:9KVE:[X.U.
M"#Q3I/UY\9_AE_P4HTW1/%/[/_[+%K^Q-;_L[7/PYT/X6?"_XB_'WXC?M/>+
M?CM\-O#,7P[T?P;JM[XZ\.ZEX>^(UG^T/XFL=4BUK6-,\0>)_C-X%U'Q):RZ
M5:^.)]7UE=;\1:R ?H#\(==\!>(/A)\-/$/PQ\:_\+#^&>J?#_PEJ7@3X@S>
M+[_QZ_C/P9/X?L)O#OBRZ\=ZQJ&JZMXPN-=T<VNJ7?BG5]4U#5-=GN9=4U*^
MNKRYGG?\]_\ @JM^U?XJ^#7[$'Q \2?LS?$GPQIOQG\=_$?]G[]GCP#XWTJY
MT/Q8/ASXB_:1^-W@?X/CQT=-WZCI\NJ^%- \3^(?$OAN#5K:?3[C7M&LA>6M
MW9QW-N_U5^QY^RKX0_9!_9#^!/[(6C:K<^//"?P6^$OA[X6SZYXEL+99/&BZ
M=I?V37]6U/16EOK*TM?$FH3ZE>MH'VB^M-.LKU=(6XO(+<32_)/[3G_!(_\
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MJGQ1T[X4?L^^ OC%%XK\.^./VVOVY/'_ (\O_B;K'B3X/:[\';GPL/'?Q?\
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M)%\&_!'4/AO\47T#6/ =K\(])\'6-MX5BNM \1)KULUPUW^OG_!.O]F'Q/\
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M 'Z@45^7_P#8_P#P6B_Z*+_P2_\ _#+_ +5O_P _JC^Q_P#@M%_T47_@E_\
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MFOX0^!/V.;WPAJ/[,?AKPO\ V?\ !V]\ _$.\^+'@ZX\*_VGJ%QYF@?$6_\
M$WC*\\5V7]IS:BO]I3^)]9?SEEMOM6VW$4?YU_"/]ES_ (*0? #PSJ?@KX#^
M#_\ @BW\$_!NM7$EWK/A+X1_LD_'?X;^&=6NIH7MY;G4]!\&_%_1M*O[B6W=
MX))KJTED>%WB9BC%3VG@#X2?\%8_A/X-T#X=?"R\_P""1_PT^'WA2R_LWPMX
M$\ ?LX_M)^#?!OAK3O.EN?L&@>&/#OQMTW1-&LOM%Q/<?9=.L;:#SII9?+\R
M1V8 ^9O%?Q'\'_\ !6#]M;X,Z?X2\8>$]-_8+_X)R?M*Z;\8+_XE7GB+1[:^
M_:T_;B^%<&JZ-\/_  ?\&H)+N.XO_@M^SQKVN:IJOC?XCJ+G1_B+\2X;#P;X
M+M]1T[PWJ?BF+Y2^#GQW^"WP4_X)2?\ !:[X6_'+QOX.\,_%?P+^T7_P5A\,
M_$[P#XBUG2=.\;>+?%7QU\4_$C7OA+_9OA>^N(M:\0K\:- \?>"['X=7EK97
M=KXN-]!9Z3/=?9;A+?Z*T_\ X)/_ !NTG6;'Q%I7[%W_  ;IZ9X@TS4[;6M-
MUW3_ /@F]XMLM9T_6;*Z2^L]6L=3MO',5[::G:7L4=Y;7\$\=U!=1I<12I,B
MN/VK\0_LJ_LS^./B9X;^.GQ!_9P_9^\9?'GPO%I1T3XR^(?@[X U[XF>'[K2
M40V+^&_'^MZ!?^,M&BTZ5<Z4+36HI+%%00NK+NH _)3Q%^U=\0_V*OV#?^"?
MG[$/PWLM$\1?\%*OBO\ L@_ _P"&'PX\ >.=6M-&\/?";4/!'P<\(>$_B7^T
MA^T)J5X95\+?"/X0:U:WESJ$,\,VM?$CQG;67PY\&V.I:O?ZC<:/W.D?$7X!
M_P#!$[_@G'^S;^SU\.=8?]H_XE)#/\'?V=?AYH.OZ%9^+?VH_P!I+QCK.L>.
M/'>II?RZA=Z/X'\&S^//%'B7XA_%'QGK.H3^'/A-X*NKB?5=1U&^CT>RUK]%
M_C9^Q/\ L9_M+>)=-\9_M&_LD?LQ_'_QAHNAP^&-'\5_&SX"_"OXJ^)=)\-6
MU_J&JV_A[3==\=>%->U2PT.#5-7U74H=)M;J*PBO]3U"\2W6XO;F27C]4_X)
MR?\ !/37/!'A3X9ZU^P?^QGJ_P ./ >J>)M<\#?#_5/V7O@AJ'@CP9K?C0Z4
M?&.L>%/"EWX'FT'P[JGBPZ#H9\3:AH]A9W>NG1M*.J377]G6?D@'SS_P3R^$
M'@O]@S]DKXF^-_V@?V@/@_JGQ&^*7QA^*7[87[;/QN@\8>'_  Q\%M'^.7QK
MU#3=3\:C2]<US4[73?"WP\\&Z5I_ACP-X9N_$%[ISWVD>&[/6+JUTN75#I=G
M^I5G>6FH6EK?V%U;7UA?6T%Y97MG/%<VEY:7,2S6UU:W,+/#<6UQ"Z2P3Q.\
M4L3K)&S(P)^:?!G[$G[&'PX^'7CWX0?#W]D7]F'P'\)?BJ(1\4/A=X,^ ?PI
M\+_#KXD"WA%O /'O@G0_"=CX:\8"&!5@A'B'3-1$<*B--J +7TM9V=II]I:V
M%A:V]C8V-O!9V5E9P16UI9VEM$L-M:VMM"J0V]O;PHD4$$2)%%$BQQJJ*  "
MQ1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5^0'A#_E/9\?/^T2W[+7_K7?[6=?K_ %^0'A#_ )3V?'S_ +1+
M?LM?^M=_M9T ?K_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5DW4
M4;SLSQH[ H074,5(,$@V[L[0)((9,+@;XU?&X9K6K+N643,"JDG;@DC)^4?[
M0^G2M*3M)NU]/U1$]EZ_HR@Z*7RZXD0 Q%4#ODY&>2"Q(9LY8Y)R<D T]@KH
M%DQ( P;;(YD(8'(8PON52IY5AD@\#&*FW#IR",<8/'Y#'Y>WJ*5B%.#QD9]?
MU&175%\W2UMO^!H82CS.][?(HD1H0-LF$ VHA_=)CH5C^XK#IN"@@87.T 5)
M@^6%5B  H7<S,JX.0VTD@-R<L/F.>2:L_NSR6P?HW]*@W+G .><#@\U7Z>1/
ML_/\/^", D)&^8R!<E0K. ISUQN [D=.A*]#BF>2%XBVQ)@#8B[%P!MVE5 4
MJ 3A2"HZ@ U8#JA^8XR.."?3T!QU'6I#*@."WZ'_  H%*-E>_P"!1$3Q@D2/
MR I(DDW%=P;;NW;@,\8!P5 4_* *1D7A2,KN24(22BRQE'25$)*I(K@.)$"O
MO&[.[FK&Y?7^=+D>H_,4"C'F5[V^1!SG.YA\[OP[ %W#!W(! +,&922,[3M^
M[Q28)X#-RRMR[GYEP$;ENL>U?+_YY$ Q[2 :LY!Z'-+Y0"AOH1UZ\>_;/I05
M[/S_  _X)3\D1[GPN]BK%PH#LZ!MKL^-S,N3M9B2I)(.2:4HI.3ECCJS,Q/W
MAEB22S .ZAF)8([H"%=@;)V<;CCKC@GT]*!MYVG(SUY'/'K0*4>57O?Y%=H"
M&AP)$V<H_F$! S%B0W4*2QR!V(7D<4TP1JJQF.(JK%P0V\%]L:!]I4 ,$CC"
MMC<H4!2 #5OGMR<C';OZT,NP@<;3DYZ?,>HQ_,_ETH%&/-?6Q6\MMJ*C,D8/
M"*[*@QTPBG:,8R..",@ ]6"WA3&/F*N74.-^US)-(2N_=M^>>8C;C:)&5<*<
M5=4%CA03] <?GT_6FAU!&3T(SP?7V%!7L_/\/^"5U3A5C/EA#N0+E0IP%.T+
MC:6 &[&-W.[.3D*;2=S)N/)+ Y/&,D]^G4\GO4V?WC'GGD<'V]N/QIY.W@@]
M-W0G Z<X!Q].OM0'L_/\/^",58MJ?-DE@#C.#ST^G;\AWIC@!V X -2;P1T8
MY_V'Y_#;^E,%Q  7\U"J#<Y5@VU00"S!<D*"P#'& 2 <&I<DG:S;LY62;]U.
MS=[=]+ J;;LY1C'E;YFTKRZ12OU6M[Z=AH)!R#@U+)SY>>ZC/OG%2.Z.JR1L
M'C**P=#O1@<_,K+E6!]5)!((SD&H\@ ,1Y@.<$C!3)&.#SE.,?3\*<9*45*.
MJ:TZ=UUVU5A*#LN9\KZI>];7H^NFH;%]/U/^-12(,KARO(& >#SU/-3# 958
M@%I,J"1\P"LQQSR<<XZ^W!J#>A9CME(;"96-\*0&)WG9E._+%5/0$DD5DZT;
MN*4I2BU%I<L5SO://4E"+D[.T4W)VLHMW%R-1G*<H0C%KE<N>3G'^;DIPG**
M7637)%:SE%-,22-E9<2KMR..<D>A]ST)]?8BEW;<<;B3A5/1CSP<=L G\*\:
M^*G[0OP-^"]G'=?%CXK^"/ )NK>4Z?8^(=?L++6-2\J,EAINCM(VK:@PP%Q9
M6,YWLBC+.JM^?WC7_@HUXW^)LITC]A#]G+QO^TO)!);Q7?Q.O["\\"?"C3Y4
M?&H:=-JOBW3M'N;W5K9)(66WA6T1X&N)5O@UNL%S]!E?#F?9PI3P.6UHX>G%
M3KYAF#64Y5AX/K5S;,OJN YE'WE2I5J]6I%7HTZFQX&/XER3+KTZV/HU\8TW
M2R[ 5*6/Q]>,7RRE3P^&J5)0Y9V@X5_8U.9W4>5-K]8'<,P X!!WKSC<H) ]
M1@X/L:^,?VH?VZOV=?V3=,EF^)WC*VN_$[*IL?AUX.2'Q+\0;^>6,O:F;P[;
M7 FTNQNG,42ZGK4FCZ.C7$<MUJUI;[YT^2[W]EO]NG]K*RDF_:>_:'B_9[\*
M$R6__"H?V:;G5X+[4;&]\F>5/%?C"ZUY[&6^MQBS:S6RU[2O(B62TCM;BXNI
M)?JSX-?L)?LW_ 3PV^C>$OAQH^JZ_=V$MCJ7Q1\76>F^)_B5JU_(C&75[O7]
M2TYY;2ZEN)'D_P!$ECAMY41K>)(8H@._^S>',KK4:F99Q3XAK*=.,LMX:2JX
M:5)U(JM)9YC?JN&;C%U%*K@\)BE%TY*'M)4^6?BXK-^)LTR^I4RG**N0X62E
M*GF7$#E"M*KRR5*F\HP5/$XE*I44(\F)K86\9IS=.$_:1_(SX5^-/VV/^"C'
MQE\:_M$?!/5_#GP+^#.FPR?"OX?W_P 2[JR\8ZGX)OM'33K_ ,0^)?"/A*72
M-3TJZ\7SW5Q##>ZE?Z2+K2K35?[-TK7HD,TM?II\.O\ @F]\$+"ZTOQA\>;C
M7?VI?B[;QVYO?'WQHU;4O$-F+NV2.5H_#O@C4]1;0_#>BQW1FN[+3PM^;:2X
MD4W30QP6UOY]_P $N] \,?!SX>_%K]E33[K7H==^ /Q<\2Z;/IGB^ZTO_A+-
M:\.>*+32/$FC^/+V#3K9('T/Q%+>7I\.W:M)&FGVYB>0,0#^J5JL86;<3YD;
M*I!#$Y>--P)V( 5C*%AR0<J3N#*OO<9<28K#YMC,HR*A1R'(L'AL+ALL67QY
M,PQF75</3G'%8S-7%8JO+$SJ3A5>&>#ISE!U$W)-1\/@3AG*\9E.'S_.)U\\
MSG&XG%RQ=7,:D_JF%S;"XBI#$8&ADJ;H4*6 IQIUL-4Q<L8ZT:W*J<$E*>-I
M6B:9H]E8Z7H^GZ?HVD:?:V]GI^G:7:6MEI]I:VR!+:QM;2S1;6*UME(2WAA!
MCB',7/S5KF$H0^%&#\Q"C)7GY=PYP3@XZ9 [X-6P%  7E0 %X(^4# X/(X['
MFEK\X:C+EYU.;CKS5*M2I.4KN3E.I4E.K5DVV^>K4J35VE)+0_48IP5J7LZ7
M,DIJG2A3A))<L5"E34*-"*BK.%&E3C)I2DI27,-\H(H9P&5P&P1G@]N1TXXQ
MP.3WH$( #+A5 )51GA6&2H[<@XI21D#DDXX )[\'@' R.IX'6FNZH"SH550Q
M,I1O+.W.XK)]QBNTE@I)&#D<4W*UI/FE)O10BY-OHK+9NR5OGM>U<KA&[ISA
M!)M3DHQIV5VY<SDGRK5MVV4M';5P &<#&1C\,Y_I1@<^_7D\\Y]?6N \6?%#
MP'X'"?\ "1^)],TVZ?)@TKS);C6-0E\J9XK6PT>SBN-2U*ZE:,M!96MI+//Y
M;F-&*$#YS\0?%;]HGX@>);'0/@G\*(?"_A&YN+2+5OB]\8+'4M,M["*9'\^3
M1?A@+_PUXQU;5%CEAFMH]1N-(T^55'VPI"L9G[:6$KUXIS5+!TOB=;'U8X:B
MDES-*<K\U22TIP@INI+W5K:_BXS/L#A/W</;YABI3C"GA,MHU,75J2DVKWA'
MDITXNSJ5JKA1I1:E4J1BTW]>:IJ5CI%C=ZGJ=Y9:=IMG;3W%W>7DZI#!%;Q/
M+<7$S2%(HX8HT>20R2+&B(Q=@H)'P/K'[5'BWXY2Z]X)_8\\))XLFM;6XTV^
M_:%\:O=Z1\&_!&H3^;;"[TU9-)BU?XCWMC;FYO[>QT&U72Y;NUMK:\U2*&<R
M#TOP3^R%X?M=4G\3?&SQYXQ_:1\67ET+CS?B;);'P3HI5@+>+PQ\,=+CM/ N
MD0VT(&R0Z-=7EU<;YKB6/S6V?6]GIEEIT$5M90I;0QV\<<5M;PI;V5L$"JD$
M$$3+%;I$B*BI%"L(4[5?H*I8G+LO:JTZ;S.NG%0G54J."I3YTU^X?/+&1=E)
M^TE0@]*<H3@Y(YZN#XASE4Z-54LEP$VI5\,HX?,<?4UO'FQ,U/+\(_9WA?!Q
MQ=>+;G'%T)Q5(_+WX<?\$T="U+Q@/BU^V'\2]9_:]^*OV>)[5?'&G1:9\+O!
MK/\ 9DOD\(_#>'46T*TAG^R6]DD&I1722Q60-UI\\R%V_3?3-'L=*L;'3M)M
MK*PT_3X;>VM=/L[:*UM+2VMHQ$EM:VL$%O;V\,40\B..*VMU6("(0QQ@1#8"
MA@ YP5^4<'&.O!!P>IY]<BE"1^8,,"=N .Y;& O)SU]>,^U8YCFN89G*F\;B
M:E2.'3AA\/3M1P&&IO\ Y=T,OI*&#A%+1-T)U$Y2E[5R::]C Y+E^4SD\)AJ
M3KM<D\3BG4QV(E>*4I2Q&)G4K3F[MJ<ZDG"T(PM"E3C&-DR$1/E&\?*OR@\-
MU P">>">1V/8JD+_ #?.1AR,$GT'O4Z Y)QP.#]?3]*5F0'#%@<=F &.?45P
M^T\OQ_X!W>S\_P /^"18QP><<9]<4;2W ..^?_U?6C D7+8"^9A4X.>?ED+#
MC=T;'!S[C%/$2 Y8D#V.#G\31[3R_'_@![/S_#_@BI Q!RP//O[4\(%(XY4G
MGW/!(^M/0QH" QY.?F.3T [=N*864DX/4G'7UI<[UTT[?UN6E9)=AV2>I)_&
MF_\  E'L<Y_2E_S[#ZGH![G _.C_ #['Z'H1[C(_*GS^5OZ]!B$_*1O3')P
M<Y]O?^M2IQ+%CC.TGGK\RU'3XP#)'GLZD'!QG<,<CCGZ_A42=_N8+=>J_-&K
M1117,= 45^8'Q6_X)A6GQ6^)'C3XCO\ M_?\%/\ X=-XTU^_U]O WPI_;"UK
MP7\-_"QOI/,.C>"_"<'A2\A\/Z!9_<L-,CNITMH_D$C=:\^_X=!67_23+_@L
M!_XG3K__ ,QE '[ 45^/_P#PZ"LO^DF7_!8#_P 3IU__ .8RC_AT%9?]),O^
M"P'_ (G3K_\ \QE '[ 45^/_ /PZ"LO^DF7_  6 _P#$Z=?_ /F,H_X=!67_
M $DR_P""P'_B=.O_ /S&4 ?L!17X_P#_  Z"LO\ I)E_P6 _\3IU_P#^8RC_
M (=!67_23+_@L!_XG3K_ /\ ,90!^P%%?C__ ,.@K+_I)E_P6 _\3IU__P"8
MRC_AT%9?]),O^"P'_B=.O_\ S&4 ?L!17X__ /#H*R_Z29?\%@/_ !.G7_\
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MT%9?]),O^"P'_B=.O_\ S&4?\.@K+_I)E_P6 _\ $Z=?_P#F,H _8"BOQ_\
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M!17X_P#_  Z"LO\ I)E_P6 _\3IU_P#^8RC_ (=!67_23+_@L!_XG3K_ /\
M,90!^P%%?C__ ,.@K+_I)E_P6 _\3IU__P"8RC_AT%9?]),O^"P'_B=.O_\
MS&4 ?L!17X__ /#H*R_Z29?\%@/_ !.G7_\ YC*/^'05E_TDR_X+ ?\ B=.O
M_P#S&4 ?L!17X_\ _#H*R_Z29?\ !8#_ ,3IU_\ ^8RC_AT%9?\ 23+_ (+
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MRC_AT%9?]),O^"P'_B=.O_\ S&4 ?L!17X__ /#H*R_Z29?\%@/_ !.G7_\
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M_I)E_P %@/\ Q.G7_P#YC*/^'05E_P!),O\ @L!_XG3K_P#\QE '[ 45^/\
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MGC6^Q0YSEQ[!A_\ $Y_6G"UC&?F?D8Y8'C\O:CVT//[G_F6J;6R7WF2S;LG
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MM*\8^%]35A>Z+KEI;W]F[F$P)/ L\3O8W<",Y@O+![6ZB>21UF#22%OB!/\
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M:)FV231O?LKR1HZ>4PS7<K;"*42>6-VQ5S%$01M! "R,9I57&<J)=QW'Y@"
M.H^R1_WI#^*?T04ALH6.6!;C'S!#^NS/ZURUJZKOFJSJ57_+5<JE/>]_9SE*
MGS)ZQER\T7=Q:;;/:HX*AAH*&'HTZ*ZRI)0J2CM*G.K%*K.E-652E*;IU4DJ
MD9))&''L41A8E7;LPHW@#;@8&YBP..,L3CN#5OS0>#%\I^\"^<CTZ<<X.?;W
MJ^+" -N&\8.0 PP.<XQMZ>WI3S:1'J7^F5X]Q\N?;G(]LUFI4VK23LFFDDTD
MUM9)I+T2L;JFXKEC[L/LPB^6G!=J<(VC33W:@HIOWFKZF;YH' BRO\(WXVC^
M[TYYR<GGGVI?- Y\M1CGL3QSUQU]_7FM$6D0  +CUY7GZY4_IBC[)#_M9SG.
M[GUZ$%?S!JO:4NTON?\ F')+_AW?\690FX(5&8EMV!V'/U]:42MWA'_ \9_4
M=/\ Z]:QMHSUW=.Q Y]<J <^V<>W2D^RQ^K_ /?0/\U-'M*79_<_\PY)>7WF
M;NC*X$/SEMV0Y^][#'KT&<=NE&[^_$V.V3MY^H![9XK1%I"#GYB?][OZ\ <Y
MY],]L<4IM8SPS2$9SRP]^.%''/U]Z7M*79V]'^&OYAR2\OO,MI,'Y(EQCG<0
MQS]2 <8QQ4JL&XV?,$+<'J0N[ '3D\#M5X6D0& 7_->?_':46L8;<&<'&."O
MI@]5/)]L>V*ESC=VO;II_P $.27E]YG L>&1E4C#9XW#^[GL3US[4I^4#'W<
M[5']U>,#/?DGGBM'[-'W+GZL./?@#FC[+$>NXX.1R.#^ _G1SQ\_N#DEY?>4
MO-CPT;(3@%.&/S<$?\!S^.,]\4V(MYD8VMMWIPHW8(889CQA0,@GZ5H-;HP&
M2V1C!^7(QT_AQQZD$^I-+Y"94G<VTA@#C 8'(;A0<CZXYZ4G.-NNW8:A*_3[
MR:BBBLC4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ\%:="L\GA*,G39F@MA#X1I'QC^*'Q(\!?LW_!#P/\8_'GA_XK_"#]O37?A
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MEZ6_X;J)Q>EG962MKMHV_6Z_X)^3O[2/QX\5_$?Q)\0TT7Q3\1?AY!-\-/\
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M\7?%/QKX'^$6H^![_P#: UCX%?%G_@I3I_A+X.?"GQ7^T]XW\-?'EOASX?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?_PL"XN/#ULE^_A75_"]IX+6;7;[QM9^+)?!]A]FN=%O=<@\2POHH\ ^#O\
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M<PQ:?J$J*WRZ=KN^^UW;]/.UP7/K?LK;;V5_U\KGF'Q#^-?[3?P4^%'[0_Q
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>ttoo-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-11-14T20:33:37.7060779+00:00 -->
<!-- Version            : 5.0.1.753 -->
<!-- Package ID         : e9bee4ab4d8b4c8a9f469bea6de545b7 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:ttoo="http://www.t2biosystems.com/20220930" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.t2biosystems.com/20220930" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" namespace="http://xbrl.sec.gov/country/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" namespace="http://xbrl.sec.gov/currency/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" namespace="http://xbrl.sec.gov/exch/2022" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" namespace="http://xbrl.sec.gov/sic/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd" namespace="http://fasb.org/srt-roles/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" namespace="http://fasb.org/srt-types/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" namespace="http://xbrl.sec.gov/stpr/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" namespace="http://fasb.org/us-roles/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" namespace="http://fasb.org/us-types/2022" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.t2biosystems.com/20220930/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ttoo-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ttoo-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ttoo-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ttoo-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" id="Role_StatementCondensedConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="Role_StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit" id="Role_StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100040 - Statement - Condensed Consolidated Statements of Series A Convertible Preferred Stock and Stockholders&apos; Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows" id="Role_StatementCondensedConsolidatedStatementOfCashFlows">
        <link:definition>100050 - Statement - Condensed Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsParenthetical" id="Role_StatementCondensedConsolidatedStatementOfCashFlowsParenthetical">
        <link:definition>100060 - Statement - Condensed Consolidated Statement of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusiness" id="Role_DisclosureNatureOfBusiness">
        <link:definition>100070 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100090 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureRestrictedCash" id="Role_DisclosureRestrictedCash">
        <link:definition>100100 - Disclosure - Restricted Cash</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformation" id="Role_DisclosureSupplementalBalanceSheetInformation">
        <link:definition>100110 - Disclosure - Supplemental Balance Sheet Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayable" id="Role_DisclosureNotesPayable">
        <link:definition>100120 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrant" id="Role_DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrant">
        <link:definition>100130 - Disclosure - Series A Redeemable Convertible Preferred Stock and Related Warrant</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficit" id="Role_DisclosureStockholdersDeficit">
        <link:definition>100140 - Disclosure - Stockholders&apos; Deficit</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100150 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureWarrantsAssociatedWithTermLoan" id="Role_DisclosureWarrantsAssociatedWithTermLoan">
        <link:definition>100160 - Disclosure - Warrants associated with Term Loan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100170 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContract" id="Role_DisclosureUSGovernmentContract">
        <link:definition>100180 - Disclosure - US Government Contract</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100190 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100200 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100210 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100220 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100230 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100240 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables" id="Role_DisclosureSupplementalBalanceSheetInformationTables">
        <link:definition>100250 - Disclosure - Supplemental Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTables" id="Role_DisclosureNotesPayableTables">
        <link:definition>100260 - Disclosure - Notes Payable (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100270 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100280 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" id="Role_DisclosureNatureOfBusinessAdditionalInformationDetail">
        <link:definition>100290 - Disclosure - Nature of Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100300 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail">
        <link:definition>100310 - Disclosure - Summary of Significant Accounting Policies - Schedule of Customers Represent Greater Than 10% Of Revenue (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail">
        <link:definition>100320 - Disclosure - Summary of Significant Accounting Policies - Summary of Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail">
        <link:definition>100330 - Disclosure - Summary of Significant Accounting Policies - Summary of Maturities of Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueByMajorResourceDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueByMajorResourceDetail">
        <link:definition>100340 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue by Major Resource (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1Detail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1Detail">
        <link:definition>100350 - Disclosure - Summary of Significant Accounting Policies - Additional Information 1 (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1DetailDefault" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1DetailDefault">
        <link:definition>100350 - Disclosure - Summary of Significant Accounting Policies - Additional Information 1 (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" id="Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail">
        <link:definition>100360 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities at Fair value on a Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetail">
        <link:definition>100370 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail" id="Role_DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail">
        <link:definition>100380 - Disclosure - Fair Value Measurements - Summary of Contingent Interest Payments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsParentheticalDetail" id="Role_DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsParentheticalDetail">
        <link:definition>100390 - Disclosure - Fair Value Measurements - Summary of Contingent Interest Payments (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsRollForwardOfFairValueOfDerivativeLiabilityDetail" id="Role_DisclosureFairValueMeasurementsRollForwardOfFairValueOfDerivativeLiabilityDetail">
        <link:definition>100400 - Disclosure - Fair Value Measurements - Roll-Forward of Fair Value of Derivative Liability (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetail" id="Role_DisclosureRestrictedCashAdditionalInformationDetail">
        <link:definition>100410 - Disclosure - Restricted Cash - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryDetail" id="Role_DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryDetail">
        <link:definition>100420 - Disclosure - Supplemental Balance Sheet Information - Schedule of Inventory (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail" id="Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail">
        <link:definition>100430 - Disclosure - Supplemental Balance Sheet Information - Schedule of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail" id="Role_DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail">
        <link:definition>100440 - Disclosure - Supplemental Balance Sheet Information - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail" id="Role_DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail">
        <link:definition>100450 - Disclosure - Supplemental Balance Sheet Information - Components of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableScheduleOfDebtDetail" id="Role_DisclosureNotesPayableScheduleOfDebtDetail">
        <link:definition>100460 - Disclosure - Notes Payable - Schedule of Debt (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail" id="Role_DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail">
        <link:definition>100470 - Disclosure - Notes Payable - Term Loan Agreement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail" id="Role_DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail">
        <link:definition>100480 - Disclosure - Series A Redeemable Convertible Preferred Stock and Related Warrant - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail" id="Role_DisclosureStockholdersDeficitAdditionalInformationDetail">
        <link:definition>100490 - Disclosure - Stockholders&apos; Deficit - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100500 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail">
        <link:definition>100510 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail" id="Role_DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail">
        <link:definition>100520 - Disclosure - Stock-Based Compensation - Schedule of Estimated Assumptions Used to Calculate Weighted-Average Grant Date Fair Value of Options Granted (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail" id="Role_DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail">
        <link:definition>100530 - Disclosure - Stock-Based Compensation - Schedule of Nonvested Restricted Stock Units Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedThatWasRecordedInCompanySResultsOfOperationsDetail" id="Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedThatWasRecordedInCompanySResultsOfOperationsDetail">
        <link:definition>100540 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted that was Recorded in the Company&apos;s Results of Operations (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureWarrantsAssociatedWithTermLoanAdditionalInformationDetail" id="Role_DisclosureWarrantsAssociatedWithTermLoanAdditionalInformationDetail">
        <link:definition>100550 - Disclosure - Warrants Associated with Term Loan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" id="Role_DisclosureNetLossPerShareAdditionalInformationDetail">
        <link:definition>100560 - Disclosure - Net Loss Per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" id="Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail">
        <link:definition>100570 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail" id="Role_DisclosureUSGovernmentContractAdditionalInformationDetail">
        <link:definition>100580 - Disclosure - US Government Contract - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
        <link:definition>100590 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" id="Role_DisclosureSubsequentEventsAdditionalInformationDetail">
        <link:definition>100610 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="ttoo_ChangeInFairValueOfDerivativeWarrantLiability" name="ChangeInFairValueOfDerivativeWarrantLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ttoo_ContributionMember" name="ContributionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit" name="MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability" name="GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ttoo_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ttoo_ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises" name="ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ttoo_ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts" name="ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ttoo_ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability" name="ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ttoo_TransferOfT2OwnedInstrumentsAndComponentsToFromInventory" name="TransferOfT2OwnedInstrumentsAndComponentsToFromInventory" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ttoo_DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock" name="DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ttoo_RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock" name="RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_WarrantsNoteDisclosureTextBlock" name="WarrantsNoteDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_UnauditedInterimFinancialInformationPolicyTextBlock" name="UnauditedInterimFinancialInformationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_GeographicInformationPolicyTextBlock" name="GeographicInformationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_CostOfProductRevenuePolicyTextBlock" name="CostOfProductRevenuePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_SummaryOfContingentInterestPaymentsTableTextBlock" name="SummaryOfContingentInterestPaymentsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_NatureOfBusinessLineItems" name="NatureOfBusinessLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_NatureOfBusinessTable" name="NatureOfBusinessTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_TermLoanAgreementMember" name="TermLoanAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_CRGMember" name="CRGMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_MinimumBidPriceOfCommonStock" name="MinimumBidPriceOfCommonStock" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ttoo_RegainComplianceByIncreasingStockPrice" name="RegainComplianceByIncreasingStockPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ttoo_MinimumMarketValueOfListedSecurities" name="MinimumMarketValueOfListedSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ttoo_T2DxMember" name="T2DxMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_CustomerAMember" name="CustomerAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_CustomerBMember" name="CustomerBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_CustomerCMember" name="CustomerCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ttoo_MaintenanceServicePeriod" name="MaintenanceServicePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_MaintenanceServiceTermOfAdditionalPeriod" name="MaintenanceServiceTermOfAdditionalPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_ProductInstrumentsMember" name="ProductInstrumentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_ProductConsumablesMember" name="ProductConsumablesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_InstrumentRentalsMember" name="InstrumentRentalsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_ContributionRevenueMember" name="ContributionRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed" name="OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_FairValueDerivativeLiabilityDiscountRate" name="FairValueDerivativeLiabilityDiscountRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_ScenarioOneMember" name="ScenarioOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_ContingentPaymentOfInterestPercentage" name="ContingentPaymentOfInterestPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_ProbabilityWeightedDiscountedCashFlowModelMember" name="ProbabilityWeightedDiscountedCashFlowModelMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_NumberOfFacilities" name="NumberOfFacilities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_T2DxInstrumentsAndComponentsMember" name="T2DxInstrumentsAndComponentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_SupplementalBalanceSheetInformationLineItems" name="SupplementalBalanceSheetInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_SupplementalBalanceSheetInformationTable" name="SupplementalBalanceSheetInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_T2OwnedInstrumentsInServiceMember" name="T2OwnedInstrumentsInServiceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ttoo_DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts" name="DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ttoo_DebtInstrumentUnaccruedPaidInKindInterest" name="DebtInstrumentUnaccruedPaidInKindInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ttoo_DebtInstrumentTermOfInterestOnlyPayments" name="DebtInstrumentTermOfInterestOnlyPayments" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_DebtInstrumentFinalPaymentFeePercentage" name="DebtInstrumentFinalPaymentFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ttoo_DebtInstrumentDeferredInterestRateInterestOnlyPayment" name="DebtInstrumentDeferredInterestRateInterestOnlyPayment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_DebtInstrumentPrepaymentFeeTerm" name="DebtInstrumentPrepaymentFeeTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_DebtInstrumentEventOfDefaultAdditionalInterestRate" name="DebtInstrumentEventOfDefaultAdditionalInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_SeriesARedeemableConvertiblePreferredStockMember" name="SeriesARedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_PurchaseAgreementMember" name="PurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_PreferredStockPricePercentageOnStatedValue" name="PreferredStockPricePercentageOnStatedValue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ttoo_PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock" name="PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ttoo_PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares" name="PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ttoo_ClassOfWarrantOrRightMaturityDate" name="ClassOfWarrantOrRightMaturityDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_NewSalesAgreementMember" name="NewSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_CanaccordGenuityLLCMember" name="CanaccordGenuityLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_OriginalSalesAgreementMember" name="OriginalSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_ProceedsFromIssuanceOfCommonStockGross" name="ProceedsFromIssuanceOfCommonStockGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ttoo_PercentageOfAgentServiceFee" name="PercentageOfAgentServiceFee" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_StockOptionPlan2006Member" name="StockOptionPlan2006Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_EmployeeAndNonemployeeStockOptionsMember" name="EmployeeAndNonemployeeStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_StockOptionPlan2014Member" name="StockOptionPlan2014Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_InducementAwardPlanMember" name="InducementAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember" name="StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" name="StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_TypeIModificationMember" name="TypeIModificationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_TypeIIIModificationMember" name="TypeIIIModificationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_ComponentOfCommonStockCapitalSharesReservedForFutureIssuance" name="ComponentOfCommonStockCapitalSharesReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ttoo_PercentageOfCommonSharesOutstanding" name="PercentageOfCommonSharesOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ttoo_MaximumAmountOfAnnualEmployeeCommonStockPurchase" name="MaximumAmountOfAnnualEmployeeCommonStockPurchase" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ttoo_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_StockIssuedAndOutstandingDuringPeriodSharesStockSplits" name="StockIssuedAndOutstandingDuringPeriodSharesStockSplits" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_StockOutstandingDuringPeriodSharesStockSplits" name="StockOutstandingDuringPeriodSharesStockSplits" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_CollaborativeArrangementInitialValueOfConsideration" name="CollaborativeArrangementInitialValueOfConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ttoo_CollaborativeArrangementAggregateConsideration" name="CollaborativeArrangementAggregateConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ttoo_CollaborativeArrangementFirstContractOptionValueExercised" name="CollaborativeArrangementFirstContractOptionValueExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ttoo_CollaborativeArrangementOptionContractValueExercised" name="CollaborativeArrangementOptionContractValueExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ttoo_CoDevelopmentPartnershipAgreementMember" name="CoDevelopmentPartnershipAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" name="BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_CollaborativeArrangementAdditionalFundingAmountReceived" name="CollaborativeArrangementAdditionalFundingAmountReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ttoo_CollaborativeArrangementAdditionalFundingAmountToBeReceived" name="CollaborativeArrangementAdditionalFundingAmountToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ttoo_MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities" name="MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_LeasesLineItems" name="LeasesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_LeasesTable" name="LeasesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_OfficeSpaceLaboratorySpaceAndEquipmentMember" name="OfficeSpaceLaboratorySpaceAndEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_LicenseAgreementMember" name="LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_OperatingLeasesEnteredIntoNovember2014Member" name="OperatingLeasesEnteredIntoNovember2014Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_OperatingLeasesEnteredIntoMay2013Member" name="OperatingLeasesEnteredIntoMay2013Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_OfficeLaboratoryAndManufacturingSpaceMember" name="OfficeLaboratoryAndManufacturingSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_LaboratorySpaceMember" name="LaboratorySpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_OperatingLeasesEnteredIntoSeptember2021Member" name="OperatingLeasesEnteredIntoSeptember2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_OfficeResearchLaboratoryAndManufacturingSpaceMember" name="OfficeResearchLaboratoryAndManufacturingSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_LesseeOperatingLeaseTerminationPeriod" name="LesseeOperatingLeaseTerminationPeriod" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_SpaceBuildOutCosts" name="SpaceBuildOutCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ttoo_SecurityDepositReceived" name="SecurityDepositReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ttoo_TermOfLease" name="TermOfLease" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_PercentageOfRoyaltyOnNetSales" name="PercentageOfRoyaltyOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_RoyaltyOnNetSalesSublicensingGrossRevenue" name="RoyaltyOnNetSalesSublicensingGrossRevenue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ttoo_LicenseFeesPayable" name="LicenseFeesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ttoo_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ttoo_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>ttoo-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-11-14T20:33:37.7060779+00:00 -->
<!-- Version            : 5.0.1.753 -->
<!-- Package ID         : e9bee4ab4d8b4c8a9f469bea6de545b7 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="ttoo-20220930.xsd#TemplateLink" roleURI="http://www.t2biosystems.com/20220930/role/TemplateLink" />
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="ttoo-20220930.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LongTermNotesPayable" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="10270.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10280.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="ttoo-20220930.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ChangeInFairValueOfDerivativeWarrantLiability" xlink:type="locator" xlink:label="ttoo_ChangeInFairValueOfDerivativeWarrantLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="ttoo_ChangeInFairValueOfDerivativeWarrantLiability" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10180.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows" xlink:href="ttoo-20220930.xsd#Role_StatementCondensedConsolidatedStatementOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows">
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="ttoo_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:type="locator" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability" xlink:type="locator" xlink:label="ttoo_GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ChangeInFairValueOfDerivativeWarrantLiability" xlink:type="locator" xlink:label="ttoo_ChangeInFairValueOfDerivativeWarrantLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability" xlink:type="locator" xlink:label="ttoo_ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts" xlink:type="locator" xlink:label="ttoo_ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises" xlink:type="locator" xlink:label="ttoo_ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="ttoo_ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="ttoo_ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="ttoo_ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InvestmentIncomeAmortizationOfPremium" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ttoo_ChangeInFairValueOfDerivativeWarrantLiability" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ttoo_GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProductionRelatedImpairmentsOrCharges" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_PaidInKindInterest" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10220.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10230.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="10240.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10270.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ttoo_IncreaseDecreaseInOperatingLeaseLiabilities" order="10280.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsParenthetical" xlink:href="ttoo-20220930.xsd#Role_StatementCondensedConsolidatedStatementOfCashFlowsParenthetical" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail">
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" xlink:type="locator" xlink:label="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator" xlink:label="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_DerivativeLiabilities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="ttoo_AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="ttoo_AccruedResearchAndDevelopmentExpensesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableScheduleOfDebtDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureNotesPayableScheduleOfDebtDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableScheduleOfDebtDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentUnaccruedPaidInKindInterest" xlink:type="locator" xlink:label="ttoo_DebtInstrumentUnaccruedPaidInKindInterest" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts" xlink:type="locator" xlink:label="ttoo_DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:type="locator" xlink:label="us-gaap_NotesPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesPayable" xlink:to="ttoo_DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesPayable" xlink:to="ttoo_DebtInstrumentUnaccruedPaidInKindInterest" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="10030.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>ttoo-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-11-14T20:33:37.7060779+00:00 -->
<!-- Version            : 5.0.1.753 -->
<!-- Package ID         : e9bee4ab4d8b4c8a9f469bea6de545b7 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="ttoo-20220930.xsd#TemplateLink" roleURI="http://www.t2biosystems.com/20220930/role/TemplateLink" />
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="ttoo-20220930.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ChangeInFairValueOfDerivativeWarrantLiability" xlink:type="locator" xlink:label="ttoo_ChangeInFairValueOfDerivativeWarrantLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ContributionMember" xlink:type="locator" xlink:label="ttoo_ContributionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10190.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ttoo_ContributionMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="ttoo_ChangeInFairValueOfDerivativeWarrantLiability" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="11960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment" order="12120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="12200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="12280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="12360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="12440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="12520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="12600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="12840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" order="12920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="13000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="13080.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="ttoo-20220930.xsd#Role_StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit" xlink:type="locator" xlink:label="ttoo_MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionOfDividends" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock" xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="ttoo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="11580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ttoo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPreferredStock" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionOfDividends" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ttoo_MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit" order="11940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail">
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MinimumMarketValueOfListedSecurities" xlink:type="locator" xlink:label="ttoo_MinimumMarketValueOfListedSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_RegainComplianceByIncreasingStockPrice" xlink:type="locator" xlink:label="ttoo_RegainComplianceByIncreasingStockPrice" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MinimumBidPriceOfCommonStock" xlink:type="locator" xlink:label="ttoo_MinimumBidPriceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CRGMember" xlink:type="locator" xlink:label="ttoo_CRGMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TermLoanAgreementMember" xlink:type="locator" xlink:label="ttoo_TermLoanAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_NatureOfBusinessTable" xlink:type="locator" xlink:label="ttoo_NatureOfBusinessTable" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_NatureOfBusinessLineItems" xlink:type="locator" xlink:label="ttoo_NatureOfBusinessLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="ttoo_NatureOfBusinessTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ttoo_NatureOfBusinessTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ttoo_NatureOfBusinessTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ttoo_TermLoanAgreementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ttoo_NatureOfBusinessTable" xlink:to="us-gaap_CreditFacilityAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="ttoo_CRGMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ttoo_NatureOfBusinessTable" xlink:to="srt_RangeAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquity" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="us-gaap_RestrictedCash" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="ttoo_MinimumBidPriceOfCommonStock" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="ttoo_RegainComplianceByIncreasingStockPrice" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="ttoo_MinimumMarketValueOfListedSecurities" order="10990.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross" xlink:type="locator" xlink:label="us-gaap_CapitalizedContractCostGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed" xlink:type="locator" xlink:label="ttoo_OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MaintenanceServiceTermOfAdditionalPeriod" xlink:type="locator" xlink:label="ttoo_MaintenanceServiceTermOfAdditionalPeriod" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MaintenanceServicePeriod" xlink:type="locator" xlink:label="ttoo_MaintenanceServicePeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202110Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate202110Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202104Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate202104Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentAssetsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_T2DxMember" xlink:type="locator" xlink:label="ttoo_T2DxMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember" xlink:type="locator" xlink:label="us-gaap_NonUsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_GeographicConcentrationRiskMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:type="locator" xlink:label="us-gaap_ProductInformationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ScheduleOfProductInformationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_GeographicConcentrationRiskMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="srt_StatementGeographicalAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="srt_RangeAxis" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="srt_ProductOrServiceAxis" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ttoo_T2DxMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202104Member" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202110Member" order="11370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="11900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="ttoo_MaintenanceServicePeriod" order="11970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="ttoo_MaintenanceServiceTermOfAdditionalPeriod" order="11990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="ttoo_OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed" order="12040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" order="12060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="12080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="12130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="12200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="12240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" order="12310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="12420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="12440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="12460.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CustomerCMember" xlink:type="locator" xlink:label="ttoo_CustomerCMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CustomerBMember" xlink:type="locator" xlink:label="ttoo_CustomerBMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CustomerAMember" xlink:type="locator" xlink:label="ttoo_CustomerAMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:type="locator" xlink:label="us-gaap_ProductInformationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ScheduleOfProductInformationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="srt_MajorCustomersAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="ttoo_CustomerAMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="ttoo_CustomerBMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="ttoo_CustomerCMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10360.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10270.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueByMajorResourceDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueByMajorResourceDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueByMajorResourceDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ContributionRevenueMember" xlink:type="locator" xlink:label="ttoo_ContributionRevenueMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_InstrumentRentalsMember" xlink:type="locator" xlink:label="ttoo_InstrumentRentalsMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProductConsumablesMember" xlink:type="locator" xlink:label="ttoo_ProductConsumablesMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProductInstrumentsMember" xlink:type="locator" xlink:label="ttoo_ProductInstrumentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ttoo_ProductInstrumentsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ttoo_ProductConsumablesMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ttoo_InstrumentRentalsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ttoo_ContributionRevenueMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1Detail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1Detail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1Detail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:type="locator" xlink:label="us-gaap_ProductInformationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ScheduleOfProductInformationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10110.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1DetailDefault" xlink:href="ttoo-20220930.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1DetailDefault" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1DetailDefault">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:type="locator" xlink:label="us-gaap_ProductInformationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ScheduleOfProductInformationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="10030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10040.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="11570.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TermLoanAgreementMember" xlink:type="locator" xlink:label="ttoo_TermLoanAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CRGMember" xlink:type="locator" xlink:label="ttoo_CRGMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CreditFacilityAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="ttoo_CRGMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ttoo_TermLoanAgreementMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_SecurityDeposit" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="10280.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail">
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_FairValueDerivativeLiabilityDiscountRate" xlink:type="locator" xlink:label="ttoo_FairValueDerivativeLiabilityDiscountRate" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CRGMember" xlink:type="locator" xlink:label="ttoo_CRGMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TermLoanAgreementMember" xlink:type="locator" xlink:label="ttoo_TermLoanAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ScenarioOneMember" xlink:type="locator" xlink:label="ttoo_ScenarioOneMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="ttoo_ScenarioOneMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ttoo_TermLoanAgreementMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CreditFacilityAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="ttoo_CRGMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ttoo_FairValueDerivativeLiabilityDiscountRate" order="10300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsParentheticalDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsParentheticalDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsParentheticalDetail">
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ContingentPaymentOfInterestPercentage" xlink:type="locator" xlink:label="ttoo_ContingentPaymentOfInterestPercentage" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TermLoanAgreementMember" xlink:type="locator" xlink:label="ttoo_TermLoanAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CRGMember" xlink:type="locator" xlink:label="ttoo_CRGMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CreditFacilityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="ttoo_CRGMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ttoo_TermLoanAgreementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ttoo_ContingentPaymentOfInterestPercentage" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsRollForwardOfFairValueOfDerivativeLiabilityDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureFairValueMeasurementsRollForwardOfFairValueOfDerivativeLiabilityDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsRollForwardOfFairValueOfDerivativeLiabilityDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProbabilityWeightedDiscountedCashFlowModelMember" xlink:type="locator" xlink:label="ttoo_ProbabilityWeightedDiscountedCashFlowModelMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="ttoo_ProbabilityWeightedDiscountedCashFlowModelMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureRestrictedCashAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetail">
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_NumberOfFacilities" xlink:type="locator" xlink:label="ttoo_NumberOfFacilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_SecurityDeposit" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="ttoo_NumberOfFacilities" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_T2DxInstrumentsAndComponentsMember" xlink:type="locator" xlink:label="ttoo_T2DxInstrumentsAndComponentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:type="locator" xlink:label="us-gaap_ToolsDiesAndMoldsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManufacturingFacilityMember" xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ToolsDiesAndMoldsMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ttoo_T2DxInstrumentsAndComponentsMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10740.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciation" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSoldDepreciation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessAndRawMaterials" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_T2OwnedInstrumentsInServiceMember" xlink:type="locator" xlink:label="ttoo_T2OwnedInstrumentsInServiceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SupplementalBalanceSheetInformationTable" xlink:type="locator" xlink:label="ttoo_SupplementalBalanceSheetInformationTable" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SupplementalBalanceSheetInformationLineItems" xlink:type="locator" xlink:label="ttoo_SupplementalBalanceSheetInformationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ttoo_SupplementalBalanceSheetInformationLineItems" xlink:to="ttoo_SupplementalBalanceSheetInformationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ttoo_SupplementalBalanceSheetInformationTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ttoo_T2OwnedInstrumentsInServiceMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ttoo_SupplementalBalanceSheetInformationTable" xlink:to="srt_ProductOrServiceAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_SupplementalBalanceSheetInformationLineItems" xlink:to="us-gaap_InventoryWorkInProcessAndRawMaterials" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_SupplementalBalanceSheetInformationLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_SupplementalBalanceSheetInformationLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSoldDepreciation" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_SupplementalBalanceSheetInformationLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10410.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail">
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentEventOfDefaultAdditionalInterestRate" xlink:type="locator" xlink:label="ttoo_DebtInstrumentEventOfDefaultAdditionalInterestRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentPrepaymentFeeTerm" xlink:type="locator" xlink:label="ttoo_DebtInstrumentPrepaymentFeeTerm" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentDeferredInterestRateInterestOnlyPayment" xlink:type="locator" xlink:label="ttoo_DebtInstrumentDeferredInterestRateInterestOnlyPayment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentFinalPaymentFeePercentage" xlink:type="locator" xlink:label="ttoo_DebtInstrumentFinalPaymentFeePercentage" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentTermOfInterestOnlyPayments" xlink:type="locator" xlink:label="ttoo_DebtInstrumentTermOfInterestOnlyPayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TermLoanAgreementMember" xlink:type="locator" xlink:label="ttoo_TermLoanAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CRGMember" xlink:type="locator" xlink:label="ttoo_CRGMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="ttoo_CRGMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ttoo_TermLoanAgreementMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ttoo_DebtInstrumentTermOfInterestOnlyPayments" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ttoo_DebtInstrumentFinalPaymentFeePercentage" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ttoo_DebtInstrumentDeferredInterestRateInterestOnlyPayment" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ttoo_DebtInstrumentPrepaymentFeeTerm" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RestrictedCash" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ttoo_DebtInstrumentEventOfDefaultAdditionalInterestRate" order="12240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:type="locator" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ClassOfWarrantOrRightMaturityDate" xlink:type="locator" xlink:label="ttoo_ClassOfWarrantOrRightMaturityDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockVotingRights" xlink:type="locator" xlink:label="us-gaap_PreferredStockVotingRights" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares" xlink:type="locator" xlink:label="ttoo_PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock" xlink:type="locator" xlink:label="ttoo_PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PreferredStockPricePercentageOnStatedValue" xlink:type="locator" xlink:label="ttoo_PreferredStockPricePercentageOnStatedValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionDate" xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:type="locator" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PurchaseAgreementMember" xlink:type="locator" xlink:label="ttoo_PurchaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="ttoo_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ttoo_SeriesARedeemableConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ttoo_PurchaseAgreementMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionDate" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="ttoo_PreferredStockPricePercentageOnStatedValue" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="ttoo_PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="ttoo_PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockVotingRights" order="11580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="11690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="ttoo_ClassOfWarrantOrRightMaturityDate" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" order="11730.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureStockholdersDeficitAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PercentageOfAgentServiceFee" xlink:type="locator" xlink:label="ttoo_PercentageOfAgentServiceFee" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="ttoo_ProceedsFromIssuanceOfCommonStockGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OriginalSalesAgreementMember" xlink:type="locator" xlink:label="ttoo_OriginalSalesAgreementMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CanaccordGenuityLLCMember" xlink:type="locator" xlink:label="ttoo_CanaccordGenuityLLCMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_NewSalesAgreementMember" xlink:type="locator" xlink:label="ttoo_NewSalesAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ttoo_NewSalesAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ttoo_CanaccordGenuityLLCMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ttoo_OriginalSalesAgreementMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ttoo_ProceedsFromIssuanceOfCommonStockGross" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ttoo_PercentageOfAgentServiceFee" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10770.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MaximumAmountOfAnnualEmployeeCommonStockPurchase" xlink:type="locator" xlink:label="ttoo_MaximumAmountOfAnnualEmployeeCommonStockPurchase" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue" xlink:type="locator" xlink:label="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue" xlink:type="locator" xlink:label="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PercentageOfCommonSharesOutstanding" xlink:type="locator" xlink:label="ttoo_PercentageOfCommonSharesOutstanding" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ComponentOfCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="ttoo_ComponentOfCommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TypeIIIModificationMember" xlink:type="locator" xlink:label="ttoo_TypeIIIModificationMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TypeIModificationMember" xlink:type="locator" xlink:label="ttoo_TypeIModificationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" xlink:type="locator" xlink:label="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember" xlink:type="locator" xlink:label="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_InducementAwardPlanMember" xlink:type="locator" xlink:label="ttoo_InducementAwardPlanMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOptionPlan2014Member" xlink:type="locator" xlink:label="ttoo_StockOptionPlan2014Member" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator" xlink:label="ttoo_EmployeeAndNonemployeeStockOptionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOptionPlan2006Member" xlink:type="locator" xlink:label="ttoo_StockOptionPlan2006Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ttoo_StockOptionPlan2006Member" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ttoo_EmployeeAndNonemployeeStockOptionsMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ttoo_StockOptionPlan2014Member" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ttoo_InducementAwardPlanMember" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ttoo_TypeIModificationMember" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ttoo_TypeIIIModificationMember" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ttoo_ComponentOfCommonStockCapitalSharesReservedForFutureIssuance" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ttoo_PercentageOfCommonSharesOutstanding" order="11900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="11990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue" order="12060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="12170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="12240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="12310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue" order="12380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="12500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ttoo_MaximumAmountOfAnnualEmployeeCommonStockPurchase" order="12540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="12580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="12860.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator" xlink:label="ttoo_EmployeeAndNonemployeeStockOptionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" xlink:type="locator" xlink:label="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ttoo_EmployeeAndNonemployeeStockOptionsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="11090.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" xlink:type="locator" xlink:label="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator" xlink:label="ttoo_EmployeeAndNonemployeeStockOptionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ttoo_EmployeeAndNonemployeeStockOptionsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOptionPlan2014Member" xlink:type="locator" xlink:label="ttoo_StockOptionPlan2014Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ttoo_StockOptionPlan2014Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10490.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedThatWasRecordedInCompanySResultsOfOperationsDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedThatWasRecordedInCompanySResultsOfOperationsDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedThatWasRecordedInCompanySResultsOfOperationsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureWarrantsAssociatedWithTermLoanAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureWarrantsAssociatedWithTermLoanAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureWarrantsAssociatedWithTermLoanAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureNetLossPerShareAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOutstandingDuringPeriodSharesStockSplits" xlink:type="locator" xlink:label="ttoo_StockOutstandingDuringPeriodSharesStockSplits" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockIssuedAndOutstandingDuringPeriodSharesStockSplits" xlink:type="locator" xlink:label="ttoo_StockIssuedAndOutstandingDuringPeriodSharesStockSplits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="ttoo_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ttoo_SeriesAConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ttoo_StockIssuedAndOutstandingDuringPeriodSharesStockSplits" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ttoo_StockOutstandingDuringPeriodSharesStockSplits" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="10250.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="ttoo_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ttoo_SeriesARedeemableConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10380.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureUSGovernmentContractAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CollaborativeArrangementAdditionalFundingAmountToBeReceived" xlink:type="locator" xlink:label="ttoo_CollaborativeArrangementAdditionalFundingAmountToBeReceived" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CollaborativeArrangementAdditionalFundingAmountReceived" xlink:type="locator" xlink:label="ttoo_CollaborativeArrangementAdditionalFundingAmountReceived" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CollaborativeArrangementOptionContractValueExercised" xlink:type="locator" xlink:label="ttoo_CollaborativeArrangementOptionContractValueExercised" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CollaborativeArrangementFirstContractOptionValueExercised" xlink:type="locator" xlink:label="ttoo_CollaborativeArrangementFirstContractOptionValueExercised" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CollaborativeArrangementAggregateConsideration" xlink:type="locator" xlink:label="ttoo_CollaborativeArrangementAggregateConsideration" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CollaborativeArrangementInitialValueOfConsideration" xlink:type="locator" xlink:label="ttoo_CollaborativeArrangementInitialValueOfConsideration" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ContributionMember" xlink:type="locator" xlink:label="ttoo_ContributionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:type="locator" xlink:label="ttoo_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CoDevelopmentPartnershipAgreementMember" xlink:type="locator" xlink:label="ttoo_CoDevelopmentPartnershipAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ttoo_CoDevelopmentPartnershipAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ttoo_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ttoo_ContributionMember" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ttoo_CollaborativeArrangementInitialValueOfConsideration" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ttoo_CollaborativeArrangementAggregateConsideration" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ttoo_CollaborativeArrangementFirstContractOptionValueExercised" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ttoo_CollaborativeArrangementOptionContractValueExercised" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ttoo_CollaborativeArrangementAdditionalFundingAmountReceived" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ttoo_CollaborativeArrangementAdditionalFundingAmountToBeReceived" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="11240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TermOfLease" xlink:type="locator" xlink:label="ttoo_TermOfLease" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SecurityDepositReceived" xlink:type="locator" xlink:label="ttoo_SecurityDepositReceived" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SpaceBuildOutCosts" xlink:type="locator" xlink:label="ttoo_SpaceBuildOutCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncentiveFromLessor" xlink:type="locator" xlink:label="us-gaap_IncentiveFromLessor" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_LesseeOperatingLeaseTerminationPeriod" xlink:type="locator" xlink:label="ttoo_LesseeOperatingLeaseTerminationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities" xlink:type="locator" xlink:label="ttoo_MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OfficeResearchLaboratoryAndManufacturingSpaceMember" xlink:type="locator" xlink:label="ttoo_OfficeResearchLaboratoryAndManufacturingSpaceMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OperatingLeasesEnteredIntoSeptember2021Member" xlink:type="locator" xlink:label="ttoo_OperatingLeasesEnteredIntoSeptember2021Member" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_LaboratorySpaceMember" xlink:type="locator" xlink:label="ttoo_LaboratorySpaceMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OfficeLaboratoryAndManufacturingSpaceMember" xlink:type="locator" xlink:label="ttoo_OfficeLaboratoryAndManufacturingSpaceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficeBuildingMember" xlink:type="locator" xlink:label="srt_OfficeBuildingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OperatingLeasesEnteredIntoMay2013Member" xlink:type="locator" xlink:label="ttoo_OperatingLeasesEnteredIntoMay2013Member" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OperatingLeasesEnteredIntoNovember2014Member" xlink:type="locator" xlink:label="ttoo_OperatingLeasesEnteredIntoNovember2014Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_LicenseAgreementMember" xlink:type="locator" xlink:label="ttoo_LicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OfficeSpaceLaboratorySpaceAndEquipmentMember" xlink:type="locator" xlink:label="ttoo_OfficeSpaceLaboratorySpaceAndEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_LeasesTable" xlink:type="locator" xlink:label="ttoo_LeasesTable" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_LeasesLineItems" xlink:type="locator" xlink:label="ttoo_LeasesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ttoo_LeasesLineItems" xlink:to="ttoo_LeasesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ttoo_LeasesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ttoo_OfficeSpaceLaboratorySpaceAndEquipmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ttoo_LeasesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ttoo_LicenseAgreementMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ttoo_LeasesTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ttoo_OperatingLeasesEnteredIntoNovember2014Member" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ttoo_OperatingLeasesEnteredIntoMay2013Member" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ttoo_LeasesTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_2" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_OfficeBuildingMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ttoo_OfficeLaboratoryAndManufacturingSpaceMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ttoo_LaboratorySpaceMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ttoo_OperatingLeasesEnteredIntoSeptember2021Member" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ttoo_OfficeResearchLaboratoryAndManufacturingSpaceMember" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_LeasesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_LeasesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_LeasesLineItems" xlink:to="ttoo_MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_LeasesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_LeasesLineItems" xlink:to="us-gaap_SecurityDeposit" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_LeasesLineItems" xlink:to="ttoo_LesseeOperatingLeaseTerminationPeriod" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_LeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_LeasesLineItems" xlink:to="us-gaap_IncentiveFromLessor" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_LeasesLineItems" xlink:to="ttoo_SpaceBuildOutCosts" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_LeasesLineItems" xlink:to="ttoo_SecurityDepositReceived" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_LeasesLineItems" xlink:to="ttoo_TermOfLease" order="11910.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="ttoo-20220930.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_RoyaltyOnNetSalesSublicensingGrossRevenue" xlink:type="locator" xlink:label="ttoo_RoyaltyOnNetSalesSublicensingGrossRevenue" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PercentageOfRoyaltyOnNetSales" xlink:type="locator" xlink:label="ttoo_PercentageOfRoyaltyOnNetSales" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_LicenseFeesPayable" xlink:type="locator" xlink:label="ttoo_LicenseFeesPayable" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_LicenseAgreementMember" xlink:type="locator" xlink:label="ttoo_LicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="ttoo_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="ttoo_CommitmentsAndContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ttoo_CommitmentsAndContingenciesLineItems" xlink:to="ttoo_CommitmentsAndContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ttoo_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ttoo_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ttoo_LicenseAgreementMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_CommitmentsAndContingenciesLineItems" xlink:to="ttoo_LicenseFeesPayable" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_CommitmentsAndContingenciesLineItems" xlink:to="ttoo_PercentageOfRoyaltyOnNetSales" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_CommitmentsAndContingenciesLineItems" xlink:to="ttoo_RoyaltyOnNetSalesSublicensingGrossRevenue" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ttoo_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" order="10600.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PurchaseAgreementMember" xlink:type="locator" xlink:label="ttoo_PurchaseAgreementMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="ttoo_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_NewSalesAgreementMember" xlink:type="locator" xlink:label="ttoo_NewSalesAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ttoo_NewSalesAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ttoo_SeriesARedeemableConvertiblePreferredStockMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ttoo_PurchaseAgreementMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable" order="10860.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>ttoo-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-11-14T20:33:37.7070773+00:00 -->
<!-- Version            : 5.0.1.753 -->
<!-- Package ID         : e9bee4ab4d8b4c8a9f469bea6de545b7 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ChangeInFairValueOfDerivativeWarrantLiability" xlink:type="locator" xlink:label="ttoo_ChangeInFairValueOfDerivativeWarrantLiability" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ChangeInFairValueOfDerivativeWarrantLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of derivative warrant liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_ChangeInFairValueOfDerivativeWarrantLiability" xlink:to="ttoo_ChangeInFairValueOfDerivativeWarrantLiability_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" xlink:type="locator" xlink:label="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" />
    <link:label xml:lang="en-US" xlink:label="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities debt maturities after one through two years amortized cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" xlink:to="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Series A redeemable convertible preferred stock and stockholders&#8217; deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative warrant liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Notes Payable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liabilities Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (see Note 14)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A redeemable convertible preferred stock; $0.001 par value; 3,000 shares authorized at September 30, 2022; 3,000 shares issued and outstanding at September 30, 2022; liquidation value of $330,000; 0 shares issued and outstanding at December 31, 2021 (see Note 7)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value; 9,997,000 and 10,000,000 shares authorized at September 30, 2022 and December 31, 2021, respectively; no shares issued and outstanding at September 30, 2022 and December 31, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 400,000,000 shares authorized; 7,050,849 and 3,328,017 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, Series A convertible redeemable preferred stock and stockholders&#8217; deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A redeemable convertible preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A redeemable convertible preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A redeemable convertible preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A redeemable convertible preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A redeemable convertible preference liquidation value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Liquidation Preference</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ContributionMember" xlink:type="locator" xlink:label="ttoo_ContributionMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ContributionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contribution.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_ContributionMember" xlink:to="ttoo_ContributionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ContributionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contribution [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ContributionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contribution [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs and expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Costs And Expenses [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of product revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Goods And Services Sold</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total costs and expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Costs And Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of derivative instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Gain Loss On Derivative Net</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ChangeInFairValueOfDerivativeWarrantLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of derivative warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ChangeInFairValueOfDerivativeWarrantLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Derivative Warrant Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deemed dividend on Series A redeemable convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDividendsAdjustment" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Dividends Adjustment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share &#8212; basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share &#8212; diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Diluted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of common shares used in computing net loss per share &#8212; basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding Basic</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of common shares used in computing net loss per share &#8212; diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Diluted Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized gain on marketable securities arising during the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net realized (gain) loss on marketable securities included in net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Reclassification Adjustment From A O C I For Sale Of Securities Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive (loss) income, net of taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit" xlink:type="locator" xlink:label="ttoo_MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit" />
    <link:label xml:lang="en-US" xlink:label="ttoo_MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Miscellaneous adjustment of Shares to reflect rounding on reverse split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit" xlink:to="ttoo_MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Surrender of shares due to tax withholding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments Related To Tax Withholding For Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Surrender of shares due to tax withholding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Paid For Tax Withholding For Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from secondary offering, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from secondary offering, net (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="ttoo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="ttoo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="ttoo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity stock issued during period (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock" xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deemed dividend on Series A redeemable convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Preferred Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionOfDividends" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Temporary equity, deemed dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionOfDividends" xlink:to="us-gaap_TemporaryEquityAccretionOfDividends_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Accretion Of Dividends</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Misc adjustment to reflect rounding on reverse stock split</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Miscellaneous Adjustment Of Shares To Reflect Rounding On Reverse Split</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability" xlink:type="locator" xlink:label="ttoo_GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability" />
    <link:label xml:lang="en-US" xlink:label="ttoo_GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain loss on issuance of Series A redeemable convertible preferred stock and derivative warrant liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability" xlink:to="ttoo_GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="ttoo_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ttoo_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase (decrease) in operating lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="ttoo_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises" xlink:type="locator" xlink:label="ttoo_ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of shares from employee stock purchase plan and stock option exercises.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises" xlink:to="ttoo_ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts" xlink:type="locator" xlink:label="ttoo_ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash inflow (outflow) associated with the amount received from entity&apos;s first offering of stock to the public, net of offering costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts" xlink:to="ttoo_ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability" xlink:type="locator" xlink:label="ttoo_ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of Series A convertible redeemable preferred stock and derivative warrant liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability" xlink:to="ttoo_ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TransferOfT2OwnedInstrumentsAndComponentsToFromInventory" xlink:type="locator" xlink:label="ttoo_TransferOfT2OwnedInstrumentsAndComponentsToFromInventory" />
    <link:label xml:lang="en-US" xlink:label="ttoo_TransferOfT2OwnedInstrumentsAndComponentsToFromInventory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Transfer of T2 owned instruments and components to (from) inventory.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_TransferOfT2OwnedInstrumentsAndComponentsToFromInventory" xlink:to="ttoo_TransferOfT2OwnedInstrumentsAndComponentsToFromInventory_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock" xlink:type="locator" xlink:label="ttoo_DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="ttoo_DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deemed dividend on Series A convertible redeemable preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock" xlink:to="ttoo_DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of bond premium</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:to="us-gaap_InvestmentIncomeAmortizationOfPremium_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Amortization Of Premium</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of operating lease right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset Amortization Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of derivative instrument</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ChangeInFairValueOfDerivativeWarrantLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of derivative warrant liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Gain) loss on sales of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Gain Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Gain) loss on issuance of Series A redeemable convertible preferred stock and derivative warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Issuance Of Series A Redeemable Convertible Preferred Stock And Derivative Warrant Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:type="locator" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:to="us-gaap_ProductionRelatedImpairmentsOrCharges_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Production Related Impairments Or Charges</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Paid In Kind Interest</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Inventories</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sales of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Available For Sale Securities Debt</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases and manufacture of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of employee restricted stock tax withholdings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Related To Tax Withholding For Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of shares from employee stock purchase plan and stock option exercises</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Shares From Employee Stock Purchase Plan And Stock Option Exercises</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in public offerings, net of offering costs</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering Net Of Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of Series A redeemable convertible preferred stock and derivative warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Series A Convertible Redeemable Preferred Stock And Derivative Warrant Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of cash flow information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of noncash activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_TransferOfT2OwnedInstrumentsAndComponentsToFromInventory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer of T2 owned instruments and components (from) to inventory</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_TransferOfT2OwnedInstrumentsAndComponentsToFromInventory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfer Of T2 Owned Instruments And Components To From Inventory</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed dividend on Series A redeemable convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deemed Dividend On Series A Convertible Redeemable Preferred Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment included in accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of cash, cash equivalents and restricted cash at end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Operations</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAbstract" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAbstract" xlink:to="us-gaap_RestrictedCashAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:to="us-gaap_RestrictedAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Balance Sheet Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock" xlink:type="locator" xlink:label="ttoo_RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ttoo_RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock and related warrant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock" xlink:to="ttoo_RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Redeemable Convertible Preferred Stock and Related Warrant</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock And Related Warrant [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_WarrantsNoteDisclosureTextBlock" xlink:type="locator" xlink:label="ttoo_WarrantsNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ttoo_WarrantsNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure for warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_WarrantsNoteDisclosureTextBlock" xlink:to="ttoo_WarrantsNoteDisclosureTextBlock_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Note Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_WarrantsNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Associated with Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_WarrantsNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Government Contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:type="locator" xlink:label="ttoo_UnauditedInterimFinancialInformationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ttoo_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for reporting unaudited interim financial information for the stated accounting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:to="ttoo_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unaudited Interim Financial Information</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unaudited Interim Financial Information Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_GeographicInformationPolicyTextBlock" xlink:type="locator" xlink:label="ttoo_GeographicInformationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ttoo_GeographicInformationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Geographic information.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_GeographicInformationPolicyTextBlock" xlink:to="ttoo_GeographicInformationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_GeographicInformationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographic Information</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_GeographicInformationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Information Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Warrant Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:type="locator" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Guarantees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:to="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Guarantees Indemnifications And Warranties Policies</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classification of Series A Redeemable Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Redeemable Preferred Stock Issue Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Policy [Text Block]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CostOfProductRevenuePolicyTextBlock" xlink:type="locator" xlink:label="ttoo_CostOfProductRevenuePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CostOfProductRevenuePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of product revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_CostOfProductRevenuePolicyTextBlock" xlink:to="ttoo_CostOfProductRevenuePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CostOfProductRevenuePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Product Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_CostOfProductRevenuePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Product Revenue Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, General and Administrative Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Standards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Customers Represent Greater Than 10% Of Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From External Customers By Geographic Areas Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Maturities of Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified By Contractual Maturity Date Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation of Revenue by Major Source</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets and Liabilities at Fair value on a Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SummaryOfContingentInterestPaymentsTableTextBlock" xlink:type="locator" xlink:label="ttoo_SummaryOfContingentInterestPaymentsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ttoo_SummaryOfContingentInterestPaymentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of contingent interest payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_SummaryOfContingentInterestPaymentsTableTextBlock" xlink:to="ttoo_SummaryOfContingentInterestPaymentsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_SummaryOfContingentInterestPaymentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Contingent Interest Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_SummaryOfContingentInterestPaymentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Contingent Interest Payments Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Roll-Forward of Fair Value of Derivative Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Derivative Liabilities At Fair Value Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Inventory Current Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Debt Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Assumptions Used to Calculate Weighted-Average Grant Date Fair Value of Options Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Nonvested Restricted Stock Units Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Nonvested Restricted Stock Units Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense for Stock Options Granted that was Recorded in the Company&apos;s Results of Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_NatureOfBusinessLineItems" xlink:type="locator" xlink:label="ttoo_NatureOfBusinessLineItems" />
    <link:label xml:lang="en-US" xlink:label="ttoo_NatureOfBusinessLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of business line items.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="ttoo_NatureOfBusinessLineItems_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_NatureOfBusinessTable" xlink:type="locator" xlink:label="ttoo_NatureOfBusinessTable" />
    <link:label xml:lang="en-US" xlink:label="ttoo_NatureOfBusinessTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of business table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_NatureOfBusinessTable" xlink:to="ttoo_NatureOfBusinessTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_NatureOfBusinessTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature Of Business [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_NatureOfBusinessTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TermLoanAgreementMember" xlink:type="locator" xlink:label="ttoo_TermLoanAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_TermLoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_TermLoanAgreementMember" xlink:to="ttoo_TermLoanAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_TermLoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_TermLoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CRGMember" xlink:type="locator" xlink:label="ttoo_CRGMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CRGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">CRG.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_CRGMember" xlink:to="ttoo_CRGMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CRGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CRG [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_CRGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C R G [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_NatureOfBusinessLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature Of Business [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_NatureOfBusinessLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents, and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stockholders&apos; deficit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum cash balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MinimumBidPriceOfCommonStock" xlink:type="locator" xlink:label="ttoo_MinimumBidPriceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="ttoo_MinimumBidPriceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum bid price of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_MinimumBidPriceOfCommonStock" xlink:to="ttoo_MinimumBidPriceOfCommonStock_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_RegainComplianceByIncreasingStockPrice" xlink:type="locator" xlink:label="ttoo_RegainComplianceByIncreasingStockPrice" />
    <link:label xml:lang="en-US" xlink:label="ttoo_RegainComplianceByIncreasingStockPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Regain compliance by increasing stock price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_RegainComplianceByIncreasingStockPrice" xlink:to="ttoo_RegainComplianceByIncreasingStockPrice_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock trading price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_MinimumBidPriceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bid price of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_MinimumBidPriceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Bid Price Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_RegainComplianceByIncreasingStockPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regain compliance by increasing the stock price</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_RegainComplianceByIncreasingStockPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Regain Compliance By Increasing Stock Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock split, conversion ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Reverse Stock Split</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MinimumMarketValueOfListedSecurities" xlink:type="locator" xlink:label="ttoo_MinimumMarketValueOfListedSecurities" />
    <link:label xml:lang="en-US" xlink:label="ttoo_MinimumMarketValueOfListedSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum market value of listed securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_MinimumMarketValueOfListedSecurities" xlink:to="ttoo_MinimumMarketValueOfListedSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_MinimumMarketValueOfListedSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum market value of listed securities</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_MinimumMarketValueOfListedSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Market Value Of Listed Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Product Information [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Product Information [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Benchmark [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Revenue Net [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_GeographicConcentrationRiskMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeographicConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographic Concentration Risk [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicConcentrationRiskMember" xlink:to="us-gaap_GeographicConcentrationRiskMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeographicConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember" xlink:type="locator" xlink:label="us-gaap_NonUsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonUsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-US [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonUsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Us [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_T2DxMember" xlink:type="locator" xlink:label="ttoo_T2DxMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_T2DxMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">T2 Dx.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_T2DxMember" xlink:to="ttoo_T2DxMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_T2DxMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">T2 Dx [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_T2DxMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">T2 Dx [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Non-Current Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid and Other Current Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202006Member" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update202006 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202104Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate202104Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate202104Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update 2021-04 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202104Member" xlink:to="us-gaap_AccountingStandardsUpdate202104Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate202104Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update202104 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202110Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate202110Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate202110Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update 2021-10 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202110Member" xlink:to="us-gaap_AccountingStandardsUpdate202110Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate202110Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update202110 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:type="locator" xlink:label="us-gaap_ProductInformationLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Information [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Percentage1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_MajorCustomersAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MajorCustomersAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Customers [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Name Of Major Customer [Domain]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CustomerAMember" xlink:type="locator" xlink:label="ttoo_CustomerAMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CustomerAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer A.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_CustomerAMember" xlink:to="ttoo_CustomerAMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CustomerAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_CustomerAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Customer A [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CustomerBMember" xlink:type="locator" xlink:label="ttoo_CustomerBMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CustomerBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer B.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_CustomerBMember" xlink:to="ttoo_CustomerBMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CustomerBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer B [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_CustomerBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Customer B [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CustomerCMember" xlink:type="locator" xlink:label="ttoo_CustomerCMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CustomerCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer C.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_CustomerCMember" xlink:to="ttoo_CustomerCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CustomerCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer C [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_CustomerCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Customer C [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Outstanding receivable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Securities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator" xlink:label="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" />
    <link:label xml:lang="en-US" xlink:label="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities debt maturities after one through two years fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:to="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities, Amortized Cost, Due in less than 1 year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Within One Year Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities, Amortized Cost, Due in 1-2 years</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities After One Through Two Years Amortized Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities, Fair Value, Due in less than 1 year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Within One Year Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities, Fair Value, Due in 1-2 years</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities After One Through Two Years Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Fair Value</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MaintenanceServicePeriod" xlink:type="locator" xlink:label="ttoo_MaintenanceServicePeriod" />
    <link:label xml:lang="en-US" xlink:label="ttoo_MaintenanceServicePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The term following the installation of the purchased product for maintenance services which include warranty, maintenance, and technical support services, in PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_MaintenanceServicePeriod" xlink:to="ttoo_MaintenanceServicePeriod_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MaintenanceServiceTermOfAdditionalPeriod" xlink:type="locator" xlink:label="ttoo_MaintenanceServiceTermOfAdditionalPeriod" />
    <link:label xml:lang="en-US" xlink:label="ttoo_MaintenanceServiceTermOfAdditionalPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The additional term for maintenance services on purchased product (which include warranty, maintenance, and technical support services) that may be purchased for additional consideration, in PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_MaintenanceServiceTermOfAdditionalPeriod" xlink:to="ttoo_MaintenanceServiceTermOfAdditionalPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_MaintenanceServicePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maintenance Services period (in years)</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_MaintenanceServicePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maintenance Service Period</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_MaintenanceServiceTermOfAdditionalPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional period for Maintenance Service option (in years)</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_MaintenanceServiceTermOfAdditionalPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maintenance Service Term Of Additional Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Table]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProductInstrumentsMember" xlink:type="locator" xlink:label="ttoo_ProductInstrumentsMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ProductInstrumentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Product, instruments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_ProductInstrumentsMember" xlink:to="ttoo_ProductInstrumentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ProductInstrumentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Instruments [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ProductInstrumentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Instruments [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProductConsumablesMember" xlink:type="locator" xlink:label="ttoo_ProductConsumablesMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ProductConsumablesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Product, consumables.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_ProductConsumablesMember" xlink:to="ttoo_ProductConsumablesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ProductConsumablesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Consumables [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ProductConsumablesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Consumables [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_InstrumentRentalsMember" xlink:type="locator" xlink:label="ttoo_InstrumentRentalsMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_InstrumentRentalsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Instrument rentals.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_InstrumentRentalsMember" xlink:to="ttoo_InstrumentRentalsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_InstrumentRentalsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Instrument Rentals [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_InstrumentRentalsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Instrument Rentals [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total Product Revenue [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ContributionRevenueMember" xlink:type="locator" xlink:label="ttoo_ContributionRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ContributionRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contribution revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_ContributionRevenueMember" xlink:to="ttoo_ContributionRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ContributionRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contribution Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ContributionRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contribution Revenue [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Line Items]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed" xlink:type="locator" xlink:label="ttoo_OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed" />
    <link:label xml:lang="en-US" xlink:label="ttoo_OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Original expected period of contracts for which value of unsatisfied performance obligations not to be disclosed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed" xlink:to="ttoo_OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Original expected period of contracts for which value of unsatisfied performance obligations not to be disclosed</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Original Expected Period Of Contracts For Which Value Of Unsatisfied Performance Obligations Not To Be Disclosed</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining performance obligation, expected timing of satisfaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Explanation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price that is allocated to unsatisfied or partially satisfied performance obligations, that has not yet been recognized as revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of revenue recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation Percentage</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized relating to contract liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross" xlink:type="locator" xlink:label="us-gaap_CapitalizedContractCostGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalizedContractCostGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs to obtain or fulfill contract capitalized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostGross" xlink:to="us-gaap_CapitalizedContractCostGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalizedContractCostGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adopted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adoption Date</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Immaterial Effect</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Basis [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Disclosure Item Amounts [Default]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Portion At Fair Value Fair Value Disclosure [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosure Item Amounts [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimate of Fair Value Measurement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimate Of Fair Value Fair Value Disclosure [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Assets, fair value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Money Market Accounts [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_FairValueDerivativeLiabilityDiscountRate" xlink:type="locator" xlink:label="ttoo_FairValueDerivativeLiabilityDiscountRate" />
    <link:label xml:lang="en-US" xlink:label="ttoo_FairValueDerivativeLiabilityDiscountRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value derivative liability discount rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_FairValueDerivativeLiabilityDiscountRate" xlink:to="ttoo_FairValueDerivativeLiabilityDiscountRate_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration by Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration By Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ScenarioOneMember" xlink:type="locator" xlink:label="ttoo_ScenarioOneMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ScenarioOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Scenario one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_ScenarioOneMember" xlink:to="ttoo_ScenarioOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ScenarioOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Interest Beginning in Q1 2023 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ScenarioOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario One [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input, Discount Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Discount Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_FairValueDerivativeLiabilityDiscountRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">4% contingent interest beginning in Q1 2023, probability</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_FairValueDerivativeLiabilityDiscountRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Derivative Liability Discount Rate</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ContingentPaymentOfInterestPercentage" xlink:type="locator" xlink:label="ttoo_ContingentPaymentOfInterestPercentage" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ContingentPaymentOfInterestPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent payment of interest, percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_ContingentPaymentOfInterestPercentage" xlink:to="ttoo_ContingentPaymentOfInterestPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ContingentPaymentOfInterestPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent payment of interest rate</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ContingentPaymentOfInterestPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Payment Of Interest Percentage</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Approach and Technique</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Approach and Technique</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique [Domain]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProbabilityWeightedDiscountedCashFlowModelMember" xlink:type="locator" xlink:label="ttoo_ProbabilityWeightedDiscountedCashFlowModelMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ProbabilityWeightedDiscountedCashFlowModelMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Probability-weighted discounted cash flow model.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_ProbabilityWeightedDiscountedCashFlowModelMember" xlink:to="ttoo_ProbabilityWeightedDiscountedCashFlowModelMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ProbabilityWeightedDiscountedCashFlowModelMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Probability Weighted Discounted Cash Flow Model</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ProbabilityWeightedDiscountedCashFlowModelMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Probability Weighted Discounted Cash Flow Model [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_NumberOfFacilities" xlink:type="locator" xlink:label="ttoo_NumberOfFacilities" />
    <link:label xml:lang="en-US" xlink:label="ttoo_NumberOfFacilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of facilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_NumberOfFacilities" xlink:to="ttoo_NumberOfFacilities_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Restricted Cash And Cash Equivalents [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Restricted Cash And Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash And Cash Equivalents Items [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Items [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposits</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_NumberOfFacilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of facilities</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_NumberOfFacilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Facilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNetAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raw materials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Raw Materials Net Of Reserves</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work-in-process</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Work In Process Net Of Reserves</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Finished Goods Net Of Reserves</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total inventories, net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Computer Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Software And Software Development Costs [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManufacturingFacilityMember" xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing Facility [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:type="locator" xlink:label="us-gaap_ToolsDiesAndMoldsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ToolsDiesAndMoldsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing Tooling and Molds [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ToolsDiesAndMoldsMember" xlink:to="us-gaap_ToolsDiesAndMoldsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ToolsDiesAndMoldsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tools Dies And Molds [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_T2DxInstrumentsAndComponentsMember" xlink:type="locator" xlink:label="ttoo_T2DxInstrumentsAndComponentsMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_T2DxInstrumentsAndComponentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the T2Dx Instruments and components of instruments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_T2DxInstrumentsAndComponentsMember" xlink:to="ttoo_T2DxInstrumentsAndComponentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_T2DxInstrumentsAndComponentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">T2-Owned Instruments and Components [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_T2DxInstrumentsAndComponentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">T2 Dx Instruments And Components [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SupplementalBalanceSheetInformationLineItems" xlink:type="locator" xlink:label="ttoo_SupplementalBalanceSheetInformationLineItems" />
    <link:label xml:lang="en-US" xlink:label="ttoo_SupplementalBalanceSheetInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplemental balance sheet information.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_SupplementalBalanceSheetInformationLineItems" xlink:to="ttoo_SupplementalBalanceSheetInformationLineItems_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SupplementalBalanceSheetInformationTable" xlink:type="locator" xlink:label="ttoo_SupplementalBalanceSheetInformationTable" />
    <link:label xml:lang="en-US" xlink:label="ttoo_SupplementalBalanceSheetInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplemental Balance Sheet Information [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_SupplementalBalanceSheetInformationTable" xlink:to="ttoo_SupplementalBalanceSheetInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_SupplementalBalanceSheetInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Balance Sheet Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_SupplementalBalanceSheetInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Information [Table]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_T2OwnedInstrumentsInServiceMember" xlink:type="locator" xlink:label="ttoo_T2OwnedInstrumentsInServiceMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_T2OwnedInstrumentsInServiceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the T2dx Instruments in service.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_T2OwnedInstrumentsInServiceMember" xlink:to="ttoo_T2OwnedInstrumentsInServiceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_T2OwnedInstrumentsInServiceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">T2 Owned Instruments in Service [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_T2OwnedInstrumentsInServiceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">T2 Owned Instruments In Service [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_SupplementalBalanceSheetInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Balance Sheet Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_SupplementalBalanceSheetInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessAndRawMaterials" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryWorkInProcessAndRawMaterials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raw materials and work-in-process inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:to="us-gaap_InventoryWorkInProcessAndRawMaterials_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryWorkInProcessAndRawMaterials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Work In Process And Raw Materials</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated useful lives (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciation" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSoldDepreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfGoodsAndServicesSoldDepreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense recorded as a component of cost of product revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSoldDepreciation" xlink:to="us-gaap_CostOfGoodsAndServicesSoldDepreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfGoodsAndServicesSoldDepreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Goods And Services Sold Depreciation</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="ttoo_AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:label xml:lang="en-US" xlink:label="ttoo_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred and payable for research and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="ttoo_AccruedResearchAndDevelopmentExpensesCurrent_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll and compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts" xlink:type="locator" xlink:label="ttoo_DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument carrying amount including paid in kind interest before unamortized discount and issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts" xlink:to="ttoo_DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentUnaccruedPaidInKindInterest" xlink:type="locator" xlink:label="ttoo_DebtInstrumentUnaccruedPaidInKindInterest" />
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentUnaccruedPaidInKindInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument unaccrued paid in kind interest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_DebtInstrumentUnaccruedPaidInKindInterest" xlink:to="ttoo_DebtInstrumentUnaccruedPaidInKindInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan Agreement including PIK interest, before unamortized discount and issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Carrying Amount Including Paid In Kind Interest Before Unamortized Discount And Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentUnaccruedPaidInKindInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: unaccrued paid-in-kind interest</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentUnaccruedPaidInKindInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unaccrued Paid In Kind Interest</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: unamortized discount and deferred issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:type="locator" xlink:label="us-gaap_NotesPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentTermOfInterestOnlyPayments" xlink:type="locator" xlink:label="ttoo_DebtInstrumentTermOfInterestOnlyPayments" />
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentTermOfInterestOnlyPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of time between issuance and maturity of debt instrument of interest only payments, in PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_DebtInstrumentTermOfInterestOnlyPayments" xlink:to="ttoo_DebtInstrumentTermOfInterestOnlyPayments_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentFinalPaymentFeePercentage" xlink:type="locator" xlink:label="ttoo_DebtInstrumentFinalPaymentFeePercentage" />
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentFinalPaymentFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Final fee as a percentage of the amount of principal outstanding upon repayment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_DebtInstrumentFinalPaymentFeePercentage" xlink:to="ttoo_DebtInstrumentFinalPaymentFeePercentage_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentDeferredInterestRateInterestOnlyPayment" xlink:type="locator" xlink:label="ttoo_DebtInstrumentDeferredInterestRateInterestOnlyPayment" />
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentDeferredInterestRateInterestOnlyPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual deferred interest rate during interest only payments for funds borrowed, under the debt agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_DebtInstrumentDeferredInterestRateInterestOnlyPayment" xlink:to="ttoo_DebtInstrumentDeferredInterestRateInterestOnlyPayment_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of long-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Long Term Debt</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Term</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentTermOfInterestOnlyPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, term of interest-only payments (in years)</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentTermOfInterestOnlyPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Term Of Interest Only Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentFinalPaymentFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Final fee as a percentage of the principal outstanding (as a percent)</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentFinalPaymentFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Final Payment Fee Percentage</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual fixed rate (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentDeferredInterestRateInterestOnlyPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred interest rate (as a percent)</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentDeferredInterestRateInterestOnlyPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Deferred Interest Rate Interest Only Payment</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentPrepaymentFeeTerm" xlink:type="locator" xlink:label="ttoo_DebtInstrumentPrepaymentFeeTerm" />
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentPrepaymentFeeTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment fee period of debt instrument, in PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_DebtInstrumentPrepaymentFeeTerm" xlink:to="ttoo_DebtInstrumentPrepaymentFeeTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentPrepaymentFeeTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, prepayment fee term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentPrepaymentFeeTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Prepayment Fee Term</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issuable for warrants outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentEventOfDefaultAdditionalInterestRate" xlink:type="locator" xlink:label="ttoo_DebtInstrumentEventOfDefaultAdditionalInterestRate" />
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentEventOfDefaultAdditionalInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional interest rate on all outstanding obligations during the occurrence and continuance of an event of default.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_DebtInstrumentEventOfDefaultAdditionalInterestRate" xlink:to="ttoo_DebtInstrumentEventOfDefaultAdditionalInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentEventOfDefaultAdditionalInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional interest rate, event of default (as a percent)</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_DebtInstrumentEventOfDefaultAdditionalInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Event Of Default Additional Interest Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="ttoo_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="ttoo_SeriesARedeemableConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PurchaseAgreementMember" xlink:type="locator" xlink:label="ttoo_PurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_PurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_PurchaseAgreementMember" xlink:to="ttoo_PurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_PurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_PurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:type="locator" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate subscription amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Share Subscribed But Unissued Subscriptions Receivable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity issued, price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PreferredStockPricePercentageOnStatedValue" xlink:type="locator" xlink:label="ttoo_PreferredStockPricePercentageOnStatedValue" />
    <link:label xml:lang="en-US" xlink:label="ttoo_PreferredStockPricePercentageOnStatedValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock price percentage on stated value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_PreferredStockPricePercentageOnStatedValue" xlink:to="ttoo_PreferredStockPricePercentageOnStatedValue_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock" xlink:type="locator" xlink:label="ttoo_PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock" />
    <link:label xml:lang="en-US" xlink:label="ttoo_PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock price percentage on stated value, held by holders of preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock" xlink:to="ttoo_PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares" xlink:type="locator" xlink:label="ttoo_PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares" />
    <link:label xml:lang="en-US" xlink:label="ttoo_PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock price percentage on stated value, automatically redeemable upon delisting of common shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares" xlink:to="ttoo_PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price of preferred shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Convertible Conversion Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionDate" xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockConvertibleConversionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion date of preferred shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionDate" xlink:to="us-gaap_PreferredStockConvertibleConversionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockConvertibleConversionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Convertible Conversion Date</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_PreferredStockPricePercentageOnStatedValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock price percentage on stated value</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_PreferredStockPricePercentageOnStatedValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Price Percentage On Stated Value</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock price percentage on stated value, held by holders of preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Price Percentage On Stated Value Held By Holders Of Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock price percentage on stated value, automatically redeemable upon delisting of common shares</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Price Percentage On Stated Value Automatically Redeemable Upon Delisting Of Common Shares</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockVotingRights" xlink:type="locator" xlink:label="us-gaap_PreferredStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Voting rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockVotingRights" xlink:to="us-gaap_PreferredStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Voting Rights</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ClassOfWarrantOrRightMaturityDate" xlink:type="locator" xlink:label="ttoo_ClassOfWarrantOrRightMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ClassOfWarrantOrRightMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right maturity date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_ClassOfWarrantOrRightMaturityDate" xlink:to="ttoo_ClassOfWarrantOrRightMaturityDate_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercisable date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ClassOfWarrantOrRightMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants maturity term</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ClassOfWarrantOrRightMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Maturity Date</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:type="locator" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_NewSalesAgreementMember" xlink:type="locator" xlink:label="ttoo_NewSalesAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_NewSalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">New sales agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_NewSalesAgreementMember" xlink:to="ttoo_NewSalesAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_NewSalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_NewSalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Sales Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CanaccordGenuityLLCMember" xlink:type="locator" xlink:label="ttoo_CanaccordGenuityLLCMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CanaccordGenuityLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Canaccord Genuity LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_CanaccordGenuityLLCMember" xlink:to="ttoo_CanaccordGenuityLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CanaccordGenuityLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Canaccord [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_CanaccordGenuityLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Canaccord Genuity L L C [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OriginalSalesAgreementMember" xlink:type="locator" xlink:label="ttoo_OriginalSalesAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_OriginalSalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Original sales agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_OriginalSalesAgreementMember" xlink:to="ttoo_OriginalSalesAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_OriginalSalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Original Sales Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_OriginalSalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Original Sales Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="ttoo_ProceedsFromIssuanceOfCommonStockGross" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock, gross.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_ProceedsFromIssuanceOfCommonStockGross" xlink:to="ttoo_ProceedsFromIssuanceOfCommonStockGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate gross sales amount of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Gross</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PercentageOfAgentServiceFee" xlink:type="locator" xlink:label="ttoo_PercentageOfAgentServiceFee" />
    <link:label xml:lang="en-US" xlink:label="ttoo_PercentageOfAgentServiceFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of agent service fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_PercentageOfAgentServiceFee" xlink:to="ttoo_PercentageOfAgentServiceFee_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_PercentageOfAgentServiceFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of agent service fee</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_PercentageOfAgentServiceFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Agent Service Fee</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares issued/sold</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOptionPlan2006Member" xlink:type="locator" xlink:label="ttoo_StockOptionPlan2006Member" />
    <link:label xml:lang="en-US" xlink:label="ttoo_StockOptionPlan2006Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Option Plan 2006 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_StockOptionPlan2006Member" xlink:to="ttoo_StockOptionPlan2006Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_StockOptionPlan2006Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2006 Stock Option Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_StockOptionPlan2006Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option Plan2006 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator" xlink:label="ttoo_EmployeeAndNonemployeeStockOptionsMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_EmployeeAndNonemployeeStockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee and nonemployee stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_EmployeeAndNonemployeeStockOptionsMember" xlink:to="ttoo_EmployeeAndNonemployeeStockOptionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_EmployeeAndNonemployeeStockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_EmployeeAndNonemployeeStockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee And Nonemployee Stock Options [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOptionPlan2014Member" xlink:type="locator" xlink:label="ttoo_StockOptionPlan2014Member" />
    <link:label xml:lang="en-US" xlink:label="ttoo_StockOptionPlan2014Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Option Plan 2014 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_StockOptionPlan2014Member" xlink:to="ttoo_StockOptionPlan2014Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_StockOptionPlan2014Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Stock Option Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_StockOptionPlan2014Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option Plan2014 [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_InducementAwardPlanMember" xlink:type="locator" xlink:label="ttoo_InducementAwardPlanMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_InducementAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement award plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_InducementAwardPlanMember" xlink:to="ttoo_InducementAwardPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_InducementAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inducement Award Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_InducementAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Award Plan [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember" xlink:type="locator" xlink:label="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock option plans two thousand and six and two thousand and fourteen.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember" xlink:to="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2006 and 2014 Stock Option Plans [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option Plans Two Thousand And Six And Two Thousand And Fourteen [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" xlink:type="locator" xlink:label="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock option plans two thousand and six and two thousand and fourteen and inducement plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" xlink:to="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2006 and 2014 Stock Option Plans and Inducement Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option Plans Two Thousand And Six And Two Thousand And Fourteen And Inducement Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:label xml:lang="en-US" xlink:label="srt_DirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Director [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_DirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TypeIModificationMember" xlink:type="locator" xlink:label="ttoo_TypeIModificationMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_TypeIModificationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Type I modification.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_TypeIModificationMember" xlink:to="ttoo_TypeIModificationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_TypeIModificationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type I Modification [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_TypeIModificationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type I Modification [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TypeIIIModificationMember" xlink:type="locator" xlink:label="ttoo_TypeIIIModificationMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_TypeIIIModificationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Type III Modification.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_TypeIIIModificationMember" xlink:to="ttoo_TypeIIIModificationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_TypeIIIModificationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type III Modification [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_TypeIIIModificationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type I I I Modification [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ComponentOfCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="ttoo_ComponentOfCommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ComponentOfCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Component of common stock capital shares reserved for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_ComponentOfCommonStockCapitalSharesReservedForFutureIssuance" xlink:to="ttoo_ComponentOfCommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PercentageOfCommonSharesOutstanding" xlink:type="locator" xlink:label="ttoo_PercentageOfCommonSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="ttoo_PercentageOfCommonSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of common share outstanding, as it relates to the number of shares reserved for future issuance calculation under the 2014 Stock Incentive Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_PercentageOfCommonSharesOutstanding" xlink:to="ttoo_PercentageOfCommonSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ComponentOfCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares available for future issuance under stock incentive plan</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ComponentOfCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Component Of Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_PercentageOfCommonSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of common shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_PercentageOfCommonSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Common Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock from exercise of stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for authorization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue" xlink:type="locator" xlink:label="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options grants in period gross value grant date fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue" xlink:to="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate fair value of options granted</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Value Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Outstanding, beginning of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Outstanding, end of the period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Vested or expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price Per Share Outstanding, beginning of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price Per Share Outstanding, end of the period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Vested or expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Vested or expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested or expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average fair value of options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of vested stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to non-vested stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue" xlink:type="locator" xlink:label="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award other than options grants in period gross value grant date fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue" xlink:to="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate fair value of restricted stock units granted</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Grants In Period Gross Value Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Nonvested restricted shares at the beginning of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Shares, Restricted shares granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Restricted shares vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Restricted shares forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Nonvested restricted shares at the end of the period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Grant Date Fair Value, Nonvested restricted shares at the beginning of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Weighted-Average Grant Date Fair Value, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Grant Date Fair Value, Nonvested restricted shares at the end of the period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to unvested stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MaximumAmountOfAnnualEmployeeCommonStockPurchase" xlink:type="locator" xlink:label="ttoo_MaximumAmountOfAnnualEmployeeCommonStockPurchase" />
    <link:label xml:lang="en-US" xlink:label="ttoo_MaximumAmountOfAnnualEmployeeCommonStockPurchase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of annual employee common stock purchase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_MaximumAmountOfAnnualEmployeeCommonStockPurchase" xlink:to="ttoo_MaximumAmountOfAnnualEmployeeCommonStockPurchase_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of full share price paid in purchase of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_MaximumAmountOfAnnualEmployeeCommonStockPurchase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amount of annual employee common stock purchases</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_MaximumAmountOfAnnualEmployeeCommonStockPurchase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount Of Annual Employee Common Stock Purchase</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Product Revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Sales [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, General and Administrative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares issuable for warrants outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="ttoo_SeriesAConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series a convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_SeriesAConvertiblePreferredStockMember" xlink:to="ttoo_SeriesAConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss attributable to common stockholders</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Purchase Common Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants to Purchase Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities excluded from the computation of diluted net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockIssuedAndOutstandingDuringPeriodSharesStockSplits" xlink:type="locator" xlink:label="ttoo_StockIssuedAndOutstandingDuringPeriodSharesStockSplits" />
    <link:label xml:lang="en-US" xlink:label="ttoo_StockIssuedAndOutstandingDuringPeriodSharesStockSplits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares issued and outstanding during the period as a result of a stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_StockIssuedAndOutstandingDuringPeriodSharesStockSplits" xlink:to="ttoo_StockIssuedAndOutstandingDuringPeriodSharesStockSplits_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOutstandingDuringPeriodSharesStockSplits" xlink:type="locator" xlink:label="ttoo_StockOutstandingDuringPeriodSharesStockSplits" />
    <link:label xml:lang="en-US" xlink:label="ttoo_StockOutstandingDuringPeriodSharesStockSplits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares outstanding during the period as a result of a stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_StockOutstandingDuringPeriodSharesStockSplits" xlink:to="ttoo_StockOutstandingDuringPeriodSharesStockSplits_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_StockIssuedAndOutstandingDuringPeriodSharesStockSplits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued and outstanding immediately before the reverse stock split</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_StockIssuedAndOutstandingDuringPeriodSharesStockSplits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued And Outstanding During Period Shares Stock Splits</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_StockOutstandingDuringPeriodSharesStockSplits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares outstanding immediately after the reverse stock split</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_StockOutstandingDuringPeriodSharesStockSplits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Outstanding During Period Shares Stock Splits</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Reverse Stock Splits</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CollaborativeArrangementInitialValueOfConsideration" xlink:type="locator" xlink:label="ttoo_CollaborativeArrangementInitialValueOfConsideration" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CollaborativeArrangementInitialValueOfConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement initial value of consideration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_CollaborativeArrangementInitialValueOfConsideration" xlink:to="ttoo_CollaborativeArrangementInitialValueOfConsideration_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CollaborativeArrangementAggregateConsideration" xlink:type="locator" xlink:label="ttoo_CollaborativeArrangementAggregateConsideration" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CollaborativeArrangementAggregateConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of aggregate consideration receivable under collaborative arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_CollaborativeArrangementAggregateConsideration" xlink:to="ttoo_CollaborativeArrangementAggregateConsideration_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CollaborativeArrangementFirstContractOptionValueExercised" xlink:type="locator" xlink:label="ttoo_CollaborativeArrangementFirstContractOptionValueExercised" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CollaborativeArrangementFirstContractOptionValueExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement first contract option value exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_CollaborativeArrangementFirstContractOptionValueExercised" xlink:to="ttoo_CollaborativeArrangementFirstContractOptionValueExercised_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CollaborativeArrangementOptionContractValueExercised" xlink:type="locator" xlink:label="ttoo_CollaborativeArrangementOptionContractValueExercised" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CollaborativeArrangementOptionContractValueExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement option contract value exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_CollaborativeArrangementOptionContractValueExercised" xlink:to="ttoo_CollaborativeArrangementOptionContractValueExercised_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CoDevelopmentPartnershipAgreementMember" xlink:type="locator" xlink:label="ttoo_CoDevelopmentPartnershipAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CoDevelopmentPartnershipAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to a Co-Development Partnership Agreement with a third party to develop certain products.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_CoDevelopmentPartnershipAgreementMember" xlink:to="ttoo_CoDevelopmentPartnershipAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CoDevelopmentPartnershipAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Co Development Partnership Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_CoDevelopmentPartnershipAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Co Development Partnership Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:type="locator" xlink:label="ttoo_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Biomedical Advanced Research and Development Authority.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:to="ttoo_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biomedical Advanced Research and Development Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Biomedical Advanced Research And Development Authority [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_CollaborativeArrangementInitialValueOfConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial value of consideration receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_CollaborativeArrangementInitialValueOfConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Initial Value Of Consideration</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_CollaborativeArrangementAggregateConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate consideration receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_CollaborativeArrangementAggregateConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Aggregate Consideration</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_CollaborativeArrangementFirstContractOptionValueExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First contract option value exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_CollaborativeArrangementFirstContractOptionValueExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement First Contract Option Value Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_CollaborativeArrangementOptionContractValueExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option contract value exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_CollaborativeArrangementOptionContractValueExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Option Contract Value Exercised</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CollaborativeArrangementAdditionalFundingAmountReceived" xlink:type="locator" xlink:label="ttoo_CollaborativeArrangementAdditionalFundingAmountReceived" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CollaborativeArrangementAdditionalFundingAmountReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative Arrangement Additional Funding Amount Received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_CollaborativeArrangementAdditionalFundingAmountReceived" xlink:to="ttoo_CollaborativeArrangementAdditionalFundingAmountReceived_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CollaborativeArrangementAdditionalFundingAmountReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement additional funding amount received</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_CollaborativeArrangementAdditionalFundingAmountReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Additional Funding Amount Received</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CollaborativeArrangementAdditionalFundingAmountToBeReceived" xlink:type="locator" xlink:label="ttoo_CollaborativeArrangementAdditionalFundingAmountToBeReceived" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CollaborativeArrangementAdditionalFundingAmountToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement additional funding amount to be received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_CollaborativeArrangementAdditionalFundingAmountToBeReceived" xlink:to="ttoo_CollaborativeArrangementAdditionalFundingAmountToBeReceived_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CollaborativeArrangementAdditionalFundingAmountToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement additional funding amount to be received</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_CollaborativeArrangementAdditionalFundingAmountToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Additional Funding Amount To Be Received</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities" xlink:type="locator" xlink:label="ttoo_MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ttoo_MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum lease period to not recognize right of use assets or lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities" xlink:to="ttoo_MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_LeasesLineItems" xlink:type="locator" xlink:label="ttoo_LeasesLineItems" />
    <link:label xml:lang="en-US" xlink:label="ttoo_LeasesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_LeasesLineItems" xlink:to="ttoo_LeasesLineItems_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_LeasesTable" xlink:type="locator" xlink:label="ttoo_LeasesTable" />
    <link:label xml:lang="en-US" xlink:label="ttoo_LeasesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_LeasesTable" xlink:to="ttoo_LeasesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_LeasesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_LeasesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Table]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OfficeSpaceLaboratorySpaceAndEquipmentMember" xlink:type="locator" xlink:label="ttoo_OfficeSpaceLaboratorySpaceAndEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_OfficeSpaceLaboratorySpaceAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office space, laboratory space, and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_OfficeSpaceLaboratorySpaceAndEquipmentMember" xlink:to="ttoo_OfficeSpaceLaboratorySpaceAndEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_OfficeSpaceLaboratorySpaceAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Space, Laboratory Space, and Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_OfficeSpaceLaboratorySpaceAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Space Laboratory Space And Equipment [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_LicenseAgreementMember" xlink:type="locator" xlink:label="ttoo_LicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to an agreement with a third party for licensing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_LicenseAgreementMember" xlink:to="ttoo_LicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OperatingLeasesEnteredIntoNovember2014Member" xlink:type="locator" xlink:label="ttoo_OperatingLeasesEnteredIntoNovember2014Member" />
    <link:label xml:lang="en-US" xlink:label="ttoo_OperatingLeasesEnteredIntoNovember2014Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to operating leases entered into November 2014.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_OperatingLeasesEnteredIntoNovember2014Member" xlink:to="ttoo_OperatingLeasesEnteredIntoNovember2014Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_OperatingLeasesEnteredIntoNovember2014Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Entered into November 2014 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_OperatingLeasesEnteredIntoNovember2014Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Entered Into November2014 [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OperatingLeasesEnteredIntoMay2013Member" xlink:type="locator" xlink:label="ttoo_OperatingLeasesEnteredIntoMay2013Member" />
    <link:label xml:lang="en-US" xlink:label="ttoo_OperatingLeasesEnteredIntoMay2013Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to operating leases entered into May 2013.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_OperatingLeasesEnteredIntoMay2013Member" xlink:to="ttoo_OperatingLeasesEnteredIntoMay2013Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_OperatingLeasesEnteredIntoMay2013Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases Entered Into May2013</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_OperatingLeasesEnteredIntoMay2013Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Entered Into May2013 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Real Estate, Type of Property</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Mortgage Loans On Real Estate Description Type Of Property [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Real Estate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Mortgage Loans On Real Estate Name Property Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficeBuildingMember" xlink:type="locator" xlink:label="srt_OfficeBuildingMember" />
    <link:label xml:lang="en-US" xlink:label="srt_OfficeBuildingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Space [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficeBuildingMember" xlink:to="srt_OfficeBuildingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_OfficeBuildingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Building [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OfficeLaboratoryAndManufacturingSpaceMember" xlink:type="locator" xlink:label="ttoo_OfficeLaboratoryAndManufacturingSpaceMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_OfficeLaboratoryAndManufacturingSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the information pertaining to office, laboratory and manufacturing space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_OfficeLaboratoryAndManufacturingSpaceMember" xlink:to="ttoo_OfficeLaboratoryAndManufacturingSpaceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_OfficeLaboratoryAndManufacturingSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Laboratory And Manufacturing Space</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_OfficeLaboratoryAndManufacturingSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Laboratory And Manufacturing Space [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_LaboratorySpaceMember" xlink:type="locator" xlink:label="ttoo_LaboratorySpaceMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_LaboratorySpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the information pertaining to laboratory space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_LaboratorySpaceMember" xlink:to="ttoo_LaboratorySpaceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_LaboratorySpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Space [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_LaboratorySpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Space [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OperatingLeasesEnteredIntoSeptember2021Member" xlink:type="locator" xlink:label="ttoo_OperatingLeasesEnteredIntoSeptember2021Member" />
    <link:label xml:lang="en-US" xlink:label="ttoo_OperatingLeasesEnteredIntoSeptember2021Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Leases Entered Into September2021.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_OperatingLeasesEnteredIntoSeptember2021Member" xlink:to="ttoo_OperatingLeasesEnteredIntoSeptember2021Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_OperatingLeasesEnteredIntoSeptember2021Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases Entered Into September 2021 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_OperatingLeasesEnteredIntoSeptember2021Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Entered Into September2021 [Member]</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OfficeResearchLaboratoryAndManufacturingSpaceMember" xlink:type="locator" xlink:label="ttoo_OfficeResearchLaboratoryAndManufacturingSpaceMember" />
    <link:label xml:lang="en-US" xlink:label="ttoo_OfficeResearchLaboratoryAndManufacturingSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office Research Laboratory and Manufacturing Space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_OfficeResearchLaboratoryAndManufacturingSpaceMember" xlink:to="ttoo_OfficeResearchLaboratoryAndManufacturingSpaceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_OfficeResearchLaboratoryAndManufacturingSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office, Research, Laboratory and Manufacturing Space [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_OfficeResearchLaboratoryAndManufacturingSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Research Laboratory And Manufacturing Space [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_LeasesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_LeasesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum lease period to not recognize right of use assets or lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Lease Period To Not Recognize Right Of Use Assets Or Lease Liabilities</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_LesseeOperatingLeaseTerminationPeriod" xlink:type="locator" xlink:label="ttoo_LesseeOperatingLeaseTerminationPeriod" />
    <link:label xml:lang="en-US" xlink:label="ttoo_LesseeOperatingLeaseTerminationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease termination period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_LesseeOperatingLeaseTerminationPeriod" xlink:to="ttoo_LesseeOperatingLeaseTerminationPeriod_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Security deposit</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_LesseeOperatingLeaseTerminationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease termination date</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_LesseeOperatingLeaseTerminationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Termination Period</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SpaceBuildOutCosts" xlink:type="locator" xlink:label="ttoo_SpaceBuildOutCosts" />
    <link:label xml:lang="en-US" xlink:label="ttoo_SpaceBuildOutCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Space build-out costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_SpaceBuildOutCosts" xlink:to="ttoo_SpaceBuildOutCosts_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SecurityDepositReceived" xlink:type="locator" xlink:label="ttoo_SecurityDepositReceived" />
    <link:label xml:lang="en-US" xlink:label="ttoo_SecurityDepositReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Security deposit received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_SecurityDepositReceived" xlink:to="ttoo_SecurityDepositReceived_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncentiveFromLessor" xlink:type="locator" xlink:label="us-gaap_IncentiveFromLessor" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncentiveFromLessor_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Space build-out costs paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncentiveFromLessor" xlink:to="us-gaap_IncentiveFromLessor_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncentiveFromLessor_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Incentive From Lessor</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_SpaceBuildOutCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Space build-out costs</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_SpaceBuildOutCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Space Build Out Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_SecurityDepositReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit received from landlord</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_SecurityDepositReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit Received</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TermOfLease" xlink:type="locator" xlink:label="ttoo_TermOfLease" />
    <link:label xml:lang="en-US" xlink:label="ttoo_TermOfLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term of lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_TermOfLease" xlink:to="ttoo_TermOfLease_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_TermOfLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of lease</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_TermOfLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term Of Lease</link:label>
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PercentageOfRoyaltyOnNetSales" xlink:type="locator" xlink:label="ttoo_PercentageOfRoyaltyOnNetSales" />
    <link:label xml:lang="en-US" xlink:label="ttoo_PercentageOfRoyaltyOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty on net sales.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_PercentageOfRoyaltyOnNetSales" xlink:to="ttoo_PercentageOfRoyaltyOnNetSales_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_RoyaltyOnNetSalesSublicensingGrossRevenue" xlink:type="locator" xlink:label="ttoo_RoyaltyOnNetSalesSublicensingGrossRevenue" />
    <link:label xml:lang="en-US" xlink:label="ttoo_RoyaltyOnNetSalesSublicensingGrossRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty on net sales sublicensing gross revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_RoyaltyOnNetSalesSublicensingGrossRevenue" xlink:to="ttoo_RoyaltyOnNetSalesSublicensingGrossRevenue_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_LicenseFeesPayable" xlink:type="locator" xlink:label="ttoo_LicenseFeesPayable" />
    <link:label xml:lang="en-US" xlink:label="ttoo_LicenseFeesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of annual licensing fees agreed to be paid by the company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_LicenseFeesPayable" xlink:to="ttoo_LicenseFeesPayable_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="ttoo_CommitmentsAndContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_CommitmentsAndContingenciesLineItems" xlink:to="ttoo_CommitmentsAndContingenciesLineItems_lbl" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="ttoo_CommitmentsAndContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttoo_CommitmentsAndContingenciesTable" xlink:to="ttoo_CommitmentsAndContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ttoo_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_LicenseFeesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license fee payable</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_LicenseFeesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Fees Payable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issued For Services</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_PercentageOfRoyaltyOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty on net sales</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_PercentageOfRoyaltyOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty On Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_RoyaltyOnNetSalesSublicensingGrossRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty on net sales sublicensing gross revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="ttoo_RoyaltyOnNetSalesSublicensingGrossRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty On Net Sales Sublicensing Gross Revenue</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties accrued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Royalties Current And Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued during period, shares, stock splits</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Temporary equity, shares issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable" xlink:to="us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Subscribed But Unissued Subscriptions Receivable</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>ttoo-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-11-14T20:33:37.7070773+00:00 -->
<!-- Version            : 5.0.1.753 -->
<!-- Package ID         : e9bee4ab4d8b4c8a9f469bea6de545b7 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/role/TemplateLink" xlink:href="ttoo-20220930.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ttoo-20220930.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="ttoo-20220930.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="ttoo-20220930.xsd#Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="ttoo-20220930.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ChangeInFairValueOfDerivativeWarrantLiability" xlink:type="locator" xlink:label="ttoo_ChangeInFairValueOfDerivativeWarrantLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ContributionMember" xlink:type="locator" xlink:label="ttoo_ContributionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ttoo_ContributionMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="ttoo_ChangeInFairValueOfDerivativeWarrantLiability" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="12190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="12430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="12510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="12590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="12750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="12830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" order="12910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="12990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="13070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="ttoo-20220930.xsd#Role_StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit" xlink:type="locator" xlink:label="ttoo_MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionOfDividends" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock" xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="ttoo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ttoo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPreferredStock" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionOfDividends" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ttoo_MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_li0l2" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_li0l2" order="12330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued_li0l2" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows" xlink:href="ttoo-20220930.xsd#Role_StatementCondensedConsolidatedStatementOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock" xlink:type="locator" xlink:label="ttoo_DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TransferOfT2OwnedInstrumentsAndComponentsToFromInventory" xlink:type="locator" xlink:label="ttoo_TransferOfT2OwnedInstrumentsAndComponentsToFromInventory" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability" xlink:type="locator" xlink:label="ttoo_ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts" xlink:type="locator" xlink:label="ttoo_ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises" xlink:type="locator" xlink:label="ttoo_ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="ttoo_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:type="locator" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability" xlink:type="locator" xlink:label="ttoo_GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ChangeInFairValueOfDerivativeWarrantLiability" xlink:type="locator" xlink:label="ttoo_ChangeInFairValueOfDerivativeWarrantLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeAmortizationOfPremium" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ttoo_ChangeInFairValueOfDerivativeWarrantLiability" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ttoo_GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProductionRelatedImpairmentsOrCharges" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="ttoo_IncreaseDecreaseInOperatingLeaseLiabilities" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ttoo_ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ttoo_ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ttoo_ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ttoo_TransferOfT2OwnedInstrumentsAndComponentsToFromInventory" order="12130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ttoo_DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsParenthetical" xlink:href="ttoo-20220930.xsd#Role_StatementCondensedConsolidatedStatementOfCashFlowsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusiness" xlink:href="ttoo-20220930.xsd#Role_DisclosureNatureOfBusiness" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusiness">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="ttoo-20220930.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="ttoo-20220930.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureRestrictedCash" xlink:href="ttoo-20220930.xsd#Role_DisclosureRestrictedCash" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureRestrictedCash">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAbstract" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAbstract" xlink:to="us-gaap_RestrictedAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformation" xlink:href="ttoo-20220930.xsd#Role_DisclosureSupplementalBalanceSheetInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformation">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayable" xlink:href="ttoo-20220930.xsd#Role_DisclosureNotesPayable" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayable">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrant" xlink:href="ttoo-20220930.xsd#Role_DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrant" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrant">
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock" xlink:type="locator" xlink:label="ttoo_RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="ttoo_RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficit" xlink:href="ttoo-20220930.xsd#Role_DisclosureStockholdersDeficit" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficit">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="ttoo-20220930.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureWarrantsAssociatedWithTermLoan" xlink:href="ttoo-20220930.xsd#Role_DisclosureWarrantsAssociatedWithTermLoan" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureWarrantsAssociatedWithTermLoan">
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_WarrantsNoteDisclosureTextBlock" xlink:type="locator" xlink:label="ttoo_WarrantsNoteDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="ttoo_WarrantsNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShare" xlink:href="ttoo-20220930.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShare">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContract" xlink:href="ttoo-20220930.xsd#Role_DisclosureUSGovernmentContract" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContract">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeases" xlink:href="ttoo-20220930.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeases">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="ttoo-20220930.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEvents" xlink:href="ttoo-20220930.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ttoo-20220930.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CostOfProductRevenuePolicyTextBlock" xlink:type="locator" xlink:label="ttoo_CostOfProductRevenuePolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:type="locator" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_GeographicInformationPolicyTextBlock" xlink:type="locator" xlink:label="ttoo_GeographicInformationPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:type="locator" xlink:label="ttoo_UnauditedInterimFinancialInformationPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ttoo_UnauditedInterimFinancialInformationPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ttoo_GeographicInformationPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ttoo_CostOfProductRevenuePolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="ttoo-20220930.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="ttoo-20220930.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SummaryOfContingentInterestPaymentsTableTextBlock" xlink:type="locator" xlink:label="ttoo_SummaryOfContingentInterestPaymentsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="ttoo_SummaryOfContingentInterestPaymentsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables" xlink:href="ttoo-20220930.xsd#Role_DisclosureSupplementalBalanceSheetInformationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTables" xlink:href="ttoo-20220930.xsd#Role_DisclosureNotesPayableTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="ttoo-20220930.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="ttoo-20220930.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureNatureOfBusinessAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail">
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MinimumMarketValueOfListedSecurities" xlink:type="locator" xlink:label="ttoo_MinimumMarketValueOfListedSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_RegainComplianceByIncreasingStockPrice" xlink:type="locator" xlink:label="ttoo_RegainComplianceByIncreasingStockPrice" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MinimumBidPriceOfCommonStock" xlink:type="locator" xlink:label="ttoo_MinimumBidPriceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_NatureOfBusinessLineItems" xlink:type="locator" xlink:label="ttoo_NatureOfBusinessLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CRGMember" xlink:type="locator" xlink:label="ttoo_CRGMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TermLoanAgreementMember" xlink:type="locator" xlink:label="ttoo_TermLoanAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_NatureOfBusinessTable" xlink:type="locator" xlink:label="ttoo_NatureOfBusinessTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ttoo_NatureOfBusinessTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_NatureOfBusinessTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_NatureOfBusinessTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ttoo_TermLoanAgreementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_NatureOfBusinessTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="ttoo_CRGMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_NatureOfBusinessTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_NatureOfBusinessTable" xlink:to="ttoo_NatureOfBusinessLineItems" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquity" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="us-gaap_RestrictedCash" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="ttoo_MinimumBidPriceOfCommonStock" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="ttoo_RegainComplianceByIncreasingStockPrice" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_NatureOfBusinessLineItems" xlink:to="ttoo_MinimumMarketValueOfListedSecurities" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross" xlink:type="locator" xlink:label="us-gaap_CapitalizedContractCostGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed" xlink:type="locator" xlink:label="ttoo_OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MaintenanceServiceTermOfAdditionalPeriod" xlink:type="locator" xlink:label="ttoo_MaintenanceServiceTermOfAdditionalPeriod" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MaintenanceServicePeriod" xlink:type="locator" xlink:label="ttoo_MaintenanceServicePeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:type="locator" xlink:label="us-gaap_ProductInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202110Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate202110Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202104Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate202104Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentAssetsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_T2DxMember" xlink:type="locator" xlink:label="ttoo_T2DxMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember" xlink:type="locator" xlink:label="us-gaap_NonUsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_GeographicConcentrationRiskMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfProductInformationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_GeographicConcentrationRiskMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="srt_StatementGeographicalAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="srt_RangeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="srt_ProductOrServiceAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ttoo_T2DxMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202104Member" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202110Member" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ProductInformationLineItems" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="ttoo_MaintenanceServicePeriod" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="ttoo_MaintenanceServiceTermOfAdditionalPeriod" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="ttoo_OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="12190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" order="12300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="12410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="12430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="12450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:type="locator" xlink:label="us-gaap_ProductInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CustomerCMember" xlink:type="locator" xlink:label="ttoo_CustomerCMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CustomerBMember" xlink:type="locator" xlink:label="ttoo_CustomerBMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CustomerAMember" xlink:type="locator" xlink:label="ttoo_CustomerAMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfProductInformationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="srt_MajorCustomersAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="ttoo_CustomerAMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="ttoo_CustomerBMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="ttoo_CustomerCMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ProductInformationLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="locator" xlink:label="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" xlink:type="locator" xlink:label="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueByMajorResourceDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueByMajorResourceDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueByMajorResourceDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ContributionRevenueMember" xlink:type="locator" xlink:label="ttoo_ContributionRevenueMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_InstrumentRentalsMember" xlink:type="locator" xlink:label="ttoo_InstrumentRentalsMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProductConsumablesMember" xlink:type="locator" xlink:label="ttoo_ProductConsumablesMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProductInstrumentsMember" xlink:type="locator" xlink:label="ttoo_ProductInstrumentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ttoo_ProductInstrumentsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ttoo_ProductConsumablesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ttoo_InstrumentRentalsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ttoo_ContributionRevenueMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1Detail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1Detail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1Detail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:type="locator" xlink:label="us-gaap_ProductInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfProductInformationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ProductInformationLineItems" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="10060.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10060.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10060.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TermLoanAgreementMember" xlink:type="locator" xlink:label="ttoo_TermLoanAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CRGMember" xlink:type="locator" xlink:label="ttoo_CRGMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="ttoo_CRGMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ttoo_TermLoanAgreementMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_SecurityDeposit" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail">
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_FairValueDerivativeLiabilityDiscountRate" xlink:type="locator" xlink:label="ttoo_FairValueDerivativeLiabilityDiscountRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CRGMember" xlink:type="locator" xlink:label="ttoo_CRGMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TermLoanAgreementMember" xlink:type="locator" xlink:label="ttoo_TermLoanAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ScenarioOneMember" xlink:type="locator" xlink:label="ttoo_ScenarioOneMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="ttoo_ScenarioOneMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ttoo_TermLoanAgreementMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="ttoo_CRGMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ttoo_FairValueDerivativeLiabilityDiscountRate" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsParentheticalDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsParentheticalDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsParentheticalDetail">
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ContingentPaymentOfInterestPercentage" xlink:type="locator" xlink:label="ttoo_ContingentPaymentOfInterestPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TermLoanAgreementMember" xlink:type="locator" xlink:label="ttoo_TermLoanAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CRGMember" xlink:type="locator" xlink:label="ttoo_CRGMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="ttoo_CRGMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ttoo_TermLoanAgreementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ttoo_ContingentPaymentOfInterestPercentage" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsRollForwardOfFairValueOfDerivativeLiabilityDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureFairValueMeasurementsRollForwardOfFairValueOfDerivativeLiabilityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsRollForwardOfFairValueOfDerivativeLiabilityDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProbabilityWeightedDiscountedCashFlowModelMember" xlink:type="locator" xlink:label="ttoo_ProbabilityWeightedDiscountedCashFlowModelMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="ttoo_ProbabilityWeightedDiscountedCashFlowModelMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilities_li0l2" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureRestrictedCashAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetail">
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_NumberOfFacilities" xlink:type="locator" xlink:label="ttoo_NumberOfFacilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAbstract" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_SecurityDeposit" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="ttoo_NumberOfFacilities" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNetAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNet" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_T2DxInstrumentsAndComponentsMember" xlink:type="locator" xlink:label="ttoo_T2DxInstrumentsAndComponentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:type="locator" xlink:label="us-gaap_ToolsDiesAndMoldsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManufacturingFacilityMember" xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ToolsDiesAndMoldsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ttoo_T2DxInstrumentsAndComponentsMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciation" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSoldDepreciation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcessAndRawMaterials" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SupplementalBalanceSheetInformationLineItems" xlink:type="locator" xlink:label="ttoo_SupplementalBalanceSheetInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_T2OwnedInstrumentsInServiceMember" xlink:type="locator" xlink:label="ttoo_T2OwnedInstrumentsInServiceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SupplementalBalanceSheetInformationTable" xlink:type="locator" xlink:label="ttoo_SupplementalBalanceSheetInformationTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="ttoo_SupplementalBalanceSheetInformationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_SupplementalBalanceSheetInformationTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ttoo_T2OwnedInstrumentsInServiceMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_SupplementalBalanceSheetInformationTable" xlink:to="srt_ProductOrServiceAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_SupplementalBalanceSheetInformationTable" xlink:to="ttoo_SupplementalBalanceSheetInformationLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_SupplementalBalanceSheetInformationLineItems" xlink:to="us-gaap_InventoryWorkInProcessAndRawMaterials" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_SupplementalBalanceSheetInformationLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_SupplementalBalanceSheetInformationLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSoldDepreciation" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_SupplementalBalanceSheetInformationLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="ttoo_AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="ttoo_AccruedResearchAndDevelopmentExpensesCurrent" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableScheduleOfDebtDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureNotesPayableScheduleOfDebtDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableScheduleOfDebtDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:type="locator" xlink:label="us-gaap_NotesPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentUnaccruedPaidInKindInterest" xlink:type="locator" xlink:label="ttoo_DebtInstrumentUnaccruedPaidInKindInterest" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts" xlink:type="locator" xlink:label="ttoo_DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="ttoo_DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="ttoo_DebtInstrumentUnaccruedPaidInKindInterest" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_NotesPayable" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail">
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentEventOfDefaultAdditionalInterestRate" xlink:type="locator" xlink:label="ttoo_DebtInstrumentEventOfDefaultAdditionalInterestRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentPrepaymentFeeTerm" xlink:type="locator" xlink:label="ttoo_DebtInstrumentPrepaymentFeeTerm" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentDeferredInterestRateInterestOnlyPayment" xlink:type="locator" xlink:label="ttoo_DebtInstrumentDeferredInterestRateInterestOnlyPayment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentFinalPaymentFeePercentage" xlink:type="locator" xlink:label="ttoo_DebtInstrumentFinalPaymentFeePercentage" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_DebtInstrumentTermOfInterestOnlyPayments" xlink:type="locator" xlink:label="ttoo_DebtInstrumentTermOfInterestOnlyPayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TermLoanAgreementMember" xlink:type="locator" xlink:label="ttoo_TermLoanAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CRGMember" xlink:type="locator" xlink:label="ttoo_CRGMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="ttoo_CRGMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ttoo_TermLoanAgreementMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ttoo_DebtInstrumentTermOfInterestOnlyPayments" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ttoo_DebtInstrumentFinalPaymentFeePercentage" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ttoo_DebtInstrumentDeferredInterestRateInterestOnlyPayment" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ttoo_DebtInstrumentPrepaymentFeeTerm" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RestrictedCash" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ttoo_DebtInstrumentEventOfDefaultAdditionalInterestRate" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" xlink:type="locator" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ClassOfWarrantOrRightMaturityDate" xlink:type="locator" xlink:label="ttoo_ClassOfWarrantOrRightMaturityDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockVotingRights" xlink:type="locator" xlink:label="us-gaap_PreferredStockVotingRights" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares" xlink:type="locator" xlink:label="ttoo_PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock" xlink:type="locator" xlink:label="ttoo_PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PreferredStockPricePercentageOnStatedValue" xlink:type="locator" xlink:label="ttoo_PreferredStockPricePercentageOnStatedValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionDate" xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:type="locator" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PurchaseAgreementMember" xlink:type="locator" xlink:label="ttoo_PurchaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="ttoo_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ttoo_SeriesARedeemableConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ttoo_PurchaseAgreementMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionDate" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="ttoo_PreferredStockPricePercentageOnStatedValue" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="ttoo_PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="ttoo_PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockVotingRights" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="ttoo_ClassOfWarrantOrRightMaturityDate" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureStockholdersDeficitAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PercentageOfAgentServiceFee" xlink:type="locator" xlink:label="ttoo_PercentageOfAgentServiceFee" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ProceedsFromIssuanceOfCommonStockGross" xlink:type="locator" xlink:label="ttoo_ProceedsFromIssuanceOfCommonStockGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OriginalSalesAgreementMember" xlink:type="locator" xlink:label="ttoo_OriginalSalesAgreementMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CanaccordGenuityLLCMember" xlink:type="locator" xlink:label="ttoo_CanaccordGenuityLLCMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_NewSalesAgreementMember" xlink:type="locator" xlink:label="ttoo_NewSalesAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ttoo_NewSalesAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ttoo_CanaccordGenuityLLCMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ttoo_OriginalSalesAgreementMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ttoo_ProceedsFromIssuanceOfCommonStockGross" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ttoo_PercentageOfAgentServiceFee" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MaximumAmountOfAnnualEmployeeCommonStockPurchase" xlink:type="locator" xlink:label="ttoo_MaximumAmountOfAnnualEmployeeCommonStockPurchase" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue" xlink:type="locator" xlink:label="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue" xlink:type="locator" xlink:label="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PercentageOfCommonSharesOutstanding" xlink:type="locator" xlink:label="ttoo_PercentageOfCommonSharesOutstanding" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ComponentOfCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="ttoo_ComponentOfCommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TypeIIIModificationMember" xlink:type="locator" xlink:label="ttoo_TypeIIIModificationMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TypeIModificationMember" xlink:type="locator" xlink:label="ttoo_TypeIModificationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" xlink:type="locator" xlink:label="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember" xlink:type="locator" xlink:label="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_InducementAwardPlanMember" xlink:type="locator" xlink:label="ttoo_InducementAwardPlanMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOptionPlan2014Member" xlink:type="locator" xlink:label="ttoo_StockOptionPlan2014Member" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator" xlink:label="ttoo_EmployeeAndNonemployeeStockOptionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOptionPlan2006Member" xlink:type="locator" xlink:label="ttoo_StockOptionPlan2006Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ttoo_StockOptionPlan2006Member" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ttoo_EmployeeAndNonemployeeStockOptionsMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ttoo_StockOptionPlan2014Member" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ttoo_InducementAwardPlanMember" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ttoo_TypeIModificationMember" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ttoo_TypeIIIModificationMember" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ttoo_ComponentOfCommonStockCapitalSharesReservedForFutureIssuance" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ttoo_PercentageOfCommonSharesOutstanding" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="12300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue" order="12370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="12490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ttoo_MaximumAmountOfAnnualEmployeeCommonStockPurchase" order="12530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="12570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="12850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator" xlink:label="ttoo_EmployeeAndNonemployeeStockOptionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" xlink:type="locator" xlink:label="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ttoo_EmployeeAndNonemployeeStockOptionsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" xlink:type="locator" xlink:label="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator" xlink:label="ttoo_EmployeeAndNonemployeeStockOptionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ttoo_EmployeeAndNonemployeeStockOptionsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOptionPlan2014Member" xlink:type="locator" xlink:label="ttoo_StockOptionPlan2014Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ttoo_StockOptionPlan2014Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedThatWasRecordedInCompanySResultsOfOperationsDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedThatWasRecordedInCompanySResultsOfOperationsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedThatWasRecordedInCompanySResultsOfOperationsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureWarrantsAssociatedWithTermLoanAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureWarrantsAssociatedWithTermLoanAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureWarrantsAssociatedWithTermLoanAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureNetLossPerShareAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockOutstandingDuringPeriodSharesStockSplits" xlink:type="locator" xlink:label="ttoo_StockOutstandingDuringPeriodSharesStockSplits" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_StockIssuedAndOutstandingDuringPeriodSharesStockSplits" xlink:type="locator" xlink:label="ttoo_StockIssuedAndOutstandingDuringPeriodSharesStockSplits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDividendsAdjustment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="ttoo_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ttoo_SeriesAConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_TemporaryEquityDividendsAdjustment" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ttoo_StockIssuedAndOutstandingDuringPeriodSharesStockSplits" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ttoo_StockOutstandingDuringPeriodSharesStockSplits" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="ttoo_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ttoo_SeriesARedeemableConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureUSGovernmentContractAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CollaborativeArrangementAdditionalFundingAmountToBeReceived" xlink:type="locator" xlink:label="ttoo_CollaborativeArrangementAdditionalFundingAmountToBeReceived" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CollaborativeArrangementAdditionalFundingAmountReceived" xlink:type="locator" xlink:label="ttoo_CollaborativeArrangementAdditionalFundingAmountReceived" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CollaborativeArrangementOptionContractValueExercised" xlink:type="locator" xlink:label="ttoo_CollaborativeArrangementOptionContractValueExercised" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CollaborativeArrangementFirstContractOptionValueExercised" xlink:type="locator" xlink:label="ttoo_CollaborativeArrangementFirstContractOptionValueExercised" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CollaborativeArrangementAggregateConsideration" xlink:type="locator" xlink:label="ttoo_CollaborativeArrangementAggregateConsideration" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CollaborativeArrangementInitialValueOfConsideration" xlink:type="locator" xlink:label="ttoo_CollaborativeArrangementInitialValueOfConsideration" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_ContributionMember" xlink:type="locator" xlink:label="ttoo_ContributionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:type="locator" xlink:label="ttoo_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CoDevelopmentPartnershipAgreementMember" xlink:type="locator" xlink:label="ttoo_CoDevelopmentPartnershipAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ttoo_CoDevelopmentPartnershipAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ttoo_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ttoo_ContributionMember" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ttoo_CollaborativeArrangementInitialValueOfConsideration" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ttoo_CollaborativeArrangementAggregateConsideration" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ttoo_CollaborativeArrangementFirstContractOptionValueExercised" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ttoo_CollaborativeArrangementOptionContractValueExercised" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ttoo_CollaborativeArrangementAdditionalFundingAmountReceived" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ttoo_CollaborativeArrangementAdditionalFundingAmountToBeReceived" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_TermOfLease" xlink:type="locator" xlink:label="ttoo_TermOfLease" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SecurityDepositReceived" xlink:type="locator" xlink:label="ttoo_SecurityDepositReceived" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SpaceBuildOutCosts" xlink:type="locator" xlink:label="ttoo_SpaceBuildOutCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncentiveFromLessor" xlink:type="locator" xlink:label="us-gaap_IncentiveFromLessor" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_LesseeOperatingLeaseTerminationPeriod" xlink:type="locator" xlink:label="ttoo_LesseeOperatingLeaseTerminationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities" xlink:type="locator" xlink:label="ttoo_MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_LeasesLineItems" xlink:type="locator" xlink:label="ttoo_LeasesLineItems" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OfficeResearchLaboratoryAndManufacturingSpaceMember" xlink:type="locator" xlink:label="ttoo_OfficeResearchLaboratoryAndManufacturingSpaceMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OperatingLeasesEnteredIntoSeptember2021Member" xlink:type="locator" xlink:label="ttoo_OperatingLeasesEnteredIntoSeptember2021Member" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_LaboratorySpaceMember" xlink:type="locator" xlink:label="ttoo_LaboratorySpaceMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OfficeLaboratoryAndManufacturingSpaceMember" xlink:type="locator" xlink:label="ttoo_OfficeLaboratoryAndManufacturingSpaceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficeBuildingMember" xlink:type="locator" xlink:label="srt_OfficeBuildingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OperatingLeasesEnteredIntoMay2013Member" xlink:type="locator" xlink:label="ttoo_OperatingLeasesEnteredIntoMay2013Member" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OperatingLeasesEnteredIntoNovember2014Member" xlink:type="locator" xlink:label="ttoo_OperatingLeasesEnteredIntoNovember2014Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_LicenseAgreementMember" xlink:type="locator" xlink:label="ttoo_LicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_OfficeSpaceLaboratorySpaceAndEquipmentMember" xlink:type="locator" xlink:label="ttoo_OfficeSpaceLaboratorySpaceAndEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_LeasesTable" xlink:type="locator" xlink:label="ttoo_LeasesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ttoo_LeasesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_LeasesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ttoo_OfficeSpaceLaboratorySpaceAndEquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_LeasesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ttoo_LicenseAgreementMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_LeasesTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ttoo_OperatingLeasesEnteredIntoNovember2014Member" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ttoo_OperatingLeasesEnteredIntoMay2013Member" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_LeasesTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_OfficeBuildingMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ttoo_OfficeLaboratoryAndManufacturingSpaceMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ttoo_LaboratorySpaceMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ttoo_OperatingLeasesEnteredIntoSeptember2021Member" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ttoo_OfficeResearchLaboratoryAndManufacturingSpaceMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_LeasesTable" xlink:to="ttoo_LeasesLineItems" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_LeasesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_LeasesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_LeasesLineItems" xlink:to="ttoo_MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_LeasesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_LeasesLineItems" xlink:to="us-gaap_SecurityDeposit" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_LeasesLineItems" xlink:to="ttoo_LesseeOperatingLeaseTerminationPeriod" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_LeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_LeasesLineItems" xlink:to="us-gaap_IncentiveFromLessor" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_LeasesLineItems" xlink:to="ttoo_SpaceBuildOutCosts" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_LeasesLineItems" xlink:to="ttoo_SecurityDepositReceived" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_LeasesLineItems" xlink:to="ttoo_TermOfLease" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="ttoo-20220930.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_RoyaltyOnNetSalesSublicensingGrossRevenue" xlink:type="locator" xlink:label="ttoo_RoyaltyOnNetSalesSublicensingGrossRevenue" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PercentageOfRoyaltyOnNetSales" xlink:type="locator" xlink:label="ttoo_PercentageOfRoyaltyOnNetSales" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_LicenseFeesPayable" xlink:type="locator" xlink:label="ttoo_LicenseFeesPayable" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="ttoo_CommitmentsAndContingenciesLineItems" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_LicenseAgreementMember" xlink:type="locator" xlink:label="ttoo_LicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="ttoo_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ttoo_CommitmentsAndContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ttoo_LicenseAgreementMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_CommitmentsAndContingenciesTable" xlink:to="ttoo_CommitmentsAndContingenciesLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_CommitmentsAndContingenciesLineItems" xlink:to="ttoo_LicenseFeesPayable" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_CommitmentsAndContingenciesLineItems" xlink:to="ttoo_PercentageOfRoyaltyOnNetSales" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_CommitmentsAndContingenciesLineItems" xlink:to="ttoo_RoyaltyOnNetSalesSublicensingGrossRevenue" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ttoo_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="ttoo-20220930.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_PurchaseAgreementMember" xlink:type="locator" xlink:label="ttoo_PurchaseAgreementMember" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="ttoo_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="ttoo-20220930.xsd#ttoo_NewSalesAgreementMember" xlink:type="locator" xlink:label="ttoo_NewSalesAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ttoo_NewSalesAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ttoo_SeriesARedeemableConvertiblePreferredStockMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ttoo_PurchaseAgreementMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724021742192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 08, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TTOO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">T2 Biosystems, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001492674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-4827488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">101 Hartwell Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lexington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">761-4646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,319,105<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724020204560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 20,366,000<span></span>
</td>
<td class="nump">$ 22,245,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,996,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,578,000<span></span>
</td>
<td class="nump">5,134,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">4,242,000<span></span>
</td>
<td class="nump">3,909,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,690,000<span></span>
</td>
<td class="nump">3,110,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">28,876,000<span></span>
</td>
<td class="nump">44,394,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,734,000<span></span>
</td>
<td class="nump">4,675,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">9,058,000<span></span>
</td>
<td class="nump">9,766,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,131,000<span></span>
</td>
<td class="nump">1,551,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">153,000<span></span>
</td>
<td class="nump">153,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">43,952,000<span></span>
</td>
<td class="nump">60,539,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,063,000<span></span>
</td>
<td class="nump">2,832,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">8,531,000<span></span>
</td>
<td class="nump">8,338,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative warrant liability</a></td>
<td class="nump">186,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">163,000<span></span>
</td>
<td class="nump">518,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,943,000<span></span>
</td>
<td class="nump">11,688,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable</a></td>
<td class="nump">49,188,000<span></span>
</td>
<td class="nump">47,790,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">8,569,000<span></span>
</td>
<td class="nump">9,359,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">1,792,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">4,791,000<span></span>
</td>
<td class="nump">4,577,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (see Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Series A redeemable convertible preferred stock; $0.001 par value; 3,000 shares authorized at September 30, 2022; 3,000 shares issued and outstanding at September 30, 2022; liquidation value of $330,000; 0 shares issued and outstanding at December 31, 2021 (see Note 7)</a></td>
<td class="nump">330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 9,997,000 and 10,000,000 shares authorized at September 30, 2022 and December 31, 2021, respectively; no shares issued and outstanding at September 30, 2022 and December 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000,000 shares authorized; 7,050,849 and 3,328,017 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">492,444,000<span></span>
</td>
<td class="nump">459,314,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(524,120,000)<span></span>
</td>
<td class="num">(472,216,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(31,669,000)<span></span>
</td>
<td class="num">(12,903,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, Series A convertible redeemable preferred stock and stockholders&#8217; deficit</a></td>
<td class="nump">$ 43,952,000<span></span>
</td>
<td class="nump">$ 60,539,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724020166272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Series A redeemable convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Series A redeemable convertible preferred stock, shares authorized</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Series A redeemable convertible preferred stock, shares issued</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Series A redeemable convertible preferred stock, shares outstanding</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Series A redeemable convertible preference liquidation value</a></td>
<td class="nump">$ 330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">9,997,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">7,050,849<span></span>
</td>
<td class="nump">3,328,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">7,050,849<span></span>
</td>
<td class="nump">3,328,017<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724020040192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 3,677<span></span>
</td>
<td class="nump">$ 7,428<span></span>
</td>
<td class="nump">$ 16,822<span></span>
</td>
<td class="nump">$ 21,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">6,375<span></span>
</td>
<td class="nump">6,384<span></span>
</td>
<td class="nump">21,056<span></span>
</td>
<td class="nump">16,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">7,017<span></span>
</td>
<td class="nump">8,536<span></span>
</td>
<td class="nump">24,071<span></span>
</td>
<td class="nump">21,983<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">19,477<span></span>
</td>
<td class="nump">19,640<span></span>
</td>
<td class="nump">62,498<span></span>
</td>
<td class="nump">53,772<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(15,800)<span></span>
</td>
<td class="num">(12,212)<span></span>
</td>
<td class="num">(45,676)<span></span>
</td>
<td class="num">(32,694)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,560)<span></span>
</td>
<td class="num">(1,919)<span></span>
</td>
<td class="num">(4,556)<span></span>
</td>
<td class="num">(5,642)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative instrument</a></td>
<td class="num">(117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,792)<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_ChangeInFairValueOfDerivativeWarrantLiability', window );">Change in fair value of derivative warrant liability</a></td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(78)<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(1,575)<span></span>
</td>
<td class="num">(1,750)<span></span>
</td>
<td class="num">(6,228)<span></span>
</td>
<td class="num">(4,403)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,375)<span></span>
</td>
<td class="num">(13,962)<span></span>
</td>
<td class="num">(51,904)<span></span>
</td>
<td class="num">(37,097)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Deemed dividend on Series A redeemable convertible preferred stock</a></td>
<td class="num">(330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (17,705)<span></span>
</td>
<td class="num">$ (13,962)<span></span>
</td>
<td class="num">$ (52,234)<span></span>
</td>
<td class="num">$ (37,097)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share &#8212; basic</a></td>
<td class="num">$ (2.95)<span></span>
</td>
<td class="num">$ (4.21)<span></span>
</td>
<td class="num">$ (12.08)<span></span>
</td>
<td class="num">$ (11.86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share &#8212; diluted</a></td>
<td class="num">$ (2.95)<span></span>
</td>
<td class="num">$ (4.21)<span></span>
</td>
<td class="num">$ (12.08)<span></span>
</td>
<td class="num">$ (11.86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares used in computing net loss per share &#8212; basic</a></td>
<td class="nump">6,008,819<span></span>
</td>
<td class="nump">3,317,646<span></span>
</td>
<td class="nump">4,323,452<span></span>
</td>
<td class="nump">3,127,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares used in computing net loss per share &#8212; diluted</a></td>
<td class="nump">6,008,819<span></span>
</td>
<td class="nump">3,317,646<span></span>
</td>
<td class="nump">4,323,452<span></span>
</td>
<td class="nump">3,127,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,375)<span></span>
</td>
<td class="num">$ (13,962)<span></span>
</td>
<td class="num">$ (51,904)<span></span>
</td>
<td class="num">$ (37,097)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Net unrealized gain on marketable securities arising during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Net realized (gain) loss on marketable securities included in net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive (loss) income, net of taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(17,375)<span></span>
</td>
<td class="num">(13,962)<span></span>
</td>
<td class="num">(51,900)<span></span>
</td>
<td class="num">(37,102)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">2,641<span></span>
</td>
<td class="nump">4,306<span></span>
</td>
<td class="nump">9,044<span></span>
</td>
<td class="nump">12,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product revenue</a></td>
<td class="nump">6,085<span></span>
</td>
<td class="nump">4,720<span></span>
</td>
<td class="nump">17,371<span></span>
</td>
<td class="nump">15,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ttoo_ContributionMember', window );">Contribution [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 1,036<span></span>
</td>
<td class="nump">$ 3,122<span></span>
</td>
<td class="nump">$ 7,778<span></span>
</td>
<td class="nump">$ 8,444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_ChangeInFairValueOfDerivativeWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of derivative warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_ChangeInFairValueOfDerivativeWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDividendsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDividendsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ttoo_ContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ttoo_ContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724015561472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Series A Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A Redeemable Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 8,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 431,689<span></span>
</td>
<td class="num">$ (422,975)<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,961,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan</a></td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,660)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,660)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="num">(566)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">433,050<span></span>
</td>
<td class="num">(433,635)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,969,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">8,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">431,689<span></span>
</td>
<td class="num">(422,975)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,961,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(37,097)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="num">(2,463)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">457,602<span></span>
</td>
<td class="num">(460,072)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,319,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="num">(566)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">433,050<span></span>
</td>
<td class="num">(433,635)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,969,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan</a></td>
<td class="nump">251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from secondary offering, net</a></td>
<td class="nump">19,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from secondary offering, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">9,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">455,112<span></span>
</td>
<td class="num">(446,110)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,315,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,962)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,962)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="num">(2,463)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">457,602<span></span>
</td>
<td class="num">(460,072)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,319,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="num">$ (12,903)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">459,314<span></span>
</td>
<td class="num">(472,216)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">3,328,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,328,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Surrender of shares due to tax withholding</a></td>
<td class="num">(231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Surrender of shares due to tax withholding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,781)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from secondary offering, net</a></td>
<td class="nump">1,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from secondary offering, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,495)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,495)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="num">(25,651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">463,068<span></span>
</td>
<td class="num">(488,711)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,428,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="num">$ (12,903)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">459,314<span></span>
</td>
<td class="num">(472,216)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">3,328,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,328,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (51,904)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="num">$ (31,669)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">492,444<span></span>
</td>
<td class="num">(524,120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Balance at Sep. 30, 2022</a></td>
<td class="nump">$ 330<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">7,050,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,050,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="num">$ (25,651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">463,068<span></span>
</td>
<td class="num">(488,711)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,428,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan</a></td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Surrender of shares due to tax withholding</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from secondary offering, net</a></td>
<td class="nump">4,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from secondary offering, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="num">(37,519)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">469,222<span></span>
</td>
<td class="num">(506,745)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,968,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from secondary offering, net</a></td>
<td class="nump">22,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">22,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from secondary offering, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,080,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Temporary equity stock issued during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Deemed dividend on Series A redeemable convertible preferred stock</a></td>
<td class="num">(330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionOfDividends', window );">Temporary equity, deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit', window );">Misc adjustment to reflect rounding on reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="num">$ (31,669)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 492,444<span></span>
</td>
<td class="num">$ (524,120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Balance at Sep. 30, 2022</a></td>
<td class="nump">$ 330<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">7,050,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,050,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Miscellaneous adjustment of Shares to reflect rounding on reverse split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity during the period due to unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724013295072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (51,904)<span></span>
</td>
<td class="num">$ (37,097)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">792<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfPremium', window );">Amortization of bond premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">907<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">5,458<span></span>
</td>
<td class="nump">5,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative instrument</a></td>
<td class="nump">1,792<span></span>
</td>
<td class="num">(1,010)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_ChangeInFairValueOfDerivativeWarrantLiability', window );">Change in fair value of derivative warrant liability</a></td>
<td class="num">(179)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss', window );">(Gain) loss on sales of marketable securities</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability', window );">(Gain) loss on issuance of Series A redeemable convertible preferred stock and derivative warrant liability</a></td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductionRelatedImpairmentsOrCharges', window );">Impairment of property and equipment</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">1,613<span></span>
</td>
<td class="nump">2,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">3,556<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">356<span></span>
</td>
<td class="num">(692)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(815)<span></span>
</td>
<td class="num">(1,915)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(791)<span></span>
</td>
<td class="nump">523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(375)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(868)<span></span>
</td>
<td class="num">(848)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(40,300)<span></span>
</td>
<td class="num">(29,032)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales of marketable securities</a></td>
<td class="nump">9,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases and manufacture of property and equipment</a></td>
<td class="num">(303)<span></span>
</td>
<td class="num">(261)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">9,695<span></span>
</td>
<td class="nump">14,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of employee restricted stock tax withholdings</a></td>
<td class="num">(243)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises', window );">Proceeds from issuance of shares from employee stock purchase plan and stock option exercises</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts', window );">Proceeds from issuance of common stock in public offerings, net of offering costs</a></td>
<td class="nump">28,110<span></span>
</td>
<td class="nump">19,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability', window );">Proceeds from issuance of Series A redeemable convertible preferred stock and derivative warrant liability</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">28,306<span></span>
</td>
<td class="nump">20,296<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(2,299)<span></span>
</td>
<td class="nump">6,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">23,796<span></span>
</td>
<td class="nump">17,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">21,497<span></span>
</td>
<td class="nump">23,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">2,916<span></span>
</td>
<td class="nump">2,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of noncash activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_TransferOfT2OwnedInstrumentsAndComponentsToFromInventory', window );">Transfer of T2 owned instruments and components (from) to inventory</a></td>
<td class="num">(482)<span></span>
</td>
<td class="num">(729)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock', window );">Deemed dividend on Series A redeemable convertible preferred stock</a></td>
<td class="nump">330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_ChangeInFairValueOfDerivativeWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of derivative warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_ChangeInFairValueOfDerivativeWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend on Series A convertible redeemable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on issuance of Series A redeemable convertible preferred stock and derivative warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) associated with the amount received from entity's first offering of stock to the public, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of Series A convertible redeemable preferred stock and derivative warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of shares from employee stock purchase plan and stock option exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_TransferOfT2OwnedInstrumentsAndComponentsToFromInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer of T2 owned instruments and components to (from) inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_TransferOfT2OwnedInstrumentsAndComponentsToFromInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of purchase premium on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductionRelatedImpairmentsOrCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductionRelatedImpairmentsOrCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724025445920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Cash Flows (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash at end of period</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 20,366<span></span>
</td>
<td class="nump">$ 22,245<span></span>
</td>
<td class="nump">$ 22,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,131<span></span>
</td>
<td class="nump">1,551<span></span>
</td>
<td class="nump">1,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 21,497<span></span>
</td>
<td class="nump">$ 23,796<span></span>
</td>
<td class="nump">$ 23,598<span></span>
</td>
<td class="nump">$ 17,344<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724020013008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T2 Biosystems, Inc. and its subsidiary (the &#8220;Company,&#8221; &#8220;we,&#8221; or &#8220;T2&#8221;) have operations based in Lexington, Massachusetts. T2 Biosystems, Inc. was incorporated on April 27, 2006 as a Delaware corporation. The Company is an&#160;<span style="font-style:italic;">in vitro</span>&#160;diagnostics company that has developed an innovative and proprietary technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company has developed a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. Our technology enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (&#8220;CFU/mL&#8221;). The Company&#8217;s initial development efforts target the detection of pathogens that cause sepsis, which is an area of significant unmet medical need in which existing therapies could be more effective with improved diagnostics. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Going Concern </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September&#160;30, 2022, the Company had cash, cash equivalents, and restricted cash of $21.5 million, an accumulated deficit of $524.1 million and stockholders&#8217; deficit of $31.7 million. The Company has historically experienced cash outflows from operating activities. The future success of the Company is dependent on its ability to successfully commercialize its products, obtain regulatory clearance for and successfully launch its future product candidates, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through proceeds from its August 2014 initial public offering, its December 2015 public offering, its September 2016 private investment in public equity (&#8220;PIPE&#8221;) financing, its September 2017 public offering, its June 2018 public offering, its July 2019 establishment of an Equity Distribution Agreement and Equity Purchase Agreement (Note 8), its March 2021 establishment of an Equity Distribution Agreement (Note 8), private placements of redeemable convertible preferred stock as well as borrowings from debt financing arrangements.&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks similar to other early commercial stage life science companies, including, but not limited to commercially launching the Company&#8217;s products, development and market acceptance of the Company&#8217;s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has impacted and may continue to impact the Company&#8217;s operations. Although the Company did not see any material impact to accounts receivable during the three and nine month period ended September 30, 2022, the Company&#8217;s exposure may increase if its customers continue to be adversely affected by the COVID-19 pandemic, including as a result of the spread of variants of the virus. Customers may reduce their purchases of products, depending on their needs and cash flow, which could negatively impact revenue. The Company has a significant development contract with the Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;) and should BARDA reduce, cancel or not grant additional milestone projects, the Company&#8217;s ability to continue its future product development may be impacted. The ability of the Company&#8217;s shipping carriers to deliver products to customers may be disrupted. The Company has reviewed its suppliers and quantities of key materials and believes that it has sufficient stocks and alternate sources of critical materials including personal protective equipment should the supply chains continue to be disrupted, although raw materials and plastics for the manufacturing of reagents and consumables are in high demand, and interruptions in supply are difficult to predict. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since authorization from the United States Food and Drug Administration, or FDA, was obtained to market the T2Dx Instrument, T2Candida Panel, and T2Bacteria Panel, and Emergency Use Authorization, or EUA, was issued for the T2SARS-CoV-2 Panel, the Company has incurred significant commercialization expenses related to product sales, marketing, manufacturing and distribution. If the FDA rescinds EUA, the Company would be unable to sell its T2SARS-CoV-2 tests. The Company may seek to fund its operations through public equity, private equity or debt financings, as well as other sources. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed, on favorable terms, or at all. The Company&#8217;s failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on the Company&#8217;s business, results of operations, financial condition and the Company&#8217;s ability to develop and commercialize T2Dx, T2Candida, T2Bacteria, T2SARS-CoV-2, and other product candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Accounting Standards Codification (&#8220;ASC&#8221;) 205-40,&#160;<span style="font-style:italic;">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</span>, management must evaluate whether there are conditions or events, considered in the </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its cash, cash equivalents, and restricted cash of $21.5 million at September 30, 2022 will not be sufficient to fund its current operating plan for at least one year from issuance of these financial statements, as certain elements of our operating plan cannot be considered probable. Absent any reductions in current operating expenses, the Company believes it will require additional financing during the first quarter of 2023. Under ASC 205-40, the future receipt of potential funding from co-development partners and other resources cannot be considered probable at this time because none of the plans are entirely within the Company&#8217;s control.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Term Loan Agreement with CRG Servicing LLC (&#8220;CRG&#8221;) (Note 6) has a minimum liquidity covenant which requires the Company to maintain a minimum cash balance of $5.0 million. There can be no assurances that the Company will continue to be in compliance with the cash covenant in future periods without additional funding. In February 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2023. In November 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2024.  </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s stock had been trading under $1.00 since September 27, 2021. <span style="color:#000000;">On November 5, 2021, the Company received a letter from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) indicating that the Company was not in compliance with the requirement of Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market as a result of the closing bid price of the Company&#8217;s common stock being below </span>$1.00 <span style="color:#000000;">per share for thirty consecutive business days (the &#8220;Bid Price Rule&#8221;). Under the Nasdaq rules, the Company had 180 days (or until May 4, 2022) to regain compliance by maintaining a minimum closing bid price of $</span>1.00 per share of the Company&#8217;s common stock for at least ten consecutive trading days during such compliance period. On May 5, 2022, the Company received a letter from Nasdaq informing the Company that its shares of common stock have failed to comply with the Bid Price Rule for continued listing and, as a result, the Company&#8217;s shares were subject to delisting. The letter further stated that the Company may appeal the Nasdaq Staff delisting determination to a Nasdaq listing qualifications hearings panel (the &#8220;Panel&#8221;).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company filed an appeal and hearing request to the Nasdaq Staff&#8217;s determination to stay the delisting of the Company&#8217;s shares of common stock from Nasdaq pending the Panel&#8217;s decision. The Nasdaq Staff informed the Company that the delisting action had been stayed, pending a final written decision by the Panel, and the hearing date had been set for June 2, 2022. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 9, 2022, the Company received a letter from the Nasdaq notifying the Company that the Nasdaq had granted the Company&#8217;s request to be transferred to The Nasdaq Capital Market, effective at the open of trading on June 13, 2022, and the Company&#8217;s request for an exception to the Bid Price Rule until November 1, 2022. </p><p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 11, 2022, at the Company&#8217;s annual meeting of stockholders, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s restated certificate of incorporation to effect a reverse stock split of the Company&#8217;s common stock. Following the receipt of the stockholders&#8217; approval, the Company&#8217;s board of directors approved the reverse stock split at the ratio of 1 post-split share for every <span style="-sec-ix-hidden:F_000445">50 pre-split shares</span>, which was effective as of October 12, 2022. On October 31, 2022, the Company received a letter from Nasdaq informing the Company that it has regained compliance with the Bid Price Rule. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;22, 2022, the Company received a letter from the Nasdaq (the &#8220;Nasdaq Staff Deficiency Letter&#8221;) indicating that, for the last thirty-five consecutive business days, the Market Value of Listed Securities, as defined by Nasdaq (&#8220;MVLS&#8221;) had been below the $35&#160;million minimum requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2).&#160;&#160;In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided an initial period of 180 calendar days, or until January&#160;18, 2023, to regain compliance. The letter states that the Nasdaq staff will provide written notification that the Company has achieved compliance with Rule&#160;5550(b)(2) if at any time before January&#160;18, 2023, the Company maintains its MVLS at $35&#160;million or more for a minimum of ten consecutive business days. The Nasdaq Staff Deficiency Letter has no immediate effect on the listing or trading of the Company&#8217;s common stock.&#160;&#160;If compliance is not achieved by January&#160;18, 2023, the Company expects that Nasdaq would provide written notification to the Company that its securities are subject to delisting. The Company will continue to monitor its MVLS and consider its available options to regain compliance with the Nasdaq minimum MVLS requirements, which may include applying for an extension of the compliance period or appealing to a Nasdaq Hearings Panel. On August 24, 2022, i<span style="color:#000000;">n a Compliance </span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">Notice, the Nasdaq notified the Company that, from August 10, 2022 to August 23, 2022, the Company&#8217;s MVLS had been $</span><span style="color:#000000;">35</span><span style="color:#000000;"> million or greater and, accordingly, the Company had regained compliance with Rule </span><span style="Background-color:#FFFFFF;">5550(b)(2) </span><span style="color:#000000;">and that the matter was now closed.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These conditions raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern for a period of one year after the date that the financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include raising additional funding, earning payments pursuant to the Company&#8217;s contract with BARDA, delaying certain research projects and capital expenditures and eliminating certain future operating expenses in order to fund operations at reduced levels for the Company to continue as a going concern for a period of 12 months from the date these unaudited condensed consolidated financial statements are issued. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these financial statements.<span style="color:#000000;"> The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724026544592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as defined in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The Company&#8217;s condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, T2 Biosystems Securities Corporation. All intercompany balances and transactions have been eliminated. &#160; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 12, 2022, we effected a reverse stock split at the ratio of 1 post-split share for every <span style="-sec-ix-hidden:F_000449_2">50 pre-split shares</span>. All common stock amounts and references have been retroactively adjusted for all figures presented to reflect this split unless specifically stated otherwise.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited Interim Financial Information </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted.&#160;Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying interim condensed consolidated balance sheet as of September&#160;30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2022 and 2021, the condensed consolidated statements of Series A convertible preferred stock and stockholders&#8217; deficit for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2022 and 2021 and the related financial data and other information disclosed in these notes are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual financial statements, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position as of September&#160;30, 2022, and the results of its operations for the three and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021. The results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022, any other interim periods, or any future year or period. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Segment Information </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#8217;s chief operating decision maker is the Chief Executive Officer. The Company views its operations and manages its business in one operating segment, which is the business of developing and, upon regulatory clearance, commercializing its diagnostic products aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Geographic Information </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sells its products domestically and internationally. Total international sales were approximately $1.2 million or 32% of total revenue and $0.6 million or 9% of total revenue for the three months ended September 30, 2022 and 2021, respectively. Total international sales were approximately $3.2 million or 19% of total revenue and $1.6 million or 8% of total revenue for the nine months ended September 30, 2022 and 2021, respectively.  </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended September 30, 2022, one international customer represented 12% of total revenue. For the three months ended September 30, 2021, no international customer represented greater than 10% of total revenue. For the nine months ended September 30, 2022 and 2021, no international customer represented greater than 10% of total revenue.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The following table shows customers that represent greater than 10% of revenue for the period presented: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer A</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer B</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer C</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2022 and December 31, 2021, the Company had outstanding receivables of $0.9 million and $0.6 million, respectively, from customers located outside of the U.S.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies the two-class method for computing earnings per share because its Series A redeemable convertible preferred stock and the warrants issued with that preferred stock are participating securities. Under the two-class method, net income for the period is allocated between common stockholders and the participating securities according to dividends declared, if any, and participation rights in undistributed earnings. Because the Company incurred a net loss for the three and nine months ended September 30, 2022, and the holders of the participating securities do not have the contractual obligation to share in the losses of the Company on a basis that is objectively determinable, none of the net loss attributable to common stockholders was allocated to the participating securities when computing earnings per share.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing net loss attributable to commons stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Any accretion of the carrying amount of the Company&#8217;s Series A redeemable convertible preferred stock to its redemption amount is treated as a deemed dividend to the preferred stockholders and will increase the amount of the net loss attributable to common stockholders. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using either the if-converted method (for its Series A redeemable, convertible preferred stock) or the treasury-stock method. For purposes of the diluted net loss per share calculation, stock options and unvested restricted stock, restricted stock contingently issuable upon achievement of certain market conditions, and the warrants issued with Series A redeemable convertible preferred stock are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. In periods in which the Company recognizes gains due to changes in the fair value of its warrant liability, the Company will further assess whether the effect of adjusting its computation of diluted net loss per share to include the potential common shares and reverse the gain associated with the warrant would result in a more diluted net loss per share, and modify the computation if necessary. The Series A redeemable convertible preferred stock was not considered a common stock equivalent because exercise of the conversion option was contingent upon occurrence of the reverse stock split, which had not yet occurred as of September 30, 2022. Therefore, basic and diluted net loss per share applicable to common stockholders was the same for all periods presented.  </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s marketable securities consist of U.S. treasury securities, which are classified as available-for-sale and included in current assets. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported as a component of stockholders&#8217; deficit in accumulated other comprehensive (loss) income. Realized gains and losses, if any, are included in other income (expense) in the condensed consolidated statements of operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security&#8217;s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported as a component of stockholders&#8217; deficit in accumulated other comprehensive loss (income). </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had no marketable securities at September 30, 2022. The following table summarizes the Company&#8217;s marketable securities at December 31, 2021 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#160; </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,996</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,996</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the maturities of the Company&#8217;s marketable securities at December 31, 2021 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:50%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due in less than 1 year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,996</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due in 1-2 years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,996</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Derivative&#160;Warrant Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with&#160;ASC Topic 815,&#160;<span style="font-style:italic;">&#8220;Derivatives and Hedging</span>.&#8221;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the liability for the warrant issued in conjunction with the Series A redeemable convertible preferred stock is a&#160;derivative&#160;instrument.&#160; The derivative warrant liability is classified on the condensed consolidated balance sheets as current because cash settlement of the warrant could be required by the holder within 12 months of the balance sheet date. The Company has identified a single compound derivative liability related to its Term Loan Agreement with CRG, that is classified as non-current on the condensed consolidated balance sheets to match the classification of the related Term Loan Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the derivative liabilities meet the definition of a&#160;derivative, they are measured at fair value at issuance and at each reporting date in accordance with&#160;ASC 820, &#8220;<span style="font-style:italic;">Fair Value Measurement,&#8221;</span>&#160;with changes in fair value recognized in change in fair value of derivative warrant liability in the period of change in the condensed consolidated statements of operations and comprehensive loss. The Company does not designate its&#160;derivative&#160;instruments as hedging instruments.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Guarantees </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while each such officer or director is, or was, serving at the Company&#8217;s request in such capacity. The term of the indemnification is the officer&#8217;s or director&#8217;s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#8217; and officers&#8217; liability insurance coverage that limits its exposure and enables the Company to recover a portion of any future amounts paid. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office, laboratory and manufacturing space under noncancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify the landlords against all costs, expenses, fines, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company&#8217;s leases. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company&#8217;s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements.  </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2022 and December&#160;31, 2021, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Topic 842, <span style="font-style:italic;">Leases</span> (&#8220;ASC 842&#8221;), at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. The exercise of lease renewal options is at our discretion and the renewal to extend the lease terms are not included in the Company&#8217;s right-of-use assets and lease liabilities as they are not reasonably certain of exercise. The Company will evaluate the renewal options and when they are reasonably certain of exercise, the Company will include the renewal period in its lease term. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued lease payments. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. </p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the guidance in ASC 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). Then the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company made the policy election to not separate lease and non-lease components. Each lease component and the related non-lease components are accounted for together as a single component. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Classification of Series A Redeemable Convertible Preferred Stock </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has applied the guidance in ASC 480-10-S99-3A, SEC Staff Announcement: Classification and Measurement of Redeemable Securities and classified the Series A redeemable convertible preferred stock as temporary equity in the mezzanine section of the balance sheet. The Series A redeemable convertible preferred stock was recorded outside of stockholders&#8217; deficit because under the terms thereof, in the event of stockholder approval of the reverse stock split or a delisting event, which are events considered not solely within the Company&#8217;s control, the Series A redeemable convertible preferred stock becomes redeemable at the option of the holders.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generates revenue from the sale of instruments, consumable diagnostic tests, related services, reagent rental agreements and government contributions. Pursuant to ASC 606, <span style="font-style:italic;">Revenue from Contracts with Customers</span> (&#8220;ASC 606&#8221;), the Company determines revenue recognition through the following steps:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.4%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:2.5%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Identification of a contract with a customer</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.4%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:2.5%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Identification of the performance obligations in the contract</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.4%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:2.5%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Determination of the transaction price</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.4%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:2.5%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Allocation of the transaction price to the performance obligations</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.4%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:2.5%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Recognition of revenue as a performance obligation is satisfied</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of revenue recognized reflects the consideration the Company expects to be entitled to receive in exchange for these goods and services. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company's performance obligations are transferred to customers at a point in time, typically upon shipment, or over time, as services are performed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most of the Company&#8217;s contracts with distributors in geographic regions outside the United States contain only a single performance obligation, whereas most of the Company&#8217;s contracts with direct sales customers in the United States contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. Excluded from the transaction price are sales tax and other similar taxes which are presented on a net basis.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue is generated by the sale of instruments and consumable diagnostic tests predominantly through the Company&#8217;s direct sales force in the United States and distributors in geographic regions outside the United States. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors&#8217; receipt of payment from their end-user customers. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company either sells instruments to customers and international distributors, or retains title and places the instrument at the customer site pursuant to a reagent rental agreement.&#160;When an instrument is purchased by a customer or international distributor, the Company recognizes revenue when the related performance obligation is satisfied (i.e. when the control of an instrument has passed to the customer; typically, at shipping point). </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When the instrument is placed under a reagent rental agreement, the Company&#8217;s customers generally agree to fixed term agreements, which can be extended, and incremental charges on each consumable diagnostic test purchased. Revenue from the sale of consumable diagnostic tests (under a reagent rental agreement) is generally recognized upon shipment. The transaction price from consumables purchases is allocated between the lease of the instrument (under a contingent rent methodology as provided for in ASC 842, <span style="font-style:italic;">Leases</span>), and the consumables when related performance obligations are satisfied, as a component of lease and product revenue, and is included as Instrument Rentals in the below table. Revenue associated with reagent rental consumables purchases is currently classified as variable consideration and constrained until a purchase order is received and related performance obligations have been satisfied.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from the sale of consumable diagnostic tests (under instrument purchase agreements) is generally recognized upon shipment. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shipping and handling costs billed to customers in connection with a product sale are recorded as a component of the transaction price and allocated to product revenue in the condensed consolidated statements of operations and comprehensive loss as they are incurred by the Company in fulfilling its performance obligations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct sales of instruments include warranty, maintenance and technical support services typically for one year following the installation of the purchased instrument (&#8220;Maintenance Services&#8221;). <span style="color:#000000;">Maintenance Services are separate performance obligations as they are service-based warranties and are recognized on a straight-line basis over the service delivery period. After the completion of the initial Maintenance Services period, customers have the option to renew or extend the Maintenance Services typically for additional</span> <span style="-sec-ix-hidden:F_000485">one-year</span> periods in exchange for additional consideration. The extended Maintenance Services are also service-based warranties that represent separate purchasing decisions. The Company recognizes revenue allocated to the extended Maintenance Services performance obligation on a straight-line basis over the service delivery period.&#160;&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fees paid to member-owned group purchasing organizations (&#8220;GPOs&#8221;) are deducted from related product revenues.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company warrants that consumable diagnostic tests will be free from defects, when handled according to product specifications, for the stated life of the product. To fulfill valid warranty claims, the Company provides replacement product free of charge. Warranty expense is recognized based on the estimated defect rates of the consumable diagnostic tests.</p>

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Contribution Revenue</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income under the government BARDA contract is earned under a cost-sharing arrangement in which the Company is reimbursed for direct costs incurred plus allowable indirect costs. The g<span style="Background-color:#FFFFFF;color:#000000;">overnment contract revenue is recognized as the related reimbursable expenses are incurred.&#160;&#160;The cost reimbursement that is reported as revenue is presented gross of the related reimbursable expenses in the Company&#8217;s consolidated statements of operations; the related reimbursable expenses are expensed as incurred as research and development expense. The Company accounts for these contracts as a government grant which analogizes with International Accounting Standards 20 (&#8220;IAS 20&#8221;),&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="Background-color:#FFFFFF;color:#000000;">.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a significant development contract with BARDA and should BARDA reduce, cancel or not grant additional milestone projects, the Company&#8217;s ability to continue future product development may be impacted. Refer to Note 12 for further details regarding the development contract with BARDA. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:9pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Disaggregation of Revenue</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company disaggregates revenue from contracts with customers by type of products and services, as it best depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. The following table disaggregates our revenue by major source (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Instruments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">814</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">522</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,528</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,427</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consumables</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,822</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,765</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,442</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,150</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Instrument rentals</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total product revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,641</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,306</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,044</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,634</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contribution revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,036</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,122</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,778</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,444</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,677</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,428</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,822</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,078</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Remaining Performance Obligations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, the Company is required to disclose the aggregate amount of the transaction price that is allocated to unsatisfied or partially satisfied performance obligations as of September 30, 2022. However, the guidance provides certain practical expedients that limit this requirement, and therefore, the Company has elected to not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. The nature of the excluded unsatisfied performance obligations pursuant to the practical expedient include consumable shipments, service contracts, warranties and installation services that will be performed within one year. The amount of the transaction price that is allocated to unsatisfied or partially satisfied performance obligations, that has not yet been recognized as revenue and that does not meet the elected practical expedient is $0.1 million as of September 30, 2022. The Company expects to recognize 86% of this amount as revenue within one year and the remainder within fifteen months.  </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Judgments</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain contracts with customers include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require judgment. Once the performance obligations are determined, the Company determines the transaction price, which includes estimating the amount of variable consideration, based on the most likely amount, to be included in the transaction price, if any. The Company then allocates the transaction price to each performance obligation in the contract based on a relative standalone selling price method. The corresponding revenue is recognized as the related performance obligations are satisfied as discussed in the revenue categories above.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.83%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Judgment is required to determine the standalone selling price for each distinct performance obligation. The Company determines standalone selling price based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as a range of selling prices, market conditions and the expected costs and margin related to the performance obligations.</p>

<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Contract Assets and Liabilities</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded $0.1 million of contract assets within other assets on the balance sheet at September 30, 2022. The contract assets represent revenue recognized for performance obligations in advance of cash receipt at the contract level based on the transaction price allocated to the respective performance obligations. The Company did not record any contract assets at December 31, 2021.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s contract liabilities consist of upfront payments for research and development contracts and maintenance services on instrument sales. Contract liabilities are classified in deferred revenue as current or noncurrent based on the timing of when revenue is expected to be recognized.&#160;<span style="color:#000000;">Contract liabilities were $0.2 million and $0.5 million at September 30, 2022 and December 31, 2021, respectively. Revenue recognized during the nine months ended September 30, 2022 relating to contract liabilities at December 31, 2021 was $0.4 million and related to straight-line revenue recognition associated with maintenance agreements.</span> </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Cost to Obtain and Fulfill a Contract</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes commission expenses paid to sales personnel that are recoverable and incremental to obtaining capital purchase agreements within the United States. These costs are classified as prepaid expenses and other current assets and other assets, based on their current or non-current nature, respectively. The Company capitalizes only those costs that are determined to be incremental and would not have occurred absent the customer contract. These capitalized costs are amortized as selling, general and administrative costs on a straight line basis over the expected period of benefit. These costs are reviewed periodically for impairment. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="color:#000000;font-size:10pt;">At September 30, 2022, capitalized costs to fulfill contracts of less than $0.1 million was included in prepaid and other current assets. At December 31, 2021, capitalized costs to fulfill contracts of $0.1 million was included in prepaid and other current assets and less than $0.1 million was included in other non-current assets</span>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost of Product Revenue </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product revenue includes the cost of materials, direct labor and manufacturing overhead costs used in the manufacture of consumable diagnostic tests sold to customers, related warranty and license and royalty fees. Cost of product revenue also includes depreciation on T2-owned revenue generating T2Dx instruments that have been placed with customers under reagent rental agreements; costs of materials, direct labor and manufacturing overhead costs on the T2Dx instruments sold to customers; and other costs such as customer support costs, royalties and license fees, warranty and repair and maintenance expense on the T2Dx instruments that have been placed with customers under reagent rental agreements.<span style="color:#000000;"> </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Costs </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs incurred in the research and development of the Company&#8217;s product candidates are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including activities associated with delivering products or services associated with contribution revenue, clinical trials to evaluate the clinical utility of our product candidates, and costs associated with the enhancements of developed products. These costs include salaries and benefits, stock compensation, research related facility and overhead costs, laboratory supplies, equipment, depreciation on T2Dx instruments used for research and development activities and contract services.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses consist primarily of costs for our sales and marketing, finance, legal, human resources, business<span style="color:#000000;"> development and general management functions, as well as professional services, such as legal, consulting and accounting services. Other selling, general and administrative expenses include commercial support activity, facility-related costs, fees and expenses associated with obtaining and maintaining patents, clinical and economic studies and publications, marketing expenses, and travel expenses. We expense the majority of selling, general and administrative expenses as incurred.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Standards </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Accounting Standards Adopted </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the FASB issued ASU No. 2020-06, <span style="font-style:italic;">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40)&#8212;Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span> (&#8220;ASU 2020-06&#8221;), which simplifies accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. The standard is effective for smaller reporting companies for fiscal years beginning after December 15, 2023 and interim periods within those fiscal years. The Company adopted the standard as of January 1, 2022. The adoption did not have a material impact on the Company&#8217;s financial statements. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the FASB issued ASU No. 2021-04, <span style="font-style:italic;">Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#8220;ASU 2021-04&#8221;)</span> which clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after a modification or exchange. This standard is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply this standard prospectively to modifications or exchanges occurring on or after the effective date of this standard. The Company adopted this standard as of January 1, 2022. The adoption did not have a material impact on the Company&#8217;s financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In November 2021, the FASB issued ASU 2021-10,</span><span style="font-style:italic;Background-color:#FFFFFF;">&#160;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span><span style="Background-color:#FFFFFF;">. This ASU requires certain disclosures when companies (a) have received government assistance and (b) use a grant or contribution accounting model by analogy to other accounting guidance. A company that has received government assistance must provide disclosures related to the nature of the transaction, accounting policies used to account for the transaction, and the amounts and line items on the financial statements that are affected by the transaction. This ASU is effective for fiscal years beginning after December 15, 2021, with early adoption permitted, and can be applied either prospectively or retrospectively. The Company adopted this standard as of January 1, 2022. </span>The adoption did not have a material impact on the Company&#8217;s financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724026649040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Fair Value Measurements </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures the following financial assets at fair value on a recurring basis. There were no transfers between levels of the fair value hierarchy during any of the periods presented. The following tables set forth the Company&#8217;s financial assets and liabilities carried at fair value categorized using the lowest level of input applicable to each financial instrument as of September&#160;30, 2022 and December&#160;31, 2021 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in Active</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets for</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identical Assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative warrant liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.9%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,792</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,792</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.9%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,978</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,792</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in Active</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets for</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identical Assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US Treasury securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,996</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,996</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,996</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,996</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash equivalents and available-for-sale marketable securities were comprised of government securities. Securities are classified as cash equivalents when the original maturities are within 90 days of the purchase dates. The Company also maintains money market accounts classified as restricted cash for $1.1 million at September 30, 2022 and $1.6 million at December 31, 2021 (Note 4).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimated the fair value of the derivative warrant liability (Note 7) using the Black-Scholes Model, which uses multiple inputs including the Company&#8217;s stock price, the exercise price of the warrant, volatility of the Company&#8217;s stock price, the risk-free interest rate and the expected term of the warrant. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a single compound derivative related to its Term Loan Agreement with CRG (the &#8220;Term Loan Agreement&#8221;) (Note 6), which is required to be re-measured at fair value on a quarterly basis. The fair value of the derivative at September 30, 2022 is $1.8 million and is classified as a non-current liability on the balance sheet at September 30, 2022 to match the classification of the related Term Loan Agreement (Note 6). As of December 31, 2021, the Company had no derivative liability. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated fair value of the derivative at September 30, 2022 was determined using a probability-weighted discounted cash flow model that includes contingent interest payments under the following scenarios:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:50%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Probability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4% contingent interest beginning in Q1 2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a roll-forward of the fair value of the derivative liability (in thousands):<span style="color:#000000;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,675</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at June 30, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,675</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.38%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,792</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724021619168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAbstract', window );"><strong>Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedAssetsDisclosureTextBlock', window );">Restricted Cash</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. Restricted Cash </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to maintain security deposits for its operating lease agreements for the duration of the lease agreements. At September 30, 2022, the Company had money market accounts for $1.1 million, which represented collateral as security deposits for its operating lease agreements for two facilities. At December 31, 2021, the Company had money market accounts for $1.6 million, which represented collateral as security deposits for its operating lease agreements for three facilities. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724024920928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5. Supplemental Balance Sheet Information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inventories </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis and are comprised of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,195</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,591</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work-in-process</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,231</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">953</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">816</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,365</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventories, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,242</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,909</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office and computer equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">749</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">749</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">783</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">783</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,573</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,507</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,445</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,445</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing tooling and molds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">478</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">478</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T2-owned instruments and components</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,150</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,668</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,785</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,768</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">774</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">512</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,934</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,107</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,432</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,734</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,675</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress is primarily comprised of equipment that has not been placed in service. T2-owned instruments and components is comprised of raw materials and work-in-process inventory that are expected to be used or used to produce T2-owned instruments, based on the Company&#8217;s business model and forecast, and completed instruments that will be used for internal research and development, clinical studies or reagent rental agreements with customers.&#160;<span style="color:#000000;">At September&#160;30, 2022, there was $1.0 million of raw materials or work-in-process inventory in T2-owned instruments and components compared with $1.4 million at December 31, 2021. Completed T2-owned instruments are placed in service once installation procedures are completed and are depreciated over five years.&#160;Depreciation expense for T2-owned instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of product revenue and was immaterial for the three months ended September 30, 2022 and 2021. Depreciation expense for T2-owned instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of product revenue and was $0.1 million for the nine months ended September 30, 2022 and 2021. </span> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense for T2-owned instruments used for internal research and development and clinical studies is recorded as a component of research and development expense. <span style="color:#000000;">Depreciation and amortization expense of $0.3 million and $0.3 million was charged to operations for the three months ended September 30, 2022 and 2021, respectively. Depreciation and amortization expense of $0.8 million and $1.0 million was charged to operations for the nine months ended September 30, 2022 and 2021, respectively.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. <span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accrued Expenses </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,894</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,687</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,482</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,250</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional services</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">392</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">384</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">974</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,295</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,174</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">468</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">869</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,531</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,338</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724024641200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. Notes Payable </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future principal payments on the notes payable are as follows (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term Loan Agreement including PIK interest, before unamortized discount and issuance costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,597</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,364</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: unaccrued paid-in-kind interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,233</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,287</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: unamortized discount and deferred issuance costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(176</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(287</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total notes payable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,188</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,790</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Term Loan Agreement with CRG is classified as non-current September 30, 2022 and at December 31, 2021, as the Company has sufficient cash and cash equivalents such that the minimum liquidity covenant would not be triggered. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;The Term Loan Agreement includes a subjective acceleration clause whereby&#160;an event of default, including a material adverse change in the business, operations, or conditions (financial or otherwise), could result in the acceleration of the obligations under the Term Loan Agreement. As amended in February 2022, the entire principal payment, together with all other outstanding obligations, under the Term Loan Agreement are due and payable upon maturity<span style="color:#000000;">, December 30, 2023. There were no covenant violations at September 30, 2022. In November 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2024.  </span> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Term Loan Agreement </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, the Company entered into a Term Loan Agreement (the &#8220;Term Loan Agreement&#8221;) with CRG. The Company initially borrowed $40.0 million pursuant to the Term Loan Agreement, which has a <span style="-sec-ix-hidden:F_000624">six-year</span> term with four years of interest-only payments (through December&#160;30, 2020), after which quarterly principal and interest payments will be due through the maturity date. Interest on the amounts borrowed under the Term Loan Agreement accrues at an annual fixed rate of 11.5%, 3.5% of which may be deferred during the interest-only period by adding such amount to the aggregate principal loan amount. In addition, if the Company achieves certain financial performance metrics, the loan will convert to interest-only until the maturity date, at which time all unpaid principal and accrued unpaid interest will be due and payable. The Company is required to pay CRG a financing fee based on the loan principal amount drawn. The Company is also required to pay a final payment fee of 8.0%, subsequently amended to 10%, of the principal outstanding upon repayment. The Company is accruing the final payment fee as interest expense and it is included as a non-current liability at September 30, 2022 and December 31, 2021 to conform to the classification of the associated debt in those periods. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may prepay all or a portion of the outstanding principal and accrued unpaid interest under the Term Loan Agreement at any time upon prior notice subject to a certain prepayment fee during the first five years of the term and no prepayment fee thereafter. As security for its obligations under the Term Loan Agreement, the Company entered into a security agreement with CRG whereby the Company granted a lien on substantially all of its assets, including intellectual property. The Term Loan Agreement also contains customary affirmative and negative covenants for a credit facility of this size and type, including a requirement to maintain a minimum cash balance of $5.0 million.  </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, the Term Loan Agreement was amended to reduce minimum revenue targets, extend the interest-only period and extend the principal repayment. The final payment fee was increased from 8% to 10% of the principal amount outstanding upon repayment. The Company issued to CRG warrants to purchase 11,365 shares of the Company&#8217;s common stock (&#8220;New Warrants&#8221;) (Note 10) at an exercise price of $77.50, with typical provisions for termination upon a change of control or a sale of all or substantially all of the assets of the Company.&#160;&#160;The Company also reduced the exercise price for the warrants previously issued to CRG to purchase an aggregate of 10,579 shares of the Company&#8217;s common stock to $77.50. All of the New Warrants are exercisable any time prior to September 9, 2029, and all of the previously issued warrants are exercisable any time prior to December 30, 2026.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, the Term Loan Agreement was amended to extend the interest-only payment period until the December 30, 2022 maturity, to extend the initial principal repayment until the December 30, 2022 maturity, and to significantly reduce the minimum product revenue target for the twenty-four month period beginning on January 1, 2020. The Company did not pay or provide any consideration in exchange for this amendment. <span style="color:#000000;">The Company accounted for the January 2021 amendment as a modification to the Term Loan Agreement.</span> In June 2021, the Company satisfied the only remaining revenue covenant which was for the 24-month period beginning on January 1, 2020.  <span style="color:#000000;"> </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2022, the Term Loan Agreement was amended to extend the interest-only payment period through December 30, 2023, and to extend the principal repayment to December 30, 2023. The Company did not pay or provide any consideration in exchange for this amendment. As the effective borrowing rate under the amended agreement is less than the effective borrowing rate under the previous agreement, a concession is deemed to have been granted under ASC 470-60. As a concession has been granted, the agreement was accounted for as a troubled debt restructuring under ASC 470-60. The amendment did not result in a gain on restructuring as the future undiscounted cash outflows required under the amended agreement exceed the carrying value of the debt immediately prior to the amendment. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2024.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Term Loan Agreement includes a subjective acceleration clause whereby an event of default, including a material adverse change in the business, operations, or conditions (financial or otherwise), could result in the acceleration of the obligations under the Term Loan Agreement. Under certain circumstances, a default interest rate of an additional 4.0%&#160;per annum will apply at the election of CRG on all outstanding obligations during the occurrence and continuance of an event of default.&#160;&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724114441408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series A Redeemable Convertible Preferred Stock and Related Warrant<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock', window );">Series A Redeemable Convertible Preferred Stock and Related Warrant</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. Series A Redeemable Convertible Preferred Stock and Related Warrant </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.9%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 15, 2022, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;), pursuant to which we entered into a private placement transaction an aggregate of 3,000 shares of Series A Redeemable Convertible Preferred Stock with a par value of $0.001 per share and a warrant to purchase up to an aggregate of 42,857 shares of common stock of the Company at an exercise price of $7.50 per share (such number of shares and exercise price adjusted for the reverse stock split described in Note 15) for an aggregate subscription amount equal to $0.3 million, before deducting estimated offering expenses payable by the Company. Pursuant to the Purchase Agreement, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock with the Secretary of State of the State of Delaware designating the rights, preferences and limitations of the Series A Redeemable Convertible Preferred Stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Series A Redeemable Convertible Preferred Stock</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Series A Redeemable Convertible Preferred Stock was issued at a price of $100 per share (the Stated Value). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Conversion<span style="font-style:normal;"> -The Series A Redeemable Convertible Preferred Stock is convertible at the option of the holder, at any time after the date of the reverse stock split proposed by the board of directors, into that number of shares of common stock (subject to certain beneficial ownership limitations) determined by dividing the stated value of the Series A Redeemable Convertible Preferred Stock share by the conversion price then in effect, rounded down to the nearest whole share (with cash paid in lieu of any fractional shares). The initial conversion price was $7.00 per share, adjusted for the reverse stock split that was effected on October 12, 2022 (the &#8220;Conversion Price&#8221;).&#160;&#160;The Conversion Price will be (1) adjusted proportionately upon occurrence of any subsequent stock splits or stock dividends and (2) lowered to a price per share equal to that of any common stock, convertible securities or option that is subsequently issued or sold by the Company for a price per share less than the Conversion Price in effect immediately prior to such issue or sale; however, the Conversion Price cannot fall below the par value per share of the Common Stock nor exceed ten dollars ($10.00) per share, in each case, as adjusted for the reverse stock split that was effected on October 12, 2022.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Redemption<span style="font-style:normal;"> - Series A Redeemable Convertible Preferred Stock do not contain any mandatory redemption provisions. Beginning on the date of the reverse stock split, as proposed by the board of directors (1) the Company may redeem in cash all or any portion of the Series A Redeemable Convertible Preferred Stock at a price per share equal to one hundred and five percent (105%) of the stated value and (2) each holder of Series A Preferred Stock may require the Company to redeem in cash all or any portion of the Series A Redeemable Convertible Preferred Stock held by such holder at a price per share equal to one hundred and ten percent (110%) of the stated value. In addition, if the Company&#8217;s common shares become delisted, the Series A Redeemable Convertible Preferred Stock will automatically be redeemed by the Company at a price per share equal to one hundred and ten percent (110%) of the Stated Value. At September 30, 2022, the Company determined that the Series A Redeemable Convertible Preferred Stock was redeemable and is being carried at its redemption value on the balance sheet, which is equal to its liquidation value under the terms of the certification of designation.&#160;&#160; </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Dividend Rights<span style="font-style:normal;">-Holders of the Series A Redeemable Convertible Preferred Stock are entitled to receive dividends on shares of Series A Redeemable Convertible Preferred Stock equal (on an as-converted to common stock basis) to and in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of the common stock.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Voting Rights -<span style="font-style:normal;">The Series A Redeemable Convertible Preferred Stock will have no voting rights other than the right to vote on certain matters. Each share of Series A Redeemable Convertible Preferred entitles the holder to 1,000,000 votes on a proposal to approve a reverse stock split of the Company&#8217;s outstanding common stock (the &#8220;Proposal&#8221;) and any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Proposal; provided, however, that such shares of Series A Redeemable Convertible Preferred Stock shall be voted in the same proportion as the shares of common stock (excluding any shares of common stock that are not voted)</span> are voted on the Proposal. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Warrant</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the execution of the Securities Purchase Agreement, the Company issued a warrant to purchase 42,857 shares of the Company&#8217;s common stock (the &#8220;Warrant&#8221;) at an exercise price equal to $7.50 per share, subject to adjustments noted below. The Warrant will become exercisable on February 15, 2023 and has a term ending February 15, 2028. At issuance, the Company determined that the Warrant should be classified as a liability because such Warrant could require cash redemption in certain circumstances. Recognition of the warrant liability created a day one loss of $0.1 million. The Warrant is carried at fair value, with changes in fair value recognized in changes in fair value of the derivative warrant liability each reporting period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exercise price of the Warrant and the number of shares issuable upon exercise will be adjusted proportionately upon the occurrence of any subsequent stock dividend or stock split of the Company&#8217;s common stock. In addition, if at any time the Company </p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">grants, issues or sells any </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ommon </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">quivalents</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or rights to purchase stock, warrants, securities or other property pro rata to holders of any class of shares of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ommon </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock (the &#8220;Purchase Rights&#8221;), then the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">older will be entitled to acquire, upon the terms applicable to </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Purchase Rights, the aggregate Purchase Rights which the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">older could have acquired if the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">older had held the number of shares of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ommon </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock acquirable upon complete exercise of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Warrant</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (subject to certain </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eneficial </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wnership limitations). Furthermore, after the issuance of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Warrant and while it</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> is outstanding, if the Company declare</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or make</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ommon </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock, by way of return of capital or otherwise (a &#8220;Distribution&#8221;), the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">older </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> be entitled to participate in </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Distribution to the same extent that the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">older would have participated if the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">older had held the number of shares of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ommon </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock acquirable upon complete exercise of this Warrant</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (subject to certain </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eneficial </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wnership limitations). </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the occurrence of a Fundamental Transaction, as defined, then, upon any subsequent exercise of the Warrant the holder will, at its option, have the right to receive for each Warrant that would have been issuable upon such exercise immediately prior to the occurrence of the Fundamental Transaction the number of shares of common stock (or its equivalent) of the successor or acquiring corporation or of the Company, if it is the surviving corporation, or such other consideration (the &#8220;Alternate Consideration&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of common stock for which the Warrant is exercisable immediately prior to the Fundamental Transaction. For purposes of any such exercise, the determination of the exercise price will be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of common stock in such Fundamental Transaction, and the Company will apportion the exercise price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of common stock are given any choice as to the securities, cash or property to be received in a Fundamental<span style="color:#000000;"> Transaction, then the Warrant holder will be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While any Warrant is outstanding, if the Company issues or sells, any common stock, convertible securities or options, for a consideration per share (the &#8220;New Issuance Price&#8221;) less than a price equal to the exercise price of the Warrant in effect immediately prior to such issue or sale (a &#8220;Dilutive Issuance&#8221;), then immediately after the Dilutive Issuance, the exercise price then in effect will be reduced to an amount equal to the New Issuance Price.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If at the time of a Warrant&#8217;s exercise there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares by the holder, then the Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221;.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable convertible preferred stock and related warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724024632240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Deficit</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Stockholders&#8217; Deficit </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Shares Authorized</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, the Company&#8217;s shareholders approved an increase in the number of authorized shares of the Company&#8217;s common stock from 200,000,000 to 400,000,000.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Equity Distribution Agreement&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 31, 2021, the Company entered into a Sales Agreement with Canaccord (&#8220;New Sales Agreement&#8221;), as agent, pursuant to which the Company may offer and sell shares of its common stock, for aggregate gross sale proceeds of up to $75.0 million from time to time from the effective date of the respective registration statement through Canaccord. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the New Sales Agreement, upon delivery of a placement notice based on the Company&#8217;s instructions and subject to the terms and conditions of the Sales Agreement, Canaccord is able to sell the shares by methods deemed to be an &#8220;at the market&#8221; offering, subject to shelf limitations if any, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company. The Company is not obligated to make any sales of shares under the New Sales Agreement. The Company or Canaccord is able to suspend or terminate the offering of shares upon notice to the other party, subject to certain conditions. Canaccord acts as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company agrees to pay Canaccord for its services of acting as agent an amount equal to <span>3%</span> of the gross proceeds from the sale of the shares pursuant to the New Sales Agreement.&#160;The Company also agrees to provide Canaccord with customary indemnification for certain liabilities. Legal and accounting fees are charged to share capital upon issuance of shares under the New Sales Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the New Sales Agreement, the Company sold 3,668,784 shares for net proceeds of $28.1 million during the nine months ended September 30, 2022 and 336,188 shares for net proceeds of $20.0 million during the nine months ended September 30, 2021. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the New Sales Agreement, the Company sold 3,080,451 shares for net proceeds of $22.2 million during the three months ended September 30, 2022 and did not sell any shares during the three months ended September 30, 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724024675616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9. Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Incentive Plans </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2006 Stock Incentive Plan </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 2006 Stock Option Plan (&#8220;2006 Plan&#8221;) was established for granting stock incentive awards to directors, officers, employees and consultants of the Company.&#160;Upon closing of the Company&#8217;s IPO in August 2014, the Company ceased granting stock incentive awards under the 2006 Plan.&#160;The 2006 Plan provided for the grant of incentive and non-qualified stock options and restricted stock grants as determined by the Company&#8217;s board of directors.&#160;Under the 2006 Plan, stock options were generally granted with exercise prices equal to or greater than the fair value of the common stock as determined by the board of directors, expired no later than 10 years from the date of grant, and vested over various periods not exceeding 4 years.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2014 Stock Incentive Plan </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 2014 Incentive Award Plan (&#8220;2014 Plan&#8221;, and together with the 2006 Plan, the &#8220;Stock Incentive Plans&#8221;) provides for the issuance of shares of common stock in the form of stock options, awards of restricted stock, awards of restricted stock units, performance awards, dividend equivalent awards, stock payment awards and stock appreciation rights to directors, officers, employees and consultants of the Company. Since the establishment of the 2014 Plan, the Company has primarily granted stock options and restricted stock units.&#160;Generally, stock options are granted with exercise prices equal to or greater than the fair value of the common stock on the date of grant, expire no later than 10 years from the date of grant, and vest over various periods not exceeding 4 years.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares reserved for future issuance under the 2014 Plan is the sum of (1)&#160;16,470 shares, (2)&#160;any shares that were granted under the 2006 Plan which are forfeited, lapse unexercised or are settled in cash subsequent to the effective date of the 2014 Plan and (3)&#160;an annual increase on the first day of each calendar year beginning January&#160;1, 2015 and ending on January&#160;1, 2026, equal to the lesser of (A)&#160;4% of the shares outstanding (on an as-converted basis) on the final day of the immediately preceding calendar year and (B)&#160;such smaller number of shares determined by the Company&#8217;s board of directors; provided, however, no more than 700,000 shares may be issued upon the exercise of incentive stock options.&#160;As of September&#160;30, 2022, there were 52,676 shares available for future grant under the 2014 Plan. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Inducement Award Plan </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Amended and Restated Inducement Award Plan (&#8220;Inducement Plan&#8221;), which was adopted in March 2018 and most recently amended and restated in January 2020, provides for the grant of equity awards to new employees, including options, restricted stock awards, restricted stock units, performance awards, dividend equivalent awards, stock payment awards and stock appreciation rights. The aggregate number of shares of common stock which may be issued or transferred pursuant to awards under the Inducement Plan is 192,500 shares. Any awards that forfeit, expire, lapse, or are settled for cash without the delivery of shares to the holder are available for the grant of an award under the Inducement Plan. Any shares repurchased by or surrendered to the Company that are returned shall be available for the grant of an award under the Inducement Plan. The payment of dividend equivalents in cash in conjunction with any outstanding award shall not be counted against the shares available for issuance under the Inducement Plan. As of September&#160;30, 2022, there were 84,501 shares available for future grant under the Inducement Plan.&#160;&#160;<span style="font-style:italic;"> </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Options </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the nine months ended September&#160;30, 2022 and 2021, the Company granted stock options with an aggregate fair value of $0.6 million and $1.1 million, respectively, which are being amortized into compensation expense over the vesting period of the options as the services are being provided. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of option activity under the Stock Incentive Plans and Inducement Plan (in thousands, except share and per share amounts): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price Per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197,171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143.96</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000698">7.09</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,520</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.50</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,608</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42.64</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,863</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119.60</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193,220</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137.64</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000699">6.78</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at September 30, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,461</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186.38</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000700">5.90</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested or expected to vest at September 30, 2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182,864</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143.27</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000701">6.66</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  There were no options exercised in the nine months ended September 30, 2022 and 1,566 options exercised in the nine months ended September 30, 2021. The weighted-average grant date fair values of stock options granted in the nine month periods ended September&#160;30, 2022 and 2021 were $17.58 per share and $54.77 per share, respectively, and were calculated using the following estimated assumptions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.27</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.92</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected terms</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0 years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0 years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total fair values of options that vested during the nine months ended September&#160;30, 2022 and 2021 were $1.4 million and $2.1 million, respectively. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2022, there was $2.1 million of total unrecognized compensation cost related to non-vested stock options granted under the Stock Incentive Plans and Inducement Plan. Total unrecognized compensation cost will be adjusted for future changes in the estimated forfeiture rate. The Company expects to recognize that cost over a remaining weighted-average period of 2.1 years as of September&#160;30, 2022. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Units </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the nine months ended September&#160;30, 2022, the Company awarded restricted stock units to certain employees and directors at no cost to them. The restricted stock units, excluding any restricted stock units with market conditions, vest through the passage of time, assuming continued service. Restricted stock units are not included in issued and outstanding common stock until the underlying shares are vested and released. The fair value of the restricted stock units, at the time of the grant, is expensed on a straight line basis. The granted restricted stock units had an aggregate fair value of $3.7 million, which are being amortized into compensation expense over the vesting period of the restricted stock units as the services are being provided. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of restricted stock unit activity under the 2014 Plan: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant&#160;Date&#160;Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value Per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.76%;" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,434</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91.77</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.76%;" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,575</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.79</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.76%;" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,352</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93.13</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.76%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,355</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42.40</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.76%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at September 30, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,302</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48.32</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2022, there was $8.5 million of total unrecognized compensation cost related to nonvested restricted stock units granted. Total unrecognized compensation cost will be adjusted for future changes in the estimated forfeiture rate. The Company expects to recognize that cost over a remaining weighted-average period of 1.7 years, as of September&#160;30, 2022.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the 2014 Employee Stock Purchase Plan (the &#8220;2014 ESPP&#8221;) participants may purchase the Company&#8217;s common stock during semi-annual offering periods at 85% of the lower of (i) the market value per share of common stock on the first day of the offering period or (ii) the market value per share of the common stock on the purchase date. Each participant can purchase up to a maximum of $25,000 per calendar year in fair market value as calculated in accordance with applicable tax rules. The first offering period began on August 7, 2014. Stock-based compensation expense from the 2014 ESPP for the three months ended September 30, 2022 and 2021 was approximately <span>$0.1</span> million. Stock-based compensation expense from the 2014 ESPP for the nine months ended September 30, 2022 and 2021 was approximately $0.3 million and $0.3 million, respectively. &#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2014 ESPP, which was amended and restated effective August 6, 2020, provides for the issuance of up to 90,478 shares of the Company&#8217;s common stock to eligible employees. At September 30, 2022, there were 29,181 shares available for issuance under the 2014 ESPP. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the stock-based compensation expense resulting from awards granted under Stock Incentive Plans, the Inducement Plan and the 2014 ESPP, that was recorded in the Company&#8217;s results of operations for the periods presented (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">309</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">211</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">269</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">851</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">707</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,060</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,114</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,280</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,655</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,354</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,423</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,440</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,573</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three and nine months ended September&#160;30, 2022 and 2021, stock-based compensation expenses capitalized as part of inventory or T2Dx instruments and components were immaterial.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, a previous director of the Company resigned. In conjunction with his resignation, all of the director&#8217;s outstanding options vested in full and the exercise term was extended to the final expiration date for each respective outstanding option. Additionally, the non-vested restricted stock units granted to the director in June 2021 vested in full upon his resignation. These were accounted for as Type I equity modifications for the accelerated vesting and Type III equity modifications for the extended exercise period and resulted in an increase of $0.8 million to stock-based compensation expense for the three and nine months ended September 30, 2021. Included within selling, general and administrative above for the three and nine months ended September 30, 2021 is $0.6 million and $0.2 million related to the Type I modification and the Type III modification, respectively, from the director&#8217;s resignation.  </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724024727360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants associated with Term Loan<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants And Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_WarrantsNoteDisclosureTextBlock', window );">Warrants Associated with Term Loan</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Warrants associated with Term Loan</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Term Loan Agreement entered into in December 2016, the Company issued to CRG warrants to purchase a total of 10,579 shares of the Company&#8217;s common stock. The warrants are exercisable any time prior to December&#160;30, 2026 at a price of $77.50 per share, with typical provisions for termination upon a change of control or a sale of all or substantially all of the assets of the Company. These warrants remain outstanding as of September 30, 2022 and December 31, 2021<span style="color:#000000;">.</span> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with a 2019 amendment of the Term Loan Agreement, the Company issued to CRG warrants to purchase 11,365 shares of the Company&#8217;s common stock (&#8220;New Warrants&#8221;) at an exercise price of $77.50, with typical provisions for termination upon a change of control or a sale of all or substantially all of the assets of the Company. All of the New Warrants are exercisable any time prior to September 9, 2029. The New Warrants remain outstanding as of September 30, 2022<span style="color:#000000;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_WarrantsNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure for warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_WarrantsNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724024703104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. Net Loss Per Share </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies the two-class method for computing earnings per share because its Series A redeemable convertible preferred stock and the warrants issued with that preferred stock are participating securities. Under the two-class method, net income for the period is allocated between common stockholders and the participating securities according to dividends declared, if any, and participation rights in undistributed earnings. Because the Company incurred a net loss for the three and nine months ended September 30, 2022, and the holders of the participating securities do not have the contractual obligation to share in the losses of the Company on a basis that is objectively determinable, none of the net loss attributable to common stockholders was allocated to the participating securities when computing earnings per share.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The net loss attributable to common stockholders was increased by $0.3 million to reflect the deemed dividend paid to holders of the Series A redeemable convertible preferred stock to accrete the carrying amount of that preferred stock to its redemption value.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock or if-converted methods, because their effect would have been anti-dilutive for the periods presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three and Nine Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common shares</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193,220</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,352</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,302</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134,599</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,801</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,944</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A redeemable convertible preferred stock</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">485,323</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">342,895</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note that the net loss per share computations for all periods presented reflect the changes in the number of shares resulting from the <span style="-sec-ix-hidden:F_000785_2">50 to 1</span> reverse stock split that was approved by shareholders on October 11, 2022 and became effective as of October 12, 2022.&#160;&#160;The number of shares of common stock issued and outstanding immediately before the reverse stock split was 352,957,478&#894; the number of shares outstanding immediately after the reverse split was 7,059,144, a decrease of 345,898,334 shares.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724024792544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>US Government Contract<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">US Government Contract</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. U.S. Government Contract</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, BARDA awarded the Company a milestone-based contract, with an initial value of $6.0 million, and a potential value of up to $69.0 million, if BARDA awards all contract options (the &#8220;U.S. Government Contract&#8221;). BARDA operates within the Office of the Assistant Secretary for Preparedness and Response (&#8220;ASPR&#8221;) at the U.S. Department of Health and Human Services (&#8220;HHS&#8221;). If BARDA awards and the Company completes all options, the Company&#8217;s management believes it will enable a significant expansion of the Company&#8217;s current portfolio of diagnostics for sepsis-causing pathogen and antibiotic resistance genes. In September 2020, BARDA exercised the first contract option valued at $10.5 million. In September 2021, BARDA exercised an option valued at approximately $6.4 million. &#160;&#160; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2021, BARDA agreed to accelerate product development by modifying the contract to advance future deliverables into the currently funded Option 1 of the BARDA contract for T2NxT, T2Biothreat, T2Resistance and T2AMR. The modification does not change the overall total potential value of the BARDA contract.&#160;&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;31, 2022, the Company announced that BARDA had exercised Option 2B under the existing multiple-year cost-share contract between BARDA and the Company and is providing an additional $4.4 million in funding to the Company. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The option exercise occurred simultaneously on March&#160;31, 2022 with a modification to the BARDA contract to make immaterial changes to, among other things, the statement of work. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2022, BARDA exercised Option 3 and agreed to provide an additional $3.7 million in funding for the multiple-year cost-share contract. The additional funding under Option 3 will be used to advance the U.S. clinical trials for the T2Biothreat<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;Panel and T2Resistance<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;Panel, and to file submissions to the FDA for U.S. regulatory clearance. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded contribution revenue of $1.0 million and $3.1 million for the three months ended September 30, 2022 and 2021, respectively, under the BARDA contract. The Company recorded contribution revenue of $7.8 million and $8.4 million for the nine months ended September 30, 2022 and 2021, respectively, under the BARDA contract.&#160;&#160;&#160;&#160;   </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had no outstanding accounts receivable at September 30, 2022 and accounts receivable of $1.9 million at December 31, 2021, respectively, under the BARDA contract. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724024632240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13. Leases </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Operating Leases </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases certain office space, laboratory space and manufacturing space. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. The Company does not recognize right-of-use assets or lease liabilities for leases determined to have a term of 12 months or less. For new and amended leases, the Company has elected to account for the lease and non-lease components as a combined lease component.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2013, the Company entered into an operating lease for additional office, laboratory and manufacturing space in Wilmington, Massachusetts. In August 2018, the Company entered into an amendment to extend the term to <span style="-sec-ix-hidden:F_000807">December 2020</span>. In October 2020, the Company entered into an amendment to extend the term to December 31, 2022. In September 2022, the Company entered into an amendment to extend the term to December 31, 2024. This amendment resulted in an increase to the operating lease right-of-use assets and lease liability accounts on the balance sheet of $0.2 million at September 30, 2022.&#160;&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2014, the Company entered into an agreement to rent additional office space in Lexington, Massachusetts. In April 2015, the Company entered into an amendment to extend the term to December 31, 2017. In connection with this agreement, the Company paid a security deposit of $50,000, which is recorded as a component of other assets in the condensed consolidated balance sheets. In May 2015, the Company entered into an amendment to expand existing manufacturing facilities in Lexington, Massachusetts. In September 2017, the Company entered into an amendment to extend the term to December 31, 2021. In June 2020, the Company vacated this office space and determined that subleasing it to a tenant was unlikely due to the impact of the COVID-19 pandemic on the local commercial real estate sub-lease market. The lease terminated on December 31, 2021.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2014, the Company entered into a lease for additional laboratory space in Lexington, Massachusetts. The lease term commenced in April 2015 and extended for six years. The rent expense, inclusive of the escalating rent payments, is recognized on a straight-line basis over the lease term. As an incentive to enter into the lease, the landlord paid approximately $1.4 million of the $2.2 million space build-out costs. The unamortized balance of the lease incentive as of January 1, 2019 was reclassified as a reduction to the initial recognition of the right-of-use asset related to this lease. In connection with this lease agreement, the Company paid a security deposit of $281,000, which was recorded as a component of both prepaid expenses and other current assets and other assets in the condensed consolidated balance sheets at December 31, 2019. In October 2020, the Company entered into an amendment to extend the term of the lease to October 31, 2025. In accordance with this amendment, the Company paid a replacement security deposit of $130,977, which is classified as restricted cash at September 30, 2022 and December 31, 2021 and received the initial $281,000 security deposit in return.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2021, the Company entered into a lease for office, research, laboratory and manufacturing space in Billerica, Massachusetts. The lease has a term of 126 months from the commencement date. At September 30, 2022, there is no effect on the operating lease right-of-use assets and lease liability accounts. The Company opened a money market account for $1.0 million, which represents collateral as a security deposit for this lease and is classified as restricted cash at September 30, 2022. Occupancy of the building has been delayed due to disagreement between the Company and the landlord as to the parties&#8217; obligations under the lease agreement. Negotiations are on-going. The Company believes that a liability is reasonably possible but not probable. An estimate of the possible loss or range of loss cannot be made at this time.     </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases are amortized over the lease term and included in costs and expenses in the condensed consolidated statement of operations and comprehensive loss. Variable lease costs are recognized in costs and expenses in the condensed consolidated statement of operations and comprehensive loss as incurred. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724022666032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14. Commitments and Contingencies</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">License Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2006, the Company entered into a license agreement with a third party, pursuant to which the third party granted the Company an exclusive, worldwide, sublicenseable license under certain patent rights to make, use, import and commercialize products and processes for diagnostic, industrial and research and development purposes. The Company agreed to pay an annual license fee ranging from $5,000 to $25,000 for the royalty&#8209;bearing license to certain patents. The Company also issued a total of 1,693 shares of common stock pursuant to the agreement in 2006 and 2007, which were recorded at fair value at the date of issuance. The Company is required to pay royalties on net sales of products and processes that are covered by patent rights licensed under the agreement at a percentage ranging between 0.5% - 3.5%, subject to reductions and offsets in certain circumstances, as well as a royalty on net sales of </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products that the Company sublicenses at </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of specified gross revenue. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalties that became due under this agreement for the three</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">months ended </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 30</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2022 and 2021</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> were </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">immaterial</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalties that became due under this agreement for the </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nine</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> months ended September 30, 2022 and 2021 were </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724024794208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15. Subsequent Events</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Equity Distribution Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subsequent to September 30, 2022, the Company sold 256,628 shares for net proceeds of $0.7 million under the New Sales Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Reverse Stock Split</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 11, 2022, at the Company&#8217;s annual meeting of stockholders, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s restated certificate of incorporation to effect a reverse stock split of the Company&#8217;s common stock. Following the receipt of the stockholders&#8217; approval, the Company&#8217;s board of directions approved the reverse stock split at the ratio of 1 post-split share for every <span style="-sec-ix-hidden:F_000835_2">50 pre-split shares</span>, and the amendment to the Company&#8217;s restated certificate of incorporation became effective as of October 12, 2022. As a result of the reverse stock split, every 50 shares of issued and outstanding common stock of the Company were automatically reclassified and combined into 1 share of common stock, with any fractional interest in shares being paid out in cash. Immediately after the reverse stock split became effective, the Company had approximately 7,059,144 shares of common stock issued and outstanding. As a result of the reverse split, there was an adjustment of 50 shares for rounding. All common stock amounts and references have been retroactively adjusted for all figures presented to reflect this split unless specifically stated otherwise.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Securities Purchase Agreement</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="color:#000000;">On October 26, 2022, the private investor in the Company&#8217;s Series A redeemable convertible preferred stock redeemed all </span>3,000 shares<span style="color:#000000;"> of the Series A redeemable convertible preferred stock for an aggregate amount of $0.3 million.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724116855424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as defined in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The Company&#8217;s condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, T2 Biosystems Securities Corporation. All intercompany balances and transactions have been eliminated. &#160; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 12, 2022, we effected a reverse stock split at the ratio of 1 post-split share for every <span style="-sec-ix-hidden:F_000449_2">50 pre-split shares</span>. All common stock amounts and references have been retroactively adjusted for all figures presented to reflect this split unless specifically stated otherwise.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_UnauditedInterimFinancialInformationPolicyTextBlock', window );">Unaudited Interim Financial Information</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited Interim Financial Information </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted.&#160;Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying interim condensed consolidated balance sheet as of September&#160;30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2022 and 2021, the condensed consolidated statements of Series A convertible preferred stock and stockholders&#8217; deficit for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2022 and 2021 and the related financial data and other information disclosed in these notes are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual financial statements, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position as of September&#160;30, 2022, and the results of its operations for the three and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021. The results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022, any other interim periods, or any future year or period. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Segment Information </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#8217;s chief operating decision maker is the Chief Executive Officer. The Company views its operations and manages its business in one operating segment, which is the business of developing and, upon regulatory clearance, commercializing its diagnostic products aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_GeographicInformationPolicyTextBlock', window );">Geographic Information</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Geographic Information </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sells its products domestically and internationally. Total international sales were approximately $1.2 million or 32% of total revenue and $0.6 million or 9% of total revenue for the three months ended September 30, 2022 and 2021, respectively. Total international sales were approximately $3.2 million or 19% of total revenue and $1.6 million or 8% of total revenue for the nine months ended September 30, 2022 and 2021, respectively.  </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended September 30, 2022, one international customer represented 12% of total revenue. For the three months ended September 30, 2021, no international customer represented greater than 10% of total revenue. For the nine months ended September 30, 2022 and 2021, no international customer represented greater than 10% of total revenue.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The following table shows customers that represent greater than 10% of revenue for the period presented: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer A</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer B</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer C</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2022 and December 31, 2021, the Company had outstanding receivables of $0.9 million and $0.6 million, respectively, from customers located outside of the U.S.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies the two-class method for computing earnings per share because its Series A redeemable convertible preferred stock and the warrants issued with that preferred stock are participating securities. Under the two-class method, net income for the period is allocated between common stockholders and the participating securities according to dividends declared, if any, and participation rights in undistributed earnings. Because the Company incurred a net loss for the three and nine months ended September 30, 2022, and the holders of the participating securities do not have the contractual obligation to share in the losses of the Company on a basis that is objectively determinable, none of the net loss attributable to common stockholders was allocated to the participating securities when computing earnings per share.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing net loss attributable to commons stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Any accretion of the carrying amount of the Company&#8217;s Series A redeemable convertible preferred stock to its redemption amount is treated as a deemed dividend to the preferred stockholders and will increase the amount of the net loss attributable to common stockholders. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using either the if-converted method (for its Series A redeemable, convertible preferred stock) or the treasury-stock method. For purposes of the diluted net loss per share calculation, stock options and unvested restricted stock, restricted stock contingently issuable upon achievement of certain market conditions, and the warrants issued with Series A redeemable convertible preferred stock are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. In periods in which the Company recognizes gains due to changes in the fair value of its warrant liability, the Company will further assess whether the effect of adjusting its computation of diluted net loss per share to include the potential common shares and reverse the gain associated with the warrant would result in a more diluted net loss per share, and modify the computation if necessary. The Series A redeemable convertible preferred stock was not considered a common stock equivalent because exercise of the conversion option was contingent upon occurrence of the reverse stock split, which had not yet occurred as of September 30, 2022. Therefore, basic and diluted net loss per share applicable to common stockholders was the same for all periods presented.  </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s marketable securities consist of U.S. treasury securities, which are classified as available-for-sale and included in current assets. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported as a component of stockholders&#8217; deficit in accumulated other comprehensive (loss) income. Realized gains and losses, if any, are included in other income (expense) in the condensed consolidated statements of operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security&#8217;s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported as a component of stockholders&#8217; deficit in accumulated other comprehensive loss (income). </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had no marketable securities at September 30, 2022. The following table summarizes the Company&#8217;s marketable securities at December 31, 2021 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#160; </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,996</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,996</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the maturities of the Company&#8217;s marketable securities at December 31, 2021 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:50%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due in less than 1 year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,996</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due in 1-2 years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,996</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Warrant Liability</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Derivative&#160;Warrant Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with&#160;ASC Topic 815,&#160;<span style="font-style:italic;">&#8220;Derivatives and Hedging</span>.&#8221;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the liability for the warrant issued in conjunction with the Series A redeemable convertible preferred stock is a&#160;derivative&#160;instrument.&#160; The derivative warrant liability is classified on the condensed consolidated balance sheets as current because cash settlement of the warrant could be required by the holder within 12 months of the balance sheet date. The Company has identified a single compound derivative liability related to its Term Loan Agreement with CRG, that is classified as non-current on the condensed consolidated balance sheets to match the classification of the related Term Loan Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the derivative liabilities meet the definition of a&#160;derivative, they are measured at fair value at issuance and at each reporting date in accordance with&#160;ASC 820, &#8220;<span style="font-style:italic;">Fair Value Measurement,&#8221;</span>&#160;with changes in fair value recognized in change in fair value of derivative warrant liability in the period of change in the condensed consolidated statements of operations and comprehensive loss. The Company does not designate its&#160;derivative&#160;instruments as hedging instruments.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies', window );">Guarantees</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Guarantees </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while each such officer or director is, or was, serving at the Company&#8217;s request in such capacity. The term of the indemnification is the officer&#8217;s or director&#8217;s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#8217; and officers&#8217; liability insurance coverage that limits its exposure and enables the Company to recover a portion of any future amounts paid. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office, laboratory and manufacturing space under noncancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify the landlords against all costs, expenses, fines, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company&#8217;s leases. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company&#8217;s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements.  </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2022 and December&#160;31, 2021, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">Leases
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Topic 842, <span style="font-style:italic;">Leases</span> (&#8220;ASC 842&#8221;), at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. The exercise of lease renewal options is at our discretion and the renewal to extend the lease terms are not included in the Company&#8217;s right-of-use assets and lease liabilities as they are not reasonably certain of exercise. The Company will evaluate the renewal options and when they are reasonably certain of exercise, the Company will include the renewal period in its lease term. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued lease payments. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. </p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the guidance in ASC 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). Then the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company made the policy election to not separate lease and non-lease components. Each lease component and the related non-lease components are accounted for together as a single component. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Classification of Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Classification of Series A Redeemable Convertible Preferred Stock </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has applied the guidance in ASC 480-10-S99-3A, SEC Staff Announcement: Classification and Measurement of Redeemable Securities and classified the Series A redeemable convertible preferred stock as temporary equity in the mezzanine section of the balance sheet. The Series A redeemable convertible preferred stock was recorded outside of stockholders&#8217; deficit because under the terms thereof, in the event of stockholder approval of the reverse stock split or a delisting event, which are events considered not solely within the Company&#8217;s control, the Series A redeemable convertible preferred stock becomes redeemable at the option of the holders.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generates revenue from the sale of instruments, consumable diagnostic tests, related services, reagent rental agreements and government contributions. Pursuant to ASC 606, <span style="font-style:italic;">Revenue from Contracts with Customers</span> (&#8220;ASC 606&#8221;), the Company determines revenue recognition through the following steps:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.4%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:2.5%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Identification of a contract with a customer</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.4%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:2.5%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Identification of the performance obligations in the contract</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.4%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:2.5%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Determination of the transaction price</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.4%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:2.5%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Allocation of the transaction price to the performance obligations</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.4%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:2.5%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Recognition of revenue as a performance obligation is satisfied</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of revenue recognized reflects the consideration the Company expects to be entitled to receive in exchange for these goods and services. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company's performance obligations are transferred to customers at a point in time, typically upon shipment, or over time, as services are performed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most of the Company&#8217;s contracts with distributors in geographic regions outside the United States contain only a single performance obligation, whereas most of the Company&#8217;s contracts with direct sales customers in the United States contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. Excluded from the transaction price are sales tax and other similar taxes which are presented on a net basis.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue is generated by the sale of instruments and consumable diagnostic tests predominantly through the Company&#8217;s direct sales force in the United States and distributors in geographic regions outside the United States. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors&#8217; receipt of payment from their end-user customers. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company either sells instruments to customers and international distributors, or retains title and places the instrument at the customer site pursuant to a reagent rental agreement.&#160;When an instrument is purchased by a customer or international distributor, the Company recognizes revenue when the related performance obligation is satisfied (i.e. when the control of an instrument has passed to the customer; typically, at shipping point). </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When the instrument is placed under a reagent rental agreement, the Company&#8217;s customers generally agree to fixed term agreements, which can be extended, and incremental charges on each consumable diagnostic test purchased. Revenue from the sale of consumable diagnostic tests (under a reagent rental agreement) is generally recognized upon shipment. The transaction price from consumables purchases is allocated between the lease of the instrument (under a contingent rent methodology as provided for in ASC 842, <span style="font-style:italic;">Leases</span>), and the consumables when related performance obligations are satisfied, as a component of lease and product revenue, and is included as Instrument Rentals in the below table. Revenue associated with reagent rental consumables purchases is currently classified as variable consideration and constrained until a purchase order is received and related performance obligations have been satisfied.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from the sale of consumable diagnostic tests (under instrument purchase agreements) is generally recognized upon shipment. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shipping and handling costs billed to customers in connection with a product sale are recorded as a component of the transaction price and allocated to product revenue in the condensed consolidated statements of operations and comprehensive loss as they are incurred by the Company in fulfilling its performance obligations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct sales of instruments include warranty, maintenance and technical support services typically for one year following the installation of the purchased instrument (&#8220;Maintenance Services&#8221;). <span style="color:#000000;">Maintenance Services are separate performance obligations as they are service-based warranties and are recognized on a straight-line basis over the service delivery period. After the completion of the initial Maintenance Services period, customers have the option to renew or extend the Maintenance Services typically for additional</span> <span style="-sec-ix-hidden:F_000485">one-year</span> periods in exchange for additional consideration. The extended Maintenance Services are also service-based warranties that represent separate purchasing decisions. The Company recognizes revenue allocated to the extended Maintenance Services performance obligation on a straight-line basis over the service delivery period.&#160;&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fees paid to member-owned group purchasing organizations (&#8220;GPOs&#8221;) are deducted from related product revenues.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company warrants that consumable diagnostic tests will be free from defects, when handled according to product specifications, for the stated life of the product. To fulfill valid warranty claims, the Company provides replacement product free of charge. Warranty expense is recognized based on the estimated defect rates of the consumable diagnostic tests.</p>

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Contribution Revenue</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income under the government BARDA contract is earned under a cost-sharing arrangement in which the Company is reimbursed for direct costs incurred plus allowable indirect costs. The g<span style="Background-color:#FFFFFF;color:#000000;">overnment contract revenue is recognized as the related reimbursable expenses are incurred.&#160;&#160;The cost reimbursement that is reported as revenue is presented gross of the related reimbursable expenses in the Company&#8217;s consolidated statements of operations; the related reimbursable expenses are expensed as incurred as research and development expense. The Company accounts for these contracts as a government grant which analogizes with International Accounting Standards 20 (&#8220;IAS 20&#8221;),&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="Background-color:#FFFFFF;color:#000000;">.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a significant development contract with BARDA and should BARDA reduce, cancel or not grant additional milestone projects, the Company&#8217;s ability to continue future product development may be impacted. Refer to Note 12 for further details regarding the development contract with BARDA. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:9pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Disaggregation of Revenue</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company disaggregates revenue from contracts with customers by type of products and services, as it best depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. The following table disaggregates our revenue by major source (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Instruments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">814</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">522</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,528</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,427</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consumables</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,822</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,765</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,442</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,150</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Instrument rentals</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total product revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,641</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,306</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,044</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,634</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contribution revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,036</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,122</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,778</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,444</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,677</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,428</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,822</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,078</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Remaining Performance Obligations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, the Company is required to disclose the aggregate amount of the transaction price that is allocated to unsatisfied or partially satisfied performance obligations as of September 30, 2022. However, the guidance provides certain practical expedients that limit this requirement, and therefore, the Company has elected to not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. The nature of the excluded unsatisfied performance obligations pursuant to the practical expedient include consumable shipments, service contracts, warranties and installation services that will be performed within one year. The amount of the transaction price that is allocated to unsatisfied or partially satisfied performance obligations, that has not yet been recognized as revenue and that does not meet the elected practical expedient is $0.1 million as of September 30, 2022. The Company expects to recognize 86% of this amount as revenue within one year and the remainder within fifteen months.  </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Judgments</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain contracts with customers include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require judgment. Once the performance obligations are determined, the Company determines the transaction price, which includes estimating the amount of variable consideration, based on the most likely amount, to be included in the transaction price, if any. The Company then allocates the transaction price to each performance obligation in the contract based on a relative standalone selling price method. The corresponding revenue is recognized as the related performance obligations are satisfied as discussed in the revenue categories above.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.83%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Judgment is required to determine the standalone selling price for each distinct performance obligation. The Company determines standalone selling price based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as a range of selling prices, market conditions and the expected costs and margin related to the performance obligations.</p>

<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Contract Assets and Liabilities</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:6pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded $0.1 million of contract assets within other assets on the balance sheet at September 30, 2022. The contract assets represent revenue recognized for performance obligations in advance of cash receipt at the contract level based on the transaction price allocated to the respective performance obligations. The Company did not record any contract assets at December 31, 2021.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s contract liabilities consist of upfront payments for research and development contracts and maintenance services on instrument sales. Contract liabilities are classified in deferred revenue as current or noncurrent based on the timing of when revenue is expected to be recognized.&#160;<span style="color:#000000;">Contract liabilities were $0.2 million and $0.5 million at September 30, 2022 and December 31, 2021, respectively. Revenue recognized during the nine months ended September 30, 2022 relating to contract liabilities at December 31, 2021 was $0.4 million and related to straight-line revenue recognition associated with maintenance agreements.</span> </p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Cost to Obtain and Fulfill a Contract</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes commission expenses paid to sales personnel that are recoverable and incremental to obtaining capital purchase agreements within the United States. These costs are classified as prepaid expenses and other current assets and other assets, based on their current or non-current nature, respectively. The Company capitalizes only those costs that are determined to be incremental and would not have occurred absent the customer contract. These capitalized costs are amortized as selling, general and administrative costs on a straight line basis over the expected period of benefit. These costs are reviewed periodically for impairment. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="color:#000000;font-size:10pt;">At September 30, 2022, capitalized costs to fulfill contracts of less than $0.1 million was included in prepaid and other current assets. At December 31, 2021, capitalized costs to fulfill contracts of $0.1 million was included in prepaid and other current assets and less than $0.1 million was included in other non-current assets</span>. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_CostOfProductRevenuePolicyTextBlock', window );">Cost of Product Revenue</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost of Product Revenue </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product revenue includes the cost of materials, direct labor and manufacturing overhead costs used in the manufacture of consumable diagnostic tests sold to customers, related warranty and license and royalty fees. Cost of product revenue also includes depreciation on T2-owned revenue generating T2Dx instruments that have been placed with customers under reagent rental agreements; costs of materials, direct labor and manufacturing overhead costs on the T2Dx instruments sold to customers; and other costs such as customer support costs, royalties and license fees, warranty and repair and maintenance expense on the T2Dx instruments that have been placed with customers under reagent rental agreements.<span style="color:#000000;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Costs </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs incurred in the research and development of the Company&#8217;s product candidates are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including activities associated with delivering products or services associated with contribution revenue, clinical trials to evaluate the clinical utility of our product candidates, and costs associated with the enhancements of developed products. These costs include salaries and benefits, stock compensation, research related facility and overhead costs, laboratory supplies, equipment, depreciation on T2Dx instruments used for research and development activities and contract services.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses consist primarily of costs for our sales and marketing, finance, legal, human resources, business<span style="color:#000000;"> development and general management functions, as well as professional services, such as legal, consulting and accounting services. Other selling, general and administrative expenses include commercial support activity, facility-related costs, fees and expenses associated with obtaining and maintaining patents, clinical and economic studies and publications, marketing expenses, and travel expenses. We expense the majority of selling, general and administrative expenses as incurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Standards </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Accounting Standards Adopted </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the FASB issued ASU No. 2020-06, <span style="font-style:italic;">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40)&#8212;Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span> (&#8220;ASU 2020-06&#8221;), which simplifies accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. The standard is effective for smaller reporting companies for fiscal years beginning after December 15, 2023 and interim periods within those fiscal years. The Company adopted the standard as of January 1, 2022. The adoption did not have a material impact on the Company&#8217;s financial statements. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the FASB issued ASU No. 2021-04, <span style="font-style:italic;">Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#8220;ASU 2021-04&#8221;)</span> which clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after a modification or exchange. This standard is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply this standard prospectively to modifications or exchanges occurring on or after the effective date of this standard. The Company adopted this standard as of January 1, 2022. The adoption did not have a material impact on the Company&#8217;s financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In November 2021, the FASB issued ASU 2021-10,</span><span style="font-style:italic;Background-color:#FFFFFF;">&#160;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span><span style="Background-color:#FFFFFF;">. This ASU requires certain disclosures when companies (a) have received government assistance and (b) use a grant or contribution accounting model by analogy to other accounting guidance. A company that has received government assistance must provide disclosures related to the nature of the transaction, accounting policies used to account for the transaction, and the amounts and line items on the financial statements that are affected by the transaction. This ASU is effective for fiscal years beginning after December 15, 2021, with early adoption permitted, and can be applied either prospectively or retrospectively. The Company adopted this standard as of January 1, 2022. </span>The adoption did not have a material impact on the Company&#8217;s financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_CostOfProductRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_CostOfProductRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_GeographicInformationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Geographic information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_GeographicInformationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_UnauditedInterimFinancialInformationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting unaudited interim financial information for the stated accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_UnauditedInterimFinancialInformationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126960819&amp;loc=d3e20905-112640<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724015362768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Customers Represent Greater Than 10% Of Revenue</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The following table shows customers that represent greater than 10% of revenue for the period presented: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer A</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer B</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer C</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Marketable Securities</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had no marketable securities at September 30, 2022. The following table summarizes the Company&#8217;s marketable securities at December 31, 2021 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#160; </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,996</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,996</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Maturities of Marketable Securities</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the maturities of the Company&#8217;s marketable securities at December 31, 2021 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:50%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due in less than 1 year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,996</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due in 1-2 years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,996</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue by Major Source</a></td>
<td class="text">The following table disaggregates our revenue by major source (in thousands):
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Instruments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">814</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">522</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,528</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,427</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consumables</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,822</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,765</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,442</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,150</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Instrument rentals</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total product revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,641</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,306</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,044</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,634</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contribution revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,036</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,122</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,778</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,444</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,677</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,428</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,822</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,078</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724025465328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities at Fair value on a Recurring Basis</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures the following financial assets at fair value on a recurring basis. There were no transfers between levels of the fair value hierarchy during any of the periods presented. The following tables set forth the Company&#8217;s financial assets and liabilities carried at fair value categorized using the lowest level of input applicable to each financial instrument as of September&#160;30, 2022 and December&#160;31, 2021 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in Active</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets for</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identical Assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative warrant liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.9%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,792</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,792</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.9%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,978</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,792</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in Active</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets for</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identical Assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US Treasury securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,996</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,996</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,996</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,996</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_SummaryOfContingentInterestPaymentsTableTextBlock', window );">Summary of Contingent Interest Payments</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated fair value of the derivative at September 30, 2022 was determined using a probability-weighted discounted cash flow model that includes contingent interest payments under the following scenarios:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:50%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Probability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4% contingent interest beginning in Q1 2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Roll-Forward of Fair Value of Derivative Liability</a></td>
<td class="text">The following table provides a roll-forward of the fair value of the derivative liability (in thousands):
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,675</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at June 30, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,675</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.38%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,792</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_SummaryOfContingentInterestPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of contingent interest payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_SummaryOfContingentInterestPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724025718832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis and are comprised of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,195</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,591</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work-in-process</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,231</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">953</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">816</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,365</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventories, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,242</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,909</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office and computer equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">749</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">749</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">783</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">783</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,573</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,507</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,445</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,445</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing tooling and molds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">478</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">478</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T2-owned instruments and components</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,150</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,668</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,785</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,768</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">774</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">512</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,934</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,107</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,432</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,734</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,675</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Components of Accrued Expenses</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,894</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,687</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,482</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,250</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional services</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">392</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">384</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">974</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,295</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,174</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">468</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">869</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,531</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,338</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724024672384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future principal payments on the notes payable are as follows (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term Loan Agreement including PIK interest, before unamortized discount and issuance costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,597</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,364</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: unaccrued paid-in-kind interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,233</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,287</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: unamortized discount and deferred issuance costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(176</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(287</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total notes payable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,188</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,790</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724019920256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of option activity under the Stock Incentive Plans and Inducement Plan (in thousands, except share and per share amounts): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price Per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197,171</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143.96</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000698">7.09</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,520</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.50</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,608</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42.64</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,863</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119.60</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193,220</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137.64</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000699">6.78</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at September 30, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,461</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186.38</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000700">5.90</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested or expected to vest at September 30, 2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182,864</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143.27</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000701">6.66</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Assumptions Used to Calculate Weighted-Average Grant Date Fair Value of Options Granted</a></td>
<td class="text">There were no options exercised in the nine months ended September 30, 2022 and 1,566 options exercised in the nine months ended September 30, 2021. The weighted-average grant date fair values of stock options granted in the nine month periods ended September&#160;30, 2022 and 2021 were $17.58 per share and $54.77 per share, respectively, and were calculated using the following estimated assumptions:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.27</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.92</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected terms</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0 years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0 years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of restricted stock unit activity under the 2014 Plan: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant&#160;Date&#160;Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value Per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.76%;" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,434</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91.77</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.76%;" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,575</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.79</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.76%;" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,352</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93.13</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.76%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,355</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42.40</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.76%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested at September 30, 2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,302</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48.32</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense for Stock Options Granted that was Recorded in the Company's Results of Operations</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the stock-based compensation expense resulting from awards granted under Stock Incentive Plans, the Inducement Plan and the 2014 ESPP, that was recorded in the Company&#8217;s results of operations for the periods presented (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">309</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">211</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">269</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">851</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">707</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,060</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,114</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,280</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,655</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,354</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,423</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,440</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,573</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724024848880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock or if-converted methods, because their effect would have been anti-dilutive for the periods presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three and Nine Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common shares</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193,220</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,352</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,302</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134,599</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,801</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,944</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A redeemable convertible preferred stock</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">485,323</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">342,895</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724016355200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 14, 2022</div></th>
<th class="th"><div>Oct. 12, 2022</div></th>
<th class="th"><div>Oct. 11, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 24, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 22, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 05, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_NatureOfBusinessLineItems', window );"><strong>Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 472,216,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,669,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,519,000<span></span>
</td>
<td class="nump">$ 25,651,000<span></span>
</td>
<td class="nump">$ 12,903,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,463,000<span></span>
</td>
<td class="num">$ (9,009,000)<span></span>
</td>
<td class="nump">$ 566,000<span></span>
</td>
<td class="num">$ (8,726,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_MinimumBidPriceOfCommonStock', window );">Bid price of common stock | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the changes in the number of shares resulting from the 50 to 1 reverse stock split that was approved by shareholders on October 11, 2022 and became effective as of October 12, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_MinimumMarketValueOfListedSecurities', window );">Minimum market value of listed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_NatureOfBusinessLineItems', window );"><strong>Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock trading price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_NatureOfBusinessLineItems', window );"><strong>Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_RegainComplianceByIncreasingStockPrice', window );">Regain compliance by increasing the stock price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ttoo_TermLoanAgreementMember', window );">Term Loan Agreement [Member] | CRG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_NatureOfBusinessLineItems', window );"><strong>Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Minimum cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_NatureOfBusinessLineItems', window );"><strong>Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On October 12, 2022, we effected a reverse stock split at the ratio of 1 post-split share for every 50 pre-split shares. All common stock amounts and references have been retroactively adjusted for all figures presented to reflect this split unless specifically stated otherwise<span></span>
</td>
<td class="text">On October 11, 2022, at the Company&#8217;s annual meeting of stockholders, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s restated certificate of incorporation to effect a reverse stock split of the Company&#8217;s common stock. Following the receipt of the stockholders&#8217; approval, the Company&#8217;s board of directors approved the reverse stock split at the ratio of 1 post-split share for every 50 pre-split shares, which was effective as of October 12, 2022. On October 31, 2022, the Company received a letter from Nasdaq informing the Company that it has regained compliance with the Bid Price Rule. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Term Loan Agreement [Member] | CRG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_NatureOfBusinessLineItems', window );"><strong>Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">Dec. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_MinimumBidPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum bid price of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_MinimumBidPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_MinimumMarketValueOfListedSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum market value of listed securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_MinimumMarketValueOfListedSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_NatureOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature of business line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_NatureOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_RegainComplianceByIncreasingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regain compliance by increasing stock price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_RegainComplianceByIncreasingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ttoo_TermLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ttoo_TermLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ttoo_CRGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ttoo_CRGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724015080096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 12, 2022</div></th>
<th class="th"><div>Oct. 11, 2022</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the changes in the number of shares resulting from the 50 to 1 reverse stock split that was approved by shareholders on October 11, 2022 and became effective as of October 12, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,677,000<span></span>
</td>
<td class="nump">$ 7,428,000<span></span>
</td>
<td class="nump">$ 16,822,000<span></span>
</td>
<td class="nump">$ 21,078,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Outstanding receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,578,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,578,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,134,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,996,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation', window );">Remaining performance obligation, expected timing of satisfaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company expects to recognize 86% of this amount as revenue within one year and the remainder within fifteen months.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized relating to contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202104Member', window );">Accounting Standards Update 2021-04 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202110Member', window );">Accounting Standards Update 2021-10 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Non-Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid and Other Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Costs to obtain or fulfill contract capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ttoo_T2DxMember', window );">T2 Dx [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_MaintenanceServicePeriod', window );">Maintenance Services period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_MaintenanceServiceTermOfAdditionalPeriod', window );">Additional period for Maintenance Service option (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed', window );">Original expected period of contracts for which value of unsatisfied performance obligations not to be disclosed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Other Non-Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Costs to obtain or fulfill contract capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Prepaid and Other Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Costs to obtain or fulfill contract capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Outstanding receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue [Member] | Geographic Concentration Risk [Member] | Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenue (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue [Member] | Geographic Concentration Risk [Member] | Non-US [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenue (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="nump">0.02<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split description</a></td>
<td class="text">On October 12, 2022, we effected a reverse stock split at the ratio of 1 post-split share for every 50 pre-split shares. All common stock amounts and references have been retroactively adjusted for all figures presented to reflect this split unless specifically stated otherwise<span></span>
</td>
<td class="text">On October 11, 2022, at the Company&#8217;s annual meeting of stockholders, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s restated certificate of incorporation to effect a reverse stock split of the Company&#8217;s common stock. Following the receipt of the stockholders&#8217; approval, the Company&#8217;s board of directors approved the reverse stock split at the ratio of 1 post-split share for every 50 pre-split shares, which was effective as of October 12, 2022. On October 31, 2022, the Company received a letter from Nasdaq informing the Company that it has regained compliance with the Bid Price Rule. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_MaintenanceServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The term following the installation of the purchased product for maintenance services which include warranty, maintenance, and technical support services, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_MaintenanceServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_MaintenanceServiceTermOfAdditionalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The additional term for maintenance services on purchased product (which include warranty, maintenance, and technical support services) that may be purchased for additional consideration, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_MaintenanceServiceTermOfAdditionalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Original expected period of contracts for which value of unsatisfied performance obligations not to be disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL120154346-209984<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL120154346-209984<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of when remaining performance obligation is expected to be recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202104Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202104Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202110Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202110Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ttoo_T2DxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ttoo_T2DxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724020206672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Customers Represent Greater Than 10% Of Revenue (Detail) - Customer Concentration Risk [Member] - Revenue [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ttoo_CustomerAMember', window );">Customer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenue (as a percent)</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ttoo_CustomerBMember', window );">Customer B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenue (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ttoo_CustomerCMember', window );">Customer C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenue (as a percent)</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ttoo_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ttoo_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ttoo_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ttoo_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ttoo_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ttoo_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724016249200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Marketable Securities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">9,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 9,996<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724015372576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Maturities of Marketable Securities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Marketable Securities, Amortized Cost, Due in less than 1 year</a></td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Marketable Securities, Fair Value, Due in less than 1 year</a></td>
<td class="nump">9,996<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities, Fair Value</a></td>
<td class="nump">$ 9,996<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724019884928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Disaggregation of Revenue by Major Resource (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 3,677<span></span>
</td>
<td class="nump">$ 7,428<span></span>
</td>
<td class="nump">$ 16,822<span></span>
</td>
<td class="nump">$ 21,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ttoo_ProductInstrumentsMember', window );">Product Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">814<span></span>
</td>
<td class="nump">522<span></span>
</td>
<td class="nump">2,528<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ttoo_ProductConsumablesMember', window );">Product Consumables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,822<span></span>
</td>
<td class="nump">3,765<span></span>
</td>
<td class="nump">6,442<span></span>
</td>
<td class="nump">11,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ttoo_InstrumentRentalsMember', window );">Instrument Rentals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">2,641<span></span>
</td>
<td class="nump">4,306<span></span>
</td>
<td class="nump">9,044<span></span>
</td>
<td class="nump">12,634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ttoo_ContributionRevenueMember', window );">Contribution Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 1,036<span></span>
</td>
<td class="nump">$ 3,122<span></span>
</td>
<td class="nump">$ 7,778<span></span>
</td>
<td class="nump">$ 8,444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ttoo_ProductInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ttoo_ProductInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ttoo_ProductConsumablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ttoo_ProductConsumablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ttoo_InstrumentRentalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ttoo_InstrumentRentalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ttoo_ContributionRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ttoo_ContributionRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724020201776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information 1 (Detail) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-10-01<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price that is allocated to unsatisfied or partially satisfied performance obligations, that has not yet been recognized as revenue</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Percentage of revenue recognition</a></td>
<td class="nump">86.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724020331040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Financial Assets and Liabilities at Fair value on a Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative warrant liability</a></td>
<td class="nump">$ 186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">1,792<span></span>
</td>
<td class="nump">$ 1,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative warrant liability</a></td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">1,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement [Member] | Recurring [Member] | U.S. Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Estimate of Fair Value Measurement [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Estimate of Fair Value Measurement [Member] | Recurring [Member] | U.S. Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Estimate of Fair Value Measurement [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative warrant liability</a></td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Estimate of Fair Value Measurement [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">1,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 1,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724021176880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">$ 1,792,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ttoo_CRGMember', window );">CRG [Member] | Term Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Accounts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Restricted cash</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ttoo_CRGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ttoo_CRGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ttoo_TermLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ttoo_TermLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724013254672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Contingent Interest Payments (Detail)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ttoo_ScenarioOneMember', window );">Contingent Interest Beginning in Q1 2023 [Member] | Measurement Input, Discount Rate [Member] | Term Loan Agreement [Member] | CRG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_FairValueDerivativeLiabilityDiscountRate', window );">4% contingent interest beginning in Q1 2023, probability</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_FairValueDerivativeLiabilityDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value derivative liability discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_FairValueDerivativeLiabilityDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ttoo_ScenarioOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ttoo_ScenarioOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ttoo_TermLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ttoo_TermLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ttoo_CRGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ttoo_CRGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724024812448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Contingent Interest Payments (Parenthetical) (Detail)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ttoo_CRGMember', window );">CRG [Member] | Term Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_ContingentPaymentOfInterestPercentage', window );">Contingent payment of interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_ContingentPaymentOfInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent payment of interest, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_ContingentPaymentOfInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ttoo_CRGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ttoo_CRGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ttoo_TermLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ttoo_TermLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724021510672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Roll-Forward of Fair Value of Derivative Liability (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Beginning balance</a></td>
<td class="nump">$ 1,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative instrument</a></td>
<td class="num">(117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,792)<span></span>
</td>
<td class="nump">$ 1,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Ending balance</a></td>
<td class="nump">1,792<span></span>
</td>
<td class="nump">$ 1,675<span></span>
</td>
<td class="nump">$ 1,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=ttoo_ProbabilityWeightedDiscountedCashFlowModelMember', window );">Probability Weighted Discounted Cash Flow Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative instrument</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 1,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=ttoo_ProbabilityWeightedDiscountedCashFlowModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=ttoo_ProbabilityWeightedDiscountedCashFlowModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724021752480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Cash - Additional Information (Detail) - Money Market Accounts [Member]<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>Facility</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Facility</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash And Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposits | $</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_NumberOfFacilities', window );">Number of facilities | Facility</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_NumberOfFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_NumberOfFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724021605728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Schedule of Inventory (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 2,195<span></span>
</td>
<td class="nump">$ 1,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">816<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories, net</a></td>
<td class="nump">$ 4,242<span></span>
</td>
<td class="nump">$ 3,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724019890256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Schedule of Property and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 20,934<span></span>
</td>
<td class="nump">$ 20,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(16,200)<span></span>
</td>
<td class="num">(15,432)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,734<span></span>
</td>
<td class="nump">4,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office and Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">749<span></span>
</td>
<td class="nump">749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">783<span></span>
</td>
<td class="nump">783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,573<span></span>
</td>
<td class="nump">5,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,445<span></span>
</td>
<td class="nump">1,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember', window );">Manufacturing Tooling and Molds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">478<span></span>
</td>
<td class="nump">478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ttoo_T2DxInstrumentsAndComponentsMember', window );">T2-Owned Instruments and Components [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">7,150<span></span>
</td>
<td class="nump">6,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,785<span></span>
</td>
<td class="nump">3,768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 774<span></span>
</td>
<td class="nump">$ 512<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ttoo_T2DxInstrumentsAndComponentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ttoo_T2DxInstrumentsAndComponentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724020185776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_SupplementalBalanceSheetInformationLineItems', window );"><strong>Supplemental Balance Sheet Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessAndRawMaterials', window );">Raw materials and work-in-process inventory</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 792<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ttoo_T2OwnedInstrumentsInServiceMember', window );">T2 Owned Instruments in Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_SupplementalBalanceSheetInformationLineItems', window );"><strong>Supplemental Balance Sheet Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ttoo_T2OwnedInstrumentsInServiceMember', window );">T2 Owned Instruments in Service [Member] | Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_SupplementalBalanceSheetInformationLineItems', window );"><strong>Supplemental Balance Sheet Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciation', window );">Depreciation expense recorded as a component of cost of product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_SupplementalBalanceSheetInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental balance sheet information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_SupplementalBalanceSheetInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessAndRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessAndRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ttoo_T2OwnedInstrumentsInServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ttoo_T2OwnedInstrumentsInServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724021152080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Components of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and compensation</a></td>
<td class="nump">$ 3,894<span></span>
</td>
<td class="nump">$ 3,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_AccruedResearchAndDevelopmentExpensesCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">1,482<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,295<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">468<span></span>
</td>
<td class="nump">869<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 8,531<span></span>
</td>
<td class="nump">$ 8,338<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for research and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724025868640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable - Schedule of Debt (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts', window );">Term Loan Agreement including PIK interest, before unamortized discount and issuance costs</a></td>
<td class="nump">$ 51,597<span></span>
</td>
<td class="nump">$ 49,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_DebtInstrumentUnaccruedPaidInKindInterest', window );">Less: unaccrued paid-in-kind interest</a></td>
<td class="num">(2,233)<span></span>
</td>
<td class="num">(1,287)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized discount and deferred issuance costs</a></td>
<td class="num">(176)<span></span>
</td>
<td class="num">(287)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Total notes payable</a></td>
<td class="nump">$ 49,188<span></span>
</td>
<td class="nump">$ 47,790<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument carrying amount including paid in kind interest before unamortized discount and issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_DebtInstrumentUnaccruedPaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument unaccrued paid in kind interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_DebtInstrumentUnaccruedPaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724020246240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable - Term Loan Agreement - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 14, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares issuable for warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ttoo_CRGMember', window );">CRG [Member] | Term Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_DebtInstrumentTermOfInterestOnlyPayments', window );">Debt instrument, term of interest-only payments (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_DebtInstrumentFinalPaymentFeePercentage', window );">Final fee as a percentage of the principal outstanding (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual fixed rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_DebtInstrumentDeferredInterestRateInterestOnlyPayment', window );">Deferred interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_DebtInstrumentPrepaymentFeeTerm', window );">Debt instrument, prepayment fee term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Minimum cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_DebtInstrumentEventOfDefaultAdditionalInterestRate', window );">Additional interest rate, event of default (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ttoo_CRGMember', window );">CRG [Member] | Term Loan Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">Dec. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_DebtInstrumentDeferredInterestRateInterestOnlyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual deferred interest rate during interest only payments for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_DebtInstrumentDeferredInterestRateInterestOnlyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_DebtInstrumentEventOfDefaultAdditionalInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional interest rate on all outstanding obligations during the occurrence and continuance of an event of default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_DebtInstrumentEventOfDefaultAdditionalInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_DebtInstrumentFinalPaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final fee as a percentage of the amount of principal outstanding upon repayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_DebtInstrumentFinalPaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_DebtInstrumentPrepaymentFeeTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment fee period of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_DebtInstrumentPrepaymentFeeTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_DebtInstrumentTermOfInterestOnlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument of interest only payments, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_DebtInstrumentTermOfInterestOnlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ttoo_CRGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ttoo_CRGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ttoo_TermLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ttoo_TermLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724015004032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series A Redeemable Convertible Preferred Stock and Related Warrant - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 15, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Series A redeemable convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Series A redeemable convertible preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ttoo_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants exercisable date</a></td>
<td class="text">Feb. 15,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_ClassOfWarrantOrRightMaturityDate', window );">Warrants maturity term</a></td>
<td class="text">Feb. 15,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares', window );">Warrant liability</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares issuable for warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,365<span></span>
</td>
<td class="nump">10,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.50<span></span>
</td>
<td class="nump">$ 77.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares issuable for warrants outstanding (in shares)</a></td>
<td class="nump">42,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable', window );">Aggregate subscription amount</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ttoo_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member] | Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Series A redeemable convertible preferred stock, shares issued</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Series A redeemable convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Temporary equity issued, price per share</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price of preferred shares</a></td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionDate', window );">Conversion date of preferred shares</a></td>
<td class="text">Oct. 12,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_PreferredStockPricePercentageOnStatedValue', window );">Preferred stock price percentage on stated value</a></td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock', window );">Preferred stock price percentage on stated value, held by holders of preferred stock</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares', window );">Preferred stock price percentage on stated value, automatically redeemable upon delisting of common shares</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Series A Redeemable Convertible Preferred Stock will have no voting rights other than the right to vote on certain matters. Each share of Series A Redeemable Convertible Preferred entitles the holder to 1,000,000 votes on a proposal to approve a reverse stock split of the Company&#8217;s outstanding common stock (the &#8220;Proposal&#8221;) and any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Proposal; provided, however, that such shares of Series A Redeemable Convertible Preferred Stock shall be voted in the same proportion as the shares of common stock (excluding any shares of common stock that are not voted)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ttoo_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member] | Purchase Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price of preferred shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_ClassOfWarrantOrRightMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_ClassOfWarrantOrRightMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_PreferredStockPricePercentageOnStatedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock price percentage on stated value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_PreferredStockPricePercentageOnStatedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock price percentage on stated value, automatically redeemable upon delisting of common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock price percentage on stated value, held by holders of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when preferred stock can be converted into common shares, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of shares that would be issued, determined under the conditions specified in the contract if the settlement were to occur at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109262807&amp;loc=d3e22047-110879<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ttoo_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ttoo_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ttoo_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ttoo_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724020136096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jul. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 01, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ttoo_NewSalesAgreementMember', window );">New Sales Agreement [Member] | Canaccord [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_ProceedsFromIssuanceOfCommonStockGross', window );">Aggregate gross sales amount of common stock</a></td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_PercentageOfAgentServiceFee', window );">Percentage of agent service fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued/sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,080,451<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,668,784<span></span>
</td>
<td class="nump">336,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,100,000<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ttoo_OriginalSalesAgreementMember', window );">Original Sales Agreement | Canaccord [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_PercentageOfAgentServiceFee', window );">Percentage of agent service fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_PercentageOfAgentServiceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of agent service fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_PercentageOfAgentServiceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock, gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ttoo_NewSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ttoo_NewSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ttoo_CanaccordGenuityLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ttoo_CanaccordGenuityLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ttoo_OriginalSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ttoo_OriginalSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724015130272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Aug. 06, 2020</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,354,000<span></span>
</td>
<td class="nump">$ 2,423,000<span></span>
</td>
<td class="nump">5,440,000<span></span>
</td>
<td class="nump">5,573,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">$ 7,017,000<span></span>
</td>
<td class="nump">8,536,000<span></span>
</td>
<td class="nump">$ 24,071,000<span></span>
</td>
<td class="nump">21,983,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Type I Modification [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Type III Modification [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="nump">29,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares available for authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of full share price paid in purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_MaximumAmountOfAnnualEmployeeCommonStockPurchase', window );">Maximum amount of annual employee common stock purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to unvested stock options</a></td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ttoo_StockOptionPlan2014Member', window );">2014 Stock Option Plan [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_ComponentOfCommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance under stock incentive plan</a></td>
<td class="nump">16,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_PercentageOfCommonSharesOutstanding', window );">Percentage of common shares outstanding</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="nump">52,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ttoo_InducementAwardPlanMember', window );">Inducement Award Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="nump">84,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares available for authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember', window );">2006 and 2014 Stock Option Plans [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue', window );">Aggregate fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to non-vested stock options</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember', window );">2006 and 2014 Stock Option Plans and Inducement Plan [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.58<span></span>
</td>
<td class="nump">$ 54.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember', window );">2006 and 2014 Stock Option Plans and Inducement Plan [Member] | Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue', window );">Aggregate fair value of restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 2006 Stock Option Plan [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 2014 Stock Option Plan [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_ComponentOfCommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Component of common stock capital shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_ComponentOfCommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_MaximumAmountOfAnnualEmployeeCommonStockPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of annual employee common stock purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_MaximumAmountOfAnnualEmployeeCommonStockPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_PercentageOfCommonSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of common share outstanding, as it relates to the number of shares reserved for future issuance calculation under the 2014 Stock Incentive Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_PercentageOfCommonSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options grants in period gross value grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award other than options grants in period gross value grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ttoo_TypeIModificationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ttoo_TypeIModificationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ttoo_TypeIIIModificationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ttoo_TypeIIIModificationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ttoo_StockOptionPlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ttoo_StockOptionPlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ttoo_EmployeeAndNonemployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ttoo_EmployeeAndNonemployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ttoo_InducementAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ttoo_InducementAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ttoo_StockOptionPlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ttoo_StockOptionPlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724013261520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Detail) - 2006 and 2014 Stock Option Plans and Inducement Plan [Member] - Stock Options [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, beginning of the period</a></td>
<td class="nump">197,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="nump">33,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,566)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Forfeited</a></td>
<td class="num">(25,608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Shares, Cancelled</a></td>
<td class="num">(11,863)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, end of the period</a></td>
<td class="nump">193,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable</a></td>
<td class="nump">127,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Shares, Vested or expected to vest</a></td>
<td class="nump">182,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share Outstanding, beginning of the period</a></td>
<td class="nump">$ 143.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Granted</a></td>
<td class="nump">21.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Forfeited</a></td>
<td class="nump">42.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Cancelled</a></td>
<td class="nump">119.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share Outstanding, end of the period</a></td>
<td class="nump">137.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable</a></td>
<td class="nump">186.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Vested or expected to vest</a></td>
<td class="nump">$ 143.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">6 years 9 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 1 month 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Vested or expected to vest</a></td>
<td class="text">6 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ttoo_EmployeeAndNonemployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ttoo_EmployeeAndNonemployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724020007104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Estimated Assumptions Used to Calculate Weighted-Average Grant Date Fair Value of Options Granted (Detail) - Stock Options [Member] - 2006 and 2014 Stock Option Plans and Inducement Plan [Member]<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted-average risk-free interest rate</a></td>
<td class="nump">2.27%<span></span>
</td>
<td class="nump">0.92%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">106.00%<span></span>
</td>
<td class="nump">104.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected terms</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ttoo_EmployeeAndNonemployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ttoo_EmployeeAndNonemployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724020178528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Nonvested Restricted Stock Units Activity (Detail) - 2014 Stock Option Plan [Member] - Restricted Stock Units [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Nonvested restricted shares at the beginning of the period | shares</a></td>
<td class="nump">142,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Restricted shares granted | shares</a></td>
<td class="nump">160,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Restricted shares vested | shares</a></td>
<td class="num">(50,352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Restricted shares forfeited | shares</a></td>
<td class="num">(28,355)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Nonvested restricted shares at the end of the period | shares</a></td>
<td class="nump">224,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Nonvested restricted shares at the beginning of the period | $ / shares</a></td>
<td class="nump">$ 91.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">22.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">93.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">42.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Nonvested restricted shares at the end of the period | $ / shares</a></td>
<td class="nump">$ 48.32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ttoo_StockOptionPlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ttoo_StockOptionPlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724019653584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted that was Recorded in the Company's Results of Operations (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,354<span></span>
</td>
<td class="nump">$ 2,423<span></span>
</td>
<td class="nump">$ 5,440<span></span>
</td>
<td class="nump">$ 5,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">851<span></span>
</td>
<td class="nump">707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,060<span></span>
</td>
<td class="nump">$ 2,114<span></span>
</td>
<td class="nump">$ 4,280<span></span>
</td>
<td class="nump">$ 4,655<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724021173344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants Associated with Term Loan - Additional Information (Detail) - Common Stock [Member] - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares issuable for warrants outstanding</a></td>
<td class="nump">11,365<span></span>
</td>
<td class="nump">10,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 77.50<span></span>
</td>
<td class="nump">$ 77.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724020319216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Net loss attributable to common stockholders | $</a></td>
<td class="nump">$ 330<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the changes in the number of shares resulting from the 50 to 1 reverse stock split that was approved by shareholders on October 11, 2022 and became effective as of October 12, 2022.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_StockIssuedAndOutstandingDuringPeriodSharesStockSplits', window );">Shares issued and outstanding immediately before the reverse stock split | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,957,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_StockOutstandingDuringPeriodSharesStockSplits', window );">Shares outstanding immediately after the reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7,059,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Remaining shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,898,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ttoo_SeriesAConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Net loss attributable to common stockholders | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_StockIssuedAndOutstandingDuringPeriodSharesStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued and outstanding during the period as a result of a stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_StockIssuedAndOutstandingDuringPeriodSharesStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_StockOutstandingDuringPeriodSharesStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares outstanding during the period as a result of a stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_StockOutstandingDuringPeriodSharesStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDividendsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDividendsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ttoo_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ttoo_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724015089552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the computation of diluted net loss per share</a></td>
<td class="nump">485,323<span></span>
</td>
<td class="nump">342,895<span></span>
</td>
<td class="nump">485,323<span></span>
</td>
<td class="nump">342,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the computation of diluted net loss per share</a></td>
<td class="nump">193,220<span></span>
</td>
<td class="nump">186,352<span></span>
</td>
<td class="nump">193,220<span></span>
</td>
<td class="nump">186,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the computation of diluted net loss per share</a></td>
<td class="nump">224,302<span></span>
</td>
<td class="nump">134,599<span></span>
</td>
<td class="nump">224,302<span></span>
</td>
<td class="nump">134,599<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the computation of diluted net loss per share</a></td>
<td class="nump">64,801<span></span>
</td>
<td class="nump">21,944<span></span>
</td>
<td class="nump">64,801<span></span>
</td>
<td class="nump">21,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ttoo_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the computation of diluted net loss per share</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ttoo_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ttoo_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724019568192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>US Government Contract - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,677,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,428,000<span></span>
</td>
<td class="nump">$ 16,822,000<span></span>
</td>
<td class="nump">$ 21,078,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ttoo_ContributionMember', window );">Contribution [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,036,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,122,000<span></span>
</td>
<td class="nump">7,778,000<span></span>
</td>
<td class="nump">8,444,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ttoo_CoDevelopmentPartnershipAgreementMember', window );">Co Development Partnership Agreement [Member] | Biomedical Advanced Research and Development Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_CollaborativeArrangementInitialValueOfConsideration', window );">Initial value of consideration receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_CollaborativeArrangementFirstContractOptionValueExercised', window );">First contract option value exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_CollaborativeArrangementOptionContractValueExercised', window );">Option contract value exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_CollaborativeArrangementAdditionalFundingAmountReceived', window );">Collaborative arrangement additional funding amount received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_CollaborativeArrangementAdditionalFundingAmountToBeReceived', window );">Collaborative arrangement additional funding amount to be received</a></td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ttoo_CoDevelopmentPartnershipAgreementMember', window );">Co Development Partnership Agreement [Member] | Biomedical Advanced Research and Development Authority [Member] | Contribution [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="nump">$ 7,800,000<span></span>
</td>
<td class="nump">$ 8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ttoo_CoDevelopmentPartnershipAgreementMember', window );">Co Development Partnership Agreement [Member] | Biomedical Advanced Research and Development Authority [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_CollaborativeArrangementAggregateConsideration', window );">Aggregate consideration receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_CollaborativeArrangementAdditionalFundingAmountReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement Additional Funding Amount Received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_CollaborativeArrangementAdditionalFundingAmountReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_CollaborativeArrangementAdditionalFundingAmountToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement additional funding amount to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_CollaborativeArrangementAdditionalFundingAmountToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_CollaborativeArrangementAggregateConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate consideration receivable under collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_CollaborativeArrangementAggregateConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_CollaborativeArrangementFirstContractOptionValueExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement first contract option value exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_CollaborativeArrangementFirstContractOptionValueExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_CollaborativeArrangementInitialValueOfConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement initial value of consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_CollaborativeArrangementInitialValueOfConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_CollaborativeArrangementOptionContractValueExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement option contract value exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_CollaborativeArrangementOptionContractValueExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126942793&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ttoo_ContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ttoo_ContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ttoo_CoDevelopmentPartnershipAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ttoo_CoDevelopmentPartnershipAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ttoo_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ttoo_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724015440544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Apr. 30, 2015</div></th>
<th class="th"><div>Nov. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,058,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,058,000<span></span>
</td>
<td class="nump">$ 9,766,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ttoo_LicenseAgreementMember', window );">License Agreement [Member] | Operating Lease Entered into November 2014 [Member] | Office Space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_LesseeOperatingLeaseTerminationPeriod', window );">Lease termination date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ttoo_OfficeSpaceLaboratorySpaceAndEquipmentMember', window );">Office Space, Laboratory Space, and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities', window );">Maximum lease period to not recognize right of use assets or lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ttoo_OfficeLaboratoryAndManufacturingSpaceMember', window );">Office Laboratory And Manufacturing Space | Operating Leases Entered Into May2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ttoo_LaboratorySpaceMember', window );">Laboratory Space [Member] | Operating Lease Entered into November 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 281,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of lease</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncentiveFromLessor', window );">Space build-out costs paid</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_SpaceBuildOutCosts', window );">Space build-out costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_SecurityDepositReceived', window );">Security deposit received from landlord</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ttoo_OfficeResearchLaboratoryAndManufacturingSpaceMember', window );">Office, Research, Laboratory and Manufacturing Space [Member] | Operating Leases Entered Into September 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_TermOfLease', window );">Term of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">126 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_LeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_LeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_LesseeOperatingLeaseTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease termination period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_LesseeOperatingLeaseTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum lease period to not recognize right of use assets or lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_SecurityDepositReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Security deposit received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_SecurityDepositReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_SpaceBuildOutCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Space build-out costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_SpaceBuildOutCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_TermOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_TermOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveFromLessor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of incentive received by lessee from lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39896-112707<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 30<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123388062&amp;loc=SL77916639-209961<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 55<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123386226&amp;loc=d3e41620-112719<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e40010-112707<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveFromLessor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ttoo_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ttoo_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ttoo_OperatingLeasesEnteredIntoNovember2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ttoo_OperatingLeasesEnteredIntoNovember2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ttoo_OfficeSpaceLaboratorySpaceAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ttoo_OfficeSpaceLaboratorySpaceAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ttoo_OfficeLaboratoryAndManufacturingSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ttoo_OfficeLaboratoryAndManufacturingSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ttoo_OperatingLeasesEnteredIntoMay2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ttoo_OperatingLeasesEnteredIntoMay2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ttoo_LaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ttoo_LaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ttoo_OfficeResearchLaboratoryAndManufacturingSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ttoo_OfficeResearchLaboratoryAndManufacturingSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ttoo_OperatingLeasesEnteredIntoSeptember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ttoo_OperatingLeasesEnteredIntoSeptember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724015093712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - License Agreement [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2007</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2006</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_RoyaltyOnNetSalesSublicensingGrossRevenue', window );">Royalty on net sales sublicensing gross revenue</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalties accrued</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_LicenseFeesPayable', window );">Annual license fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_PercentageOfRoyaltyOnNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_LicenseFeesPayable', window );">Annual license fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ttoo_PercentageOfRoyaltyOnNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_LicenseFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of annual licensing fees agreed to be paid by the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_LicenseFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_PercentageOfRoyaltyOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_PercentageOfRoyaltyOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ttoo_RoyaltyOnNetSalesSublicensingGrossRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty on net sales sublicensing gross revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ttoo_RoyaltyOnNetSalesSublicensingGrossRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ttoo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ttoo_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ttoo_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139724013030112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 12, 2022</div></th>
<th class="th">
<div>Oct. 11, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 09, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 26, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 15, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the changes in the number of shares resulting from the 50 to 1 reverse stock split that was approved by shareholders on October 11, 2022 and became effective as of October 12, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Stock issued during period, shares, stock splits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,898,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,050,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,050,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,328,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,050,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,050,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,328,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from secondary offering, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,080,451<span></span>
</td>
<td class="nump">517,352<span></span>
</td>
<td class="nump">70,981<span></span>
</td>
<td class="nump">336,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,050,849<span></span>
</td>
<td class="nump">3,968,983<span></span>
</td>
<td class="nump">3,428,245<span></span>
</td>
<td class="nump">3,315,273<span></span>
</td>
<td class="nump">7,050,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,328,017<span></span>
</td>
<td class="nump">3,319,355<span></span>
</td>
<td class="nump">2,969,832<span></span>
</td>
<td class="nump">2,961,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="nump">0.02<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split description</a></td>
<td class="text">On October 12, 2022, we effected a reverse stock split at the ratio of 1 post-split share for every 50 pre-split shares. All common stock amounts and references have been retroactively adjusted for all figures presented to reflect this split unless specifically stated otherwise<span></span>
</td>
<td class="text">On October 11, 2022, at the Company&#8217;s annual meeting of stockholders, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s restated certificate of incorporation to effect a reverse stock split of the Company&#8217;s common stock. Following the receipt of the stockholders&#8217; approval, the Company&#8217;s board of directors approved the reverse stock split at the ratio of 1 post-split share for every 50 pre-split shares, which was effective as of October 12, 2022. On October 31, 2022, the Company received a letter from Nasdaq informing the Company that it has regained compliance with the Bid Price Rule. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">50 shares of issued and outstanding common stock of the Company were automatically reclassified and combined into 1 share of common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Stock issued during period, shares, stock splits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,059,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,059,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ttoo_NewSalesAgreementMember', window );">New Sales Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from secondary offering, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ttoo_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Series A Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ttoo_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Subsequent Event [Member] | Series A Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable', window );">Aggregate amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated nonredeemable preferred stock or preferred stock redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ttoo_NewSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ttoo_NewSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ttoo_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ttoo_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ttoo_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ttoo_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>ttoo-10q_20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:ttoo="http://www.t2biosystems.com/20220930"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ttoo-20220930.xsd" xlink:type="simple"/>
    <context id="C_0001492674_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_20221108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <instant>2022-11-08</instant>
        </period>
    </context>
    <context id="C_0001492674_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooContributionMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooContributionMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooContributionMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooContributionMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001492674_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001492674_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0001492674_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001492674_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001492674_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220401_20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_20220401_20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220401_20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20220401_20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220401_20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_0001492674_20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ttoo:CRGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttoo:TermLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220201_20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ttoo:CRGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttoo:TermLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221113_20221114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ttoo:CRGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttoo:TermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-13</startDate>
            <endDate>2022-11-14</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtRangeAxis_srtMaximumMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_20211105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <instant>2021-11-05</instant>
        </period>
    </context>
    <context id="C_0001492674_srtRangeAxis_srtMinimumMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011_20221011">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-11</startDate>
            <endDate>2022-10-11</endDate>
        </period>
    </context>
    <context id="C_0001492674_20220722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <instant>2022-07-22</instant>
        </period>
    </context>
    <context id="C_0001492674_20220824">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <instant>2022-08-24</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221012_20221012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-12</startDate>
            <endDate>2022-10-12</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtMajorCustomersAxis_ttooCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ttoo:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtMajorCustomersAxis_ttooCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ttoo:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtMajorCustomersAxis_ttooCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ttoo:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtMajorCustomersAxis_ttooCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ttoo:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtMajorCustomersAxis_ttooCustomerBMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ttoo:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtMajorCustomersAxis_ttooCustomerBMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ttoo:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtMajorCustomersAxis_ttooCustomerCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ttoo:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooT2DxMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:T2DxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooProductInstrumentsMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ProductInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooProductInstrumentsMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ProductInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooProductInstrumentsMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ProductInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooProductInstrumentsMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ProductInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooProductConsumablesMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ProductConsumablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooProductConsumablesMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ProductConsumablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooProductConsumablesMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ProductConsumablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooProductConsumablesMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ProductConsumablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooInstrumentRentalsMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:InstrumentRentalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooInstrumentRentalsMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:InstrumentRentalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooInstrumentRentalsMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:InstrumentRentalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooInstrumentRentalsMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:InstrumentRentalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooContributionRevenueMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooContributionRevenueMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooContributionRevenueMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_ttooContributionRevenueMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtRangeAxis_srtMaximumMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-10-01_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentAssetsMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentAssetsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202006Member_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202104Member_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202104Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202110Member_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202110Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ttoo:CRGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttoo:TermLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapContingentConsiderationByTypeAxis_ttooScenarioOneMember_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ttoo:ScenarioOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ttoo:CRGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttoo:TermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ttoo:CRGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttoo:TermLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapValuationTechniqueAxis_ttooProbabilityWeightedDiscountedCashFlowModelMember_20220101_20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ttoo:ProbabilityWeightedDiscountedCashFlowModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapValuationTechniqueAxis_ttooProbabilityWeightedDiscountedCashFlowModelMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ttoo:ProbabilityWeightedDiscountedCashFlowModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapToolsDiesAndMoldsMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapToolsDiesAndMoldsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooT2DxInstrumentsAndComponentsMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:T2DxInstrumentsAndComponentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooT2DxInstrumentsAndComponentsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:T2DxInstrumentsAndComponentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooT2OwnedInstrumentsInServiceMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:T2OwnedInstrumentsInServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooT2OwnedInstrumentsInServiceMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:T2OwnedInstrumentsInServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooT2OwnedInstrumentsInServiceMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:T2OwnedInstrumentsInServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161201_20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ttoo:CRGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttoo:TermLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ttoo:CRGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttoo:TermLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ttoo:CRGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttoo:TermLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ttoo:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ttoo:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ttoo:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815_20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-15</startDate>
            <endDate>2022-08-15</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="C_0001492674_20210701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20210330_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ttoo:CanaccordGenuityLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-30</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooOriginalSalesAgreementMember_20190730_20190730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ttoo:CanaccordGenuityLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:OriginalSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-30</startDate>
            <endDate>2019-07-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20190730_20190730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ttoo:CanaccordGenuityLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-30</startDate>
            <endDate>2019-07-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ttoo:CanaccordGenuityLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ttoo:CanaccordGenuityLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ttoo:CanaccordGenuityLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ttoo:CanaccordGenuityLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2006Member_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPlanNameAxis_ttooInducementAwardPlanMember_20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:InducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPlanNameAxis_ttooInducementAwardPlanMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:InducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttoo:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttoo:StockOptionPlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-06</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIModificationMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:TypeIModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIModificationMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:TypeIModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIIIModificationMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:TypeIIIModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIIIModificationMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:TypeIIIModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesAConvertiblePreferredStockMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ttoo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ttoo:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ttoo:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20200901_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20210901_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20220101_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20220901_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srtProductOrServiceAxis_ttooContributionMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20220701_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srtProductOrServiceAxis_ttooContributionMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srtProductOrServiceAxis_ttooContributionMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srtProductOrServiceAxis_ttooContributionMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20210101_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ttoo:ContributionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttoo:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:CoDevelopmentPartnershipAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeSpaceLaboratorySpaceAndEquipmentMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:OfficeSpaceLaboratorySpaceAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeSpaceLaboratorySpaceAndEquipmentMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:OfficeSpaceLaboratorySpaceAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtMortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_srtOfficeBuildingMember_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20150401_20150430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoNovember2014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-04-01</startDate>
            <endDate>2015-04-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtMortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_srtOfficeBuildingMember_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20170901_20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoNovember2014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoMay2013Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeLaboratoryAndManufacturingSpaceMember_20180801_20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoMay2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:OfficeLaboratoryAndManufacturingSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoMay2013Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeLaboratoryAndManufacturingSpaceMember_20201001_20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoMay2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:OfficeLaboratoryAndManufacturingSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoMay2013Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeLaboratoryAndManufacturingSpaceMember_20220901_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoMay2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:OfficeLaboratoryAndManufacturingSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtMortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_srtOfficeBuildingMember_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20141130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoNovember2014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-30</instant>
        </period>
    </context>
    <context id="C_0001492674_srtMortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_srtOfficeBuildingMember_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20141130_20141130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoNovember2014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-11-30</startDate>
            <endDate>2014-11-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoMay2013Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeLaboratoryAndManufacturingSpaceMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoMay2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:OfficeLaboratoryAndManufacturingSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20141130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoNovember2014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:LaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoNovember2014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:LaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20141101_20141130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoNovember2014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:LaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-11-01</startDate>
            <endDate>2014-11-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20201001_20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoNovember2014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:LaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoNovember2014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:LaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoNovember2014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:LaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoSeptember2021Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeResearchLaboratoryAndManufacturingSpaceMember_20210901_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoSeptember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:OfficeResearchLaboratoryAndManufacturingSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoSeptember2021Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeResearchLaboratoryAndManufacturingSpaceMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ttoo:OperatingLeasesEnteredIntoSeptember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ttoo:OfficeResearchLaboratoryAndManufacturingSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20061231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2006-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20061231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2006-12-31</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20060101_20071231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-01-01</startDate>
            <endDate>2007-12-31</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20220101_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttoo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20221001_20221109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-11-09</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011_20221011">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-11</startDate>
            <endDate>2022-10-11</endDate>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-11</instant>
        </period>
    </context>
    <context id="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20221026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001492674</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ttoo:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttoo:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-26</instant>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_ttooSegment">
        <measure>ttoo:Segment</measure>
    </unit>
    <unit id="U_ttooFacility">
        <measure>ttoo:Facility</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001492674_20220101_20220930" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="C_0001492674_20220101_20220930" id="F_000003">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001492674_20220101_20220930" id="F_000004">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001492674_20220101_20220930" id="F_000007">0001492674</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001492674_20220101_20220930" id="F_000008">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011_20221011"
      decimals="2"
      id="F_000445_2"
      unitRef="U_xbrlipure">0.02</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221012_20221012"
      decimals="2"
      id="F_000449"
      unitRef="U_xbrlipure">0.02</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202006Member_20220930"
      id="F_000524">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202006Member_20220930"
      id="F_000526">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202104Member_20220930"
      id="F_000527">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202104Member_20220930"
      id="F_000529">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202110Member_20220930"
      id="F_000530">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202110Member_20220930"
      id="F_000532">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001492674_20220101_20220930"
      decimals="2"
      id="F_000785"
      unitRef="U_xbrlipure">0.02</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011_20221011"
      decimals="2"
      id="F_000835"
      unitRef="U_xbrlipure">0.02</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011_20221011"
      decimals="2"
      id="F_000445"
      unitRef="U_xbrlipure">0.02</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221012_20221012"
      decimals="2"
      id="F_000449_2"
      unitRef="U_xbrlipure">0.02</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <ttoo:MaintenanceServiceTermOfAdditionalPeriod
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooT2DxMember_20220101_20220930"
      id="F_000485">P1Y</ttoo:MaintenanceServiceTermOfAdditionalPeriod>
    <us-gaap:DebtInstrumentTerm
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161201_20161231"
      id="F_000624">P6Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001492674_20220101_20220930"
      decimals="2"
      id="F_000785_2"
      unitRef="U_xbrlipure">0.02</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoMay2013Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeLaboratoryAndManufacturingSpaceMember_20180801_20180831"
      id="F_000807">2020-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011_20221011"
      decimals="2"
      id="F_000835_2"
      unitRef="U_xbrlipure">0.02</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20210101_20211231"
      id="F_000698">P7Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930"
      id="F_000699">P6Y9M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930"
      id="F_000700">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930"
      id="F_000701">P6Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001492674_20220930"
      id="F_000068"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001492674_20211231"
      id="F_000069"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001492674_20220930"
      id="F_000071"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001492674_20211231"
      id="F_000072"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="C_0001492674_20220101_20220930" id="F_000000">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="C_0001492674_20220101_20220930" id="F_000026">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001492674_20220101_20220930" id="F_000002">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="C_0001492674_20220101_20220930" id="F_000027">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001492674_20220101_20220930" id="F_000014">001-36571</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001492674_20220101_20220930" id="F_000006">T2 Biosystems, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001492674_20220101_20220930" id="F_000025">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001492674_20220101_20220930" id="F_000015">20-4827488</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001492674_20220101_20220930" id="F_000016">101 Hartwell Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0001492674_20220101_20220930" id="F_000017">Lexington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001492674_20220101_20220930" id="F_000018">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001492674_20220101_20220930" id="F_000019">02421</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001492674_20220101_20220930" id="F_000020">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001492674_20220101_20220930" id="F_000021">761-4646</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001492674_20220101_20220930" id="F_000023">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001492674_20220101_20220930" id="F_000005">TTOO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001492674_20220101_20220930" id="F_000024">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="C_0001492674_20220101_20220930" id="F_000012">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001492674_20220101_20220930" id="F_000022">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001492674_20220101_20220930" id="F_000009">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001492674_20220101_20220930" id="F_000010">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001492674_20220101_20220930" id="F_000011">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="C_0001492674_20220101_20220930" id="F_000013">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001492674_20221108"
      decimals="INF"
      id="F_000028"
      unitRef="U_xbrlishares">7319105</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000029"
      unitRef="U_iso4217USD">20366000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000030"
      unitRef="U_iso4217USD">22245000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000031"
      unitRef="U_iso4217USD">9996000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000032"
      unitRef="U_iso4217USD">1578000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000033"
      unitRef="U_iso4217USD">5134000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000034"
      unitRef="U_iso4217USD">4242000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000035"
      unitRef="U_iso4217USD">3909000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">2690000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">3110000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">28876000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">44394000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">4734000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">4675000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">9058000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">9766000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">1131000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">1551000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">153000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">153000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">43952000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">60539000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">2063000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">2832000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">8531000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">8338000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">186000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">163000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">518000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">10943000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">11688000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">49188000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">47790000</us-gaap:LongTermNotesPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">8569000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">9359000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">8000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">28000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">1792000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">4791000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">4577000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_0001492674_20220930"
      decimals="INF"
      id="F_000084"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001492674_20220930"
      decimals="INF"
      id="F_000085"
      unitRef="U_xbrlishares">3000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001492674_20220930"
      decimals="INF"
      id="F_000086"
      unitRef="U_xbrlishares">3000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001492674_20220930"
      decimals="INF"
      id="F_000088"
      unitRef="U_xbrlishares">3000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000090"
      unitRef="U_iso4217USD">330000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001492674_20211231"
      decimals="INF"
      id="F_000087"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001492674_20211231"
      decimals="INF"
      id="F_000089"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">330000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001492674_20220930"
      decimals="INF"
      id="F_000091"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001492674_20211231"
      decimals="INF"
      id="F_000092"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001492674_20220930"
      decimals="INF"
      id="F_000093"
      unitRef="U_xbrlishares">9997000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001492674_20211231"
      decimals="INF"
      id="F_000094"
      unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001492674_20220930"
      decimals="INF"
      id="F_000095"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001492674_20211231"
      decimals="INF"
      id="F_000096"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001492674_20220930"
      decimals="INF"
      id="F_000097"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001492674_20211231"
      decimals="INF"
      id="F_000098"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001492674_20220930"
      decimals="INF"
      id="F_000099"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001492674_20211231"
      decimals="INF"
      id="F_000100"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001492674_20220930"
      decimals="INF"
      id="F_000101"
      unitRef="U_xbrlishares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001492674_20211231"
      decimals="INF"
      id="F_000102"
      unitRef="U_xbrlishares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001492674_20220930"
      decimals="INF"
      id="F_000103"
      unitRef="U_xbrlishares">7050849</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001492674_20220930"
      decimals="INF"
      id="F_000105"
      unitRef="U_xbrlishares">7050849</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001492674_20211231"
      decimals="INF"
      id="F_000104"
      unitRef="U_xbrlishares">3328017</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001492674_20211231"
      decimals="INF"
      id="F_000106"
      unitRef="U_xbrlishares">3328017</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">7000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">492444000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000076"
      unitRef="U_iso4217USD">459314000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000077"
      unitRef="U_iso4217USD">-4000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000078"
      unitRef="U_iso4217USD">-524120000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000079"
      unitRef="U_iso4217USD">-472216000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000080"
      unitRef="U_iso4217USD">-31669000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000081"
      unitRef="U_iso4217USD">-12903000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000082"
      unitRef="U_iso4217USD">43952000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000083"
      unitRef="U_iso4217USD">60539000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20220701_20220930"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">2641000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20210701_20210930"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">4306000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20220101_20220930"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">9044000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20210101_20210930"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">12634000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooContributionMember_20220701_20220930"
      decimals="-3"
      id="F_000111"
      unitRef="U_iso4217USD">1036000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooContributionMember_20210701_20210930"
      decimals="-3"
      id="F_000112"
      unitRef="U_iso4217USD">3122000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooContributionMember_20220101_20220930"
      decimals="-3"
      id="F_000113"
      unitRef="U_iso4217USD">7778000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooContributionMember_20210101_20210930"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">8444000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">3677000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_20210701_20210930"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">7428000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">16822000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">21078000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20220701_20220930"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">6085000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20210701_20210930"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">4720000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20220101_20220930"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">17371000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20210101_20210930"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">15341000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">6375000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001492674_20210701_20210930"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">6384000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">21056000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">16448000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">7017000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001492674_20210701_20210930"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">8536000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">24071000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">21983000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">19477000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_0001492674_20210701_20210930"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">19640000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">62498000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">53772000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">-15800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001492674_20210701_20210930"
      decimals="-3"
      id="F_000136"
      unitRef="U_iso4217USD">-12212000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">-45676000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000138"
      unitRef="U_iso4217USD">-32694000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">1000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001492674_20210701_20210930"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">6000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">6000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">18000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">1560000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0001492674_20210701_20210930"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">1919000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">4556000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">5642000</us-gaap:InterestExpense>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">-117000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">-1792000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">1010000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <ttoo:ChangeInFairValueOfDerivativeWarrantLiability
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000150"
      unitRef="U_iso4217USD">179000</ttoo:ChangeInFairValueOfDerivativeWarrantLiability>
    <ttoo:ChangeInFairValueOfDerivativeWarrantLiability
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">179000</ttoo:ChangeInFairValueOfDerivativeWarrantLiability>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">-78000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001492674_20210701_20210930"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">163000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">-65000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">211000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">-1575000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001492674_20210701_20210930"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">-1750000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">-6228000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">-4403000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">-17375000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001492674_20210701_20210930"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">-13962000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">-51904000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">-37097000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityDividendsAdjustment
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">330000</us-gaap:TemporaryEquityDividendsAdjustment>
    <us-gaap:TemporaryEquityDividendsAdjustment
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">330000</us-gaap:TemporaryEquityDividendsAdjustment>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">-17705000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0001492674_20210701_20210930"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">-13962000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">-52234000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">-37097000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0001492674_20220701_20220930"
      decimals="2"
      id="F_000192"
      unitRef="U_iso4217USD_xbrlishares">-2.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0001492674_20220701_20220930"
      decimals="2"
      id="F_000170"
      unitRef="U_iso4217USD_xbrlishares">-2.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0001492674_20210701_20210930"
      decimals="2"
      id="F_000193"
      unitRef="U_iso4217USD_xbrlishares">-4.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0001492674_20210701_20210930"
      decimals="2"
      id="F_000171"
      unitRef="U_iso4217USD_xbrlishares">-4.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0001492674_20220101_20220930"
      decimals="2"
      id="F_000194"
      unitRef="U_iso4217USD_xbrlishares">-12.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0001492674_20220101_20220930"
      decimals="2"
      id="F_000172"
      unitRef="U_iso4217USD_xbrlishares">-12.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0001492674_20210101_20210930"
      decimals="2"
      id="F_000195"
      unitRef="U_iso4217USD_xbrlishares">-11.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0001492674_20210101_20210930"
      decimals="2"
      id="F_000173"
      unitRef="U_iso4217USD_xbrlishares">-11.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0001492674_20220701_20220930"
      decimals="0"
      id="F_000196"
      unitRef="U_xbrlishares">6008819</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0001492674_20220701_20220930"
      decimals="0"
      id="F_000174"
      unitRef="U_xbrlishares">6008819</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0001492674_20210701_20210930"
      decimals="0"
      id="F_000197"
      unitRef="U_xbrlishares">3317646</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0001492674_20210701_20210930"
      decimals="0"
      id="F_000175"
      unitRef="U_xbrlishares">3317646</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0001492674_20220101_20220930"
      decimals="0"
      id="F_000198"
      unitRef="U_xbrlishares">4323452</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0001492674_20220101_20220930"
      decimals="0"
      id="F_000176"
      unitRef="U_xbrlishares">4323452</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0001492674_20210101_20210930"
      decimals="0"
      id="F_000199"
      unitRef="U_xbrlishares">3127951</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0001492674_20210101_20210930"
      decimals="0"
      id="F_000177"
      unitRef="U_xbrlishares">3127951</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">-17375000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001492674_20210701_20210930"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">-13962000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">-51904000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">-37097000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">9000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">-2000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">14000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">4000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">-5000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">-17375000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001492674_20210701_20210930"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">-13962000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">-51900000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">-37102000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000200"
      unitRef="U_xbrlishares">2961579</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">431689000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">-422975000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231"
      decimals="-3"
      id="F_000204"
      unitRef="U_iso4217USD">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_20201231"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">8726000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">1308000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001492674_20210101_20210331"
      decimals="-3"
      id="F_000207"
      unitRef="U_iso4217USD">1308000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="INF"
      id="F_000208"
      unitRef="U_xbrlishares">8253</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">53000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001492674_20210101_20210331"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">53000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331"
      decimals="-3"
      id="F_000211"
      unitRef="U_iso4217USD">7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001492674_20210101_20210331"
      decimals="-3"
      id="F_000212"
      unitRef="U_iso4217USD">7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331"
      decimals="-3"
      id="F_000213"
      unitRef="U_iso4217USD">-10660000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001492674_20210101_20210331"
      decimals="-3"
      id="F_000214"
      unitRef="U_iso4217USD">-10660000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331"
      decimals="INF"
      id="F_000215"
      unitRef="U_xbrlishares">2969832</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331"
      decimals="-3"
      id="F_000216"
      unitRef="U_iso4217USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331"
      decimals="-3"
      id="F_000217"
      unitRef="U_iso4217USD">433050000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">-433635000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331"
      decimals="-3"
      id="F_000219"
      unitRef="U_iso4217USD">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_20210331"
      decimals="-3"
      id="F_000220"
      unitRef="U_iso4217USD">-566000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630"
      decimals="-3"
      id="F_000221"
      unitRef="U_iso4217USD">1843000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001492674_20210401_20210630"
      decimals="-3"
      id="F_000222"
      unitRef="U_iso4217USD">1843000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630"
      decimals="INF"
      id="F_000223"
      unitRef="U_xbrlishares">9253</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630"
      decimals="-3"
      id="F_000224"
      unitRef="U_iso4217USD">251000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001492674_20210401_20210630"
      decimals="-3"
      id="F_000225"
      unitRef="U_iso4217USD">251000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210401_20210630"
      decimals="INF"
      id="F_000226"
      unitRef="U_xbrlishares">336188</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210401_20210630"
      decimals="-3"
      id="F_000227"
      unitRef="U_iso4217USD">19968000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001492674_20210401_20210630"
      decimals="-3"
      id="F_000228"
      unitRef="U_iso4217USD">19968000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210401_20210630"
      decimals="-3"
      id="F_000229"
      unitRef="U_iso4217USD">-12000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001492674_20210401_20210630"
      decimals="-3"
      id="F_000230"
      unitRef="U_iso4217USD">-12000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210401_20210630"
      decimals="-3"
      id="F_000231"
      unitRef="U_iso4217USD">-12475000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001492674_20210401_20210630"
      decimals="-3"
      id="F_000232"
      unitRef="U_iso4217USD">-12475000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630"
      decimals="INF"
      id="F_000233"
      unitRef="U_xbrlishares">3315273</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210630"
      decimals="-3"
      id="F_000234"
      unitRef="U_iso4217USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210630"
      decimals="-3"
      id="F_000235"
      unitRef="U_iso4217USD">455112000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210630"
      decimals="-3"
      id="F_000236"
      unitRef="U_iso4217USD">-446110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210630"
      decimals="-3"
      id="F_000237"
      unitRef="U_iso4217USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_20210630"
      decimals="-3"
      id="F_000238"
      unitRef="U_iso4217USD">9009000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210701_20210930"
      decimals="-3"
      id="F_000239"
      unitRef="U_iso4217USD">2466000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001492674_20210701_20210930"
      decimals="-3"
      id="F_000240"
      unitRef="U_iso4217USD">2466000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210701_20210930"
      decimals="INF"
      id="F_000241"
      unitRef="U_xbrlishares">4082</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210701_20210930"
      decimals="-3"
      id="F_000242"
      unitRef="U_iso4217USD">24000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001492674_20210701_20210930"
      decimals="-3"
      id="F_000243"
      unitRef="U_iso4217USD">24000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210701_20210930"
      decimals="-3"
      id="F_000244"
      unitRef="U_iso4217USD">-13962000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001492674_20210701_20210930"
      decimals="-3"
      id="F_000245"
      unitRef="U_iso4217USD">-13962000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210930"
      decimals="INF"
      id="F_000246"
      unitRef="U_xbrlishares">3319355</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210930"
      decimals="-3"
      id="F_000247"
      unitRef="U_iso4217USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210930"
      decimals="-3"
      id="F_000248"
      unitRef="U_iso4217USD">457602000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210930"
      decimals="-3"
      id="F_000249"
      unitRef="U_iso4217USD">-460072000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210930"
      decimals="-3"
      id="F_000250"
      unitRef="U_iso4217USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_20210930"
      decimals="-3"
      id="F_000251"
      unitRef="U_iso4217USD">-2463000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="INF"
      id="F_000252"
      unitRef="U_xbrlishares">3328017</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="-3"
      id="F_000253"
      unitRef="U_iso4217USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231"
      decimals="-3"
      id="F_000254"
      unitRef="U_iso4217USD">459314000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231"
      decimals="-3"
      id="F_000255"
      unitRef="U_iso4217USD">-472216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231"
      decimals="-3"
      id="F_000256"
      unitRef="U_iso4217USD">-4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000257"
      unitRef="U_iso4217USD">-12903000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331"
      decimals="-3"
      id="F_000258"
      unitRef="U_iso4217USD">2552000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001492674_20220101_20220331"
      decimals="-3"
      id="F_000259"
      unitRef="U_iso4217USD">2552000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331"
      decimals="INF"
      id="F_000260"
      unitRef="U_xbrlishares">40028</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331"
      decimals="INF"
      id="F_000261"
      unitRef="U_xbrlishares">10781</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331"
      decimals="-3"
      id="F_000262"
      unitRef="U_iso4217USD">231000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001492674_20220101_20220331"
      decimals="-3"
      id="F_000263"
      unitRef="U_iso4217USD">231000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220101_20220331"
      decimals="INF"
      id="F_000264"
      unitRef="U_xbrlishares">70981</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220101_20220331"
      decimals="-3"
      id="F_000265"
      unitRef="U_iso4217USD">1433000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001492674_20220101_20220331"
      decimals="-3"
      id="F_000266"
      unitRef="U_iso4217USD">1433000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20220101_20220331"
      decimals="-3"
      id="F_000267"
      unitRef="U_iso4217USD">-7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001492674_20220101_20220331"
      decimals="-3"
      id="F_000268"
      unitRef="U_iso4217USD">-7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220101_20220331"
      decimals="-3"
      id="F_000269"
      unitRef="U_iso4217USD">-16495000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001492674_20220101_20220331"
      decimals="-3"
      id="F_000270"
      unitRef="U_iso4217USD">-16495000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331"
      decimals="INF"
      id="F_000271"
      unitRef="U_xbrlishares">3428245</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220331"
      decimals="-3"
      id="F_000272"
      unitRef="U_iso4217USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220331"
      decimals="-3"
      id="F_000273"
      unitRef="U_iso4217USD">463068000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220331"
      decimals="-3"
      id="F_000274"
      unitRef="U_iso4217USD">-488711000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20220331"
      decimals="-3"
      id="F_000275"
      unitRef="U_iso4217USD">-11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_20220331"
      decimals="-3"
      id="F_000276"
      unitRef="U_iso4217USD">-25651000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220401_20220630"
      decimals="-3"
      id="F_000277"
      unitRef="U_iso4217USD">1534000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001492674_20220401_20220630"
      decimals="-3"
      id="F_000278"
      unitRef="U_iso4217USD">1534000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220401_20220630"
      decimals="INF"
      id="F_000279"
      unitRef="U_xbrlishares">23386</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220401_20220630"
      decimals="-3"
      id="F_000280"
      unitRef="U_iso4217USD">139000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001492674_20220401_20220630"
      decimals="-3"
      id="F_000281"
      unitRef="U_iso4217USD">139000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220401_20220630"
      decimals="-3"
      id="F_000282"
      unitRef="U_iso4217USD">12000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001492674_20220401_20220630"
      decimals="-3"
      id="F_000283"
      unitRef="U_iso4217USD">12000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220401_20220630"
      decimals="INF"
      id="F_000284"
      unitRef="U_xbrlishares">517352</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220401_20220630"
      decimals="-3"
      id="F_000285"
      unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220401_20220630"
      decimals="-3"
      id="F_000286"
      unitRef="U_iso4217USD">4493000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001492674_20220401_20220630"
      decimals="-3"
      id="F_000287"
      unitRef="U_iso4217USD">4494000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20220401_20220630"
      decimals="-3"
      id="F_000288"
      unitRef="U_iso4217USD">11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001492674_20220401_20220630"
      decimals="-3"
      id="F_000289"
      unitRef="U_iso4217USD">11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220401_20220630"
      decimals="-3"
      id="F_000290"
      unitRef="U_iso4217USD">-18034000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001492674_20220401_20220630"
      decimals="-3"
      id="F_000291"
      unitRef="U_iso4217USD">-18034000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220630"
      decimals="INF"
      id="F_000292"
      unitRef="U_xbrlishares">3968983</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220630"
      decimals="-3"
      id="F_000293"
      unitRef="U_iso4217USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220630"
      decimals="-3"
      id="F_000294"
      unitRef="U_iso4217USD">469222000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220630"
      decimals="-3"
      id="F_000295"
      unitRef="U_iso4217USD">-506745000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_20220630"
      decimals="-3"
      id="F_000296"
      unitRef="U_iso4217USD">-37519000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220701_20220930"
      decimals="-3"
      id="F_000297"
      unitRef="U_iso4217USD">1372000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000298"
      unitRef="U_iso4217USD">1372000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220701_20220930"
      decimals="INF"
      id="F_000299"
      unitRef="U_xbrlishares">1365</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220701_20220930"
      decimals="INF"
      id="F_000300"
      unitRef="U_xbrlishares">3080451</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220701_20220930"
      decimals="-3"
      id="F_000301"
      unitRef="U_iso4217USD">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220701_20220930"
      decimals="-3"
      id="F_000302"
      unitRef="U_iso4217USD">22180000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000303"
      unitRef="U_iso4217USD">22183000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ttoo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20220701_20220930"
      decimals="INF"
      id="F_000304"
      unitRef="U_xbrlishares">3000</ttoo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityAccretionOfDividends
      contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20220701_20220930"
      decimals="-3"
      id="F_000305"
      unitRef="U_iso4217USD">330000</us-gaap:TemporaryEquityAccretionOfDividends>
    <us-gaap:DividendsPreferredStock
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220701_20220930"
      decimals="-3"
      id="F_000306"
      unitRef="U_iso4217USD">330000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000307"
      unitRef="U_iso4217USD">330000</us-gaap:DividendsPreferredStock>
    <ttoo:MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220701_20220930"
      decimals="INF"
      id="F_000308"
      unitRef="U_xbrlishares">50</ttoo:MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220701_20220930"
      decimals="-3"
      id="F_000309"
      unitRef="U_iso4217USD">-17375000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000310"
      unitRef="U_iso4217USD">-17375000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20220930"
      decimals="INF"
      id="F_000311"
      unitRef="U_xbrlishares">3000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20220930"
      decimals="-3"
      id="F_000312"
      unitRef="U_iso4217USD">330000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220930"
      decimals="INF"
      id="F_000313"
      unitRef="U_xbrlishares">7050849</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20220930"
      decimals="-3"
      id="F_000314"
      unitRef="U_iso4217USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20220930"
      decimals="-3"
      id="F_000315"
      unitRef="U_iso4217USD">492444000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20220930"
      decimals="-3"
      id="F_000316"
      unitRef="U_iso4217USD">-524120000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000317"
      unitRef="U_iso4217USD">-31669000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000318"
      unitRef="U_iso4217USD">-51904000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000319"
      unitRef="U_iso4217USD">-37097000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000320"
      unitRef="U_iso4217USD">792000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000321"
      unitRef="U_iso4217USD">1000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000322"
      unitRef="U_iso4217USD">114000</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000323"
      unitRef="U_iso4217USD">907000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000324"
      unitRef="U_iso4217USD">982000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000325"
      unitRef="U_iso4217USD">5458000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000326"
      unitRef="U_iso4217USD">5617000</us-gaap:ShareBasedCompensation>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000327"
      unitRef="U_iso4217USD">-1792000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000328"
      unitRef="U_iso4217USD">1010000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <ttoo:ChangeInFairValueOfDerivativeWarrantLiability
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000329"
      unitRef="U_iso4217USD">179000</ttoo:ChangeInFairValueOfDerivativeWarrantLiability>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000330"
      unitRef="U_iso4217USD">-2000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000331"
      unitRef="U_iso4217USD">14000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <ttoo:GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000332"
      unitRef="U_iso4217USD">-65000</ttoo:GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability>
    <us-gaap:ProductionRelatedImpairmentsOrCharges
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000333"
      unitRef="U_iso4217USD">30000</us-gaap:ProductionRelatedImpairmentsOrCharges>
    <us-gaap:PaidInKindInterest
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000334"
      unitRef="U_iso4217USD">1613000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000335"
      unitRef="U_iso4217USD">2803000</us-gaap:PaidInKindInterest>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000336"
      unitRef="U_iso4217USD">-3556000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000337"
      unitRef="U_iso4217USD">-877000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000338"
      unitRef="U_iso4217USD">-356000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000339"
      unitRef="U_iso4217USD">692000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000340"
      unitRef="U_iso4217USD">815000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000341"
      unitRef="U_iso4217USD">1915000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000342"
      unitRef="U_iso4217USD">-791000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000343"
      unitRef="U_iso4217USD">523000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000344"
      unitRef="U_iso4217USD">61000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000345"
      unitRef="U_iso4217USD">619000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000346"
      unitRef="U_iso4217USD">-375000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000347"
      unitRef="U_iso4217USD">9000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <ttoo:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000348"
      unitRef="U_iso4217USD">-868000</ttoo:IncreaseDecreaseInOperatingLeaseLiabilities>
    <ttoo:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000349"
      unitRef="U_iso4217USD">-848000</ttoo:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000350"
      unitRef="U_iso4217USD">-40300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000351"
      unitRef="U_iso4217USD">-29032000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000352"
      unitRef="U_iso4217USD">15251000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000353"
      unitRef="U_iso4217USD">9998000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000354"
      unitRef="U_iso4217USD">303000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000355"
      unitRef="U_iso4217USD">261000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000356"
      unitRef="U_iso4217USD">9695000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000357"
      unitRef="U_iso4217USD">14990000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000358"
      unitRef="U_iso4217USD">243000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <ttoo:ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000359"
      unitRef="U_iso4217USD">139000</ttoo:ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises>
    <ttoo:ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000360"
      unitRef="U_iso4217USD">328000</ttoo:ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises>
    <ttoo:ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000361"
      unitRef="U_iso4217USD">28110000</ttoo:ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts>
    <ttoo:ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000362"
      unitRef="U_iso4217USD">19968000</ttoo:ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts>
    <ttoo:ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000363"
      unitRef="U_iso4217USD">300000</ttoo:ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000364"
      unitRef="U_iso4217USD">28306000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000365"
      unitRef="U_iso4217USD">20296000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000366"
      unitRef="U_iso4217USD">-2299000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000367"
      unitRef="U_iso4217USD">6254000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000368"
      unitRef="U_iso4217USD">23796000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001492674_20201231"
      decimals="-3"
      id="F_000369"
      unitRef="U_iso4217USD">17344000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000370"
      unitRef="U_iso4217USD">21497000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001492674_20210930"
      decimals="-3"
      id="F_000371"
      unitRef="U_iso4217USD">23598000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000372"
      unitRef="U_iso4217USD">2916000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000373"
      unitRef="U_iso4217USD">2815000</us-gaap:InterestPaidNet>
    <ttoo:TransferOfT2OwnedInstrumentsAndComponentsToFromInventory
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000374"
      unitRef="U_iso4217USD">-482000</ttoo:TransferOfT2OwnedInstrumentsAndComponentsToFromInventory>
    <ttoo:TransferOfT2OwnedInstrumentsAndComponentsToFromInventory
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000375"
      unitRef="U_iso4217USD">-729000</ttoo:TransferOfT2OwnedInstrumentsAndComponentsToFromInventory>
    <ttoo:DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000376"
      unitRef="U_iso4217USD">330000</ttoo:DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000377"
      unitRef="U_iso4217USD">199000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000378"
      unitRef="U_iso4217USD">72000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000379"
      unitRef="U_iso4217USD">80000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000380"
      unitRef="U_iso4217USD">20366000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001492674_20210930"
      decimals="-3"
      id="F_000381"
      unitRef="U_iso4217USD">22047000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000382"
      unitRef="U_iso4217USD">1131000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_0001492674_20210930"
      decimals="-3"
      id="F_000383"
      unitRef="U_iso4217USD">1551000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000384"
      unitRef="U_iso4217USD">21497000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001492674_20210930"
      decimals="-3"
      id="F_000385"
      unitRef="U_iso4217USD">23598000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:NatureOfOperations contextRef="C_0001492674_20220101_20220930" id="F_000386">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. Nature of Business &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;T2 Biosystems, Inc. and its subsidiary (the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; or &#x201c;T2&#x201d;) have operations based in Lexington, Massachusetts. T2 Biosystems, Inc. was incorporated on April 27, 2006 as a Delaware corporation. The Company is an&#160;&lt;span style="font-style:italic;"&gt;in vitro&lt;/span&gt;&#160;diagnostics company that has developed an innovative and proprietary technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company has developed a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. Our technology enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (&#x201c;CFU/mL&#x201d;). The Company&#x2019;s initial development efforts target the detection of pathogens that cause sepsis, which is an area of significant unmet medical need in which existing therapies could be more effective with improved diagnostics. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liquidity and Going Concern &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At September&#160;30, 2022, the Company had cash, cash equivalents, and restricted cash of $21.5 million, an accumulated deficit of $524.1 million and stockholders&#x2019; deficit of $31.7 million. The Company has historically experienced cash outflows from operating activities. The future success of the Company is dependent on its ability to successfully commercialize its products, obtain regulatory clearance for and successfully launch its future product candidates, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through proceeds from its August 2014 initial public offering, its December 2015 public offering, its September 2016 private investment in public equity (&#x201c;PIPE&#x201d;) financing, its September 2017 public offering, its June 2018 public offering, its July 2019 establishment of an Equity Distribution Agreement and Equity Purchase Agreement (Note 8), its March 2021 establishment of an Equity Distribution Agreement (Note 8), private placements of redeemable convertible preferred stock as well as borrowings from debt financing arrangements.&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to a number of risks similar to other early commercial stage life science companies, including, but not limited to commercially launching the Company&#x2019;s products, development and market acceptance of the Company&#x2019;s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The COVID-19 pandemic has impacted and may continue to impact the Company&#x2019;s operations. Although the Company did not see any material impact to accounts receivable during the three and nine month period ended September 30, 2022, the Company&#x2019;s exposure may increase if its customers continue to be adversely affected by the COVID-19 pandemic, including as a result of the spread of variants of the virus. Customers may reduce their purchases of products, depending on their needs and cash flow, which could negatively impact revenue. The Company has a significant development contract with the Biomedical Advanced Research and Development Authority (&#x201c;BARDA&#x201d;) and should BARDA reduce, cancel or not grant additional milestone projects, the Company&#x2019;s ability to continue its future product development may be impacted. The ability of the Company&#x2019;s shipping carriers to deliver products to customers may be disrupted. The Company has reviewed its suppliers and quantities of key materials and believes that it has sufficient stocks and alternate sources of critical materials including personal protective equipment should the supply chains continue to be disrupted, although raw materials and plastics for the manufacturing of reagents and consumables are in high demand, and interruptions in supply are difficult to predict. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since authorization from the United States Food and Drug Administration, or FDA, was obtained to market the T2Dx Instrument, T2Candida Panel, and T2Bacteria Panel, and Emergency Use Authorization, or EUA, was issued for the T2SARS-CoV-2 Panel, the Company has incurred significant commercialization expenses related to product sales, marketing, manufacturing and distribution. If the FDA rescinds EUA, the Company would be unable to sell its T2SARS-CoV-2 tests. The Company may seek to fund its operations through public equity, private equity or debt financings, as well as other sources. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed, on favorable terms, or at all. The Company&#x2019;s failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on the Company&#x2019;s business, results of operations, financial condition and the Company&#x2019;s ability to develop and commercialize T2Dx, T2Candida, T2Bacteria, T2SARS-CoV-2, and other product candidates.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the requirements of Accounting Standards Codification (&#x201c;ASC&#x201d;) 205-40,&#160;&lt;span style="font-style:italic;"&gt;Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern&lt;/span&gt;, management must evaluate whether there are conditions or events, considered in the &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#x2019;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#x2019;s ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company believes that its cash, cash equivalents, and restricted cash of $21.5 million at September 30, 2022 will not be sufficient to fund its current operating plan for at least one year from issuance of these financial statements, as certain elements of our operating plan cannot be considered probable. Absent any reductions in current operating expenses, the Company believes it will require additional financing during the first quarter of 2023. Under ASC 205-40, the future receipt of potential funding from co-development partners and other resources cannot be considered probable at this time because none of the plans are entirely within the Company&#x2019;s control.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Term Loan Agreement with CRG Servicing LLC (&#x201c;CRG&#x201d;) (Note 6) has a minimum liquidity covenant which requires the Company to maintain a minimum cash balance of $5.0 million. There can be no assurances that the Company will continue to be in compliance with the cash covenant in future periods without additional funding. In February 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2023. In November 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2024.  &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s stock had been trading under $1.00 since September 27, 2021. &lt;span style="color:#000000;"&gt;On November 5, 2021, the Company received a letter from The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) indicating that the Company was not in compliance with the requirement of Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market as a result of the closing bid price of the Company&#x2019;s common stock being below &lt;/span&gt;$1.00 &lt;span style="color:#000000;"&gt;per share for thirty consecutive business days (the &#x201c;Bid Price Rule&#x201d;). Under the Nasdaq rules, the Company had 180 days (or until May 4, 2022) to regain compliance by maintaining a minimum closing bid price of $&lt;/span&gt;1.00 per share of the Company&#x2019;s common stock for at least ten consecutive trading days during such compliance period. On May 5, 2022, the Company received a letter from Nasdaq informing the Company that its shares of common stock have failed to comply with the Bid Price Rule for continued listing and, as a result, the Company&#x2019;s shares were subject to delisting. The letter further stated that the Company may appeal the Nasdaq Staff delisting determination to a Nasdaq listing qualifications hearings panel (the &#x201c;Panel&#x201d;).&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company filed an appeal and hearing request to the Nasdaq Staff&#x2019;s determination to stay the delisting of the Company&#x2019;s shares of common stock from Nasdaq pending the Panel&#x2019;s decision. The Nasdaq Staff informed the Company that the delisting action had been stayed, pending a final written decision by the Panel, and the hearing date had been set for June 2, 2022. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 9, 2022, the Company received a letter from the Nasdaq notifying the Company that the Nasdaq had granted the Company&#x2019;s request to be transferred to The Nasdaq Capital Market, effective at the open of trading on June 13, 2022, and the Company&#x2019;s request for an exception to the Bid Price Rule until November 1, 2022. &lt;/p&gt;&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 11, 2022, at the Company&#x2019;s annual meeting of stockholders, the Company&#x2019;s stockholders approved an amendment to the Company&#x2019;s restated certificate of incorporation to effect a reverse stock split of the Company&#x2019;s common stock. Following the receipt of the stockholders&#x2019; approval, the Company&#x2019;s board of directors approved the reverse stock split at the ratio of 1 post-split share for every &lt;span style="-sec-ix-hidden:F_000445"&gt;50 pre-split shares&lt;/span&gt;, which was effective as of October 12, 2022. On October 31, 2022, the Company received a letter from Nasdaq informing the Company that it has regained compliance with the Bid Price Rule. &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July&#160;22, 2022, the Company received a letter from the Nasdaq (the &#x201c;Nasdaq Staff Deficiency Letter&#x201d;) indicating that, for the last thirty-five consecutive business days, the Market Value of Listed Securities, as defined by Nasdaq (&#x201c;MVLS&#x201d;) had been below the $35&#160;million minimum requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2).&#160;&#160;In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided an initial period of 180 calendar days, or until January&#160;18, 2023, to regain compliance. The letter states that the Nasdaq staff will provide written notification that the Company has achieved compliance with Rule&#160;5550(b)(2) if at any time before January&#160;18, 2023, the Company maintains its MVLS at $35&#160;million or more for a minimum of ten consecutive business days. The Nasdaq Staff Deficiency Letter has no immediate effect on the listing or trading of the Company&#x2019;s common stock.&#160;&#160;If compliance is not achieved by January&#160;18, 2023, the Company expects that Nasdaq would provide written notification to the Company that its securities are subject to delisting. The Company will continue to monitor its MVLS and consider its available options to regain compliance with the Nasdaq minimum MVLS requirements, which may include applying for an extension of the compliance period or appealing to a Nasdaq Hearings Panel. On August 24, 2022, i&lt;span style="color:#000000;"&gt;n a Compliance &lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;"&gt;Notice, the Nasdaq notified the Company that, from August 10, 2022 to August 23, 2022, the Company&#x2019;s MVLS had been $&lt;/span&gt;&lt;span style="color:#000000;"&gt;35&lt;/span&gt;&lt;span style="color:#000000;"&gt; million or greater and, accordingly, the Company had regained compliance with Rule &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;5550(b)(2) &lt;/span&gt;&lt;span style="color:#000000;"&gt;and that the matter was now closed.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;These conditions raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern for a period of one year after the date that the financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include raising additional funding, earning payments pursuant to the Company&#x2019;s contract with BARDA, delaying certain research projects and capital expenditures and eliminating certain future operating expenses in order to fund operations at reduced levels for the Company to continue as a going concern for a period of 12 months from the date these unaudited condensed consolidated financial statements are issued. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company&#x2019;s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these financial statements.&lt;span style="color:#000000;"&gt; The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001492674_20220930"
      decimals="-5"
      id="F_000435"
      unitRef="U_iso4217USD">21500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001492674_20220930"
      decimals="-5"
      id="F_000436"
      unitRef="U_iso4217USD">-524100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001492674_20220930"
      decimals="-5"
      id="F_000437"
      unitRef="U_iso4217USD">-31700000</us-gaap:StockholdersEquity>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001492674_20220930"
      decimals="-5"
      id="F_000438"
      unitRef="U_iso4217USD">21500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCash
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220930"
      decimals="-5"
      id="F_000439"
      unitRef="U_iso4217USD">5000000.0</us-gaap:RestrictedCash>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220201_20220228"
      id="F_000440">2023-12-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221113_20221114"
      id="F_000441">2024-12-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_20220930"
      decimals="INF"
      id="F_000442"
      unitRef="U_iso4217USD_xbrlishares">1.00</us-gaap:SaleOfStockPricePerShare>
    <ttoo:MinimumBidPriceOfCommonStock
      contextRef="C_0001492674_20211105"
      decimals="INF"
      id="F_000443"
      unitRef="U_iso4217USD_xbrlishares">1.00</ttoo:MinimumBidPriceOfCommonStock>
    <ttoo:RegainComplianceByIncreasingStockPrice
      contextRef="C_0001492674_srtRangeAxis_srtMinimumMember_20220930"
      decimals="INF"
      id="F_000444"
      unitRef="U_iso4217USD_xbrlishares">1.00</ttoo:RegainComplianceByIncreasingStockPrice>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011_20221011"
      id="F_000446">On October 11, 2022, at the Company&#x2019;s annual meeting of stockholders, the Company&#x2019;s stockholders approved an amendment to the Company&#x2019;s restated certificate of incorporation to effect a reverse stock split of the Company&#x2019;s common stock. Following the receipt of the stockholders&#x2019; approval, the Company&#x2019;s board of directors approved the reverse stock split at the ratio of 1 post-split share for every 50 pre-split shares, which was effective as of October 12, 2022. On October 31, 2022, the Company received a letter from Nasdaq informing the Company that it has regained compliance with the Bid Price Rule. </us-gaap:StockholdersEquityReverseStockSplit>
    <ttoo:MinimumMarketValueOfListedSecurities
      contextRef="C_0001492674_20220722"
      decimals="INF"
      id="F_000447"
      unitRef="U_iso4217USD">35000000</ttoo:MinimumMarketValueOfListedSecurities>
    <ttoo:MinimumMarketValueOfListedSecurities
      contextRef="C_0001492674_20220824"
      decimals="INF"
      id="F_000448"
      unitRef="U_iso4217USD">35000000</ttoo:MinimumMarketValueOfListedSecurities>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000387">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. Summary of Significant Accounting Policies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as defined in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The Company&#x2019;s condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, T2 Biosystems Securities Corporation. All intercompany balances and transactions have been eliminated. &#160; &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 12, 2022, we effected a reverse stock split at the ratio of 1 post-split share for every &lt;span style="-sec-ix-hidden:F_000449_2"&gt;50 pre-split shares&lt;/span&gt;. All common stock amounts and references have been retroactively adjusted for all figures presented to reflect this split unless specifically stated otherwise.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unaudited Interim Financial Information &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain information and footnote disclosures normally included in the Company&#x2019;s annual financial statements have been condensed or omitted.&#160;Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying interim condensed consolidated balance sheet as of September&#160;30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2022 and 2021, the condensed consolidated statements of Series A convertible preferred stock and stockholders&#x2019; deficit for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2022 and 2021 and the related financial data and other information disclosed in these notes are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual financial statements, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company&#x2019;s financial position as of September&#160;30, 2022, and the results of its operations for the three and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021. The results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022, any other interim periods, or any future year or period. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Segment Information &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#x2019;s chief operating decision maker is the Chief Executive Officer. The Company views its operations and manages its business in one operating segment, which is the business of developing and, upon regulatory clearance, commercializing its diagnostic products aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Geographic Information &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company sells its products domestically and internationally. Total international sales were approximately $1.2 million or 32% of total revenue and $0.6 million or 9% of total revenue for the three months ended September 30, 2022 and 2021, respectively. Total international sales were approximately $3.2 million or 19% of total revenue and $1.6 million or 8% of total revenue for the nine months ended September 30, 2022 and 2021, respectively.  &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the three months ended September 30, 2022, one international customer represented 12% of total revenue. For the three months ended September 30, 2021, no international customer represented greater than 10% of total revenue. For the nine months ended September 30, 2022 and 2021, no international customer represented greater than 10% of total revenue.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; The following table shows customers that represent greater than 10% of revenue for the period presented: &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nine Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer A&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer B&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer C&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2022 and December 31, 2021, the Company had outstanding receivables of $0.9 million and $0.6 million, respectively, from customers located outside of the U.S.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies the two-class method for computing earnings per share because its Series A redeemable convertible preferred stock and the warrants issued with that preferred stock are participating securities. Under the two-class method, net income for the period is allocated between common stockholders and the participating securities according to dividends declared, if any, and participation rights in undistributed earnings. Because the Company incurred a net loss for the three and nine months ended September 30, 2022, and the holders of the participating securities do not have the contractual obligation to share in the losses of the Company on a basis that is objectively determinable, none of the net loss attributable to common stockholders was allocated to the participating securities when computing earnings per share.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is calculated by dividing net loss attributable to commons stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Any accretion of the carrying amount of the Company&#x2019;s Series A redeemable convertible preferred stock to its redemption amount is treated as a deemed dividend to the preferred stockholders and will increase the amount of the net loss attributable to common stockholders. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using either the if-converted method (for its Series A redeemable, convertible preferred stock) or the treasury-stock method. For purposes of the diluted net loss per share calculation, stock options and unvested restricted stock, restricted stock contingently issuable upon achievement of certain market conditions, and the warrants issued with Series A redeemable convertible preferred stock are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. In periods in which the Company recognizes gains due to changes in the fair value of its warrant liability, the Company will further assess whether the effect of adjusting its computation of diluted net loss per share to include the potential common shares and reverse the gain associated with the warrant would result in a more diluted net loss per share, and modify the computation if necessary. The Series A redeemable convertible preferred stock was not considered a common stock equivalent because exercise of the conversion option was contingent upon occurrence of the reverse stock split, which had not yet occurred as of September 30, 2022. Therefore, basic and diluted net loss per share applicable to common stockholders was the same for all periods presented.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable Securities &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s marketable securities consist of U.S. treasury securities, which are classified as available-for-sale and included in current assets. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported as a component of stockholders&#x2019; deficit in accumulated other comprehensive (loss) income. Realized gains and losses, if any, are included in other income (expense) in the condensed consolidated statements of operations. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security&#x2019;s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported as a component of stockholders&#x2019; deficit in accumulated other comprehensive loss (income). &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had no marketable securities at September 30, 2022. The following table summarizes the Company&#x2019;s marketable securities at December 31, 2021 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &#160; &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the maturities of the Company&#x2019;s marketable securities at December 31, 2021 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:50%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due in less than 1 year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due in 1-2 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative&#160;Warrant Liability&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with&#160;ASC Topic 815,&#160;&lt;span style="font-style:italic;"&gt;&#x201c;Derivatives and Hedging&lt;/span&gt;.&#x201d;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the liability for the warrant issued in conjunction with the Series A redeemable convertible preferred stock is a&#160;derivative&#160;instrument.&#160; The derivative warrant liability is classified on the condensed consolidated balance sheets as current because cash settlement of the warrant could be required by the holder within 12 months of the balance sheet date. The Company has identified a single compound derivative liability related to its Term Loan Agreement with CRG, that is classified as non-current on the condensed consolidated balance sheets to match the classification of the related Term Loan Agreement.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As the derivative liabilities meet the definition of a&#160;derivative, they are measured at fair value at issuance and at each reporting date in accordance with&#160;ASC 820, &#x201c;&lt;span style="font-style:italic;"&gt;Fair Value Measurement,&#x201d;&lt;/span&gt;&#160;with changes in fair value recognized in change in fair value of derivative warrant liability in the period of change in the condensed consolidated statements of operations and comprehensive loss. The Company does not designate its&#160;derivative&#160;instruments as hedging instruments.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Guarantees &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while each such officer or director is, or was, serving at the Company&#x2019;s request in such capacity. The term of the indemnification is the officer&#x2019;s or director&#x2019;s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#x2019; and officers&#x2019; liability insurance coverage that limits its exposure and enables the Company to recover a portion of any future amounts paid. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases office, laboratory and manufacturing space under noncancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify the landlords against all costs, expenses, fines, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company&#x2019;s leases. &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company&#x2019;s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements.  &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September&#160;30, 2022 and December&#160;31, 2021, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to Topic 842, &lt;span style="font-style:italic;"&gt;Leases&lt;/span&gt; (&#x201c;ASC 842&#x201d;), at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. The exercise of lease renewal options is at our discretion and the renewal to extend the lease terms are not included in the Company&#x2019;s right-of-use assets and lease liabilities as they are not reasonably certain of exercise. The Company will evaluate the renewal options and when they are reasonably certain of exercise, the Company will include the renewal period in its lease term. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued lease payments. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance with the guidance in ASC 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). Then the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company made the policy election to not separate lease and non-lease components. Each lease component and the related non-lease components are accounted for together as a single component. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Classification of Series A Redeemable Convertible Preferred Stock &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has applied the guidance in ASC 480-10-S99-3A, SEC Staff Announcement: Classification and Measurement of Redeemable Securities and classified the Series A redeemable convertible preferred stock as temporary equity in the mezzanine section of the balance sheet. The Series A redeemable convertible preferred stock was recorded outside of stockholders&#x2019; deficit because under the terms thereof, in the event of stockholder approval of the reverse stock split or a delisting event, which are events considered not solely within the Company&#x2019;s control, the Series A redeemable convertible preferred stock becomes redeemable at the option of the holders.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company generates revenue from the sale of instruments, consumable diagnostic tests, related services, reagent rental agreements and government contributions. Pursuant to ASC 606, &lt;span style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt; (&#x201c;ASC 606&#x201d;), the Company determines revenue recognition through the following steps:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.4%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.5%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Identification of a contract with a customer&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.4%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.5%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Identification of the performance obligations in the contract&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.4%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.5%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Determination of the transaction price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.4%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.5%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Allocation of the transaction price to the performance obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.4%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.5%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Recognition of revenue as a performance obligation is satisfied&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The amount of revenue recognized reflects the consideration the Company expects to be entitled to receive in exchange for these goods and services. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company's performance obligations are transferred to customers at a point in time, typically upon shipment, or over time, as services are performed.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Most of the Company&#x2019;s contracts with distributors in geographic regions outside the United States contain only a single performance obligation, whereas most of the Company&#x2019;s contracts with direct sales customers in the United States contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. Excluded from the transaction price are sales tax and other similar taxes which are presented on a net basis.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue is generated by the sale of instruments and consumable diagnostic tests predominantly through the Company&#x2019;s direct sales force in the United States and distributors in geographic regions outside the United States. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors&#x2019; receipt of payment from their end-user customers. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company either sells instruments to customers and international distributors, or retains title and places the instrument at the customer site pursuant to a reagent rental agreement.&#160;When an instrument is purchased by a customer or international distributor, the Company recognizes revenue when the related performance obligation is satisfied (i.e. when the control of an instrument has passed to the customer; typically, at shipping point). &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When the instrument is placed under a reagent rental agreement, the Company&#x2019;s customers generally agree to fixed term agreements, which can be extended, and incremental charges on each consumable diagnostic test purchased. Revenue from the sale of consumable diagnostic tests (under a reagent rental agreement) is generally recognized upon shipment. The transaction price from consumables purchases is allocated between the lease of the instrument (under a contingent rent methodology as provided for in ASC 842, &lt;span style="font-style:italic;"&gt;Leases&lt;/span&gt;), and the consumables when related performance obligations are satisfied, as a component of lease and product revenue, and is included as Instrument Rentals in the below table. Revenue associated with reagent rental consumables purchases is currently classified as variable consideration and constrained until a purchase order is received and related performance obligations have been satisfied.&#160;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue from the sale of consumable diagnostic tests (under instrument purchase agreements) is generally recognized upon shipment. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shipping and handling costs billed to customers in connection with a product sale are recorded as a component of the transaction price and allocated to product revenue in the condensed consolidated statements of operations and comprehensive loss as they are incurred by the Company in fulfilling its performance obligations.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Direct sales of instruments include warranty, maintenance and technical support services typically for one year following the installation of the purchased instrument (&#x201c;Maintenance Services&#x201d;). &lt;span style="color:#000000;"&gt;Maintenance Services are separate performance obligations as they are service-based warranties and are recognized on a straight-line basis over the service delivery period. After the completion of the initial Maintenance Services period, customers have the option to renew or extend the Maintenance Services typically for additional&lt;/span&gt; &lt;span style="-sec-ix-hidden:F_000485"&gt;one-year&lt;/span&gt; periods in exchange for additional consideration. The extended Maintenance Services are also service-based warranties that represent separate purchasing decisions. The Company recognizes revenue allocated to the extended Maintenance Services performance obligation on a straight-line basis over the service delivery period.&#160;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fees paid to member-owned group purchasing organizations (&#x201c;GPOs&#x201d;) are deducted from related product revenues.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company warrants that consumable diagnostic tests will be free from defects, when handled according to product specifications, for the stated life of the product. To fulfill valid warranty claims, the Company provides replacement product free of charge. Warranty expense is recognized based on the estimated defect rates of the consumable diagnostic tests.&lt;/p&gt;

&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Contribution Revenue&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income under the government BARDA contract is earned under a cost-sharing arrangement in which the Company is reimbursed for direct costs incurred plus allowable indirect costs. The g&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;overnment contract revenue is recognized as the related reimbursable expenses are incurred.&#160;&#160;The cost reimbursement that is reported as revenue is presented gross of the related reimbursable expenses in the Company&#x2019;s consolidated statements of operations; the related reimbursable expenses are expensed as incurred as research and development expense. The Company accounts for these contracts as a government grant which analogizes with International Accounting Standards 20 (&#x201c;IAS 20&#x201d;),&#160;&lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;color:#000000;"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has a significant development contract with BARDA and should BARDA reduce, cancel or not grant additional milestone projects, the Company&#x2019;s ability to continue future product development may be impacted. Refer to Note 12 for further details regarding the development contract with BARDA. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Disaggregation of Revenue&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company disaggregates revenue from contracts with customers by type of products and services, as it best depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. The following table disaggregates our revenue by major source (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nine Months Ended,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Instruments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;814&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;522&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,528&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,427&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consumables&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,765&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,442&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,150&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Instrument rentals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total product revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,641&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,306&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,044&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,634&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contribution revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,036&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,122&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,778&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,444&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,677&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,428&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,078&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Remaining Performance Obligations&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under ASC 606, the Company is required to disclose the aggregate amount of the transaction price that is allocated to unsatisfied or partially satisfied performance obligations as of September 30, 2022. However, the guidance provides certain practical expedients that limit this requirement, and therefore, the Company has elected to not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. The nature of the excluded unsatisfied performance obligations pursuant to the practical expedient include consumable shipments, service contracts, warranties and installation services that will be performed within one year. The amount of the transaction price that is allocated to unsatisfied or partially satisfied performance obligations, that has not yet been recognized as revenue and that does not meet the elected practical expedient is $0.1 million as of September 30, 2022. The Company expects to recognize 86% of this amount as revenue within one year and the remainder within fifteen months.  &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Judgments&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain contracts with customers include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require judgment. Once the performance obligations are determined, the Company determines the transaction price, which includes estimating the amount of variable consideration, based on the most likely amount, to be included in the transaction price, if any. The Company then allocates the transaction price to each performance obligation in the contract based on a relative standalone selling price method. The corresponding revenue is recognized as the related performance obligations are satisfied as discussed in the revenue categories above.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.83%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Judgment is required to determine the standalone selling price for each distinct performance obligation. The Company determines standalone selling price based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as a range of selling prices, market conditions and the expected costs and margin related to the performance obligations.&lt;/p&gt;

&lt;p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Contract Assets and Liabilities&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded $0.1 million of contract assets within other assets on the balance sheet at September 30, 2022. The contract assets represent revenue recognized for performance obligations in advance of cash receipt at the contract level based on the transaction price allocated to the respective performance obligations. The Company did not record any contract assets at December 31, 2021.&#160;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s contract liabilities consist of upfront payments for research and development contracts and maintenance services on instrument sales. Contract liabilities are classified in deferred revenue as current or noncurrent based on the timing of when revenue is expected to be recognized.&#160;&lt;span style="color:#000000;"&gt;Contract liabilities were $0.2 million and $0.5 million at September 30, 2022 and December 31, 2021, respectively. Revenue recognized during the nine months ended September 30, 2022 relating to contract liabilities at December 31, 2021 was $0.4 million and related to straight-line revenue recognition associated with maintenance agreements.&lt;/span&gt; &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Cost to Obtain and Fulfill a Contract&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes commission expenses paid to sales personnel that are recoverable and incremental to obtaining capital purchase agreements within the United States. These costs are classified as prepaid expenses and other current assets and other assets, based on their current or non-current nature, respectively. The Company capitalizes only those costs that are determined to be incremental and would not have occurred absent the customer contract. These capitalized costs are amortized as selling, general and administrative costs on a straight line basis over the expected period of benefit. These costs are reviewed periodically for impairment. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;span style="color:#000000;font-size:10pt;"&gt;At September 30, 2022, capitalized costs to fulfill contracts of less than $0.1 million was included in prepaid and other current assets. At December 31, 2021, capitalized costs to fulfill contracts of $0.1 million was included in prepaid and other current assets and less than $0.1 million was included in other non-current assets&lt;/span&gt;. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of Product Revenue &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of product revenue includes the cost of materials, direct labor and manufacturing overhead costs used in the manufacture of consumable diagnostic tests sold to customers, related warranty and license and royalty fees. Cost of product revenue also includes depreciation on T2-owned revenue generating T2Dx instruments that have been placed with customers under reagent rental agreements; costs of materials, direct labor and manufacturing overhead costs on the T2Dx instruments sold to customers; and other costs such as customer support costs, royalties and license fees, warranty and repair and maintenance expense on the T2Dx instruments that have been placed with customers under reagent rental agreements.&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development Costs &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs incurred in the research and development of the Company&#x2019;s product candidates are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including activities associated with delivering products or services associated with contribution revenue, clinical trials to evaluate the clinical utility of our product candidates, and costs associated with the enhancements of developed products. These costs include salaries and benefits, stock compensation, research related facility and overhead costs, laboratory supplies, equipment, depreciation on T2Dx instruments used for research and development activities and contract services.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses consist primarily of costs for our sales and marketing, finance, legal, human resources, business&lt;span style="color:#000000;"&gt; development and general management functions, as well as professional services, such as legal, consulting and accounting services. Other selling, general and administrative expenses include commercial support activity, facility-related costs, fees and expenses associated with obtaining and maintaining patents, clinical and economic studies and publications, marketing expenses, and travel expenses. We expense the majority of selling, general and administrative expenses as incurred.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recent Accounting Standards &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Accounting Standards Adopted &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;span style="font-style:italic;"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity's Own Equity (Subtopic 815-40)&#x2014;Accounting for Convertible Instruments and Contracts in an Entity's Own Equity&lt;/span&gt; (&#x201c;ASU 2020-06&#x201d;), which simplifies accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. The standard is effective for smaller reporting companies for fiscal years beginning after December 15, 2023 and interim periods within those fiscal years. The Company adopted the standard as of January 1, 2022. The adoption did not have a material impact on the Company&#x2019;s financial statements. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2021, the FASB issued ASU No. 2021-04, &lt;span style="font-style:italic;"&gt;Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#x201c;ASU 2021-04&#x201d;)&lt;/span&gt; which clarifies and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after a modification or exchange. This standard is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply this standard prospectively to modifications or exchanges occurring on or after the effective date of this standard. The Company adopted this standard as of January 1, 2022. The adoption did not have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In November 2021, the FASB issued ASU 2021-10,&lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;"&gt;&#160;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;. This ASU requires certain disclosures when companies (a) have received government assistance and (b) use a grant or contribution accounting model by analogy to other accounting guidance. A company that has received government assistance must provide disclosures related to the nature of the transaction, accounting policies used to account for the transaction, and the amounts and line items on the financial statements that are affected by the transaction. This ASU is effective for fiscal years beginning after December 15, 2021, with early adoption permitted, and can be applied either prospectively or retrospectively. The Company adopted this standard as of January 1, 2022. &lt;/span&gt;The adoption did not have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000401">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as defined in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The Company&#x2019;s condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, T2 Biosystems Securities Corporation. All intercompany balances and transactions have been eliminated. &#160; &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 12, 2022, we effected a reverse stock split at the ratio of 1 post-split share for every &lt;span style="-sec-ix-hidden:F_000449_2"&gt;50 pre-split shares&lt;/span&gt;. All common stock amounts and references have been retroactively adjusted for all figures presented to reflect this split unless specifically stated otherwise.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221012_20221012"
      id="F_000450">On October 12, 2022, we effected a reverse stock split at the ratio of 1 post-split share for every 50 pre-split shares. All common stock amounts and references have been retroactively adjusted for all figures presented to reflect this split unless specifically stated otherwise</us-gaap:StockholdersEquityReverseStockSplit>
    <ttoo:UnauditedInterimFinancialInformationPolicyTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000402">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unaudited Interim Financial Information &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain information and footnote disclosures normally included in the Company&#x2019;s annual financial statements have been condensed or omitted.&#160;Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying interim condensed consolidated balance sheet as of September&#160;30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September&#160;30, 2022 and 2021, the condensed consolidated statements of Series A convertible preferred stock and stockholders&#x2019; deficit for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2022 and 2021 and the related financial data and other information disclosed in these notes are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual financial statements, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company&#x2019;s financial position as of September&#160;30, 2022, and the results of its operations for the three and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021. The results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022, any other interim periods, or any future year or period. &lt;/p&gt;</ttoo:UnauditedInterimFinancialInformationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000403">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Segment Information &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#x2019;s chief operating decision maker is the Chief Executive Officer. The Company views its operations and manages its business in one operating segment, which is the business of developing and, upon regulatory clearance, commercializing its diagnostic products aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. &lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001492674_20220101_20220930"
      decimals="INF"
      id="F_000451"
      unitRef="U_ttooSegment">1</us-gaap:NumberOfOperatingSegments>
    <ttoo:GeographicInformationPolicyTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000418">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Geographic Information &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company sells its products domestically and internationally. Total international sales were approximately $1.2 million or 32% of total revenue and $0.6 million or 9% of total revenue for the three months ended September 30, 2022 and 2021, respectively. Total international sales were approximately $3.2 million or 19% of total revenue and $1.6 million or 8% of total revenue for the nine months ended September 30, 2022 and 2021, respectively.  &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the three months ended September 30, 2022, one international customer represented 12% of total revenue. For the three months ended September 30, 2021, no international customer represented greater than 10% of total revenue. For the nine months ended September 30, 2022 and 2021, no international customer represented greater than 10% of total revenue.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; The following table shows customers that represent greater than 10% of revenue for the period presented: &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nine Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer A&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer B&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer C&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2022 and December 31, 2021, the Company had outstanding receivables of $0.9 million and $0.6 million, respectively, from customers located outside of the U.S.&lt;/p&gt;</ttoo:GeographicInformationPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20220701_20220930"
      decimals="-5"
      id="F_000452"
      unitRef="U_iso4217USD">1200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20220701_20220930"
      decimals="2"
      id="F_000456"
      unitRef="U_xbrlipure">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20210701_20210930"
      decimals="-5"
      id="F_000453"
      unitRef="U_iso4217USD">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20210701_20210930"
      decimals="2"
      id="F_000457"
      unitRef="U_xbrlipure">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20220101_20220930"
      decimals="-5"
      id="F_000454"
      unitRef="U_iso4217USD">3200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20220101_20220930"
      decimals="2"
      id="F_000458"
      unitRef="U_xbrlipure">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20210101_20210930"
      decimals="-5"
      id="F_000455"
      unitRef="U_iso4217USD">1600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20210101_20210930"
      decimals="2"
      id="F_000459"
      unitRef="U_xbrlipure">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20220701_20220930"
      decimals="2"
      id="F_000460"
      unitRef="U_xbrlipure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20210701_20210930"
      decimals="2"
      id="F_000462"
      unitRef="U_xbrlipure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20220101_20220930"
      decimals="2"
      id="F_000461"
      unitRef="U_xbrlipure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_us-gaapNonUsMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapGeographicConcentrationRiskMember_20210101_20210930"
      decimals="2"
      id="F_000463"
      unitRef="U_xbrlipure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000419">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; The following table shows customers that represent greater than 10% of revenue for the period presented: &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nine Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer A&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer B&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer C&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001492674_srtMajorCustomersAxis_ttooCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20220701_20220930"
      decimals="2"
      id="F_000464"
      unitRef="U_xbrlipure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001492674_srtMajorCustomersAxis_ttooCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210701_20210930"
      decimals="2"
      id="F_000465"
      unitRef="U_xbrlipure">0.42</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001492674_srtMajorCustomersAxis_ttooCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20220101_20220930"
      decimals="2"
      id="F_000466"
      unitRef="U_xbrlipure">0.46</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001492674_srtMajorCustomersAxis_ttooCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20210930"
      decimals="2"
      id="F_000467"
      unitRef="U_xbrlipure">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001492674_srtMajorCustomersAxis_ttooCustomerBMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210701_20210930"
      decimals="2"
      id="F_000468"
      unitRef="U_xbrlipure">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001492674_srtMajorCustomersAxis_ttooCustomerBMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20210930"
      decimals="2"
      id="F_000469"
      unitRef="U_xbrlipure">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001492674_srtMajorCustomersAxis_ttooCustomerCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20220701_20220930"
      decimals="2"
      id="F_000470"
      unitRef="U_xbrlipure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20220930"
      decimals="-5"
      id="F_000471"
      unitRef="U_iso4217USD">900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001492674_srtStatementGeographicalAxis_us-gaapNonUsMember_20211231"
      decimals="-5"
      id="F_000472"
      unitRef="U_iso4217USD">600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000405">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies the two-class method for computing earnings per share because its Series A redeemable convertible preferred stock and the warrants issued with that preferred stock are participating securities. Under the two-class method, net income for the period is allocated between common stockholders and the participating securities according to dividends declared, if any, and participation rights in undistributed earnings. Because the Company incurred a net loss for the three and nine months ended September 30, 2022, and the holders of the participating securities do not have the contractual obligation to share in the losses of the Company on a basis that is objectively determinable, none of the net loss attributable to common stockholders was allocated to the participating securities when computing earnings per share.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is calculated by dividing net loss attributable to commons stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Any accretion of the carrying amount of the Company&#x2019;s Series A redeemable convertible preferred stock to its redemption amount is treated as a deemed dividend to the preferred stockholders and will increase the amount of the net loss attributable to common stockholders. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using either the if-converted method (for its Series A redeemable, convertible preferred stock) or the treasury-stock method. For purposes of the diluted net loss per share calculation, stock options and unvested restricted stock, restricted stock contingently issuable upon achievement of certain market conditions, and the warrants issued with Series A redeemable convertible preferred stock are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. In periods in which the Company recognizes gains due to changes in the fair value of its warrant liability, the Company will further assess whether the effect of adjusting its computation of diluted net loss per share to include the potential common shares and reverse the gain associated with the warrant would result in a more diluted net loss per share, and modify the computation if necessary. The Series A redeemable convertible preferred stock was not considered a common stock equivalent because exercise of the conversion option was contingent upon occurrence of the reverse stock split, which had not yet occurred as of September 30, 2022. Therefore, basic and diluted net loss per share applicable to common stockholders was the same for all periods presented.  &lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="C_0001492674_20220101_20220930" id="F_000406">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable Securities &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s marketable securities consist of U.S. treasury securities, which are classified as available-for-sale and included in current assets. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported as a component of stockholders&#x2019; deficit in accumulated other comprehensive (loss) income. Realized gains and losses, if any, are included in other income (expense) in the condensed consolidated statements of operations. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security&#x2019;s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported as a component of stockholders&#x2019; deficit in accumulated other comprehensive loss (income). &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had no marketable securities at September 30, 2022. The following table summarizes the Company&#x2019;s marketable securities at December 31, 2021 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &#160; &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the maturities of the Company&#x2019;s marketable securities at December 31, 2021 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:50%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due in less than 1 year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due in 1-2 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000420">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had no marketable securities at September 30, 2022. The following table summarizes the Company&#x2019;s marketable securities at December 31, 2021 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &#160; &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001492674_20220930"
      decimals="INF"
      id="F_000473"
      unitRef="U_iso4217USD">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001492674_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20211231"
      decimals="-3"
      id="F_000474"
      unitRef="U_iso4217USD">10000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001492674_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20211231"
      decimals="-3"
      id="F_000476"
      unitRef="U_iso4217USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001492674_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20211231"
      decimals="-3"
      id="F_000478"
      unitRef="U_iso4217USD">9996000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000475"
      unitRef="U_iso4217USD">10000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000477"
      unitRef="U_iso4217USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000479"
      unitRef="U_iso4217USD">9996000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000421">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the maturities of the Company&#x2019;s marketable securities at December 31, 2021 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:50%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due in less than 1 year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due in 1-2 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000480"
      unitRef="U_iso4217USD">10000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000482"
      unitRef="U_iso4217USD">9996000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000481"
      unitRef="U_iso4217USD">10000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000483"
      unitRef="U_iso4217USD">9996000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DerivativesPolicyTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000407">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative&#160;Warrant Liability&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with&#160;ASC Topic 815,&#160;&lt;span style="font-style:italic;"&gt;&#x201c;Derivatives and Hedging&lt;/span&gt;.&#x201d;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the liability for the warrant issued in conjunction with the Series A redeemable convertible preferred stock is a&#160;derivative&#160;instrument.&#160; The derivative warrant liability is classified on the condensed consolidated balance sheets as current because cash settlement of the warrant could be required by the holder within 12 months of the balance sheet date. The Company has identified a single compound derivative liability related to its Term Loan Agreement with CRG, that is classified as non-current on the condensed consolidated balance sheets to match the classification of the related Term Loan Agreement.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As the derivative liabilities meet the definition of a&#160;derivative, they are measured at fair value at issuance and at each reporting date in accordance with&#160;ASC 820, &#x201c;&lt;span style="font-style:italic;"&gt;Fair Value Measurement,&#x201d;&lt;/span&gt;&#160;with changes in fair value recognized in change in fair value of derivative warrant liability in the period of change in the condensed consolidated statements of operations and comprehensive loss. The Company does not designate its&#160;derivative&#160;instruments as hedging instruments.&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies contextRef="C_0001492674_20220101_20220930" id="F_000408">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Guarantees &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while each such officer or director is, or was, serving at the Company&#x2019;s request in such capacity. The term of the indemnification is the officer&#x2019;s or director&#x2019;s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#x2019; and officers&#x2019; liability insurance coverage that limits its exposure and enables the Company to recover a portion of any future amounts paid. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases office, laboratory and manufacturing space under noncancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify the landlords against all costs, expenses, fines, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company&#x2019;s leases. &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company&#x2019;s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements.  &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September&#160;30, 2022 and December&#160;31, 2021, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established. &lt;/p&gt;</us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000409">Leases
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to Topic 842, &lt;span style="font-style:italic;"&gt;Leases&lt;/span&gt; (&#x201c;ASC 842&#x201d;), at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. The exercise of lease renewal options is at our discretion and the renewal to extend the lease terms are not included in the Company&#x2019;s right-of-use assets and lease liabilities as they are not reasonably certain of exercise. The Company will evaluate the renewal options and when they are reasonably certain of exercise, the Company will include the renewal period in its lease term. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued lease payments. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance with the guidance in ASC 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). Then the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company made the policy election to not separate lease and non-lease components. Each lease component and the related non-lease components are accounted for together as a single component. &lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy contextRef="C_0001492674_20220101_20220930" id="F_000411">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Classification of Series A Redeemable Convertible Preferred Stock &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has applied the guidance in ASC 480-10-S99-3A, SEC Staff Announcement: Classification and Measurement of Redeemable Securities and classified the Series A redeemable convertible preferred stock as temporary equity in the mezzanine section of the balance sheet. The Series A redeemable convertible preferred stock was recorded outside of stockholders&#x2019; deficit because under the terms thereof, in the event of stockholder approval of the reverse stock split or a delisting event, which are events considered not solely within the Company&#x2019;s control, the Series A redeemable convertible preferred stock becomes redeemable at the option of the holders.&lt;/p&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000413">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company generates revenue from the sale of instruments, consumable diagnostic tests, related services, reagent rental agreements and government contributions. Pursuant to ASC 606, &lt;span style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt; (&#x201c;ASC 606&#x201d;), the Company determines revenue recognition through the following steps:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.4%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.5%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Identification of a contract with a customer&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.4%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.5%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Identification of the performance obligations in the contract&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.4%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.5%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Determination of the transaction price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.4%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.5%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Allocation of the transaction price to the performance obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.4%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.5%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Recognition of revenue as a performance obligation is satisfied&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The amount of revenue recognized reflects the consideration the Company expects to be entitled to receive in exchange for these goods and services. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company's performance obligations are transferred to customers at a point in time, typically upon shipment, or over time, as services are performed.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Most of the Company&#x2019;s contracts with distributors in geographic regions outside the United States contain only a single performance obligation, whereas most of the Company&#x2019;s contracts with direct sales customers in the United States contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. Excluded from the transaction price are sales tax and other similar taxes which are presented on a net basis.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue is generated by the sale of instruments and consumable diagnostic tests predominantly through the Company&#x2019;s direct sales force in the United States and distributors in geographic regions outside the United States. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors&#x2019; receipt of payment from their end-user customers. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company either sells instruments to customers and international distributors, or retains title and places the instrument at the customer site pursuant to a reagent rental agreement.&#160;When an instrument is purchased by a customer or international distributor, the Company recognizes revenue when the related performance obligation is satisfied (i.e. when the control of an instrument has passed to the customer; typically, at shipping point). &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When the instrument is placed under a reagent rental agreement, the Company&#x2019;s customers generally agree to fixed term agreements, which can be extended, and incremental charges on each consumable diagnostic test purchased. Revenue from the sale of consumable diagnostic tests (under a reagent rental agreement) is generally recognized upon shipment. The transaction price from consumables purchases is allocated between the lease of the instrument (under a contingent rent methodology as provided for in ASC 842, &lt;span style="font-style:italic;"&gt;Leases&lt;/span&gt;), and the consumables when related performance obligations are satisfied, as a component of lease and product revenue, and is included as Instrument Rentals in the below table. Revenue associated with reagent rental consumables purchases is currently classified as variable consideration and constrained until a purchase order is received and related performance obligations have been satisfied.&#160;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue from the sale of consumable diagnostic tests (under instrument purchase agreements) is generally recognized upon shipment. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shipping and handling costs billed to customers in connection with a product sale are recorded as a component of the transaction price and allocated to product revenue in the condensed consolidated statements of operations and comprehensive loss as they are incurred by the Company in fulfilling its performance obligations.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Direct sales of instruments include warranty, maintenance and technical support services typically for one year following the installation of the purchased instrument (&#x201c;Maintenance Services&#x201d;). &lt;span style="color:#000000;"&gt;Maintenance Services are separate performance obligations as they are service-based warranties and are recognized on a straight-line basis over the service delivery period. After the completion of the initial Maintenance Services period, customers have the option to renew or extend the Maintenance Services typically for additional&lt;/span&gt; &lt;span style="-sec-ix-hidden:F_000485"&gt;one-year&lt;/span&gt; periods in exchange for additional consideration. The extended Maintenance Services are also service-based warranties that represent separate purchasing decisions. The Company recognizes revenue allocated to the extended Maintenance Services performance obligation on a straight-line basis over the service delivery period.&#160;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fees paid to member-owned group purchasing organizations (&#x201c;GPOs&#x201d;) are deducted from related product revenues.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company warrants that consumable diagnostic tests will be free from defects, when handled according to product specifications, for the stated life of the product. To fulfill valid warranty claims, the Company provides replacement product free of charge. Warranty expense is recognized based on the estimated defect rates of the consumable diagnostic tests.&lt;/p&gt;

&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Contribution Revenue&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income under the government BARDA contract is earned under a cost-sharing arrangement in which the Company is reimbursed for direct costs incurred plus allowable indirect costs. The g&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;overnment contract revenue is recognized as the related reimbursable expenses are incurred.&#160;&#160;The cost reimbursement that is reported as revenue is presented gross of the related reimbursable expenses in the Company&#x2019;s consolidated statements of operations; the related reimbursable expenses are expensed as incurred as research and development expense. The Company accounts for these contracts as a government grant which analogizes with International Accounting Standards 20 (&#x201c;IAS 20&#x201d;),&#160;&lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;color:#000000;"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has a significant development contract with BARDA and should BARDA reduce, cancel or not grant additional milestone projects, the Company&#x2019;s ability to continue future product development may be impacted. Refer to Note 12 for further details regarding the development contract with BARDA. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Disaggregation of Revenue&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company disaggregates revenue from contracts with customers by type of products and services, as it best depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. The following table disaggregates our revenue by major source (in thousands):&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nine Months Ended,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Instruments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;814&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;522&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,528&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,427&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consumables&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,765&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,442&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,150&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Instrument rentals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total product revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,641&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,306&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,044&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,634&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contribution revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,036&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,122&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,778&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,444&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,677&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,428&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,078&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Remaining Performance Obligations&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under ASC 606, the Company is required to disclose the aggregate amount of the transaction price that is allocated to unsatisfied or partially satisfied performance obligations as of September 30, 2022. However, the guidance provides certain practical expedients that limit this requirement, and therefore, the Company has elected to not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. The nature of the excluded unsatisfied performance obligations pursuant to the practical expedient include consumable shipments, service contracts, warranties and installation services that will be performed within one year. The amount of the transaction price that is allocated to unsatisfied or partially satisfied performance obligations, that has not yet been recognized as revenue and that does not meet the elected practical expedient is $0.1 million as of September 30, 2022. The Company expects to recognize 86% of this amount as revenue within one year and the remainder within fifteen months.  &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Judgments&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain contracts with customers include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require judgment. Once the performance obligations are determined, the Company determines the transaction price, which includes estimating the amount of variable consideration, based on the most likely amount, to be included in the transaction price, if any. The Company then allocates the transaction price to each performance obligation in the contract based on a relative standalone selling price method. The corresponding revenue is recognized as the related performance obligations are satisfied as discussed in the revenue categories above.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.83%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Judgment is required to determine the standalone selling price for each distinct performance obligation. The Company determines standalone selling price based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as a range of selling prices, market conditions and the expected costs and margin related to the performance obligations.&lt;/p&gt;

&lt;p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Contract Assets and Liabilities&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded $0.1 million of contract assets within other assets on the balance sheet at September 30, 2022. The contract assets represent revenue recognized for performance obligations in advance of cash receipt at the contract level based on the transaction price allocated to the respective performance obligations. The Company did not record any contract assets at December 31, 2021.&#160;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s contract liabilities consist of upfront payments for research and development contracts and maintenance services on instrument sales. Contract liabilities are classified in deferred revenue as current or noncurrent based on the timing of when revenue is expected to be recognized.&#160;&lt;span style="color:#000000;"&gt;Contract liabilities were $0.2 million and $0.5 million at September 30, 2022 and December 31, 2021, respectively. Revenue recognized during the nine months ended September 30, 2022 relating to contract liabilities at December 31, 2021 was $0.4 million and related to straight-line revenue recognition associated with maintenance agreements.&lt;/span&gt; &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Cost to Obtain and Fulfill a Contract&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes commission expenses paid to sales personnel that are recoverable and incremental to obtaining capital purchase agreements within the United States. These costs are classified as prepaid expenses and other current assets and other assets, based on their current or non-current nature, respectively. The Company capitalizes only those costs that are determined to be incremental and would not have occurred absent the customer contract. These capitalized costs are amortized as selling, general and administrative costs on a straight line basis over the expected period of benefit. These costs are reviewed periodically for impairment. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;span style="color:#000000;font-size:10pt;"&gt;At September 30, 2022, capitalized costs to fulfill contracts of less than $0.1 million was included in prepaid and other current assets. At December 31, 2021, capitalized costs to fulfill contracts of $0.1 million was included in prepaid and other current assets and less than $0.1 million was included in other non-current assets&lt;/span&gt;. &lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <ttoo:MaintenanceServicePeriod
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooT2DxMember_20220101_20220930"
      id="F_000484">P1Y</ttoo:MaintenanceServicePeriod>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000422">The following table disaggregates our revenue by major source (in thousands):
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nine Months Ended,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Instruments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;814&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;522&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,528&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,427&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consumables&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,765&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,442&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,150&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Instrument rentals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total product revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,641&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,306&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,044&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,634&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contribution revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,036&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,122&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,778&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,444&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.8%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,677&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,428&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,078&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:2.5%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooProductInstrumentsMember_20220701_20220930"
      decimals="-3"
      id="F_000486"
      unitRef="U_iso4217USD">814000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooProductInstrumentsMember_20210701_20210930"
      decimals="-3"
      id="F_000487"
      unitRef="U_iso4217USD">522000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooProductInstrumentsMember_20220101_20220930"
      decimals="-3"
      id="F_000488"
      unitRef="U_iso4217USD">2528000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooProductInstrumentsMember_20210101_20210930"
      decimals="-3"
      id="F_000489"
      unitRef="U_iso4217USD">1427000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooProductConsumablesMember_20220701_20220930"
      decimals="-3"
      id="F_000490"
      unitRef="U_iso4217USD">1822000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooProductConsumablesMember_20210701_20210930"
      decimals="-3"
      id="F_000491"
      unitRef="U_iso4217USD">3765000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooProductConsumablesMember_20220101_20220930"
      decimals="-3"
      id="F_000492"
      unitRef="U_iso4217USD">6442000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooProductConsumablesMember_20210101_20210930"
      decimals="-3"
      id="F_000493"
      unitRef="U_iso4217USD">11150000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooInstrumentRentalsMember_20220701_20220930"
      decimals="-3"
      id="F_000494"
      unitRef="U_iso4217USD">5000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooInstrumentRentalsMember_20210701_20210930"
      decimals="-3"
      id="F_000495"
      unitRef="U_iso4217USD">19000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooInstrumentRentalsMember_20220101_20220930"
      decimals="-3"
      id="F_000496"
      unitRef="U_iso4217USD">74000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooInstrumentRentalsMember_20210101_20210930"
      decimals="-3"
      id="F_000497"
      unitRef="U_iso4217USD">57000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20220701_20220930"
      decimals="-3"
      id="F_000498"
      unitRef="U_iso4217USD">2641000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20210701_20210930"
      decimals="-3"
      id="F_000499"
      unitRef="U_iso4217USD">4306000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20220101_20220930"
      decimals="-3"
      id="F_000500"
      unitRef="U_iso4217USD">9044000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_20210101_20210930"
      decimals="-3"
      id="F_000501"
      unitRef="U_iso4217USD">12634000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooContributionRevenueMember_20220701_20220930"
      decimals="-3"
      id="F_000502"
      unitRef="U_iso4217USD">1036000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooContributionRevenueMember_20210701_20210930"
      decimals="-3"
      id="F_000503"
      unitRef="U_iso4217USD">3122000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooContributionRevenueMember_20220101_20220930"
      decimals="-3"
      id="F_000504"
      unitRef="U_iso4217USD">7778000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtProductOrServiceAxis_ttooContributionRevenueMember_20210101_20210930"
      decimals="-3"
      id="F_000505"
      unitRef="U_iso4217USD">8444000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000506"
      unitRef="U_iso4217USD">3677000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_20210701_20210930"
      decimals="-3"
      id="F_000507"
      unitRef="U_iso4217USD">7428000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000508"
      unitRef="U_iso4217USD">16822000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000509"
      unitRef="U_iso4217USD">21078000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ttoo:OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed
      contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_20220101_20220930"
      id="F_000510">P1Y</ttoo:OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_0001492674_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-10-01_20220930"
      decimals="-5"
      id="F_000513"
      unitRef="U_iso4217USD">100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation contextRef="C_0001492674_20220101_20220930" id="F_000511">The Company expects to recognize 86% of this amount as revenue within one year and the remainder within fifteen months.</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="C_0001492674_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-10-01_20220930"
      decimals="2"
      id="F_000514"
      unitRef="U_xbrlipure">0.86</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_0001492674_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-10-01_20220930"
      id="F_000515">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_20220930"
      id="F_000512">P15M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001492674_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentAssetsMember_20220930"
      decimals="-5"
      id="F_000516"
      unitRef="U_iso4217USD">100000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001492674_20211231"
      decimals="0"
      id="F_000517"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001492674_20220930"
      decimals="-5"
      id="F_000518"
      unitRef="U_iso4217USD">200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001492674_20211231"
      decimals="-5"
      id="F_000519"
      unitRef="U_iso4217USD">500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001492674_20220101_20220930"
      decimals="-5"
      id="F_000520"
      unitRef="U_iso4217USD">400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20220930"
      decimals="INF"
      id="F_000523"
      unitRef="U_iso4217USD">100000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_0001492674_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20211231"
      decimals="-5"
      id="F_000521"
      unitRef="U_iso4217USD">100000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentAssetsMember_20211231"
      decimals="INF"
      id="F_000522"
      unitRef="U_iso4217USD">100000</us-gaap:CapitalizedContractCostGross>
    <ttoo:CostOfProductRevenuePolicyTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000414">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of Product Revenue &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of product revenue includes the cost of materials, direct labor and manufacturing overhead costs used in the manufacture of consumable diagnostic tests sold to customers, related warranty and license and royalty fees. Cost of product revenue also includes depreciation on T2-owned revenue generating T2Dx instruments that have been placed with customers under reagent rental agreements; costs of materials, direct labor and manufacturing overhead costs on the T2Dx instruments sold to customers; and other costs such as customer support costs, royalties and license fees, warranty and repair and maintenance expense on the T2Dx instruments that have been placed with customers under reagent rental agreements.&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;</ttoo:CostOfProductRevenuePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001492674_20220101_20220930" id="F_000415">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development Costs &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs incurred in the research and development of the Company&#x2019;s product candidates are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including activities associated with delivering products or services associated with contribution revenue, clinical trials to evaluate the clinical utility of our product candidates, and costs associated with the enhancements of developed products. These costs include salaries and benefits, stock compensation, research related facility and overhead costs, laboratory supplies, equipment, depreciation on T2Dx instruments used for research and development activities and contract services.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000416">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses consist primarily of costs for our sales and marketing, finance, legal, human resources, business&lt;span style="color:#000000;"&gt; development and general management functions, as well as professional services, such as legal, consulting and accounting services. Other selling, general and administrative expenses include commercial support activity, facility-related costs, fees and expenses associated with obtaining and maintaining patents, clinical and economic studies and publications, marketing expenses, and travel expenses. We expense the majority of selling, general and administrative expenses as incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000417">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recent Accounting Standards &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Accounting Standards Adopted &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;span style="font-style:italic;"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity's Own Equity (Subtopic 815-40)&#x2014;Accounting for Convertible Instruments and Contracts in an Entity's Own Equity&lt;/span&gt; (&#x201c;ASU 2020-06&#x201d;), which simplifies accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. The standard is effective for smaller reporting companies for fiscal years beginning after December 15, 2023 and interim periods within those fiscal years. The Company adopted the standard as of January 1, 2022. The adoption did not have a material impact on the Company&#x2019;s financial statements. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2021, the FASB issued ASU No. 2021-04, &lt;span style="font-style:italic;"&gt;Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#x201c;ASU 2021-04&#x201d;)&lt;/span&gt; which clarifies and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after a modification or exchange. This standard is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply this standard prospectively to modifications or exchanges occurring on or after the effective date of this standard. The Company adopted this standard as of January 1, 2022. The adoption did not have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In November 2021, the FASB issued ASU 2021-10,&lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;"&gt;&#160;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;. This ASU requires certain disclosures when companies (a) have received government assistance and (b) use a grant or contribution accounting model by analogy to other accounting guidance. A company that has received government assistance must provide disclosures related to the nature of the transaction, accounting policies used to account for the transaction, and the amounts and line items on the financial statements that are affected by the transaction. This ASU is effective for fiscal years beginning after December 15, 2021, with early adoption permitted, and can be applied either prospectively or retrospectively. The Company adopted this standard as of January 1, 2022. &lt;/span&gt;The adoption did not have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202006Member_20220930"
      id="F_000525">2022-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202104Member_20220930"
      id="F_000528">2022-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001492674_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate202110Member_20220930"
      id="F_000531">2022-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000388">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. Fair Value Measurements &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures the following financial assets at fair value on a recurring basis. There were no transfers between levels of the fair value hierarchy during any of the periods presented. The following tables set forth the Company&#x2019;s financial assets and liabilities carried at fair value categorized using the lowest level of input applicable to each financial instrument as of September&#160;30, 2022 and December&#160;31, 2021 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted Prices&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;in Active&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Markets for&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Identical Assets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Observable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unobservable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative warrant liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.9%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,792&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,792&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.9%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,978&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,792&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted Prices&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;in Active&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Markets for&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Identical Assets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Observable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unobservable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US Treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s cash equivalents and available-for-sale marketable securities were comprised of government securities. Securities are classified as cash equivalents when the original maturities are within 90 days of the purchase dates. The Company also maintains money market accounts classified as restricted cash for $1.1 million at September 30, 2022 and $1.6 million at December 31, 2021 (Note 4).&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimated the fair value of the derivative warrant liability (Note 7) using the Black-Scholes Model, which uses multiple inputs including the Company&#x2019;s stock price, the exercise price of the warrant, volatility of the Company&#x2019;s stock price, the risk-free interest rate and the expected term of the warrant. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has a single compound derivative related to its Term Loan Agreement with CRG (the &#x201c;Term Loan Agreement&#x201d;) (Note 6), which is required to be re-measured at fair value on a quarterly basis. The fair value of the derivative at September 30, 2022 is $1.8 million and is classified as a non-current liability on the balance sheet at September 30, 2022 to match the classification of the related Term Loan Agreement (Note 6). As of December 31, 2021, the Company had no derivative liability. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The estimated fair value of the derivative at September 30, 2022 was determined using a probability-weighted discounted cash flow model that includes contingent interest payments under the following scenarios:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:50%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Probability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4% contingent interest beginning in Q1 2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a roll-forward of the fair value of the derivative liability (in thousands):&lt;span style="color:#000000;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value of derivative liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,675&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at June 30, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,675&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value of derivative liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;117&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.38%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at September 30, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,792&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000423">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures the following financial assets at fair value on a recurring basis. There were no transfers between levels of the fair value hierarchy during any of the periods presented. The following tables set forth the Company&#x2019;s financial assets and liabilities carried at fair value categorized using the lowest level of input applicable to each financial instrument as of September&#160;30, 2022 and December&#160;31, 2021 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted Prices&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;in Active&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Markets for&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Identical Assets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Observable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unobservable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative warrant liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.9%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,792&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,792&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.9%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,978&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,792&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted Prices&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;in Active&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Markets for&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Identical Assets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Observable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unobservable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US Treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="C_0001492674_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220930"
      decimals="-3"
      id="F_000533"
      unitRef="U_iso4217USD">186000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="C_0001492674_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220930"
      decimals="-3"
      id="F_000534"
      unitRef="U_iso4217USD">186000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilities
      contextRef="C_0001492674_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220930"
      decimals="-3"
      id="F_000535"
      unitRef="U_iso4217USD">1792000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="C_0001492674_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220930"
      decimals="-3"
      id="F_000536"
      unitRef="U_iso4217USD">1792000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001492674_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220930"
      decimals="-3"
      id="F_000537"
      unitRef="U_iso4217USD">1978000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001492674_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220930"
      decimals="-3"
      id="F_000538"
      unitRef="U_iso4217USD">186000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001492674_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20220930"
      decimals="-3"
      id="F_000539"
      unitRef="U_iso4217USD">1792000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001492674_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000540"
      unitRef="U_iso4217USD">9996000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001492674_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasurySecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000541"
      unitRef="U_iso4217USD">9996000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001492674_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000542"
      unitRef="U_iso4217USD">9996000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001492674_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000543"
      unitRef="U_iso4217USD">9996000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:SecurityDeposit
      contextRef="C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20220930"
      decimals="-5"
      id="F_000544"
      unitRef="U_iso4217USD">1100000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20211231"
      decimals="-5"
      id="F_000545"
      unitRef="U_iso4217USD">1600000</us-gaap:SecurityDeposit>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220930"
      decimals="-5"
      id="F_000546"
      unitRef="U_iso4217USD">1800000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20211231"
      decimals="0"
      id="F_000547"
      unitRef="U_iso4217USD">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <ttoo:SummaryOfContingentInterestPaymentsTableTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000424">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The estimated fair value of the derivative at September 30, 2022 was determined using a probability-weighted discounted cash flow model that includes contingent interest payments under the following scenarios:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:50%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Probability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4% contingent interest beginning in Q1 2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ttoo:SummaryOfContingentInterestPaymentsTableTextBlock>
    <ttoo:ContingentPaymentOfInterestPercentage
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220101_20220930"
      decimals="2"
      id="F_000549"
      unitRef="U_xbrlipure">0.04</ttoo:ContingentPaymentOfInterestPercentage>
    <ttoo:FairValueDerivativeLiabilityDiscountRate
      contextRef="C_0001492674_us-gaapContingentConsiderationByTypeAxis_ttooScenarioOneMember_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_20220101_20220930"
      decimals="2"
      id="F_000548"
      unitRef="U_xbrlipure">0.50</ttoo:FairValueDerivativeLiabilityDiscountRate>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000425">The following table provides a roll-forward of the fair value of the derivative liability (in thousands):
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value of derivative liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,675&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at June 30, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,675&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value of derivative liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;117&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.38%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at September 30, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,792&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_0001492674_us-gaapValuationTechniqueAxis_ttooProbabilityWeightedDiscountedCashFlowModelMember_20220101_20220630"
      decimals="-3"
      id="F_000550"
      unitRef="U_iso4217USD">1675000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeLiabilities
      contextRef="C_0001492674_20220630"
      decimals="-3"
      id="F_000551"
      unitRef="U_iso4217USD">1675000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_0001492674_us-gaapValuationTechniqueAxis_ttooProbabilityWeightedDiscountedCashFlowModelMember_20220701_20220930"
      decimals="-3"
      id="F_000552"
      unitRef="U_iso4217USD">117000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeLiabilities
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000553"
      unitRef="U_iso4217USD">1792000</us-gaap:DerivativeLiabilities>
    <us-gaap:RestrictedAssetsDisclosureTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000389">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. Restricted Cash &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is required to maintain security deposits for its operating lease agreements for the duration of the lease agreements. At September 30, 2022, the Company had money market accounts for $1.1 million, which represented collateral as security deposits for its operating lease agreements for two facilities. At December 31, 2021, the Company had money market accounts for $1.6 million, which represented collateral as security deposits for its operating lease agreements for three facilities. &lt;/p&gt;</us-gaap:RestrictedAssetsDisclosureTextBlock>
    <us-gaap:SecurityDeposit
      contextRef="C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20220930"
      decimals="-5"
      id="F_000555"
      unitRef="U_iso4217USD">1100000</us-gaap:SecurityDeposit>
    <ttoo:NumberOfFacilities
      contextRef="C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20220101_20220930"
      decimals="INF"
      id="F_000557"
      unitRef="U_ttooFacility">2</ttoo:NumberOfFacilities>
    <us-gaap:SecurityDeposit
      contextRef="C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20211231"
      decimals="-5"
      id="F_000554"
      unitRef="U_iso4217USD">1600000</us-gaap:SecurityDeposit>
    <ttoo:NumberOfFacilities
      contextRef="C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20210101_20211231"
      decimals="INF"
      id="F_000556"
      unitRef="U_ttooFacility">3</ttoo:NumberOfFacilities>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000390">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. Supplemental Balance Sheet Information &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis and are comprised of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,195&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,591&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Work-in-process&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,231&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;953&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;816&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,365&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total inventories, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,242&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,909&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office and computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;749&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;749&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;783&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;783&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,507&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;197&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;197&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,445&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,445&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing tooling and molds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;T2-owned instruments and components&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,150&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,668&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,785&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,768&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;774&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;512&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,934&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,107&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,432&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,734&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,675&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress is primarily comprised of equipment that has not been placed in service. T2-owned instruments and components is comprised of raw materials and work-in-process inventory that are expected to be used or used to produce T2-owned instruments, based on the Company&#x2019;s business model and forecast, and completed instruments that will be used for internal research and development, clinical studies or reagent rental agreements with customers.&#160;&lt;span style="color:#000000;"&gt;At September&#160;30, 2022, there was $1.0 million of raw materials or work-in-process inventory in T2-owned instruments and components compared with $1.4 million at December 31, 2021. Completed T2-owned instruments are placed in service once installation procedures are completed and are depreciated over five years.&#160;Depreciation expense for T2-owned instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of product revenue and was immaterial for the three months ended September 30, 2022 and 2021. Depreciation expense for T2-owned instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of product revenue and was $0.1 million for the nine months ended September 30, 2022 and 2021. &lt;/span&gt; &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense for T2-owned instruments used for internal research and development and clinical studies is recorded as a component of research and development expense. &lt;span style="color:#000000;"&gt;Depreciation and amortization expense of $0.3 million and $0.3 million was charged to operations for the three months ended September 30, 2022 and 2021, respectively. Depreciation and amortization expense of $0.8 million and $1.0 million was charged to operations for the nine months ended September 30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued Expenses &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consist of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued payroll and compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,894&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,687&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,482&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,250&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;392&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;384&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;974&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,295&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,174&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;468&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;869&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,531&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,338&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000426">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis and are comprised of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,195&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,591&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Work-in-process&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,231&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;953&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;816&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,365&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total inventories, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,242&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,909&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000558"
      unitRef="U_iso4217USD">2195000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000559"
      unitRef="U_iso4217USD">1591000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000560"
      unitRef="U_iso4217USD">1231000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000561"
      unitRef="U_iso4217USD">953000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000562"
      unitRef="U_iso4217USD">816000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000563"
      unitRef="U_iso4217USD">1365000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000564"
      unitRef="U_iso4217USD">4242000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000565"
      unitRef="U_iso4217USD">3909000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000427">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office and computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;749&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;749&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;783&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;783&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,507&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;197&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;197&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,445&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,445&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing tooling and molds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;T2-owned instruments and components&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,150&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,668&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,785&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,768&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;774&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;512&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,934&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,107&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,432&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,734&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,675&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20220930"
      decimals="-3"
      id="F_000566"
      unitRef="U_iso4217USD">749000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20211231"
      decimals="-3"
      id="F_000567"
      unitRef="U_iso4217USD">749000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20220930"
      decimals="-3"
      id="F_000568"
      unitRef="U_iso4217USD">783000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20211231"
      decimals="-3"
      id="F_000569"
      unitRef="U_iso4217USD">783000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20220930"
      decimals="-3"
      id="F_000570"
      unitRef="U_iso4217USD">5573000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20211231"
      decimals="-3"
      id="F_000571"
      unitRef="U_iso4217USD">5507000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20220930"
      decimals="-3"
      id="F_000572"
      unitRef="U_iso4217USD">197000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231"
      decimals="-3"
      id="F_000573"
      unitRef="U_iso4217USD">197000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20220930"
      decimals="-3"
      id="F_000574"
      unitRef="U_iso4217USD">1445000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20211231"
      decimals="-3"
      id="F_000575"
      unitRef="U_iso4217USD">1445000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapToolsDiesAndMoldsMember_20220930"
      decimals="-3"
      id="F_000576"
      unitRef="U_iso4217USD">478000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapToolsDiesAndMoldsMember_20211231"
      decimals="-3"
      id="F_000577"
      unitRef="U_iso4217USD">478000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooT2DxInstrumentsAndComponentsMember_20220930"
      decimals="-3"
      id="F_000578"
      unitRef="U_iso4217USD">7150000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooT2DxInstrumentsAndComponentsMember_20211231"
      decimals="-3"
      id="F_000579"
      unitRef="U_iso4217USD">6668000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20220930"
      decimals="-3"
      id="F_000580"
      unitRef="U_iso4217USD">3785000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231"
      decimals="-3"
      id="F_000581"
      unitRef="U_iso4217USD">3768000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20220930"
      decimals="-3"
      id="F_000582"
      unitRef="U_iso4217USD">774000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231"
      decimals="-3"
      id="F_000583"
      unitRef="U_iso4217USD">512000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000584"
      unitRef="U_iso4217USD">20934000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000585"
      unitRef="U_iso4217USD">20107000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000586"
      unitRef="U_iso4217USD">16200000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000587"
      unitRef="U_iso4217USD">15432000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000588"
      unitRef="U_iso4217USD">4734000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000589"
      unitRef="U_iso4217USD">4675000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="C_0001492674_20220930"
      decimals="-5"
      id="F_000590"
      unitRef="U_iso4217USD">1000000.0</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="C_0001492674_20211231"
      decimals="-5"
      id="F_000591"
      unitRef="U_iso4217USD">1400000</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooT2OwnedInstrumentsInServiceMember_20220101_20220930"
      id="F_000592">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciation
      contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooT2OwnedInstrumentsInServiceMember_20210101_20210930"
      decimals="-5"
      id="F_000594"
      unitRef="U_iso4217USD">100000</us-gaap:CostOfGoodsAndServicesSoldDepreciation>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciation
      contextRef="C_0001492674_srtProductOrServiceAxis_us-gaapProductMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooT2OwnedInstrumentsInServiceMember_20220101_20220930"
      decimals="-5"
      id="F_000593"
      unitRef="U_iso4217USD">100000</us-gaap:CostOfGoodsAndServicesSoldDepreciation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001492674_20220701_20220930"
      decimals="-5"
      id="F_000595"
      unitRef="U_iso4217USD">300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001492674_20210701_20210930"
      decimals="-5"
      id="F_000596"
      unitRef="U_iso4217USD">300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001492674_20220101_20220930"
      decimals="-5"
      id="F_000597"
      unitRef="U_iso4217USD">800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001492674_20210101_20210930"
      decimals="-5"
      id="F_000598"
      unitRef="U_iso4217USD">1000000.0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000428">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consist of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued payroll and compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,894&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,687&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,482&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,250&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;392&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;384&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;974&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,295&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,174&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;468&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;869&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,531&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,338&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000599"
      unitRef="U_iso4217USD">3894000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000600"
      unitRef="U_iso4217USD">3687000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <ttoo:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000601"
      unitRef="U_iso4217USD">1482000</ttoo:AccruedResearchAndDevelopmentExpensesCurrent>
    <ttoo:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000602"
      unitRef="U_iso4217USD">1250000</ttoo:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000603"
      unitRef="U_iso4217USD">392000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000604"
      unitRef="U_iso4217USD">384000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000605"
      unitRef="U_iso4217USD">1000000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000606"
      unitRef="U_iso4217USD">974000</us-gaap:InterestPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000607"
      unitRef="U_iso4217USD">1295000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000608"
      unitRef="U_iso4217USD">1174000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000609"
      unitRef="U_iso4217USD">468000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000610"
      unitRef="U_iso4217USD">869000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000611"
      unitRef="U_iso4217USD">8531000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000612"
      unitRef="U_iso4217USD">8338000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000391">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. Notes Payable &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future principal payments on the notes payable are as follows (in thousands): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term Loan Agreement including PIK interest, before unamortized discount and issuance costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,597&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,364&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: unaccrued paid-in-kind interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,233&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,287&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: unamortized discount and deferred issuance costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(176&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(287&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total notes payable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,188&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,790&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Term Loan Agreement with CRG is classified as non-current September 30, 2022 and at December 31, 2021, as the Company has sufficient cash and cash equivalents such that the minimum liquidity covenant would not be triggered. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;The Term Loan Agreement includes a subjective acceleration clause whereby&#160;an event of default, including a material adverse change in the business, operations, or conditions (financial or otherwise), could result in the acceleration of the obligations under the Term Loan Agreement. As amended in February 2022, the entire principal payment, together with all other outstanding obligations, under the Term Loan Agreement are due and payable upon maturity&lt;span style="color:#000000;"&gt;, December 30, 2023. There were no covenant violations at September 30, 2022. In November 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2024.  &lt;/span&gt; &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Term Loan Agreement &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2016, the Company entered into a Term Loan Agreement (the &#x201c;Term Loan Agreement&#x201d;) with CRG. The Company initially borrowed $40.0 million pursuant to the Term Loan Agreement, which has a &lt;span style="-sec-ix-hidden:F_000624"&gt;six-year&lt;/span&gt; term with four years of interest-only payments (through December&#160;30, 2020), after which quarterly principal and interest payments will be due through the maturity date. Interest on the amounts borrowed under the Term Loan Agreement accrues at an annual fixed rate of 11.5%, 3.5% of which may be deferred during the interest-only period by adding such amount to the aggregate principal loan amount. In addition, if the Company achieves certain financial performance metrics, the loan will convert to interest-only until the maturity date, at which time all unpaid principal and accrued unpaid interest will be due and payable. The Company is required to pay CRG a financing fee based on the loan principal amount drawn. The Company is also required to pay a final payment fee of 8.0%, subsequently amended to 10%, of the principal outstanding upon repayment. The Company is accruing the final payment fee as interest expense and it is included as a non-current liability at September 30, 2022 and December 31, 2021 to conform to the classification of the associated debt in those periods. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may prepay all or a portion of the outstanding principal and accrued unpaid interest under the Term Loan Agreement at any time upon prior notice subject to a certain prepayment fee during the first five years of the term and no prepayment fee thereafter. As security for its obligations under the Term Loan Agreement, the Company entered into a security agreement with CRG whereby the Company granted a lien on substantially all of its assets, including intellectual property. The Term Loan Agreement also contains customary affirmative and negative covenants for a credit facility of this size and type, including a requirement to maintain a minimum cash balance of $5.0 million.  &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2019, the Term Loan Agreement was amended to reduce minimum revenue targets, extend the interest-only period and extend the principal repayment. The final payment fee was increased from 8% to 10% of the principal amount outstanding upon repayment. The Company issued to CRG warrants to purchase 11,365 shares of the Company&#x2019;s common stock (&#x201c;New Warrants&#x201d;) (Note 10) at an exercise price of $77.50, with typical provisions for termination upon a change of control or a sale of all or substantially all of the assets of the Company.&#160;&#160;The Company also reduced the exercise price for the warrants previously issued to CRG to purchase an aggregate of 10,579 shares of the Company&#x2019;s common stock to $77.50. All of the New Warrants are exercisable any time prior to September 9, 2029, and all of the previously issued warrants are exercisable any time prior to December 30, 2026.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2021, the Term Loan Agreement was amended to extend the interest-only payment period until the December 30, 2022 maturity, to extend the initial principal repayment until the December 30, 2022 maturity, and to significantly reduce the minimum product revenue target for the twenty-four month period beginning on January 1, 2020. The Company did not pay or provide any consideration in exchange for this amendment. &lt;span style="color:#000000;"&gt;The Company accounted for the January 2021 amendment as a modification to the Term Loan Agreement.&lt;/span&gt; In June 2021, the Company satisfied the only remaining revenue covenant which was for the 24-month period beginning on January 1, 2020.  &lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2022, the Term Loan Agreement was amended to extend the interest-only payment period through December 30, 2023, and to extend the principal repayment to December 30, 2023. The Company did not pay or provide any consideration in exchange for this amendment. As the effective borrowing rate under the amended agreement is less than the effective borrowing rate under the previous agreement, a concession is deemed to have been granted under ASC 470-60. As a concession has been granted, the agreement was accounted for as a troubled debt restructuring under ASC 470-60. The amendment did not result in a gain on restructuring as the future undiscounted cash outflows required under the amended agreement exceed the carrying value of the debt immediately prior to the amendment. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2024.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Term Loan Agreement includes a subjective acceleration clause whereby an event of default, including a material adverse change in the business, operations, or conditions (financial or otherwise), could result in the acceleration of the obligations under the Term Loan Agreement. Under certain circumstances, a default interest rate of an additional 4.0%&#160;per annum will apply at the election of CRG on all outstanding obligations during the occurrence and continuance of an event of default.&#160;&#160;&#160;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000429">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future principal payments on the notes payable are as follows (in thousands): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term Loan Agreement including PIK interest, before unamortized discount and issuance costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,597&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,364&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: unaccrued paid-in-kind interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,233&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,287&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: unamortized discount and deferred issuance costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(176&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(287&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total notes payable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,188&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,790&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <ttoo:DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000613"
      unitRef="U_iso4217USD">51597000</ttoo:DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts>
    <ttoo:DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000614"
      unitRef="U_iso4217USD">49364000</ttoo:DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts>
    <ttoo:DebtInstrumentUnaccruedPaidInKindInterest
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000615"
      unitRef="U_iso4217USD">2233000</ttoo:DebtInstrumentUnaccruedPaidInKindInterest>
    <ttoo:DebtInstrumentUnaccruedPaidInKindInterest
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000616"
      unitRef="U_iso4217USD">1287000</ttoo:DebtInstrumentUnaccruedPaidInKindInterest>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000617"
      unitRef="U_iso4217USD">176000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000618"
      unitRef="U_iso4217USD">287000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:NotesPayable
      contextRef="C_0001492674_20220930"
      decimals="-3"
      id="F_000619"
      unitRef="U_iso4217USD">49188000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="C_0001492674_20211231"
      decimals="-3"
      id="F_000620"
      unitRef="U_iso4217USD">47790000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220201_20220228"
      id="F_000621">2023-12-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221113_20221114"
      id="F_000622">2024-12-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161201_20161231"
      decimals="-5"
      id="F_000623"
      unitRef="U_iso4217USD">40000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <ttoo:DebtInstrumentTermOfInterestOnlyPayments
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161201_20161231"
      id="F_000625">P4Y</ttoo:DebtInstrumentTermOfInterestOnlyPayments>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161231"
      decimals="INF"
      id="F_000628"
      unitRef="U_xbrlipure">0.115</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ttoo:DebtInstrumentDeferredInterestRateInterestOnlyPayment
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161201_20161231"
      decimals="INF"
      id="F_000629"
      unitRef="U_xbrlipure">0.035</ttoo:DebtInstrumentDeferredInterestRateInterestOnlyPayment>
    <ttoo:DebtInstrumentFinalPaymentFeePercentage
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161231"
      decimals="INF"
      id="F_000626"
      unitRef="U_xbrlipure">0.080</ttoo:DebtInstrumentFinalPaymentFeePercentage>
    <ttoo:DebtInstrumentFinalPaymentFeePercentage
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220930"
      decimals="INF"
      id="F_000627"
      unitRef="U_xbrlipure">0.10</ttoo:DebtInstrumentFinalPaymentFeePercentage>
    <ttoo:DebtInstrumentPrepaymentFeeTerm
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161201_20161231"
      id="F_000630">P5Y</ttoo:DebtInstrumentPrepaymentFeeTerm>
    <us-gaap:RestrictedCash
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220930"
      decimals="-5"
      id="F_000631"
      unitRef="U_iso4217USD">5000000.0</us-gaap:RestrictedCash>
    <ttoo:DebtInstrumentFinalPaymentFeePercentage
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161231"
      decimals="INF"
      id="F_000632"
      unitRef="U_xbrlipure">0.08</ttoo:DebtInstrumentFinalPaymentFeePercentage>
    <ttoo:DebtInstrumentFinalPaymentFeePercentage
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20191231"
      decimals="INF"
      id="F_000633"
      unitRef="U_xbrlipure">0.10</ttoo:DebtInstrumentFinalPaymentFeePercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000634"
      unitRef="U_xbrlishares">11365</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000636"
      unitRef="U_iso4217USD_xbrlishares">77.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231"
      decimals="INF"
      id="F_000635"
      unitRef="U_xbrlishares">10579</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231"
      decimals="INF"
      id="F_000637"
      unitRef="U_iso4217USD_xbrlishares">77.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220201_20220228"
      id="F_000638">2023-12-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221113_20221114"
      id="F_000639">2024-12-30</us-gaap:DebtInstrumentMaturityDate>
    <ttoo:DebtInstrumentEventOfDefaultAdditionalInterestRate
      contextRef="C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220101_20220930"
      decimals="INF"
      id="F_000640"
      unitRef="U_xbrlipure">0.040</ttoo:DebtInstrumentEventOfDefaultAdditionalInterestRate>
    <ttoo:RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000392">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. Series A Redeemable Convertible Preferred Stock and Related Warrant &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.9%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 15, 2022, the Company entered into a securities purchase agreement (the &#x201c;Securities Purchase Agreement&#x201d;), pursuant to which we entered into a private placement transaction an aggregate of 3,000 shares of Series A Redeemable Convertible Preferred Stock with a par value of $0.001 per share and a warrant to purchase up to an aggregate of 42,857 shares of common stock of the Company at an exercise price of $7.50 per share (such number of shares and exercise price adjusted for the reverse stock split described in Note 15) for an aggregate subscription amount equal to $0.3 million, before deducting estimated offering expenses payable by the Company. Pursuant to the Purchase Agreement, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock with the Secretary of State of the State of Delaware designating the rights, preferences and limitations of the Series A Redeemable Convertible Preferred Stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Series A Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Series A Redeemable Convertible Preferred Stock was issued at a price of $100 per share (the Stated Value). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Conversion&lt;span style="font-style:normal;"&gt; -The Series A Redeemable Convertible Preferred Stock is convertible at the option of the holder, at any time after the date of the reverse stock split proposed by the board of directors, into that number of shares of common stock (subject to certain beneficial ownership limitations) determined by dividing the stated value of the Series A Redeemable Convertible Preferred Stock share by the conversion price then in effect, rounded down to the nearest whole share (with cash paid in lieu of any fractional shares). The initial conversion price was $7.00 per share, adjusted for the reverse stock split that was effected on October 12, 2022 (the &#x201c;Conversion Price&#x201d;).&#160;&#160;The Conversion Price will be (1) adjusted proportionately upon occurrence of any subsequent stock splits or stock dividends and (2) lowered to a price per share equal to that of any common stock, convertible securities or option that is subsequently issued or sold by the Company for a price per share less than the Conversion Price in effect immediately prior to such issue or sale; however, the Conversion Price cannot fall below the par value per share of the Common Stock nor exceed ten dollars ($10.00) per share, in each case, as adjusted for the reverse stock split that was effected on October 12, 2022.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Redemption&lt;span style="font-style:normal;"&gt; - Series A Redeemable Convertible Preferred Stock do not contain any mandatory redemption provisions. Beginning on the date of the reverse stock split, as proposed by the board of directors (1) the Company may redeem in cash all or any portion of the Series A Redeemable Convertible Preferred Stock at a price per share equal to one hundred and five percent (105%) of the stated value and (2) each holder of Series A Preferred Stock may require the Company to redeem in cash all or any portion of the Series A Redeemable Convertible Preferred Stock held by such holder at a price per share equal to one hundred and ten percent (110%) of the stated value. In addition, if the Company&#x2019;s common shares become delisted, the Series A Redeemable Convertible Preferred Stock will automatically be redeemed by the Company at a price per share equal to one hundred and ten percent (110%) of the Stated Value. At September 30, 2022, the Company determined that the Series A Redeemable Convertible Preferred Stock was redeemable and is being carried at its redemption value on the balance sheet, which is equal to its liquidation value under the terms of the certification of designation.&#160;&#160; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Dividend Rights&lt;span style="font-style:normal;"&gt;-Holders of the Series A Redeemable Convertible Preferred Stock are entitled to receive dividends on shares of Series A Redeemable Convertible Preferred Stock equal (on an as-converted to common stock basis) to and in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of the common stock.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Voting Rights -&lt;span style="font-style:normal;"&gt;The Series A Redeemable Convertible Preferred Stock will have no voting rights other than the right to vote on certain matters. Each share of Series A Redeemable Convertible Preferred entitles the holder to 1,000,000 votes on a proposal to approve a reverse stock split of the Company&#x2019;s outstanding common stock (the &#x201c;Proposal&#x201d;) and any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Proposal; provided, however, that such shares of Series A Redeemable Convertible Preferred Stock shall be voted in the same proportion as the shares of common stock (excluding any shares of common stock that are not voted)&lt;/span&gt; are voted on the Proposal. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Warrant&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the execution of the Securities Purchase Agreement, the Company issued a warrant to purchase 42,857 shares of the Company&#x2019;s common stock (the &#x201c;Warrant&#x201d;) at an exercise price equal to $7.50 per share, subject to adjustments noted below. The Warrant will become exercisable on February 15, 2023 and has a term ending February 15, 2028. At issuance, the Company determined that the Warrant should be classified as a liability because such Warrant could require cash redemption in certain circumstances. Recognition of the warrant liability created a day one loss of $0.1 million. The Warrant is carried at fair value, with changes in fair value recognized in changes in fair value of the derivative warrant liability each reporting period. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The exercise price of the Warrant and the number of shares issuable upon exercise will be adjusted proportionately upon the occurrence of any subsequent stock dividend or stock split of the Company&#x2019;s common stock. In addition, if at any time the Company &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;grants, issues or sells any &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;c&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ommon &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;s&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;tock &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;e&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;quivalents&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;or rights to purchase stock, warrants, securities or other property pro rata to holders of any class of shares of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;c&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ommon &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;s&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;tock (the &#x201c;Purchase Rights&#x201d;), then the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;h&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;older will be entitled to acquire, upon the terms applicable to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Purchase Rights, the aggregate Purchase Rights which the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;h&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;older could have acquired if the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;h&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;older had held the number of shares of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;c&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ommon &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;s&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;tock acquirable upon complete exercise of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Warrant&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; (subject to certain &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;b&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;eneficial &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;o&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;wnership limitations). Furthermore, after the issuance of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Warrant and while it&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; is outstanding, if the Company declare&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;s&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; or make&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;s&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;c&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ommon &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;s&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;tock, by way of return of capital or otherwise (a &#x201c;Distribution&#x201d;), the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;h&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;older &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;will&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; be entitled to participate in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;that&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Distribution to the same extent that the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;h&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;older would have participated if the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;h&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;older had held the number of shares of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;c&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ommon &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;s&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;tock acquirable upon complete exercise of this Warrant&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; (subject to certain &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;b&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;eneficial &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;o&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;wnership limitations). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;After the occurrence of a Fundamental Transaction, as defined, then, upon any subsequent exercise of the Warrant the holder will, at its option, have the right to receive for each Warrant that would have been issuable upon such exercise immediately prior to the occurrence of the Fundamental Transaction the number of shares of common stock (or its equivalent) of the successor or acquiring corporation or of the Company, if it is the surviving corporation, or such other consideration (the &#x201c;Alternate Consideration&#x201d;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of common stock for which the Warrant is exercisable immediately prior to the Fundamental Transaction. For purposes of any such exercise, the determination of the exercise price will be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of common stock in such Fundamental Transaction, and the Company will apportion the exercise price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of common stock are given any choice as to the securities, cash or property to be received in a Fundamental&lt;span style="color:#000000;"&gt; Transaction, then the Warrant holder will be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;While any Warrant is outstanding, if the Company issues or sells, any common stock, convertible securities or options, for a consideration per share (the &#x201c;New Issuance Price&#x201d;) less than a price equal to the exercise price of the Warrant in effect immediately prior to such issue or sale (a &#x201c;Dilutive Issuance&#x201d;), then immediately after the Dilutive Issuance, the exercise price then in effect will be reduced to an amount equal to the New Issuance Price.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If at the time of a Warrant&#x2019;s exercise there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares by the holder, then the Warrant may also be exercised, in whole or in part, at such time by means of a &#x201c;cashless exercise&#x201d;.&lt;/p&gt;</ttoo:RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815"
      decimals="INF"
      id="F_000641"
      unitRef="U_xbrlishares">3000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815"
      decimals="INF"
      id="F_000642"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815"
      decimals="INF"
      id="F_000643"
      unitRef="U_xbrlishares">42857</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815"
      decimals="2"
      id="F_000644"
      unitRef="U_iso4217USD_xbrlishares">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815"
      decimals="-5"
      id="F_000645"
      unitRef="U_iso4217USD">300000</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815"
      decimals="INF"
      id="F_000646"
      unitRef="U_iso4217USD_xbrlishares">100</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815"
      decimals="INF"
      id="F_000647"
      unitRef="U_iso4217USD_xbrlishares">7.00</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionDate
      contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815"
      id="F_000648">2022-10-12</us-gaap:PreferredStockConvertibleConversionDate>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815"
      decimals="INF"
      id="F_000650"
      unitRef="U_iso4217USD_xbrlishares">10.00</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionDate
      contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815"
      id="F_000649">2022-10-12</us-gaap:PreferredStockConvertibleConversionDate>
    <ttoo:PreferredStockPricePercentageOnStatedValue
      contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815"
      decimals="INF"
      id="F_000651"
      unitRef="U_xbrlipure">1.05</ttoo:PreferredStockPricePercentageOnStatedValue>
    <ttoo:PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock
      contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815"
      decimals="INF"
      id="F_000652"
      unitRef="U_xbrlipure">1.10</ttoo:PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock>
    <ttoo:PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares
      contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815"
      decimals="INF"
      id="F_000653"
      unitRef="U_xbrlipure">1.10</ttoo:PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares>
    <us-gaap:PreferredStockVotingRights
      contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220101_20220930"
      id="F_000654">The Series A Redeemable Convertible Preferred Stock will have no voting rights other than the right to vote on certain matters. Each share of Series A Redeemable Convertible Preferred entitles the holder to 1,000,000 votes on a proposal to approve a reverse stock split of the Company&#x2019;s outstanding common stock (the &#x201c;Proposal&#x201d;) and any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Proposal; provided, however, that such shares of Series A Redeemable Convertible Preferred Stock shall be voted in the same proportion as the shares of common stock (excluding any shares of common stock that are not voted)</us-gaap:PreferredStockVotingRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815"
      decimals="INF"
      id="F_000655"
      unitRef="U_xbrlishares">42857</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815"
      decimals="2"
      id="F_000656"
      unitRef="U_iso4217USD_xbrlishares">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815_20220815"
      id="F_000657">2023-02-15</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <ttoo:ClassOfWarrantOrRightMaturityDate
      contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815_20220815"
      id="F_000658">2028-02-15</ttoo:ClassOfWarrantOrRightMaturityDate>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
      contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815"
      decimals="-5"
      id="F_000659"
      unitRef="U_iso4217USD">100000</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000393">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. Stockholders&#x2019; Deficit &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Shares Authorized&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.9%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2021, the Company&#x2019;s shareholders approved an increase in the number of authorized shares of the Company&#x2019;s common stock from 200,000,000 to 400,000,000.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Equity Distribution Agreement&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 31, 2021, the Company entered into a Sales Agreement with Canaccord (&#x201c;New Sales Agreement&#x201d;), as agent, pursuant to which the Company may offer and sell shares of its common stock, for aggregate gross sale proceeds of up to $75.0 million from time to time from the effective date of the respective registration statement through Canaccord. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the New Sales Agreement, upon delivery of a placement notice based on the Company&#x2019;s instructions and subject to the terms and conditions of the Sales Agreement, Canaccord is able to sell the shares by methods deemed to be an &#x201c;at the market&#x201d; offering, subject to shelf limitations if any, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company. The Company is not obligated to make any sales of shares under the New Sales Agreement. The Company or Canaccord is able to suspend or terminate the offering of shares upon notice to the other party, subject to certain conditions. Canaccord acts as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal law, rules&#160;and regulations and the rules&#160;of Nasdaq. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company agrees to pay Canaccord for its services of acting as agent an amount equal to &lt;span&gt;3%&lt;/span&gt; of the gross proceeds from the sale of the shares pursuant to the New Sales Agreement.&#160;The Company also agrees to provide Canaccord with customary indemnification for certain liabilities. Legal and accounting fees are charged to share capital upon issuance of shares under the New Sales Agreement.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the New Sales Agreement, the Company sold 3,668,784 shares for net proceeds of $28.1 million during the nine months ended September 30, 2022 and 336,188 shares for net proceeds of $20.0 million during the nine months ended September 30, 2021. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the New Sales Agreement, the Company sold 3,080,451 shares for net proceeds of $22.2 million during the three months ended September 30, 2022 and did not sell any shares during the three months ended September 30, 2021.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001492674_20210630"
      decimals="INF"
      id="F_000660"
      unitRef="U_xbrlishares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001492674_20210701"
      decimals="INF"
      id="F_000661"
      unitRef="U_xbrlishares">400000000</us-gaap:CommonStockSharesAuthorized>
    <ttoo:ProceedsFromIssuanceOfCommonStockGross
      contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20210330_20210331"
      decimals="INF"
      id="F_000662"
      unitRef="U_iso4217USD">75000000.0</ttoo:ProceedsFromIssuanceOfCommonStockGross>
    <ttoo:PercentageOfAgentServiceFee
      contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooOriginalSalesAgreementMember_20190730_20190730"
      decimals="2"
      id="F_000663"
      unitRef="U_xbrlipure">0.03</ttoo:PercentageOfAgentServiceFee>
    <ttoo:PercentageOfAgentServiceFee
      contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20190730_20190730"
      decimals="2"
      id="F_000664"
      unitRef="U_xbrlipure">0.03</ttoo:PercentageOfAgentServiceFee>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20220101_20220930"
      decimals="INF"
      id="F_000667"
      unitRef="U_xbrlishares">3668784</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20220101_20220930"
      decimals="-5"
      id="F_000670"
      unitRef="U_iso4217USD">28100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20210101_20210930"
      decimals="INF"
      id="F_000668"
      unitRef="U_xbrlishares">336188</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20210101_20210930"
      decimals="-5"
      id="F_000671"
      unitRef="U_iso4217USD">20000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20220701_20220930"
      decimals="INF"
      id="F_000665"
      unitRef="U_xbrlishares">3080451</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20220701_20220930"
      decimals="-5"
      id="F_000669"
      unitRef="U_iso4217USD">22200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20210701_20210930"
      decimals="INF"
      id="F_000666"
      unitRef="U_xbrlishares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000394">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;9. Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock Incentive Plans &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2006 Stock Incentive Plan &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s 2006 Stock Option Plan (&#x201c;2006 Plan&#x201d;) was established for granting stock incentive awards to directors, officers, employees and consultants of the Company.&#160;Upon closing of the Company&#x2019;s IPO in August 2014, the Company ceased granting stock incentive awards under the 2006 Plan.&#160;The 2006 Plan provided for the grant of incentive and non-qualified stock options and restricted stock grants as determined by the Company&#x2019;s board of directors.&#160;Under the 2006 Plan, stock options were generally granted with exercise prices equal to or greater than the fair value of the common stock as determined by the board of directors, expired no later than 10 years from the date of grant, and vested over various periods not exceeding 4 years.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2014 Stock Incentive Plan &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s 2014 Incentive Award Plan (&#x201c;2014 Plan&#x201d;, and together with the 2006 Plan, the &#x201c;Stock Incentive Plans&#x201d;) provides for the issuance of shares of common stock in the form of stock options, awards of restricted stock, awards of restricted stock units, performance awards, dividend equivalent awards, stock payment awards and stock appreciation rights to directors, officers, employees and consultants of the Company. Since the establishment of the 2014 Plan, the Company has primarily granted stock options and restricted stock units.&#160;Generally, stock options are granted with exercise prices equal to or greater than the fair value of the common stock on the date of grant, expire no later than 10 years from the date of grant, and vest over various periods not exceeding 4 years.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The number of shares reserved for future issuance under the 2014 Plan is the sum of (1)&#160;16,470 shares, (2)&#160;any shares that were granted under the 2006 Plan which are forfeited, lapse unexercised or are settled in cash subsequent to the effective date of the 2014 Plan and (3)&#160;an annual increase on the first day of each calendar year beginning January&#160;1, 2015 and ending on January&#160;1, 2026, equal to the lesser of (A)&#160;4% of the shares outstanding (on an as-converted basis) on the final day of the immediately preceding calendar year and (B)&#160;such smaller number of shares determined by the Company&#x2019;s board of directors; provided, however, no more than 700,000 shares may be issued upon the exercise of incentive stock options.&#160;As of September&#160;30, 2022, there were 52,676 shares available for future grant under the 2014 Plan. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Inducement Award Plan &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s Amended and Restated Inducement Award Plan (&#x201c;Inducement Plan&#x201d;), which was adopted in March 2018 and most recently amended and restated in January 2020, provides for the grant of equity awards to new employees, including options, restricted stock awards, restricted stock units, performance awards, dividend equivalent awards, stock payment awards and stock appreciation rights. The aggregate number of shares of common stock which may be issued or transferred pursuant to awards under the Inducement Plan is 192,500 shares. Any awards that forfeit, expire, lapse, or are settled for cash without the delivery of shares to the holder are available for the grant of an award under the Inducement Plan. Any shares repurchased by or surrendered to the Company that are returned shall be available for the grant of an award under the Inducement Plan. The payment of dividend equivalents in cash in conjunction with any outstanding award shall not be counted against the shares available for issuance under the Inducement Plan. As of September&#160;30, 2022, there were 84,501 shares available for future grant under the Inducement Plan.&#160;&#160;&lt;span style="font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock Options &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the nine months ended September&#160;30, 2022 and 2021, the Company granted stock options with an aggregate fair value of $0.6 million and $1.1 million, respectively, which are being amortized into compensation expense over the vesting period of the options as the services are being provided. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a summary of option activity under the Stock Incentive Plans and Inducement Plan (in thousands, except share and per share amounts): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price Per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;197,171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143.96&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000698"&gt;7.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25,608&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42.64&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,863&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at September 30, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;193,220&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;137.64&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000699"&gt;6.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at September 30, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;127,461&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186.38&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000700"&gt;5.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested or expected to vest at September 30, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;182,864&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143.27&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000701"&gt;6.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;  There were no options exercised in the nine months ended September 30, 2022 and 1,566 options exercised in the nine months ended September 30, 2021. The weighted-average grant date fair values of stock options granted in the nine month periods ended September&#160;30, 2022 and 2021 were $17.58 per share and $54.77 per share, respectively, and were calculated using the following estimated assumptions: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nine Months Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.27&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;106&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected terms&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.0 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.0 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The total fair values of options that vested during the nine months ended September&#160;30, 2022 and 2021 were $1.4 million and $2.1 million, respectively. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September&#160;30, 2022, there was $2.1 million of total unrecognized compensation cost related to non-vested stock options granted under the Stock Incentive Plans and Inducement Plan. Total unrecognized compensation cost will be adjusted for future changes in the estimated forfeiture rate. The Company expects to recognize that cost over a remaining weighted-average period of 2.1 years as of September&#160;30, 2022. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted Stock Units &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the nine months ended September&#160;30, 2022, the Company awarded restricted stock units to certain employees and directors at no cost to them. The restricted stock units, excluding any restricted stock units with market conditions, vest through the passage of time, assuming continued service. Restricted stock units are not included in issued and outstanding common stock until the underlying shares are vested and released. The fair value of the restricted stock units, at the time of the grant, is expensed on a straight line basis. The granted restricted stock units had an aggregate fair value of $3.7 million, which are being amortized into compensation expense over the vesting period of the restricted stock units as the services are being provided. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a summary of restricted stock unit activity under the 2014 Plan: &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant&#160;Date&#160;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value Per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.76%;" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;142,434&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91.77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.76%;" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160,575&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22.79&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.76%;" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(50,352&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93.13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.76%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28,355&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42.40&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.76%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested at September 30, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;224,302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48.32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September&#160;30, 2022, there was $8.5 million of total unrecognized compensation cost related to nonvested restricted stock units granted. Total unrecognized compensation cost will be adjusted for future changes in the estimated forfeiture rate. The Company expects to recognize that cost over a remaining weighted-average period of 1.7 years, as of September&#160;30, 2022.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee Stock Purchase Plan&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the 2014 Employee Stock Purchase Plan (the &#x201c;2014 ESPP&#x201d;) participants may purchase the Company&#x2019;s common stock during semi-annual offering periods at 85% of the lower of (i) the market value per share of common stock on the first day of the offering period or (ii) the market value per share of the common stock on the purchase date. Each participant can purchase up to a maximum of $25,000 per calendar year in fair market value as calculated in accordance with applicable tax rules. The first offering period began on August 7, 2014. Stock-based compensation expense from the 2014 ESPP for the three months ended September 30, 2022 and 2021 was approximately &lt;span&gt;$0.1&lt;/span&gt; million. Stock-based compensation expense from the 2014 ESPP for the nine months ended September 30, 2022 and 2021 was approximately $0.3 million and $0.3 million, respectively. &#160;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2014 ESPP, which was amended and restated effective August 6, 2020, provides for the issuance of up to 90,478 shares of the Company&#x2019;s common stock to eligible employees. At September 30, 2022, there were 29,181 shares available for issuance under the 2014 ESPP. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation Expense &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the stock-based compensation expense resulting from awards granted under Stock Incentive Plans, the Inducement Plan and the 2014 ESPP, that was recorded in the Company&#x2019;s results of operations for the periods presented (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nine Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of product revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;309&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;211&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;269&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;707&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,060&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,280&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,655&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,354&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,423&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,440&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the three and nine months ended September&#160;30, 2022 and 2021, stock-based compensation expenses capitalized as part of inventory or T2Dx instruments and components were immaterial.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2021, a previous director of the Company resigned. In conjunction with his resignation, all of the director&#x2019;s outstanding options vested in full and the exercise term was extended to the final expiration date for each respective outstanding option. Additionally, the non-vested restricted stock units granted to the director in June 2021 vested in full upon his resignation. These were accounted for as Type I equity modifications for the accelerated vesting and Type III equity modifications for the extended exercise period and resulted in an increase of $0.8 million to stock-based compensation expense for the three and nine months ended September 30, 2021. Included within selling, general and administrative above for the three and nine months ended September 30, 2021 is $0.6 million and $0.2 million related to the Type I modification and the Type III modification, respectively, from the director&#x2019;s resignation.  &lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2006Member_20220101_20220930"
      id="F_000672">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2006Member_20220101_20220930"
      id="F_000673">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930"
      id="F_000674">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930"
      id="F_000675">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ttoo:ComponentOfCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220930"
      decimals="INF"
      id="F_000676"
      unitRef="U_xbrlishares">16470</ttoo:ComponentOfCommonStockCapitalSharesReservedForFutureIssuance>
    <ttoo:PercentageOfCommonSharesOutstanding
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220930"
      decimals="INF"
      id="F_000677"
      unitRef="U_xbrlipure">0.04</ttoo:PercentageOfCommonSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930"
      decimals="INF"
      id="F_000678"
      unitRef="U_xbrlishares">700000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220930"
      decimals="INF"
      id="F_000679"
      unitRef="U_xbrlishares">52676</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001492674_us-gaapPlanNameAxis_ttooInducementAwardPlanMember_20180331"
      decimals="INF"
      id="F_000680"
      unitRef="U_xbrlishares">192500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001492674_us-gaapPlanNameAxis_ttooInducementAwardPlanMember_20220930"
      decimals="INF"
      id="F_000681"
      unitRef="U_xbrlishares">84501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <ttoo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember_20220101_20220930"
      decimals="-5"
      id="F_000682"
      unitRef="U_iso4217USD">600000</ttoo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue>
    <ttoo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember_20210101_20210930"
      decimals="-5"
      id="F_000683"
      unitRef="U_iso4217USD">1100000</ttoo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000430">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a summary of option activity under the Stock Incentive Plans and Inducement Plan (in thousands, except share and per share amounts): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price Per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;197,171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143.96&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000698"&gt;7.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25,608&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42.64&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,863&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at September 30, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;193,220&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;137.64&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000699"&gt;6.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at September 30, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;127,461&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186.38&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000700"&gt;5.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested or expected to vest at September 30, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;182,864&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143.27&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000701"&gt;6.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.48%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20211231"
      decimals="INF"
      id="F_000684"
      unitRef="U_xbrlishares">197171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20211231"
      decimals="2"
      id="F_000691"
      unitRef="U_iso4217USD_xbrlishares">143.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20211231"
      decimals="-3"
      id="F_000702"
      unitRef="U_iso4217USD">51000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930"
      decimals="INF"
      id="F_000685"
      unitRef="U_xbrlishares">33520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930"
      decimals="2"
      id="F_000692"
      unitRef="U_iso4217USD_xbrlishares">21.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930"
      decimals="INF"
      id="F_000686"
      unitRef="U_xbrlishares">25608</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930"
      decimals="2"
      id="F_000693"
      unitRef="U_iso4217USD_xbrlishares">42.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930"
      decimals="INF"
      id="F_000687"
      unitRef="U_xbrlishares">11863</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930"
      decimals="2"
      id="F_000694"
      unitRef="U_iso4217USD_xbrlishares">119.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220930"
      decimals="INF"
      id="F_000688"
      unitRef="U_xbrlishares">193220</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220930"
      decimals="2"
      id="F_000695"
      unitRef="U_iso4217USD_xbrlishares">137.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220930"
      decimals="INF"
      id="F_000689"
      unitRef="U_xbrlishares">127461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220930"
      decimals="2"
      id="F_000696"
      unitRef="U_iso4217USD_xbrlishares">186.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220930"
      decimals="INF"
      id="F_000690"
      unitRef="U_xbrlishares">182864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220930"
      decimals="2"
      id="F_000697"
      unitRef="U_iso4217USD_xbrlishares">143.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000431">There were no options exercised in the nine months ended September 30, 2022 and 1,566 options exercised in the nine months ended September 30, 2021. The weighted-average grant date fair values of stock options granted in the nine month periods ended September&#160;30, 2022 and 2021 were $17.58 per share and $54.77 per share, respectively, and were calculated using the following estimated assumptions:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nine Months Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.27&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;106&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected terms&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.0 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.0 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930"
      decimals="INF"
      id="F_000703"
      unitRef="U_xbrlishares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20210101_20210930"
      decimals="INF"
      id="F_000704"
      unitRef="U_xbrlishares">1566</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930"
      decimals="2"
      id="F_000705"
      unitRef="U_iso4217USD_xbrlishares">17.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20210101_20210930"
      decimals="2"
      id="F_000706"
      unitRef="U_iso4217USD_xbrlishares">54.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930"
      decimals="4"
      id="F_000707"
      unitRef="U_xbrlipure">0.0227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20210101_20210930"
      decimals="4"
      id="F_000708"
      unitRef="U_xbrlipure">0.0092</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930"
      decimals="2"
      id="F_000709"
      unitRef="U_xbrlipure">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20210101_20210930"
      decimals="2"
      id="F_000710"
      unitRef="U_xbrlipure">1.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930"
      id="F_000711">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20210101_20210930"
      id="F_000712">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_0001492674_20220101_20220930"
      decimals="-5"
      id="F_000713"
      unitRef="U_iso4217USD">1400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_0001492674_20210101_20210930"
      decimals="-5"
      id="F_000714"
      unitRef="U_iso4217USD">2100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember_20220930"
      decimals="-5"
      id="F_000715"
      unitRef="U_iso4217USD">2100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember_20220101_20220930"
      id="F_000716">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <ttoo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue
      contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930"
      decimals="-5"
      id="F_000717"
      unitRef="U_iso4217USD">3700000</ttoo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000432">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a summary of restricted stock unit activity under the 2014 Plan: &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant&#160;Date&#160;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value Per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.76%;" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;142,434&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91.77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.76%;" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160,575&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22.79&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.76%;" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(50,352&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93.13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.76%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28,355&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42.40&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.76%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested at September 30, 2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;224,302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48.32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20211231"
      decimals="INF"
      id="F_000718"
      unitRef="U_xbrlishares">142434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20211231"
      decimals="2"
      id="F_000723"
      unitRef="U_iso4217USD_xbrlishares">91.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930"
      decimals="INF"
      id="F_000719"
      unitRef="U_xbrlishares">160575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930"
      decimals="2"
      id="F_000724"
      unitRef="U_iso4217USD_xbrlishares">22.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930"
      decimals="INF"
      id="F_000720"
      unitRef="U_xbrlishares">50352</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930"
      decimals="2"
      id="F_000725"
      unitRef="U_iso4217USD_xbrlishares">93.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930"
      decimals="INF"
      id="F_000721"
      unitRef="U_xbrlishares">28355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220101_20220930"
      decimals="2"
      id="F_000726"
      unitRef="U_iso4217USD_xbrlishares">42.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220930"
      decimals="INF"
      id="F_000722"
      unitRef="U_xbrlishares">224302</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20220930"
      decimals="2"
      id="F_000727"
      unitRef="U_iso4217USD_xbrlishares">48.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220930"
      decimals="-5"
      id="F_000728"
      unitRef="U_iso4217USD">8500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220930"
      id="F_000729">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20220101_20220930"
      decimals="2"
      id="F_000730"
      unitRef="U_xbrlipure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <ttoo:MaximumAmountOfAnnualEmployeeCommonStockPurchase
      contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20220101_20220930"
      decimals="INF"
      id="F_000731"
      unitRef="U_iso4217USD">25000</ttoo:MaximumAmountOfAnnualEmployeeCommonStockPurchase>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210701_20210930"
      decimals="-5"
      id="F_000733"
      unitRef="U_iso4217USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20220701_20220930"
      decimals="-5"
      id="F_000732"
      unitRef="U_iso4217USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20220101_20220930"
      decimals="-5"
      id="F_000734"
      unitRef="U_iso4217USD">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20210930"
      decimals="-5"
      id="F_000735"
      unitRef="U_iso4217USD">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200806"
      decimals="INF"
      id="F_000736"
      unitRef="U_xbrlishares">90478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001492674_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20220930"
      decimals="INF"
      id="F_000737"
      unitRef="U_xbrlishares">29181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000433">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the stock-based compensation expense resulting from awards granted under Stock Incentive Plans, the Inducement Plan and the 2014 ESPP, that was recorded in the Company&#x2019;s results of operations for the periods presented (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nine Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of product revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;309&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;211&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;269&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;707&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,060&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,280&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,655&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,354&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,423&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,440&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20220701_20220930"
      decimals="-3"
      id="F_000738"
      unitRef="U_iso4217USD">64000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20210701_20210930"
      decimals="-3"
      id="F_000739"
      unitRef="U_iso4217USD">40000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20220101_20220930"
      decimals="-3"
      id="F_000740"
      unitRef="U_iso4217USD">309000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20210101_20210930"
      decimals="-3"
      id="F_000741"
      unitRef="U_iso4217USD">211000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220701_20220930"
      decimals="-3"
      id="F_000742"
      unitRef="U_iso4217USD">230000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210701_20210930"
      decimals="-3"
      id="F_000743"
      unitRef="U_iso4217USD">269000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20220101_20220930"
      decimals="-3"
      id="F_000744"
      unitRef="U_iso4217USD">851000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210930"
      decimals="-3"
      id="F_000745"
      unitRef="U_iso4217USD">707000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20220701_20220930"
      decimals="-3"
      id="F_000746"
      unitRef="U_iso4217USD">1060000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210701_20210930"
      decimals="-3"
      id="F_000747"
      unitRef="U_iso4217USD">2114000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20220101_20220930"
      decimals="-3"
      id="F_000748"
      unitRef="U_iso4217USD">4280000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210930"
      decimals="-3"
      id="F_000749"
      unitRef="U_iso4217USD">4655000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_20220701_20220930"
      decimals="-3"
      id="F_000750"
      unitRef="U_iso4217USD">1354000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_20210701_20210930"
      decimals="-3"
      id="F_000751"
      unitRef="U_iso4217USD">2423000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_20220101_20220930"
      decimals="-3"
      id="F_000752"
      unitRef="U_iso4217USD">5440000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_20210101_20210930"
      decimals="-3"
      id="F_000753"
      unitRef="U_iso4217USD">5573000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIModificationMember_20210701_20210930"
      decimals="-5"
      id="F_000754"
      unitRef="U_iso4217USD">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIModificationMember_20210101_20210930"
      decimals="-5"
      id="F_000755"
      unitRef="U_iso4217USD">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIIIModificationMember_20210701_20210930"
      decimals="-5"
      id="F_000756"
      unitRef="U_iso4217USD">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIIIModificationMember_20210101_20210930"
      decimals="-5"
      id="F_000757"
      unitRef="U_iso4217USD">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIModificationMember_20210701_20210930"
      decimals="-5"
      id="F_000758"
      unitRef="U_iso4217USD">600000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIModificationMember_20210101_20210930"
      decimals="-5"
      id="F_000759"
      unitRef="U_iso4217USD">600000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIIIModificationMember_20210101_20210930"
      decimals="-5"
      id="F_000761"
      unitRef="U_iso4217USD">200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001492674_srtTitleOfIndividualAxis_srtDirectorMember_us-gaapTypeOfArrangementAxis_ttooTypeIIIModificationMember_20210701_20210930"
      decimals="-5"
      id="F_000760"
      unitRef="U_iso4217USD">200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <ttoo:WarrantsNoteDisclosureTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000395">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;10. Warrants associated with Term Loan&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Term Loan Agreement entered into in December 2016, the Company issued to CRG warrants to purchase a total of 10,579 shares of the Company&#x2019;s common stock. The warrants are exercisable any time prior to December&#160;30, 2026 at a price of $77.50 per share, with typical provisions for termination upon a change of control or a sale of all or substantially all of the assets of the Company. These warrants remain outstanding as of September 30, 2022 and December 31, 2021&lt;span style="color:#000000;"&gt;.&lt;/span&gt; &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with a 2019 amendment of the Term Loan Agreement, the Company issued to CRG warrants to purchase 11,365 shares of the Company&#x2019;s common stock (&#x201c;New Warrants&#x201d;) at an exercise price of $77.50, with typical provisions for termination upon a change of control or a sale of all or substantially all of the assets of the Company. All of the New Warrants are exercisable any time prior to September 9, 2029. The New Warrants remain outstanding as of September 30, 2022&lt;span style="color:#000000;"&gt;.&lt;/span&gt;&lt;/p&gt;</ttoo:WarrantsNoteDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231"
      decimals="INF"
      id="F_000762"
      unitRef="U_xbrlishares">10579</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231"
      decimals="INF"
      id="F_000763"
      unitRef="U_iso4217USD_xbrlishares">77.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000764"
      unitRef="U_xbrlishares">11365</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000765"
      unitRef="U_iso4217USD_xbrlishares">77.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000396">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;11. Net Loss Per Share &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies the two-class method for computing earnings per share because its Series A redeemable convertible preferred stock and the warrants issued with that preferred stock are participating securities. Under the two-class method, net income for the period is allocated between common stockholders and the participating securities according to dividends declared, if any, and participation rights in undistributed earnings. Because the Company incurred a net loss for the three and nine months ended September 30, 2022, and the holders of the participating securities do not have the contractual obligation to share in the losses of the Company on a basis that is objectively determinable, none of the net loss attributable to common stockholders was allocated to the participating securities when computing earnings per share.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The net loss attributable to common stockholders was increased by $0.3 million to reflect the deemed dividend paid to holders of the Series A redeemable convertible preferred stock to accrete the carrying amount of that preferred stock to its redemption value.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock or if-converted methods, because their effect would have been anti-dilutive for the periods presented: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three and Nine Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;193,220&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186,352&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;224,302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;134,599&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,801&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,944&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;485,323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;342,895&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Note that the net loss per share computations for all periods presented reflect the changes in the number of shares resulting from the &lt;span style="-sec-ix-hidden:F_000785_2"&gt;50 to 1&lt;/span&gt; reverse stock split that was approved by shareholders on October 11, 2022 and became effective as of October 12, 2022.&#160;&#160;The number of shares of common stock issued and outstanding immediately before the reverse stock split was 352,957,478&#x37e; the number of shares outstanding immediately after the reverse split was 7,059,144, a decrease of 345,898,334 shares.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:TemporaryEquityDividendsAdjustment
      contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesAConvertiblePreferredStockMember_20220101_20220930"
      decimals="-5"
      id="F_000766"
      unitRef="U_iso4217USD">300000</us-gaap:TemporaryEquityDividendsAdjustment>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000434">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock or if-converted methods, because their effect would have been anti-dilutive for the periods presented: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three and Nine Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;193,220&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186,352&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;224,302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;134,599&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,801&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,944&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.38%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;485,323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;342,895&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20220101_20220930"
      decimals="INF"
      id="F_000776"
      unitRef="U_xbrlishares">193220</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20220701_20220930"
      decimals="INF"
      id="F_000767"
      unitRef="U_xbrlishares">193220</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20210930"
      decimals="INF"
      id="F_000777"
      unitRef="U_xbrlishares">186352</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210701_20210930"
      decimals="INF"
      id="F_000768"
      unitRef="U_xbrlishares">186352</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20220101_20220930"
      decimals="INF"
      id="F_000778"
      unitRef="U_xbrlishares">224302</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20220701_20220930"
      decimals="INF"
      id="F_000769"
      unitRef="U_xbrlishares">224302</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210930"
      decimals="INF"
      id="F_000779"
      unitRef="U_xbrlishares">134599</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210701_20210930"
      decimals="INF"
      id="F_000770"
      unitRef="U_xbrlishares">134599</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20220101_20220930"
      decimals="INF"
      id="F_000780"
      unitRef="U_xbrlishares">64801</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20220701_20220930"
      decimals="INF"
      id="F_000771"
      unitRef="U_xbrlishares">64801</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20210930"
      decimals="INF"
      id="F_000781"
      unitRef="U_xbrlishares">21944</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001492674_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210701_20210930"
      decimals="INF"
      id="F_000772"
      unitRef="U_xbrlishares">21944</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_20220101_20220930"
      decimals="INF"
      id="F_000782"
      unitRef="U_xbrlishares">3000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_20220701_20220930"
      decimals="INF"
      id="F_000773"
      unitRef="U_xbrlishares">3000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001492674_20220101_20220930"
      decimals="INF"
      id="F_000783"
      unitRef="U_xbrlishares">485323</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001492674_20220701_20220930"
      decimals="INF"
      id="F_000774"
      unitRef="U_xbrlishares">485323</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001492674_20210101_20210930"
      decimals="INF"
      id="F_000784"
      unitRef="U_xbrlishares">342895</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001492674_20210701_20210930"
      decimals="INF"
      id="F_000775"
      unitRef="U_xbrlishares">342895</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="C_0001492674_20220101_20220930" id="F_000786">the changes in the number of shares resulting from the 50 to 1 reverse stock split that was approved by shareholders on October 11, 2022 and became effective as of October 12, 2022.</us-gaap:StockholdersEquityReverseStockSplit>
    <ttoo:StockIssuedAndOutstandingDuringPeriodSharesStockSplits
      contextRef="C_0001492674_20220101_20220930"
      decimals="INF"
      id="F_000787"
      unitRef="U_xbrlishares">352957478</ttoo:StockIssuedAndOutstandingDuringPeriodSharesStockSplits>
    <ttoo:StockOutstandingDuringPeriodSharesStockSplits contextRef="C_0001492674_20220101_20220930" id="F_000788">7,059,144</ttoo:StockOutstandingDuringPeriodSharesStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="C_0001492674_20220101_20220930"
      decimals="INF"
      id="F_000789"
      unitRef="U_xbrlishares">345898334</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000397">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12. U.S. Government Contract&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2019, BARDA awarded the Company a milestone-based contract, with an initial value of $6.0 million, and a potential value of up to $69.0 million, if BARDA awards all contract options (the &#x201c;U.S. Government Contract&#x201d;). BARDA operates within the Office of the Assistant Secretary for Preparedness and Response (&#x201c;ASPR&#x201d;) at the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;). If BARDA awards and the Company completes all options, the Company&#x2019;s management believes it will enable a significant expansion of the Company&#x2019;s current portfolio of diagnostics for sepsis-causing pathogen and antibiotic resistance genes. In September 2020, BARDA exercised the first contract option valued at $10.5 million. In September 2021, BARDA exercised an option valued at approximately $6.4 million. &#160;&#160; &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2021, BARDA agreed to accelerate product development by modifying the contract to advance future deliverables into the currently funded Option 1 of the BARDA contract for T2NxT, T2Biothreat, T2Resistance and T2AMR. The modification does not change the overall total potential value of the BARDA contract.&#160;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March&#160;31, 2022, the Company announced that BARDA had exercised Option 2B under the existing multiple-year cost-share contract between BARDA and the Company and is providing an additional $4.4 million in funding to the Company. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The option exercise occurred simultaneously on March&#160;31, 2022 with a modification to the BARDA contract to make immaterial changes to, among other things, the statement of work. &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2022, BARDA exercised Option 3 and agreed to provide an additional $3.7 million in funding for the multiple-year cost-share contract. The additional funding under Option 3 will be used to advance the U.S. clinical trials for the T2Biothreat&lt;span style="font-size:8.5pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;Panel and T2Resistance&lt;span style="font-size:8.5pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;Panel, and to file submissions to the FDA for U.S. regulatory clearance. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded contribution revenue of $1.0 million and $3.1 million for the three months ended September 30, 2022 and 2021, respectively, under the BARDA contract. The Company recorded contribution revenue of $7.8 million and $8.4 million for the nine months ended September 30, 2022 and 2021, respectively, under the BARDA contract.&#160;&#160;&#160;&#160;   &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had no outstanding accounts receivable at September 30, 2022 and accounts receivable of $1.9 million at December 31, 2021, respectively, under the BARDA contract. &lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ttoo:CollaborativeArrangementInitialValueOfConsideration
      contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20190930"
      decimals="-5"
      id="F_000790"
      unitRef="U_iso4217USD">6000000.0</ttoo:CollaborativeArrangementInitialValueOfConsideration>
    <ttoo:CollaborativeArrangementAggregateConsideration
      contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20190930"
      decimals="INF"
      id="F_000791"
      unitRef="U_iso4217USD">69000000.0</ttoo:CollaborativeArrangementAggregateConsideration>
    <ttoo:CollaborativeArrangementFirstContractOptionValueExercised
      contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20200901_20200930"
      decimals="-5"
      id="F_000792"
      unitRef="U_iso4217USD">10500000</ttoo:CollaborativeArrangementFirstContractOptionValueExercised>
    <ttoo:CollaborativeArrangementOptionContractValueExercised
      contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20210901_20210930"
      decimals="-5"
      id="F_000793"
      unitRef="U_iso4217USD">6400000</ttoo:CollaborativeArrangementOptionContractValueExercised>
    <ttoo:CollaborativeArrangementAdditionalFundingAmountReceived
      contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20220101_20220331"
      decimals="-5"
      id="F_000794"
      unitRef="U_iso4217USD">4400000</ttoo:CollaborativeArrangementAdditionalFundingAmountReceived>
    <ttoo:CollaborativeArrangementAdditionalFundingAmountToBeReceived
      contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20220901_20220930"
      decimals="-5"
      id="F_000795"
      unitRef="U_iso4217USD">3700000</ttoo:CollaborativeArrangementAdditionalFundingAmountToBeReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srtProductOrServiceAxis_ttooContributionMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20220701_20220930"
      decimals="-5"
      id="F_000796"
      unitRef="U_iso4217USD">1000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srtProductOrServiceAxis_ttooContributionMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20210701_20210930"
      decimals="-5"
      id="F_000797"
      unitRef="U_iso4217USD">3100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srtProductOrServiceAxis_ttooContributionMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20220101_20220930"
      decimals="-5"
      id="F_000798"
      unitRef="U_iso4217USD">7800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_srtProductOrServiceAxis_ttooContributionMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20210101_20210930"
      decimals="-5"
      id="F_000799"
      unitRef="U_iso4217USD">8400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNet
      contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20220930"
      decimals="-6"
      id="F_000800"
      unitRef="U_iso4217USD">0</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20211231"
      decimals="-5"
      id="F_000801"
      unitRef="U_iso4217USD">1900000</us-gaap:AccountsReceivableNet>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000398">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;13. Leases &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Operating Leases &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases certain office space, laboratory space and manufacturing space. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. The Company does not recognize right-of-use assets or lease liabilities for leases determined to have a term of 12 months or less. For new and amended leases, the Company has elected to account for the lease and non-lease components as a combined lease component.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2013, the Company entered into an operating lease for additional office, laboratory and manufacturing space in Wilmington, Massachusetts. In August 2018, the Company entered into an amendment to extend the term to &lt;span style="-sec-ix-hidden:F_000807"&gt;December 2020&lt;/span&gt;. In October 2020, the Company entered into an amendment to extend the term to December 31, 2022. In September 2022, the Company entered into an amendment to extend the term to December 31, 2024. This amendment resulted in an increase to the operating lease right-of-use assets and lease liability accounts on the balance sheet of $0.2 million at September 30, 2022.&#160;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2014, the Company entered into an agreement to rent additional office space in Lexington, Massachusetts. In April 2015, the Company entered into an amendment to extend the term to December 31, 2017. In connection with this agreement, the Company paid a security deposit of $50,000, which is recorded as a component of other assets in the condensed consolidated balance sheets. In May 2015, the Company entered into an amendment to expand existing manufacturing facilities in Lexington, Massachusetts. In September 2017, the Company entered into an amendment to extend the term to December 31, 2021. In June 2020, the Company vacated this office space and determined that subleasing it to a tenant was unlikely due to the impact of the COVID-19 pandemic on the local commercial real estate sub-lease market. The lease terminated on December 31, 2021.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2014, the Company entered into a lease for additional laboratory space in Lexington, Massachusetts. The lease term commenced in April 2015 and extended for six years. The rent expense, inclusive of the escalating rent payments, is recognized on a straight-line basis over the lease term. As an incentive to enter into the lease, the landlord paid approximately $1.4 million of the $2.2 million space build-out costs. The unamortized balance of the lease incentive as of January 1, 2019 was reclassified as a reduction to the initial recognition of the right-of-use asset related to this lease. In connection with this lease agreement, the Company paid a security deposit of $281,000, which was recorded as a component of both prepaid expenses and other current assets and other assets in the condensed consolidated balance sheets at December 31, 2019. In October 2020, the Company entered into an amendment to extend the term of the lease to October 31, 2025. In accordance with this amendment, the Company paid a replacement security deposit of $130,977, which is classified as restricted cash at September 30, 2022 and December 31, 2021 and received the initial $281,000 security deposit in return.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2021, the Company entered into a lease for office, research, laboratory and manufacturing space in Billerica, Massachusetts. The lease has a term of 126 months from the commencement date. At September 30, 2022, there is no effect on the operating lease right-of-use assets and lease liability accounts. The Company opened a money market account for $1.0 million, which represents collateral as a security deposit for this lease and is classified as restricted cash at September 30, 2022. Occupancy of the building has been delayed due to disagreement between the Company and the landlord as to the parties&#x2019; obligations under the lease agreement. Negotiations are on-going. The Company believes that a liability is reasonably possible but not probable. An estimate of the possible loss or range of loss cannot be made at this time.     &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases are amortized over the lease term and included in costs and expenses in the condensed consolidated statement of operations and comprehensive loss. Variable lease costs are recognized in costs and expenses in the condensed consolidated statement of operations and comprehensive loss as incurred. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeSpaceLaboratorySpaceAndEquipmentMember_20220930"
      decimals="INF"
      id="F_000802"
      unitRef="U_iso4217USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeSpaceLaboratorySpaceAndEquipmentMember_20220930"
      decimals="INF"
      id="F_000803"
      unitRef="U_iso4217USD">0</us-gaap:OperatingLeaseLiability>
    <ttoo:MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities
      contextRef="C_0001492674_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeSpaceLaboratorySpaceAndEquipmentMember_20220101_20220930"
      id="F_000804">P12M</ttoo:MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoMay2013Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeLaboratoryAndManufacturingSpaceMember_20201001_20201031"
      id="F_000808">2022-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoMay2013Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeLaboratoryAndManufacturingSpaceMember_20220901_20220930"
      id="F_000809">2024-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoMay2013Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeLaboratoryAndManufacturingSpaceMember_20220930"
      decimals="-5"
      id="F_000813"
      unitRef="U_iso4217USD">200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoMay2013Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeLaboratoryAndManufacturingSpaceMember_20220930"
      decimals="-5"
      id="F_000812"
      unitRef="U_iso4217USD">200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001492674_srtMortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_srtOfficeBuildingMember_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20150401_20150430"
      id="F_000805">2017-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:SecurityDeposit
      contextRef="C_0001492674_srtMortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_srtOfficeBuildingMember_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20141130"
      decimals="0"
      id="F_000810"
      unitRef="U_iso4217USD">50000</us-gaap:SecurityDeposit>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001492674_srtMortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_srtOfficeBuildingMember_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20170901_20170930"
      id="F_000806">2021-12-31</us-gaap:LeaseExpirationDate1>
    <ttoo:LesseeOperatingLeaseTerminationPeriod
      contextRef="C_0001492674_srtMortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_srtOfficeBuildingMember_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20141130_20141130"
      id="F_000811">2021-12-31</ttoo:LesseeOperatingLeaseTerminationPeriod>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20141130"
      id="F_000814">P6Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:IncentiveFromLessor
      contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20141130"
      decimals="-5"
      id="F_000816"
      unitRef="U_iso4217USD">1400000</us-gaap:IncentiveFromLessor>
    <ttoo:SpaceBuildOutCosts
      contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20141101_20141130"
      decimals="-5"
      id="F_000817"
      unitRef="U_iso4217USD">2200000</ttoo:SpaceBuildOutCosts>
    <us-gaap:SecurityDeposit
      contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20191231"
      decimals="0"
      id="F_000815"
      unitRef="U_iso4217USD">281000</us-gaap:SecurityDeposit>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20201001_20201031"
      id="F_000818">2025-10-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:SecurityDeposit
      contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20220930"
      decimals="0"
      id="F_000819"
      unitRef="U_iso4217USD">130977</us-gaap:SecurityDeposit>
    <ttoo:SecurityDepositReceived
      contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooLaboratorySpaceMember_20211231"
      decimals="0"
      id="F_000820"
      unitRef="U_iso4217USD">281000</ttoo:SecurityDepositReceived>
    <ttoo:TermOfLease
      contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoSeptember2021Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeResearchLaboratoryAndManufacturingSpaceMember_20210901_20210930"
      id="F_000821">P126M</ttoo:TermOfLease>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoSeptember2021Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeResearchLaboratoryAndManufacturingSpaceMember_20220930"
      decimals="INF"
      id="F_000823"
      unitRef="U_iso4217USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoSeptember2021Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeResearchLaboratoryAndManufacturingSpaceMember_20220930"
      decimals="INF"
      id="F_000824"
      unitRef="U_iso4217USD">0</us-gaap:OperatingLeaseLiability>
    <us-gaap:SecurityDeposit
      contextRef="C_0001492674_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoSeptember2021Member_us-gaapPropertyPlantAndEquipmentByTypeAxis_ttooOfficeResearchLaboratoryAndManufacturingSpaceMember_20220930"
      decimals="-5"
      id="F_000822"
      unitRef="U_iso4217USD">1000000.0</us-gaap:SecurityDeposit>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000399">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;14. Commitments and Contingencies&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;License Agreement&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2006, the Company entered into a license agreement with a third party, pursuant to which the third party granted the Company an exclusive, worldwide, sublicenseable license under certain patent rights to make, use, import and commercialize products and processes for diagnostic, industrial and research and development purposes. The Company agreed to pay an annual license fee ranging from $5,000 to $25,000 for the royalty&#x2011;bearing license to certain patents. The Company also issued a total of 1,693 shares of common stock pursuant to the agreement in 2006 and 2007, which were recorded at fair value at the date of issuance. The Company is required to pay royalties on net sales of products and processes that are covered by patent rights licensed under the agreement at a percentage ranging between 0.5% - 3.5%, subject to reductions and offsets in certain circumstances, as well as a royalty on net sales of &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;products that the Company sublicenses at &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;% of specified gross revenue. &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Royalties that became due under this agreement for the three&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;months ended &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; 30&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, 2022 and 2021&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; were &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;immaterial&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Royalties that became due under this agreement for the &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;nine&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; months ended September 30, 2022 and 2021 were &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ttoo:LicenseFeesPayable
      contextRef="C_0001492674_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20061231"
      decimals="INF"
      id="F_000825"
      unitRef="U_iso4217USD">5000</ttoo:LicenseFeesPayable>
    <ttoo:LicenseFeesPayable
      contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20061231"
      decimals="INF"
      id="F_000826"
      unitRef="U_iso4217USD">25000</ttoo:LicenseFeesPayable>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_0001492674_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20060101_20071231"
      decimals="INF"
      id="F_000827"
      unitRef="U_xbrlishares">1693</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <ttoo:PercentageOfRoyaltyOnNetSales
      contextRef="C_0001492674_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20220101_20220930"
      decimals="INF"
      id="F_000828"
      unitRef="U_xbrlipure">0.005</ttoo:PercentageOfRoyaltyOnNetSales>
    <ttoo:PercentageOfRoyaltyOnNetSales
      contextRef="C_0001492674_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20220101_20220930"
      decimals="INF"
      id="F_000829"
      unitRef="U_xbrlipure">0.035</ttoo:PercentageOfRoyaltyOnNetSales>
    <ttoo:RoyaltyOnNetSalesSublicensingGrossRevenue
      contextRef="C_0001492674_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20220101_20220930"
      decimals="2"
      id="F_000830"
      unitRef="U_xbrlipure">0.10</ttoo:RoyaltyOnNetSalesSublicensingGrossRevenue>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="C_0001492674_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20220930"
      decimals="-5"
      id="F_000831"
      unitRef="U_iso4217USD">100000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="C_0001492674_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20210930"
      decimals="-5"
      id="F_000832"
      unitRef="U_iso4217USD">100000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_0001492674_20220101_20220930" id="F_000400">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;15. Subsequent Events&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Equity Distribution Agreement&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subsequent to September 30, 2022, the Company sold 256,628 shares for net proceeds of $0.7 million under the New Sales Agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Reverse Stock Split&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 11, 2022, at the Company&#x2019;s annual meeting of stockholders, the Company&#x2019;s stockholders approved an amendment to the Company&#x2019;s restated certificate of incorporation to effect a reverse stock split of the Company&#x2019;s common stock. Following the receipt of the stockholders&#x2019; approval, the Company&#x2019;s board of directions approved the reverse stock split at the ratio of 1 post-split share for every &lt;span style="-sec-ix-hidden:F_000835_2"&gt;50 pre-split shares&lt;/span&gt;, and the amendment to the Company&#x2019;s restated certificate of incorporation became effective as of October 12, 2022. As a result of the reverse stock split, every 50 shares of issued and outstanding common stock of the Company were automatically reclassified and combined into 1 share of common stock, with any fractional interest in shares being paid out in cash. Immediately after the reverse stock split became effective, the Company had approximately 7,059,144 shares of common stock issued and outstanding. As a result of the reverse split, there was an adjustment of 50 shares for rounding. All common stock amounts and references have been retroactively adjusted for all figures presented to reflect this split unless specifically stated otherwise.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Securities Purchase Agreement&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;span style="color:#000000;"&gt;On October 26, 2022, the private investor in the Company&#x2019;s Series A redeemable convertible preferred stock redeemed all &lt;/span&gt;3,000 shares&lt;span style="color:#000000;"&gt; of the Series A redeemable convertible preferred stock for an aggregate amount of $0.3 million.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20221001_20221109"
      decimals="INF"
      id="F_000833"
      unitRef="U_xbrlishares">256628</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001492674_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20221001_20221109"
      decimals="-5"
      id="F_000834"
      unitRef="U_iso4217USD">700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011_20221011"
      id="F_000836">50 shares of issued and outstanding common stock of the Company were automatically reclassified and combined into 1 share of common stock</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011"
      decimals="INF"
      id="F_000838"
      unitRef="U_xbrlishares">7059144</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011"
      decimals="INF"
      id="F_000839"
      unitRef="U_xbrlishares">7059144</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011_20221011"
      decimals="INF"
      id="F_000837"
      unitRef="U_xbrlishares">50</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20221026"
      decimals="INF"
      id="F_000840"
      unitRef="U_xbrlishares">3000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable
      contextRef="C_0001492674_us-gaapStatementClassOfStockAxis_ttooSeriesARedeemableConvertiblePreferredStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20221026"
      decimals="-5"
      id="F_000841"
      unitRef="U_iso4217USD">300000</us-gaap:PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001492674_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ttooCanaccordGenuityLLCMember_us-gaapSubsidiarySaleOfStockAxis_ttooNewSalesAgreementMember_20210101_20210930"
      decimals="INF"
      id="F_000668_2"
      unitRef="U_xbrlishares">336188</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M(!A%>!QESWG82S/S+UU]>0))@)4I@/!1N4. /5%A/U-M*\L#D+JI1[,(:%N
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MN\<59\8#*V#^OQ1FAMF]V,^.^\_,\_\ 4$L#!!0    ( ,*%;E5'*JW#H@,
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M_?0>_81$CKYN9*E8GJCKB09G3)>3N'GQI_K%9.#%$?I%YGJCT-_!@>2T_01
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M&@/X?2VE/MR8%[1G_I;_!5!+ P04    " #"A6Y52DRLG=@"  !<"0  &
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M/]BH)]5I;ED!Z"5G@( W)5:R9Q0..O6-I;^1!B J'DJL$BK=H3*A_R?.(P%
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M64M0K[N&1E(IS!U[D =5H]CQ$%F-71BL*70;"(?K-*N1>"<?)$8\!7KTYEW
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M?FV00]+D5M<VZ$9X":I-[#'@Z50H\5D]%SH4;'UVL2A\+\5AF&!"[P=HL^'
MBRT'B<F/RG50D0=(<EBVHM*P2++\;SK*!8J,<&4FF"*I*!2"P94#(L]=G6R\
MBL\"F418Q<;GO^)$[G4@0XA<DW%<J35 Q;&GAGS!50?NH#9X$%W>IK9>R.]*
MG.U4CAC_<H=LAD_9GK")CCBD:'\$TZ_.*5MW$PRC*B=7?(_Z$SZ#I'/QF#+(
M>IE#X1J<5BJ%O7X2/A F%LE#XS14\DOE)$&N(>;VOC]L@HX'F?4AH'&1$]H.
M-BA"GR2VXZS+@U '<DHPB[:$H"E_(=NU@$BSAE3*@*X"J:;!- %A^0,+HH_
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M!,FDLZLB@0^*4-BX1^_]?""BC%V/FBL76J)5\L;E4@B6&/9[&$?9%@PO=LT
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M2N3@='X"G4V^VO@1T:@YT/9P$8N@[O+)XO1%4/5"]12OK"(C3$F,OFN/E,.
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M>_JX<XT=G<M :P&OL_1J)Y:=EYWAX3Z>8>=&)X^^&\)KH6'OX&A4+UG]EZ,
MZ!T='+9 EO,-?SYR_O_5G:6BX\Z7._'9A@1>(OZ1C<'#G:/>T=%^]7SHE)?5
M^/I_/;-Z^]R20)%TB:!O!9RO0Q'A:)5SJ313W(8CMAUF<$JQ9P+M-:.R)D2
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MS&$I7#&)B4']4IQU (L6('T!X#U<&DV%@X\ZQ_QQ?<QD>D;ICM$B/0AX@]4
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M/8[ MH[8!F2JX$(K0^QI85CP1P2M3^#UM3&T"_P&_6=I]AM02P,$%     @
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M#3K,U!?N^L7ITE]RI]JAO/GI0O!<&-J [S.MW>:%&+3_>IS]#5!+ P04
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M-R6 (Y&J'J!4)QGPO--D.C<5;]5:5Q6E%%-]3E;D'7\Z,W(\I" I95!!E61
M3@WD*28:\'N(EJ=FL:3X[(D&4Z$2(''1>(JC%5I3&I<Q?9W/+O]^UBX\2*EM
MS+&W0RD9T(.Q%F&+Z&&L&FP=*OQE.]^H$(\<+U''QUF#X-X;8S[;;XRI^!Z
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MJAOG&P$88*]*!1)]TY58(P +Q$881 0CJ!<6%?;#D!!&+7!A;BF"I*6S'DD
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M3- [C2?^-)Q[9]XX#J9C[Q6%'8@*6J+(GT]':(FBBV :[LJ[[^L0>.0CXY+
MHQG--@UF<SRURSH!.0*/S!#/_/&4MSR?!J.Y-PDNPMX,O[F3;L4NR\D/OLQ\
M_<B$\QB[&#L=QC.(-)WV)ORXQ0KPI];!M[38G2._.-0C?S*=_J5Y(AL[MZV[
M2>=N%J?2(2J8O<-M!RU[*W:'F >QRNKC430+)O-^&!'B3,;!;+9]N8LZU(='
M@PHGC2UG-J9%S"T@$+[DW"J!];F5'?%)TO8+N-Y 3(]MRL'Q^ZY^*FT^/UY4
M2A&^*6)'HL("7DQ6_]X+@XL8?]ZT;M/EMXU6V39BON_]ZOK>E-B(S@!47A1.
MT1*%XWX[$7@#SW)GR]XOLF1=UL"%'9NUUN)\[NHWZ3>FEM9<P7B8'.)CR>$+
MDB<@OC^>,P#OHRE !\MEP9EDD$022Y6MS8G;EL5CM[/#'OH-H(_8^!(I;K6C
M1.D?#0O0R_=@6L52F38^MH[H*"/U(<<)^N</!S=,!+N5K?%X04Z<$DUM2M@+
MWVTF);7:&H0\8H6 CS:.W%O=?")R_[7D8\@YF)"I8[4;VEF"HR_DWZDR=:=.
M@MBBM!NVM#2W2CIV%$%*=L<96O_(NDQZP L^*](ETHL[^#"HUZNJ;):V=+@&
M4I FR15U#N1AY.!C=TF5;#I5.$HR4&!_,<DX7[N#ED5)=R"AK?;YZ^ $ _J@
M,Y:"G3;;<.'<L<I*M1%LSX49%]@=!=JK7!U3EK1\F+;6=G4E*6U:@I92/0)$
M"FR#W$O0U8FM5-C5VL@ZHNJ53.^EEZ-@M@6,OX$_'A'KK]/)@Q,?8I==S>%+
MJ""3+/&:%/4C*8II6X\1_DK%(FOW@_1M'/OC$5&/BP@YL^-LT33T)[.)ASB?
M73A&XYU.0G\TB<&V+D9!-!HPM#E:)I:AC</AJ@<83QR/_5$88]GQ/!C%WA=!
M_3R8_$6H=S(=,;%SS/\'^(8M+7S[]^#W&X>@#KVOW '?'EP^#=WQWKZGO5L2
MV_O#U=7V9D0B)!.]YAL JJ^TE82#=<0!HCFR852N'[LZ;;E8J&H;M8SW\TE7
M.$7LN7JJ/N,7#K0M?FQIXF[UYU#5ET^3P^6(U)_J!Z<^5OSO=IZR\=]06;FG
M'O#18MNG67.=B;Y@T+DMMS_"08@*IK38L(P+3V.<',@$T_<8KJ:C;%)6*1<M
M[#%^O<YTPD>=6MZ)JLF4 VFKB-W=7P.1"]J,N[>=<<E[W%Y[V^\ #H)N=Y/1
M^4=7 $+Z5%_#(ZD4N@;HWG%,91NJ.$3NTM?-/2B;'BJ';N\'W$ZF_K&Z:/\>
MSYKD(O3'LWFOCOB@'V.0RO12DZ([W@*">P@;!Z6A^,*/YD=*0\>N:4@!]WR(
M\,999)BL:I[69BO CDMV#UD50C49YU"VKZMM#JGS0=KL'RR9\FWLT([V^D@:
M1L0JW1X9=_5M17''%L"A9?&M$5NPX&\U6+A!8>;L"0Y!Y(7]4]W0-ONG/G'L
MU+?]]8IQ>T%.A9U2-KI1H(!(>WS:'U/58,3EDCB*/-!!Q85])K3HFI5K4HX7
MCT(OGEYX\TGDS<(9CIM(@L72;S\-X $R!<W4Q+I(S5[DAU.,\J-H[(W]>![B
M_RDRM,UM#UF62A%(Z"0D^$$\HH*./V9Y)^ %G/I[P<O?3WQ=H?$A"0BZUAJR
M<OJE&U_@I+T"@@[!]+D(_3%^?2>H3%LU]MLC>^.<K\N"'SF(=$Y 46F9T26.
M^+G)-DX(20YQPY>G[0%B)Y[)K_2R(%;P]D ]>:6-Z\'"8\8L:V=H9^Q<M$_<
MVV.F8R0$WTV6=1'0W7G1J=U^QG-76ZVZ6KN][..+ ZLW6W2AHA-EE>U)^L"R
M0)[4'F'L+3@?U;8'X?OI42M IS"Z6FH*9=%Y9S]\B;>C)$XPQ@$<921;;R?1
ML<^/FS6 H;V$RLM4+Y"AAM&,03B_5(SD+8DGS=FQ;Q\8W6ER>[MOLYO+$( 1
MERV+WJTP%[;G'?^$$AY$Q\6WQ$A$CN;.?>1BD,,\'.Y"7H,>?N.*=%+9K]J'
M0=R]Z+%HFM[9J*_>SG,[&_1;=PMPV^\:=F-DX">'OO@[[WV_F:MJR5^I&GMK
M8S_E[-YV'\)>VN\_M]WM5[2_R&H)[!"96F!H&,PF)_;RL'VHRS5_#7I=UG69
M\\^5DDAJU 'MB[*LVP=:H/L\^,5_ %!+ P04    " #"A6Y577X5^&@#  #%
M"   &0   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6S-5FUOVS80_BL'=2A6
MP+!>_!8GM@$G6;<":Q$DW?JAV =:.EM$)%(C3W'R[W>D9$4I7'?YU@^6Q>/=
MP^?>>%KLM;FW.2+!8UDHNPQRHNH\#&V:8RGL4%>H>&>K32F(EV87VLJ@R+Q1
M681)%$W#4D@5K!9>=F-6"UU3(17>&+!U60KS=(F%WB^#.#@(;N4N)R<(5XM*
M[/ .Z:_JQO J[% R6:*R4BLPN%T&Z_C\<NSTO<+?$O>V]P[.DXW6]V[Q(5L&
MD2.$!:;D$ 3_/> 5%H4#8AK_MIA!=Z0S[+\?T-][W]F7C;!XI8LO,J-\&9P%
MD.%6U 7=ZOT?V/HS<7BI+JQ_PK[1'<\"2&M+NFR-F4$I5?,O'MLX] S.HN\8
M)*U!XGDW!WF6UX+$:F'T'HS39C3WXEWUUDQ.*I>4.S*\*]F.5E^$,4*1!6&M
M3J4@S)@!Y? 930E_:J$6(?$Y3CM,6\S+!C/Y#N8</FI%N87?5(;92_N0^74D
MDP/)R^0DX!U60QA% TBB)#F!-^J<'GF\T8^<7JL,?!U:^*0)X5K:M-"V-@A?
MUQM+AHOFGV,!:/#'Q_%=(YW;2J2X#+A3+)H'#%9OW\33Z.($^W''?GP*O<?^
M-2D[C1E'0_AQ*< '!:E6JNTHOTDY]A36.X/(/4O /S2,(!5I?L UIEANT' .
MX^G FUWILA+J":2U-6NRWM7M[[ _T.!U59LTYYX#P2L2!>@MQ-%@,IN#S06'
MU@EZ4&_?G"7Q[,(RR[)DAMP^Z?T0/K-&!\MF@(]H4FG%IF!H9D!\ST!EI#;N
MU(YJ6W)3$,0,>#]%=^ OL]EP$D'%&I[%H(W$4R53YE@9_2#=I65AZP Y.%()
M'[&Z<A<1L$]JYZ$XFF2XZ5E/@!6%%XK""VS-%<B4):^?&F'C+.<'Z5O7O9>V
MYZ=!=R<#7\0.)9-JQX;.B+N)7OB7< RRGM>QE\8P/)9OX1(X!\%)SGRB6QI'
M:N#568[CP6@Z>45JX5<G3J*+3WS]'^K7B^*+=SYKZI!K_#9_/TG6UL\:?2?^
M1YD^YW'N$S9O"OT%RFN*8'CL;@I[HZ5$L_,#U"6A5M1,F4[:S>AU,YJ>U9L!
M_U&8G>3P%KAETV@XFP1@FJ'9+$A7?E!M-/'8\Z\Y?V>@<0J\O]5\1[<+=T#W
MY;+Z#U!+ P04    " #"A6Y5_A-F;]X$  "@"P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6R55MMRVS80?>=78)A.GAB)%\F5'5LS=II..M.DGCAI
M'CI] ,FEB 8$6  TK;_O+GBQG,B:YL$6+[MG]YR]$)>]-E]M#>#80R.5O0IK
MY]J+Y=(6-33<+G0+"M]4VC3<X:W9+6UK@)?>J9'+-([/E@T7*MQ>^F>W9GNI
M.R>%@EO#;-<TW.QO0.K^*DS"Z<%'L:L=/5AN+UN^@SMPG]M;@W?+&:44#2@K
MM&(&JJOP.KFX69&]-_A30&\/KADQR;7^2C>_E5=A3 F!A,(1 L>?>W@#4A(0
MIO'OB!G.(<GQ\'I"_]5S1RXYM_!&RR^B=/55N E9"17OI/NH^W<P\ED37J&E
M]?]9/]AF<<B*SCK=C,Z802/4\,L?1AT.'#;/.:2C0^KS'@+Y+'_ACF\OC>Z9
M(6M$HPM/U7MC<D)14>Z<P;<"_=SV ];]=VTMNP7#[FINX'+I$)?>+HL1XV;
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MWJ<45R)3^$^CHH@;B"N$Z'I')BQF,Q*-:WNO[9]N,4ZQ=T)%U"GKXSH&&XV
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M'LU&_<*/9EE&7IC<7#5Z2>\I_MR\\WB;;*04IB8;C+/*T^)Z=#M[<7?*Y^7
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MXC.[0-%=G6TX&X(Z&FRTYPGERR\NYK/SKY3+*K/4S&;<SXM!D]CH&*L?:.D
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MMIQ^N*#U>M!Z?8G]Q_)QF6*VF,"WEA]>6AE>X:,DXS)OXY78[AVBYJ!1?+!
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M9M."G!9R9L6'I^@_NJG%,M-KWAA@@@E%_%.$41U$09$7Q?&E<\<X^_)WRXB
M01"'&*H$*D+1G#O><]N.*\89$1W%D@X/\#8.CUJ"V+T;O-TP'?32/IP)0)QX
M&#Q7:'0MLZ3F0 ,8A40-.,T= )LFQ.)(W%*V3*430'8)QG64UW1Z@ 0.HU)\
M)-AQ0P*F=6DM5B;Y,7$8.CKD_:=BOEMF][.H/VH0G1FZ2IPZ  H'1RCP\\'H
M+2F0%F\QO-WG_C]4,@ ^4*#@T]L=1PMX?B00TH[DR<41S@:?+;.Y0VW.%W+P
MK:90.>PC%FYJ@OX0BII&KW1&?'H?&N!8BCV*>YQI<(:6JU-<#WTRCLL?G'MP
M8IWC+0%8C@+(:G(=E:;H #ZC5Q,Y&_A5], 13M CX\=#1WD<67F$"*_+_80!
MY7G9/-O5Y:X(I$+:CU2+45+60NH[[WO6 (?!H8 _.+VDLF",#[XA@04[!U1A
MO 4T#QTT>9DQ^LDW%#HC#$LL?QN77Q0Q34HA+#,>5F$/UH>E<AS) FJI^H\7
M2#/,Y7R5S '9+,R:#E7D3O<B=2S!1EU:JKJU(7[8DIXXFD,:P "BA(Z\\3D%
MK]!]"XABGSX4\&"%%>M<_XFY3$ EJ(^:F0I,7 H6Y#Z>B'$498-^@M@HT_%2
MHZ/>M/:(FU=U2<3+@1 4W(Z6/9MX[J/ '\GU>R"'1%&0Q]L5%6P9 YGV8)A9
M.3C "3)\#G>) !6))OYWB1&[(<8Q1_4HBH.QB"':9V+;8JY4PDO!'L"R<-%9
M]CD>2GRH'%&A!P08]Q&?L_K45PR[&*>.>0&**#%;TK2>TYB]BH3,%DRLN.#F
M06K11H;0GD>X]H 0&9CVQHYIZ["Q M&U).V,2!LXWB#A/6 UN.#\  L,N !/
MG0OP=- %>$\"AH#QB=XN+^ ;INF,!V[]DX'E(SD!1#'Z-DYT!\_8TR&1A8:V
M7FG1R38H.@%<33 8(J$?G]GDTZ^(7\FR.!R2JF75,*U+MC4TQ^\".4&,5><
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M /R.KR:V?^ "MT7YA<![\?]02P,$%     @ PH5N53EX,S"%!   &PP  !D
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MC/\40)H%.!\);(_EAW%0_?=8_ -02P,$%     @ PH5N56E1W,:X!   W0H
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M9[E[/H>OU:Y#TF6'@A[&ZC[XH3I:>ID?) LO]=,T]SX(_!&V@& 2K%7W8S\
M [(\H3>.4$L!U/@30C1Q;*.):ED6>TD0>N'"+Z*8A@#^?< G_*O*H1T:5V.5
M0%M PQE_8E0DK=)VW["\ET'JXP?LO<(L\>,HQ.QXCA]9FD$;C6F6G&!I.K$T
M/<FHZRDRQ)[+LM0#K+[YCFN#$>880T_C'1#$'N$G<_, W_,'#:0IN= U1I3J
M-R]B-Z9Y-@E0;^:ZW#J)2MSC/C/6SL%0HEH>4@<!/28U6M7(*(#1,ZBYHS#
MCR+THCR>3LD.)2(,<7:!9!9@QBU2"(/@9D,<8XWD:]E(*YVBL"!F!W0.,=%$
MF&=!\V(P+T^+?;/Z[V?G@W*2Y: U>?$4_X67^PG:((U1E!\CR?S)E:,5>N,N
M5I2KH;/C[6/:G>YNE^.5Y?'X>/'[R/4&Y08_:X@NWF3H8'J\3(T+JWIW@5DK
MB^N0FVYQ_Q2:#N![K90]+$C!=*-=_@M02P,$%     @ PH5N53$7+:WA @
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MKV;E+5-;+C2DN"&H?S'HN:"J^5-MC,S+GE]+0Q.D-'<TLE%9![K?2-)?;VR
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M1.BG3(@X8X4GM7=VSEMIZL6/C).V,J$ULZ#:$*K94,V!:BY4&T$U#ZKY4"V
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M<@/Q^K0H^.:)+."E*+_5U7OX&U!+ P04    " #"A6Y52(Z@7 D/  !KG0
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MIH(P"CC>S(P[>!O"2>:06_Q%\%&<7(,LE!5C7[.;A_7,L+(5X1A',D,@]>^
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M\\Q ?;YA3+[<9!-4AY+S'U!+ P04    " #"A6Y5T;WF%=$"  "#!@  &0
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M=$+M8 ^(!S>Y;2V<.+.=%J3]^-E.FC4B9&/* R]M;-]S?,^QKW6'.\8?Q09
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MW*A^%K@.4.LKQN1^H%NFHD/V?P-02P,$%     @ PH5N52]K;B*H @  .@8
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M(P*JGE2U863IID,B#<T:M]S0<$=E'>A\):4Y&#9!\[N(_P!02P,$%     @
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M"%X2I@+D\Q6EXN5"[9'6>^+3_P%02P,$%     @ PH5N52D?$"D'!   ^!4
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MFCI7#DIA@<M,/K'-1Z@W--!\"<N$^46;>JWGH*04DN4U6'F0$UK]XY<Z$%L
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M;]HP%/TK5E9-K52:+PB40:06-+5:-Z'2;@_3'DQR :N.G=D.M/OUNT[2B+*
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M#0_7G<YGYIP4]"5S9HNK)IDI7>L8N7;+R*\6L\IL2$*B)#S*U2L+J!\$2MN
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M)?7+1\'G(J\:R.\7659NWU0!=H]OO?H_4$L#!!0    ( ,*%;E48V#1N7@4
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M,WRNFM?E+TWSUMU1N6;8?CAD2.D-S]%<V;P?S42+RK;@E=#8T.TPQR<7I G
M_4P(O9^8 [I'//X#4$L#!!0    ( ,*%;E41]^36: ,  )D+   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;*V6W8[3.A" 7\4*1P@DMDF<I#]+&VF[
ML,#%<E9;L5P<<>$FT\;:Q ZVVX+$PV,[:5I.DZS0]J:QW9GQ-^,9>Z8[+AYE
M!J#0CR)G<N9D2I67KBN3# HB![P$IO]9<5$0I:=B[<I2 $FM4I&[V/.&;D$H
M<^*I7;L3\91O5$X9W DD-T5!Q,\YY'PW<WQGOW!/UYDR"VX\+<D:%J"^E'="
MS]S&2DH+8))RA@2L9LZ5?SGW Z-@)1XH[.31&!E7EIP_FLFG=.9XA@AR2)0Q
M0?1G"]>0Y\:2YOA>&W6:/8WB\7AO_<8ZKYU9$@G7//]*4Y7-G+&#4EB13:[N
M^>XCU Y%QE["<VE_T:Z6]1R4;*3B1:VL"0K*JB_Y40?B2"' '0JX5L"6N]K(
M4KXCBL13P7=(&&EMS0RLJU9;PU%F3F6AA/Z7:CT5+Q1/'B_FVJ\47?-"'[8D
M-EP7:*$S(-WD@/@*?>9L"U)IH7O]$30Q0ZN+OC"J)+HRT:7J)WKU#A2A^6MM
M 'M^6 O]6UJC=SEAZ+];*)8@OFF)#F-[B:FKM(L&U$UJ=^:5.[C#G0FZY4QE
M$KUG*:1_ZKLZ-$U\\#X^<]QK< 'E  7>&^T,QN@?Y"*9$0&R_O3L$#0G$-@=
M@JX=C*&6$VASOK(4MELR!7PI2Y+ S-$5*D%LP8E?OO"'WML>SK#A#/NLQY\W
MYDQ,,EAB^>8H*<3A'.OP$(54!F@):\H896NC9Q9*$)2GZ%=K_"HG*XS(8IA+
M91O[(0Z#<.IN6_"C!C_Z2_S[$^BU(,Q,^^BB4[JA%XVB=KIA0S=\-ET=ZSZX
MX0G<1>0%$6Z'&S5PHV?#Z?=A!?0IOM$I'QX'44?PQ@W?^/R9"2S]BYP<GX!C
MG9)>1V G#?BD%_RK?3,@O;C:@M!O(/I@$A#IBQS0#:$"/9!\ \\LM,.=U>98
M!3@^<FSB#T:C=K]\[_"J>&?Q[$-3<?V8]7:3/PY@,)IT<!Z]?OY9.!_VM?<$
MIG^".0D&?M"!B0^8^"R8-T=5^ 0I/B$-\:#CCO4/;YG?^P2=,Z/;"O0)GX*3
M9 ['@^#_1>H>=4L%B+7M"25*^(:IJG%J5IN^\ZKJM@[B5=-Z2X0N.XER6&E5
M;S#2-X2H^L!JHGAI>Z\E5[J3L\-,]\X@C(#^?\6YVD_,!DTW'O\&4$L#!!0
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MEP^E*7>R9%T\2V2>9%D2%9LK1H6P\P'B_?LDR9YV<@>[1P--_P502P,$%
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MR0XA_TX09$I ICN!G#4X<"B"S C(;(>0O4CF!&2^2\@404X(R,DN(3,$N4]
M[O-"7LM8>R7<0IS505L5 N(Z(+@.>+EF=55)_]* S?2#U7"8A([RM"A<#1TE
M@CPD( ]Y(;]*[<6]-+42ORL9()#- 3B"XQ'5<8]X\6Y5B%X7S4-W+L,28Y$^
M81;*K%ZM3!LI:5XUTMJZE1_&I(PR9E;*-20W0=S(%]F>]PV*,LB862$SY350
MG8I;52IH#<[>]"Y/39*T@4DY9,PLD5ETQ>/2F5+Y\).X4'"8CAB.<L>861XM
MW-Z9['KF"EH*[](M2AMC9F_\);V'OBX(&8(K="N-9QV7XD[Y2EQA3$H<8VYS
M0+M7+L KHCR\OM+WGCY*'6-F=_PY$]\<O!*VS:WA]8@>2@!,1SECS"R-*S"%
MPHY(*$<DS(Z %Z#2L=566X4TT8)R2-E"]R$I8R3LQI@']4_=W,TO3QN&3<BJ
M@]D19);22Y83RAH)MS5(3)PN)Y0U$F9K;$FGQ,]WC>=Z-YWR1\+M#RI_Z=]T
M2B,)LT9Z^<LZAK]@.LH>";,]MDGX!RC&I%22,*ODO>0^C"3EDX39)^\K.+$G
M3LM2-WM*@X<^*-&DS**A^R!<#:>4:E)VU5"8.<:DQ)/N5#P3C$D.>.U4//L8
MDQ)/REVND)@'&),23\HN'@KS$&-2XDF9Q;--XWMB!JV7&),R4,ILH.V8;>>)
M,2D#I<P&(J+9/ X8D[)0NINAL ZSEQ1EE(4R9@MMQ[QUQNQA3,I"&;.%-D;N
M>D*')!-C4A;*V"U$9<*XKL@H"V7L%J(P<>J1D1,O[!:B,''JD5$6RG9:_N#4
M(Z,LE'UJ^?/#/;5I$^4+-<>8E(4R[E&T#<QNC,])*TX?O,)U4$99*..>CJ'&
MG?O=.V6AC-E"'XX[O_6>>/*2LE#.70MM*WX[4HQ)62CGKH6V8S:Y!\:D+)1S
M6XC A.8Q)F6AG-M"%&9_8IVR4/X94S?;;GH?D_P @-E"KY,DIQ],DO0Q*0OE
MW!9Z/WZT97 FIRR4?_I<3L^8&).R4+Z3B9W7B&),RD+YI\SP;";M'WW6-:$L
M--GEU(_ M="$LM#DLR=_^H'%F)2%)JV%ANW.X>2XA-S JO(:3A%@?2%-<>-%
M\]-]>)#ES23AHC;F'-;]82$E*]??"*Z_;SSY#U!+ P04    " #"A6Y5=TMQ
MA08"  #Q)   &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=E+:N-
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M&^IM!'H;ZFT$>MMLLX1 ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U
M;T>]G4!O1[V=0&]'O9U ;T>]G4!OGVUV$^CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3
MZ.VHMQ/H':AW$.@=J'<0Z!VH=Q#H':AW$.@=J'<0Z!VSGY4$>@?J'01Z!^H=
M!'H'ZAT$>@?J'01ZMZAW2Z!WBWJW!'JWJ'?[G7J7Z?.0R[7G:XW/_TZJI_.]
M^?KXR_+KY.R]7'!.MQ7E^2]02P,$%     @ PH5N5?\GIW7C 0  ;"0  !,
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MW2&?#7\RFKT!4$L! A0#%     @ PH5N50=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #"A6Y5TG43
M@N\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " #"A6Y5F5R<(Q &  "<)P  $P              @ '- 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,*%;E5;6?<KS04  -0>
M   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " #"A6Y5%'PG/;P&  !R'@  &               @($1#@
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ PH5N54<JK<.B
M P  N@X  !@              ("! Q4  'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;%!+ 0(4 Q0    ( ,*%;E4))S914@@  $$O   8              "
M@=L8  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #"A6Y5
M\ )KK/0.   QFP  &               @(%C(0  >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L! A0#%     @ PH5N54*Z3I]N"   _R<  !@
M     ("!C3   'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (
M ,*%;E5*3*R=V (  %P)   8              " @3$Y  !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"% ,4    " #"A6Y5I]7+MBH2  "&,P  &
M            @($_/   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#
M%     @ PH5N52FFH$B<)   Q'@  !@              ("!GTX  'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( ,*%;E73?UJ-&@8  /X/
M   9              " @7%S  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M4$L! A0#%     @ PH5N5?CT5CN> @  H@8  !D              ("!PGD
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #"A6Y5P5J1
M0DP&   !$0  &0              @(&7?   >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+ 0(4 Q0    ( ,*%;E6H_AF4J @  %,8   9
M  " @1J#  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @
MPH5N534MAIW=#   1"D  !D              ("!^8L  'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"% ,4    " #"A6Y5%5!J/E@%   ;#0  &0
M            @($-F0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4
M Q0    ( ,*%;E7$!=E4.PX  "HL   9              " @9R>  !X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ PH5N55U^%?AH P
MQ0@  !D              ("!#JT  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q02P$"% ,4    " #"A6Y5_A-F;]X$  "@"P  &0              @(&M
ML   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ,*%;E5,
M)+ RMP4  "D.   9              " @<*U  !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L! A0#%     @ PH5N5="H!%5!!P  )A0  !D
M     ("!L+L  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,*%;E4>NFULNP0  (<,   9              "
M@?GU  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ PH5N
M56E1W,:X!   W0H  !D              ("!Z_H  'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6Q02P$"% ,4    " #"A6Y5,1<MK>$"   0!@  &0
M        @(':_P  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0
M   ( ,*%;E4X>^8K4P8  ,\/   9              " @?(" 0!X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ PH5N54M"$M)? P  ^ 8
M !D              ("!? D! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"% ,4    " #"A6Y5\I,G9(,+  #SA@  &0              @($2#0$
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( ,*%;E5(CJ!<
M"0\  &N=   9              " @<P8 0!X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL4$L! A0#%     @ PH5N50V\,?Z+ P  RQ(  !D
M ("!#"@! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #"
MA6Y5PE@5<JD"   /"   &0              @('.*P$ >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( ,*%;E7M'_=U<0(  "\&   9
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M970S."YX;6Q02P$"% ,4    " #"A6Y5+VMN(J@"   Z!@  &0
M    @(&500$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (
M ,*%;E587#P!BP(  -8%   9              " @71$ 0!X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL4$L! A0#%     @ PH5N5=7,9)^8 P  V \  !D
M             ("!-D<! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"
M% ,4    " #"A6Y50UVGG*\"  #8!@  &0              @($%2P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( ,*%;E7JB28#I0(
M /0&   9              " @>M- 0!X;"]W;W)K<VAE971S+W-H965T-#,N
M>&UL4$L! A0#%     @ PH5N50+R3G7[!   'Q\  !D              ("!
MQU ! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " #"A6Y5
M*1\0*0<$  #X%0  &0              @('Y50$ >&PO=V]R:W-H965T<R]S
M:&5E=#0U+GAM;%!+ 0(4 Q0    ( ,*%;E52DAK6)@,  $H)   9
M      " @3=: 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%
M  @ PH5N54G)IT76 @  : <  !D              ("!E%T! 'AL+W=O<FMS
M:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " #"A6Y5V01$RLX%  !4*
M&0              @(&A8 $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+
M 0(4 Q0    ( ,*%;E6]].MI6 @  .1!   9              " @:9F 0!X
M;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ PH5N5:YW=^4:
M!0  HR<  !D              ("!-6\! 'AL+W=O<FMS:&5E=',O<VAE970U
M,"YX;6Q02P$"% ,4    " #"A6Y56/L.AND*  #*=0  &0
M@(&&= $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( ,*%
M;E48V#1N7@4  * =   9              " @:9_ 0!X;"]W;W)K<VAE971S
M+W-H965T-3(N>&UL4$L! A0#%     @ PH5N57*F-&?R @  T <  !D
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M=#4W+GAM;%!+ 0(4 Q0    ( ,*%;E5)-(XD800  &\;   9
M  " @4R7 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @
MPH5N5;! 9 _N!@  )D@  !D              ("!Y)L! 'AL+W=O<FMS:&5E
M=',O<VAE970U.2YX;6Q02P$"% ,4    " #"A6Y5%5(JNW8)  "C=P  &0
M            @($)HP$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4
M Q0    ( ,*%;E7M)7IW 00  " 7   9              " @;:L 0!X;"]W
M;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ PH5N5<E@A [T#
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M2P$"% ,4    " #"A6Y5=TMQA08"  #Q)   &@              @ %BQP$
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #"A6Y5_R>G
M=>,!  !L)   $P              @ &@R0$ 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     1@!& "$3  "TRP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>291</ContextCount>
  <ElementCount>335</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>85</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Consolidated Statements of Series A Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Series A Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Condensed Consolidated Statement of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsParenthetical</Role>
      <ShortName>Condensed Consolidated Statement of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureRestrictedCash</Role>
      <ShortName>Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Supplemental Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformation</Role>
      <ShortName>Supplemental Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Series A Redeemable Convertible Preferred Stock and Related Warrant</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrant</Role>
      <ShortName>Series A Redeemable Convertible Preferred Stock and Related Warrant</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficit</Role>
      <ShortName>Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Warrants associated with Term Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureWarrantsAssociatedWithTermLoan</Role>
      <ShortName>Warrants associated with Term Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - US Government Contract</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContract</Role>
      <ShortName>US Government Contract</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Supplemental Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables</Role>
      <ShortName>Supplemental Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTables</Role>
      <ShortName>Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayable</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Nature of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Nature of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Summary of Significant Accounting Policies - Schedule of Customers Represent Greater Than 10% Of Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Customers Represent Greater Than 10% Of Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Summary of Significant Accounting Policies - Summary of Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Summary of Significant Accounting Policies - Summary of Maturities of Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Maturities of Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue by Major Resource (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueByMajorResourceDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Disaggregation of Revenue by Major Resource (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Summary of Significant Accounting Policies - Additional Information 1 (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1Detail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information 1 (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities at Fair value on a Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Schedule of Financial Assets and Liabilities at Fair value on a Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Fair Value Measurements - Summary of Contingent Interest Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Contingent Interest Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Fair Value Measurements - Summary of Contingent Interest Payments (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsParentheticalDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Contingent Interest Payments (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Fair Value Measurements - Roll-Forward of Fair Value of Derivative Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsRollForwardOfFairValueOfDerivativeLiabilityDetail</Role>
      <ShortName>Fair Value Measurements - Roll-Forward of Fair Value of Derivative Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Restricted Cash - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetail</Role>
      <ShortName>Restricted Cash - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Supplemental Balance Sheet Information - Schedule of Inventory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryDetail</Role>
      <ShortName>Supplemental Balance Sheet Information - Schedule of Inventory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Supplemental Balance Sheet Information - Schedule of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail</Role>
      <ShortName>Supplemental Balance Sheet Information - Schedule of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Supplemental Balance Sheet Information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail</Role>
      <ShortName>Supplemental Balance Sheet Information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Supplemental Balance Sheet Information - Components of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail</Role>
      <ShortName>Supplemental Balance Sheet Information - Components of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Notes Payable - Schedule of Debt (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableScheduleOfDebtDetail</Role>
      <ShortName>Notes Payable - Schedule of Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Notes Payable - Term Loan Agreement - Additional Information (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail</Role>
      <ShortName>Notes Payable - Term Loan Agreement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Series A Redeemable Convertible Preferred Stock and Related Warrant - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail</Role>
      <ShortName>Series A Redeemable Convertible Preferred Stock and Related Warrant - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Stockholders' Deficit - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Deficit - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Stock-Based Compensation - Schedule of Estimated Assumptions Used to Calculate Weighted-Average Grant Date Fair Value of Options Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Estimated Assumptions Used to Calculate Weighted-Average Grant Date Fair Value of Options Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Stock-Based Compensation - Schedule of Nonvested Restricted Stock Units Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Nonvested Restricted Stock Units Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted that was Recorded in the Company's Results of Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedThatWasRecordedInCompanySResultsOfOperationsDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted that was Recorded in the Company's Results of Operations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Warrants Associated with Term Loan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureWarrantsAssociatedWithTermLoanAdditionalInformationDetail</Role>
      <ShortName>Warrants Associated with Term Loan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Net Loss Per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail</Role>
      <ShortName>Net Loss Per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail</Role>
      <ShortName>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100580 - Disclosure - US Government Contract - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail</Role>
      <ShortName>US Government Contract - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ttoo-10q_20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 21 fact(s) appearing in ix:hidden were eligible for transformation: ttoo:MaintenanceServiceTermOfAdditionalPeriod, us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted, us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect, us-gaap:DebtInstrumentTerm, us-gaap:LeaseExpirationDate1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  ttoo-10q_20220930.htm 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="ttoo-10q_20220930.htm">ttoo-10q_20220930.htm</File>
    <File>ttoo-20220930.xsd</File>
    <File>ttoo-20220930_cal.xml</File>
    <File>ttoo-20220930_def.xml</File>
    <File>ttoo-20220930_lab.xml</File>
    <File>ttoo-20220930_pre.xml</File>
    <File>ttoo-ex104_892.htm</File>
    <File>ttoo-ex105_1066.htm</File>
    <File>ttoo-ex311_11.htm</File>
    <File>ttoo-ex312_12.htm</File>
    <File>ttoo-ex321_14.htm</File>
    <File>ttoo-ex322_7.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="737">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ttoo-10q_20220930.htm": {
   "axisCustom": 0,
   "axisStandard": 35,
   "contextCount": 291,
   "dts": {
    "calculationLink": {
     "local": [
      "ttoo-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ttoo-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ttoo-10q_20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ttoo-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ttoo-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ttoo-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 576,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 24,
    "http://www.t2biosystems.com/20220930": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 30
   },
   "keyCustom": 60,
   "keyStandard": 275,
   "memberCustom": 39,
   "memberStandard": 44,
   "nsprefix": "ttoo",
   "nsuri": "http://www.t2biosystems.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Fair Value Measurements",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Restricted Cash",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureRestrictedCash",
     "shortName": "Restricted Cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Supplemental Balance Sheet Information",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformation",
     "shortName": "Supplemental Balance Sheet Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Notes Payable",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayable",
     "shortName": "Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ttoo:RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Series A Redeemable Convertible Preferred Stock and Related Warrant",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrant",
     "shortName": "Series A Redeemable Convertible Preferred Stock and Related Warrant",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ttoo:RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Stockholders' Deficit",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficit",
     "shortName": "Stockholders' Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Stock-Based Compensation",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ttoo:WarrantsNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Warrants associated with Term Loan",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureWarrantsAssociatedWithTermLoan",
     "shortName": "Warrants associated with Term Loan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ttoo:WarrantsNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Net Loss Per Share",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - US Government Contract",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContract",
     "shortName": "US Government Contract",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Leases",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Commitments and Contingencies",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Subsequent Events",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Supplemental Balance Sheet Information (Tables)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables",
     "shortName": "Supplemental Balance Sheet Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Notes Payable (Tables)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTables",
     "shortName": "Notes Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220930",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Nature of Business - Additional Information (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
     "shortName": "Nature of Business - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_ttooSegment",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_srtMajorCustomersAxis_ttooCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20220701_20220930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Summary of Significant Accounting Policies - Schedule of Customers Represent Greater Than 10% Of Revenue (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Customers Represent Greater Than 10% Of Revenue (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_srtMajorCustomersAxis_ttooCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20220701_20220930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:MarketableSecuritiesPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Summary of Significant Accounting Policies - Summary of Marketable Securities (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail",
     "shortName": "Summary of Significant Accounting Policies - Summary of Marketable Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:MarketableSecuritiesPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:MarketableSecuritiesPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Summary of Significant Accounting Policies - Summary of Maturities of Marketable Securities (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail",
     "shortName": "Summary of Significant Accounting Policies - Summary of Maturities of Marketable Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:MarketableSecuritiesPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220701_20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue by Major Resource (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueByMajorResourceDetail",
     "shortName": "Summary of Significant Accounting Policies - Disaggregation of Revenue by Major Resource (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_srtProductOrServiceAxis_ttooProductInstrumentsMember_20220701_20220930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-10-01_20220930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Summary of Significant Accounting Policies - Additional Information 1 (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1Detail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information 1 (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-10-01_20220930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:MarketableSecuritiesPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities at Fair value on a Recurring Basis (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Schedule of Financial Assets and Liabilities at Fair value on a Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapFairValueByMeasurementBasisAxis_us-gaapEstimateOfFairValueFairValueDisclosureMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220930",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ttoo:SummaryOfContingentInterestPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapContingentConsiderationByTypeAxis_ttooScenarioOneMember_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_20220101_20220930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ttoo:FairValueDerivativeLiabilityDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Fair Value Measurements - Summary of Contingent Interest Payments (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail",
     "shortName": "Fair Value Measurements - Summary of Contingent Interest Payments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ttoo:SummaryOfContingentInterestPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapContingentConsiderationByTypeAxis_ttooScenarioOneMember_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_20220101_20220930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ttoo:FairValueDerivativeLiabilityDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220701_20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220701_20220930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ttoo:SummaryOfContingentInterestPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220101_20220930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ttoo:ContingentPaymentOfInterestPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Fair Value Measurements - Summary of Contingent Interest Payments (Parenthetical) (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsParentheticalDetail",
     "shortName": "Fair Value Measurements - Summary of Contingent Interest Payments (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ttoo:SummaryOfContingentInterestPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20220101_20220930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ttoo:ContingentPaymentOfInterestPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Fair Value Measurements - Roll-Forward of Fair Value of Derivative Liability (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsRollForwardOfFairValueOfDerivativeLiabilityDetail",
     "shortName": "Fair Value Measurements - Roll-Forward of Fair Value of Derivative Liability (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapValuationTechniqueAxis_ttooProbabilityWeightedDiscountedCashFlowModelMember_20220701_20220930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20220930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecurityDeposit",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Restricted Cash - Additional Information (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetail",
     "shortName": "Restricted Cash - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RestrictedAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20220101_20220930",
      "decimals": "INF",
      "lang": null,
      "name": "ttoo:NumberOfFacilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_ttooFacility",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Supplemental Balance Sheet Information - Schedule of Inventory (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryDetail",
     "shortName": "Supplemental Balance Sheet Information - Schedule of Inventory (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Supplemental Balance Sheet Information - Schedule of Property and Equipment (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail",
     "shortName": "Supplemental Balance Sheet Information - Schedule of Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryWorkInProcessAndRawMaterials",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Supplemental Balance Sheet Information - Additional Information (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail",
     "shortName": "Supplemental Balance Sheet Information - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20211231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:InventoryWorkInProcessAndRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Supplemental Balance Sheet Information - Components of Accrued Expenses (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail",
     "shortName": "Supplemental Balance Sheet Information - Components of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ttoo:DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Notes Payable - Schedule of Debt (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableScheduleOfDebtDetail",
     "shortName": "Notes Payable - Schedule of Debt (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ttoo:DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Notes Payable - Term Loan Agreement - Additional Information (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail",
     "shortName": "Notes Payable - Term Loan Agreement - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapCreditFacilityAxis_ttooCRGMember_us-gaapDebtInstrumentAxis_ttooTermLoanAgreementMember_20161201_20161231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Series A Redeemable Convertible Preferred Stock and Related Warrant - Additional Information (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail",
     "shortName": "Series A Redeemable Convertible Preferred Stock and Related Warrant - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ttoo:RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapSubsidiarySaleOfStockAxis_ttooPurchaseAgreementMember_20220815_20220815",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Condensed Consolidated Statements of Series A Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Condensed Consolidated Statements of Series A Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20210101_20210331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Stockholders' Deficit - Additional Information (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail",
     "shortName": "Stockholders' Deficit - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20210701",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Stock-Based Compensation - Schedule of Estimated Assumptions Used to Calculate Weighted-Average Grant Date Fair Value of Options Granted (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail",
     "shortName": "Stock-Based Compensation - Schedule of Estimated Assumptions Used to Calculate Weighted-Average Grant Date Fair Value of Options Granted (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapAwardTypeAxis_ttooEmployeeAndNonemployeeStockOptionsMember_us-gaapPlanNameAxis_ttooStockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember_20220101_20220930",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Stock-Based Compensation - Schedule of Nonvested Restricted Stock Units Activity (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail",
     "shortName": "Stock-Based Compensation - Schedule of Nonvested Restricted Stock Units Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ttooStockOptionPlan2014Member_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220701_20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted that was Recorded in the Company's Results of Operations (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedThatWasRecordedInCompanySResultsOfOperationsDetail",
     "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted that was Recorded in the Company's Results of Operations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20220701_20220930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Warrants Associated with Term Loan - Additional Information (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureWarrantsAssociatedWithTermLoanAdditionalInformationDetail",
     "shortName": "Warrants Associated with Term Loan - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220701_20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityDividendsAdjustment",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Net Loss Per Share - Additional Information (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
     "shortName": "Net Loss Per Share - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": "INF",
      "lang": null,
      "name": "ttoo:StockIssuedAndOutstandingDuringPeriodSharesStockSplits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220701_20220930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail",
     "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220701_20220930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220701_20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - US Government Contract - Additional Information (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail",
     "shortName": "US Government Contract - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_srtCounterpartyNameAxis_ttooBiomedicalAdvancedResearchAndDevelopmentAuthorityMember_us-gaapTypeOfArrangementAxis_ttooCoDevelopmentPartnershipAgreementMember_20190930",
      "decimals": "-5",
      "lang": null,
      "name": "ttoo:CollaborativeArrangementInitialValueOfConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Condensed Consolidated Statement of Cash Flows",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows",
     "shortName": "Condensed Consolidated Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_srtMortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_srtOfficeBuildingMember_us-gaapLeaseContractualTermAxis_ttooOperatingLeasesEnteredIntoNovember2014Member_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20170901_20170930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LeaseExpirationDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20060101_20071231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapTypeOfArrangementAxis_ttooLicenseAgreementMember_20060101_20071231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Subsequent Events - Additional Information (Detail)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
     "shortName": "Subsequent Events - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20221011_20221011",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Condensed Consolidated Statement of Cash Flows (Parenthetical)",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsParenthetical",
     "shortName": "Condensed Consolidated Statement of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20210930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Nature of Business",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusiness",
     "shortName": "Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ttoo-10q_20220930.htm",
      "contextRef": "C_0001492674_20220101_20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 85,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r51",
      "r53",
      "r111",
      "r112",
      "r264",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r187",
      "r344",
      "r349",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major Customers [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r263",
      "r303",
      "r365",
      "r366",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r569",
      "r622",
      "r626",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r263",
      "r303",
      "r365",
      "r366",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r569",
      "r622",
      "r626",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": {
     "auth_ref": [
      "r640",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mortgage Loans On Real Estate Description Type Of Property [Axis]",
        "terseLabel": "Real Estate, Type of Property"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": {
     "auth_ref": [
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mortgage Loans On Real Estate Name Property Type [Domain]",
        "terseLabel": "Real Estate"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r187",
      "r344",
      "r349",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Of Major Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficeBuildingMember": {
     "auth_ref": [
      "r640",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Building [Member]",
        "terseLabel": "Office Space [Member]"
       }
      }
     },
     "localname": "OfficeBuildingMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r183",
      "r244",
      "r245",
      "r344",
      "r347",
      "r572",
      "r621",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueByMajorResourceDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r183",
      "r244",
      "r245",
      "r344",
      "r347",
      "r572",
      "r621",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueByMajorResourceDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r238",
      "r243",
      "r244",
      "r245",
      "r246",
      "r263",
      "r303",
      "r355",
      "r365",
      "r366",
      "r399",
      "r400",
      "r401",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r569",
      "r622",
      "r626",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r238",
      "r243",
      "r244",
      "r245",
      "r246",
      "r263",
      "r303",
      "r355",
      "r365",
      "r366",
      "r399",
      "r400",
      "r401",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r569",
      "r622",
      "r626",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r52",
      "r53",
      "r111",
      "r112",
      "r264",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r184",
      "r185",
      "r344",
      "r348",
      "r624",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r184",
      "r185",
      "r344",
      "r348",
      "r624",
      "r640",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r188",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_AccruedResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for research and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research And Development Expenses Current",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities debt maturities after one through two years amortized cost.",
        "label": "Available For Sale Securities Debt Maturities After One Through Two Years Amortized Cost",
        "terseLabel": "Marketable Securities, Amortized Cost, Due in 1-2 years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities debt maturities after one through two years fair value.",
        "label": "Available For Sale Securities Debt Maturities After One Through Two Years Fair Value",
        "terseLabel": "Marketable Securities, Fair Value, Due in 1-2 years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biomedical Advanced Research and Development Authority.",
        "label": "Biomedical Advanced Research And Development Authority [Member]",
        "terseLabel": "Biomedical Advanced Research and Development Authority [Member]"
       }
      }
     },
     "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_CRGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CRG.",
        "label": "C R G [Member]",
        "terseLabel": "CRG [Member]"
       }
      }
     },
     "localname": "CRGMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsParentheticalDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_CanaccordGenuityLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Canaccord Genuity LLC.",
        "label": "Canaccord Genuity L L C [Member]",
        "terseLabel": "Canaccord [Member]"
       }
      }
     },
     "localname": "CanaccordGenuityLLCMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_ChangeInFairValueOfDerivativeWarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10120.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of derivative warrant liability.",
        "label": "Change In Fair Value Of Derivative Warrant Liability",
        "negatedLabel": "Change in fair value of derivative warrant liability",
        "terseLabel": "Change in fair value of derivative warrant liability"
       }
      }
     },
     "localname": "ChangeInFairValueOfDerivativeWarrantLiability",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_ClassOfWarrantOrRightMaturityDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right maturity date.",
        "label": "Class Of Warrant Or Right Maturity Date",
        "terseLabel": "Warrants maturity term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightMaturityDate",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "ttoo_CoDevelopmentPartnershipAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to a Co-Development Partnership Agreement with a third party to develop certain products.",
        "label": "Co Development Partnership Agreement [Member]",
        "terseLabel": "Co Development Partnership Agreement [Member]"
       }
      }
     },
     "localname": "CoDevelopmentPartnershipAgreementMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_CollaborativeArrangementAdditionalFundingAmountReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement Additional Funding Amount Received.",
        "label": "Collaborative Arrangement Additional Funding Amount Received",
        "terseLabel": "Collaborative arrangement additional funding amount received"
       }
      }
     },
     "localname": "CollaborativeArrangementAdditionalFundingAmountReceived",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_CollaborativeArrangementAdditionalFundingAmountToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement additional funding amount to be received.",
        "label": "Collaborative Arrangement Additional Funding Amount To Be Received",
        "terseLabel": "Collaborative arrangement additional funding amount to be received"
       }
      }
     },
     "localname": "CollaborativeArrangementAdditionalFundingAmountToBeReceived",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_CollaborativeArrangementAggregateConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of aggregate consideration receivable under collaborative arrangement.",
        "label": "Collaborative Arrangement Aggregate Consideration",
        "terseLabel": "Aggregate consideration receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementAggregateConsideration",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_CollaborativeArrangementFirstContractOptionValueExercised": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement first contract option value exercised.",
        "label": "Collaborative Arrangement First Contract Option Value Exercised",
        "terseLabel": "First contract option value exercised"
       }
      }
     },
     "localname": "CollaborativeArrangementFirstContractOptionValueExercised",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_CollaborativeArrangementInitialValueOfConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement initial value of consideration.",
        "label": "Collaborative Arrangement Initial Value Of Consideration",
        "terseLabel": "Initial value of consideration receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementInitialValueOfConsideration",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_CollaborativeArrangementOptionContractValueExercised": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement option contract value exercised.",
        "label": "Collaborative Arrangement Option Contract Value Exercised",
        "terseLabel": "Option contract value exercised"
       }
      }
     },
     "localname": "CollaborativeArrangementOptionContractValueExercised",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments and Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ttoo_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ttoo_ComponentOfCommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of common stock capital shares reserved for future issuance.",
        "label": "Component Of Common Stock Capital Shares Reserved For Future Issuance",
        "verboseLabel": "Shares available for future issuance under stock incentive plan"
       }
      }
     },
     "localname": "ComponentOfCommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ttoo_ContingentPaymentOfInterestPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent payment of interest, percentage.",
        "label": "Contingent Payment Of Interest Percentage",
        "terseLabel": "Contingent payment of interest rate"
       }
      }
     },
     "localname": "ContingentPaymentOfInterestPercentage",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsParentheticalDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ttoo_ContributionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contribution.",
        "label": "Contribution [Member]",
        "terseLabel": "Contribution [Member]"
       }
      }
     },
     "localname": "ContributionMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_ContributionRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contribution revenue.",
        "label": "Contribution Revenue [Member]",
        "terseLabel": "Contribution Revenue [Member]"
       }
      }
     },
     "localname": "ContributionRevenueMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueByMajorResourceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_CostOfProductRevenuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product revenue.",
        "label": "Cost Of Product Revenue Policy [Text Block]",
        "terseLabel": "Cost of Product Revenue"
       }
      }
     },
     "localname": "CostOfProductRevenuePolicyTextBlock",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ttoo_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer A.",
        "label": "Customer A [Member]",
        "terseLabel": "Customer A [Member]"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer B.",
        "label": "Customer B [Member]",
        "terseLabel": "Customer B [Member]"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_CustomerCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer C.",
        "label": "Customer C [Member]",
        "terseLabel": "Customer C [Member]"
       }
      }
     },
     "localname": "CustomerCMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableScheduleOfDebtDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_NotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument carrying amount including paid in kind interest before unamortized discount and issuance costs.",
        "label": "Debt Instrument Carrying Amount Including Paid In Kind Interest Before Unamortized Discount And Issuance Costs",
        "terseLabel": "Term Loan Agreement including PIK interest, before unamortized discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmountIncludingPaidInKindInterestBeforeUnamortizedDiscountAndIssuanceCosts",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableScheduleOfDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_DebtInstrumentDeferredInterestRateInterestOnlyPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual deferred interest rate during interest only payments for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument Deferred Interest Rate Interest Only Payment",
        "terseLabel": "Deferred interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentDeferredInterestRateInterestOnlyPayment",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ttoo_DebtInstrumentEventOfDefaultAdditionalInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional interest rate on all outstanding obligations during the occurrence and continuance of an event of default.",
        "label": "Debt Instrument Event Of Default Additional Interest Rate",
        "terseLabel": "Additional interest rate, event of default (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentEventOfDefaultAdditionalInterestRate",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ttoo_DebtInstrumentFinalPaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final fee as a percentage of the amount of principal outstanding upon repayment.",
        "label": "Debt Instrument Final Payment Fee Percentage",
        "terseLabel": "Final fee as a percentage of the principal outstanding (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentFinalPaymentFeePercentage",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ttoo_DebtInstrumentPrepaymentFeeTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment fee period of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument Prepayment Fee Term",
        "terseLabel": "Debt instrument, prepayment fee term (in years)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeeTerm",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ttoo_DebtInstrumentTermOfInterestOnlyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument of interest only payments, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument Term Of Interest Only Payments",
        "terseLabel": "Debt instrument, term of interest-only payments (in years)"
       }
      }
     },
     "localname": "DebtInstrumentTermOfInterestOnlyPayments",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ttoo_DebtInstrumentUnaccruedPaidInKindInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableScheduleOfDebtDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_NotesPayable",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument unaccrued paid in kind interest.",
        "label": "Debt Instrument Unaccrued Paid In Kind Interest",
        "negatedLabel": "Less: unaccrued paid-in-kind interest"
       }
      }
     },
     "localname": "DebtInstrumentUnaccruedPaidInKindInterest",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableScheduleOfDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed dividend on Series A convertible redeemable preferred stock.",
        "label": "Deemed Dividend On Series A Convertible Redeemable Preferred Stock",
        "terseLabel": "Deemed dividend on Series A redeemable convertible preferred stock"
       }
      }
     },
     "localname": "DeemedDividendOnSeriesAConvertibleRedeemablePreferredStock",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_EmployeeAndNonemployeeStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee and nonemployee stock options.",
        "label": "Employee And Nonemployee Stock Options [Member]",
        "terseLabel": "Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeAndNonemployeeStockOptionsMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_FairValueDerivativeLiabilityDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value derivative liability discount rate.",
        "label": "Fair Value Derivative Liability Discount Rate",
        "terseLabel": "4% contingent interest beginning in Q1 2023, probability"
       }
      }
     },
     "localname": "FairValueDerivativeLiabilityDiscountRate",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ttoo_GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain loss on issuance of Series A redeemable convertible preferred stock and derivative warrant liability.",
        "label": "Gain Loss On Issuance Of Series A Redeemable Convertible Preferred Stock And Derivative Warrant Liability",
        "negatedLabel": "(Gain) loss on issuance of Series A redeemable convertible preferred stock and derivative warrant liability"
       }
      }
     },
     "localname": "GainLossOnIssuanceOfSeriesARedeemableConvertiblePreferredStockAndDerivativeWarrantLiability",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_GeographicInformationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographic information.",
        "label": "Geographic Information Policy [Text Block]",
        "terseLabel": "Geographic Information"
       }
      }
     },
     "localname": "GeographicInformationPolicyTextBlock",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ttoo_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10280.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_InducementAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement award plan.",
        "label": "Inducement Award Plan [Member]",
        "terseLabel": "Inducement Award Plan [Member]"
       }
      }
     },
     "localname": "InducementAwardPlanMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_InstrumentRentalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument rentals.",
        "label": "Instrument Rentals [Member]",
        "terseLabel": "Instrument Rentals [Member]"
       }
      }
     },
     "localname": "InstrumentRentalsMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueByMajorResourceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_LaboratorySpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to laboratory space.",
        "label": "Laboratory Space [Member]",
        "terseLabel": "Laboratory Space [Member]"
       }
      }
     },
     "localname": "LaboratorySpaceMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_LeasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases.",
        "label": "Leases [Line Items]",
        "terseLabel": "Leases [Line Items]"
       }
      }
     },
     "localname": "LeasesLineItems",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ttoo_LeasesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases.",
        "label": "Leases [Table]",
        "terseLabel": "Leases [Table]"
       }
      }
     },
     "localname": "LeasesTable",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ttoo_LesseeOperatingLeaseTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease termination period.",
        "label": "Lessee Operating Lease Termination Period",
        "terseLabel": "Lease termination date"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTerminationPeriod",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "ttoo_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to an agreement with a third party for licensing.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_LicenseFeesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of annual licensing fees agreed to be paid by the company.",
        "label": "License Fees Payable",
        "terseLabel": "Annual license fee payable"
       }
      }
     },
     "localname": "LicenseFeesPayable",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_MaintenanceServicePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term following the installation of the purchased product for maintenance services which include warranty, maintenance, and technical support services, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Maintenance Service Period",
        "terseLabel": "Maintenance Services period (in years)"
       }
      }
     },
     "localname": "MaintenanceServicePeriod",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ttoo_MaintenanceServiceTermOfAdditionalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The additional term for maintenance services on purchased product (which include warranty, maintenance, and technical support services) that may be purchased for additional consideration, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Maintenance Service Term Of Additional Period",
        "terseLabel": "Additional period for Maintenance Service option (in years)"
       }
      }
     },
     "localname": "MaintenanceServiceTermOfAdditionalPeriod",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ttoo_MaximumAmountOfAnnualEmployeeCommonStockPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of annual employee common stock purchase",
        "label": "Maximum Amount Of Annual Employee Common Stock Purchase",
        "terseLabel": "Maximum amount of annual employee common stock purchases"
       }
      }
     },
     "localname": "MaximumAmountOfAnnualEmployeeCommonStockPurchase",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum lease period to not recognize right of use assets or lease liabilities.",
        "label": "Maximum Lease Period To Not Recognize Right Of Use Assets Or Lease Liabilities",
        "terseLabel": "Maximum lease period to not recognize right of use assets or lease liabilities"
       }
      }
     },
     "localname": "MaximumLeasePeriodToNotRecognizeRightOfUseAssetsOrLeaseLiabilities",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ttoo_MinimumBidPriceOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum bid price of common stock.",
        "label": "Minimum Bid Price Of Common Stock",
        "terseLabel": "Bid price of common stock"
       }
      }
     },
     "localname": "MinimumBidPriceOfCommonStock",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ttoo_MinimumMarketValueOfListedSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum market value of listed securities.",
        "label": "Minimum Market Value Of Listed Securities",
        "terseLabel": "Minimum market value of listed securities"
       }
      }
     },
     "localname": "MinimumMarketValueOfListedSecurities",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Miscellaneous adjustment of Shares to reflect rounding on reverse split.",
        "label": "Miscellaneous Adjustment Of Shares To Reflect Rounding On Reverse Split",
        "terseLabel": "Misc adjustment to reflect rounding on reverse stock split"
       }
      }
     },
     "localname": "MiscellaneousAdjustmentOfSharesToReflectRoundingOnReverseSplit",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "ttoo_NatureOfBusinessLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of business line items.",
        "label": "Nature Of Business [Line Items]",
        "terseLabel": "Nature Of Business [Line Items]"
       }
      }
     },
     "localname": "NatureOfBusinessLineItems",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ttoo_NatureOfBusinessTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of business table.",
        "label": "Nature Of Business [Table]",
        "terseLabel": "Nature Of Business [Table]"
       }
      }
     },
     "localname": "NatureOfBusinessTable",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ttoo_NewSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New sales agreement.",
        "label": "New Sales Agreement [Member]",
        "terseLabel": "New Sales Agreement [Member]"
       }
      }
     },
     "localname": "NewSalesAgreementMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_NumberOfFacilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of facilities.",
        "label": "Number Of Facilities",
        "terseLabel": "Number of facilities"
       }
      }
     },
     "localname": "NumberOfFacilities",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "ttoo_OfficeLaboratoryAndManufacturingSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to office, laboratory and manufacturing space.",
        "label": "Office Laboratory And Manufacturing Space [Member]",
        "terseLabel": "Office Laboratory And Manufacturing Space"
       }
      }
     },
     "localname": "OfficeLaboratoryAndManufacturingSpaceMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_OfficeResearchLaboratoryAndManufacturingSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Research Laboratory and Manufacturing Space.",
        "label": "Office Research Laboratory And Manufacturing Space [Member]",
        "terseLabel": "Office, Research, Laboratory and Manufacturing Space [Member]"
       }
      }
     },
     "localname": "OfficeResearchLaboratoryAndManufacturingSpaceMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_OfficeSpaceLaboratorySpaceAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space, laboratory space, and equipment.",
        "label": "Office Space Laboratory Space And Equipment [Member]",
        "terseLabel": "Office Space, Laboratory Space, and Equipment [Member]"
       }
      }
     },
     "localname": "OfficeSpaceLaboratorySpaceAndEquipmentMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_OperatingLeasesEnteredIntoMay2013Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to operating leases entered into May 2013.",
        "label": "Operating Leases Entered Into May2013 [Member]",
        "terseLabel": "Operating Leases Entered Into May2013"
       }
      }
     },
     "localname": "OperatingLeasesEnteredIntoMay2013Member",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_OperatingLeasesEnteredIntoNovember2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to operating leases entered into November 2014.",
        "label": "Operating Leases Entered Into November2014 [Member]",
        "terseLabel": "Operating Lease Entered into November 2014 [Member]"
       }
      }
     },
     "localname": "OperatingLeasesEnteredIntoNovember2014Member",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_OperatingLeasesEnteredIntoSeptember2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases Entered Into September2021.",
        "label": "Operating Leases Entered Into September2021 [Member]",
        "terseLabel": "Operating Leases Entered Into September 2021 [Member]"
       }
      }
     },
     "localname": "OperatingLeasesEnteredIntoSeptember2021Member",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Original expected period of contracts for which value of unsatisfied performance obligations not to be disclosed.",
        "label": "Original Expected Period Of Contracts For Which Value Of Unsatisfied Performance Obligations Not To Be Disclosed",
        "terseLabel": "Original expected period of contracts for which value of unsatisfied performance obligations not to be disclosed"
       }
      }
     },
     "localname": "OriginalExpectedPeriodOfContractsForWhichValueOfUnsatisfiedPerformanceObligationsNotToBeDisclosed",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ttoo_OriginalSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Original sales agreement.",
        "label": "Original Sales Agreement [Member]",
        "terseLabel": "Original Sales Agreement"
       }
      }
     },
     "localname": "OriginalSalesAgreementMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_PercentageOfAgentServiceFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of agent service fee.",
        "label": "Percentage Of Agent Service Fee",
        "terseLabel": "Percentage of agent service fee"
       }
      }
     },
     "localname": "PercentageOfAgentServiceFee",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ttoo_PercentageOfCommonSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of common share outstanding, as it relates to the number of shares reserved for future issuance calculation under the 2014 Stock Incentive Plan.",
        "label": "Percentage Of Common Shares Outstanding",
        "verboseLabel": "Percentage of common shares outstanding"
       }
      }
     },
     "localname": "PercentageOfCommonSharesOutstanding",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ttoo_PercentageOfRoyaltyOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty on net sales.",
        "label": "Percentage Of Royalty On Net Sales",
        "terseLabel": "Percentage of royalty on net sales"
       }
      }
     },
     "localname": "PercentageOfRoyaltyOnNetSales",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ttoo_PreferredStockPricePercentageOnStatedValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock price percentage on stated value.",
        "label": "Preferred Stock Price Percentage On Stated Value",
        "terseLabel": "Preferred stock price percentage on stated value"
       }
      }
     },
     "localname": "PreferredStockPricePercentageOnStatedValue",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ttoo_PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock price percentage on stated value, automatically redeemable upon delisting of common shares.",
        "label": "Preferred Stock Price Percentage On Stated Value Automatically Redeemable Upon Delisting Of Common Shares",
        "terseLabel": "Preferred stock price percentage on stated value, automatically redeemable upon delisting of common shares"
       }
      }
     },
     "localname": "PreferredStockPricePercentageOnStatedValueAutomaticallyRedeemableUponDelistingOfCommonShares",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ttoo_PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock price percentage on stated value, held by holders of preferred stock.",
        "label": "Preferred Stock Price Percentage On Stated Value Held By Holders Of Preferred Stock",
        "terseLabel": "Preferred stock price percentage on stated value, held by holders of preferred stock"
       }
      }
     },
     "localname": "PreferredStockPricePercentageOnStatedValueHeldByHoldersOfPreferredStock",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ttoo_ProbabilityWeightedDiscountedCashFlowModelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probability-weighted discounted cash flow model.",
        "label": "Probability Weighted Discounted Cash Flow Model [Member]",
        "terseLabel": "Probability Weighted Discounted Cash Flow Model"
       }
      }
     },
     "localname": "ProbabilityWeightedDiscountedCashFlowModelMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsRollForwardOfFairValueOfDerivativeLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow (outflow) associated with the amount received from entity's first offering of stock to the public, net of offering costs.",
        "label": "Proceeds From Issuance Initial Public Offering Net Of Offering Costs",
        "terseLabel": "Proceeds from issuance of common stock in public offerings, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCosts",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_ProceedsFromIssuanceOfCommonStockGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock, gross.",
        "label": "Proceeds From Issuance Of Common Stock Gross",
        "terseLabel": "Aggregate gross sales amount of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of Series A convertible redeemable preferred stock and derivative warrant liability.",
        "label": "Proceeds From Issuance Of Series A Convertible Redeemable Preferred Stock And Derivative Warrant Liability",
        "terseLabel": "Proceeds from issuance of Series A redeemable convertible preferred stock and derivative warrant liability"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSeriesAConvertibleRedeemablePreferredStockAndDerivativeWarrantLiability",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises": {
     "auth_ref": [],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of shares from employee stock purchase plan and stock option exercises.",
        "label": "Proceeds From Issuance Of Shares From Employee Stock Purchase Plan And Stock Option Exercises",
        "terseLabel": "Proceeds from issuance of shares from employee stock purchase plan and stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesFromEmployeeStockPurchasePlanAndStockOptionExercises",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_ProductConsumablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, consumables.",
        "label": "Product Consumables [Member]",
        "terseLabel": "Product Consumables [Member]"
       }
      }
     },
     "localname": "ProductConsumablesMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueByMajorResourceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_ProductInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, instruments.",
        "label": "Product Instruments [Member]",
        "terseLabel": "Product Instruments [Member]"
       }
      }
     },
     "localname": "ProductInstrumentsMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueByMajorResourceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase agreement.",
        "label": "Purchase Agreement [Member]",
        "terseLabel": "Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PurchaseAgreementMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock and related warrant.",
        "label": "Redeemable Convertible Preferred Stock And Related Warrant [Text Block]",
        "terseLabel": "Series A Redeemable Convertible Preferred Stock and Related Warrant"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockAndRelatedWarrantTextBlock",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrant"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ttoo_RegainComplianceByIncreasingStockPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regain compliance by increasing stock price.",
        "label": "Regain Compliance By Increasing Stock Price",
        "terseLabel": "Regain compliance by increasing the stock price"
       }
      }
     },
     "localname": "RegainComplianceByIncreasingStockPrice",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ttoo_RoyaltyOnNetSalesSublicensingGrossRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty on net sales sublicensing gross revenue.",
        "label": "Royalty On Net Sales Sublicensing Gross Revenue",
        "terseLabel": "Royalty on net sales sublicensing gross revenue"
       }
      }
     },
     "localname": "RoyaltyOnNetSalesSublicensingGrossRevenue",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ttoo_ScenarioOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario one.",
        "label": "Scenario One [Member]",
        "terseLabel": "Contingent Interest Beginning in Q1 2023 [Member]"
       }
      }
     },
     "localname": "ScenarioOneMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_SecurityDepositReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security deposit received.",
        "label": "Security Deposit Received",
        "terseLabel": "Security deposit received from landlord"
       }
      }
     },
     "localname": "SecurityDepositReceived",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series a convertible preferred stock.",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Redeemable Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_SeriesARedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A redeemable convertible preferred stock.",
        "label": "Series A Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Redeemable Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options grants in period gross value grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Value Grant Date Fair Value",
        "terseLabel": "Aggregate fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossValueGrantDateFairValue",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award other than options grants in period gross value grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Grants In Period Gross Value Grant Date Fair Value",
        "terseLabel": "Aggregate fair value of restricted stock units granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodGrossValueGrantDateFairValue",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_SpaceBuildOutCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Space build-out costs.",
        "label": "Space Build Out Costs",
        "terseLabel": "Space build-out costs"
       }
      }
     },
     "localname": "SpaceBuildOutCosts",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_StockIssuedAndOutstandingDuringPeriodSharesStockSplits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued and outstanding during the period as a result of a stock split.",
        "label": "Stock Issued And Outstanding During Period Shares Stock Splits",
        "terseLabel": "Shares issued and outstanding immediately before the reverse stock split"
       }
      }
     },
     "localname": "StockIssuedAndOutstandingDuringPeriodSharesStockSplits",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ttoo_StockOptionPlan2006Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option Plan 2006 [Member]",
        "label": "Stock Option Plan2006 [Member]",
        "terseLabel": "2006 Stock Option Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2006Member",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_StockOptionPlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option Plan 2014 [Member]",
        "label": "Stock Option Plan2014 [Member]",
        "terseLabel": "2014 Stock Option Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2014Member",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option plans two thousand and six and two thousand and fourteen and inducement plan.",
        "label": "Stock Option Plans Two Thousand And Six And Two Thousand And Fourteen And Inducement Plan [Member]",
        "verboseLabel": "2006 and 2014 Stock Option Plans and Inducement Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenAndInducementPlanMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option plans two thousand and six and two thousand and fourteen.",
        "label": "Stock Option Plans Two Thousand And Six And Two Thousand And Fourteen [Member]",
        "terseLabel": "2006 and 2014 Stock Option Plans [Member]"
       }
      }
     },
     "localname": "StockOptionPlansTwoThousandAndSixAndTwoThousandAndFourteenMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_StockOutstandingDuringPeriodSharesStockSplits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares outstanding during the period as a result of a stock split.",
        "label": "Stock Outstanding During Period Shares Stock Splits",
        "terseLabel": "Shares outstanding immediately after the reverse stock split"
       }
      }
     },
     "localname": "StockOutstandingDuringPeriodSharesStockSplits",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ttoo_SummaryOfContingentInterestPaymentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of contingent interest payments.",
        "label": "Summary Of Contingent Interest Payments Table [Text Block]",
        "terseLabel": "Summary of Contingent Interest Payments"
       }
      }
     },
     "localname": "SummaryOfContingentInterestPaymentsTableTextBlock",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ttoo_SupplementalBalanceSheetInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental balance sheet information.",
        "label": "Supplemental Balance Sheet Information [Line Items]",
        "terseLabel": "Supplemental Balance Sheet Information [Line Items]"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationLineItems",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ttoo_SupplementalBalanceSheetInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Balance Sheet Information [Table]",
        "label": "Supplemental Balance Sheet Information [Table]",
        "terseLabel": "Supplemental Balance Sheet Information [Table]"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationTable",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ttoo_T2DxInstrumentsAndComponentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the T2Dx Instruments and components of instruments.",
        "label": "T2 Dx Instruments And Components [Member]",
        "terseLabel": "T2-Owned Instruments and Components [Member]"
       }
      }
     },
     "localname": "T2DxInstrumentsAndComponentsMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_T2DxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "T2 Dx.",
        "label": "T2 Dx [Member]",
        "terseLabel": "T2 Dx [Member]"
       }
      }
     },
     "localname": "T2DxMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_T2OwnedInstrumentsInServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the T2dx Instruments in service.",
        "label": "T2 Owned Instruments In Service [Member]",
        "terseLabel": "T2 Owned Instruments in Service [Member]"
       }
      }
     },
     "localname": "T2OwnedInstrumentsInServiceMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Temporary equity stock issued during period (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "ttoo_TermLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan agreement.",
        "label": "Term Loan Agreement [Member]",
        "terseLabel": "Term Loan Agreement [Member]"
       }
      }
     },
     "localname": "TermLoanAgreementMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsParentheticalDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_TermOfLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lease.",
        "label": "Term Of Lease",
        "terseLabel": "Term of lease"
       }
      }
     },
     "localname": "TermOfLease",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ttoo_TransferOfT2OwnedInstrumentsAndComponentsToFromInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer of T2 owned instruments and components to (from) inventory.",
        "label": "Transfer Of T2 Owned Instruments And Components To From Inventory",
        "terseLabel": "Transfer of T2 owned instruments and components (from) to inventory"
       }
      }
     },
     "localname": "TransferOfT2OwnedInstrumentsAndComponentsToFromInventory",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ttoo_TypeIIIModificationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type III Modification.",
        "label": "Type I I I Modification [Member]",
        "terseLabel": "Type III Modification [Member]"
       }
      }
     },
     "localname": "TypeIIIModificationMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_TypeIModificationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type I modification.",
        "label": "Type I Modification [Member]",
        "terseLabel": "Type I Modification [Member]"
       }
      }
     },
     "localname": "TypeIModificationMember",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ttoo_UnauditedInterimFinancialInformationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting unaudited interim financial information for the stated accounting period.",
        "label": "Unaudited Interim Financial Information Policy [Text Block]",
        "terseLabel": "Unaudited Interim Financial Information"
       }
      }
     },
     "localname": "UnauditedInterimFinancialInformationPolicyTextBlock",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ttoo_WarrantsNoteDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants.",
        "label": "Warrants Note Disclosure [Text Block]",
        "terseLabel": "Warrants Associated with Term Loan"
       }
      }
     },
     "localname": "WarrantsNoteDisclosureTextBlock",
     "nsuri": "http://www.t2biosystems.com/20220930",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureWarrantsAssociatedWithTermLoan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "auth_ref": [
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.",
        "label": "Accounting Standards Update202006 [Member]",
        "terseLabel": "Accounting Standards Update 2020-06 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202006Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate202104Member": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2021-04 Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force).",
        "label": "Accounting Standards Update202104 [Member]",
        "terseLabel": "Accounting Standards Update 2021-04 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202104Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate202110Member": {
     "auth_ref": [
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2021-10 Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance.",
        "label": "Accounting Standards Update202110 [Member]",
        "terseLabel": "Accounting Standards Update 2021-10 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202110Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r39",
      "r535"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r608",
      "r642"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable Net",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r189",
      "r190"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10260.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "terseLabel": "Accounts receivable",
        "verboseLabel": "Outstanding receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r594",
      "r617"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Accrued Royalties Current And Noncurrent",
        "terseLabel": "Royalties accrued"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r14",
      "r235"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r58",
      "r59",
      "r60",
      "r612",
      "r634",
      "r638"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r57",
      "r60",
      "r68",
      "r69",
      "r70",
      "r116",
      "r117",
      "r118",
      "r438",
      "r528",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r410",
      "r411",
      "r412",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r120",
      "r121",
      "r122",
      "r123",
      "r133",
      "r192",
      "r193",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r410",
      "r411",
      "r412",
      "r419",
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r426",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r481",
      "r482",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r498",
      "r499",
      "r511",
      "r512",
      "r513",
      "r514",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r573",
      "r574",
      "r575",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Adjustments Related To Tax Withholding For Share Based Compensation",
        "negatedLabel": "Surrender of shares due to tax withholding"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r368",
      "r414",
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r404"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedThatWasRecordedInCompanySResultsOfOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Anti-dilutive securities excluded from the computation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r16",
      "r109",
      "r167",
      "r176",
      "r181",
      "r210",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r433",
      "r439",
      "r480",
      "r533",
      "r535",
      "r589",
      "r609"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r37",
      "r109",
      "r210",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r433",
      "r439",
      "r480",
      "r533",
      "r535"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10190.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r199"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r197",
      "r226"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Available For Sale Securities Debt Maturities Within One Year Amortized Cost",
        "terseLabel": "Marketable Securities, Amortized Cost, Due in less than 1 year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r201",
      "r202",
      "r602"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Available For Sale Securities Debt Maturities Within One Year Fair Value",
        "terseLabel": "Marketable Securities, Fair Value, Due in less than 1 year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r195",
      "r198",
      "r226",
      "r593"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Fair Value",
        "totalLabel": "Marketable Securities, Fair Value",
        "verboseLabel": "Assets, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMaturitiesOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r447",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostGross": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost Gross",
        "terseLabel": "Costs to obtain or fulfill contract capitalized"
       }
      }
     },
     "localname": "CapitalizedContractCostGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r12",
      "r98"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10240.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsParenthetical": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r92",
      "r98",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "terseLabel": "Cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash at end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r92",
      "r98",
      "r103"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsParenthetical": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r92",
      "r490"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r0",
      "r1",
      "r119",
      "r192",
      "r193",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r419",
      "r424",
      "r425",
      "r451",
      "r454",
      "r455",
      "r465",
      "r481",
      "r483",
      "r484",
      "r485",
      "r488",
      "r489",
      "r498",
      "r510",
      "r511",
      "r512",
      "r513",
      "r523",
      "r524",
      "r573",
      "r574",
      "r627",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change In Accounting Principle Accounting Standards Update Adopted",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r0",
      "r1",
      "r126",
      "r192",
      "r193",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r419",
      "r424",
      "r425",
      "r426",
      "r451",
      "r454",
      "r455",
      "r456",
      "r459",
      "r465",
      "r481",
      "r483",
      "r484",
      "r485",
      "r488",
      "r489",
      "r498",
      "r510",
      "r511",
      "r512",
      "r513",
      "r523",
      "r524",
      "r573",
      "r574",
      "r627",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change In Accounting Principle Accounting Standards Update Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r120",
      "r132",
      "r194",
      "r218",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect",
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r20",
      "r22",
      "r23",
      "r106",
      "r109",
      "r137",
      "r138",
      "r139",
      "r142",
      "r144",
      "r152",
      "r153",
      "r154",
      "r210",
      "r249",
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r300",
      "r301",
      "r306",
      "r310",
      "r317",
      "r480",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.",
        "label": "Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable",
        "terseLabel": "Warrants exercisable date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "terseLabel": "Exercise price of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureWarrantsAssociatedWithTermLoanAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Warrant Or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureWarrantsAssociatedWithTermLoanAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
        "terseLabel": "Number of shares issuable for warrants outstanding (in shares)",
        "verboseLabel": "Number of shares issuable for warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureWarrantsAssociatedWithTermLoanAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r327",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class Of Warrant Or Right [Table]",
        "terseLabel": "Class Of Warrant Or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureWarrantsAssociatedWithTermLoanAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r427",
      "r428",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "US Government Contract"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContract"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r46",
      "r595",
      "r616"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (see Note 14)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r247",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r116",
      "r117",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureWarrantsAssociatedWithTermLoanAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of subscription receivable from investors who have been allocated common stock.",
        "label": "Common Stock Share Subscribed But Unissued Subscriptions Receivable",
        "terseLabel": "Aggregate subscription amount"
       }
      }
     },
     "localname": "CommonStockShareSubscribedButUnissuedSubscriptionsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r23",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23",
      "r535"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.001 par value; 400,000,000 shares authorized; 7,050,849 and 3,328,017 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r67",
      "r73",
      "r431",
      "r442",
      "r597",
      "r619"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r158",
      "r159",
      "r187",
      "r478",
      "r479",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r158",
      "r159",
      "r187",
      "r478",
      "r479",
      "r639",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk By Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r158",
      "r159",
      "r187",
      "r478",
      "r479",
      "r639",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk By Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r158",
      "r159",
      "r187",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk Percentage1",
        "terseLabel": "Total revenue (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r158",
      "r159",
      "r187",
      "r478",
      "r479",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction in Progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration By Type [Axis]",
        "terseLabel": "Contingent Consideration by Type"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r329",
      "r331",
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract With Customer Asset Net",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r329",
      "r330",
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract With Customer Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r329",
      "r330",
      "r345"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10180.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract With Customer Liability Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r329",
      "r330",
      "r345"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract With Customer Liability Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract With Customer Liability Revenue Recognized",
        "terseLabel": "Revenue recognized relating to contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r78",
      "r572"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10160.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost Of Goods And Services Sold",
        "terseLabel": "Cost of product revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciation": {
     "auth_ref": [
      "r75",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of tangible asset over its useful life directly used in production of good and rendering of service.",
        "label": "Cost Of Goods And Services Sold Depreciation",
        "terseLabel": "Depreciation expense recorded as a component of cost of product revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost Of Sales [Member]",
        "terseLabel": "Cost of Product Revenue [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedThatWasRecordedInCompanySResultsOfOperationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10150.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs And Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs And Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsParentheticalDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsParentheticalDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r156",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r105",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r277",
      "r284",
      "r285",
      "r287",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r108",
      "r114",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r289",
      "r290",
      "r291",
      "r292",
      "r504",
      "r590",
      "r591",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsParentheticalDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r42",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Annual fixed rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r43",
      "r263",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument Maturity Date",
        "terseLabel": "Debt maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r44",
      "r108",
      "r114",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r289",
      "r290",
      "r291",
      "r292",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsParentheticalDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r44",
      "r108",
      "r114",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r286",
      "r289",
      "r290",
      "r291",
      "r292",
      "r318",
      "r321",
      "r322",
      "r323",
      "r501",
      "r502",
      "r504",
      "r505",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Debt Instrument [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument Term",
        "terseLabel": "Debt term (in years)"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r273",
      "r288",
      "r289",
      "r290",
      "r503"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableScheduleOfDebtDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_NotesPayable",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net",
        "negatedLabel": "Less: unamortized discount and deferred issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableScheduleOfDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale Gain Loss",
        "negatedLabel": "(Gain) loss on sales of marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale Table [Text Block]",
        "terseLabel": "Summary of Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r96",
      "r166"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10110.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative Gain Loss On Derivative Net",
        "negatedLabel": "Change in fair value of derivative instrument",
        "terseLabel": "Change in fair value of derivative instrument"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsRollForwardOfFairValueOfDerivativeLiabilityDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r49",
      "r50",
      "r53",
      "r477"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liabilities",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsRollForwardOfFairValueOfDerivativeLiabilityDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liabilities Current",
        "terseLabel": "Derivative warrant liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liabilities Noncurrent",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r113",
      "r443",
      "r444",
      "r445",
      "r446",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives Policy [Text Block]",
        "terseLabel": "Derivative Warrant Liability"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation Of Revenue [Line Items]",
        "terseLabel": "Disaggregation Of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueByMajorResourceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r344",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue [Table]",
        "terseLabel": "Disaggregation Of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueByMajorResourceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue Table [Text Block]",
        "terseLabel": "Disaggregation of Revenue by Major Source"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r371",
      "r372",
      "r405",
      "r406",
      "r408",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPreferredStock": {
     "auth_ref": [
      "r324",
      "r605"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends Preferred Stock",
        "negatedLabel": "Deemed dividend on Series A redeemable convertible preferred stock"
       }
      }
     },
     "localname": "DividendsPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r74",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r134",
      "r137",
      "r142",
      "r143",
      "r144",
      "r148",
      "r149",
      "r463",
      "r464",
      "r598",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share Basic",
        "terseLabel": "Net loss per share \u2014 basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r74",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r137",
      "r142",
      "r143",
      "r144",
      "r148",
      "r149",
      "r463",
      "r464",
      "r598",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Diluted",
        "terseLabel": "Net loss per share \u2014 diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r145",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Accrued payroll and compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedThatWasRecordedInCompanySResultsOfOperationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Weighted-average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
        "terseLabel": "Unrecognized compensation cost related to unvested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized compensation cost related to non-vested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Options to Purchase Common Shares [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r68",
      "r69",
      "r70",
      "r116",
      "r117",
      "r118",
      "r121",
      "r129",
      "r131",
      "r151",
      "r217",
      "r317",
      "r324",
      "r410",
      "r411",
      "r412",
      "r421",
      "r422",
      "r462",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r528",
      "r629",
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureWarrantsAssociatedWithTermLoanAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r275",
      "r289",
      "r290",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate Of Fair Value Fair Value Disclosure [Member]",
        "terseLabel": "Estimate of Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsRollForwardOfFairValueOfDerivativeLiabilityDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r466",
      "r467",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsRollForwardOfFairValueOfDerivativeLiabilityDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r466",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Fair Value By Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r275",
      "r289",
      "r290",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r467",
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r275",
      "r289",
      "r290",
      "r466",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Fair Value By Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r466",
      "r467",
      "r469",
      "r470",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r275",
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Disclosure Item Amounts [Domain]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r275",
      "r356",
      "r357",
      "r362",
      "r364",
      "r467",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r275",
      "r289",
      "r290",
      "r356",
      "r357",
      "r362",
      "r364",
      "r467",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r275",
      "r289",
      "r290",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r467",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r275",
      "r289",
      "r290",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r472",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r203",
      "r204",
      "r207",
      "r208",
      "r209",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r286",
      "r315",
      "r452",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r157",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk [Member]"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities.",
        "label": "Guarantees Indemnifications And Warranties Policies",
        "terseLabel": "Guarantees"
       }
      }
     },
     "localname": "GuaranteesIndemnificationsAndWarrantiesPolicies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncentiveFromLessor": {
     "auth_ref": [
      "r506",
      "r507",
      "r508",
      "r509"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of incentive received by lessee from lessor.",
        "label": "Incentive From Lessor",
        "terseLabel": "Space build-out costs paid"
       }
      }
     },
     "localname": "IncentiveFromLessor",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r237",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedThatWasRecordedInCompanySResultsOfOperationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedThatWasRecordedInCompanySResultsOfOperationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10250.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10220.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10260.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r95",
      "r570"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10270.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10240.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase Decrease In Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10230.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r71",
      "r165",
      "r500",
      "r503",
      "r599"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10100.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r90",
      "r93",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid Net",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r30",
      "r231"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory Finished Goods Net Of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r7",
      "r36",
      "r535"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10270.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Net [Abstract]"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r32",
      "r231"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory Raw Materials Net Of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessAndRawMaterials": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.",
        "label": "Inventory Work In Process And Raw Materials",
        "terseLabel": "Raw materials and work-in-process inventory"
       }
      }
     },
     "localname": "InventoryWorkInProcessAndRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r31",
      "r231"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory Work In Process Net Of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeAmortizationOfPremium": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization of purchase premium on nonoperating securities.",
        "label": "Investment Income Amortization Of Premium",
        "terseLabel": "Amortization of bond premium"
       }
      }
     },
     "localname": "InvestmentIncomeAmortizationOfPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r80",
      "r164"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10090.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified By Contractual Maturity Date Table [Text Block]",
        "terseLabel": "Summary of Maturities of Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date1",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Term of lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r109",
      "r210",
      "r480",
      "r535",
      "r592",
      "r614"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities, Series A convertible redeemable preferred stock and stockholders\u2019 deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities, Series A redeemable convertible preferred stock and stockholders\u2019 deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r41",
      "r109",
      "r210",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r434",
      "r439",
      "r440",
      "r480",
      "r533",
      "r534",
      "r535"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Long Term Notes Payable",
        "terseLabel": "Notes payable"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ManufacturingFacilityMember": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure used in the manufacturing of goods.",
        "label": "Manufacturing Facility [Member]",
        "terseLabel": "Manufacturing Equipment [Member]"
       }
      }
     },
     "localname": "ManufacturingFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10250.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]",
        "terseLabel": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities Policy",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]",
        "terseLabel": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfContingentInterestPaymentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "verboseLabel": "Money Market Accounts [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r155",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature Of Operations",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r92",
      "r94",
      "r97"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r63",
      "r66",
      "r70",
      "r72",
      "r97",
      "r109",
      "r120",
      "r124",
      "r125",
      "r126",
      "r127",
      "r130",
      "r131",
      "r140",
      "r167",
      "r175",
      "r177",
      "r180",
      "r182",
      "r210",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r464",
      "r480",
      "r596",
      "r618"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r134",
      "r135",
      "r141",
      "r144",
      "r167",
      "r175",
      "r177",
      "r180",
      "r182"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income Loss Available To Common Stockholders Basic",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recent Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non Us [Member]",
        "terseLabel": "Non-US [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing And Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosures of noncash activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "totalLabel": "Total other expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r19",
      "r591",
      "r610"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableScheduleOfDebtDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "totalLabel": "Total notes payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableScheduleOfDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office and Computer Equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r167",
      "r175",
      "r177",
      "r180",
      "r182"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r516"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r516"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r515"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10210.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease Right Of Use Asset Amortization Expense",
        "terseLabel": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationComponentsOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10230.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "auth_ref": [
      "r55",
      "r56"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10030.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax",
        "terseLabel": "Net unrealized gain on marketable securities arising during the period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r64",
      "r67",
      "r431",
      "r432",
      "r437"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent",
        "totalLabel": "Total other comprehensive (loss) income, net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r58",
      "r61",
      "r62",
      "r205"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10040.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income Loss Reclassification Adjustment From A O C I For Sale Of Securities Net Of Tax",
        "negatedLabel": "Net realized (gain) loss on marketable securities included in net loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r55",
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Non-Current Assets [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10130.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income Expense [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10210.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid In Kind Interest",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payments Related To Tax Withholding For Share Based Compensation",
        "negatedLabel": "Payment of employee restricted stock tax withholdings"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases and manufacture of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion At Fair Value Fair Value Disclosure [Member]",
        "terseLabel": "Fair Value Disclosure Item Amounts [Default]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionDate": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when preferred stock can be converted into common shares, in YYYY-MM-DD format.",
        "label": "Preferred Stock Convertible Conversion Date",
        "terseLabel": "Conversion date of preferred shares"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share conversion price of preferred stock.",
        "label": "Preferred Stock Convertible Conversion Price",
        "terseLabel": "Conversion price of preferred shares"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionPrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r22",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable": {
     "auth_ref": [
      "r22",
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of subscription receivable from investors who have been allocated nonredeemable preferred stock or preferred stock redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Shares Subscribed But Unissued Subscriptions Receivable",
        "terseLabel": "Aggregate amount"
       }
      }
     },
     "localname": "PreferredStockSharesSubscribedButUnissuedSubscriptionsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r22",
      "r535"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.001 par value; 9,997,000 and 10,000,000 shares authorized at September 30, 2022 and December 31, 2021, respectively; no shares issued and outstanding at September 30, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockVotingRights": {
     "auth_ref": [
      "r22",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Preferred Stock Voting Rights",
        "terseLabel": "Voting rights"
       }
      }
     },
     "localname": "PreferredStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10280.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Member]",
        "terseLabel": "Prepaid and Other Current Assets [Member]"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds From Issuance Of Long Term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r84",
      "r85",
      "r196"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r84",
      "r85",
      "r196"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds From Sale Of Available For Sale Securities Debt",
        "terseLabel": "Proceeds from sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]",
        "terseLabel": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1Detail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product [Member]",
        "verboseLabel": "Total Product Revenue [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueByMajorResourceDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductionRelatedImpairmentsOrCharges": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.",
        "label": "Production Related Impairments Or Charges",
        "terseLabel": "Impairment of property and equipment"
       }
      }
     },
     "localname": "ProductionRelatedImpairmentsOrCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r63",
      "r66",
      "r70",
      "r91",
      "r109",
      "r120",
      "r130",
      "r131",
      "r167",
      "r175",
      "r177",
      "r180",
      "r182",
      "r210",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r431",
      "r435",
      "r436",
      "r441",
      "r442",
      "r464",
      "r480",
      "r600"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r13",
      "r234"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r236",
      "r535",
      "r604",
      "r615"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10200.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "verboseLabel": "Estimated useful lives (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Redeemable Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r363",
      "r529",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r363",
      "r529",
      "r532",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r418",
      "r571",
      "r656"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10170.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedThatWasRecordedInCompanySResultsOfOperationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction.",
        "label": "Restricted Assets Disclosure [Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureRestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r12",
      "r103",
      "r588",
      "r611"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Minimum cash balance"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash [Abstract]"
       }
      }
     },
     "localname": "RestrictedCashAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Axis]",
        "terseLabel": "Restricted Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restricted Cash And Cash Equivalents Items [Line Items]",
        "terseLabel": "Restricted Cash And Cash Equivalents Items [Line Items]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r98",
      "r103",
      "r641"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10220.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsParenthetical": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r324",
      "r535",
      "r613",
      "r633",
      "r638"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r116",
      "r117",
      "r118",
      "r121",
      "r129",
      "r131",
      "r217",
      "r410",
      "r411",
      "r412",
      "r421",
      "r422",
      "r462",
      "r629",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contract With Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r162",
      "r163",
      "r174",
      "r178",
      "r179",
      "r183",
      "r184",
      "r187",
      "r343",
      "r344",
      "r572"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10140.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueByMajorResourceDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r104",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue From Contract With Customer Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue From External Customers By Geographic Areas Table [Text Block]",
        "terseLabel": "Schedule of Customers Represent Greater Than 10% Of Revenue"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue Remaining Performance Obligation",
        "terseLabel": "Transaction price that is allocated to unsatisfied or partially satisfied performance obligations, that has not yet been recognized as revenue"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of when remaining performance obligation is expected to be recognized as revenue.",
        "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Explanation",
        "terseLabel": "Remaining performance obligation, expected timing of satisfaction"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1Detail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.",
        "label": "Revenue Remaining Performance Obligation Percentage",
        "terseLabel": "Percentage of revenue recognition"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1Detail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r520",
      "r521"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stock Price Per Share",
        "terseLabel": "Stock trading price"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r158",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Sales Revenue Net [Member]",
        "terseLabel": "Revenue [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Components of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule Of Debt Table [Text Block]",
        "terseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule Of Derivative Liabilities At Fair Value Table [Text Block]",
        "terseLabel": "Roll-Forward of Fair Value of Derivative Liability"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r403",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedThatWasRecordedInCompanySResultsOfOperationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense for Stock Options Granted that was Recorded in the Company's Results of Operations"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities at Fair value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r10",
      "r33",
      "r34",
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule Of Inventory Current Table [Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule Of Nonvested Restricted Stock Units Activity Table [Text Block]",
        "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule Of Product Information [Table]",
        "terseLabel": "Schedule Of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation1Detail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCustomersRepresentGreaterThan10OfRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r103",
      "r588",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Schedule Of Restricted Cash And Cash Equivalents [Table]",
        "terseLabel": "Schedule Of Restricted Cash And Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r367",
      "r369",
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r375",
      "r391",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of Estimated Assumptions Used to Calculate Weighted-Average Grant Date Fair Value of Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r20",
      "r22",
      "r23",
      "r106",
      "r152",
      "r153",
      "r295",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r306",
      "r310",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "positiveLabel": "Security deposit",
        "terseLabel": "Security deposits",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureRestrictedCashAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10180.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling General And Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling General And Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseForStockOptionsGrantedThatWasRecordedInCompanySResultsOfOperationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling General And Administrative Expenses Policy [Text Block]",
        "terseLabel": "Selling, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "negatedLabel": "Number of Shares, Restricted shares forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "verboseLabel": "Number of Shares, Restricted shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value",
        "positiveLabel": "Weighted-Average Grant Date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Number of Shares, Nonvested restricted shares at the end of the period",
        "periodStartLabel": "Number of Shares, Nonvested restricted shares at the beginning of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-Average Grant Date Fair Value, Nonvested restricted shares at the end of the period",
        "periodStartLabel": "Weighted-Average Grant Date Fair Value, Nonvested restricted shares at the beginning of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Number of Shares, Restricted shares vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Weighted-average risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Shares available for authorization"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Number of Shares, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period",
        "negatedLabel": "Number of Shares, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Number of Shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of Shares Outstanding, end of the period",
        "periodStartLabel": "Number of Shares Outstanding, beginning of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price Per Share Outstanding, end of the period",
        "periodStartLabel": "Weighted-Average Exercise Price Per Share Outstanding, beginning of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested or expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "Number of Shares, Vested or expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Vested or expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfNonvestedRestrictedStockUnitsActivityDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected terms"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedAssumptionsUsedToCalculateWeightedAverageGrantDateFairValueOfOptionsGrantedDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Vested or expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1",
        "terseLabel": "Fair value of vested stock options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent",
        "terseLabel": "Percentage of full share price paid in purchase of common stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Temporary equity issued, price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Shares Paid For Tax Withholding For Share Based Compensation",
        "negatedLabel": "Surrender of shares due to tax withholding (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of shares that would be issued, determined under the conditions specified in the contract if the settlement were to occur at the reporting date.",
        "label": "Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software And Software Development Costs [Member]",
        "terseLabel": "Software [Member]"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r20",
      "r22",
      "r23",
      "r106",
      "r109",
      "r137",
      "r138",
      "r139",
      "r142",
      "r144",
      "r152",
      "r153",
      "r154",
      "r210",
      "r249",
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r300",
      "r301",
      "r306",
      "r310",
      "r317",
      "r480",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Series A Redeemable Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r48",
      "r68",
      "r69",
      "r70",
      "r116",
      "r117",
      "r118",
      "r121",
      "r129",
      "r131",
      "r151",
      "r217",
      "r317",
      "r324",
      "r410",
      "r411",
      "r412",
      "r421",
      "r422",
      "r462",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r528",
      "r629",
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureWarrantsAssociatedWithTermLoanAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r151",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period Shares Issued For Services",
        "terseLabel": "Shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r317",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of common stock from secondary offering, net (in shares)",
        "verboseLabel": "Number of shares issued/sold"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.",
        "label": "Stock Issued During Period Shares Reverse Stock Splits",
        "terseLabel": "Remaining shares issued",
        "verboseLabel": "Stock issued during period, shares, stock splits"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r22",
      "r23",
      "r317",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period Shares Share Based Compensation",
        "terseLabel": "Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r22",
      "r23",
      "r317",
      "r324",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of Shares, Exercised",
        "verboseLabel": "Issuance of common stock from exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r317",
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock from secondary offering, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r22",
      "r23",
      "r324",
      "r392"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period Value Share Based Compensation",
        "terseLabel": "Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r23",
      "r27",
      "r28",
      "r109",
      "r191",
      "r210",
      "r480",
      "r535"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "negatedLabel": "Stockholders' deficit",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r107",
      "r301",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r324",
      "r328",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Deficit"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": {
     "auth_ref": [
      "r20",
      "r21",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.",
        "label": "Stockholders Equity Note Redeemable Preferred Stock Issue Policy",
        "terseLabel": "Classification of Series A Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders Equity Note Stock Split Conversion Ratio1",
        "terseLabel": "Stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders Equity Reverse Stock Split",
        "terseLabel": "Reverse stock split description"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r497",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r497",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r497",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r497",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNotesPayableTermLoanAgreementAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r536",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityAccretionOfDividends": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of accretion of temporary equity during the period due to unpaid dividends.",
        "label": "Temporary Equity Accretion Of Dividends",
        "verboseLabel": "Temporary equity, deemed dividend"
       }
      }
     },
     "localname": "TemporaryEquityAccretionOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r11",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity By Class Of Stock [Table]",
        "terseLabel": "Temporary Equity By Class Of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r47",
      "r109",
      "r210",
      "r480"
     ],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Series A redeemable convertible preferred stock; $0.001 par value; 3,000 shares authorized at September 30, 2022; 3,000 shares issued and outstanding at September 30, 2022; liquidation value of $330,000; 0 shares issued and outstanding at December 31, 2021 (see Note 7)"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityDividendsAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).",
        "label": "Temporary Equity Dividends Adjustment",
        "negatedLabel": "Deemed dividend on Series A redeemable convertible preferred stock",
        "verboseLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "TemporaryEquityDividendsAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Liquidation Preference",
        "terseLabel": "Series A redeemable convertible preference liquidation value"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r11",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity Par Or Stated Value Per Share",
        "terseLabel": "Series A redeemable convertible preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Authorized",
        "terseLabel": "Series A redeemable convertible preferred stock, shares authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Issued",
        "terseLabel": "Series A redeemable convertible preferred stock, shares issued",
        "verboseLabel": "Temporary equity, shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSeriesARedeemableConvertiblePreferredStockAndRelatedWarrantAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Series A redeemable convertible preferred stock, shares outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Value New Issues",
        "terseLabel": "Temporary Equity, Stock Issued During Period, Value, New Issues"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfSeriesAConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ToolsDiesAndMoldsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used to cut, shape, and form metal and other materials into goods for sale.",
        "label": "Tools Dies And Molds [Member]",
        "terseLabel": "Manufacturing Tooling and Molds [Member]"
       }
      }
     },
     "localname": "ToolsDiesAndMoldsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r203",
      "r204",
      "r207",
      "r208",
      "r209",
      "r286",
      "r315",
      "r452",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r120",
      "r121",
      "r122",
      "r123",
      "r133",
      "r192",
      "r193",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r410",
      "r411",
      "r412",
      "r419",
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r426",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r481",
      "r482",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r498",
      "r499",
      "r511",
      "r512",
      "r513",
      "r514",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r573",
      "r574",
      "r575",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureUSGovernmentContractAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r110",
      "r356",
      "r364",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "U S Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury Securities [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail",
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsRollForwardOfFairValueOfDerivativeLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureFairValueMeasurementsRollForwardOfFairValueOfDerivativeLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "verboseLabel": "Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants And Rights Note Disclosure [Abstract]"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r136",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number Of Diluted Shares Outstanding",
        "terseLabel": "Weighted-average number of common shares used in computing net loss per share \u2014 diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r134",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number Of Shares Outstanding Basic",
        "terseLabel": "Weighted-average number of common shares used in computing net loss per share \u2014 basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.t2biosystems.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126960819&loc=d3e20905-112640"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e40010-112707"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123386226&loc=d3e41620-112719"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123388062&loc=SL77916639-209961"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r657": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r658": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r659": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r660": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r661": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r662": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r663": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r664": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r665": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r666": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r667": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r668": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r669": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001564590-22-037656-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-22-037656-xbrl.zip
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M<%,ZXJCX+1R.O,:-GCA92$2C)TYFH$)/G+3<G5#3N846.'O%\PON2ZU"9LD
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M6"4+#30$,  &P  8  -@( D#3G,A"PTTA 8,B*XA_86% =$U66B@(31@ #]
M^@L+ \[K( L--"1W.]^S< J%ZTGVDS0*FE1@&SP99: Q[86W221@0%07IY0K
M="BE,';=IU]M6W=;ECYIQ^/V;%-/].S)O3>VUTOE\QJJNZA)(%'C !@  V
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MD53/<XS'L>=7;'@V=S2'0^[&^E4: ]ODLX3^*"00RT95+)R1;%;%(B%PO(1
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M6LT3C!1](P7_BZ0Q*Y"16EAXR8PVP%#!F\JW 8(WM?U@O*/K TP0678HD$[
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M[!,-' (/I> .R)Y;>Z D.5<2!+Q$4( V$, !E '*H 0$227!;E"JL$ ]".
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M', 0L<I>FCO&6W[)2JKAUH82FUTWI\WK7A!E$91,HE8#E GA+RP.H$P$592
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MMIA4*9<DH8@XG"U;G'F(PRO$K,*YH0K4LG,3'ZM\>S;H>$<&")):A#X\1%
MZ2P!]7=R&(%OP#>9 H*ZI=N\&;!8"D,=)S 29:! 2[N MR6_^_KHF(8[4!WF
M+B5X*ZL)WDM[.+2MGF=K?_;\RSNN.V9Z0L5""W=?K!-:R0]W[JZWY86_5DH5
MN592&A7TER,G@T0-"") (BB ;Q$!Y@"WZ$NIU56F]5EP8)M\FMV ,P]*LOXB
M[&R!%51*3\;H&O$B:3I=%$"EH-(<X!:=2FL'H](61U8\E&K>JX;>L2[5D>&I
MYCNTNE-)4[56*\EHD4Y0(.E:_"*9!;HH@'?!NSG +48Y</U@Q+MM5^G>U<35
M:IU3;QG42TXF<8076!>L"];-KX)%)]W&X:+=:&=F;DTH5\&NY&2/KG$OD@6@
MBP(H%A2; ]RB4^SY7A2[5QJX62J7F^!*<D(4MM)'.RQS(RCYW\CZ?]A[U^:V
MD5U=^*^P<F;.FU1)'EU]2?::*L5.9GF?Q$[9SIK:GZ9:9,OBA"(U;-*.]Z]_
M@6Z2(G6S[H)$?)B)K O)[@?  Z#1:*V'U:Y0T@']&PS!%15:I^5/?"WW=5[F
M;#WA#:W[:MA1=OM$ @<^XWO_W:!828@K"0>\1%!@;2"  U,&4P8E($@J">\H
M/1B<6%\(X,"DPJ1""0B22L)Q"!$46!L(X,"4P91!"0B22L*4000%U@8".#!E
MK%1N<3%>;M%Q_HY5A.6)ZB'H.%/WW.EN-'HE^#*W$'PG_XE=!?-_+\,GUY;?
M9.@&SIVT@T=?7^4_PHOE[G8#GJ4MSR]6K =I5%JGIV0:G;,%(FZ!F(^)H,#:
M0  'YF,.X2@!05))F#*(H,#:0  'I@RF#$I D%02I@PB*+ V$,"!*6.5K%^K
M1BCKQ[FZ<MD-/H1P]RA@XWA]"F'0P[U; S 2"K=S6;TP&%A/4D4P,?AA""]#
MUXZDDWQ!^(XE?\K0=I7^M7DW&*)Z*3[#</_J1$*#V*S1P('=(3X1BA(0))6$
M(V@B*+ V$,"!*8,I@Q(0))6$MWP=#$ZL+P1P8%*9GY:=<01@JSZU^94Y]N\J
M#F&N37K5' >H__]Q/"&[W9.+9B5J7SLGL%6IG?,!"_2$E*@!X1B-" JL#01P
M8#KE&(T2$"25A"F#" JL#01P8,I8J3"FL6  IHM:MAI_S2C"672#6ZXRAMO_
MTY-,HE:#.90("JP-!'!@#N6PBQ(0))6$*8,("JP-!'!@RF#*H 0$225ARB""
M FL# 1R8,E;*U#6WFJGC_-IARQ.A(\,*>\S2*L)DE@MUA'ID0Q!4/SIF:&YD
M9'F!6GGSV&;P,#O%& ZJ&[OK\\$IYRFH1+$J'H6Z%ES'[>7LN;?+0IJ5-WNL
M783!*9?BD#1\3%*'@Q63%)/44:!#BJ1F[X9C&J,&'M/8$6#%-,8T=A3HD*(Q
M)BDJT#!)'0%63%),4D>!#I,40\,D=9Q8,4DQ21T%.DQ2# V3U'%BQ22U('YO
MEZ\@;8U7D-[(Z-JW@X'\$BBUH6W<=S(2KB^=3R+T 6&U\/YM+7C5!4\_J#<K
M%Z>;:Z_%E+U567UW,+B4R8(090!FZ\/!BMF:0\JC0(=#2H:&2>HXL6*2VEY(
MV5XUI.1XL,1\6X@']W8\WKQ]BDX0=SUI-4[F<^]1H?)1>/K(/!%9]W(8Z;R-
MU:Q5+%31?9U\-V?S8ADQ(KJE/V?I<%87J8\NH,?^$B$PB_[2=O$\;H=JSWV!
M9GDA,PTGJQ]A<,JE."0M(]/<*F#^0@Y'9CAFN#)H'C&&6WCO)'/@WL%C#BP#
MF$R$.^CG-^OLP]/QW'GN!$)SWJ%I[K?=\PV7/-:P66G6+RK-=IM,#T#V 0A;
M'HYRR4+##,]1+I/[EIKUGDUMUML//)AI95AZI[1>[.#;9/(^#,%C\F9HF+R9
MO)F\=TG>YSLC[X[SZIF74XA\H8JX5ONL<EK;7$D<,_T1TPDS/5EHF.F9Z9GI
MMU6_?K$SJI^W+WKM\O?6::U2.V.R/Q!!77D_-/,\\SSS//-\N7E^:9IOUW87
MT=MV/(@]^*9S&_5EB-\*95_ZRGV29F?<PFEZ.N?L,9\39@XF=;+0,*DSJ3.I
M;REX;]?78O7-1-Z-2NN4E],/1,:F[3O_+1(P-?"NXSXM-_+"0'_-#:P^C K,
ML_95YTV/N6-MSBUS=L.&J\HP?\MZ8SC-D,P>6VW'F#63X?3#=#Q#\2BKW5"*
M'U71@^&\%]ZS>%%OK-_V/=.[NV4BK%IV$UW_UQLP9;;T/-1FL O9WXF=T'\7
M'O2]B*/@0V(I0$L],53R??KB@Y58DQH\Z1MZ+1IV=W;Q@C#54\W8E?NZS^8+
M^S\Y>N>6:"H6\'0P<@#C],WN<)D=5@"GOH)5.I$S?<LB1ZRM-PD 7?#*9D)Y
MO@B2J\+V( ?#(!3ABV5<PCTK$ZV>0#0@(F'EMG?&8WF,8*-!P0JV(<XY9RM8
MP.V;A!>8K68K2!6B2=7:6VNTF:J5N.*4U.;L>)EIMI^G7?+]Z<'NYYRTGSTS
M[TM)3Q9,MZV*VKT,7;A:Q[J3CI0#G9BX#/PG&48NOOX6RIX,0^E8.DM+3Z5^
MI44U6X:+JF%;Q LO%RAL^8BC9G9@4E0E-F@44%A25XX=DU&R@((].UML ;]$
MYFRT)XVB,K%)HX "F[0#Q(159^\P+5@NMDPIV/$1$%'LF'R(H,#DP_[T 8&6
MVQ%BZ2TA%'6*+1L%%%AMV-8=-&@/0<1I@WV#0*B.8 /UNUQ<<,S%O82!(+WN
M=B@U;=LN.MAG*0&3R_ZK!PF6ZI)&BHT:?>!H&+6#K,\MA_$KU_SN)>:?%N ?
M4MRR9:"P6VWU>F\U3VRDZ!LI]K](&K,2&:G<PLO!: ,;*O:FCML L3<UK8!\
MU"-P[_K )H@L.Y1()]AX'0A0^9YK^C3PL\/1IW*;.EX5/IS%2%X5)@+$058@
M\0)+D;+TX=K,4@2A(6'\UM0HJJQ5&H^=S>5F\Z@# "?:NTZR&21895,N!-B:
M'3ZP[/R1A8:8U6/GC\UEZ<TE$>>/S25Y<TDW2\BV[_75JQ*:MDLQ=/>X79$#
M6[99M'!@FT4>MRO9<VUW__X8VRRN4V1;5&Y;9$XSMMY^"92:=:(]/4IGR[5G
MRW74.L&V[#!Q,X?B6&\3_XK-&460")4PSM2NJ0?D; "#-:=\@R> ?12>\&UI
MB<BZDK8<=&5H->L5"\]3IM?Z:3L'Y=!!@^[Y]N4Z6IHH#J;A<,F/EM?;$AKT
MP&$E(8-#N=2!*@HD6MC3 >H7<AAMH7_]42H8\PT1(*A;NAU6UC(LK!X'@0/'
M+##2_W)_XN>?0V'C85Q6[+O1G>S]Z\WWOWYV0\]5NHSYC>4Z_WKS^2]XVD:[
M\<;RQ0!F)E;51R&&[\W!A'J#MJEZOE8JELX;RX9[PJ/HZUWBC^NMB\;I6>NO
MY)?WD8CD &;%I$6Q/T6 9X>KSD]7I5_*7?VKS@+]A1F@>J-9?V,YTG9A'.I?
M;ZYO/K^Q<+0B^M<;]R=,3CQP@BCYPIO?FY5FX[Q2JY_]UV_%$?].3B[9/I#!
MH4R6@"X*'*YQN'8$N,VA6E<%K4;][/O]58%IF^-,FV^"8CASIR1;A0=2MD"H
MFD"I3*7D9(RN$>=)9^;<-U#,G(>)V_+,V=H9<W:<]!AK;%9][2>[/5YAT=F1
M:HY@6^V+2K/>8IHE)Y!T+3Y/.M/LOH%BFCU,W-XNS[/MG?'LG8R$ZTOGDPA]
MP%B]%J9JB:LNRK1GC4JC?LI,2TXF9U5(,\DRR3+)DL*(279+)'NZNV!V=)2)
M/D*^<&* V8>W*._FR)5IE9P4'@"M'K<98)X]$*"89P\3MQ5X]FPMGMU,)%IO
M5"YJO+)*3YX*C+GR?M#+SY]KGR^W@,?Q[P?5RECM"B5QI_M@"$ZIT(HM?^+K
ME0^TVAHDO"=T/ZI0.M-$% >NKUY_CPXKR9$K"8>]1%!@;2"  U,&4P8E($@J
M"6_KI H+JP<!')A#F$,H 4%223CL(((":P,!')@RF#(H 4%22;CND86_M#@P
M0ZRT#>]\O**BX_P=JPC+$-5#T'&F;IW3/63T.N]E;IGW3OX3NPKF_UZ&3ZXM
MO\G0#9P[:0>/OK[*?X07RUUMZFO4ZK6Z>=%<<7=?H])N-S96Z,$6Z,@M$-,O
M"W]I<6#ZY0"-$A DE809@H6_M#@P0S!#4 *"I)+PJ@\1%%@;".# E+%23N^"
M4$Z/,W'ELAM\#M_N4<!F[OH@OJ"'^ZX&8"04;L6R>F$PL)ZDBF!B\,,07H:N
M'4G'?($/Z=N_PI#0$39<-'!@AX</3:($!$DEX1B9" JL#01P8,I@RJ $!$DE
MX0U95&%A]2"  W/(_#SKC'/V3FM3VU&9L_6NXA#FVN1+S9E[^O\?QS.LVSP>
M:';F];7#^%JU2JUQSDVNR$DI40O",1D1%%@;".# ?,HQ&24@2"H)%T.R\)<6
M!V8(9@A*0)!4$F8(%O[2XL ,P0Q!"0B22L(,P<)?6AR8(9@A* %!4DEX88((
M"JP-!'!@RF#*H 3$QG8/\:E-JY_:%(>AA"<+<8>0*7*QG%A:46!%XJ?U[$9]
M/& -9H?/;]J_AI!0"K94-'!@.N>6&I2 (*DD' $208&U@0 .3!E,&92 (*DD
MO%V(*BRL'@1P8 [Y,/_T^EG[A>H3^X7T=[ /T^<@?! __QPE6^"-0]HP5*]5
MSL[KW**)G)R^HPA!F0P%42->.D4@B@.3*0=DE( @J21<Y\?"7UH<F"%>";>F
MM\$];<QI@WLG/8B1G(=@MT%7QUGKU*I<0]PFQUKTA/0 8JVCFF^B!KMT<D\4
M!R9.#JTH 4%229@A6/A+BP,S!#,$)2!(*@FOUQ!!@;6!  Y,&:MEXYJ[R<9Q
M#NW 1:N00^/3I*B=)J4DJ)XCPA?XN">QQ7'%\F7$)TD=%CWR)M8CQX'=%-[I
M30D(DDK"D2T1%%@;".# E,&400D(DDK"6\.HPL+J00 'YI /*YTDU5KJ)"EX
M=/V1HKD7[*Q6N=C@7C V&D=N-#@,(X(":P,!')A".0RC! 1))>&J11;^TN+
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MMVO#'?#( $%2B[@/#Q$4F'0*0/U"#B/F&^:;@P*"NJ6;O1NP7 I#'2=F),I
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MX/.^]]\:BI6$N))PV$L$!=8& C@P93!E4 *"I)+P[M*#P8GUA0 .3"I,*I2
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M9<?9_O%AC4:E?EYC5B4GJT3M"+,J$118&PC@P*S*2X.4@""I)$P91%!@;2"
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M')@R8*1OET_CG8ZG\;)D73&I1N/T*T[9T1; =Q0A*),%(&J=2Z<(1'%@EN3
MBA(0))6$*8,("JP-!'!@RF#*H 0$225ARB"" FL# 1R8,E;+Q9VMGXOC#-J!
MBTTA@\9'5>T>@*^NLBWA_!VK")/95A18H'R>M"-+3S%,"VX4"^63#)4TV\ L
M-?3<B$^J.BS^X^VL1XX#^R&\YYL2$"25A$-7(BBP-A# @2F#*8,2$"25A'=
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M+?! :B6'RH6Y@]C/[ALEM4! !/Y @9V%^8:Q1_# (-F9K/C2&!/SJTP/$$1
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M**%X'AL(IH]TTA$]7KPFF,NX!\ 8NZ&]$&# M& <5S?C@4F!8:8-_+L^6%6
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M)&V:)7$FGST-W(MA:28Y;F2F)''\"X%IMB*52T_WW!"&_T\LPL@LT<"L-D_
M:T>&@!@@]?W-ETUZ42>ZA]K8CH@/IQLOJB?0#JKYW.,0KNX7R[) >).\W-RI
ML;1U /,7@1K"=TR!$>I3RHG&**.AP <)T1HG)F<:N^B\;["5Q9']FY$'&0ZL
M+X'(KW;J_/;EW1^@.^&3J]'_\N5R5!=V]T<6Y9F%T=-W2>H<,V*#>&!Y6262
M'0!?((N8='PB8JH@B#I)!EZ27HS/KJ'M4U=XJ5*M8*<NYK?*F6-XDA]<8MXS
M^BQL35L=\(3^ B0#F(&OVJ:DW[N2W6B4U\N^AY.+<YM-;?*KU\U:^Z0VOY8#
MHU0 K8N"#38%(F><)S7BQBR#AIH]EG!&(P$?>ZZ>VVPY0\]X!ICK9TL#>N5)
MZ2_J4+R8N +Y.+&N?>NS[(8Q+CB:Y2@4()A\O5P539>T"EBF*%G,P:_H?+34
MIA54,EGP,LMSF$8TCL.LBOA6:^)P@2(L7Y.+7($QWB_TC;3NOM$X+U;WH'^C
ME_L<\8+<(OTWOV?E'0F!-<=3#GKV;P"WI!)C/[,_T>V:X.PGO[H'CQ4,$;S_
M";W9AY>AU#^=_G$.N7J]WDQ?M)9'KC6)W#965/;/*A.+@KK\!6LQ=;P*%W),
M]3%Z#(L9]K]^=D.LV8&957DCWYKH.WH/1O2VIROPOL$DRV\RO,>?S9$Z%49W
MF.+64@!_?!4_D8/FF.OKF\^X6:0VQ4PKO:*4*XW2.Q3 4;4*N9;B#M0WO]_F
M=+AM?E'TUTRM@"[9]V2$KI?VFW"^;X1RQ#^6'C-6.N&"4YZRS><9:X.DZ-2M
M5OQQOA F=3&#(W+)823EY,9?DL+KNQC<KW:K77LKWF%4C/YREET#K\!\*TF
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MDTW<^B2)&3R!@B:0:4/@P7..XB.]B1OE16_AP$4<,3"-(A+=3?^<_MO\P+1
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MH6G.DDZTJ\G/E&T]97FW]$ZF;MA45.0:]Z5F'N&;:N?UY+YDLFXD-=FK:[K
M8:&]63S0%X.WTCT@RSF&S8G003ZB+!F6VFO^AU32+9F6HW;];K-E*&5&:TQH
MFO80IF\U7""Q^5@%@[(Y#'7/0[V083+X"HVF2)Q%\(YDP6"[^8H=$\-EG9:2
MG1!8LM3+K8ME.R7PT*"P8EHWFK>J\!9^!=>8A]K(XB=:M_I8KJA7%@-=SCSJ
M,F%:I.I$O%))NU?]@%G!VT2R9.X3X9BT4=7?^O0S+1*[Q;4J/,$H7^&$#6_5
MN*DTN[&1#LQ'67D9/.:<&@2,YQ+9S!<AM"<2NS>ZZWIVA)S_F/QJR9/DQJH0
M<MND,>K&(RR>P4]7N$4:!&5R8UPP+F.Y<X%P K-AZX..=,^0;)-8#+(W]:2(
M2J$?I/8A<0EG=&16UISXL(Z]FFK*C[8IX<4!5W<ML^PT;]VJUNO6SL5%H^K4
MZQ?5ECQM587=ZU;/6LV:T^PZO;-Z:TXFL%ZL/?I#!H^A&()^;26Q,V4@\ 1_
MX3B6.B22$L^/IFR"ZJ<Y5=/E8<8L;,0_H%2%E#$:-FY6A9-]+ <M9I1D,[..
MY&97)[X'E!A$PBN^;7I-FUV^>@_/S_2<GN5W'+0GND?<F8,!/H?!X#*I\/G3
MC?KI.06??B:]WSO:*Y#.@_@Y?[_X?1KAC:1&>/D<^4W@?U?Y'>1G,\BTV"*H
M?M*8W?@,7)\Y<Z$WRP]C;(F1FXJ)_7VZ@ZZ?-#B_<]6/;\">&"$^ROH&QYRV
M?!F_V\>7C]*W^]A2O+"D@.@G*-W(Z-6+C"])C!YIXLN+@-#(,*@VWOS>G,3@
M5QW?:;%-#IG0DKV";$Z$77N7S7HZ+?7YLED[.=VL;$Z4DY18-F>#4)3-BT5$
MLYCF6#SG!U'2,&UENGTKW2*G";-#GJ(F-#=MI2=[;Y97$V:#4-2$^D*JL**5
MGCC[<^^R64^GY14K7=^TE9[HMUABV9P-0E$VSY>QTDLNS!2-])96!<G$&I^7
MH;**+@4O,E9Z(A7,VZ@:8UDE.)VHLUE=">;TI#L&%5G4R:XOXF1CQXC%\0?E
MP$VVK\.?;GK25?U+R\)$=,FRL*936Y_LHS9/%I8TF+N0B8FD.\O$FN[=TA!,
M!-8,P9I>S!2U7$1/Y^X[J$]IWYUYUI]^:C7ULO-#/[Z,!M3!#5H/N'*X\<7H
M(_.9S-ZF4:LEO=JJ^EA#,3J?T^RM3 U@T?S5:[^:74M%1S79:9;9S/<[60?/
M+\3 O1SW"?\Q@^KJG9+_>@/HVIB('@I<H,O^'N*>T.3OPGK$>Q%'P0?S:]R;
M[(FADN_3%Q^L9]>)^N_/:K]^T((2A?K_CO6DQ_:O-V8TV46[LS8Z)P]0]60O
MTF-/W[C38-=.SMJY-Q]PT<J\91Z@"<'<^:\?DF&F<Z@+L2SS15,4CW5*?O1A
MIE 7EP1GKY8E?V9/6UR;P3<67$"KIQ*_0:G.+<?]%CG[ 80F'OG5LEE&Z'R;
M2V=3H8$GP?)Z3$KL#J;TK8^C.<U4J74Z'[K1!M>2P/:@8ZJOQI'^A([T''M^
M;(.?+//;LVGY]<-SWXUPAXJP<4#/X/9\6&(Q_9 FGVWY84'#MIPZ;#>8$V%3
M3L64+VI6RFSR?TO"*@ZNB /%W$P9FHR;&Q2XN=XZ:>:@PQF>2LQ,WOF^+K5&
M8^^4568JVK>%6TE-V 2R"3P:7'$UBDU@"4U@:22<+==QXDK">>-\ UT+]ZHZ
ME495V 0>)ZXDG#<V@:NG7&%D<R"Z_/RY]OER.PLYDR[@!J:?3"566LAF=595
MCZW-_;%/_7K\O[UI7X!;=F&A&*=7<&HNY@>\BE6.]D-\F$VP/AGPEB[2GMCS
MN7J1]E?Q=Q!FE<*Z"!I;7Z3O=/93@)W>?@,[9!J3N\CHJ<ENDF9D!/Y7>@@P
MCS./,T[,XSOE\8G]\27D\45W-[8F=[K24Q/F\7TCP#S./,XX,8_OE,<WV![N
M8'E\T1WIK<G&.O34A'E\WP@PCS./,T[,XSOE\0VVTCQ8'E^TK4EK6EL3:FI2
M9AY?K4IAF]M-CYO2LRJ%C_LJXF%OBMBTE\S\4(7!.$OE]H7T.3P-@N"43$=6
M#K69'([,*I5,\*G"P.2P0J"\P4[[KP3*'PD'R@NVY6UM+%!F8\0L?* S3M7\
METSPJ<+ +,PA&A4<F!S8*I52\*G"P.2P0HBVP0.G#CA$6_"(AC:':-0$?@-K
MF;SC>NVUS$MZ:_I'/O54*XY*9GZHPL"^T/*^T-D&SQU\Q1>Z).L+K7&B(#TM
M*)DQXOIL-O^E%'RJ,# +KYVN9AUA<CC0&:=JE4HF^%1A8')@<J"" Y,#6Z52
M"CY5&)@<F!RHX#!MB>TW?20XO)N<$+ZQ0\EK<X\D3W..R5'W:]V9^+GR'86G
MPF>G+5K-6L7"M*PE?,>ZDG;R;EV_"__',^,O@\%0^"]67SA6$$<J@N^""%LA
M?-U]0L3T17^9DQEW5=!JU,^^WU\54N/U\=1XQ[9!V2)UEUWZ1D:7<8A=O^>G
MQN\C 4."K_TA@T?0G+YK"R^?I;X)_.\JGY$>2T17VUDF^O3-[[63BXE,M 4(
M>3@PG*L51MO8WVCK]4:S/F^TDWU1TM%6 &<UE/#FD_1>*E8O# :6G:Y!6%Y@
MPZ,8P7 =B8* ,O/]Y/XD4RT<B>O'PN3S"[J6FY_:1$.Z3R+T0=#4-QG>]T4H
MOP6>:[\\P*1\A-O^F#-%4UK"2!CN$!4ZC.425K5^/L.4Y%O#+ZO0JVHOB(?U
M)5#*@AFQ])18<\Z(7<E2:G.U1P/UD#,X8CCT7+@;"E3T'%1M3\#8!S+J!XX%
M5P+\!\,X0ELD$U&QAC S2L],5]HB5M)R(P4&+\0+=4"6'2D'J&HH/$\RC%Q\
M/0QE3X+>.3"-(%E:P_&NSR*$IX8+N$K%\.FS&_7A Q%-_@+N.!1P.=L="OU(
M2MIQZ$9PWQ/K.TQN.'4<%<L'4%T?AB+UF/!+, @7AN@J2WBI@G5E]"RECV,>
M@+G1=^V#\*$2IH\[ZP$L 98FU$8["BP@5]!4WU%H#SQX<'@(MP<7 >W&*^6N
M C?2'B!, %HXQU51Z'9C?)YTQD^LC\E$Y[D"!A3KV1%Z?!X*;3JZ2)]9CW?R
M\<1C& V>>"SQQ.,IS%3)1I>.-C$Q,P?K!"!.$=#5DWDFM!)HU6+A64$75,,,
M#&;"" H,#;^&SRBSJZ<#07-O=85RE<$=_@VZ?Z?F$&8PDN' ]5&B $H0[/0"
MV;!%9.9,"QW<=!J SR(/-7QI[@"?^T8.9LK^R;%9A8\ @#V:TI&2 QS 8G;L
M&1UY,<*-L_+*_*LB /!+K>_ZD:53!=D)Q2.@&&MA!$SU_;1XY $L.$0. (0J
MEFEP11L,^ K*(-*C61M/;=?H*O*?&!P #Z8:]*F#IL^V0ZF_FXB3#9;H!:\N
M!N@SC(FI#FK./BQOZ& ^T#[BMP=#?;_D^BCOH=2SBK)IX=7@=6H[,ADM7B]O
MD)[!?T [ %=)C$/QT9=1D).CX[DKU]-F=!&9%HX>8B):"\AH3B93H^O@_<!F
M6;+7 ^LU(<<Y"9SZ^U2@4X,'3Q8K;7U PA-N<WO51-;@TX2FW^(%9E!P99YH
MOK-2ND !BL.7JGE0<]T3ZS-\/(S#89 SVL[L24UG5'NTB>IJ@3?"&L-S*/PI
MS!](HQVECU&9>,<R[NPC3!40 #H&6G#C(2J/W7?ED_;,]0S#V 30"U;<2&T$
M'%??LS+?PUC:70EE9F$,?W3E;'A!U0PY=M&?D#]M+T;JU8Z],3795.$@9D]J
M!4T#_,(-4ZEZ#F(/71487N16,YE#&0!Z2X1(X?,K/#\+8+SVLW=AHIXAD.D7
M^!>"S.#1!Q55UB-,);![;(Q$7P $*B7OGH"'@ '&FG]1WI*)M3Q7=%W/C5Z*
MP:RV3KTXU,(KD/DUKV:R/%*3D?;A90WM+C YVK3Z>FZ- @41#-D%'R0%QB@K
M"D((,A,F1A)'B0\4V*[6_\3ES"0EF6/X:>RAXPBV>1"$\V3?"-L@<,!()@[1
M: S@^/D0?BHEPI<3"[WO984/?1?TMW("*&8)7^:4RY\RM%V5>4OF!DK/JN$A
MO.Q(TXQZ!;;V*GT[^UTZ<^9&"N*%J))($:8K\+E>8$*2'VHNFYK_T$.'@04X
M75WM;>"DS8%7!R?V:TX=/J,2@[DJ8$W+04T&S@L=1)>EH";)<'X^;)?<5Z\E
M;-X/TP$-@<BJ7;#T/ZJB!^-Y+[QG\:+>6+\MEP"=-LBYD?CTA.#8W(^R%,WS
ML[\<VX_^JO6ZM7-QT:@Z]?I%M25/6U5A][K5LU:SYC2[3N^LWGJ3"##8]4XT
M?@&[UFK7N^UVM==HR&KK0LBJ$#;\>=X6K7;SW#D7XLV<;,E$V]^OFF10(.^S
M4,%D3,J7*!G-A36:C*/S(1^F! "#T<AS$:.VS4K3&6;F,I\J]YW4;&I? A,4
M;L]-G/\GX7IXQ2H\456!(=>V,2$W?&$9LQQI(M4AS.1/'-F-"BF)T 0U^B91
MGL UX\4^/*('T^HDO(^W3$+T4 Z#,(M,D,U@DHS'E3? R9S G7L01ANN!!X8
M)(YUH+D>?QU*"*@5.BIO\0[ODG3,B74WZQ%R"1.=0!C-A+EJDL]Y*W\.X<KR
M7>JFH >(;S@:$6R:*HQ?F:1S-3L%PR1.W$#8,WTY8I\+$).2,2840.FN?)8F
MPP?NO=)>APMB[H;:L09I\4!\(^N?6( 8A)B5AJ]J+Z@7@K.1>.;@?[LAX(VQ
MC*TO[FH?"WX_$)BB<ES,M^0N?6+]B:F528=2TW@NPR1M#T(@<*6E%SRGL2WX
M1_^KD85'TQFC2OZI797=T3'Z X\1XU=E/JA*?5#7I)H2?U3 0T& 'H3:2[LN
M7'7"\9_V(YR-G/O[WGKKHE!&.@V(F3 )ODENE#"E;UWXBG:3]<QZ[@],>.G+
MHEO5U3Z-;>XZ\7/X&'TI[;Z#AS;RGE6DP8*+P]6=0!K?$?4$O&VX4O*#PL4R
MXS9MDF$ZDN#/@(*JE@.O.$'3IJ:2:&9ZP3&\7W0:5L< 9JPX#GV#)*HS]TGC
MN<QJ:7?1S1DK>*Y1SO0^[BHCJ5F*1.&\P""2/XK#,(JQ+;.GG_6M,5KOC-&9
MZ7@T)O:S7(%E'[%LIN 0H./.D@=\O?$UFX.W@_EU#HQ4EE].;"[B +Z^FCAM
M+?3ZYO,;U.Z! +?5A3&!+KSWX\%S$#H0M;SYW0^FK!=.]3S V,Z(MN &'EA/
MG=8ROXH'< T=ZD]+;<Z\_L2R-8JRA7E7!5JIWKT?)]&EHHA]"XIEPI+4$T@J
M(\P\F [L_WH#X-E@@;%R!*8S^SNI-=%_%X;^7L11\"'IWVX##&*HY/OTQ0?+
M5*2<U9)2N8F=SUO?B&X>H-4X6>)0\%T=U?YZ.%E/181,2=F&3F@_:356Q6-3
MLT_P1/8(W1%4/D "@_[]MVMHMT]:I_.12F=M5UJS=]Q2EC#XI52Q9X7:3<T?
M#0 F%6=68XU2TPM!G)AIZ "1,4V# M'4&R>UU@)' 3$3Y5-@:19C3G+OV,9\
M&:B(N;8D-GS.]JN\6=^@M3ANX-CF'SRN?X2!4B6R]]^SY;L2#?H/7"5DEF.6
M8Y9CEF.6._[QEI+EON@*&*8YICFF.::Y,M+<9^&&)3+X_\$*I+W;^T47 \K,
M"_OI5+_^:MHQ]36955^]KX8S)!;4R*!#M3/3ABBX5!V$?J$'8WUSWE2YNW0M
M7P[;FNBN,U:(/%:FG"["XLHDMA=0<VIDDTM^=GWAVZ[PKGT5A3$6X.=[[GR_
M?TC,_N@V\UKP- LUMEA?ZP11\GG6G:>)V^4J\"QD&N.3],C(".Y^"69CD3E[
M ^P-'!:6[ T<KS>PYYZ=S'ATC2@SW@&!Q8S'C,>,MPBV;Y</@"<:@KP2 (_V
M!.ME^]%:-B[P?M3;MQ_$SWU$Q:/0M\51[T&(ZSNF_X/ B>G_>+!D^C]>^E^>
M_<]?8_\1^Q;] +)I[XO*Q<5D6WKF?XKRNJE2A"UN['6"&%MF-$[*P_8/020\
M@AMY2P@%U1K.Y=FZ !X[7C1@7,WQ6@U*=KP*CM?$J34;K#N@5#:PK4+.F610
M*IM"MND&<S49(\]<S5S-7+VQJ@ FM.,UHDQH=+!@0F-"8T+;TJ+_V:X7_7>Y
M9L\,37+-GLF9R9G)F<FY7.2\/#=?;&%)GM"*>KG8>>^LD"RH_Z9/?H!W\2"(
MB4,#9Q[:4A^7Q6M]X*D^<^HR.^WKX\MED)V5_55$^OR;*_ 6^1"7Z0OLKY]B
M,C"SZ$Z<+%[V<TU&$K[;4TW:^S[5Y+1VTGSE<(:2'VN2M4@ZI= BJ7E^<OI*
M[XS2=4#BPS0.IO=/N:T:0:#H]8 [.SGC'G!+XIK5\5A\M,'^%6K_2E0H.>9F
MF&P(RV((L1FF1:-%9)F-X'Y:/\Y4I<0=/-Y4_U6L3YKVI%+F/.FZ]2)%2&]/
MW@+VC-=H]@O1Z6*TP^LO2ZV_G$\<5#Y__>5KEJG]TXWZKG_KR_\!C2X4[!](
MK?XVK4FIC 71_?*+!1L,"W,M<RUS[2ZXMK$1KL584H>2AU$!P31[E.T#UEK*
M."98DABW7FWHV'9O9SXM0KC<%HAV?GR,>+GUSVS\2.YJXSXW^U>N*<%?><F)
MJIUC2CH8J)B2F)*. !P:2X'S8J<2;NM:J_<:I4:KO*OK<+.8O*MK\YG.B9TT
M1]KO:UL-4VEN[]H_:^\>&^Z22@ *IFJF:J;J[5!U\[@W8)>+H??."@MMP%YT
M0W9MHG'/%7SC243NDU3?P$#8+QO?;CU_;S76*Q?0^'6RUGE9[5]]>V$Z%P:&
M/T4(OXNL+Z[HNIX;O<S8^8P#.1U.,WOYD;5_I6/4'D8;PBT)FA^+".[G1LKJ
MI:<N6&YV[(*RH@#L3B3#@>M+R^U9*K;[A2^ IL(W,E&R@E!+CW!]JR>QZD+O
M2Q>1]4\,=J;W8@EEX59.QY%.X8?P V';8!C@*:3U[$9]@T7G_M("(P+2?%YO
M5Q(UP4T<*1:Y^7 CN(>=9! ;M0\Y&;>$[UC_E@[@]/A?O^'O?S_1WZI_*.P,
MGP:Q[@-PF!AGX#D&!6P(X*52C22BWWE.Y-U5*H9O A2 X=^Q;X@/L=!?NX?I
MA"?O6*%TI!SHS?/PQ2<)$2>^'H:R)T/X$.80[ A<SA)F<ITQ!1M)T(EYP\*'
M'GTK>Z+1L\+%[*QQA!7X^HG@[C#]2N+.'E_[.=AJS.H*3TN1ZDN),@H_C4.D
M%*LK;1$K^*%0?4O)*/(D/D7:*R&]K1W$'EQ&PDC_B5T<4?=%?Z$/9DF&>DJP
M4J%A#0"#?M9KH7!C"Q_FQ,K#T8='<5%@S"B$I4 <]2P.ADBU^2D8#3V4NH,:
M*B-JZ@,@:GT)0 ,ZCZ$TSZ\QNKS[HV)@+DX6W!3DI9K.P5)S!_<$/\,V I!>
MTQ9:,))!IX\WY;E.QK5J[18<E!2M8UIN3,$,U62 (F ^!]OJIC,VH1$(F7S1
MAG2@S[5!Q"*KA_N<T$)+2QC-U+"@&8._I0!(0CG$9(__J"5MK@4];]0J5F(5
M7[6>HRU6UE?S1(AE)3&7B?4TU]9R9_>%_VA,>.ZI0VD'C[[>LHH&17]G["LP
M'?-UWDCJ$+X3./CMT57F2+"*X!_#3O"3 'ZMQ=50 &I:*/OP,XU7H%110YU
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M@#?F.R)T)NRS]EX>$T?-7%M'I^:YM!5+#"F8,1W[)!<PD1A$*0[$ 0XPU*-
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M":!EA1EK"2$7;0FRGO@+/Q1ZI>AHN.-M:[-JA\+K10-%_YV2^J\@H[-FHAP
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MH5XICP;W"+JL>@:-?J3J12?)MV2E/$.=78*3^$LS!JOPN\3XNJP/0'8A91T
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MZ8V#; I_O)6B/US"?\<XI?Z@/VXEC)%" @U_U0\#/ AYV3I:#&SY%(EI^[/
MX[-6?OO#B\-NNS7X[>[C*W7F>7]QD(L8W/(I"A]I2B(\Z7<OF=R(H37\D#_
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M@GZKRX^\6F=1AE5!, Q\C'N'Z9)3,&5!_BRHGL()%_=,*0<,JTUL,(]#AU8
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MB[&S;:$^>CUZ@RDVX)P'K("PY#!"F<-4%!'(26S-PSR?[8</)#M%Z7-VD9S
M",)8K&B>C9%;L9['&25 :')C;G\+;?/Y28=*>V M%\#!"!^"@S*(2L<_JJ/B
MC:)WGT\HD34B ?@\(!W2VI0RL9%%46S2"5F@1WF!@LF"KMQ4-9(O!Q?[\TP*
M3K$('+2\*Q+$0%XX9882KN#5>7*2C:+Y*$Z3J%_M06EUBC6E)ZBT6LW]*RW!
M^J>GNY8D<=1\^MHEGIUAP;#Y9'L1C>949.L^0O.EPQ:&8EI#:S@>VJQ99X[=
MK7=[5_WZJ-ON@1GO7EV-KT9#UFEOD.70*9#?:5@(48M :OW*; 0HEU5+TRC%
M:OT[9P+^BL]NQRF*>#7Q=> JPPS$*]S;X!L3!O,';.VXQ\K( R$25LL1:0^Z
MPRN[.ZJ[XU$+AUVPNCWL.O5^S^GVQ^->;^!V=DO2Z%98H$KI1PYZ7NHZ#GT_
M?":G,94164/X&&E"C";F@ZZD<T-]."3]08M1!VR0C5!#G90\8TDC]>:G20OE
M<1./15B:,Y<=E[@R<9ETV\3H "9<HVRI-#L=&XE(,XLZIFJ9IU;LJRW/-FP%
M/=?</N6@+&R?0#N-]X+"BUDL1PW ,KU@"@8;*4N'3QT2P\/*8JF+HUBY2"QM
M514_R3[1U]QKG<5P30R&Y*+(WBJ+JD&WO1AZ3W@4QP;0/ .'^3X># !@3S^+
M(P?H<V[;;ZD_4QPZ ':P;T]C]E;^\<[B!Q-<P;:)E_G<_4U.1A!&]8XG(W3[
MC:O"X0BY$SVJ3\VIK&S8Y6R$-=W+]*@$;4[.V0\^6HVV?NA0=7Z5VST\I %0
MBAE8"5J@-&KXQ;!4?3!.J]'L+D==5IYV(6@3?5V@PY98\^>VZ:(BO:#-<U?Q
MJ +TAQ<YPD</<!N-=5*8,1I+=[3][RS$$.%7&HEZ07(;/+EK"II>T)Y_I=)U
MRN9>T*X_XX*HPO]:]+5?S-9?_T(!DM8;8Z%<GH5R,2K,6!XGB;8[V!15[027
MY"Q3R?,E[3<]">""-OT9TQ$7:&BTCV]HK.N7&X/$&"3&(#$&R<4;)+\%H5'1
M%[!AH:([1D7KAYNBPOA1E$<L%DG SI:@Z.;3I^:GFP.H"UXTL7?H:U/1KE3"
MO=V6/PX&_!+CZ9Q@OYM]>CBH9X(*@5IJ&KV$A#)X6H&G9LZ2W1Y7BNZ/<#'[
M4/T&>2N9S/"0!F@P&L9H&(,GHV'.$'E&PVB!!J-AC(8Q>#(:Y@R19S2,%F@P
M&L9H&(,GHV'.$'D7KV&V2X<=K'IBYW18J],8Z(V#;,J?/%HI;=:?'RN#;'2_
M7E"_,+'T5_TPP+7Z92OMC8_Z[!2&Y&3"3BD$$*>:KIY>E0[6^3!7)O70^!QU
M7M5/<>+A?"AE$D_)U*3\.:'EC_Z$H^18X,S5QZ>7JM."TF$^2P[%K7?2HT,[
MK]ZWAOW"T:'ZT?V%21Y=%8!1NX;XC=J]3+4KSE'0#SD7QAZZ2BFC&PSQ&]UP
MF;IA<Y>L>S"7+/WSGW+$)35"E+I.O"F$?F^OXX@9'\^(LG/7*$:/&^(W>OPR
M];CQ\73!@Q[]@;M/4#[?+.G.V='](&>'X93GS3&Z5'*L,W+APH6;'JAJKCTA
MX[*-A,V=_<)AJZ7._D4D7M5#B8+9HQLFXO><OUX;7+7WYK'O2<_H-<=!&VXX
MKC0S-H VJ# VP!F@RM@ +Q(H,"KI?)G+J"1M4&%4TAF@RJ@DHY+. #E&)1E4
M&)5T'J@R*NE0D=+^_B.E6]9#=<ZN'LJ$7L]>/!ZG;7A)EMP-9WC$<KMQ45ER
M;4X@> %LG!R/Z%+0LW(TQ3+D7:0YJ&W1W,N@TIB*.5-QL&@J*@9BB<UELNN9
MB7<U&&I3#U]EXE7JJHL2><:2,*@PEH2Q)(PE<2HU_$:?Z2M$C3[3!A5&GQE]
M9O3983SCX0$]8]-=KG5WN;$^]%5YQOK0!A7&^C#6A[$^#F-]7.EG?9A:#F.:
M;,AG1U>'HI3CQP3/*8=O7>]IL\WG]OK#H@S)OY*3R)?9(XL\I_"Y0MCE#PS'
MU[;:TS+IMWPE+PGF5E\<@#Z)Y(:F]@.KCR)F_UFWQ["?M[;_;,_C5]:/NX-[
MZ='9Y:@ R*,\](*93?(V%:R=X? /UPF2/\:MX7AHLV:=.7:WWNU=]>NC;KM7
M;W;=JZOQU6C(.NU72Q[4;7?X@^Q!=WAE=T=U=SQJU;M7 U:WAUVGWN\YW?YX
MW.L-W,Z&#+<?(, K!;43\0MY\8]7( 4=YOLH$4"VI)^%K*'/N86^M6=)^$Y(
M&^!TWY[&[*W\XYW%)=)54\Q[*E1-O9!(Q,*I%>6DU3Y!)3_N(A77Q%LJ),_&
M+]"A4%Z%Z"CTW4H=-5Q'>.X5#[ 2V#8@HOU*!R._M789]DOQS-'1]L'V[<!A
MEIT(07H)F_[('+*6.<UV6K4+VCLX"*VC6_0O8:GK 6ZCGC3&@U%/NJ/M?V=A
MPESK*WB5++X@*>T%UK6#34P7M.=?[>A/EL08JKJ@77_&!7F.[5O7<0S;OZ"M
MOZ98J]5Z8^R1R[-'+@F^QL[0'6UWL"EO#&(XN"0_^#:9L$O2M;>CF$5/&"*^
MH$WSM.8%;5B8%>WCFQ4Z-:'K@1MC?ACSPY@?QOR@7?\6A$8A7\"&A4+N&(6L
M'VYT.3BE4EV(8H?S+8;E8;^W^@TM,^>:'7>J7V41\D75BNN*IS4+QB^[&%Q7
MY%W\Z6AZH,%H&*-A#)Z,ACE#Y!D-HP4:C(8Q&L;@R6B8,T2>T3!:H,%H&*-A
M#)Z,ACE#Y%V\ACGVZ0A;-_ENA!;]CT?X[<ZZCVCHQ=R*<> %S0;1H(K('(ZE
M_UBF905&%R[?]$"5.1SK0).5NLW%R4K73[;G8[G5IS"ZLWUVEPK3CVR49)\V
MFK%$!0PWOAWGAB']=B=%=O;84YZJU&JU.ZVMIBI=U:ZN]!_X:$[(.KZ,-):%
M-J@PEL49H,I8%H>R+%JG8EEL.0"R94P58ZKHS;3&5#&H,*;*N:#*F"HG?5B3
M44G'9RZCDK1!A5%)9X JHY*,2CH#Y.C1W[HLJ6].\WGADA=SL)(VJ-BIQ,\<
MK+2O@Y6.7@%H#E;:?Y"^70C2TZB!7<]4,A'PEU94)W($TF5I+F-$:(,*8T08
M(\(8$8<Q(CJ',2),7MY8)><I/HU58E!AK!)CE1BKY*4R*$:?G:\0-?I,&U08
M?6;TF=%G1I_M&3E'EZ&B(.!'.CL<OA5'B>]VB'G%:>T_+IRR7L43_Y[%B3>>
MK^8*]=V=!K"O-DQP/V'63?@XM8,Y\</@76PY=CRQV']F'O "!DDL.W M6[:.
MU.&9]1A^L1[I*$ ZRSWK][>>6<0L!QX9>3%SK7!L/81/+ HPWJ)<U["ROA#+
MQENP@\0;>W"/7;*&YPD+K 16&X(D\@+;A]<GZOW/7C+Q NNJ:;GV/,;WXM73
M6>1,[)C!EPF^5-FO9?MQ"$_Q@@3^'UN/ *:YV)1E.PXP.[PWOZR(Q4GD.7C:
M):T08&']=?-P77<Q7"=@,?_(IF'L):N#=-_2A=S .JX#^N>G#%[EWZKQL%]Q
MN[_2;C^!6(NS"%B[>=5IYB)@O33,U7_UOM5H%8)<%A"KCWNW$\#K-*%G69UF
MS<+G$0%M ::>UF J!@H7P%2,!:I@DL=;6YT60:EEO?X2)LSJOFDL.75B+9'3
M/Q618S$1\W6)6<>V%Z$"GC')OJ 7 2EXQ*KU;$?P^,3R/7OD^4 $ EZ#-]8L
M!MU*UW_P04_7[YQ)Z,,>?@U=YM= ='C.!"Z";QYG?N)-06!Y%*V&?QQ_YLJ[
M%P5AG(3.G]84C[6MT07L.XL<$&O\.[E(L;*:]13ZL%9:F_AIY1-!2/Y9'T<,
M5Y0P%"]6!/ @CN%OG#(2-_#CX\(+&];E$ K(<,NV$,\^URYHBJGD$3&?TU%H
M>8#8>P37+Z$=6-</ %U2/J@AK)MO/UNO$8B(DW;S7<F%]$OKW1M!8/TWDH0\
M5  @)B+^GA&^M?[(TPDN\K1*P,#DUG]F=@2(\^?6"+,=7/TLI?)R^0DOWD)\
M]A?%Y\?T/;\()@+E^24,, <"^UXM3F]@GU[RR7:(R$E, EF% --\6@:[23\'
M('IG",_T.H0U@CJ%] 8Z9[A$F (E>(N:V@8Z"NIB9XK0"+D5,;)].P 6CB<,
MM7TIU!.T#A+ .]X@G^Z012@Q)ZFNC-PD]32L:S)'"@*_IHH(H'#7VAS'@Q/"
M<4%A-G.)M3H8AYA<>P9W*&;!J_=!6,2YPBHI3KD<%+#[ LL!\9K!J-M.K2U<
MW]N[V2-(P/GM^(8L_ =8XF<A>K_:<\H*WJ-->P] ^N"#N%X",B+<5K.E4# #
MHIWBNZ(9JW2FST0X9]I["YGV#$SJ,E1K7@!/X#K<!MT8C@1>Q7+A1]>+R1Q/
MS6X_? 9[';0[O L>S]4X[-=)<9KITZG *G 3+(H;&J$/3\ 7Q@X+8&\A/]IG
M[W[>$B\3WB5\6.Y"\2@ ,87#?#P+T($%II]%!($^YUS>M_8L"=^)& *0AV]/
M8_96_O'.XG&&7E,,0"U4U+]0ZT-_V.CVM^WY4G"QOV/75.0LQC=NX&6CR-,L
M-KP?3'0:K:V;[PZ""!7(.IVQIMVAG.U!PYS)F<?:UTQ=F-8N[;"C2U]7)4<)
MK72^":PE'L7W4>1[4RH)5!R*JYRQG-G(PC:^':?&,HM0F-@/:Y04'M)OS)O?
MF7/13OW'>OO5^V[!E?BAU%@<,<!L@):A%UC_VT)3M:-=#I!K\/,EVA/.H%]4
M=EQ3/+7[#3/.?N^*89A3#%EE=B'>-/\HO/5O=K*.;DBE,/P5>X RBK!]F-_/
MIRQ5 7?"3[\-%BK #Z1:9/8GJQ6G^O9T316_JUO?7$GUFMI4CR\3@A<EXWY8
M580@428"CR\=0SK3NH3J:&XQ*>Q,F#OSV>VX-/9]G:2R:F]Q76$ZSIA[G60+
M^\,)DC]:/#2:11AY=&\:A4\>1BAM*X*?L(CBV8Y<&2U=&C]5,IX>9B_"66P'
M;OSF[2+I_1UC%9(>\JC,J :O>;](//NLGEDHGLGA3H+H98.?P\K@YY'<SD&_
MT1GN9,'K?QS(!Y%A*RMUT$^K-:YVPX?F6DQ32_W2C D-RXD'C7Y[#2R<M2]T
MY$I@PQZ:2ZF+4P['/%)-V$;F2#78VLW$#AZP-'#!02AS#HX]T/7J99!V<KRD
MQYA0,]'U9%#%+3(ST76'"'9YL62O<-):%C#ZV?:"7\(XO@VR[[ZP-<HE,;!$
M<8Y[YDP"[S^S+&:MU";\+BK9/J:%;-AR\,D/GZE&O314W%\HB%UW#$FKUA_T
MS/$@)T'#.M2#&=5](L4J%Q8U_-<L8&FYL'$*C\X->H#=U&"<!I[R5JPIPMB3
M"5LXTJ\TY[DJM:F':6GBIF<N RY.19JXJ1Z8,7'3T^<E/8)Q)FYZ,J@R<=-#
M&9V%(RITC)L.*DILT;A5+-C6P(1&3X),36A49UP<\WRV<DOW$)-&];=TE7AI
M<<;"L<?!EC"/F0>KC7=NYL&>40&GF0=[!+NX<.K*5L'8$GMUS6#LX*JM33#V
MM,;97I8.T%L?'QT5JT8+'[J+KSAON.2;BGZXSO!J40AE,T_Y(5#9V4E['VFV
M% S#:7G;F#J59%.6W!;IW8:5@<7"&,)A9F<>4<2HTS(7!E7*&<=R_/(<U T-
MT(UI@#'^&TZI[SIXL'R&XY)MV0_-+Z&.Q%F4FWVX>&'#NBYS0HI3#LL'+6\W
M2KFG]XS@'48IRZ&C$9M&+&9\^!TV-B: *1]'7&Z-S250QOB;;*;/P7F0:_\'
M.00[Q)/:G-56SHO N:K#_O.73\NG3";/)6,FQ^F^B*K7&-VY5Z+6>S[X#H.O
M-2/JOM9$W9)$70#X:J*> &R6DW5J>:@-Y%56QE6A=/IN-IWZ!'[;%T&H.YRE
MFUD;\8$Z[6$Q?[C41SYH=EN]X54=C""GWFVR=GWD=GKU9K_39@-[U.^QT0;V
M2DLG@Z77L%0(6S+.1S"V/@<<^4CG&[7R+QHMQ]SBY^ )EA!&>(##\@&^A4'6
MV<@'^9#Y#9]OK/'HWB/:ABJH\:R,.*&IO7;"#;GP&50;6'5.&"<6B-( 2"QB
ML-__TG &9:#YV(MBW%5-_!7.$C[:G)\1LGCR1W[6[L+TBLTH=]&I*@ZA.(X3
M^;*3+ 9''^/;WR$E=K@YI$OE4W["KS91G7VE*%=5/1PTJE/0'IK,&=5N=F^K
MTQBN8)R+&]Z;!@LX_CK-VI*@S+EM?I<$[=XJ3RYY%+&1U?H@PLAJW=$F0V!"
M5+<N3%1O/;+,B.J3K3:KE _""3K?=/4W^QF/OF+PO1_K5_)":O1\H7_"!6,7
M5=2A83%8.V>XF*[;/15Z#1<#T&G8&23EKU)0?F')[?@;BUGT=+BJKW:M=65:
M<+6C*5UEME&51E5J@">C*D\3;YNKRD(YXJZJLEAMLGZ!=.^J6%^E'R5>O*H\
MSMB$RW7O?P^C/V%E]6D4.BS>VL$_7/S56"U'&G9PX8)(#S1PR\08'AL9'OU"
MA6)J>*"X^QQ\Y<+N19ST5@UL%FWF#!B&UYSAC;HSU'^Y:##J;AMU5Q@$N;.Z
M*W6T,YUVU>L8C:8;W>B2*M]#<? YH>63%WCQA+G60QBZ1TN@:U%TI@U.]$\5
MF F#FJ.JO799H+%F-K-F"A,&4VM&BM*?49+NZKQGULRP56Q2U6UTBID#>'QA
M8'2H/K@P.O0,4&5TZ*%T:&$:V<XZ=)?4>Z>O3Y6:4;"GD(]?%D/08$S92Z/E
M/L2Y#U[6N5_#OGP-&]@N$#>ZAM+-2-<7+$T\=$;$C'0]@A%5F+R5&E'+3S78
MJ5R@6VMW]S?)]5#'$IA)KL<7_48-ZX,+HX:-&C9J^#!JN##5=7TUO'W0HE.[
M:EX9-7P^0[P7QUON<=A<87YWQ6LJIV+0Q,GVM(S1]1ESAX=ET92/220W-+4?
M6'T4,?O/NCV&_;RU_6=['K^R?MP=O*NGN!5 OS G/3>R=(,IH<O&C([=KMOM
M=/OU0??*K7='K5Y]U!]<U1WF=J[Z(*U:[4W&C.YO\R<YB?UKA'-\DSD-C,21
MN%.<<+IB .A@41W(IWSUX>G7@9L^R(S^7 9OEL(;@!-[..WSA8=TFM&99G3F
M\5TW+;+Z!1&LR; E,X[M!-!F1F<>VRV[Y'EL1E;K@P@CJW5'FQF=:43UT22$
M&9WYLO[V[7CLX7G,@4M'8<R FS.W6[]R3--Z;.:#:8 G,Q_L-/&V>6:O<)93
M92CWYRB,USB!K?+^#_/[^92I1ZUQV9Q>L.R8QERST*"[O[2@&2-VYJ+=:%2C
M437 D]&HIXFWS37J^LG1%]2H*X:)&(VJ(>GIT@ATN<&#NW"</-L1TZ\6TE@U
M9IS1Y:+!C"C;QC IG)KQ@H:)E*1PE?SS(WMB?DC7WX1Q$J_O_@_-Y#/MR%%7
M46$4I:'^RT6#493;*,K"F1FZ*LI57KU1E/J1HRD).#8&?K%'861C\YJI!-"(
M#?0 ^\5+(SW08 R7+0R70>',C1<T7-9-XZ_5^MNK]0;[LUV,M#AS:6%TI:'^
MRT6#T97;Z,K"@1W'U97;C\D 7=D<&%VI&T6:[/VQ,?!I%H$4F)GTO0:TKP?8
M+UX$Z8$&8[!L8[ 4SN1X08,E%:5PV2>P1N"O]?/UK:O]F2=&-IRY;#":T5#_
MY:+!:,9M-&/AI UM-..*!+W1C!K2GTG0'QL#O]K!; SL,(M@_R9'KQ$GZ 'V
MBQ=(>J#!&"O;&"N%$RU>T%C)"=9/MN/Y7C+?1[Z^5>MV]3E?S$@.S26'T9N&
M^B\7#49O;J,W"T=0Z*,W=SF7T^A-#:G3Y.Z/C8%\"" )0Q__Q2E^CZ'OQOH%
MR8Q)8V*3EXL&8])L8](<<_;>/8C4^*/'8KCL5Q2I:Z?SNX.A25KH1GRZ"@:C
M%@WU7RX:C%K<1BT><X#>$K6X(I=OU**&Q&=R^<?&P'V['CX'S+6\($ZB&7)=
MG$[CA_O@HW[A+F.UF"CCY:+!6"W;6"U'F:X'D [OVQ^_?\Z$*UQYDXK6?>3V
M![56KVER%+I1J*[2P^A.0_V7BP:C.[?1G4<9N+>^[MP^O]^O]?O["PL8Z:%9
M6,#D][?%P"_,CMDD]%W+>YQ&X1-[W"428/(79Q8XOWAYI <:C#6SA34S/.84
MOE2N?E;$ZCZB )W:8+B_2D4C.<Y<<AB]::C_<M%@].8V>O.8$_E6Z,WM(P"@
M-_<8 3"20[,(P*XAF9R[+X_B%!#.G<9)VYK:$8#RC-%R$U(PCDL,+[" %Q\B
M%A^M1$"U9@QV= VZ+\?-11XWK"NJ\F<.[X0N8SWEK*=CC@=4Q?;GX*L0VNL?
MZ#?H:I,C64NDJ.+>B!6CC2\0%T8;GP&JC#8^E#8^YDC"5=IX12-#K]4VVO@D
MR-*4,>B' 3VB>2;]<J0@JI13"%1C]^B*I[S=LSVNC-&3,WKV-]IPIU*%=K-V
MU=E?1,'D7,Y<&AAE:92EP9-1EB^K+/<WSW"G^@10EJT]'A]HE*5FOKTI4-AS
MWT(<6[;CS!YGOITP%UAN&@%7V<3U.-? ?@RCQ/LO?6$2)3K@3-?HNTF4G RJ
M3*)D/?R]WMP.*@Q!O,ZDZT=%N,+?/L,_P#2Z5F1LI=ETJ/!"JU]K-_49B&!2
M),L(\HU1P3J@05>Y;E3PR:#*J."#J>#"P,674<$[')O0JW4[IDKA- CRS?$+
M%)8%,=QP-O*9U6Y<CC:6_$KQBO1XQ9H5L*W/6-P/ADK-I0M$D*ZI@#72 ,N0
M=Y'VU%_U0^.:&9V]H/*L;:W-3:WUIT1^80>+8'1K XWJ(ZJLITJY?U'BX[BJ
MP*AE?7!AU+)1RT8M'T8MKS^ <J5:WCZJT:WU!_J,6#HMM7QT32 "&S\F-D '
MOG6]I_<2EU]FCRSRG,V D=O[#XOLI"ZA@J__/8L3;SQ?S=GJFSJ-[@_Z,'+5
M. C+B^%OX)\(5D$G241>S%PK'&?A#"N9V(DUL6-X7&*-&(/;?:!-/(G"BEGT
MY#FL8:UQ/ 6^+/>*R'ZV@)L!I<#?=/%S&/T)$*S#^AQ:7O $=X;1G"\"^,-B
MWZ?,P8*1)(3%6#-Z5L3_A:_@3G?FL-+UU*R139<'\#AFX81:.YC_[2]#$&3O
M8FLTB[T W_H8NLRG]0!@F6/'22W=BL^2A4W2RIX]WT^7 W?!%;"OP/8M #.S
M(V="3W#9$_-#$25R?"_P0&@!R<U<#_ /MT7,?D"8HR" 7VS $A^A V]()I8#
MI!@"#\0-0;4@)0))LGEJ>_7^.K'NV#2A=C5^>:=9L]#AJ>'^ 9;/@-2_;BSD
MKPIS^3Y+-/T.^*-..<0>2/MO]O.O$L&;.F&]5*3W7[UO-8J)8@M8Q\<5%T@)
M %E-24"UZQ K_@GTYG+ ;P&EPA2F/4"IJ!,7H%3T1E,H 95^9 Y1@]5I$2&T
M&L0$G*;+@0)44N!V8"#X#UYF^SXOV"(PNS,@=KHEXQ2JY()OTO(NY+\G6,+?
M<R)=!=SZ QA^B]EXYO_BC=D^)UG?(A248=:?@SN^;W4.0ZO94LA6,4OJ,7/>
M B2  -V8!:_>C[TG9LU!!L2+:DPPL9H9(O$6Q(QD2"E&!#8 FU(86#'8"_##
M+(IG-LKK<(D8 1D,+T-#!)X!R,I('MG("6/ZETM1O!](=L:X;(;+O4?)9+1
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MD)UP:XDXQ[1 X%B6Q&J8& G/]X%JT+R>1A@*3N9</)42(*I6Q#20%M@DP,/
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MD :\)Q(X<]D?@.WDV7KFU# U\W$%6XRT3\[A#M(V7!P7 &.QE1' @/%=&:?
MWD)3.4LHSP>!D$9(0RF<A^4!7 WW'K(,F7['!L@4-\C0HQ'X_!G/??33@0#
M?Y<H:D*/6!6^C"P/SP 'ZWY [S%RD@0%#4IJ ':#UW_@W?-U82)A.=(4WZ8_
M##?(A%$*LA%/QKN%?%H51:\:%9OC4>@"C/-OIWY IR"9'HSQ"EXM0_=4:@#O
M 0I"H@1CT!16-IU[#K"<E/Z,KZ8O)3W2@ .2= YQ^Q+:E/"]V$'"$@%2 MA\
M?L)/TXIG!J@'#AY1./?WL;ROKE_"1ZY@H.1S55#2/6./#EI)=Z"WIB[4^36.
M$EHXMX9=.NK#@CQ(9I#(^';[APFQ[%G62[<Y99E.;F0_#GQW0*38D\1PPRA.
MR7CP0^3LL@6AB(EU.M(94B]^J5#ALPD5%0G^57%:4GKF*(ZPB=5KYKMWIB\>
MK$>U\L6#N:J?AJ!+="+\=+RV/8/[Y8C<5;8D@=  09$-X<1CQ.A4; I'@;1D
MJ@+$CLD4??ML'?ITF&4[4:6#69C$!S@Y:YZM/!9[%9PO.,/R$/<HZ2S3E+W-
MVT>(@4-%S4M/G3\U8O[@)N^"BL>MGU%_CK[8MW?F;;+FSQO>" JFBF@%Y2MX
M6"_VK=@^*$18&6VXO,JG1:NMM <DJBEHP%2+H0/^"0,(!P0#BI6(KZ"E27'M
ME-XZ "O7L&9]Y3"^!$:,*<+*(T\8B/TH7;7)OLV;[,UKYR!3Y* P9&IGFIV;
MNQMX.EMHZY'M,)S78<@IKTH*:'V#<S_]._/3\768I'&&'R:3::%<1G/$89NY
M'XR2ETI.VYUNNYRZN?[RN9*E?QMF0R]*U06OWK>/.XWCKFT;-(X!3!5>\]7]
M_@DB4_%@E7T53S^9AR*KYY^EYXM*CUDJOS.]0GNS*E\'L%3\RJQ*D">L@<ZK
M]Q?MYMEN;,<Y*/&UKE#,QD+9AQB*^96KV,SKPK(Q%U,P<?!BR@PTD*EE+:DE
M(R;KFZKXI/E4+:0UQT2:7?3Z9.3DM-4X.3M9FREE9=2>RR@;.3$##Y8=C$"#
M5=G/#'Y,[\U^ >V]0Q&0>9./WW<ZS;,+J[]-XPI;E6(@4GAN@WEA0AL),043
M!R^ES$"#-:O>OUX^%-)9WX#J)XVIZ@B<7;"5G@J%G+0:W1.[4-DX1GAC'@9L
M$,0,/!P8)YB*!JNMGQD$J0TF>RF]O2]!D(MNL]VUJMLTKC"E'L38P0W&8.HS
M#[/;7IF(J9,<C,&0J1F0Q3J##USLF8&JLT7[N _;EELE\C)][\A&++A<5.]3
M\*5SWNB>F%.&LI!L*ZNB@Y)O*T=DC#(2]D]P&3'4Q?*,N;AYT@!8"CU[S4O/
M"^C4)G-OW!S(X C[$LTY[C2/6]86V D^,:7.95Z(QXLRG$O::<ZW#?8)+97Y
M*_D\<Z%'F6\K,CK'@%L023;*8VJC]CQ\VC"00;A<K*-[+>@\5!-QEETX?0/A
M84UW63XVU#EN=%OF5.;,,@AG:C K]7;3P-@_D64$<BSC3,7-UF:_S D.K8Z9
MO6:CYP6'SNR\EZ7L XP(G3>[U@#8MVW#I;5Z2P&C_.[%FJ"G]Y_@=ZL'G+?R
MN"3!JO.K\W5%]8-6L++5]3R=8S6/>Q#K%QH!XQ_U8NE\/W+Z\#YOG>#1&8-L
M^F5U\+=6!_X$[ L)V;TX_LMSP_2OOGMV?GK:[1^=RI/CH^.6<W'4:W>]HU[G
M^.+".S[Q6OWC)?EH/6=?YQ:G;>^YVN#"W4YMF.GF%N[F=^(O32K"C:BWI[?,
MG3?K-0W/W)&KPKHSULFIE85[O?>V4YOX8O;>V\5I:<&UM.UB=V%U+6WCB;VT
MF]] MRDIN<V5N)JZU$+<KUD,O)'PUNG%WU-OP9UO-&Q;&_Q175PX[]7%:[SL
M/_[/.=#K.[[Z]NM7^KW][HT TS?U77^$,Q?$T!F+D?YR:8LN7MT^>Y=4U\-Z
MO)PWD4/_R G!/@B J/N2/F3Y0,MSGXJ_P@-E61UUI[=']IYVO'J3CI<&Q%?@
M/7G3OZ+3$XQ 8J"U^+2,N,UZB>_Y3CR^=7!7)WV[+"\^E9=C+Y8YUYKG"%RF
M\[KF^5GO(@VB1]HP)E[[;^B#(2\,YMVU &)>QHM75! 3L2[H^S'(<L\9Z_M-
M8$> %GGM/WEK_.NTV^>$XI%Z^>2X@S(U"1=H+[\F&Z&N<> Q/_QA-EQM\6ZW
M75F\^SO?ZW((3F-ZT[\D$M3H*.-:'6(;R'XR:'[2@&/4C0_$ !))Z#DQ*0U4
M\+2XN((HT"-PE9NQY0&7.*X+OJX3NI)73#NC4>"[M.\S=7Z(. NDVIK,U#%)
M$CUY#V@#9%QF]R 8Q5F#)$R3)<L1<=CTO;K].!J6)!+(&#)3:+OS():S=G?G
MN6Y:(XUS9,F*A7/'T0\R98*Q^ >NV7J_ L'49O9>!D'D(K"F&Q^?^&4V1RGM
MUAE32GN^1;K\J]9R5MM^U8Y^U2>,[U:S/25D5/N 2$ ;Y<^CQSFKY!<BQQ4(
ML38_:?O866P!=ZM9;]C+72.$T0K J/51;AL8;0V,)[AR'C :Z.NA5^4_ (TT
M!1O8FS6S]S_L<5=F8+WPG3ARR)R+)(A.-BE "=J,$*#5URDQ,["TVM*>Y#+
M3Y*,U"18(FR<+%\GT%U?_2AG_X%BZ2&763J(8O1L-T?SK=9YZW094^6BU3@^
M.Z_3/\-%6XIS/0: L@1:]-$<D>I88(Y<3JM]RV-:^,\*N%E?^F8"-P^.'Z!!
M]3F**3^S21F]K#5YT6B?U[6I1I&CCTY<D'- -N%, J<UQ:0@F2LUVN<&Q0'8
M,B LBC*FA5(C0H>UIT6MCNLFXZT[D%Z&>%LH?J5T&?QTTY^,4&'L*KF#5_D
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M0B]-OD2I_.@G;A E62SO $$?0.5^7RX=)0%V([QSG,DEHCWM\QD1#N7[]:+
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MQCO\;]3[6T>  ()*QP(5-3!'*_4-\M=V4H89$1T\=!H",8%<H%I%IV:^X..
MZ6 F[3^[W,!$J; T0'5N&'AGO$I(N::-[B38<+$3C]FD^ZCYZ-)#H**MMX19
MJ,Q.LOWRD"C+J<NK0C1]U7*F:B3.JS*?B(_6"]3*"2FX?0#4S$%,](R\7#X
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MG":\-RA7.6&2EB:'.?26H& S3 VK]^A+22HXW_^Q@H5:'26F"/>SE,E79XQ
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M% 1=<3L*_)J@6N..S2W*K)NBP:^=K]2LQM7SO=.J$F0H)94?8J@4P3, 00;
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MJ>57O/R6O^!5\7Y?]>NM2[(LY&9K I[N9F,U]^*JICMCZ !;Z_-H1ZN/94F
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M-!?V:NDYB!2 B,1SRUCB8T<CZ5#:%8A;/N*G/,YA0;3<X(M7C@XO/(;S]OL
M#"0%G D-MU =P!'.@ROMD>'1$?/1@!OHU=T1;4BD498(S!A'<24GP/=/0![
M[0 0(+K@%%_A-<1U0US##46G(4C*M][]3E-*\1'X0?OL72(^%F!&4%V&3C!.
M?"+:SSD\KZ*0Y]G1-=\*C^$F]QCH">UW3Q*X0"!RTJ)RR/9EZ3/]X=EE?O1O
M?O)=?.;WU\_"+Z@_P^, Q"DM;J#/X8- _X[O&$1)%B.3]J(L%;^S",6;ZKN1
M)X0[H&GU0T/W,UR&(6)Z!CG\7Q*_2'QCH"F!55B>^"A=.>S)F*_JMANBT^K
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MT8^CH8A&$BMLHW#E.+ =E+-GZ4>[3F\W\+2@D7#H!L!)X[QEA[%M&P]OS,.
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M6C-05'LKN01E1:+*V407NC?(DG0@<:'<$PWY"[G4$S27H5JNB-6"@V*V!*;
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M7^(UC>3285+O<T[@IT(5PAX<""Y33^7D<UQU@NP=._YB=2(6K6)EE6J ;J:
M8NEN#KS[OUR^N^@ QFQ7)5)K=T>5@KHH#4LCJ/G[D*NJ$./C!+LXHSM<3(W9
M]O@SW01/Y9^BH,7A]G%M8U.LDJ+*1#/Y0U6&F:FBV "%CJ<[VX,\SXHX@V=5
MJ4H2!4:K!]H1-5E6P^OU[-N,&ZPMN")^.>5<7XIIKN_@V$B!14J1]=<(,WP!
M-Q(;%4!0N(S(4-D+LS$ENE)%9[_[ZV79!.RST03L#6'*9WXS_;3W*\%(/E;+
M\QWJ(]^(*-JAPX#VD@2ZW]9LRDP'U_%49NT<JJ2H%"$-4G4'-<IN;E(&"BZI
M/&;1MJQKQ.NH#4HRL__U_&%L#Y8,L!9(5=92'Y!&%*:^?K*GR8(=L1(9SA=A
M83'A5/C4Z[L^[%@GZ,\11)D\COP@P :"H*6I7I'<I!JKNBE]'F>C&O=<*8E1
M[>8DX!;LGBHG%7PDPCES/7?D-A2)[NAS:20+$K]06>M8MA50EW,&3"/\.*.<
MFH S@0IN0#01(*L"$+0C5>@A/.!NQ.*,LZKY<T-@;=BHI>-<8MF0UNA+;DA*
M)PJ2F<C9M4[T09A#+#^9<EU,I=)#\10^C2HMR83XIDIKAX T ]!YX%4A)3W(
M+\H<^GA6X\QEIWBJ&Z5*@%/@MRDR0N3T:DYNG:.K2@!#7&U\85.E$$55 ]0"
M,-JRT7CJ46H>,&[-+2F]3\\<KK*3AB7K)0;(^JAT6"D9U2$C39W=E6U3"CPT
M1C&6CFT]BYQK@8V9)RR.L_*/ZHADXL.Z@U==5\/R%"RO+!4[;:L!,QQ1.T4I
M[7,"F43=:FT5A_>;A7\Y.F#A5(Y*J9 JU"$-$;6M<(#=6*M7 EJ@5  QO3*E
M7ILW>,?2Q&6=->.*$:,PI;Q"(!99=6U.DTZUZNMRNU<JX:$4I4D1C3SB!4JY
M+?E#:;]*:[7>\HFO2[:&4)LCG0FH'B322*KEV*YP1  F9>P7$S"*!VJ.DNB)
M&8TWRYY4]3*:AV!66S$KE?Y6X+4@?BLIK/+^):=7PJS)56MN$IEV&CC?A)C"
M2Z@.Z8;I*L/V'/!CH]-CX$WS<@ /79:!J&9[:CE?'&];\D^N/Z[^IH2=+D#"
M-R.:J'<J(6D2K%%^)7MXT<@,Z@%+6S,(IU+K3"TL$?01T5 \6SP80VIYU5 N
M Y Q2=5!25K!XQF+F6%D,\9,W4K*$69F\Q9_3),U$MT'0'I&I,^DVD7SUF$3
MU%29ZJNX&J'N!9+2NL%OM,P4BEO]$P<+_!-24@Q E;XU/-7@""%Y=K2TN\=\
MDR&19,7KO>7="J(,>5V1ICR)0NI:%8[)R@EU EK"]T@F8:D-A31K90KOCV7K
MT9O$*!LD"I8UB)6J6OF3F2KQ0U*<$M\@6R;P)MZ(,3O M-!D)@*#++&B.PVY
MUX4I$Y'CI,545?OAPH874A7VHL5*5:=5%Z!94<M/B2HS]E6W6>49C9!K8U^#
M%1!U<4B@J@[M[[5('6K"(:YN+ML_:,01W\&:S:@I$'NJ-:SAK_? H4$OP.O_
MX&49L!DP6W.);HU(2<AFX%A-BBSVD;L.7.[8=?X*HPF_DWZ[: =WHZH:9330
M^.F6V$F(C$+X!MU I922F$3Z ,GH@#%L&**N,HS G 6V.(;;10P6I&2@<P:L
M\"2-0621/*(GR2F%-F"8>1D7=PD0/?!V1,D(K14JML=66"D(CXR*49'_)C?8
M*;/(8<\LW?1.%5%5M8Y,$9(T7:F"53K^F'::I89&C70%AD*.J<F4%-J,']%C
M_72X0C9Q<%E.9VB6\=NQ2W\4K4B 2QDDK:+ J_FJ_-5IPF.(& 1AD";-*)+%
MY.*[\A@00B;3,:I5/DT\*#DUB0)*V0<%  WFF'N@*P/>,)&JW>JSLIV^M$\*
M+* &TA/Q_.A5P"TD!]D_C-@T=L?7IK!1J YJ2;D]) E9\EB?S<6[!@R2;=_*
M[9 E@L&RZB%<R?S+<6CD?>9B=%#4\B$@(<F_LAJA#A5@,-)QP47AM!I<NG(4
M^5[!Y?6L"9JW(+OCJSUP9SG3_X3&E5ZR2%5'?ZG!EMP(%6NGF+)W0/(WC@#.
MCR ;D(<!D8!'TE2W1, ?A]-I4_]QKQJ*=&7 D">6C=+D)A^7TI3CH=H+I5I9
MX_",>:MA?NHBLI^:^KFR0'Y^_*#FM<56T:@7F;.]/#!2L1$@ 1;-:4'A6=#^
M?9"*D3=(4NEQJ(A>:DZ R1[2Z)#-1@!3Z=I96U-FEJ%=R7=BN@[@VF'7A1MR
M,B!\Z@:1Y&P]BYUDN /8OH/M*J-P*(<6HM/25!/>P%L%2L2ZD&;=W+DE<O;J
M]T^^7\#7ONZZ,"C"B-SKZ/4D+QU1+UR4%,8H44>I8,-U(/(;_,T'+_9&0G,Z
MCK#$080&JF<,:TG-T!=PJW D;Z3TOC,@]"LZ@!BC) \5@T1^'N^,$C)Y_RK'
M&LI)/V!<2BTUS*0 ]E#\23DHJ%\J1[.2@4?^RI,8/?/AQ!CDHG\-UB9[>B@N
M!]_2!V77S8D7"(?"'+J'ZMWNP.<8$S]^1C'Q6U])]FB+F54[X]R4>R+=.3AP
MF3U@/H93/0Q8RPE-K.H;G6N!Y<E8A]8U7+-U6"!( 1CH3!-2G"EL7?/F*#K'
M3KH!+ ;4JL0V.7J(@2@Z9K=NN5%N'B>[%Y%[13:U(:>DM(*5>E_[&-^(U&[L
M6I^;N5;U7897LU'OIX?I&>0E(FMJ#F= NFG>Y:*0PVJ(O]CMLCR*W1.?G##X
M[=7YU=F'K_VO7SY>G/UQ?GEU=G'V]NOER?NSRZ]G__IR?O7_?;T\._UR<7X%
M AQD-Y-Z'[L8&XW_+RE'"?CR&: 7]LL28'MS/ #1Z0LKB9]1944,>&P?&?..
M]=(E:'B$8G+>)MH'Q@5EZH($7U!67I"<9Y?S@*P46X5Q!+!4EF3S[KYVF7OL
M8T<=6RF<EX+FC)T 904@L@G-00>ZQFQ^_/<T%4,@)DH+2/QO4O..>"(<=0CD
MWHQ34,7'*/JSL9<*;:=A8#*)Y;.R1"=@Q0337,*DR&@"!J8Z<X]I?.I??"#X
MYH*^P6#!.[@TI]?=^9>.R%:/3?U#U8E=FB!FC 8!9,1%3HH1-E?KR3:C'6<.
MIYXA$>Y^?7OV[N3+^ZO+KU\^?_H(A/?Q_-.%HK_SLTN3!'<[SELQ],@#_06,
M:D" &*,D!NF].#+[F.1&)[;YX5#/$.9[7S^<?SP#AOON#%CMV_/+T_>?+K]<
M5&&]UW$^8+Q/YJB\#3,?A!;9_A;&[8?Q_E>@XO./[SY=?#BY.O_TT03M?L?Y
M1$S]G 9+L(?H$7(85H%V:]3;C_#=G!OD?B<EA>U.Q+Z?Z5)?NFH3KJTFYN68
MN?O=EV+FMNB5:V6!!U_/_M^?YV_.0;5Y=_[QY./I^<G[KY=7)_#=V<>KKY>G
M?YZ97/&@XYQ]'X>#$$-![W3\G;**R;MUZ8_!9(T:!. #^F(T7+DL![IO!PQ^
M]2]>D2>_WJ,;ABK?XL.4U6W\^WZGU__Y5[DK=6#R>3K=SN'^-'<42U^E'*[*
M+A9?XY+5<,U8=_2$2/>[Q!R&X\<"+:AYJ[[*K4JH:X/^K@I#AD'G:._GVET^
MQ<W5KNZ.2L@:NDB\+%^H/KB@%YB?7,DMJK_?E(?0356Z>X^$="\%Q=Z*S$]#
M<E(UEO"J\XYYGP=3U5:GA-@D#()(W$[@>"N-%_TTMTJ7>' WLOU8HEAV5[4+
M?4(2:!-8EJD:?\RKD!CZPRA]G57GYG]W.[WV4,.J#2J>@!9>$K3_QW/&J1@"
MN\[SZ2^O7]_<W'0RX7=&R?7KD]0?XQSHUR(8>>EKK!)[W=L[[A\<[KT&DN_U
MNGL'^\>]O>[^\?'>X6NOM[?3.SK:/?K:$]]W@UYGG$]JD27:6( 9Q&3Y_T*1
M#)Q\"SNY$!1]#IS3LB,+NF//8_CY5#ZA0J4X^M"+9^:<'&<KU+_D-'YR :N4
M%RG#'$#FVB*Z>))<M4<[_W2VWH413BCL.'#*G=V#_</>MO3,&L[8/CIC>WO;
M6HOR?G\D@?@$3,M*S75(32L47PB;;!**_?8@NQ6*[1&*Q[N]_GZ_U^_WCP\/
M7@?'_>[1<0 "<55Y6!.#)VJD'/YQ'UF)5=X4;\19:KLN3_A\.IEYN&_*S,I;
M[Y28/UPZ_ECN906F%9B;*#!WVX/L5F"V36#V^P>]_M'^ZV"O>WRXM]<BB?G)
MSQ-,2V*#K]__889F_<6KRLT7Q<&>K=!\OFS$2LQU2\R]]F"ZE9BMD9C[!WO[
MQR /NOWC_?[!:SA_L@/B<O?KWN[APT3F6X&EVEH6?M:"+7,=@ALG.+\W,N7-
M7-Q3(P'WLT[ O:0DVF6%YNZM0I,2:9=SSQY8H6F%IA6:FR<T]]N#Z59HMEUH
M[H'0/%A1:)[(@".*0FU7OIG1I/2:!;FLU-M[2JFW[+F<AGRPC6!;5DQ:,;EA
M8G+/YO18,;FTF-SK@9C<7U%,DN@"L?87EULN*0OW[G";6@O0BK9VT[L5;>L5
M;;VNE6U6MBTMVWI=%&Z[#<)M82GF;5+/*$C_K'H+G*BV0JX,*7ID*"HYM;]2
M7!'1VTI(*R&?,=>X4T(ND3+]Q#CXDGAFHXAL4?;JB\;U%R$A^U]W>T?W\9*J
M])M+:D_%,</7'Y*@'+$#7Y["05+/KTE'3AF5$@JE(;I;5><_T\>*G[\)$S5_
MY22X]FAVQX7LI$@_>,M];VD_)W)^@^X^^*5SB>UEL%&@VO"?PHMR?O3/ L"$
M04Z>W+*TE.Y;*6VE]#/F7-:.7;N0;E'&[(M&]1<AI#'_9V_EHLN1G'<(\D9F
M^#RVM6HS>JP<?,[,P<K!M<O!O?]K<?V%"T(MQO:^'AWW?["M:33J/VZ;P6FE
MG95V5MIMDK3;M])N8Z3=_M=>]^!>":@D.-!D.D)[ZTJ +?4^@>?GS#<]/KVG
MNXPKJ7;51T$F1SZY6 S9(0ET>O&'E#\ &>?]^U,KA*P0LD)H8X30;J_3:Y$0
MLCDT3RJ%=GN]K[VF8OM[)<"4)872Y)JF8>R'4["4Q'?A%WF(0XMIVEF*XS=P
MID?.+D,>$^V<^+ES@=V.I4:TZ^WT]K:\;?X3Y5-O/^"/N &<G-%M+G8I:,*?
M1.>NCL5=>ND AWCN?/H>B1F]"K[I=[M]*^*LB&N3B+,Y,$\NX_HMDG$O&ME;
M(.+Z7WM-7L7'%G%#W;W?BC@KXC:;ZJV(6[>(@T/^7ROC-D7&]<&,:TH >009
M9\J=WA'%KTX[50G4V]WO+B>KCKL'5E996=4JZK6R:OVRJF]EU>;(JO[7IEYE
M+U)4+<$Z[ "(=>SJ9?>S?NEH]\.96*_;ZYQ_O+0H_F+%U'F,(L7Y?V\NWCOG
M<9;3M/FWB5]0L@4EKO=^Y5GTZMM ?1LDL+68QSD++\69\/C#<YPOZ?D4]7KK
MY9Y#J>X#X7M%!LOD&;\M]T8@CE+A8*I&$,@9\'J-<EOJ?1M)\E;26$FS*9+F
M\O3/YV4./6L<7ZNHN?*^)W$RF3EGWW,19VC%X,3GB:=EST:2G>7VEMMO"K<_
M/7EON?W&<OM3+_*+B/U7[\/XVP"[1EG>;WF_Y?T;P/O?GKVSO']C>?];,0SC
MT+)^R_HMZ]\XUO_^Y(UE_1O+^M][ Q%9KF^YON7Z&\7U/U^<6:Z_L5S_<RHR
MV*;U]ECFWW+F_Y)SK-? ^-O4Q<R6U#\J<$^3:Y$ZG[W1HH2?K67S>K:=!E)\
MG7N#2,"G07A=N37:(H'K%U_@B\U;Z_7+:S/NM7)O/Z_SUO9I3@N<9YR6>#82
M.X-4>-]VO"&<YQ<ONO%FV2OG]6K8TG3(VT[53!3K>24 6;V408LX+P4^XH$S
M2-) I+^]ZKYR?!%%R#*!T/3?DO#H;[G._]_>U?2F#031O[+BE%34H6"H"DJD
M)"5IH@803@[MS>"E=DLP]=J1R*_OCG<!!PR% /Y8)B=+P>!YGGF>G>?9$6?
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M3IE1IU\E8N[N!6_,EOG/U%+F#AV+E+3/U3%/]8#;QJ;'35**C;_RE7$],E9
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M#Z4BY0_]IB(DQVSTJ880Z3'?4(IPKH0_JK<=S[ -D9$SQ>C/HM*(R)V@&G9
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MJ!V0E-6TL&-Y3H.*L63%]8)O0XML&"KLIS&9(;V,.P]FY_+%WLF*NRO")55
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M! Q,,,C)ZM2 @=](!X+=[&Z5V+R,WF3B;%:G8*>KL^<^=U-*1W35VB9;YV2
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MOCYDMYJ*\06M]X+F=> 44ZI/L0Q1\+3NH+6C-P_J!D35:YL DMT)VG@IH8N
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M;-8*QN46A9=?\'_&+/C[Z?]02P,$%     @ PH5N58U3MRLR/P  [ZX$ !4
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M 1,$!JV95.93X,B)EM=_)7Z\O/)??6K!>@5=#Z%.!%J7[T[ZS>A'D[H/F2_
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MF8!<L\&QWGE4=Y )3^-?3LJD]8]7Z!4%.$7B$A,9]0( JIF\\73JNZC%^Z@
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ME;"9RL4'-;"@83W-U&H@J..M5SCHLA]93!E:""L,TCQI*>L5T[:"J;N>,-W
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MEPU7C3PF\[D3+5=U(YG"'KF4,I8-5G?CB/@R=E\\(D"'I8V=&_X6%6,FN*Q
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MFZY=IIJ6;5,()X9?"0@V. 49$1%DE8S$_!]RL*VD! $5$Y#4&.1<4)!_P>!
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M47;3><\MS/(T#G,8=2]*?R(PJL^A5*CJ(R;/Q;Z3U;S9#H@?#J4!)M97YW*
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M$!8LHRX?(2A7XVCER7H#2A9S#$^5 53X<_C)-]^\^8.Z'T@2- A@,@PF]11
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MXSAA:=5YBPDR@L.V:US&29"$<8#JRW%53T3TDM"'H(>D?:>H& F7 _OA"V/
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M!;N]7F7.K$S:H-)7C97]P:04@&;]4B=$_L8$\63Y7M<(L"$""P,<N<)ZZE.
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M[KEXN]N3OXD3":^.MPZ#A*5TYR4@J(&%BOJMYUAXDW\)4DB<LOSQ'#Y#A)E
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MLH-FCM7B J(,Q24*/SQ#$C2LID*_ 4)M;!BO:A9]F,%U\B>8]N;(2JXS0LD
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MA:_""TOQS)QC%AMNQ9PR[+X_GP<7N:Y3G/LU]RTX0O4L9W%;IBE2M^W,=]P
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MA,B9_CZ(-^%'@*T5]M>.WA3Y.TJC_*P8RVJWKQG%:,JS$NO66$ )!@R6-J\
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M2??'*?:_"UPD>Y\I0"Q[W7Y%>!E8FY5K6QY,C#004,'N+BF\.!YDP1L(*-X
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MJ6R>8_K>S%XFNC%U=U7S&;#3">\(;+D_ P-7@T8YS*XHS".SNV_"!Y3Q^#5
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M(#EGK4!*UU22"S.\12_(>]=!LE>1Z6$*9W*F<-;C%$[E3.&TQVN5/5#^YJ+
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M)E\B*!36P7&4RU=(6X 'C*CZ'>:0YP#<,WSPH0B;81 56"1_8^R1O^Q&*!Y
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MS@_WP^'X7Y, OAL_U9H2?3R)G4I^G@3[[:*IN(]P+[P=ZR9.YW:-@^Q']/=
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M0;>\)OM P: OY^I2Z,M2#4RMIJI%9Q2K+J] SBQ'ML#UI<_78"4>//)ESTY
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MW) !25F:-T(MABB$3?5/W8>]]2F 7K65%KX45 8.#[("'E@YTS?L7OAHQ%_
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MI<E"Z'CM':*OX.3T-O=HV?:A(G)%=9OT'"JD.^"!KX>$B7U3_J19D2/AAHD
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M9R72>V+##9D K;I##?"=&JL+S,@/B)Z5H*,5EF33)PZEIL#KHW(<8@JB(-:
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M;BHS54#'6$T5"SA%E9VXBIQ0J&<73:J"8=Y5 '-.,#C?XYC1V?[J(A"99RB
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M>\?+3+&C^8,M;BWJ-<;)Y,S0GD3'7[I/1%T>1A#QF<_**N)8CN%Z\$EG._R
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MR%N$/4&_)//L4(#XI2BL#7HOL/(3OML_@PQ!QTPI9A91,"V&+9%'"SD--((
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MGY,1!#N >UK1.T]/?(&7!_& M6%^&<+MMK@5?HQV'?P$R)$:[][R5^^OT"H
M^P4<H[WZEMAF9H^!O L4. (WX-]A"G 9.0RO[3NGSWTT>  9@P#D>B_VO#%3
M(F* 4I#/2,32OT/=OU!Z:%U^J[ .$L7'RW:#N-\)P*.'C=-6M<'B((YBLEH-
M'F'_AV%P*Q4\HXQMJ[=,X0"(6=A.C37-P%93TA D","@"T;J^*%Q.MM)S^((
MS,D@//X7CZ/@/OA?&+6>B,#\VU%HUOLW!"3(ERPI?^#.]YLP -MZ)PL,S> *
MQ[@U>@J@\L99IWG98K6J%6&SV,( 8##DB5YTO'\$TYM)]N@_!*9@G,EGSD4/
M6!3A4">LB0;M$(0Y ;8@&),C)N _'B?-8X_GV?I$XWSVOA_5#O;K^V_W3:1B
M>:K8XMM%^[#4WD\QS>1+:-TH1B0!O V2HEBUWD5/U5_]KAJ>Z/^?>A[ZO:2I
M?Z)NH/%CI0>G^$)JO("G['@Q^9Y2^ZJA</!5ZZ1JU]8/(BW11U()\-9Z&3G$
M5)_#E*2.2*8)[L-X*/31[]46!]P8V!GRZ_O;4NX*Y-E]0O*<+Y[NI,8.DE3L
M";*+96ZLC!V ]L@RP"5&2G5O?Q'06+'UHBFX"_H3;&;I\*ZGW<(\KY"E#48,
ML(R)CZ4\T!WKIT/1@PN^(^:3->[3!NG@K.G?]:+K^G5M;W;(^.W*,MIJ[OJ3
M:NZ$&B@V,5]2+Z*Z,4+QEXF-+0*#)?K]N3PS8\;E]HI8)\L0V@#5]B8J$#>U
M:F8Q]!W\6UMR,3-8&AD5>1,];>.U(_^&X(\1WVI=)$,&#X./%(V/'U /94FM
MME\]./K%7J+LF-%-=W#V/(_C@<.32T<!2#D 2G<N??#KOHI0!NY$E!G- :5=
M%;JM(V^X%ZGI070D0Q49_QFOG<,V&9\79,)-GW7CB(D?V5> ',-HO*- -L!S
M6_MUW]UF7_F8"(#>3XESUA23OF=F)[,[FTED%FW;\WB9=X#M@8&VT]=3U?;N
MMX[7$\LXA7F]!P>^_OHUT-S;PT-V6Y_8@P6 7T!)%JYE<DN ]LE,00C2WS![
M'EIH,&6STPT%_[[#>T#NQ]P;\;$Z&4DWZ@-\,%_15MP/V#LYF(A+J]D4QK^;
MC)JG%YY:5BYBKA:)S"NM?[Y@/E!&8Q)""ZJ^)UUB3G2O&8!:\*\94#MK!H]6
MBVL&%-M:,X#VZVL&T#L5#W-@T/AO#G_)Z_0Z2&,LSP)OU3.R'R3[J_>XXS#"
M7%__B5>UO6XBY/YFXH-Y!R_7HZ\?%'B)YE91[9BY]6;R5EOTKL\ D) [T5DP
M&'(?G,#KM]^[;W\/]VJKQV]M;&#_26,#L"+7N+_@DS9Z/5U7XPNEE@X-8/A,
M9$?"H>_C6=>7#1),N?MIE$RE\8I\!,!),3 ,A2.(Q,OX[G.F'R:?6:#8@.H4
M;%3%))LS,7XW!E=?_!!.')F@BBL\&"&D/'>.8H9QJ&+,-\^(;$V)OIGQH?WJ
MW@&@94L6*Y)"XIV,"9W,AB%GHT\.1AE95Q2:4I//5I:<HP][<IM4Z,V9@JH)
M"IF3-L@/6!>8!!D2"-<16/VA90B+?0]E"#Z:X=5<')[&76FSBN.24RM&4+M"
M^$P! 2HL34DWJ)05SY$+FGP&".E<]'CL14A"C5ND,RH_T]>VLC5-6:7 _3%S
MJ-I51_PL V4*7O.<N3WS3I:N P<&#8W,Z0HJB)!^#&@T144E[=R3=IS'US/9
M#1QR2:5HH9"#+J@&L6"E$Z#%!.M#P57@4WXNB(D8AX'S'<27$ZA(%\R('T/A
M*T#P5CZ^G'FU)\3$LS!0$208"*F]/E&3$)GKS!,W'"5I#(-XVQC0U@2JRWU\
M(P]-)>KC:<9]K1FW?JZ@'/^.#L[J#L;!DSH8;0%6M0*L\BBI#_O&0RQIED*=
ML+;@/7!>!V4AT<:9ZS:7&5H2T+L_TKM/R6A2Q5I Y>L 'V4_:X?5_3>;NJ'R
M*3:4BK9!-0ZU.P8 ]0/*".#&:LU"F1C<6RJMQ>M@42$R)M3)1,5-3M/ 'ZB
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MO;^5.*&!35(O:>DWE2!Q,I-5],$%>]8)$RU^JJ*U@9<)LF"*R<8\J..(I/*
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MC*42[C99M]-]W+N,?\LKV[=#=M>#IQER/ZA>4-\/JC?A_P=02P,$%     @
MPH5N55&%E&H_"   C#\  !$   !T=&]O+65X,S$R7S$R+FAT;>U;77/B.!9]
MGZK]#QJZIBNI @R$;&\!G:HT(3/9ZDYZ":G=>=H2M@RJEBV/)4.87[_GRN8C
M(=T-W9E-FL #8.E*NKKV.3Y7LCL_GUUU![]_[+'?!A_>LX\W[]Y?=%FIXGG_
M/NIZWMG@+*]H5FMU-DAY;*25.N;*\WJ7)58:6YNT/&\ZG5:G1U6=CKQ!WQO;
M2#4]I;41U< &I9.__=2A,O<K>$"_5EHE\,=:K2OB]JC>^&^]4845ZKQY9<>;
MF_]<J;#+7UE7QQ.16I&RR7&U5FU4WQRQ2H4,ACJ8X?>G3L*,G2GQMA3Q="3C
MRE!CB*A52VR[*+$Z<8=6W-J*C ,1VU;MEW:H8UL)>235K#60D3#L4DQ97T<\
MSNN,_%.TZG6T+)V\CH<F:7>\Y&1E1-<A5W(4MU(Y&B\&W,Z%J:"VK:%6P>JX
M9/YU%\F15JS3B*N\<TOG+$0!2F.16TUX*CE&9(5AZ:1W.Y9#:5^_JO^]UCZJ
M5QOL\U/SX:Q(OSRW>N,93:[;ZP\NSB^ZIX.+J\OOG-AS.FD?;_K7-Z>7 S:X
M8O4WK'O>9XUFK5H_XI5Z<Y?FV;_Z<//^U]-![XS=7)[U^CLTM^M>EZ[* GBU
M!KLZ9X/?>NSZM/_N]+)W7;GZS_O>[^RT.Z":1JVVALQOP^$64RO"4KC\7;.]
M*+-_ZG',/E39=9+R42;*S >?RW#&[)C#-)]<("?,G<^W)25"6T*1Y4,EV%"G
M@4C?EFHEM%/*)-R7\6AQG/ @F!_/XY,WJ?A:*9X8T9K_:;.I#.P804!,W @I
M?05L4HR,^)7FG>2FS>IQ\Y?V="RMJ-#0%()IRI/2=N?C"4] A\KGGCZA'_5J
MQZ.J$SK?N-\'ZZ'_AI@^FH,;2H&:DP(7;,PG@J5B(L54!+B0I6%_9)QDBIJA
M/-&I93IFY^@\!WJ]5OD7TR$;--@[J<W,6!&9<EYW$?O5-EO$!5\I?='ECU\@
M8X^/W<='8X?P\8X;H +7?S1CGW!!*!&,P/L.)@4X HTN8FV9C\9<QHS',Y;%
M-LT$ILB!#MR["#"<13B",XJ%W$=1RG0D+;,ZMULSB(4OC.'IC$PB_DE@W)4^
M#<H".(,A%<6&QB #7Z9^%L$L1G-X H0P7-?^F)F,OI;MIR(512<T@4@:A90%
M( -\[!@3-(GPG8/4;P+7=(!I(HM!4(:SU3#L4?_"47_T$E O6"ACX(H@NL11
M&9"'.:K3E7H9DTN<5ASPWU=9@#Z!U170E(%S2??9!% CEB#V4&I) P4"S;VA
MP32!6\HHDT6F8 #L:P#4#6></SXW8Q8J/35S8DC%2!H*EF6<"G._X65Y!=]F
M[LR:MWN(OW"(-W<(XH,[>'C]ZA^-^INV*4!<I'5T(]1A*'%X8 YSA4N(N6 \
M%0Z;P)JD*QR>,6'H:I=F3,W(+((8($% QX$TOM(F0SN2":E6.4B35/LB0+%A
M!\!D( #R''B]6W_,XY%@I[@#]S,E3"&_:87D^$"L^%,_#O*B0]>GI%6$.*<)
M&HG1#7N%/7(TDU?;#1FN#QEB2)K[?7:!!>45K1^6,8X>BS&>YNI>KO ^#-,]
M0_XU?ASPP]VAR#-AX#2HP:4-7V>P,F4T/L_,YDTHM1@*<% Q4IZLZ"Q%!Y C
M$VF<R(&5B%T_M-"VE$>K$BL5BCM2*[*5)1V5"_E%E1)2";X8K63 K7-T:&0@
M$2>:@,QS*B?Z8NHI,Y3GN+N"<4F1DT3:"#AD(<&H4<+!IGZF."DY3,LYL<R7
MT"+/OE:31OP;"C*$V$)[$?RXXFI/E7NJ_!:J'.XL56XLP-88<W/IMC%Q@FPG
M,B ^Y$;'CC*X 9?2ZA"1)$^#.6&!0B4?2B7MC%+&AX8E^G;<YF@K9]X[IBNK
M2TX4WQ832K(T 6T:E^+Z/AC(.>#6F48B1N:JP)ZH$0G1,IEDL<T9$O0M$ZC1
M/4?N.?)E<:2_0QS9@]>9TUQ$("(,A6_E!- W#RQ0+1+R#31D?OCPFI6C1#2$
M_C/YRMA09_;S'FRB<OG"6M"R7_CUQ7$VG"\H.I87>23@3]MU_I)930F+.T2E
M<+Y5J57K>Z[[0E"> 0,^O7<'P6/SXK.[#,]R(EHG--I=+);I7,V#K+F%CJ2$
M6OM^EA)MK62O#_0::6-13H\IH2_CHZ/B40%V\)DF(?@7"N^>=>&X#U9T&Z.T
M9QIG"[\.<Z_&W"Q2?=*&CJ]%X$2SBT<A:&=,R4]"%;ND]^S+WQVB'YNC]TKL
M4?PXWF]]%%L?[GFA8,Y.Y:6T(:6URA!+E4,8WR(G7EO 6[C(LT!:G9I%&NH*
MT&442?"W^(*.'&HDNE0?2/CG.CD CT"V&9*%^*40S\E/_)%)N.^(+HM]MZEZ
MN-_->,&2["62WD[M9IPJQ6BQ3(+4:(^2]CU]*< ^10JYV%68"OZ)<L)\L<IE
MA6Z9S3VP-7_&8BM.*S8 \EWC!U0+#]#0B(5H^2S_%8MS: (2 T64\\34("LU
M681H8\)N,H58?/!IE!];T.RY;,]E+WV[X10Y8)A"_)3!+,+I-G"3>X2S(+%R
MGD+)>*+51% >%?-1\21J6D@]$25*SP1JIV.=ZSI^AR)!:8^29%:_0C;?]]9;
M'IC&__EZRB7QX[WQL2%7-K]$E7>Y@V=6MPL7YB%U^]ZL5GUSG%CVJN8^[<VO
M^Y5#FJ@[OGM.J. )4>X9[_Y+.BMP]_*H;1DZFOBNQ^VQ8K9#(>F.I0C9^8+-
MKO)L>!\:W$N++5E$966?UCU+O A7L7APN!:O;^+^9_8JX!GNLBUVB?M=-,0M
MK]XLLT:ML=W;C7_)2]SW0[;NP>,,V?&*5]8[7O%N_/\ 4$L#!!0    ( ,*%
M;E7">NB:" 4  /(5   1    ='1O;RUE>#,R,5\Q-"YH=&W=6&UOVS80_EY@
M_^'JHD4*6*]V^F*[ 5S'73-T=AJKV/IIH$0J(D"1&DG;<7_]CGI)$W=]"5IL
M30(C%LGC\9[GCG<G3^X?+V?)^],YO$Y^?P.G[UZ^.9E!SPN"/P:S(#A.CIN%
MH1]&D&@B#;=<22*"8+[H0:^PMAH%P7:[];<#7^GS(#D+"EN*82"4,LRGEO:.
M?KDW<7/U-R/4?5MN!<,':Y7RV,4@COZ*ACY*X5K0+4Z"3OR^Y\'B5Y@IN6':
M,@V;0S_T8__I #S/":2*[O#[WJ0"8W>"O>B51)]SZ:4*CRA'867'[8Q553VT
M[,)Z7%(F[2A\.,Z5M%Y.2BYVHX27S,"";>%,E40V:X9_8*,HPIV]HT<R-=5X
M$E1'5TZL%1+!S^5(\_/B\L";F;!E;N\H58)>/=>)?]U$9\A(*ET2T2BWSF<Y
M3N"L9(W4AFA.\$1H!7M'\XN"I]P^>A ]"<>#V(_@\] R-);I+V.+XI\(W&Q^
MEIR\.IE-DY/E D/\;/5NND@@6=XED-$S>.>O_)D/J_G, 6U\&0T.P_Y=PCE=
MP?1X>9K,C^^J)Z_Y[WGX!):O('D]A]7T[.5T,5]YRS_?S-_#=):XE3@,XWWT
M-\,Z] ^'#V^,KF6FM?J[ )](R)24+'.5!;;<%F +!F_7Q&5ZL8,S5BEM0>60
MQ/"2*[,SEI6FWU!T(C,?#MR.1P^>Q7$XGJFR(G)7CZ+Q8T"EK_"L]D*$WEM
MD^HC*J:YHL DY?(<5JQ"M2D6EP'>F3B,8R &<BX8_6C5BF5KC340&2&2POPB
M*X@\9UB9RI(;XQ#@QTE28AD43#.T^ZIY#9K.N@Y$'WY3A805FO2!B3[,"LYR
M5(_'6;YAL,QSGJ%IJ,SI:C'V ><LS_&A6FNS1F+!*KB2#!I6KR8#Q$2H0JCT
MVIYKDB[LVI-61*=$,N,M+P3;P32K'>'"KH_K!!UYNZ,O\B%!F&V,Y6N! 9<A
MN\*Y^-+MFOV]YIJ5:+)Q^/=X/2"/FT<,K.CP@':C?#]F+N.EY3%Z/A@V+D'5
ME-%Q'56WF]&X891+)TGJ2XWWVQ(N,>1X<SDZN@EW%[S2S#AF^VZ9" &X#:\F
M$<B[J9!JTZ]WY5P2F;EY5$CK3K3F"Z76HN93X?VICS1[-\6_$:F?Z\T:0N/_
MF- FF!K[*=] 7=A>] 3+;0^G+$D%@U1IRO2+7MC#G""$J4B&2>UR7!%*NW'+
M0+/#RY00I#)LU#V,,>RI+49#1%WKU^X?A4U[;LDI%:P'G9Y&.@I1O+6B8]4H
MP2F$_M/#RL*#L/ZK57Z[%]JAPUJ/K[O%3?R/D1Z8X%K:=B["MQ=ZY-YA]+]0
MAZCV>2-KJRYY<ZCO.FD_A+ [Q,<I9B_N+*E3V6?J_A>35W3+$!]4FF,:KS"/
MLTN@J@'Z^).0".K\AG.8^FYQ53S&DC:"A=HT+68T;%O,VUWKDX*;M@?E65/K
M29;5)=>U.XQD15?KKS:;KJ(]_;8NL[X5IG!=@52VCQ&389_NE+A]:*F[.6U[
M1B'=?;5I3;$U9]C)T;:U;[>T?4+];H"F5LJPNH=H3,6.^N;-W,UZCI_/N5,P
MF(21(J4Y6HG7M>8 /;Y%!I!XQ(517>Y[X*-W"R0C92A8:;7!)$<[OW5L.^=N
M.?HV=3UVVR/N><3)Y&LMN2D^*OB6]S -'+MUM#'/85WAC#.2&?MC>L'O^JEP
MW^^?6O!CCIP$[0^CDZ#]!?8?4$L#!!0    ( ,*%;E6O>S=I$ 4  'X6   0
M    ='1O;RUE>#,R,E\W+FAT;=U8ZV\3.1#_CG3_PQ $*E+VF91"$BJ%-#UZ
M@@2:17=\.CEK;]:2UUYL)VGNK[_Q/OKB>%14!VT5-6M[/)[YS<._S>CAT7R2
M?'PWA=?)VS?P[L.K-R<3Z'A!\&=O$@1'R5&]T/?#"!)-I.&6*TE$$$QG'>CD
MUI:#(-ANM_ZVYRN]"I+3(+>%Z ="*<-\:FGG\+<'(S=7?3-"W;?E5C!\L%8I
MCYWUXOCO Q^%<"EHUT9!*_W0\V#V.TR4W#!MF8;-OA_ZL7_0 \]S DM%=_C]
M8%2"L3O!7G8*HE=<>DN%)Q2#L+3#9L:JLAI:=F8]+BF3=A ^'F9*6B\C!1>[
M0<(+9F#&MG"J"B+K-</_88,HPIV=PR=R:<KA*"@/+YU8*22"K^1 \U5^?N#-
M3-@RMW>P5()>/M>)?]M$9\A *ET042NW+F093N"L9+74AFA.\$1H!#N'T[.<
M+[E]\BAZ%@Y[L1_#EUU+T5BFO^Y;%/]"SDVFI\G)\<EDG)S,9YCAIXL/XUD"
MR?P^.1D]AP_^PI_XL)A.G*-U+*/>?MB]3WZ.%S ^FK]+ID?W-9)7XO<B? ;S
M8TA>3V$Q/GTUGDT7WORO-]./,)XD;B4.P\^*]6:^]OW]_N,;>]<@TUC]0PZ?
M2$B5E"QU%PMLN<W!Y@S>KXGK]&('IZQ4VH+*((GA%5=F9RPK3+>&Z$2F/NRY
M'4\>/8_C<#A114GDKAI%PZ> 2H_QK*8@0N\]H$G5$2737%%@DG*Y@@4K4>T2
M+Y<>UDP<QC$0 QD7C%Y8M6#I6N,5B(@026%ZEN9$KAC>3$7!C7$>X,=)4F(9
MY$PSM/NR>;4WK76M$UWX0^42WF+]EIJLUJP+DYRS#(ZY)#+E1, \RWB*UJ$^
MIZYQLPLX9WF&#^5:FS5B"U;!I7Y0 WNY'Z!;A"KTEE[9<T7295YSTH+H)9',
M>/,SP78P3JM8N,SKXCK!6-[M!(Q\2-#-)LVRM<"<2Q%=X:)\'GG-/JVY9@6:
M;)S_UW#=(T_K1\RM:'^/MJ/L>MJ<ITR#8_2BUZ]#@JHIH\,JL>XVHG&-*)=.
MDE1UC25N"9>8<KRNCQ9NPEV-EYH9AVS7+1,A +=A=6+:XT*)4)MNM2L[+P=4
M2"LN6N&%4FM1X:FPJJLCS;5*\6\$ZI?H60UH_#\#6B=3;3_E&ZCNMI<=P3+;
MP2E+EH+!4FG*],M.V,&>((0I28I][7Q<$DK;<8- O<-+E1"D-&S0/@PQ[:G-
M!WWTNM*OW3\*F^;<@E,J6 =:/;5T%*)X8T6+JE&"4PC]@_W2PJ.P^JM4?G\4
MFJ'SM1I?#8N;^(F9'IC@>N=V4<)W&'KHWF3T?Z"'CGT5.N?X+>-6)>P5X+QZ
MZB="=UNPW2]4OG#K?[5U17?/S;U2<W2P1 ])FJJUM(Z"J8;BN(Y^T>F;V:>?
M94A0]3V<PY9XAV_+([SJ!C!3FYI]1OV&?=YM#I#DW#3<E*<U!W"1=E>QHT&,
MI'G+ 2Z34'?3'7P?^ZS2Q.2.+4AEN\#.4J3P3HG;AY8B#BUMH[#<?9/,+I&U
M,V1XM&']S9:&/U2O#6AJJ0RKN$5M*C+MFY.\FW&17R^X8S#8DQ$BI3E:614I
M8H 1WR(""#SZA5E=7(_ 171S!&/)4+#4:L,1DC9N+=HNN%N.L5TZ[MUPQVL1
MJ?K$6DMN\@L%W_.*IH$CBT<;LPS6)<XX(YFQM\,1?^A7Q)]VXGFF?6[![1PY
M"II?:4=!\VOPOU!+ 0(4 Q0    ( ,*%;E5+U^QRQS," ':\*@ 5
M      "  0    !T=&]O+3$P<5\R,#(R,#DS,"YH=&U02P$"% ,4    " #"
MA6Y5Q+U$64H7  #/!0$ $0              @ 'Z,P( ='1O;RTR,#(R,#DS
M,"YX<V102P$"% ,4    " #"A6Y5;CC#6> /  "\Z   %0
M@ %S2P( ='1O;RTR,#(R,#DS,%]C86PN>&UL4$L! A0#%     @ PH5N58U3
MMRLR/P  [ZX$ !4              ( !AEL" '1T;V\M,C R,C Y,S!?9&5F
M+GAM;%!+ 0(4 Q0    ( ,*%;E7WY,8GY8\  #6*"  5              "
M >N: @!T=&]O+3(P,C(P.3,P7VQA8BYX;6Q02P$"% ,4    " #"A6Y5M5B'
M$$58  !=$@< %0              @ $#*P, ='1O;RTR,#(R,#DS,%]P<F4N
M>&UL4$L! A0#%     @ PH5N59XTOW*[3@  ["4$ !(              ( !
M>X,# '1T;V\M97@Q,#1?.#DR+FAT;5!+ 0(4 Q0    ( ,*%;E7:+%2AIQL
M /[=   3              "  6;2 P!T=&]O+65X,3 U7S$P-C8N:'1M4$L!
M A0#%     @ PH5N5=.,_I)2"   >C\  !$              ( !/NX# '1T
M;V\M97@S,3%?,3$N:'1M4$L! A0#%     @ PH5N55&%E&H_"   C#\  !$
M             ( !O_8# '1T;V\M97@S,3)?,3(N:'1M4$L! A0#%     @
MPH5N5<)ZZ)H(!0  \A4  !$              ( !+?\# '1T;V\M97@S,C%?
M,30N:'1M4$L! A0#%     @ PH5N5:][-VD0!0  ?A8  !
M ( !9 0$ '1T;V\M97@S,C)?-RYH=&U02P4&      P #  * P  H@D$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
